Clustering O 0 0.0008322950452566147
of O 0 2.1116065909154713e-05
missense O 0 0.004101853352040052
mutations O 0 0.0002215350541519001
in O 0 3.8776706787757576e-06
the O 0 2.1574835045612417e-05
ataxia B-Disease 1 0.9999758005142212
- I-Disease 1 0.9988769888877869
telangiectasia I-Disease 1 0.9997664093971252
gene O 0 2.0126084564253688e-05
in O 0 6.481570267169445e-07
a O 0 2.4026787741604494e-06
sporadic B-Disease 0 0.00040366212488152087
T I-Disease 1 0.996560275554657
- I-Disease 1 0.8812353610992432
cell I-Disease 0 0.3661935329437256
leukaemia I-Disease 1 0.9795029163360596
. O 0 7.20351526979357e-05

Ataxia B-Disease 1 0.9999004602432251
- I-Disease 1 0.9993487000465393
telangiectasia I-Disease 1 0.9998595714569092
( O 0 9.23546904232353e-05
A B-Disease 0 0.017859147861599922
- I-Disease 1 0.9995970129966736
T I-Disease 1 0.9999613761901855
) O 0 1.169827328340034e-06
is O 0 3.2132777505466947e-07
a O 0 1.1299268862785539e-06
recessive B-Disease 0 0.0004045297100674361
multi I-Disease 0 0.13765409588813782
- I-Disease 1 0.9925590753555298
system I-Disease 0 0.058232322335243225
disorder I-Disease 1 0.9459157586097717
caused O 0 1.2929473996337038e-05
by O 0 3.788145477301441e-07
mutations O 0 2.053794560197275e-06
in O 0 5.49173861941199e-08
the O 0 9.957442870245359e-08
ATM O 0 1.4084579561313149e-05
gene O 0 1.2387965853122296e-06
at O 0 6.093973183851631e-07
11q22 O 0 6.847665645182133e-05
- O 0 0.00012265844270586967
q23 O 0 0.0001316703128395602
( O 0 4.3032287067035213e-07
ref O 0 6.500151357613504e-05
. O 0 1.3071785076590459e-07
3 O 0 9.82961410045391e-07
) O 0 8.04992055236653e-07
. O 0 2.617848622321617e-06

The O 0 4.0404553146800026e-05
risk O 0 0.0005448688170872629
of O 0 9.116266483033542e-06
cancer B-Disease 1 0.85787034034729
, O 0 2.4730256882321555e-06
especially O 0 4.733484274765942e-06
lymphoid B-Disease 0 0.0030739502981305122
neoplasias I-Disease 0 0.04575307294726372
, O 0 9.480746143708529e-07
is O 0 3.091458324888663e-07
substantially O 0 8.611650628154166e-06
elevated O 0 2.6883020836976357e-05
in O 0 4.852296910939913e-07
A B-Disease 0 0.0018672780133783817
- I-Disease 1 0.9998195767402649
T I-Disease 1 0.9999978542327881
patients O 0 0.008479845710098743
and O 0 1.0874373401748016e-06
has O 0 5.35898493581044e-07
long O 0 9.522869731881656e-06
been O 0 9.893066135191475e-07
associated O 0 1.0850984835997224e-05
with O 0 1.817411794036161e-05
chromosomal O 1 0.9997560381889343
instability O 1 0.585640013217926
. O 0 8.744459773879498e-05

By O 0 7.895299495430663e-05
analysing O 0 0.00315079209394753
tumour B-Disease 1 0.9998722076416016
DNA O 0 0.006712063681334257
from O 0 1.3524028872780036e-05
patients O 0 0.0001476084435125813
with O 0 1.5069255141497706e-06
sporadic B-Disease 0 0.0005642916657961905
T I-Disease 1 0.968693196773529
- I-Disease 0 0.06137395650148392
cell I-Disease 0 0.01790468581020832
prolymphocytic I-Disease 1 0.8833835124969482
leukaemia I-Disease 1 0.9988790154457092
( O 0 1.081883874576306e-05
T B-Disease 1 0.7883862853050232
- I-Disease 0 0.004345449153333902
PLL I-Disease 0 0.0008932051714509726
) O 0 2.902174287555681e-07
, O 0 1.3993957281854819e-07
a O 0 2.773661549326789e-07
rare O 0 1.6226655134232715e-05
clonal B-Disease 0 0.046583596616983414
malignancy I-Disease 1 0.6996700167655945
with O 0 5.106459184389678e-07
similarities O 0 8.542398859390232e-07
to O 0 9.806078793417328e-08
a O 0 5.992598630655266e-07
mature B-Disease 0 0.00021246331743896008
T I-Disease 1 0.922751247882843
- I-Disease 0 0.05500253289937973
cell I-Disease 0 0.02973516844213009
leukaemia I-Disease 1 0.7252663373947144
seen O 0 3.7951278955006273e-06
in O 0 5.711086714654812e-07
A B-Disease 0 0.00035501140519045293
- I-Disease 1 0.9826958179473877
T I-Disease 1 0.99982750415802
, O 0 3.115630704542127e-07
we O 0 6.834643784259242e-08
demonstrate O 0 1.680402874626452e-07
a O 0 7.287050607374113e-08
high O 0 2.839732360371272e-07
frequency O 0 1.3180931546230568e-07
of O 0 6.457656098746156e-08
ATM O 0 3.363725045346655e-05
mutations O 0 3.692747213790426e-06
in O 0 1.1354065918567358e-06
T B-Disease 0 0.241952046751976
- I-Disease 0 0.006111388560384512
PLL I-Disease 0 0.0040914625860750675
. O 0 2.6145226001972333e-05

In O 0 1.4518450370815117e-05
marked O 0 1.5386751329060644e-05
contrast O 0 5.593622518063057e-06
to O 0 2.2761184936825885e-07
the O 0 2.8161906584500684e-07
ATM O 0 0.00010456710151629522
mutation O 0 1.9428848645475227e-06
pattern O 0 1.8462775415173382e-06
in O 0 2.6584623924463813e-07
A B-Disease 0 0.00014247804938349873
- I-Disease 1 0.9937147498130798
T I-Disease 1 0.9998874664306641
, O 0 4.3645883351928205e-07
the O 0 4.01533668537013e-08
most O 0 4.150816934611612e-08
frequent O 0 2.096858651157163e-07
nucleotide O 0 6.84156873376196e-07
changes O 0 1.5774006101310079e-07
in O 0 1.369157729413928e-07
this O 0 5.050713411947072e-07
leukaemia B-Disease 1 0.6588804125785828
were O 0 4.032439392176457e-06
missense O 0 0.0011841829400509596
mutations O 0 8.319045446114615e-05
. O 0 1.6106461771414615e-05

These O 0 1.8229455235996284e-05
clustered O 0 0.00013439117174129933
in O 0 6.382409765137709e-07
the O 0 1.5746064718769048e-07
region O 0 2.3444700048003142e-07
corresponding O 0 6.395619323029678e-08
to O 0 1.4473681808624406e-08
the O 0 1.5541802511620517e-08
kinase O 0 7.117376412679732e-07
domain O 0 9.767233422053323e-08
, O 0 2.5208461096326573e-08
which O 0 1.574391106373696e-08
is O 0 1.886968092890129e-08
highly O 0 8.718679822550257e-08
conserved O 0 1.0551373463840719e-07
in O 0 6.556509646316044e-08
ATM O 0 1.5776875443407334e-05
- O 0 2.55012528214138e-05
related O 0 6.544727852997312e-07
proteins O 0 1.478567099866268e-07
in O 0 8.95758489605214e-08
mouse O 0 4.816506589122582e-06
, O 0 4.383158511700458e-07
yeast O 0 6.5474396251374856e-06
and O 0 1.4056344070922933e-06
Drosophila O 0 2.3853546736063436e-05
. O 0 1.3193965060054325e-05

The O 0 2.4075065084616654e-05
resulting O 0 2.2372707462636754e-05
amino O 0 4.300281034375075e-06
- O 0 3.2782514608697966e-05
acid O 0 1.0372559700044803e-06
substitutions O 0 4.4628706064031576e-07
are O 0 4.0859660543901555e-08
predicted O 0 4.7122560431489546e-07
to O 0 2.4803302522968806e-08
interfere O 0 3.922135078937572e-07
with O 0 8.87871109966909e-08
ATP O 0 4.2447838495718315e-05
binding O 0 5.029342446505325e-06
or O 0 1.3297534451339743e-06
substrate O 0 0.00011201630695722997
recognition O 0 6.522391686303308e-06
. O 0 7.888058462413028e-06

Two O 0 1.243254700966645e-05
of O 0 3.30924285663059e-06
seventeen O 0 3.2055027986643836e-05
mutated O 0 0.00034236229839734733
T B-Disease 0 0.3590605854988098
- I-Disease 0 0.00046205465332604945
PLL I-Disease 0 0.0004677621182054281
samples O 0 3.9308251871261746e-06
had O 0 2.915548407145252e-07
a O 0 3.0187274546733533e-07
previously O 0 9.018664286486455e-07
reported O 0 6.300510449364083e-06
A B-Disease 0 0.00017567319446243346
- I-Disease 1 0.9499382376670837
T I-Disease 1 0.9966076612472534
allele O 0 8.828026329865679e-05
. O 0 1.994759622903075e-05

In O 0 3.568605097825639e-05
contrast O 0 8.414186595473439e-05
, O 0 2.6279039957444184e-06
no O 0 7.361242069237051e-07
mutations O 0 2.550630142650334e-06
were O 0 1.3517632169168792e-07
detected O 0 6.884090453240788e-07
in O 0 2.0508879927660928e-08
the O 0 3.782130875151779e-08
p53 O 0 1.3261403637443436e-06
gene O 0 6.450159162341151e-07
, O 0 1.4306810669495462e-07
suggesting O 0 6.634238616243238e-07
that O 0 5.5184404601504866e-08
this O 0 3.4951659699800075e-07
tumour B-Disease 1 0.9916404485702515
suppressor O 0 8.062939014052972e-05
is O 0 1.8425961911816557e-07
not O 0 9.676724488372201e-08
frequently O 0 3.6238964185031364e-07
altered O 0 1.1804245332314167e-06
in O 0 4.2742792061289947e-07
this O 0 3.6855487905995687e-06
leukaemia B-Disease 1 0.9658201932907104
. O 0 3.0884912121109664e-05

Occasional O 0 0.0005007080617360771
missense O 0 0.004371159709990025
mutations O 0 0.00014627695782110095
in O 0 1.924337766467943e-06
ATM O 0 0.00014325261872727424
were O 0 3.851104395380389e-07
also O 0 1.960468409833993e-07
found O 0 4.929095211991807e-07
in O 0 9.610843108021072e-07
tumour B-Disease 1 0.9990071654319763
DNA O 0 0.00045204965863376856
from O 0 2.4520679744455265e-06
patients O 0 4.07900006393902e-05
with O 0 4.425366739724268e-07
B B-Disease 0 0.0005824695690535009
- I-Disease 0 0.003341828240081668
cell I-Disease 0 0.00031655305065214634
non I-Disease 0 7.13193803676404e-05
- I-Disease 1 0.9962789416313171
Hodgkins I-Disease 1 0.9999954700469971
lymphomas I-Disease 1 0.9974708557128906
( O 0 5.838292054249905e-07
B B-Disease 0 5.444983980851248e-05
- I-Disease 0 5.611438973573968e-05
NHL I-Disease 0 9.476714808442921e-07
) O 0 4.2144943535049606e-08
and O 0 3.748506216538772e-08
a O 0 2.0605067163614876e-07
B B-Disease 0 7.430192636093125e-05
- I-Disease 0 0.0001266699837287888
NHL I-Disease 0 1.0037959327746648e-05
cell O 0 3.725116403074935e-05
line O 0 1.0573122381174471e-05
. O 0 5.114548002893571e-06

The O 0 9.594748007657472e-06
evidence O 0 4.739392352348659e-06
of O 0 2.7353462428436615e-07
a O 0 3.183829733188759e-07
significant O 0 5.558783868764294e-07
proportion O 0 7.619630082444928e-07
of O 0 1.8015765590462252e-07
loss O 0 4.0015424019657075e-05
- O 0 0.0002458345261402428
of O 0 5.513431915460387e-07
- O 0 0.0030207382515072823
function O 0 9.537588994135149e-07
mutations O 0 7.66995015055727e-07
and O 0 5.7570606060153295e-08
a O 0 1.0013629037075589e-07
complete O 0 1.1991517112619476e-06
absence O 0 6.048804266356456e-07
of O 0 3.9249108851890924e-08
the O 0 5.2086750912394564e-08
normal O 0 3.0550631890946534e-07
copy O 0 2.610819933579478e-07
of O 0 3.7589234835877505e-08
ATM O 0 1.3062731341051403e-05
in O 0 2.7293207693901422e-08
the O 0 2.8515012573393506e-08
majority O 0 3.223184990019945e-07
of O 0 1.942121912179573e-07
mutated O 0 8.818670903565362e-05
tumours B-Disease 1 0.9746400713920593
establishes O 0 9.943881195795257e-06
somatic O 0 2.5453824491705745e-05
inactivation O 0 0.0009407878969796002
of O 0 1.0425802088320779e-07
this O 0 8.461886125132878e-08
gene O 0 6.935443934708019e-07
in O 0 6.565594645735473e-08
the O 0 6.029251409245262e-08
pathogenesis O 0 2.0593784938682802e-05
of O 0 1.894393761858737e-07
sporadic B-Disease 0 9.991373372031376e-05
T I-Disease 1 0.8443477153778076
- I-Disease 0 0.0022065979428589344
PLL I-Disease 0 0.0010100395884364843
and O 0 6.910289016559545e-07
suggests O 0 7.014560310381057e-07
that O 0 6.946618213987676e-08
ATM O 0 1.4077476407692302e-05
acts O 0 4.714620729373564e-07
as O 0 2.9085526875860523e-07
a O 0 6.421162652259227e-06
tumour B-Disease 1 0.998138427734375
suppressor O 0 0.0014500622637569904
. O 0 2.0693318219855428e-05

As O 0 1.825549770728685e-05
constitutional O 0 3.345949517097324e-05
DNA O 0 8.845183765515685e-05
was O 0 1.1951512988161994e-06
not O 0 1.9886255131496e-07
available O 0 2.456243066717434e-07
, O 0 2.795183604575868e-07
a O 0 7.371105539277778e-07
putative O 0 0.0014660994056612253
hereditary O 0 0.07658522576093674
predisposition O 0 0.03401864692568779
to O 0 8.611092198407277e-06
T B-Disease 1 0.9382915496826172
- I-Disease 0 0.004190115723758936
PLL I-Disease 0 0.0002730398264247924
will O 0 2.222173378640946e-07
require O 0 2.7943602276536694e-07
further O 0 2.5239884848815564e-07
investigation O 0 5.478976163431071e-06
. O 0 1.7154750366898952e-06
. O 0 8.1873222370632e-06

Myotonic B-Disease 1 0.9999517202377319
dystrophy I-Disease 1 0.9997844099998474
protein O 0 0.00014833126624580473
kinase O 0 0.00011232735414523631
is O 0 8.86928035015444e-07
involved O 0 4.907088850814034e-07
in O 0 5.261355440211446e-08
the O 0 2.4568914014366783e-08
modulation O 0 3.510867543354834e-07
of O 0 7.36875875873011e-08
the O 0 2.469372475388809e-07
Ca2 O 0 0.00016896968008950353
+ O 0 0.0002554680686444044
homeostasis O 0 0.000906962261069566
in O 0 6.5063695728895254e-06
skeletal O 0 0.06389728933572769
muscle O 0 0.00494614290073514
cells O 0 0.00022831653768662363
. O 0 3.2630367059027776e-05

Myotonic B-Disease 1 0.9999747276306152
dystrophy I-Disease 1 0.9999856948852539
( O 0 0.0034670159220695496
DM B-Disease 1 0.9999847412109375
) O 0 1.6126488844747655e-05
, O 0 9.582006441632984e-07
the O 0 3.67892226904587e-07
most O 0 1.676901433711464e-06
prevalent O 0 0.0017654940020292997
muscular B-Disease 1 0.9992745518684387
disorder I-Disease 1 0.9914708733558655
in O 0 6.590043540199986e-06
adults O 0 0.0003556614392437041
, O 0 1.932834948092932e-06
is O 0 5.433060437098902e-07
caused O 0 2.250919578727917e-06
by O 0 1.5812683784588444e-07
( O 0 2.6220808990728983e-07
CTG O 0 0.00020225186017341912
) O 0 1.7068458646463114e-07
n O 0 1.4992842807259876e-05
- O 0 1.2518839866970666e-05
repeat O 0 7.458490927092498e-07
expansion O 0 2.319311533938162e-07
in O 0 1.8004373103508442e-08
a O 0 2.5293614314136903e-08
gene O 0 1.2723113229640148e-07
encoding O 0 1.6765052635037136e-07
a O 0 6.684971509685056e-08
protein O 0 4.993608513359504e-07
kinase O 0 3.7076631542731775e-06
( O 0 4.2623810259101447e-07
DM B-Disease 1 0.7195537686347961
protein O 0 1.144462316915451e-06
kinase O 0 3.74785986423376e-06
; O 0 4.37196177927035e-07
DMPK O 0 0.0001983458350878209
) O 0 5.2418826612665725e-08
and O 0 3.51444420232383e-08
involves O 0 2.4152009814315534e-07
changes O 0 1.6543316405659425e-07
in O 0 1.688971167368436e-07
cytoarchitecture O 0 0.00015877981786616147
and O 0 2.897483682318125e-06
ion O 0 0.0026221214793622494
homeostasis O 0 0.00581030547618866
. O 0 2.8563990781549364e-05

To O 0 1.192530726257246e-05
obtain O 0 1.804639759939164e-05
clues O 0 5.995369974698406e-06
to O 0 2.1319117138318688e-07
the O 0 1.0488389534657472e-07
normal O 0 5.39360769380437e-07
biological O 0 4.7141440973064164e-07
role O 0 6.906508787096755e-08
of O 0 4.9631328380428386e-08
DMPK O 0 0.000400456425268203
in O 0 2.1939459315944987e-07
cellular O 0 1.6104711903608404e-05
ion O 0 0.0002251008409075439
homeostasis O 0 0.0004819321329705417
, O 0 3.6140119163974305e-07
we O 0 1.3101950457894418e-07
have O 0 3.5976633228074206e-08
compared O 0 2.2741527061498346e-07
the O 0 4.57757529659375e-08
resting O 0 1.1464655472082086e-05
[ O 0 1.9146996237395797e-06
Ca2 O 0 1.261254965356784e-05
+ O 0 2.537430736992974e-05
] O 0 6.330456926662009e-06
i O 0 3.798846819336177e-07
, O 0 2.7436900751354187e-08
the O 0 1.6159653171143873e-08
amplitude O 0 2.51190499511722e-07
and O 0 2.764454976045272e-08
shape O 0 2.628249546887673e-07
of O 0 6.533776542028136e-08
depolarization O 0 7.305358303710818e-05
- O 0 0.005852184724062681
induced O 0 0.0007740893634036183
Ca2 O 0 0.00016229180619120598
+ O 0 0.0001724860048852861
transients O 0 0.00014210722292773426
, O 0 1.1216528861268671e-07
and O 0 2.58957051357811e-08
the O 0 1.4083332722236719e-08
content O 0 3.519025781884011e-08
of O 0 1.9125861783209075e-08
ATP O 0 3.4133515782741597e-06
- O 0 4.361556420917623e-06
driven O 0 6.904492693138309e-07
ion O 0 9.681700248620473e-06
pumps O 0 3.1187180411507143e-06
in O 0 2.764722069059644e-07
cultured O 0 3.422766531002708e-05
skeletal O 0 0.0002875695936381817
muscle O 0 4.4481890654424205e-05
cells O 0 2.645848780957749e-06
of O 0 1.0708706099649135e-07
wild O 0 2.6773948320624186e-06
- O 0 0.00011351188732078299
type O 0 1.9851422621286474e-06
and O 0 3.2927803772508923e-07
DMPK O 0 0.0012043144088238478
[ O 0 6.763139481336111e-06
- O 0 0.00014034222112968564
/ O 0 7.070275751175359e-05
- O 0 0.0004905552486889064
] O 0 3.968616874772124e-05
knockout O 0 0.0005739857442677021
mice O 0 0.00013069860870018601
. O 0 1.120841898227809e-05

In O 0 2.9231201551738195e-05
vitro O 0 0.00041486878762952983
- O 0 0.00047270304639823735
differentiated O 0 3.3581927709747106e-05
DMPK O 0 0.002425585640594363
[ O 0 1.1920645192731172e-05
- O 0 0.00016074356972239912
/ O 0 4.36399677710142e-05
- O 0 9.602528007235378e-05
] O 0 5.854416940564988e-06
myotubes O 0 3.080831447732635e-05
exhibit O 0 1.500091912021162e-06
a O 0 3.8253753587014216e-07
higher O 0 1.1624650824160199e-06
resting O 0 2.08052388188662e-05
[ O 0 2.6920140498987166e-06
Ca2 O 0 2.480565854057204e-05
+ O 0 1.9152208551531658e-05
] O 0 1.9991134649899323e-06
i O 0 1.8634824527907767e-07
than O 0 4.973699319066327e-08
do O 0 9.568896075506927e-08
wild O 0 5.998447818456043e-07
- O 0 6.119718455011025e-05
type O 0 2.0121804482187144e-05
myotubes O 0 0.0006943352054804564
because O 0 1.910752729372689e-07
of O 0 2.0280463530752968e-08
an O 0 3.262329073550063e-08
altered O 0 5.84382348733925e-07
open O 0 2.666661487182864e-07
probability O 0 1.4344819021516741e-07
of O 0 3.687625849124743e-08
voltage O 0 1.5204691408143844e-06
- O 0 2.5351595468237065e-05
dependent O 0 2.1990581444697455e-06
l O 0 5.117730688652955e-05
- O 0 2.9694481781916693e-05
type O 0 2.499508127584704e-06
Ca2 O 0 1.5360552424681373e-05
+ O 0 8.353260454896372e-06
and O 0 6.480501042460673e-07
Na O 0 9.489570948062465e-05
+ O 0 1.8878949049394578e-05
channels O 0 4.634380275092553e-06
. O 0 5.900237283640308e-06

The O 0 1.787323890312109e-05
mutant O 0 7.440146146109328e-05
myotubes O 0 0.0007044636877253652
exhibit O 0 9.700851478555705e-06
smaller O 0 2.272163555971929e-06
and O 0 2.948827386717312e-07
slower O 0 4.4929997784493025e-06
Ca2 O 0 4.525832991930656e-05
+ O 0 1.037422043737024e-05
responses O 0 6.23832022483839e-07
upon O 0 2.012206863355459e-07
triggering O 0 3.906943675247021e-06
by O 0 2.918886821134947e-07
acetylcholine O 0 2.1344279957702383e-05
or O 0 5.359138413041364e-07
high O 0 3.892944278049981e-06
external O 0 9.198478437610902e-06
K O 0 0.00028074393048882484
+ O 0 8.003455877769738e-05
. O 0 7.524350621679332e-06

In O 0 1.3362723620957695e-05
addition O 0 4.355380042397883e-06
, O 0 8.883637860890303e-07
we O 0 1.481080573739746e-07
observed O 0 2.8839562560278864e-07
that O 0 2.7004835700950025e-08
these O 0 7.210881847186101e-08
Ca2 O 0 4.144338527112268e-05
+ O 0 5.5792799685150385e-05
transients O 0 8.076905942289159e-05
partially O 0 2.699350943657919e-06
result O 0 1.0734820676816526e-07
from O 0 3.6606177644671334e-08
an O 0 1.4131066983225082e-08
influx O 0 1.2129972049024218e-07
of O 0 1.8429261672281427e-08
extracellular O 0 1.2976039442946785e-06
Ca2 O 0 7.648827704542782e-06
+ O 0 2.06820186576806e-06
through O 0 7.217417419269623e-08
the O 0 1.7456470402521518e-07
l O 0 5.96223289903719e-05
- O 0 7.603617268614471e-05
type O 0 1.519556280982215e-05
Ca2 O 0 6.946364737814292e-05
+ O 0 2.445810241624713e-05
channel O 0 1.669939956627786e-05
. O 0 8.006815733097028e-06

Neither O 0 4.5807657443219796e-05
the O 0 1.258706674889254e-06
content O 0 1.2432715266186278e-06
nor O 0 8.952799248618248e-07
the O 0 4.453116986269379e-08
activity O 0 1.7152741804693505e-07
of O 0 1.0923645277216565e-07
Na O 0 0.000113905050966423
+ O 0 2.8064394427929074e-05
/ O 0 8.433368748228531e-06
K O 0 1.1429851838329341e-05
+ O 0 5.596824394160649e-06
ATPase O 0 1.5581505067530088e-05
and O 0 7.426523325193557e-07
sarcoplasmic O 0 0.00024508844944648445
reticulum O 0 0.00015380566765088588
Ca2 O 0 0.00018935090338345617
+ O 0 6.0967850004089996e-05
- O 0 3.0400125979213044e-05
ATPase O 0 4.492456355364993e-05
are O 0 2.3448679087323399e-07
affected O 0 1.159721136900771e-06
by O 0 8.71774659572111e-07
DMPK O 0 0.00522043788805604
absence O 0 3.7610898289131e-05
. O 0 2.3825243260944262e-05

In O 0 1.5173347492236644e-05
conclusion O 0 1.1541445019247476e-05
, O 0 8.258867296717654e-07
our O 0 3.20642101314661e-07
data O 0 4.0700174963603786e-07
suggest O 0 6.083701009629294e-07
that O 0 9.196087802365582e-08
DMPK O 0 0.0002313738368684426
is O 0 1.10580188561471e-07
involved O 0 1.5072748738020891e-07
in O 0 6.435978150420851e-08
modulating O 0 4.590568551066099e-06
the O 0 8.868876477663434e-08
initial O 0 4.2123809862459893e-07
events O 0 8.527375428002415e-08
of O 0 7.26678663909297e-08
excitation O 0 6.0511688388942275e-06
- O 0 0.0002816329069901258
contraction O 0 2.619721090013627e-05
coupling O 0 1.2920365406898782e-05
in O 0 1.757089194143191e-06
skeletal O 0 0.008184595964848995
muscle O 0 0.00035625597229227424
. O 0 4.654711119655985e-06
. O 0 2.6760144464788027e-05

Constitutional O 0 0.0009080652380362153
RB1 O 1 0.7824398279190063
- O 0 0.008634629659354687
gene O 0 0.00020522045088000596
mutations O 0 0.0002034442441072315
in O 0 1.531325324322097e-05
patients O 0 0.0016965873073786497
with O 0 1.1002516657754313e-05
isolated O 0 0.002266501309350133
unilateral B-Disease 0 0.005008663982152939
retinoblastoma I-Disease 1 0.9594884514808655
. O 0 0.00011359580821590498

In O 0 5.628251165035181e-05
most O 0 3.113984712399542e-05
patients O 0 0.0018974491395056248
with O 0 3.2926402582234005e-06
isolated O 0 0.00012573205458465964
unilateral B-Disease 0 0.00024707429111003876
retinoblastoma I-Disease 1 0.6815295815467834
, O 0 1.2523927580332384e-05
tumor B-Disease 0 0.008964164182543755
development O 0 6.97598750321049e-07
is O 0 1.0386007431861799e-07
initiated O 0 8.157076649695227e-07
by O 0 1.527799184941614e-07
somatic O 0 7.88087800174253e-06
inactivation O 0 0.0008379630744457245
of O 0 1.535242262207248e-07
both O 0 1.73203744679995e-07
alleles O 0 8.63464094891242e-07
of O 0 2.0932321831423906e-07
the O 0 3.0636456358479336e-06
RB1 O 0 0.1275208443403244
gene O 0 2.8215879865456372e-05
. O 0 1.933462408487685e-05

However O 0 2.531753125367686e-05
, O 0 1.7584235365575296e-06
some O 0 1.4668187020561163e-07
of O 0 1.5748032922147104e-07
these O 0 7.623576721016434e-07
patients O 0 0.00020083940762560815
can O 0 9.932913371812901e-07
transmit O 0 0.0002671344263944775
retinoblastoma B-Disease 1 0.8623959422111511
predisposition O 0 0.014425395056605339
to O 0 1.3141886938683456e-06
their O 0 1.7599503507881309e-06
offspring O 0 9.408209007233381e-05
. O 0 1.46867023431696e-05

To O 0 1.3387634680839255e-05
determine O 0 3.838596512650838e-06
the O 0 3.248762254770554e-07
frequency O 0 1.0604430826788303e-06
and O 0 2.0761446251071902e-07
nature O 0 2.7190387186237785e-07
of O 0 1.5688910082189977e-07
constitutional O 0 6.762468728993554e-06
RB1 O 0 0.4366334080696106
- O 0 0.005079453811049461
gene O 0 2.2468560928246006e-05
mutations O 0 1.8067750715999864e-05
in O 0 1.2015636912110494e-06
patients O 0 6.924547051312402e-05
with O 0 7.271950721587928e-07
isolated O 0 3.524851854308508e-05
unilateral B-Disease 0 9.168151154881343e-05
retinoblastoma I-Disease 0 0.008748091757297516
, O 0 5.233331989984435e-07
we O 0 1.7371408489452733e-07
analyzed O 0 1.1464045428510872e-06
DNA O 0 2.554909997343202e-06
from O 0 2.3960311068549345e-07
peripheral O 0 0.00012230631546117365
blood O 0 4.561249807011336e-05
and O 0 1.1581782928260509e-06
from O 0 8.890240678738337e-06
tumor B-Disease 1 0.7974656224250793
tissue O 0 0.0018880265997722745
. O 0 2.6522748157731257e-05

The O 0 4.3672130232152995e-06
analysis O 0 4.60405044577783e-06
of O 0 2.846192501237965e-06
tumors B-Disease 1 0.9989105463027954
from O 0 6.131263603492698e-07
54 O 0 6.889535143272951e-06
( O 0 2.0297186154039082e-07
71 O 0 2.9092232125549344e-06
% O 0 8.739608858832071e-08
) O 0 1.7836377708135842e-08
of O 0 2.4826636746411168e-08
76 O 0 1.2640099157579243e-05
informative O 0 0.00011279598402325064
patients O 0 0.0007556644268333912
showed O 0 1.0447251042933203e-05
loss O 0 7.751803423161618e-06
of O 0 3.7152872778278834e-07
constitutional O 0 3.962215123465285e-05
heterozygosity O 0 0.11232783645391464
( O 0 1.3339270481083076e-05
LOH O 1 0.9987115859985352
) O 0 1.0740837979028584e-06
at O 0 3.356307843205286e-06
intragenic O 0 0.0005816624034196138
loci O 0 5.013219561078586e-05
. O 0 1.612185951671563e-05

Three O 0 1.0624125025060493e-05
of O 0 4.55159715784248e-06
13 O 0 4.7715806431369856e-05
uninformative O 1 0.9285581111907959
patients O 0 0.024592135101556778
had O 0 5.3596108955389354e-06
constitutional O 0 4.3110878323204815e-05
deletions O 0 0.0010082349181175232
. O 0 6.359528924804181e-05

For O 0 1.7861806554719806e-05
39 O 0 2.952339855255559e-05
randomly O 0 1.1235933925490826e-05
selected O 0 1.219891055370681e-05
tumors B-Disease 1 0.9933416247367859
, O 0 1.665239324211143e-06
SSCP O 0 0.010813994333148003
, O 0 2.036051682807738e-06
hetero O 0 0.005971395876258612
- O 0 0.00023435427283402532
duplex O 0 0.000645197054836899
analysis O 0 7.749075052743137e-07
, O 0 1.2995279519145697e-07
sequencing O 0 8.22254321519722e-07
, O 0 8.720260069594588e-08
and O 0 4.958449295600076e-08
Southern O 0 2.192929144939626e-07
blot O 0 1.3827477232553065e-05
analysis O 0 3.4492578038225474e-07
were O 0 8.764916969994374e-08
used O 0 1.554136304093845e-07
to O 0 4.2247364717695746e-07
identify O 0 8.185104888980277e-06
mutations O 0 2.08237579499837e-05
. O 0 6.975873930059606e-06

Mutations O 0 0.00044337051804177463
were O 0 4.702847036242019e-06
detected O 0 6.101036433392437e-06
in O 0 1.9083341840087087e-07
21 O 0 6.977131761232158e-07
( O 0 1.6572545291637653e-07
91 O 0 1.7201736000060919e-06
% O 0 1.404216618539067e-07
) O 0 5.7843898559895024e-08
of O 0 2.3526115455752006e-07
23 O 0 9.990239777835086e-05
tumors B-Disease 1 0.9990609288215637
with O 0 4.1892639274010435e-05
LOH O 1 0.999634861946106
. O 0 5.65135596843902e-05

In O 0 8.34790898807114e-06
6 O 0 9.362597666040529e-06
( O 0 3.631971878803597e-07
38 O 0 8.631412811155315e-07
% O 0 1.0197602762218594e-07
) O 0 3.0984708132564265e-08
of O 0 3.6735574582280606e-08
16 O 0 7.249782356666401e-06
tumors B-Disease 1 0.9983547329902649
without O 0 1.3754380233876873e-05
LOH O 1 0.99986732006073
, O 0 1.050971150107216e-06
one O 0 2.152966374069365e-07
mutation O 0 1.4345820318339975e-06
was O 0 1.686304216264034e-07
detected O 0 1.534181137685664e-06
, O 0 6.111968531286038e-08
and O 0 4.459194258288335e-08
in O 0 3.7364429772424046e-08
9 O 0 4.829799422623182e-07
( O 0 5.793919299890149e-08
56 O 0 6.490143391602032e-07
% O 0 6.469355895433182e-08
) O 0 1.7042426136981703e-08
of O 0 3.1972778202771224e-08
the O 0 6.514154051728838e-07
tumors B-Disease 1 0.999560534954071
without O 0 3.187597030773759e-05
LOH O 1 0.9999605417251587
, O 0 1.5748393025205587e-06
both O 0 3.669720172183588e-07
mutations O 0 4.088760306331096e-06
were O 0 4.273150295830419e-07
found O 0 2.351932153032976e-06
. O 0 5.32807462150231e-06

Thus O 0 7.258819096023217e-05
, O 0 2.7455439521872904e-06
a O 0 3.573144624624547e-07
total O 0 1.3401863441231399e-07
of O 0 9.718804960812122e-08
45 O 0 1.4457590395977604e-06
mutations O 0 1.7363139477311051e-06
were O 0 2.256635838193688e-07
identified O 0 3.7013994642620673e-06
in O 0 2.624843318699277e-06
tumors B-Disease 1 0.996245801448822
of O 0 1.8707469280343503e-06
36 O 0 0.0005407875287346542
patients O 0 0.0022605848498642445
. O 0 2.376438533246983e-05

Thirty O 0 0.00017932915943674743
- O 0 0.00012959339073859155
nine O 0 1.5576872556266608e-06
of O 0 1.2264509052783978e-07
the O 0 1.198982033656648e-07
mutations O 0 1.7352974737150362e-06
- O 0 1.8504711988498457e-05
including O 0 4.7161495331238257e-07
34 O 0 1.7137173244918813e-06
small O 0 8.631305945527856e-07
mutations O 0 1.4180714060785249e-06
, O 0 1.0057424049136898e-07
2 O 0 2.5226529487554217e-07
large O 0 3.686641889544262e-07
structural O 0 5.9212684391241055e-06
alterations O 0 5.062502623331966e-06
, O 0 2.5055123842321336e-07
and O 0 2.640064167280798e-07
hypermethylation O 0 0.006047278176993132
in O 0 5.309442485668114e-07
3 O 0 7.501758227590472e-05
tumors O 1 0.9998657703399658
- O 0 0.0002113788650603965
were O 0 8.76724044474031e-08
not O 0 7.15344228296999e-08
detected O 0 9.636266895540757e-07
in O 0 3.046700314257578e-08
the O 0 8.609136870063594e-08
corresponding O 0 2.040082790699671e-06
peripheral O 0 0.0002815671032294631
blood O 0 0.00015517917927354574
DNA O 0 0.00013205205323174596
. O 0 1.6278421753668226e-05

In O 0 1.5577938029309735e-05
6 O 0 1.2501755008997861e-05
( O 0 6.68382313051552e-07
17 O 0 7.300321271941357e-07
% O 0 9.579724746799911e-08
) O 0 1.9959266239766293e-08
of O 0 1.8944472657267397e-08
the O 0 8.0773759236763e-08
36 O 0 1.6895019143703394e-05
patients O 0 0.00010252289939671755
, O 0 2.183324028237621e-07
a O 0 2.7552752612791664e-07
mutation O 0 1.1976853784290142e-06
was O 0 2.010311845879187e-07
detected O 0 1.0080698302772362e-06
in O 0 3.992746044900741e-08
constitutional O 0 5.633214641420636e-07
DNA O 0 8.163293387042359e-06
, O 0 1.2621190137451777e-07
and O 0 4.175297263486755e-08
1 O 0 1.0136691486195559e-07
of O 0 1.5955281540414035e-08
these O 0 3.528737835267748e-08
mutations O 0 4.5499464818021806e-07
is O 0 3.114783453384007e-08
known O 0 7.386911704543309e-08
to O 0 3.8922056688761586e-08
be O 0 9.716432458617419e-08
associated O 0 9.188976264340454e-07
with O 0 1.2150759403084521e-06
reduced O 0 5.283248538034968e-05
expressivity O 0 0.02972349151968956
. O 0 2.5035587896127254e-05

The O 0 8.744410479266662e-06
presence O 0 5.971284281258704e-06
of O 0 4.7538188141516e-07
a O 0 5.771286168965162e-07
constitutional O 0 4.208440259390045e-06
mutation O 0 6.784749075450236e-06
was O 0 7.179159524639545e-07
not O 0 2.2682417011310463e-07
associated O 0 4.0262463585349906e-07
with O 0 7.888398556588072e-08
an O 0 7.224166154173872e-08
early O 0 1.879043338703923e-06
age O 0 8.491103471897077e-06
at O 0 1.2372331184451468e-05
treatment O 0 0.0002725487865973264
. O 0 1.2701920240942854e-05

In O 0 3.421239307499491e-05
1 O 0 3.2481686503160745e-05
patient O 0 0.0004969355650246143
, O 0 2.226656761195045e-06
somatic O 0 0.00030631900881417096
mosaicism O 1 0.7374333143234253
was O 0 4.831015303352615e-06
demonstrated O 0 1.9037657921217033e-06
by O 0 1.221296628273194e-07
molecular O 0 7.130529979804123e-07
analysis O 0 1.3310891233686561e-07
of O 0 4.6604132108996055e-08
DNA O 0 5.56947770746774e-06
and O 0 3.424348449243553e-07
RNA O 0 1.7815860928749316e-06
from O 0 1.069372046913486e-06
peripheral O 0 0.0004848044482059777
blood O 0 0.00017332534480374306
. O 0 1.8308393919141963e-05

In O 0 6.13977390457876e-05
2 O 0 0.00013806424976792186
patients O 0 0.001121139619499445
without O 0 1.5701169786552782e-06
a O 0 2.8675665362243308e-06
detectable O 0 0.00012620844063349068
mutation O 0 3.5015523280890193e-06
in O 0 4.4098587181906623e-07
peripheral O 0 0.0003132936835754663
blood O 0 0.00013871639384888113
, O 0 1.8138716768589802e-06
mosaicism O 0 0.04360446333885193
was O 0 1.3240287444205023e-06
suggested O 0 1.3351082088775001e-06
because O 0 1.4175967066876183e-07
1 O 0 1.6301227390158601e-07
of O 0 7.529718004661845e-08
the O 0 8.840737564241863e-07
patients O 0 0.0018453598022460938
showed O 0 0.0029972228221595287
multifocal O 1 0.9999569654464722
tumors B-Disease 1 0.9999549388885498
and O 0 5.683024255631608e-07
the O 0 8.95351917051812e-08
other O 0 8.222592384754535e-08
later O 0 4.3797322746286227e-07
developed O 0 3.075237373195705e-06
bilateral B-Disease 0 7.011232810327783e-05
retinoblastoma I-Disease 0 0.14235703647136688
. O 0 3.675236439448781e-05

In O 0 1.644381154619623e-05
conclusion O 0 1.07340110844234e-05
, O 0 9.023352731674095e-07
our O 0 4.4495260453913943e-07
results O 0 5.967681886431819e-07
emphasize O 0 1.3179012512409827e-06
that O 0 7.502035970219367e-08
the O 0 1.106445424170488e-07
manifestation O 0 3.1876015782472678e-06
and O 0 3.730201854068582e-07
transmissibility O 0 7.426777301589027e-05
of O 0 2.6376912387604534e-07
retinoblastoma B-Disease 0 0.0018506549531593919
depend O 0 1.1724351907105302e-06
on O 0 2.1379523218456598e-07
the O 0 5.773400602038237e-08
nature O 0 1.1021149504131245e-07
of O 0 3.220910471668503e-08
the O 0 3.508109003291793e-08
first O 0 5.817294734811185e-08
mutation O 0 4.2904107999675034e-07
, O 0 3.592458952539346e-08
its O 0 1.6722522033774112e-08
time O 0 2.3860975417733243e-08
in O 0 2.187694114752503e-08
development O 0 7.499361487361966e-08
, O 0 5.5778162533215436e-08
and O 0 2.7446532158137416e-08
the O 0 9.861500060992512e-09
number O 0 2.128295228942534e-08
and O 0 4.070781400855594e-08
types O 0 1.5670293862513063e-07
of O 0 6.646562411560808e-08
cells O 0 2.6837728910322767e-06
that O 0 6.51149534292017e-08
are O 0 1.7178852829147218e-07
affected O 0 2.4588123324065236e-06
. O 0 9.822605306908372e-07
. O 0 5.861125828232616e-06

Hereditary B-Disease 1 0.9999526739120483
deficiency I-Disease 1 0.9996768236160278
of I-Disease 0 3.04645595861075e-06
the I-Disease 0 2.0371296614030143e-06
fifth I-Disease 0 6.4112191466847435e-06
component I-Disease 0 2.6250686460116412e-06
of I-Disease 0 2.604155895369331e-07
complement I-Disease 0 3.439122338022571e-06
in O 0 1.5826896060389117e-06
man O 0 2.6820234779734164e-05
. O 0 1.7842041415860876e-05

I O 0 0.00272250734269619
. O 0 0.0004752224194817245

Clinical O 0 0.05120303854346275
, O 0 2.8768807169399224e-05
immunochemical O 0 0.009088368155062199
, O 0 3.100675485256943e-06
and O 0 2.1753169221483404e-06
family O 0 9.117162335314788e-06
studies O 0 1.1508812349347863e-05
. O 0 2.2683858333039097e-05

The O 0 1.0173906957788859e-05
first O 0 2.8531278530863347e-06
recognized O 0 3.41971804118657e-06
human O 0 3.967390966863604e-06
kindred O 0 0.020412035286426544
with O 0 0.0015616874443367124
hereditary B-Disease 1 0.9999445676803589
deficiency I-Disease 1 0.9957297444343567
of I-Disease 0 4.048922335186944e-07
the I-Disease 0 2.1020102280999708e-07
fifth I-Disease 0 3.088522362304502e-06
component I-Disease 0 1.7491911421529949e-06
of I-Disease 0 1.1319853143731962e-07
complement I-Disease 0 2.533869746912387e-06
( O 0 5.650340426655021e-07
C5 O 0 0.00031334179220721126
) O 0 3.5544209708859853e-07
is O 0 4.188906075341947e-07
described O 0 9.80085133051034e-06
. O 0 1.1415113476687111e-05

The O 0 3.8327671063598245e-05
proband O 0 0.002016949001699686
, O 0 2.9580787668237463e-06
a O 0 8.014874310902087e-07
20 O 0 8.480837436763977e-07
- O 0 4.9137106543639675e-05
year O 0 2.2667461507808184e-06
- O 0 0.0004564483533613384
old O 0 4.7582172555848956e-05
black O 0 7.249659392982721e-05
female O 0 1.8245820683659986e-05
with O 0 0.003507094457745552
systemic B-Disease 1 0.999998927116394
lupus I-Disease 1 0.9999996423721313
erythematosus I-Disease 1 0.9999966621398926
since O 0 5.973039515083656e-05
age O 0 3.233106326661073e-05
11 O 0 6.326696166070178e-06
, O 0 2.4558312361477874e-06
lacked O 0 0.0004057112382724881
serum O 0 0.1922534704208374
hemolytic O 1 0.9816101789474487
complement O 0 2.3865879938966827e-06
activity O 0 1.2380844509607414e-06
, O 0 3.2468602739754715e-07
even O 0 4.3215629830228863e-07
during O 0 4.707823791250121e-06
remission O 0 0.0031760712154209614
. O 0 1.8995720893144608e-05

C5 O 0 0.02006876841187477
was O 0 0.00010610854951664805
undetectable O 0 0.001253754016943276
in O 0 2.060437282125349e-06
her O 0 4.8666684051568154e-06
serum O 0 4.324585825088434e-05
by O 0 3.648538324796391e-07
both O 0 6.026377263879112e-07
immunodiffusion O 0 0.016373969614505768
and O 0 5.6292708904948086e-05
hemolytic O 1 0.9995841383934021
assays O 0 0.000727752863895148
. O 0 2.1910571376793087e-05

Other O 0 1.2322734619374387e-05
complement O 0 1.2484038961702026e-05
components O 0 6.357918664434692e-06
were O 0 4.2187332383036846e-07
normal O 0 1.096919845622324e-06
during O 0 1.361908289254643e-06
remission O 0 0.00018567239749245346
of O 0 5.851838068338111e-06
lupus O 1 0.9995560050010681
, O 0 2.5040508262463845e-06
but O 0 9.613428346710862e-07
C1 O 0 0.0010368485236540437
, O 0 5.668701987815439e-07
C4 O 0 0.00014908520097378641
, O 0 1.4915455039954395e-06
C2 O 0 0.0001934609463205561
, O 0 2.1186278331697395e-07
and O 0 4.264223036898329e-07
C3 O 0 0.007428446318954229
levels O 0 4.65440052721533e-06
fell O 0 5.757187682320364e-05
during O 0 1.384848656016402e-05
exacerbations O 0 0.08827619254589081
. O 0 2.3130098270485178e-05

A O 0 9.323203266831115e-05
younger O 0 8.559516572859138e-05
half O 0 1.559177690069191e-05
- O 0 0.00534848915413022
sister O 0 0.00035837857285514474
, O 0 3.0784622140345164e-06
who O 0 2.215958829765441e-06
had O 0 1.3635770983455586e-06
no O 0 6.87298552293214e-06
underlying O 0 0.0706237256526947
disease O 0 0.009035381488502026
, O 0 6.872230642329669e-07
was O 0 4.756177247600135e-07
also O 0 1.745843434264316e-07
found O 0 3.8301681115626707e-07
to O 0 4.4339253690850455e-07
lack O 0 1.8574548448668793e-05
immunochemically O 0 0.4146135449409485
detectable O 0 0.001522486680187285
C5 O 0 0.0030523890163749456
. O 0 3.039606599486433e-05

By O 0 0.0004143419791944325
hemolytic O 1 0.999715268611908
assay O 0 0.0007351141539402306
, O 0 5.00961050420301e-06
she O 0 1.2814825822715648e-06
exhibited O 0 1.3012410136070685e-06
1 O 0 8.026340765354689e-07
- O 0 6.52084345347248e-05
2 O 0 4.1632742409092316e-07
% O 0 3.014957883351599e-08
of O 0 1.182842890301572e-08
the O 0 3.288643313226203e-08
normal O 0 4.0257856426251237e-07
serum O 0 1.2127745321777184e-05
C5 O 0 3.572193600120954e-05
level O 0 2.2671800081752735e-07
and O 0 5.4033705509937136e-08
normal O 0 2.2642261399141717e-07
concentrations O 0 6.638845775341906e-07
of O 0 4.4582588287767067e-08
other O 0 1.0110798598361725e-07
complement O 0 2.9282064133440144e-06
components O 0 1.130423515860457e-05
. O 0 7.501087111450033e-06

C5 O 0 0.0048623476177453995
levels O 0 2.6952149710268714e-05
of O 0 8.817338539302e-07
other O 0 3.3344173289151513e-07
family O 0 8.748854725126876e-07
members O 0 1.0599239885777934e-07
were O 0 6.091543980346614e-08
either O 0 1.0356512802900397e-07
normal O 0 1.9709553100710764e-07
or O 0 6.487272230515373e-08
approximately O 0 6.673989361161148e-08
half O 0 1.784993060027773e-07
- O 0 2.3442144083674066e-05
normal O 0 7.971447644194996e-07
, O 0 1.4860394514926156e-07
consistent O 0 4.884947202299372e-07
with O 0 1.157651468020049e-06
autosomal O 0 0.00043219246435910463
codominant O 0 0.04239438846707344
inheritance O 0 1.2843166587117594e-05
of O 0 2.2508520203246007e-07
the O 0 1.0618042551868712e-06
gene O 0 7.058695337036625e-05
determining O 0 0.0026252311654388905
C5 B-Disease 1 0.9999788999557495
deficiency I-Disease 1 0.9999287128448486
. O 0 9.531588148092851e-05

Normal O 0 0.019794218242168427
hemolytic O 1 0.9998683929443359
titers O 0 0.15761220455169678
were O 0 4.368112968222704e-06
restored O 0 6.434501301555429e-06
to O 0 4.865438540946343e-07
both O 0 1.1136285138491075e-06
homozygous O 0 0.00015508511569350958
C5 B-Disease 1 0.9987965822219849
- I-Disease 1 0.9994328618049622
deficient I-Disease 1 0.999454915523529
( O 0 4.778172296937555e-06
C5D B-Disease 1 0.9940361976623535
) O 0 5.340867801351123e-07
sera O 0 1.7918040612130426e-05
by O 0 7.34164018467709e-08
addition O 0 8.533216089290363e-08
of O 0 9.570648273893312e-08
highly O 0 2.7616836177912774e-06
purified O 0 3.779635881073773e-05
human O 0 8.241327122959774e-06
C5 O 0 0.002036420162767172
. O 0 2.5898756575770676e-05

In O 0 1.611767766007688e-05
specific O 0 8.554304258723278e-06
C5 O 0 0.0009706249693408608
titrations O 0 0.014296425506472588
, O 0 2.20884840018698e-06
however O 0 3.5317046354066406e-07
, O 0 1.2862685139225505e-07
it O 0 3.1210692696959086e-08
was O 0 1.2196589693758142e-07
noted O 0 1.0111993731243274e-07
that O 0 1.749696210140428e-08
when O 0 5.0146780949944514e-08
limited O 0 1.0389613436245781e-07
amounts O 0 1.3849243885033502e-07
of O 0 3.582619001463172e-08
C5 O 0 3.1718685931991786e-05
were O 0 7.520589662135535e-08
assayed O 0 2.664439534783014e-06
in O 0 3.8805012536613503e-08
the O 0 2.0606830020142297e-08
presence O 0 8.309526577932047e-08
of O 0 4.699152000853246e-08
low O 0 8.434205483354162e-06
dilutions O 0 5.742438224842772e-05
of O 0 1.2369875435069844e-07
either O 0 1.5475667396458448e-06
C5D B-Disease 1 0.995763897895813
serum O 0 0.00010758628195617348
, O 0 1.7179016253976442e-07
curving O 0 2.2480082861875417e-06
rather O 0 7.335887630688376e-08
than O 0 7.649723698932576e-08
linear O 0 3.960597496188711e-06
dose O 0 1.121866353059886e-05
- O 0 2.4521017621736974e-05
response O 0 5.942244456491608e-07
plots O 0 6.239129675122967e-07
were O 0 1.1009048250798514e-07
consistently O 0 6.548449391630129e-07
obtained O 0 1.354015921606333e-07
, O 0 1.0804621553006655e-07
suggesting O 0 6.635851832470507e-07
some O 0 1.9659766792301525e-07
inhibitory O 0 1.1002611245203298e-05
effect O 0 5.913559562031878e-06
. O 0 6.965909506106982e-06

Further O 0 2.4946713892859407e-05
studies O 0 9.48549040913349e-06
suggested O 0 4.864055881625973e-06
that O 0 3.0033359621484124e-07
low O 0 8.809649443719536e-06
dilutions O 0 0.00010809675586642697
of O 0 1.3370870419748826e-06
C5D B-Disease 1 0.9988738894462585
serum O 0 0.0002601474989205599
contain O 0 6.007063007018587e-07
a O 0 1.878257336329625e-07
factor O 0 4.4687223521577835e-07
( O 0 3.021745698106315e-08
or O 0 3.631133083104032e-08
factors O 0 5.1310038884366804e-08
) O 0 1.9912876680905356e-08
interfering O 0 2.821483917614387e-07
at O 0 8.89844429252662e-08
some O 0 1.288686757305868e-08
step O 0 4.3112757452945516e-07
in O 0 6.21925266841572e-08
the O 0 5.600479653367074e-07
hemolytic O 1 0.9447508454322815
assay O 0 4.148097559664166e-06
of O 0 1.9836080866753036e-07
C5 O 0 0.0003111941332463175
, O 0 3.0684330454278097e-07
rather O 0 1.6999483420931938e-07
than O 0 1.1747492578706442e-07
a O 0 2.712000082283339e-07
true O 0 2.698985326787806e-06
C5 O 0 0.002980944700539112
inhibitor O 0 0.0003173956065438688
or O 0 7.538794761785539e-06
inactivator O 0 0.0014107325114309788
. O 0 2.2326712496578693e-05

Of O 0 2.3298594896914437e-05
clinical O 0 0.0010573958279564977
interest O 0 1.0173237569688354e-05
are O 0 6.636402645199269e-07
( O 0 4.6804211706330534e-07
a O 0 3.414119191802456e-07
) O 0 7.755560460509514e-08
the O 0 4.3312585518151536e-08
documentation O 0 1.6113107221826795e-06
of O 0 1.4808856576564722e-06
membranous O 1 0.9992294311523438
glomerulonephritis B-Disease 1 0.9999969005584717
, O 0 0.0029223200399428606
vasculitis B-Disease 1 0.9999798536300659
, O 0 0.0002723954967223108
and O 0 0.08897493034601212
arthritis B-Disease 1 0.9999996423721313
in O 0 1.1108887747468543e-06
an O 0 1.7881652070173004e-07
individual O 0 3.4338319210291957e-07
lacking O 0 8.212009561248124e-06
C5 O 0 0.0014018259244039655
( O 0 2.0144534573773853e-07
and O 0 7.496143439311709e-08
its O 0 5.221486887307947e-08
biologic O 0 1.781592618499417e-05
functions O 0 9.178862825365286e-08
) O 0 4.513143636586392e-08
, O 0 8.060154499389682e-08
and O 0 5.2854748133768226e-08
( O 0 9.72125206999408e-08
b O 0 3.3996095680777216e-06
) O 0 4.4057724579715796e-08
a O 0 7.821816438990936e-08
remarkable O 0 1.503978069195e-06
propensity O 0 7.616222865181044e-05
to O 0 7.526525223511271e-06
bacterial B-Disease 1 0.9925414323806763
infections I-Disease 0 0.4791661500930786
in O 0 1.133211213755203e-07
the O 0 2.0646217535613687e-07
proband O 0 0.013610773719847202
, O 0 2.773084872842446e-07
even O 0 9.261128042226119e-08
during O 0 9.07529980054278e-08
periods O 0 2.4863533099050983e-07
of O 0 7.155490067134451e-08
low O 0 1.6737807527533732e-05
- O 0 0.00041954946937039495
dose O 0 7.531737992394483e-06
or O 0 2.2986087344634143e-07
alternate O 0 5.56974669052579e-07
- O 0 8.336635801242664e-05
day O 0 1.756394158292096e-05
corticosteroid O 0 0.017326736822724342
therapy O 0 0.0004188455641269684
. O 0 2.2939424525247887e-05

Other O 0 8.221436473832e-06
observations O 0 9.770242286322173e-06
indicate O 0 5.292019523039926e-06
that O 0 1.6255614809779217e-07
the O 0 4.2687065615609754e-07
C5D B-Disease 1 0.9875898361206055
state O 0 2.974019253088045e-07
is O 0 7.428607062820447e-08
compatible O 0 8.836893812258495e-07
with O 0 9.295938951936478e-08
normal O 0 8.978116738944664e-07
coagulation O 0 0.00015051702212076634
function O 0 2.8655631467700005e-07
and O 0 5.6825051331088616e-08
the O 0 3.981248042350671e-08
capacity O 0 2.0144669576893648e-07
to O 0 2.0126213939875015e-07
mount O 0 5.595606126007624e-05
a O 0 6.629806648561498e-06
neutrophilic O 1 0.9766432642936707
leukocytosis O 1 0.9239031076431274
during O 0 0.00047413312131538987
pyogenic B-Disease 1 0.9971765279769897
infection I-Disease 0 0.010714046657085419
. O 0 9.690642400528304e-06
. O 0 2.0348332327557728e-05

Susceptibility O 1 0.6113351583480835
to O 0 0.0026046133134514093
ankylosing B-Disease 1 0.9999984502792358
spondylitis I-Disease 1 0.9999996423721313
in O 0 0.00020408519776538014
twins O 0 0.008680900558829308
: O 0 1.223353478962963e-06
the O 0 1.1116364362351305e-07
role O 0 1.7401386287474452e-07
of O 0 5.8441859351887615e-08
genes O 0 7.134788120310986e-07
, O 0 6.665630394309119e-07
HLA O 0 0.09716776758432388
, O 0 5.441180519483169e-07
and O 0 3.2933425586634257e-07
the O 0 6.88660520609119e-07
environment O 0 2.2631307729170658e-05
. O 0 9.26280154089909e-06

OBJECTIVE O 0 8.601188164902851e-05
To O 0 3.1040246994962217e-06
determine O 0 2.388293296462507e-06
the O 0 1.9964831210472767e-07
relative O 0 7.926804755697958e-06
effects O 0 4.153615918767173e-06
of O 0 2.564987653386197e-07
genetic O 0 1.902891744975932e-05
and O 0 1.1282502327958355e-06
environmental O 0 1.981895911740139e-05
factors O 0 1.498597612226149e-06
in O 0 9.388091939399601e-07
susceptibility O 0 0.05732414126396179
to O 0 0.008292586542665958
ankylosing B-Disease 1 0.9999998807907104
spondylitis I-Disease 1 1.0
( O 0 8.592597441747785e-05
AS B-Disease 0 0.00010483586811460555
) O 0 6.211935669853119e-06
. O 0 1.4149780326988548e-05

METHODS O 0 0.00022170347801875323
Twins O 0 0.000808245618827641
with O 0 3.270153001722065e-06
AS B-Disease 0 1.0300942449248396e-05
were O 0 3.44610810998347e-07
identified O 0 4.733515766019991e-07
from O 0 6.960079446116652e-08
the O 0 1.175069712644472e-07
Royal O 0 6.364567525452003e-06
National O 0 1.648554825806059e-05
Hospital O 0 0.06415757536888123
for O 0 0.001093831961043179
Rheumatic B-Disease 1 0.999995231628418
Diseases I-Disease 1 0.9814298748970032
database O 0 0.00019092325237579644
. O 0 3.404328163014725e-05

Clinical O 0 0.009678439237177372
and O 0 3.6672190617537126e-05
radiographic O 0 0.11168355494737625
examinations O 0 0.00014576692774426192
were O 0 1.3907482525610249e-06
performed O 0 1.6357926142518409e-06
to O 0 3.2874839916985366e-07
establish O 0 5.852747563039884e-06
diagnoses O 0 0.17184987664222717
, O 0 1.2234921996423509e-05
and O 0 0.0003291125176474452
disease O 1 0.6015937924385071
severity O 0 0.018831569701433182
was O 0 4.006297331216047e-06
assessed O 0 1.0744366591097787e-05
using O 0 3.02303732269138e-07
a O 0 2.6399760599815636e-07
combination O 0 1.34104209337238e-06
of O 0 2.271228964900729e-07
validated O 0 1.4046510841581039e-05
scoring O 0 6.415903953893576e-06
systems O 0 4.558145519695245e-05
. O 0 1.2371564480417874e-05

HLA O 0 0.05045288801193237
typing O 0 0.00038478971691802144
for O 0 1.3101832337270025e-05
HLA O 0 0.015653280541300774
- O 0 0.00029542879201471806
B27 O 0 0.00010267494508298114
, O 0 1.3756169892076286e-06
HLA O 0 0.0010389592498540878
- O 0 0.00013905609375797212
B60 O 0 7.247882604133338e-05
, O 0 3.522400788824598e-07
and O 0 4.937563744533691e-07
HLA O 0 0.025412682443857193
- O 0 0.0015438919654116035
DR1 O 0 0.00255929259583354
was O 0 3.6671769976237556e-07
performed O 0 3.767738689930411e-07
by O 0 1.3687635203041282e-07
polymerase O 0 2.2994971004663967e-05
chain O 0 6.336200840451056e-06
reaction O 0 1.580192048322715e-07
with O 0 2.1153082840896786e-08
sequence O 0 6.387573847632666e-08
- O 0 1.272782697014918e-06
specific O 0 7.283605185648412e-08
primers O 0 1.9070620282946038e-06
, O 0 1.3698368661607674e-07
and O 0 1.8829383918728126e-07
zygosity O 0 0.0001637117675272748
was O 0 7.795289320711163e-07
assessed O 0 4.9941936595132574e-06
using O 0 2.6775887818075716e-06
microsatellite O 0 0.0032792275305837393
markers O 0 0.00019918425823561847
. O 0 1.8748385627986863e-05

Genetic O 0 0.0022550164721906185
and O 0 1.1063531019317452e-05
environmental O 0 2.025039793807082e-05
variance O 0 8.179291398846544e-06
components O 0 6.673093139397679e-06
were O 0 2.9160210601730796e-07
assessed O 0 3.8022210446797544e-06
with O 0 6.77071554378017e-08
the O 0 4.133223185931456e-08
program O 0 8.956301371654263e-07
Mx O 0 5.1663049816852435e-05
, O 0 4.905862382997839e-08
using O 0 3.7280141640394504e-08
data O 0 4.397486108587145e-08
from O 0 1.4443429563471e-08
this O 0 7.653544464858442e-09
and O 0 2.9249576982692815e-08
previous O 0 1.0913753811792049e-07
studies O 0 9.894229435758461e-08
of O 0 1.2568315810312924e-07
twins O 0 0.00012987518857698888
with O 0 1.4900713267707033e-06
AS B-Disease 0 5.771838186774403e-05
. O 0 1.4243144505599048e-05

RESULTS O 0 0.00010782167373690754
Six O 0 7.864772669563536e-06
of O 0 1.4299596386990743e-06
8 O 0 2.0175377358100377e-05
monozygotic O 0 0.008928557857871056
( O 0 6.047187980584567e-06
MZ O 1 0.8274509310722351
) O 0 1.6397817717006546e-06
twin O 0 0.00027034306549467146
pairs O 0 4.215164608467603e-06
were O 0 2.7628636871668277e-06
disease O 0 0.0005285171791911125
concordant O 0 0.0021006702445447445
, O 0 1.636613433220191e-06
compared O 0 3.301053993709502e-06
with O 0 6.816638631335081e-08
4 O 0 1.4454306551670015e-07
of O 0 3.725853403580004e-08
15 O 0 3.23812770375298e-07
B27 O 0 4.589063973980956e-05
- O 0 4.286793409846723e-05
positive O 0 7.303740972020023e-07
dizygotic O 0 0.00011793449084507301
( O 0 4.179791517344711e-07
DZ O 0 0.0005771029973402619
) O 0 1.97963188952599e-07
twin O 0 1.9155588233843446e-05
pairs O 0 3.8290360748760577e-07
( O 0 7.17360961743907e-08
27 O 0 2.565959107414528e-07
% O 0 4.404251896517053e-08
) O 0 1.5622076077193014e-08
and O 0 1.8803644863396585e-08
4 O 0 7.840607452180848e-08
of O 0 4.294127720072538e-08
32 O 0 2.992414010805078e-06
DZ O 0 0.045348141342401505
twin O 0 4.6450470108538866e-05
pairs O 0 4.5613640509145625e-07
overall O 0 8.295581324091472e-07
( O 0 8.309938692718788e-08
12 O 0 9.203229467402707e-08
. O 0 6.95058091082501e-08
5 O 0 5.059858949607587e-07
% O 0 4.938797815157159e-07
) O 0 6.922729767211422e-07
. O 0 2.489602138666669e-06

Nonsignificant O 0 0.09723541885614395
increases O 0 0.0001235299714608118
in O 0 1.4617917258874513e-06
similarity O 0 2.5572405775164953e-06
with O 0 2.170320101413381e-07
regard O 0 5.778897502750624e-07
to O 0 1.9865841238697612e-07
age O 0 9.924516234605107e-06
at O 0 0.0003313307242933661
disease O 0 0.01937216892838478
onset O 0 0.006705117411911488
and O 0 1.7918765138347226e-07
all O 0 3.932081682478383e-08
of O 0 1.4551872595802706e-07
the O 0 5.695700110663893e-06
disease O 0 0.013897967524826527
severity O 0 0.0003323956916574389
scores O 0 7.233677479234757e-06
assessed O 0 8.297327440232038e-06
were O 0 3.920916071820102e-07
noted O 0 3.167142040183535e-06
in O 0 4.24268500864855e-06
disease O 0 0.013575060293078423
- O 0 0.450909823179245
concordant O 1 0.9527633786201477
MZ O 1 0.9996457099914551
twins O 0 0.011587817221879959
compared O 0 4.275170431355946e-05
with O 0 7.894786904216744e-06
concordant O 0 0.192569762468338
DZ O 1 0.8697730302810669
twins O 0 0.0021069070789963007
. O 0 5.221281753620133e-05

HLA O 1 0.5323237180709839
- O 0 0.0031425105407834053
B27 O 0 0.0006776293157599866
and O 0 2.566906232459587e-06
B60 O 0 0.0001290438958676532
were O 0 5.292834543979552e-07
associated O 0 1.2959479818164255e-06
with O 0 2.0883392437553994e-07
the O 0 6.122832019173075e-07
disease O 0 4.377801815280691e-05
in O 0 1.87755702540926e-07
probands O 0 0.020726114511489868
, O 0 4.355486566964828e-07
and O 0 8.019977570938863e-08
the O 0 6.427242738027417e-08
rate O 0 1.0677313184714876e-06
of O 0 5.584090558841126e-07
disease O 0 0.00011587889457587153
concordance O 0 3.0174145649652928e-05
was O 0 1.704295300442027e-06
significantly O 0 4.172207354713464e-06
increased O 0 1.026075437948748e-06
among O 0 1.1543154414539458e-06
DZ O 0 0.18037278950214386
twin O 0 0.00013608044537249953
pairs O 0 5.939978677815816e-07
in O 0 3.5279569488011475e-08
which O 0 2.6331914426691583e-08
the O 0 1.033630496749538e-07
co O 0 9.06974237295799e-05
- O 0 0.00811755657196045
twin O 0 0.00010321554145775735
was O 0 2.319141430007221e-07
positive O 0 1.9531140083017817e-07
for O 0 8.041421040161367e-08
both O 0 3.1371004638458544e-07
B27 O 0 0.00012788997264578938
and O 0 4.061896561324829e-06
DR1 O 0 0.02360333688557148
. O 0 2.2194732082425617e-05

Additive O 0 0.00033008598256856203
genetic O 0 0.0002273201971547678
effects O 0 3.435081453062594e-05
were O 0 5.960270641480747e-07
estimated O 0 6.866348485345952e-07
to O 0 7.825158832019952e-08
contribute O 0 2.6493938776184223e-07
97 O 0 2.8132724310125923e-06
% O 0 1.4882745347222226e-07
of O 0 4.673864140158912e-08
the O 0 1.9046433408220764e-07
population O 0 8.006005032257235e-07
variance O 0 1.0306268450221978e-05
. O 0 7.82395636633737e-06

CONCLUSION O 0 0.0002870461321435869
Susceptibility O 0 0.001822775462642312
to O 0 3.5110190310660983e-06
AS B-Disease 0 3.1858146485319594e-06
is O 0 1.6156485571627854e-07
largely O 0 3.513677597766218e-07
genetically O 0 1.573410258970398e-06
determined O 0 1.907917067001108e-06
, O 0 1.9159402597779263e-07
and O 0 1.0049484444607515e-07
the O 0 1.0631756452994523e-07
environmental O 0 4.622576852852944e-06
trigger O 0 3.4645124742382905e-06
for O 0 3.0377705684259126e-07
the O 0 7.659967195650097e-06
disease O 0 0.0034401905722916126
is O 0 1.273548832614324e-06
probably O 0 1.5590558177791536e-05
ubiquitous O 0 0.00012415986566338688
. O 0 1.3242939530755393e-05

HLA O 1 0.7964202165603638
- O 0 0.002821702975779772
B27 O 0 0.0006552952108904719
accounts O 0 4.593235189531697e-06
for O 0 3.7216028658804134e-07
a O 0 4.882404596173728e-07
minority O 0 6.502497171823052e-07
of O 0 5.2173554365708696e-08
the O 0 1.0640561498576062e-07
overall O 0 1.3875469448976219e-05
genetic O 0 0.00015121903561521322
susceptibility O 0 0.0005534624215215445
to O 0 1.919288479257375e-06
AS B-Disease 0 4.557650026981719e-05
. O 0 2.1386047592386603e-05

Cell O 0 0.001067292527295649
cycle O 0 0.00012536572467070073
- O 0 0.0002939552068710327
dependent O 0 1.3061685422144365e-05
colocalization O 0 0.00010507127444725484
of O 0 7.041497269710817e-07
BARD1 O 0 0.01589982397854328
and O 0 1.4571678548236378e-06
BRCA1 O 0 0.00012922294263262302
proteins O 0 7.256979301928368e-07
in O 0 2.869917068437644e-07
discrete O 0 1.1785733477154281e-05
nuclear O 0 0.0001635445369174704
domains O 0 1.9233988496125676e-05
. O 0 9.626955943531357e-06

Germ O 0 0.4210781157016754
- O 0 0.0021628618706017733
line O 0 5.7842462410917506e-05
mutations O 0 1.48072549563949e-05
of O 0 4.297683915410744e-07
the O 0 6.127937695055152e-07
BRCA1 O 0 0.00030243085348047316
gene O 0 1.4734850083186757e-05
predispose O 0 5.072011845186353e-05
women O 0 5.019219315727241e-07
to O 0 1.940159819469045e-07
early O 0 5.052224878454581e-06
- O 1 0.8491829633712769
onset O 1 0.9997556805610657
breast B-Disease 1 0.9999899864196777
and I-Disease 1 0.9877090454101562
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999899864196777
by O 0 1.327255063188204e-06
compromising O 0 0.00015682808589190245
the O 0 7.296667376976984e-07
genes O 0 7.755449587421026e-06
presumptive O 0 0.07206298410892487
function O 0 1.5670892707930761e-06
as O 0 3.868231601700245e-07
a O 0 5.5538203014293686e-06
tumor B-Disease 0 0.02904989756643772
suppressor O 0 0.0004856212472077459
. O 0 1.7424883480998687e-05

Although O 0 2.6137146051041782e-05
the O 0 2.068332150884089e-06
biochemical O 0 1.616763256606646e-05
properties O 0 4.038859060528921e-06
of O 0 4.916954026157327e-07
BRCA1 O 0 0.00020556943491101265
polypeptides O 0 1.0735229807323776e-05
are O 0 1.9285913310795877e-07
not O 0 2.0768456465702911e-07
understood O 0 1.3155955684851506e-06
, O 0 1.2525383397132828e-07
their O 0 4.8179352063471015e-08
expression O 0 3.148429925659002e-07
pattern O 0 7.035972657831735e-07
and O 0 1.0993037591333632e-07
subcellular O 0 5.711925950890873e-06
localization O 0 2.6619989057508064e-06
suggest O 0 7.081250146256934e-07
a O 0 1.527997426364891e-07
role O 0 4.3912254454880895e-07
in O 0 3.1377260256704176e-07
cell O 0 7.260757411131635e-05
- O 0 0.00040878457366488874
cycle O 0 1.9942384824389592e-05
regulation O 0 2.023783054028172e-05
. O 0 2.0053454136359505e-05

When O 0 6.629098788835108e-05
resting O 0 0.001691161305643618
cells O 0 3.061503957724199e-05
are O 0 2.8643228233704576e-07
induced O 0 2.756979847617913e-05
to O 0 3.581676821795554e-07
proliferate O 0 3.790659684455022e-05
, O 0 7.687548730928029e-08
the O 0 3.248761615282092e-08
steady O 0 2.0823920294787968e-06
- O 0 1.87425048352452e-05
state O 0 7.005561997175391e-08
levels O 0 5.192526231212469e-08
of O 0 1.3453798963780628e-08
BRCA1 O 0 9.03081672731787e-06
increase O 0 1.8755956432414678e-07
in O 0 6.74403608513785e-08
late O 0 2.1871721855859505e-06
G1 O 0 0.0005110450438223779
and O 0 2.2976750813086255e-07
reach O 0 3.4195349485344195e-07
a O 0 1.1907570751645835e-07
maximum O 0 5.938823051110376e-07
during O 0 2.277739213241148e-06
S O 0 0.0011734662111848593
phase O 0 0.00013946682156529278
. O 0 1.8087681382894516e-05

Moreover O 0 0.00032414772431366146
, O 0 6.199335985002108e-06
in O 0 9.878311857391964e-07
S O 0 0.00035137057420797646
phase O 0 7.306403131224215e-05
cells O 0 1.7723585187923163e-05
, O 0 4.5760299371977453e-07
BRCA1 O 0 3.773912612814456e-05
polypeptides O 0 3.278965323261218e-06
are O 0 1.7340059343950998e-07
hyperphosphorylated O 0 9.098250302486122e-05
and O 0 3.401415256121254e-07
accumulate O 0 1.0261584975523874e-05
into O 0 2.583670664080273e-07
discrete O 0 7.923161319922656e-06
subnuclear O 0 0.0011011138558387756
foci O 0 0.0002677803277038038
termed O 0 9.7517782705836e-05
" O 0 1.2555210560094565e-05
BRCA1 O 0 0.003079167101532221
nuclear O 0 0.0007627825252711773
dots O 0 0.0007430961122736335
. O 0 3.064869451918639e-05

" O 0 0.000320046441629529
BRCA1 O 0 0.2817964553833008
associates O 0 0.04634378105401993
in O 0 7.111791092029307e-06
vivo O 0 0.0008980398415587842
with O 0 1.641828475840157e-06
a O 0 5.716940449929098e-06
structurally O 0 0.0019908661488443613
related O 0 4.6452947572106495e-05
protein O 0 2.698504613363184e-05
termed O 0 0.00014770939014852047
BARD1 O 0 0.01914042979478836
. O 0 2.287842653458938e-05

Here O 0 1.960675581358373e-05
we O 0 1.2188850178063149e-06
show O 0 6.487667860710644e-07
that O 0 7.306925198236058e-08
the O 0 5.566965199932383e-08
steady O 0 2.4538460365874926e-06
- O 0 2.685084291442763e-05
state O 0 2.0617882512397046e-07
levels O 0 1.1353920825740715e-07
of O 0 3.685649829776594e-08
BARD1 O 0 0.0008843147079460323
, O 0 1.8561058823252097e-07
unlike O 0 2.1600926913833973e-07
those O 0 4.249234919484479e-08
of O 0 8.994702227482776e-08
BRCA1 O 0 0.00022302710567601025
, O 0 3.8987673178780824e-07
remain O 0 6.081780838940176e-07
relatively O 0 7.119331826288544e-07
constant O 0 1.13857390715566e-06
during O 0 2.1853977614227915e-06
cell O 0 0.00013737453264184296
cycle O 0 6.451537774410099e-05
progression O 0 0.0003948216908611357
. O 0 1.7186917830258608e-05

However O 0 4.1101829992840067e-05
, O 0 8.700589205545839e-06
immunostaining O 0 0.001077385968528688
revealed O 0 1.1657461982395034e-05
that O 0 7.030137680885673e-07
BARD1 O 0 0.0037564702797681093
resides O 0 8.723221071704756e-06
within O 0 4.793050720763858e-07
BRCA1 O 0 0.0001454414741601795
nuclear O 0 5.560594217968173e-05
dots O 0 1.286260703636799e-05
during O 0 1.2321455642450019e-06
S O 0 0.00012715550838038325
phase O 0 2.061018903987133e-06
of O 0 4.717831814105011e-08
the O 0 1.0070706935039198e-07
cell O 0 6.534439307870343e-06
cycle O 0 1.4880916978654568e-06
, O 0 1.2767017665282765e-07
but O 0 4.786052798522178e-08
not O 0 2.8636007343152414e-08
during O 0 1.8577954108423e-07
the O 0 3.561223991255247e-07
G1 O 0 0.001976810395717621
phase O 0 7.84017684054561e-05
. O 0 1.0065356036648154e-05

Nevertheless O 0 0.00030705786775797606
, O 0 8.747279935050756e-06
BARD1 O 0 0.0009603587677702308
polypeptides O 0 1.6628444427624345e-05
are O 0 1.9952574348280905e-07
found O 0 1.4610429843742168e-07
exclusively O 0 7.795335932314629e-08
in O 0 3.05721918891777e-08
the O 0 4.5436937767817653e-08
nuclear O 0 1.8703331079450436e-06
fractions O 0 4.023006852094113e-07
of O 0 3.038343621142303e-08
both O 0 7.899841136804753e-08
G1 O 0 0.00014621822629123926
- O 0 3.2280502637149766e-05
and O 0 4.296241513657151e-07
S O 0 0.0008870531455613673
- O 0 0.00031788466731086373
phase O 0 0.00031824340112507343
cells O 0 4.990095840184949e-05
. O 0 1.0484751328476705e-05

Therefore O 0 4.721865479950793e-05
, O 0 6.496208243333967e-06
progression O 0 2.3622484150109813e-05
to O 0 6.991412533352559e-07
S O 0 0.00041689843055792153
phase O 0 2.6089008315466344e-05
is O 0 2.700976153846568e-07
accompanied O 0 6.044588758413738e-07
by O 0 7.519829381408272e-08
the O 0 5.994323970526239e-08
aggregation O 0 1.7813092654250795e-06
of O 0 1.7930065610016754e-07
nuclear O 0 2.663107261469122e-05
BARD1 O 0 0.0002042588166659698
polypeptides O 0 5.863994374522008e-06
into O 0 1.74940794295253e-06
BRCA1 O 0 0.0002486780285835266
nuclear O 0 0.00016396705177612603
dots O 0 0.00019081332720816135
. O 0 2.380371188337449e-05

This O 0 2.8974700398975983e-05
cell O 0 0.00017350756388623267
cycle O 0 2.6926460122922435e-05
- O 0 7.866913074394688e-05
dependent O 0 5.762811724707717e-06
colocalization O 0 8.710123074706644e-05
of O 0 4.980572612112155e-07
BARD1 O 0 0.05922265723347664
and O 0 4.50793140771566e-06
BRCA1 O 0 0.0007244617445394397
indicates O 0 3.086113792960532e-06
a O 0 2.810615171711106e-07
role O 0 4.916016678180313e-07
for O 0 2.826210163675569e-07
BARD1 O 0 0.006235071923583746
in O 0 2.1001978893764317e-06
BRCA1 O 0 0.007891633547842503
- O 0 0.08923079073429108
mediated O 0 0.20676979422569275
tumor B-Disease 1 0.8785831928253174
suppression O 0 0.0002737078466452658
. O 0 2.4281453079311177e-05

Ethnic O 0 9.664038225309923e-05
differences O 0 3.5701468732440844e-05
in O 0 1.4668972880826914e-06
the O 0 1.6581492445766344e-06
HFE O 0 0.0011509126052260399
codon O 0 2.3637832782696933e-05
282 O 0 4.097284181625582e-05
( O 0 5.95353776589036e-06
Cys O 0 0.028053628280758858
/ O 0 0.0002917547826655209
Tyr O 0 0.0033606227952986956
) O 0 3.784422688113409e-06
polymorphism O 0 0.00016333055100403726
. O 0 2.3463437173631974e-05

Recent O 0 0.00017018610378727317
studies O 0 2.1698617274523713e-05
have O 0 2.6502100354264257e-06
shown O 0 9.05137221707264e-06
that O 0 2.1739051589975134e-05
hereditary B-Disease 1 0.999992847442627
hemochromatosis I-Disease 1 0.9999998807907104
( O 0 0.00025611338787712157
HH B-Disease 1 0.9999303817749023
) O 0 1.9532403712219093e-06
is O 0 2.6748935511022864e-07
likely O 0 7.282492333615664e-07
to O 0 6.302544619529726e-08
be O 0 6.374185801405474e-08
caused O 0 6.552677973559184e-07
by O 0 1.0666265382042184e-07
homozygosity O 0 0.00017212325474247336
for O 0 1.3057542957994883e-07
a O 0 6.281895821302896e-07
Cys282Tyr O 0 0.004584414418786764
mutation O 0 1.4369809377967613e-06
in O 0 7.989257966301011e-08
the O 0 1.5307394107821892e-07
HFE O 0 0.0003473542456049472
gene O 0 2.784309799608309e-06
located O 0 2.9184823233663337e-06
4 O 0 4.733786681754282e-06
. O 0 7.33160368326935e-06

5 O 0 0.00031340032001025975
Mb O 0 0.001821276731789112
telomeric O 0 0.0076245758682489395
to O 0 2.3802826035534963e-05
HLA O 0 0.42581748962402344
- O 0 0.0008307891548611224
A O 0 1.4017846297065262e-05
. O 0 1.8664182789507322e-05

Population O 0 2.4654791559441946e-05
studies O 0 3.281267481725081e-06
of O 0 2.626951811635081e-07
this O 0 1.94272033127163e-07
polymorphism O 0 1.3252895769255701e-05
are O 0 8.859932876248422e-08
facilitated O 0 2.323977696505608e-06
by O 0 1.3712407564980822e-07
the O 0 8.922067706862435e-08
fact O 0 2.3636624746359303e-07
that O 0 4.824151389470899e-08
the O 0 3.119826033071149e-07
Cys282Tyr O 0 0.0036661303602159023
mutation O 0 6.8744661803066265e-06
creates O 0 2.125199671354494e-06
a O 0 1.0988630947394995e-06
Rsal O 0 0.00045322629739530385
restriction O 0 1.1325277228024788e-05
site O 0 2.037874401139561e-05
. O 0 1.1412120329623576e-05

We O 0 1.6023868738557212e-05
have O 0 1.5141644098548568e-06
studied O 0 1.5693506156821968e-06
the O 0 4.786427325598197e-07
codon O 0 4.92111939820461e-06
282 O 0 1.3559825674747117e-05
( O 0 1.411522134731058e-06
Cys O 0 0.028358733281493187
/ O 0 0.00017077910888474435
Tyr O 0 0.003179890336468816
) O 0 3.691313850140432e-07
polymorphism O 0 3.881955763063161e-06
in O 0 1.0236265524099508e-07
different O 0 1.3527935038837313e-07
ethnic O 0 1.0272239023834118e-06
groups O 0 1.6934950508584734e-06
. O 0 6.006335297570331e-06

In O 0 4.144267222727649e-05
agreement O 0 1.3621714970213361e-05
with O 0 8.042277386266505e-07
previous O 0 7.387284313153941e-07
observations O 0 1.385475570714334e-06
the O 0 2.1329873334252625e-07
Tyr O 0 0.0007555755437351763
allele O 0 3.5354657939024037e-06
appeared O 0 4.077667199453572e-07
to O 0 9.17998335125958e-08
be O 0 1.0940472350284836e-07
rare O 0 1.6346931488442351e-06
or O 0 2.5826139449236507e-07
absent O 0 2.260298060718924e-06
in O 0 1.6953180193013395e-07
Asiatic O 0 6.789053259126376e-06
( O 0 2.1183812748404307e-07
Indian O 0 3.2129776172951097e-07
, O 0 1.8540201551786595e-07
Chinese O 0 1.9595394462612603e-07
) O 0 4.981921506441722e-07
populations O 0 3.666316843009554e-06
. O 0 3.492174755592714e-06

The O 0 1.0823410775628872e-05
highest O 0 1.0262084288115148e-05
allele O 0 8.746228559175506e-06
frequency O 0 1.335444380856643e-06
( O 0 2.0016344137729902e-07
7 O 0 2.990240943745448e-07
. O 0 5.80547911965823e-08
5 O 0 1.9984413768270315e-07
% O 0 1.2711059582670714e-07
) O 0 4.803969133604369e-08
was O 0 2.19489592723221e-07
found O 0 3.69936998367848e-07
in O 0 3.654263025509863e-07
Swedes O 0 7.712469960097224e-05
. O 0 1.0060231943498366e-05

Saamis O 0 0.014985291287302971
( O 0 1.006972433970077e-05
2 O 0 2.6212535431113793e-06
% O 0 4.742878445540555e-07
) O 0 6.283891451630552e-08
and O 0 9.464326211627849e-08
Mordvinians O 0 6.50501242489554e-05
( O 0 5.689467386105207e-08
1 O 0 6.315661238431858e-08
. O 0 1.2360837686742343e-08
8 O 0 1.1409549216523374e-07
% O 0 3.917499213912379e-08
) O 0 2.1892009982593663e-08
had O 0 3.900894185449033e-08
significantly O 0 2.6290069854439935e-07
lower O 0 2.343332141663268e-07
frequencies O 0 9.672720580056193e-08
of O 0 6.968633670112467e-08
the O 0 7.025017225714691e-07
Tyr O 0 0.002028478542342782
allele O 0 4.336367783253081e-05
. O 0 1.4055315659788903e-05

Comparisons O 0 0.00017195755208376795
with O 0 4.4258067646296695e-06
allele O 0 1.086635165847838e-05
frequencies O 0 1.595624553374364e-06
based O 0 5.720882541027095e-07
on O 0 6.455414904849022e-07
prevalence O 0 9.423606388736516e-05
estimates O 0 1.5381161801997223e-06
of O 0 6.466394779636175e-07
HH B-Disease 1 0.9975945353507996
showed O 0 1.113207054004306e-05
some O 0 1.0864799548926385e-07
disagreements O 0 4.944697593600722e-06
with O 0 1.9432854969636537e-07
the O 0 2.050724390301184e-07
RFLP O 0 0.0001470392307965085
data O 0 2.0181466879876098e-06
, O 0 6.525395406242751e-07
particularly O 0 1.8824656535798567e-06
in O 0 1.232780164173164e-06
Finns O 0 0.00017442605167161673
. O 0 1.7795311578083783e-05

The O 0 1.57321755978046e-05
newly O 0 3.500582533888519e-05
described O 0 3.0933369998820126e-05
HFE O 0 0.07728821039199829
marker O 0 0.00015523484034929425
provides O 0 1.2067624766132212e-06
a O 0 2.2581944847388513e-07
new O 0 1.7159825915769034e-07
approach O 0 6.177731961543032e-07
to O 0 5.425118843049859e-08
the O 0 3.73074584558708e-08
screening O 0 1.6684138017808436e-06
of O 0 1.564065712500451e-07
HH B-Disease 1 0.8466735482215881
as O 0 8.103238968715232e-08
well O 0 6.132052732255033e-08
as O 0 2.578294377997281e-08
studies O 0 5.096407917903889e-08
of O 0 2.421584355261075e-08
the O 0 1.0321116405975772e-07
relationship O 0 8.389525874008541e-07
between O 0 3.0234036785259377e-07
the O 0 1.211241738019453e-06
HFE O 1 0.5100551843643188
Tyr O 0 0.011830328032374382
allele O 0 2.517677603464108e-05
and O 0 3.1171659884421388e-06
different O 0 7.065619229251752e-06
disorders O 1 0.9329032301902771
including O 0 0.0006772183696739376
cancer B-Disease 1 0.9978339076042175

Autosomal B-Disease 1 0.9912108182907104
dominant I-Disease 1 0.7344078421592712
neurohypophyseal I-Disease 1 0.9999198913574219
diabetes I-Disease 1 0.9999963045120239
insipidus I-Disease 1 0.9999605417251587
associated O 0 0.00042040945845656097
with O 0 2.451892896715435e-06
a O 0 3.177000735377078e-06
missense O 0 9.65922954492271e-05
mutation O 0 4.800333044840954e-06
encoding O 0 4.857037765759742e-06
Gly23 O 0 0.0005147556657902896
- O 0 0.0010427990928292274
- O 0 0.00838145986199379
> O 0 0.00037012979737482965
Val O 0 0.001163543201982975
in O 0 2.552063278926653e-06
neurophysin O 0 0.001978229731321335
II O 0 0.005967350676655769
. O 0 1.963568320206832e-05

Autosomal B-Disease 1 0.9838176965713501
dominant I-Disease 0 0.2651052474975586
neurohypophyseal I-Disease 1 0.9997934699058533
diabetes I-Disease 1 0.9999911785125732
insipidus I-Disease 1 0.9999063014984131
( O 0 9.107746882364154e-05
ADNDI B-Disease 1 0.8055605888366699
) O 0 3.439879947109148e-06
is O 0 2.625764636832173e-06
an O 0 5.1157836423953995e-05
inherited B-Disease 1 0.9999982118606567
disease I-Disease 1 0.9996144771575928
caused O 0 3.4271339245606214e-05
by O 0 2.007914190471638e-06
progressive O 0 0.01758703961968422
degeneration O 0 0.1238090991973877
of O 0 3.602099525323865e-07
the O 0 8.7950490978983e-07
magnocellular O 0 0.003006820334121585
neurons O 0 4.035109213873511e-06
of O 0 6.909604621796461e-08
the O 0 1.293462190687933e-07
hypothalamus O 0 5.76865113544045e-06
leading O 0 4.975653951078129e-07
to O 0 1.4222534616692428e-07
decreased O 0 3.0803917070443276e-06
ability O 0 1.9237123183302174e-07
to O 0 3.611317112017787e-08
produce O 0 2.328313684074601e-07
the O 0 2.489582584530581e-07
hormone O 0 4.94023879582528e-06
arginine O 0 7.918351002444979e-06
vasopressin O 0 2.58617310464615e-05
( O 0 1.7683961459624697e-06
AVP O 0 0.00034445367055013776
) O 0 3.7025256460765377e-06
. O 0 9.163518370769452e-06

Affected O 0 0.0003540589241310954
individuals O 0 1.3078698430035729e-05
are O 0 7.712220053690544e-07
not O 0 5.245023544375726e-07
symptomatic O 0 0.002228860277682543
at O 0 9.754434358910657e-06
birth O 0 4.092719609616324e-05
, O 0 6.522570856759558e-07
but O 0 5.991015541439992e-07
usually O 0 5.071959549241001e-06
develop O 0 0.0022045865189284086
diabetes B-Disease 1 0.9992514252662659
insipidus I-Disease 1 0.9871941208839417
at O 0 7.747317795292474e-06
1 O 0 4.908824848826043e-06
- O 0 0.0005118917906656861
6 O 0 1.730772783048451e-05
yr O 0 0.008366137742996216
of O 0 8.119396284200775e-07
age O 0 1.0142161045223475e-05
. O 0 8.263159543275833e-06

The O 0 2.408503132755868e-05
genetic O 0 9.548562957206741e-05
locus O 0 3.128620301140472e-05
of O 0 1.8362929949944373e-06
the O 0 5.681362381437793e-06
disease O 0 0.0005915075889788568
is O 0 1.3067285919987626e-07
the O 0 3.297217574527167e-07
AVP O 0 0.005195133853703737
- O 0 0.03766799345612526
neurophysin O 0 0.2091585099697113
II O 0 0.01297296304255724
( O 0 6.092293460824294e-07
NPII O 0 0.0006257878849282861
) O 0 1.4158861461055494e-07
gene O 0 2.550848705595854e-07
, O 0 9.058629046876376e-08
and O 0 2.250223190003453e-07
mutations O 0 1.245611883859965e-06
that O 0 5.791532586840731e-08
cause O 0 2.594312263681786e-06
ADNDI B-Disease 0 0.017968766391277313
have O 0 1.2319323161591456e-07
been O 0 1.1067387362118097e-07
found O 0 1.0218611379286813e-07
in O 0 1.7271098329274537e-08
both O 0 1.1263840526964941e-08
the O 0 1.2191712528419885e-08
signal O 0 1.3306220125741675e-07
peptide O 0 1.4791142177728034e-07
of O 0 1.2020636930287765e-08
the O 0 3.0734554457012564e-08
prepro O 0 4.972240640199743e-05
- O 0 7.866200030548498e-05
AVP O 0 0.0007374513661488891
- O 0 0.00021016885875724256
NPII O 0 0.00020246949861757457
precursor O 0 1.667759875090269e-06
and O 0 3.029941240129119e-07
within O 0 9.275770480599022e-07
NPII O 0 0.0006784487050026655
itself O 0 9.129394129558932e-06
. O 0 9.931835847964976e-06

An O 0 1.853758112702053e-05
affected O 0 5.937217065365985e-05
girl O 0 0.0003069583617616445
who O 0 2.251651721962844e-06
presented O 0 1.8434907360642683e-06
at O 0 7.997924171831983e-07
9 O 0 7.706301516918757e-07
months O 0 2.4668702280905563e-07
of O 0 5.276510250951105e-08
age O 0 1.5247235296556028e-06
and O 0 2.5715371521073394e-07
her O 0 1.8982326537297922e-06
similarly O 0 8.1300731835654e-06
affected O 0 1.1770833907576161e-06
younger O 0 8.541048373444937e-06
brother O 0 2.1564714188571088e-05
and O 0 5.093405093248293e-07
father O 0 3.3069461551349377e-06
were O 0 5.4563130902351986e-08
all O 0 2.993082048874385e-08
found O 0 7.102636345734936e-08
to O 0 3.273686033367085e-08
have O 0 3.829970296465035e-08
a O 0 1.5031865530090727e-07
novel O 0 2.408531372566358e-06
missense O 0 8.99331716937013e-05
mutation O 0 1.4485455039903172e-06
( O 0 2.2961110346386704e-07
G1758 O 0 6.303077680058777e-05
- O 0 0.0005526953609660268
- O 0 0.011506987735629082
> O 0 0.0005730073899030685
T O 0 0.00032502564135938883
) O 0 5.0689919817159534e-08
encoding O 0 1.5586277868351317e-07
the O 0 1.9475056234341537e-08
amino O 0 8.07298690119751e-08
acid O 0 1.3055850445198303e-07
substitution O 0 3.45720792438442e-07
Gly23 O 0 2.271736775583122e-05
- O 0 6.566652882611379e-05
- O 0 0.00026971203624270856
> O 0 6.555840809596702e-05
Val O 0 0.0003427839546930045
within O 0 3.3576043279026635e-06
NPII O 0 0.0007419027388095856
. O 0 1.2009350029984489e-05

The O 0 6.637378828600049e-05
mutation O 0 8.207664359360933e-05
was O 0 5.854249593539862e-06
confirmed O 0 4.098812951269792e-06
by O 0 1.1153056220791768e-06
restriction O 0 6.354087872750824e-06
endonuclease O 0 0.0003965028445236385
analysis O 0 1.8089855075231753e-05
. O 0 1.5849213014007546e-05

A O 0 0.00015609036199748516
T1 O 0 0.22743743658065796
- O 0 0.00018533154798205942
weighted O 0 1.433261058991775e-05
magnetic O 0 7.477816780010471e-06
resonance O 0 8.460128810838796e-06
imaging O 0 1.6140134903253056e-05
of O 0 1.5834233124678576e-07
the O 0 6.796359457439394e-07
fathers O 0 0.00011175969848409295
pituitary O 0 0.06837137788534164
gland O 0 0.002069386886432767
demonstrates O 0 1.1940293006773572e-05
an O 0 1.2127327408961719e-06
attenuated O 0 0.0010105968685820699
posterior O 0 0.09305381774902344
pituitary O 0 0.31772086024284363
bright O 0 0.001165648689493537
spot O 0 0.00015052994422148913
. O 0 3.082382681895979e-05

This O 0 1.697454172244761e-05
mutation O 0 9.874813258647919e-05
may O 0 2.9214982077974128e-06
be O 0 6.991186296545493e-08
valuable O 0 2.2759384421533468e-07
for O 0 8.787531413645411e-08
developing O 0 5.827500331179181e-07
models O 0 8.40316204175906e-07
of O 0 6.612660854443675e-07
dominantly B-Disease 1 0.8259792327880859
inherited I-Disease 1 0.9878907203674316
neurodegeneration I-Disease 1 0.9999971389770508
, O 0 2.218309873569524e-06
as O 0 6.945544583913943e-08
the O 0 3.352188926442068e-08
early O 0 1.673206782015768e-07
age O 0 2.6925891916107503e-07
of O 0 1.2402371396547096e-07
onset O 0 0.007567293476313353
of O 0 4.433284175320296e-06
symptoms O 0 0.00549793615937233
suggests O 0 5.353633696358884e-06
that O 0 7.808534974174108e-08
this O 0 1.5024411936792603e-07
mutation O 0 5.104207957629114e-06
may O 0 6.318709324659721e-07
be O 0 6.588426515463652e-08
particularly O 0 5.795101287731086e-07
deleterious O 0 4.9486411626276094e-06
to O 0 2.0295443903250998e-07
the O 0 8.320467941302923e-07
magnocellular O 0 0.006951391231268644
neuron O 0 0.00016327682533301413
. O 0 2.0281991055526305e-06
. O 0 9.979409696825314e-06

Frequent O 0 0.0005731706623919308
inactivation O 0 0.005219516810029745
of O 0 2.1372470655478537e-05
PTEN O 0 0.4381972849369049
/ O 0 0.004747885279357433
MMAC1 O 0 0.3113890588283539
in O 0 0.00012853267253376544
primary O 1 0.9713869094848633
prostate B-Disease 1 0.9999995231628418
cancer I-Disease 1 0.9999809265136719
. O 0 0.0005071777850389481

Sporadic B-Disease 1 0.9982889294624329
prostate I-Disease 1 0.9999994039535522
carcinoma I-Disease 1 0.9999997615814209
is O 0 3.6866658774670213e-05
the O 0 2.050502644124208e-06
most O 0 1.890588691821904e-06
common O 0 1.2978282939002384e-05
male B-Disease 0 0.0002887762675527483
cancer I-Disease 0 0.41006535291671753
in O 0 1.3832138279212813e-07
the O 0 6.67216895067213e-08
Western O 0 2.3502971657762828e-07
world O 0 1.617319611568746e-07
, O 0 1.517008882956361e-07
yet O 0 1.4583966390091518e-07
many O 0 1.0556744811651697e-08
of O 0 1.086023715402007e-08
the O 0 2.4671237497386755e-08
major O 0 3.8165421756275464e-07
genetic O 0 5.61107071916922e-07
events O 0 6.704878785512847e-08
involved O 0 1.8463323669948295e-07
in O 0 4.930157970761684e-08
the O 0 6.797850460316113e-08
progression O 0 5.406753643910633e-06
of O 0 7.319771810898601e-08
this O 0 2.1172463959828747e-07
often O 0 1.6950130884652026e-05
fatal O 1 0.920478105545044
cancer B-Disease 1 0.6354978084564209
remain O 0 1.7781235328584444e-06
to O 0 4.866756739829725e-07
be O 0 2.0094735191378277e-06
elucidated O 0 0.000248426862526685
. O 0 1.95238917513052e-05

Numerous O 0 0.00015650111890863627
cytogenetic O 0 0.017046740278601646
and O 0 1.4977851606090553e-05
allelotype O 0 0.009487864561378956
studies O 0 9.00392569747055e-06
have O 0 8.517392302564986e-07
reported O 0 3.868972271448001e-06
frequent O 0 4.915453700959915e-06
loss O 0 2.23592905967962e-05
of O 0 9.4356647650784e-07
heterozygosity O 0 0.005517571698874235
on O 0 5.946824785496574e-06
chromosomal O 0 0.07019276916980743
arm O 0 0.0070620994083583355
10q O 0 0.006330589763820171
in O 0 5.103367948322557e-05
sporadic B-Disease 1 0.9581597447395325
prostate I-Disease 1 0.9999996423721313
cancer I-Disease 1 0.9999860525131226
. O 0 0.00031064602080732584

Deletion O 0 0.0005842170212417841
mapping O 0 0.0002959740231744945
studies O 0 2.145632061001379e-05
have O 0 1.3762099797531846e-06
unambiguously O 0 3.0719853384653106e-05
identified O 0 1.742302060847578e-06
a O 0 2.4050717684076517e-07
region O 0 4.4029542323187343e-07
of O 0 1.107507401343355e-07
chromosome O 0 1.8450491552357562e-05
10q23 O 0 9.279078949475661e-05
to O 0 1.4105570755873487e-07
be O 0 4.4305984658876696e-08
the O 0 1.5402548569909413e-07
minimal O 0 4.2484834921197034e-06
area O 0 1.0655971891537774e-06
of O 0 6.415540383386542e-07
loss O 0 0.00011259727762080729
. O 0 1.9445868019829504e-05

A O 0 4.3541902414290234e-05
new O 0 2.3226559278555214e-05
tumor B-Disease 0 0.0064168656244874
suppressor O 0 0.00013992557069286704
gene O 0 1.11732842924539e-05
, O 0 2.356914819756639e-06
PTEN O 0 0.0027115491684526205
/ O 0 0.00025763644953258336
MMAC1 O 0 0.03740851208567619
, O 0 1.2423198541000602e-06
was O 0 8.797423447504116e-07
isolated O 0 1.3463469258567784e-05
recently O 0 1.94210110748827e-06
at O 0 4.456928479612543e-07
this O 0 4.05215843102269e-08
region O 0 1.239814935161121e-07
of O 0 4.7479652209858614e-08
chromosome O 0 1.1385334801161662e-05
10q23 O 0 0.0001278613053727895
and O 0 4.1452008758824377e-07
found O 0 1.9644566862098145e-07
to O 0 4.2008672096471855e-08
be O 0 5.721854634543888e-08
inactivated O 0 3.5736220524995588e-06
by O 0 1.3292421385813213e-07
mutation O 0 1.3317827551873052e-06
in O 0 4.109688234166242e-07
three O 0 0.00023184374731499702
prostate B-Disease 1 0.9999998807907104
cancer I-Disease 1 0.9999933242797852
cell O 0 0.07830014824867249
lines O 0 0.00023511475592385978
. O 0 3.278179792687297e-05

We O 0 3.631914296420291e-05
screened O 0 0.00025597080821171403
80 O 0 0.0011563501320779324
prostate B-Disease 1 0.9999849796295166
tumors I-Disease 1 0.9999454021453857
by O 0 2.23207393901248e-06
microsatellite O 0 0.0005434134509414434
analysis O 0 2.5506790279905545e-06
and O 0 7.371850188064855e-07
found O 0 7.647242341590754e-07
chromosome O 0 1.2215231436130125e-05
10q23 O 0 2.7761654564528726e-05
to O 0 9.630931430137935e-08
be O 0 4.057556779457627e-08
deleted O 0 9.326766985395807e-07
in O 0 2.4864553438419534e-07
23 O 0 3.4230658911837963e-06
cases O 0 3.359099991939729e-06
. O 0 6.98507392371539e-06

We O 0 1.0367762115492951e-05
then O 0 1.5262598935805727e-06
proceeded O 0 1.8147749187846784e-06
with O 0 1.3640358531574748e-07
sequence O 0 2.4595647118985653e-07
analysis O 0 2.1478641087924188e-07
of O 0 3.401615700227012e-08
the O 0 8.211981850081429e-08
entire O 0 2.4581370325904572e-06
PTEN O 0 0.004800640512257814
/ O 0 8.513873035553843e-05
MMAC1 O 0 0.0032631177455186844
coding O 0 2.2577913114218973e-05
region O 0 1.2711971066892147e-06
and O 0 3.3661183351796353e-07
tested O 0 2.5968297450162936e-06
for O 0 1.4673629777917085e-07
homozygous O 0 5.333316039468627e-06
deletion O 0 8.79580602486385e-06
with O 0 1.7361819004690915e-07
new O 0 5.669593861057365e-07
intragenic O 0 0.004415272735059261
markers O 0 1.5113313565962017e-05
in O 0 1.0865669963777691e-07
these O 0 6.640480165742702e-08
23 O 0 1.5269208688550862e-06
cases O 0 6.199721838129335e-07
with O 0 5.915794076827297e-07
10q23 O 0 0.0008186478517018259
loss O 0 4.701071884483099e-05
of O 0 4.167336101090768e-06
heterozygosity O 0 0.10179946571588516
. O 0 4.2486881284276024e-05

The O 0 1.2252775377419312e-05
identification O 0 8.535674169252161e-06
of O 0 4.2130560018449614e-07
the O 0 3.103818357885757e-07
second O 0 1.945226358657237e-06
mutational O 0 0.0009361339034512639
event O 0 2.716151357162744e-06
in O 0 1.8804618662215944e-07
10 O 0 3.1309016890190833e-07
( O 0 1.8318610273126978e-07
43 O 0 2.0459044662857195e-06
% O 0 9.398626730217075e-07
) O 0 2.2759804778615944e-06
tumors B-Disease 1 0.9815464615821838
establishes O 0 5.118043191032484e-05
PTEN O 0 0.04641466587781906
/ O 0 0.0002661376493051648
MMAC1 O 0 0.002766673220321536
as O 0 2.1887464640713006e-07
a O 0 2.3393175752062234e-07
main O 0 6.669280310234171e-07
inactivation O 0 8.705390064278618e-05
target O 0 4.0472082218911964e-07
of O 0 1.5613592552199407e-07
10q O 0 9.500898158876225e-05
loss O 0 3.0386183425434865e-05
in O 0 7.420983365591383e-06
sporadic B-Disease 1 0.9215428233146667
prostate I-Disease 1 0.9999998807907104
cancer I-Disease 1 0.9999897480010986
. O 0 2.8194037440698594e-05
. O 0 3.2374220609199256e-05

Risk O 0 0.0035974665079265833
reversals O 0 0.0003229573485441506
in O 0 5.884548045287374e-06
predictive O 0 0.00012340482498984784
testing O 0 0.0009589808760210872
for O 0 0.0028661335818469524
Huntington B-Disease 1 0.9999903440475464
disease I-Disease 1 0.9995571970939636
. O 0 0.0001544107944937423

The O 0 4.975529009243473e-06
first O 0 1.9065819287789054e-06
predictive O 0 2.5865852876449935e-05
testing O 0 8.563305163988844e-05
for O 0 0.00048713828437030315
Huntington B-Disease 1 0.9999967813491821
disease I-Disease 1 0.9885236620903015
( O 0 1.0057852932732203e-06
HD B-Disease 0 0.005803071428090334
) O 0 2.533176086672029e-07
was O 0 1.3541773569158977e-07
based O 0 8.635614534568958e-08
on O 0 5.083340681721893e-08
analysis O 0 1.3990889158321806e-07
of O 0 1.0994988031143293e-07
linked O 0 3.93349546357058e-06
polymorphic O 0 1.7501188267488033e-05
DNA O 0 1.2824929399357643e-05
markers O 0 4.144392278249143e-06
to O 0 8.445326926675989e-08
estimate O 0 5.779845650977222e-07
the O 0 4.7694857840951954e-08
likelihood O 0 9.428449629922397e-07
of O 0 1.3516653041278914e-07
inheriting O 0 1.5320201782742515e-05
the O 0 3.194922442162351e-07
mutation O 0 4.308766165195266e-06
for O 0 1.1637051784418873e-06
HD B-Disease 0 0.001851041684858501
. O 0 2.2294307200354524e-05

Limits O 0 4.552906102617271e-05
to O 0 1.937875595103833e-06
accuracy O 0 4.380085101729492e-06
included O 0 8.007677934074309e-07
recombination O 0 5.522716946870787e-06
between O 0 3.760272306863044e-07
the O 0 1.8699641657349275e-07
DNA O 0 2.5121564249275252e-05
markers O 0 8.52884022606304e-06
and O 0 8.703111831209753e-08
the O 0 8.601750778325368e-08
mutation O 0 1.1673087101371493e-06
, O 0 2.536913825679221e-07
pedigree O 0 1.2442475053831004e-05
structure O 0 7.591929147565679e-07
, O 0 1.636253017522904e-07
and O 0 1.347506781712582e-07
whether O 0 3.247417907914496e-07
DNA O 0 5.906711521674879e-06
samples O 0 9.247983143723104e-07
were O 0 5.8178162731792327e-08
available O 0 1.4616477983508958e-07
from O 0 2.3449797481589485e-07
family O 0 1.7866819916889654e-06
members O 0 1.8841323026208556e-06
. O 0 6.932534688530723e-06

With O 0 1.2631520803552121e-05
direct O 0 2.785879587463569e-06
tests O 0 3.564928420018987e-06
for O 0 1.726196785512002e-07
the O 0 2.387304505191423e-07
HD B-Disease 0 0.0005952816572971642
mutation O 0 3.6562262266670587e-06
, O 0 1.799401019297875e-07
we O 0 7.714207583831012e-08
have O 0 3.253859048868435e-08
assessed O 0 4.523114398580219e-07
the O 0 2.8216630809652088e-08
accuracy O 0 6.017246505507501e-07
of O 0 4.4776033547577754e-08
results O 0 5.348049398889998e-07
obtained O 0 1.6952178327755973e-07
by O 0 8.217105573748995e-08
linkage O 0 1.6523827071068808e-06
approaches O 0 1.1375308304195642e-06
when O 0 1.8370552368196513e-07
requested O 0 3.3636476359788503e-07
to O 0 6.30148662139618e-08
do O 0 8.898325631889747e-08
so O 0 5.358867127824851e-08
by O 0 5.75066216867981e-08
the O 0 1.5290235921838757e-07
test O 0 7.881690180511214e-06
individuals O 0 1.8452601580065675e-06
. O 0 5.113026418257505e-06

For O 0 1.2786803381459322e-05
six O 0 4.672029263019795e-06
such O 0 1.1937535191464121e-06
individuals O 0 6.247715305107704e-07
, O 0 2.654122965850547e-07
there O 0 1.4063287778753875e-07
was O 0 4.2583667436701944e-07
significant O 0 1.2910949180877651e-06
disparity O 0 2.749202940321993e-05
between O 0 6.931741154403426e-07
the O 0 8.092479220067617e-07
tests O 0 2.0860710719716735e-05
. O 0 1.0138369361811783e-05

Three O 0 1.136593800765695e-05
went O 0 5.715173756470904e-06
from O 0 5.598434427156462e-07
a O 0 5.913887548558705e-07
decreased O 0 4.390189496916719e-05
risk O 0 7.052283308439655e-06
to O 0 4.221139704441157e-08
an O 0 3.821549654503542e-08
increased O 0 1.0326861001885845e-06
risk O 0 9.318905540567357e-06
, O 0 7.599275875236344e-08
while O 0 7.151587766429657e-08
in O 0 2.4728290526354613e-08
another O 0 5.356915266929718e-08
three O 0 4.147224075268241e-08
the O 0 1.9095649861355923e-07
risk O 0 1.576724935148377e-05
was O 0 2.7997855340800015e-06
decreased O 0 3.295591886853799e-05
. O 0 1.0993160685757175e-05

Knowledge O 0 2.1296009435900487e-05
of O 0 1.2646313507502782e-06
the O 0 5.203382897889242e-07
potential O 0 2.0542627225950127e-06
reasons O 0 3.219851691937947e-07
for O 0 5.759366672464239e-08
these O 0 2.5689773863746268e-08
changes O 0 6.61268657609071e-08
in O 0 5.507756739575598e-08
results O 0 2.954761555429286e-07
and O 0 7.299584581232921e-08
impact O 0 1.2361974199848191e-07
of O 0 3.9022410192046664e-08
these O 0 1.0253422288997172e-07
risk O 0 9.921885066432878e-06
reversals O 0 1.3584639418695588e-05
on O 0 9.000156637739565e-07
both O 0 1.673402834967419e-06
patients O 0 0.000123584148241207
and O 0 1.9912425841539516e-07
the O 0 1.514291341209173e-07
counseling O 0 2.043859421974048e-05
team O 0 1.7318194522886188e-07
can O 0 4.720829593907183e-08
assist O 0 1.6243373579527542e-07
in O 0 2.4331773929020528e-08
the O 0 1.5214910220606725e-08
development O 0 5.637874522790298e-08
of O 0 2.5383698698533408e-08
strategies O 0 8.451689836874721e-07
for O 0 4.81250737038863e-08
the O 0 9.835692793558337e-08
prevention O 0 6.4594946707075e-06
and O 0 2.603105144771689e-07
, O 0 2.258050244563492e-07
where O 0 1.3210755867021362e-07
necessary O 0 3.99694528141481e-07
, O 0 1.638517233004677e-07
management O 0 2.2879926575569698e-07
of O 0 2.4280362609374606e-08
a O 0 6.866021067253314e-07
risk O 0 2.3278407752513885e-05
reversal O 0 9.85113456408726e-06
in O 0 6.815104569568575e-08
any O 0 1.1780768005564823e-07
predictive O 0 4.533497303782497e-06
testing O 0 5.5142600103863515e-06
program O 0 2.894749059123569e-06
. O 0 9.626556902730954e-07
. O 0 7.4643935477070045e-06

A O 0 0.00012777879601344466
novel O 0 7.58761671022512e-05
common O 0 2.0532484995783307e-05
missense O 0 0.0004118575307074934
mutation O 0 2.3202339434647e-05
G301C O 0 7.4834591941908e-05
in O 0 2.890164978452958e-07
the O 0 1.5041129586279567e-07
N O 0 6.723026308463886e-05
- O 0 0.0001138389270636253
acetylgalactosamine O 0 0.0004046170215588063
- O 0 0.0001375021820422262
6 O 0 6.194549314386677e-06
- O 0 0.0014482972910627723
sulfate O 0 0.0016167283756658435
sulfatase O 0 0.0008316644816659391
gene O 0 3.7597233131236862e-06
in O 0 2.6369266379333567e-06
mucopolysaccharidosis B-Disease 0 0.00859938096255064
IVA I-Disease 0 0.2652309536933899
. O 0 4.1475686884950846e-05

Mucopolysaccharidosis B-Disease 1 0.9528311491012573
IVA I-Disease 1 0.9966667294502258
( O 0 0.00035549161839298904
MPS B-Disease 1 0.9850311279296875
IVA I-Disease 1 0.9999749660491943
) O 0 1.8465399989509024e-05
is O 0 2.787059429465444e-06
an O 0 6.163082616694737e-06
autosomal B-Disease 1 0.973111093044281
recessive I-Disease 1 0.9996352195739746
lysosomal I-Disease 1 0.9999905824661255
storage I-Disease 1 0.9999748468399048
disorder I-Disease 1 0.9997935891151428
caused O 0 7.79469555709511e-05
by O 0 1.751979084474442e-06
a O 0 4.9029968067770824e-05
genetic B-Disease 1 0.9881540536880493
defect I-Disease 1 0.9819969534873962
in O 0 1.3123300277584349e-06
N O 0 0.004086095839738846
- O 0 0.00342506798915565
acetylgalactosamine O 0 0.018700510263442993
- O 0 0.0011341576464474201
6 O 0 2.475617111485917e-05
- O 0 0.01624377816915512
sulfate O 0 0.03426766395568848
sulfatase O 0 0.009305840358138084
( O 0 2.3018537831376307e-06
GALNS O 0 0.0002288446412421763
) O 0 2.1517482764465967e-06
. O 0 5.697705091733951e-06

In O 0 1.1946204722335096e-05
previous O 0 8.291529411508236e-06
studies O 0 3.4648562632355606e-06
, O 0 7.012874903011834e-07
we O 0 2.952066324724001e-07
have O 0 1.0431132579924451e-07
found O 0 1.3214486216384103e-07
two O 0 3.217085620121907e-08
common O 0 3.114492699296534e-07
mutations O 0 1.0222447599517182e-06
in O 0 9.226711483734107e-08
Caucasians O 0 1.0646459486451931e-05
and O 0 3.362172265042318e-07
Japanese O 0 1.4387773035196005e-06
, O 0 9.204491675518511e-07
respectively O 0 4.742416876979405e-06
. O 0 7.869634828239214e-06

To O 0 1.1672568689391483e-05
characterize O 0 8.42982335598208e-05
the O 0 2.2350347990141017e-06
mutational O 0 0.00032989474129863083
spectrum O 0 4.9407190090278164e-05
in O 0 3.8434797033914947e-07
various O 0 1.242885900865076e-07
ethnic O 0 3.722152825957892e-07
groups O 0 3.069691558721388e-07
, O 0 2.1344565936942672e-07
mutations O 0 6.385380970641563e-07
in O 0 4.0260655254087396e-08
the O 0 1.0255866556008186e-07
GALNS O 0 0.0004088961286470294
gene O 0 1.7658177284829435e-06
in O 0 2.274269945701235e-07
Colombian O 0 5.8597070164978504e-05
MPS B-Disease 1 0.9555329084396362
IVA I-Disease 1 0.999997615814209
patients O 0 0.013148504309356213
were O 0 6.611797402911179e-07
investigated O 0 6.675235636066645e-05
, O 0 9.994724905482144e-07
and O 0 1.013982000586111e-06
genetic O 0 8.356702892342582e-06
backgrounds O 0 2.1202602056291653e-06
were O 0 8.804542517282243e-08
extensively O 0 4.786555223290634e-07
analyzed O 0 1.5385650158350472e-06
to O 0 1.7845437128016783e-07
identify O 0 2.19724711314484e-06
racial O 0 9.290972116104967e-07
origin O 0 9.279889212621129e-08
, O 0 6.636896898726263e-08
based O 0 1.4198236897300376e-07
on O 0 2.8594672585313674e-07
mitochondrial O 0 3.709709562826902e-05
DNA O 0 6.203937664395198e-05
( O 0 6.852408205304528e-07
mtDNA O 0 4.315156274969922e-06
) O 0 6.465481874329271e-07
lineages O 0 6.599899279535748e-06
. O 0 5.096449967822991e-06

Three O 0 2.602062886580825e-05
novel O 0 6.064486660761759e-05
missense O 0 0.0026194965466856956
mutations O 0 0.00022319363779388368
never O 0 1.0058179213956464e-05
identified O 0 7.66943321650615e-06
previously O 0 8.219540745812992e-07
in O 0 1.3636585549647862e-07
other O 0 7.477565588942525e-08
populations O 0 5.118058084008226e-07
and O 0 1.1192593518671856e-07
found O 0 1.3752520544585423e-07
in O 0 3.5549422960912125e-08
16 O 0 1.0052629306755989e-07
out O 0 3.6974295625213927e-08
of O 0 5.7518690255164984e-08
19 O 0 1.3098593854010687e-06
Colombian O 0 2.2688531316816807e-05
MPS B-Disease 0 0.057576172053813934
IVA I-Disease 1 0.9978151321411133
unrelated O 0 4.8152211093110964e-05
alleles O 0 4.787404577655252e-06
account O 0 6.758593258382461e-07
for O 0 9.353319683214067e-07
84 O 0 4.7520818043267354e-05
. O 0 1.5156079825828783e-05

2 O 0 4.3824467866215855e-05
% O 0 2.117576514137909e-06
of O 0 2.537053944706713e-07
the O 0 3.195925160071056e-07
alleles O 0 2.6871714453591267e-06
in O 0 2.300198502780404e-07
this O 0 3.3466315585428674e-07
study O 0 3.2036991797212977e-06
. O 0 1.162358148576459e-05

The O 0 2.913607568189036e-05
G301C O 0 0.0008098987746052444
and O 0 7.361281404882902e-06
S162F O 0 0.0009364906582050025
mutations O 0 3.0286750188679434e-05
account O 0 2.478711394360289e-06
for O 0 1.8150605001210351e-06
68 O 0 4.995776907890104e-05
. O 0 1.2892879567516502e-05

4 O 0 0.00010442092752782628
% O 0 1.5316174540203065e-05
and O 0 3.893642315233592e-06
10 O 0 6.556073913088767e-06
. O 0 1.2199899174447637e-05

5 O 0 3.5674787795869634e-05
% O 0 3.3317260204057675e-06
of O 0 5.270254632705473e-07
mutations O 0 6.354560809995746e-06
, O 0 4.7404589054167445e-07
respectively O 0 6.389785198734899e-07
, O 0 1.1834887914119463e-07
whereas O 0 2.6381539441899804e-07
the O 0 4.083722160430625e-08
remaining O 0 4.950614993504132e-07
F69V O 0 0.0002628195215947926
is O 0 9.36857986744144e-08
limited O 0 1.9159750763719785e-07
to O 0 8.60562323623526e-08
a O 0 5.452337745737168e-07
single O 0 3.129151536995778e-06
allele O 0 3.0969320505391806e-05
. O 0 7.6039668783778325e-06

The O 0 2.8083533834433183e-05
skewed O 0 0.00020668894285336137
prevalence O 0 0.00033511489164084196
of O 0 1.6473964024044108e-06
G301C O 0 0.00029030360747128725
in O 0 5.37014216206444e-07
only O 0 2.9937561407678004e-07
Colombian O 0 8.25271345092915e-05
patients O 0 0.00016573347966186702
and O 0 5.708500339096645e-07
haplotype O 0 1.4812311746936757e-05
analysis O 0 5.461471346279723e-07
by O 0 1.6946133030160127e-07
restriction O 0 1.0261761644869694e-06
fragment O 0 5.279377546685282e-06
length O 0 5.812730705656577e-06
polymorphisms O 0 2.2436679500970058e-05
in O 0 1.410141408086929e-07
the O 0 1.6564123939133424e-07
GALNS O 0 0.0008706115768291056
gene O 0 1.2878854249720462e-06
suggest O 0 6.993752776907058e-07
that O 0 1.5693055388510402e-07
G301C O 0 3.836171526927501e-05
originated O 0 7.594970270474732e-07
from O 0 2.1972185493268626e-07
a O 0 7.490811526622565e-07
common O 0 4.538342182058841e-06
ancestor O 0 2.1723755708080716e-05
. O 0 1.620945658942219e-05

Investigation O 0 0.00014622115122620016
of O 0 3.4160805171268294e-06
the O 0 1.3939403515905724e-06
genetic O 0 2.146336373698432e-05
background O 0 1.7650769450483494e-06
by O 0 1.9788618033089733e-07
means O 0 2.0440174353097973e-07
of O 0 5.80110679493373e-08
mtDNA O 0 1.3194430721341632e-06
lineages O 0 7.841367732908111e-07
indicate O 0 2.7012671921511355e-07
that O 0 3.582947272207093e-08
all O 0 6.65612773786961e-08
our O 0 1.1184980621692375e-06
patients O 0 3.9309579733526334e-05
are O 0 8.094835379779397e-08
probably O 0 7.040422929094348e-07
of O 0 2.6276430276084284e-07
native O 0 3.3872736366902245e-06
American O 0 9.674759894551244e-06
descent O 0 0.0009225131943821907

Low O 0 0.00015109207015484571
frequency O 0 2.261730514874216e-05
of O 0 3.2347002161259297e-06
BRCA1 O 0 0.0015046412590891123
germline O 0 0.0070130107924342155
mutations O 0 3.1783358281245455e-05
in O 0 1.7415594584235805e-06
45 O 0 4.551208621705882e-05
German O 0 0.2763407230377197
breast B-Disease 1 0.999996542930603
/ I-Disease 1 0.9999951124191284
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999978542327881
families O 0 0.001950767356902361
. O 0 0.00016737019177526236

In O 0 9.752238838700578e-06
this O 0 7.347817927438882e-07
study O 0 1.5232759551508934e-06
we O 0 3.744705168173823e-07
investigated O 0 8.210200576286297e-06
45 O 0 1.124447680922458e-05
German O 0 0.061665669083595276
breast B-Disease 1 0.9999914169311523
/ I-Disease 1 0.9999964237213135
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999982118606567
families O 0 4.382220868137665e-05
for O 0 5.805373348266585e-06
germline O 0 0.34131306409835815
mutations O 0 1.7351587302982807e-05
in O 0 2.7747199737859773e-07
the O 0 7.224682576634223e-07
BRCA1 O 0 0.0005320563213899732
gene O 0 3.086824290221557e-05
. O 0 1.738944229146e-05

We O 0 4.74384542030748e-05
identified O 0 2.3593463993165642e-05
four O 0 3.2800724056869512e-06
germline O 0 0.002635481534525752
mutations O 0 2.5508719772915356e-05
in O 0 6.929440701242129e-07
three O 0 3.213068703189492e-05
breast B-Disease 1 0.9999866485595703
cancer I-Disease 1 0.9993615746498108
families O 0 1.0273383850289974e-05
and O 0 9.179717608276405e-07
in O 0 6.542837240886001e-07
one O 0 1.768529364198912e-05
breast B-Disease 1 0.9999868869781494
- I-Disease 1 0.9999996423721313
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999988079071045
family O 0 0.00025889131939038634
. O 0 7.397132435471576e-07
among O 0 2.706181874145841e-07
these O 0 4.425319843903708e-08
were O 0 8.866610556879095e-08
one O 0 2.646444556830829e-07
frameshift O 0 0.0008936345693655312
mutation O 0 2.5024512524396414e-06
, O 0 1.8813892666003085e-07
one O 0 1.420281279251867e-07
nonsense O 0 2.0168681658105925e-05
mutation O 0 1.2218703204780468e-06
, O 0 8.288110819876238e-08
one O 0 5.313575357490663e-08
novel O 0 4.4673586785393127e-07
splice O 0 2.379436045885086e-05
site O 0 5.4237916629062966e-06
mutation O 0 1.3436574590741657e-06
, O 0 2.4101092321870965e-07
and O 0 3.598837565732538e-07
one O 0 1.203552301376476e-06
missense O 0 0.0002895763609558344
mutation O 0 5.55942788196262e-05
. O 0 1.2507432074926328e-05

The O 0 3.5976492654299363e-05
missense O 0 0.0021239786874502897
mutation O 0 0.00015386285667773336
was O 0 3.8042160213080933e-06
also O 0 5.528796123144275e-07
found O 0 5.073113129583362e-07
in O 0 5.822034836455714e-07
2 O 0 1.0712689800129738e-05
. O 0 1.200969381898176e-05

8 O 0 4.830177203984931e-05
% O 0 2.1115326944709523e-06
of O 0 2.2319666470593802e-07
the O 0 1.279375823060036e-07
general O 0 7.538375257354346e-07
population O 0 1.23780409921892e-07
, O 0 1.401309503989978e-07
suggesting O 0 1.1562060535652563e-06
that O 0 5.260713109578319e-08
it O 0 1.0306244035973577e-07
is O 0 9.313772011410038e-07
not O 0 7.018292762950296e-06
disease O 0 0.001311999512836337
associated O 0 2.1650786948157474e-05
. O 0 2.0432806195458397e-05

The O 0 1.5650130080757663e-05
average O 0 2.8569331334438175e-05
age O 0 1.40332558657974e-05
of O 0 6.843703431513859e-06
disease O 0 0.09640827775001526
onset O 0 0.3548538088798523
in O 0 1.824668515837402e-06
those O 0 1.9879441879311344e-06
families O 0 1.4286879377323203e-05
harbouring O 0 0.36236122250556946
causative O 0 0.0007177923689596355
mutations O 0 1.2665645954257343e-05
was O 0 1.1594999023145647e-06
between O 0 1.605935381121526e-06
32 O 0 1.7913649571710266e-05
. O 0 1.450611944164848e-05

3 O 0 0.00016661336121615022
and O 0 1.581905598868616e-05
37 O 0 7.087941776262596e-05
. O 0 2.836177372955717e-05

4 O 0 7.736660336377099e-05
years O 0 1.1862853170896415e-05
, O 0 1.4209738310455577e-06
whereas O 0 9.536834113532677e-07
the O 0 2.382028299052763e-07
family O 0 3.3226640425709775e-06
harbouring O 0 0.00034382863668724895
the O 0 6.018129852236598e-07
missense O 0 0.00016743529704399407
mutation O 0 4.363678272056859e-06
had O 0 1.6443154038370267e-07
an O 0 2.7417598857937264e-08
average O 0 6.46323201181076e-07
age O 0 3.458635546849109e-07
of O 0 1.4938203207748302e-07
onset O 0 0.0003817836695816368
of O 0 1.0221638149232604e-06
51 O 0 0.00011978347174590454
. O 0 2.0400697394507006e-05

2 O 0 0.000473903986858204
years O 0 0.00017849088180810213
. O 0 8.98399084690027e-05

These O 0 1.2000786227872595e-05
findings O 0 1.4981937965785619e-05
show O 0 3.302887080280925e-06
that O 0 5.293168214848265e-07
BRCA1 O 0 0.00025582779198884964
is O 0 4.781426810041012e-07
implicated O 0 2.2516651370096952e-05
in O 0 1.0604375688672008e-07
a O 0 2.7885886311196373e-07
small O 0 8.102711603896751e-07
fraction O 0 4.804881427844521e-06
of O 0 1.016415080812294e-05
breast B-Disease 1 0.9999866485595703
/ I-Disease 1 0.9999949932098389
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999984502792358
families O 0 2.500480695744045e-05
suggesting O 0 3.8127147945488105e-06
the O 0 1.442815431573763e-07
involvement O 0 2.5416459266125457e-06
of O 0 2.1845508513251843e-07
another O 0 5.289355613058433e-06
susceptibility O 0 0.002677316078916192
gene O 0 2.3955881260917522e-05
( O 0 4.003035428468138e-06
s O 0 0.000958056712988764
) O 0 3.0245648304116912e-05

Paternal O 0 0.10230334848165512
transmission O 0 0.033926770091056824
of O 0 0.032302480190992355
congenital B-Disease 1 0.9999980926513672
myotonic I-Disease 1 0.9999967813491821
dystrophy I-Disease 1 0.9999924898147583
. O 0 0.017382070422172546

We O 0 4.10044303862378e-05
report O 0 1.3063951882941183e-05
a O 0 3.545676463545533e-06
rare O 0 1.7444735931348987e-05
case O 0 1.1427976460254285e-05
of O 0 2.1276848201523535e-05
paternally O 1 0.9990220069885254
transmitted O 1 0.9987659454345703
congenital B-Disease 1 0.9999997615814209
myotonic I-Disease 1 0.9999996423721313
dystrophy I-Disease 1 0.9999988079071045
( O 0 0.10291263461112976
DM B-Disease 1 0.9999886751174927
) O 0 7.976294727995992e-05
. O 0 3.9502177969552577e-05

The O 0 2.5420255042263307e-05
proband O 0 0.0010706112952902913
is O 0 1.7193617622979218e-06
a O 0 6.104507406234916e-07
23 O 0 1.1733937981261988e-06
year O 0 7.697509545323555e-07
old O 0 0.0002012607583310455
, O 0 0.00014262550394050777
mentally B-Disease 1 0.9999794960021973
retarded I-Disease 1 0.9993836879730225
male O 0 0.00028621728415600955
who O 0 0.0022362777963280678
suffers O 1 0.9998108744621277
severe O 1 0.9954183101654053
muscular B-Disease 1 0.9994695782661438
weakness I-Disease 1 0.9305638670921326
. O 0 0.00023360110935755074

He O 0 8.45163594931364e-05
presented O 0 8.425836858805269e-05
with O 0 5.714071085094474e-05
respiratory O 0 0.4839213490486145
and O 0 8.151826477842405e-06
feeding O 0 0.0003847967309411615
difficulties O 0 0.0013484095688909292
at O 0 5.364826211007312e-05
birth O 0 0.0002810647711157799
. O 0 3.83075384888798e-05

His O 0 0.00014194402319844812
two O 0 6.276548083405942e-05
sibs O 1 0.9896920323371887
suffer O 0 0.08286122977733612
from O 0 4.837252345168963e-05
childhood O 1 0.5614815354347229
onset O 1 0.9995061159133911
DM B-Disease 1 0.9999798536300659
. O 0 0.0010064609814435244

Their O 0 1.95860666281078e-05
late O 0 3.887045750161633e-05
father O 0 2.0701292669400573e-05
had O 0 3.572521052319644e-07
the O 0 8.337420354109781e-08
adult O 0 9.798185374165769e-07
type O 0 2.2563765469385544e-06
of O 0 9.6950395800377e-07
DM B-Disease 1 0.9999922513961792
, O 0 2.8440570076782024e-06
with O 0 9.034106938088371e-07
onset O 0 0.0009699949296191335
around O 0 7.032095368231239e-07
30 O 0 1.5219110309772077e-06
years O 0 3.333213498990517e-06
. O 0 9.84958478511544e-06

Only O 0 5.829028850712348e-06
six O 0 2.6519771836319705e-06
other O 0 3.1981142001313856e-07
cases O 0 5.547863111132756e-07
of O 0 3.801162620220566e-07
paternal O 0 0.0002936949604190886
transmission O 0 0.0004501168441493064
of O 0 0.0012693788157775998
congenital B-Disease 1 0.9999995231628418
DM I-Disease 1 0.9999996423721313
have O 0 2.1268977434374392e-05
been O 0 4.44599845650373e-06
reported O 0 5.940201663179323e-05
recently O 0 4.435363371158019e-05
. O 0 2.2374648324330337e-05

We O 0 2.799865796987433e-05
review O 0 1.2808282917831093e-05
the O 0 1.1162314876855817e-06
sex O 0 1.797703589545563e-05
related O 0 2.4561271857237443e-05
effects O 0 2.5991910661105067e-05
on O 0 3.0873088689986616e-06
transmission O 0 0.0003715832135640085
of O 0 0.0005507538444362581
congenital B-Disease 1 0.9999971389770508
DM I-Disease 1 0.9999970197677612
. O 0 0.0009409949416294694

Decreased O 0 0.002928180852904916
fertility O 0 0.0008342423825524747
of O 0 2.8252015908947214e-06
males O 0 9.29804355109809e-06
with O 0 1.1120059753011446e-06
adult O 0 6.487593054771423e-05
onset O 1 0.9751623868942261
DM B-Disease 1 0.9999980926513672
and O 0 1.1569755770324264e-05
contraction O 0 1.5864350643823855e-05
of O 0 1.259520558960503e-07
the O 0 2.100701550489248e-07
repeat O 0 6.189860414451687e-06
upon O 0 1.7135558039171883e-07
male O 0 3.3486011830063944e-07
transmission O 0 9.677146408648696e-07
contribute O 0 2.011942257240662e-07
to O 0 6.119235251844657e-08
the O 0 6.628408044662137e-08
almost O 0 2.1261959659568674e-07
absent O 0 2.3959837562870234e-06
occurrence O 0 1.6267384808088536e-06
of O 0 3.3554391620782553e-07
paternal O 0 8.140264253597707e-05
transmission O 0 0.00026370983687229455
of O 0 0.0003938895824830979
congenital B-Disease 1 0.9999959468841553
DM I-Disease 1 0.9999890327453613
. O 0 0.000642827246338129

Also O 0 1.2782585145032499e-05
the O 0 1.294308958676993e-06
fathers O 0 3.455820660747122e-06
of O 0 2.8963791010028217e-07
the O 0 4.768384656017588e-07
reported O 0 1.6302470612572506e-05
congenitally O 0 0.006585334427654743
affected O 0 1.3325869076652452e-05
children O 0 2.613747255963972e-06
showed O 0 4.060192623001058e-06
, O 0 1.395255537772755e-07
on O 0 1.356167729227309e-07
average O 0 7.737939426988305e-07
, O 0 2.0318121585205517e-07
shorter O 0 4.064764198119519e-06
CTG O 0 0.00024656220921315253
repeat O 0 4.754902420245344e-06
lengths O 0 3.2032050512498245e-05
and O 0 5.98091730807937e-07
hence O 0 1.7326004808637663e-06
less O 0 1.1510140211612452e-05
severe O 0 0.13796685636043549
clinical O 1 0.643130362033844
symptoms O 0 0.015549793839454651
than O 0 1.0270122174915741e-06
the O 0 8.770416002334969e-07
mothers O 0 5.4662621550960466e-05
of O 0 1.0689651617212803e-06
children O 0 0.0001345076016150415
with O 0 0.013442153111100197
congenital B-Disease 1 0.9999946355819702
DM I-Disease 1 0.9999947547912598
. O 0 0.000922376464586705

We O 0 2.3104943466023542e-05
conclude O 0 4.939442078466527e-05
that O 0 1.2297952025619452e-06
paternal O 0 8.424639236181974e-05
transmission O 0 0.00011697020090650767
of O 0 0.0004942851373925805
congenital B-Disease 1 0.9999996423721313
DM I-Disease 1 0.9999998807907104
is O 0 7.512008596677333e-05
rare O 0 5.113895531394519e-05
and O 0 1.5499756500503281e-06
preferentially O 0 2.6211304430034943e-05
occurs O 0 6.034987336533959e-07
with O 0 1.6429829940989293e-07
onset O 0 0.0003392334911040962
of O 0 1.5497790855079074e-06
DM B-Disease 1 0.999967098236084
past O 0 1.3893524055674789e-06
30 O 0 3.7521689932873414e-07
years O 0 1.4867141828744934e-07
in O 0 5.512275791375032e-08
the O 0 1.6104520739190775e-07
father O 0 7.414552328555146e-06
. O 0 1.2147492043368402e-06
. O 0 9.042691999638919e-06

The O 0 4.0781640564091504e-05
RB1 O 0 0.22432205080986023
gene O 0 0.00012309559679124504
mutation O 0 4.70327322545927e-05
in O 0 1.1217080100323074e-06
a O 0 2.0370266611280385e-06
child O 0 0.00017717995797283947
with O 0 0.00010234278306597844
ectopic B-Disease 1 0.9998505115509033
intracranial I-Disease 1 0.9999665021896362
retinoblastoma I-Disease 1 0.9986114501953125
. O 0 0.00025841707247309387

The O 0 9.259419312002137e-05
RB1 O 0 0.25619274377822876
gene O 0 0.00010097807535203174
mutation O 0 4.182334305369295e-05
was O 0 3.712832722158055e-06
investigated O 0 4.257253385731019e-05
in O 0 5.074549562777975e-07
a O 0 1.5601224276906578e-06
child O 0 4.015196827822365e-05
with O 0 9.424293239135295e-06
ectopic B-Disease 1 0.9948764443397522
intracranial I-Disease 1 0.9998507499694824
retinoblastoma I-Disease 0 0.38964223861694336
using O 0 2.442324557705433e-06
DNA O 0 3.0731251172255725e-05
obtained O 0 7.762210998407681e-07
from O 0 1.1446648784385616e-07
both O 0 7.187086481508231e-08
the O 0 1.5066855496570497e-07
pineal B-Disease 0 0.004219973925501108
and I-Disease 0 3.599588308134116e-05
retinal I-Disease 1 0.9916572570800781
tumours I-Disease 1 0.999761164188385
of O 0 1.81306234026124e-06
the O 0 8.621503184258472e-06
patient O 0 0.0028532014694064856
. O 0 3.73855400539469e-05

A O 0 6.569358811248094e-05
nonsense O 0 0.0001613084605196491
mutation O 0 1.9916953533538617e-05
in O 0 6.481113246081804e-07
exon O 0 2.8713218853226863e-05
17 O 0 1.3206289395384374e-06
( O 0 8.089340042261028e-08
codon O 0 3.193179907157173e-07
556 O 0 7.988036827555334e-07
) O 0 3.5122862840353264e-08
of O 0 1.9637763415403242e-08
the O 0 1.0874087053025505e-07
RB1 O 0 0.0004932997399009764
gene O 0 6.479160106209747e-07
was O 0 8.849765009699695e-08
found O 0 3.378731605607754e-08
to O 0 1.4414230697923358e-08
be O 0 1.2157460815842569e-08
present O 0 7.346963570853404e-08
homozygously O 0 0.00020849886641371995
in O 0 6.155806175911493e-08
both O 0 5.7579608636615376e-08
the O 0 2.751593797256646e-07
retinal B-Disease 0 0.000746574136428535
and I-Disease 0 1.6082542515505338e-06
the I-Disease 0 1.1197585081390571e-05
pineal I-Disease 1 0.9761127829551697
tumours I-Disease 1 0.9996501207351685
. O 0 9.231860167346895e-05

The O 0 1.1397100934118498e-05
same O 0 4.877503670286387e-06
mutation O 0 1.383648759656353e-05
was O 0 6.006123953739007e-07
present O 0 5.664865057042334e-07
heterozygously O 0 0.0002580054278951138
in O 0 1.8320270100957714e-07
the O 0 8.97848764225273e-08
DNA O 0 2.8363997444103006e-06
from O 0 3.784974467180291e-08
the O 0 3.466722020561974e-08
constitutional O 0 4.936956656820257e-07
cells O 0 7.254730576278234e-07
of O 0 4.228682470852618e-08
the O 0 1.764145025617836e-07
patient O 0 7.048880797810853e-05
, O 0 6.955301046218665e-07
proving O 0 1.8807102605933324e-05
it O 0 2.8143265495828018e-08
to O 0 6.106434113917203e-08
be O 0 5.779703116104429e-08
of O 0 4.762894718624011e-07
germline O 0 0.0009256626362912357
origin O 0 4.5171882447903045e-06
. O 0 1.659990994085092e-05

The O 0 1.600885298103094e-05
initial O 0 4.1145602153846994e-05
mutation O 0 2.119899363606237e-05
was O 0 1.0353495554227266e-06
shown O 0 5.747195928051951e-07
to O 0 1.4648490775925893e-07
have O 0 1.1790367437924942e-07
occurred O 0 5.379419576456712e-07
in O 0 8.488056835176394e-08
the O 0 6.878781277919188e-07
paternally O 0 0.0006591599667444825
derived O 0 2.2717844331054948e-05
RB1 O 0 0.01507182139903307
allele O 0 6.937362195458263e-05
. O 0 1.7063157429220155e-05

The O 0 9.818064427236095e-06
mutation O 0 2.3897242499515414e-05
is O 0 5.477019726640719e-07
in O 0 1.404736309496002e-07
an O 0 6.185241119283091e-08
area O 0 3.506600876335142e-07
of O 0 2.3284417949298586e-08
the O 0 2.8823361475360798e-08
gene O 0 1.424127873406178e-07
that O 0 8.845222332354297e-09
encodes O 0 6.301126376229149e-08
the O 0 1.9702330433801762e-08
protein O 0 1.698263076832518e-07
- O 0 9.40712561714463e-06
binding O 0 6.656997015852539e-07
region O 0 3.3475507166258467e-07
known O 0 8.159257447459822e-08
as O 0 1.51851935470404e-08
the O 0 6.336414770657939e-08
pocket O 0 0.00015428377082571387
region O 0 9.179884727927856e-07
and O 0 1.114309000627145e-07
has O 0 4.8061409074762196e-08
been O 0 5.695841309716343e-08
detected O 0 9.890358114716946e-07
in O 0 2.8036273747034102e-08
other O 0 6.560838272662295e-08
cases O 0 3.387310982816416e-07
of O 0 6.178951252877596e-07
retinoblastoma B-Disease 0 0.17556467652320862
. O 0 4.214404725644272e-06
. O 0 1.790895294107031e-05

Low O 0 0.0004043804365210235
levels O 0 7.343247489188798e-06
of O 0 5.44770159649488e-07
beta O 0 1.0943924280581996e-05
hexosaminidase O 0 9.53939015744254e-05
A O 0 6.160916541375627e-07
in O 0 2.5097310185628885e-07
healthy O 0 8.141229045577347e-06
individuals O 0 1.157328028966731e-06
with O 0 1.6258378309430555e-05
apparent O 1 0.8661393523216248
deficiency O 1 0.7332899570465088
of O 0 3.7360726423685264e-07
this O 0 1.9869812604156323e-06
enzyme O 0 4.329161674831994e-05
. O 0 1.2899213288619649e-05

Appreciable O 0 0.001462073647417128
beta O 0 0.0005331026040948927
hexosaminidase O 0 0.005701734218746424
A O 0 5.0881021707027685e-06
( O 0 5.607962521025911e-07
hex O 0 6.257123004616005e-06
A O 0 1.8328553608171205e-07
) O 0 5.0468610623966015e-08
activity O 0 1.82648989266454e-07
has O 0 4.499975503335918e-08
been O 0 5.235987288187971e-08
detected O 0 7.645652431165217e-07
in O 0 8.62318785266325e-08
cultured O 0 2.903427775891032e-05
skin O 0 0.0005892615881748497
fibroblasts O 0 0.0003442717425059527
and O 0 0.00028917548479512334
melanoma B-Disease 1 0.9999871253967285
tissue O 0 0.05726486071944237
from O 0 2.6954844543070067e-06
healthy O 0 4.426312807481736e-05
individuals O 0 7.433574182869052e-07
previously O 0 2.265278681079508e-06
reported O 0 3.898584054695675e-06
as O 0 5.5964915190998e-07
having O 0 3.250036752433516e-05
deficiency B-Disease 0 0.018335798755288124
of I-Disease 0 1.0647038095612515e-07
hex I-Disease 0 3.18756683554966e-05
A I-Disease 0 2.720880729611963e-07
activity O 0 4.848300818593998e-07
indistinguishable O 0 6.419488158826425e-07
from O 0 4.917722762343146e-08
that O 0 2.995018277829331e-08
of O 0 2.3458321152247663e-07
patients O 0 0.0004737504350487143
with O 0 0.0005071270861662924
Tay B-Disease 1 0.9999994039535522
- I-Disease 1 0.9999951124191284
Sachs I-Disease 1 0.999997615814209
disease I-Disease 1 0.5019078254699707
( O 0 1.5689383872086182e-05
TSD B-Disease 1 0.7991496324539185
) O 0 1.0462836144142784e-05
. O 0 1.6042475181166083e-05

Identification O 0 0.00019379732839297503
and O 0 8.080879524641205e-06
quantitation O 0 0.000446247955551371
of O 0 1.8988373540196335e-06
hex O 0 0.0001254641538253054
A O 0 1.4585887129214825e-06
, O 0 3.061596203224326e-07
amounting O 0 2.472118012519786e-06
to O 0 5.797870699097984e-07
3 O 0 7.229380571516231e-06
. O 0 7.048652150842827e-06

5 O 0 0.00023587995383422822
% O 0 4.644856016966514e-05
- O 0 0.0007125118281692266
6 O 0 6.0438243963290006e-05
. O 0 1.954600702447351e-05

9 O 0 9.346463048132136e-05
% O 0 1.5407910041176365e-06
of O 0 2.407738293186412e-07
total O 0 3.714351919370529e-07
beta O 0 3.003292476932984e-06
hexosaminidase O 0 4.8113008233485743e-05
activity O 0 6.982975833125238e-07
, O 0 1.164773806294761e-07
has O 0 3.676725768286815e-08
been O 0 1.917041814181175e-08
obtained O 0 8.456255073951979e-08
by O 0 1.1292002710661109e-07
cellulose O 0 0.00031712427153252065
acetate O 0 0.00032887698034755886
gel O 0 0.0033632719423621893
electrophoresis O 0 0.00037507369415834546
, O 0 8.313107855428825e-07
DEAE O 0 0.0002479195536579937
- O 0 4.288355557946488e-05
cellulose O 0 3.5086337447864935e-05
ion O 0 4.856494706473313e-05
- O 0 1.840600998548325e-05
exchange O 0 1.720815134831355e-06
chromatography O 0 6.068380025681108e-05
, O 0 2.576974793555564e-07
radial O 0 7.315839866350871e-06
immunodiffusion O 0 0.00015376429655589163
, O 0 6.032184955984121e-07
and O 0 2.0699994820461143e-06
radioimmunoassay O 0 0.002385082421824336
. O 0 2.2862199330120347e-05

Previous O 0 8.795475150691345e-05
family O 0 4.5858570956625044e-05
studies O 0 6.040565040166257e-06
suggested O 0 5.8846039792115334e-06
that O 0 2.0484959861732932e-07
these O 0 1.6118411849674885e-07
individuals O 0 7.596223667860613e-07
may O 0 4.894604899163824e-07
be O 0 1.1446113745705588e-07
compound O 0 6.680995738861384e-06
heterozygotes O 0 1.4643012036685832e-05
for O 0 7.483929209683993e-08
the O 0 1.1006339661889797e-07
common O 0 5.27861971022503e-07
mutant O 0 9.171044439426623e-06
TSD B-Disease 0 0.023243127390742302
gene O 0 3.072130084547098e-06
and O 0 3.230721574709605e-07
a O 0 1.1742412198145757e-06
rare O 0 1.4940475921321195e-05
( O 0 1.1091389069406432e-06
allelic O 0 5.695535946870223e-05
) O 0 1.2264185897947755e-06
mutant O 0 1.9036866433452815e-05
gene O 0 2.1106441636220552e-05
. O 0 1.0737257071014028e-05

Thus O 0 3.6347693821880966e-05
, O 0 2.403249482085812e-06
the O 0 2.655956166108808e-07
postulated O 0 4.762031949212542e-06
rate O 0 7.169628588599153e-07
mutant O 0 4.143676960666198e-06
gene O 0 1.2482103102229303e-06
appears O 0 5.465639674184786e-07
to O 0 4.179815249472085e-08
code O 0 6.296909305092413e-08
for O 0 2.0029132130616745e-08
the O 0 2.314789959712016e-08
expression O 0 6.138454011761496e-08
of O 0 4.5900073075699765e-08
low O 0 2.899067339967587e-06
amounts O 0 5.804515126328624e-07
of O 0 2.6627404281498457e-07
hex O 0 4.987651118426584e-05
A O 0 2.3492220861953683e-06
. O 0 7.09123696651659e-06

Heterozygotes O 0 0.005758597049862146
for O 0 1.4940048458811361e-05
the O 0 3.472444632279803e-06
rare O 0 2.2771855583414435e-05
mutant O 0 0.00011686517245834693
may O 0 2.8001595637761056e-06
be O 0 1.4116524482687964e-07
indistinguishable O 0 2.1017926883359905e-06
from O 0 2.5767806732801546e-07
heterozygotes O 0 1.374992098135408e-05
for O 0 1.560678981604724e-07
the O 0 7.339056651289866e-07
common O 0 1.1035995157726575e-05
TSD B-Disease 0 0.1714676320552826
mutant O 0 0.00021788525918964297
. O 0 2.88184528471902e-05

However O 0 2.1177513190195896e-05
, O 0 1.4870022368995706e-06
direct O 0 8.533832556167908e-07
visualization O 0 1.533631257188972e-05
and O 0 8.123725478981214e-07
quantitation O 0 0.00013610601308755577
of O 0 2.928162814441748e-07
hex O 0 3.982926136814058e-05
A O 0 2.0719198801089078e-07
by O 0 5.36647739579621e-08
the O 0 4.668536135454815e-08
methods O 0 1.0886087693506852e-06
described O 0 4.6791592467343435e-06
may O 0 8.652132237330079e-07
prevent O 0 1.111923324970121e-06
false O 0 1.8327939415030414e-06
- O 0 0.0005694219726137817
positive O 0 6.56684323985246e-06
prenatal O 0 0.25253772735595703
diagnosis O 0 0.03761579096317291
of O 0 1.4941865629225504e-06
TSD B-Disease 1 0.9707598686218262
in O 0 6.815260803705314e-06
fetuses O 0 0.0005878359079360962
having O 0 3.702027697727317e-07
the O 0 1.349994391830478e-07
incomplete O 0 1.4781083336856682e-05
hex B-Disease 0 0.003289714688435197
A I-Disease 0 4.344895205576904e-05
deficiency I-Disease 0 0.013856694102287292
of O 0 7.04517262306581e-08
the O 0 1.4291209993189113e-07
type O 0 9.191297067445703e-06
described O 0 2.249614681204548e-06
in O 0 1.3728042347338487e-07
the O 0 1.6782632883405313e-07
four O 0 1.788801228030934e-06
healthy O 0 9.735267667565495e-05
individuals O 0 3.6087621992919594e-05

The O 0 4.4673277443507686e-05
tumor B-Disease 0 0.007403069641441107
suppressor O 0 0.0003438466810621321
gene O 0 5.468546078191139e-05
Smad4 O 0 0.004950827453285456
/ O 0 0.0004163052944932133
Dpc4 O 0 0.0014966133749112487
is O 0 5.284351232148765e-07
required O 0 2.051131104963133e-07
for O 0 1.5539258413355128e-07
gastrulation O 0 0.0009334560600109398
and O 0 3.5609525639301864e-07
later O 0 2.46336270492975e-07
for O 0 1.7006034624955646e-07
anterior O 0 4.5483149733627215e-05
development O 0 2.738504463195568e-07
of O 0 1.1711831149341378e-07
the O 0 6.034590001036122e-07
mouse O 0 8.21711728349328e-05
embryo O 0 0.00015830725897103548
. O 0 1.67861144291237e-05

Mutations O 0 0.0006717037176713347
in O 0 4.541247108136304e-06
the O 0 2.7022820177080575e-06
SMAD4 O 0 0.07269791513681412
/ O 0 0.0020562615245580673
DPC4 O 1 0.5349623560905457
tumor B-Disease 0 0.20786447823047638
suppressor O 0 0.00018989206000696868
gene O 0 3.780342922254931e-06
, O 0 3.3261213161495107e-07
a O 0 2.415198707694799e-07
key O 0 9.266805136576295e-07
signal O 0 7.602776008752699e-07
transducer O 0 3.2619363992125727e-06
in O 0 7.971129889483564e-08
most O 0 1.2410973226906208e-07
TGFbeta O 0 0.0010900726774707437
- O 0 0.00170890090521425
related O 0 5.389112175180344e-06
pathways O 0 1.6253893591056112e-06
, O 0 9.328851291456886e-08
are O 0 1.4933155156882094e-08
involved O 0 8.023740605267449e-08
in O 0 9.559008873338826e-08
50 O 0 7.698669151068316e-07
% O 0 8.519504604009853e-07
of O 0 1.8357750377617776e-05
pancreatic B-Disease 1 0.9999845027923584
cancers I-Disease 1 0.9985678195953369
. O 0 7.440856279572472e-05

Homozygous O 0 0.005555432755500078
Smad4 O 0 0.0736011415719986
mutant O 0 0.004868457093834877
mice O 0 0.02254631370306015
die O 0 0.001096662599593401
before O 0 3.555991270332015e-06
day O 0 8.094477379927412e-06
7 O 0 1.9156701455358416e-05
. O 0 1.2540323950815946e-05

5 O 0 0.00012584707292262465
of O 0 3.348206155351363e-05
embryogenesis O 0 0.003729409072548151
. O 0 0.0002066221204586327

Mutant O 0 0.00044020911445841193
embryos O 0 0.00011455851199571043
have O 0 3.8364159991033375e-06
reduced O 0 3.675545031001093e-06
size O 0 1.2157680430391338e-05
, O 0 8.146993764057697e-07
fail O 0 7.110481874406105e-06
to O 0 1.8747033436739002e-07
gastrulate O 0 0.00026704531046561897
or O 0 3.032829454241437e-07
express O 0 4.648610456570168e-07
a O 0 3.6365884170663776e-07
mesodermal O 0 0.000334906333591789
marker O 0 3.704420305439271e-05
, O 0 2.329157666736137e-07
and O 0 2.2796466225827317e-07
show O 0 1.6008129932743032e-06
abnormal O 0 4.758462091558613e-05
visceral O 0 0.00024227809626609087
endoderm O 0 0.0022026088554412127
development O 0 3.520599420880899e-05
. O 0 1.925520336953923e-05

Growth B-Disease 1 0.9902032613754272
retardation I-Disease 1 0.9997571110725403
of O 0 5.859695647814078e-06
the O 0 4.254017312632641e-06
Smad4 O 1 0.581326425075531
- O 0 0.41924846172332764
deficient O 0 0.01652620919048786
embryos O 0 7.155569164751796e-06
results O 0 5.363899049370957e-07
from O 0 1.7799035845200706e-07
reduced O 0 1.8868817051043152e-06
cell O 0 2.7276633772999048e-05
proliferation O 0 2.049961403827183e-05
rather O 0 2.753090200258157e-07
than O 0 3.8342466268659336e-07
increased O 0 3.054776243516244e-06
apoptosis O 0 7.670370541745797e-05
. O 0 8.729670298635028e-06

Aggregation O 0 0.00034545795642770827
of O 0 9.544791282678489e-06
mutant O 0 0.00027164004859514534
Smad4 O 0 0.05309200659394264
ES O 0 0.001459009014070034
cells O 0 1.822102422011085e-05
with O 0 9.190491709887283e-07
wild O 0 7.851597729313653e-06
- O 0 0.00022984304814599454
type O 0 1.8358925444772467e-05
tetraploid O 0 0.0002071612689178437
morulae O 0 0.0022492262069135904
rescues O 0 0.00022542302031069994
the O 0 5.615954705717741e-06
gastrulation B-Disease 0 0.3364352881908417
defect I-Disease 0 0.04220406711101532
. O 0 6.020147702656686e-05

These O 0 1.0157154974876903e-05
results O 0 9.288985893363133e-06
indicate O 0 2.393649538134923e-06
that O 0 1.3882593918879138e-07
Smad4 O 0 0.00031420838786289096
is O 0 1.5180985712959227e-07
initially O 0 2.3077370769897243e-07
required O 0 5.661409119284144e-08
for O 0 2.291503520268634e-08
the O 0 1.947371863764147e-08
differentiation O 0 5.854639653080085e-07
of O 0 3.7797946106366e-08
the O 0 1.056774792118631e-07
visceral O 0 2.5585632101865485e-05
endoderm O 0 0.0002805111580528319
and O 0 2.1612672185256088e-07
that O 0 7.406888613559204e-08
the O 0 1.965509852652758e-07
gastrulation B-Disease 0 0.11565081775188446
defect I-Disease 0 0.0032426572870463133
in O 0 1.3560899958520167e-07
the O 0 1.883042415329328e-07
epiblast O 0 0.002690474037081003
is O 0 1.3886527483464306e-07
secondary O 0 3.741806438029016e-07
and O 0 1.3702968715278985e-07
non O 0 3.567125077097444e-06
- O 0 0.003942712675780058
cell O 0 0.0001287511404370889
autonomous O 0 6.73408840157208e-06
. O 0 7.89276873547351e-06

Rescued O 0 0.003433896228671074
embryos O 0 0.0010767360217869282
show O 0 0.0001479162892792374
severe O 0 0.022010071203112602
anterior O 0 0.14141307771205902
truncations O 0 0.25131741166114807
, O 0 2.66218794422457e-05
indicating O 0 1.7702959667076357e-05
a O 0 5.927466872890363e-07
second O 0 4.612078612353798e-07
important O 0 1.801166007453503e-07
role O 0 2.6426764065945463e-07
for O 0 4.768530175169872e-07
Smad4 O 0 0.001326562836766243
in O 0 1.8998264295078116e-06
anterior O 0 0.0009618926560506225
patterning O 0 0.0010702477302402258
during O 0 4.240931593813002e-05
embryogenesis O 0 0.0036255279555916786
. O 0 7.317392737604678e-05

Prevalence O 0 0.00885923020541668
of O 0 1.7242913600057364e-05
p16 O 0 0.000997214112430811
and O 0 1.6111776858451776e-05
CDK4 O 0 0.0471130833029747
germline O 0 0.06410589814186096
mutations O 0 4.579760934575461e-05
in O 0 2.450588226565742e-06
48 O 0 0.0012929497752338648
melanoma B-Disease 1 0.9999791383743286
- O 1 0.9846030473709106
prone O 1 0.5605304837226868
families O 0 1.5220710338326171e-05
in O 0 2.015699919866165e-06
France O 0 3.069610465900041e-05
. O 0 2.163518547604326e-05

The O 0 9.39853343879804e-05
French O 0 0.002866438589990139
Familial B-Disease 1 0.9995391368865967
Melanoma I-Disease 1 0.9999731779098511
Study O 0 0.00026352761778980494
Group O 0 0.00013851547555532306
. O 0 5.952569335931912e-05

Germline O 1 0.7695503830909729
mutations O 0 0.0008137612021528184
in O 0 3.6646704302256694e-06
the O 0 1.1547283520485507e-06
p16 O 0 6.711720197927207e-05
and O 0 2.226104697911069e-06
CDK4 O 0 0.008582563139498234
genes O 0 4.206394351058407e-06
have O 0 2.2285486522832798e-07
been O 0 1.38091110102323e-07
reported O 0 7.505062740165158e-07
in O 0 6.393814544480847e-08
a O 0 1.8566441895018215e-07
subset O 0 4.603115030477056e-06
of O 0 1.3294567224875209e-06
melanoma B-Disease 1 0.9993625283241272
pedigrees O 0 0.001414939179085195
, O 0 9.574533805789542e-07
but O 0 2.9520236921598553e-07
their O 0 2.8140482299932046e-07
prevalence O 0 0.00022739951964467764
is O 0 1.6438012551134307e-07
not O 0 1.2262076154456736e-07
well O 0 7.173568405960395e-07
known O 0 4.727573923446471e-06
. O 0 5.8047094171342906e-06

We O 0 2.5870414901874028e-05
searched O 0 3.638938142103143e-05
for O 0 7.766690828248102e-07
such O 0 1.255244796993793e-06
germline O 0 0.002926724962890148
mutations O 0 1.4741258382855449e-05
in O 0 6.964513659113436e-07
48 O 0 2.2613787223235704e-05
French O 0 0.0008970897761173546
melanoma B-Disease 1 0.9999840259552002
- O 1 0.9901098608970642
prone O 0 0.294105589389801
families O 0 1.9090782643615967e-06
selected O 0 2.612192133710778e-07
according O 0 8.856790145728155e-08
to O 0 4.178858503678384e-08
two O 0 5.830257876482392e-08
major O 0 1.1869831268995767e-06
criteria O 0 1.1071784911109717e-06
families O 0 2.0218864449361718e-07
with O 0 9.828342228956899e-08
at O 0 2.698337198125955e-07
least O 0 6.508502536917149e-08
three O 0 4.887929705432725e-08
affected O 0 2.1929585614088865e-07
members O 0 3.327199493696753e-08
( O 0 7.073056451645243e-08
n O 0 1.3498824955604505e-05
= O 0 1.4799298924117466e-06
20 O 0 7.777053667723521e-08
) O 0 1.8547181568351334e-08
or O 0 4.9038604288398346e-08
families O 0 8.083294034122446e-08
with O 0 3.264625902943408e-08
two O 0 3.54180578199248e-08
affected O 0 4.074915125329426e-07
members O 0 3.4890973665824276e-08
, O 0 4.536038744618054e-08
one O 0 7.99762478465027e-09
of O 0 1.020528461737058e-08
them O 0 3.498953660141524e-08
affected O 0 1.7494768655978987e-07
before O 0 6.206323632795829e-08
the O 0 3.111054880378106e-08
age O 0 9.390118549390536e-08
of O 0 3.4645410096345586e-08
50 O 0 2.5891762334140367e-07
( O 0 1.0896323487941117e-07
n O 0 1.7878284779726528e-05
= O 0 3.7945630992908264e-06
28 O 0 1.8635017795531894e-07
) O 0 1.8264266543610574e-08
, O 0 1.6902868438251062e-08
and O 0 2.1469359623438322e-08
one O 0 5.710058204044799e-08
additional O 0 7.456357593582652e-07
minor O 0 2.050708280876279e-05
criterion O 0 9.22275212360546e-05
. O 0 1.154578148998553e-05

Sixteen O 0 9.042797319125384e-05
different O 0 1.0492213732504752e-05
p16 O 0 0.0004216251545585692
germline O 0 0.004624317865818739
mutations O 0 3.3735039323801175e-05
were O 0 5.962965587968938e-07
found O 0 4.694081781053683e-07
in O 0 1.1190715554221242e-07
21 O 0 9.948803381121252e-07
families O 0 5.266104494694446e-07
, O 0 2.566274588389206e-07
while O 0 2.7114285217066936e-07
one O 0 2.476978977483668e-07
germline O 0 0.0011043923441320658
mutation O 0 3.7195522963884287e-06
, O 0 5.513768428500043e-07
Arg24His O 0 0.0005695538711734116
, O 0 5.028202281209815e-07
was O 0 4.6160388933458307e-07
detected O 0 2.137633600796107e-06
in O 0 8.347906543804129e-08
the O 0 3.2477026934429887e-07
CDK4 O 0 0.001775064505636692
gene O 0 2.4307029889314435e-05
. O 0 1.2796026567230001e-05

The O 0 8.438581062364392e-06
frequency O 0 9.73531678027939e-06
of O 0 1.6084213712019846e-06
p16 O 0 0.0001039119524648413
gene O 0 9.289996341976803e-06
mutation O 0 3.3499090932309628e-06
in O 0 1.0597722877037086e-07
our O 0 1.27753239098638e-07
sample O 0 3.5819979871121177e-07
( O 0 8.011522112383318e-08
44 O 0 3.028690400697087e-07
% O 0 9.724126215360229e-08
) O 0 2.7154673176710276e-08
is O 0 2.024544798473471e-08
among O 0 3.378222501737582e-08
the O 0 3.427020089930011e-08
highest O 0 2.8756644496752415e-06
rates O 0 1.4301124338089721e-06
yet O 0 3.147307268136501e-07
reported O 0 3.1320365678766393e-07
and O 0 4.42263647926211e-08
the O 0 8.354484748451796e-08
CDK4 O 0 0.006099510472267866
mutation O 0 1.1379789839338628e-06
is O 0 3.852066399190335e-08
the O 0 4.333944403356327e-08
second O 0 5.008656103200337e-07
mutation O 0 2.3317008981393883e-06
detected O 0 1.0272080999129685e-06
in O 0 3.722557195828813e-08
this O 0 1.1216722128892798e-07
gene O 0 3.992756774096051e-06
worldwide O 0 2.9959833227621857e-06
. O 0 1.0282058610755485e-05

In O 0 1.756159690557979e-05
summary O 0 1.906855686684139e-05
, O 0 1.624180640646955e-06
our O 0 7.927506544547214e-07
results O 0 1.0821590876730625e-06
show O 0 4.7281017145905935e-07
frequent O 0 7.760478411000804e-07
involvement O 0 1.719451915960235e-06
of O 0 8.773631066105736e-08
the O 0 1.4360614386532689e-07
p16 O 0 1.4445585293287877e-05
gene O 0 1.992269517359091e-06
in O 0 1.7597925534573733e-06
familial B-Disease 1 0.9474936723709106
melanoma I-Disease 1 0.9999160766601562
and O 0 2.7840417260449613e-06
confirm O 0 2.4292141915793763e-06
the O 0 6.093380022775818e-08
role O 0 7.340590002513636e-08
of O 0 2.4763641803815517e-08
the O 0 1.0339183376117944e-07
CDK4 O 0 0.0006385438609868288
gene O 0 9.366753488393442e-07
as O 0 1.16349497147894e-07
a O 0 5.495706773217535e-06
melanoma B-Disease 1 0.9997995495796204
- O 0 0.09515207260847092
predisposing O 0 0.0008040391840040684
gene O 0 7.820972314220853e-06
. O 0 1.8343642977924901e-06
. O 0 9.645243153499905e-06

Progression O 0 0.0006889592623338103
of O 0 1.2264395081729162e-05
somatic O 0 0.0006993424613028765
CTG O 0 0.024277905002236366
repeat O 0 0.00013490371929947287
length O 0 1.3605967069452163e-05
heterogeneity O 0 7.723082671873271e-05
in O 0 2.9855422667424136e-07
the O 0 7.666425290153711e-07
blood O 0 0.0005359493661671877
cells O 0 0.0001544994447613135
of O 0 0.00019612164760474116
myotonic B-Disease 1 0.9999990463256836
dystrophy I-Disease 1 0.9999980926513672
patients O 1 0.9720540642738342
. O 0 0.00020908514852635562

The O 0 1.777453326212708e-05
genetic O 0 5.4638232541037723e-05
basis O 0 9.234824574377853e-06
of O 0 7.566057320218533e-05
myotonic B-Disease 1 0.999998927116394
dystrophy I-Disease 1 0.9999980926513672
( O 0 0.0008640575688332319
DM B-Disease 1 0.9999970197677612
) O 0 2.2444330625148723e-06
is O 0 1.0101371827886396e-07
the O 0 3.91389924914165e-08
expansion O 0 3.1161982860794524e-07
of O 0 7.89798804134989e-08
an O 0 2.2794854714902613e-07
unstable O 0 0.000287646078504622
CTG O 0 0.001658217515796423
repeat O 0 4.464515313884476e-06
in O 0 4.829951905094276e-08
the O 0 3.666871961627294e-08
34 O 0 6.140187451819656e-07
UTR O 0 7.270346031873487e-06
of O 0 5.979411099588106e-08
the O 0 2.2477480854377063e-07
DM B-Disease 1 0.9936829805374146
protein O 0 1.6916532104005455e-06
kinase O 0 2.61685499935993e-06
gene O 0 8.785776799413725e-07
on O 0 6.477850433839194e-07
chromosome O 0 2.1601166736218147e-05
19 O 0 8.200387128454167e-06
. O 0 8.200622687581927e-06

One O 0 4.556326530291699e-06
of O 0 5.696915650332812e-07
the O 0 3.046195331535273e-07
principal O 0 8.003073617146583e-07
features O 0 3.0984298859948467e-07
of O 0 1.4761830868792458e-07
the O 0 1.5873876009209198e-06
DM B-Disease 1 0.9999879598617554
mutation O 0 1.3867253073840402e-05
is O 0 9.6518952830138e-08
an O 0 3.7586939782841e-08
extraordinarily O 0 4.569422162603587e-05
high O 0 1.720552518236218e-06
level O 0 1.1864586468846028e-07
of O 0 4.790079799477098e-08
somatic O 0 4.74162952741608e-05
mosaicism O 0 0.10728836804628372
, O 0 5.064633796791895e-07
due O 0 5.283257564769883e-07
to O 0 7.452107553262977e-08
an O 0 5.923799406559738e-08
extremely O 0 4.882459961663699e-06
high O 0 1.2957229955645744e-06
degree O 0 2.7089549803349655e-07
of O 0 5.242992884291198e-08
somatic O 0 4.2126521293539554e-05
instability O 0 9.865594620350748e-06
both O 0 1.0516895798673431e-07
within O 0 6.792329543259257e-08
and O 0 1.534750424525555e-07
between O 0 3.1570260716762277e-07
different O 0 8.046143875617418e-07
tissues O 0 8.117141260299832e-05
. O 0 1.2467155102058314e-05

This O 0 1.7027377907652408e-05
instability O 0 8.716720913071185e-05
appears O 0 4.062903826707043e-06
to O 0 1.649677727755261e-07
be O 0 5.187240503801149e-08
biased O 0 3.251805935633456e-07
towards O 0 6.244439276770208e-08
further O 0 4.0439434911831995e-08
expansion O 0 3.6395479696693656e-07
and O 0 5.5710223989535734e-08
continuous O 0 2.329708479464898e-07
throughout O 0 6.305862854105726e-08
the O 0 2.827621869982977e-08
life O 0 1.1020414092399733e-07
of O 0 2.5992397567620174e-08
an O 0 2.0763657460065588e-08
individual O 0 5.47035980957844e-08
, O 0 6.841686683856096e-08
features O 0 2.6093985638908634e-07
that O 0 4.0630322217793946e-08
could O 0 1.4621609523146617e-07
be O 0 3.86976921618043e-08
associated O 0 3.113269428922649e-07
with O 0 8.476052215655727e-08
the O 0 9.108422460712973e-08
progressive O 0 1.0943381312245037e-05
nature O 0 6.68962627514702e-07
of O 0 4.6849896762068965e-07
the O 0 1.5535835700575262e-05
disease O 0 0.004030670039355755
. O 0 1.7968193787964992e-05

Although O 0 2.8731681595672853e-05
increasing O 0 1.0872136044781655e-05
measured O 0 9.447257980355062e-06
allele O 0 9.968833182938397e-06
size O 0 1.239001994690625e-05
between O 0 1.0263404874422122e-05
patients O 0 0.00023756959126330912
clearly O 0 2.14202100323746e-06
correlates O 0 7.477224698959617e-06
with O 0 2.6273048092662066e-07
an O 0 8.445262267287035e-08
increased O 0 4.144783815718256e-06
severity O 0 0.0008709137327969074
of O 0 3.4404902180540375e-06
symptoms O 0 0.0017679972806945443
and O 0 4.280994403416116e-07
an O 0 5.552627513338848e-08
earlier O 0 1.621145997887652e-06
age O 0 9.382417260894726e-07
of O 0 1.463754131236783e-07
onset O 0 0.019537923857569695
, O 0 3.393299152776308e-07
this O 0 2.7699863736074803e-08
correlation O 0 9.995096661441494e-07
is O 0 5.022527815867761e-08
not O 0 2.268593846110889e-08
precise O 0 2.8514421046565985e-07
and O 0 1.1412041089897684e-07
measured O 0 1.2508903637353797e-06
allele O 0 1.017436147776607e-06
length O 0 1.5309394711948698e-06
cannot O 0 4.501052899286151e-07
be O 0 2.564903844870514e-08
used O 0 2.6148534004732937e-08
as O 0 2.0666774958044698e-08
an O 0 2.435499091291149e-08
accurate O 0 1.2345378763711778e-06
predictor O 0 1.8764341803034768e-05
of O 0 1.2460262155400414e-07
age O 0 1.6494180954396143e-06
of O 0 2.7202083856536774e-06
onset O 0 0.12115367501974106
. O 0 3.320776522741653e-05

In O 0 7.829002242942806e-06
order O 0 2.006065415116609e-06
to O 0 2.8282647690502927e-07
further O 0 3.709070597324171e-07
characterize O 0 7.517930953326868e-06
the O 0 3.0254832950049604e-07
dynamics O 0 2.0163988665444776e-05
of O 0 2.9662230645044474e-06
DM B-Disease 1 0.9999643564224243
CTG O 0 0.1793494075536728
repeat O 0 7.20471070962958e-05
somatic O 0 0.00012881252041552216
instability O 0 7.236604869831353e-05
, O 0 5.371022666622594e-07
we O 0 1.4659838143415982e-07
have O 0 5.4905548552142136e-08
studied O 0 1.9906330805952166e-07
repeat O 0 2.2303822788671823e-06
length O 0 6.846640303592721e-07
changes O 0 1.4903227452123247e-07
over O 0 1.4376674073446338e-07
time O 0 1.5826563526388782e-07
in O 0 1.19142089261004e-06
111 O 1 0.7029250264167786
myotonic B-Disease 1 0.9999996423721313
dystrophy I-Disease 1 0.9999995231628418
patients O 0 0.43368592858314514
with O 0 4.704614184447564e-06
varying O 0 4.356968202046119e-05
clinical O 0 0.010188395157456398
severity O 0 0.00796545296907425
and O 0 3.3118317332991865e-06
CTG O 0 0.014189571142196655
repeat O 0 1.5374005670309998e-05
size O 0 1.007022433441307e-06
over O 0 1.2533460846952948e-07
time O 0 6.053218726265186e-08
intervals O 0 1.8985409155902744e-07
of O 0 5.1858357608125516e-08
1 O 0 4.952664767188253e-07
- O 0 3.879905489156954e-05
7 O 0 2.5552319584676297e-06
years O 0 2.374068571953103e-06
. O 0 8.384379725612234e-06

We O 0 2.582946945040021e-05
have O 0 1.1728388926712796e-06
found O 0 3.4548281746538123e-07
a O 0 8.500548176471057e-08
direct O 0 1.9714384791313933e-07
progression O 0 5.359395800041966e-06
of O 0 7.205396457266033e-08
the O 0 9.396443090281537e-08
size O 0 4.272520982340211e-06
heterogeneity O 0 1.4468362678599078e-05
over O 0 1.6725623197544337e-07
time O 0 1.0815157480692505e-07
related O 0 3.7822903209416836e-07
to O 0 8.653504579569926e-08
initial O 0 1.3774140370514942e-06
CTG O 0 0.0008544111624360085
repeat O 0 8.8652905105846e-06
size O 0 1.9981280274805613e-06
and O 0 8.361229220099631e-08
the O 0 2.1927489157747004e-08
time O 0 5.67782478810841e-08
interval O 0 3.608942051869235e-07
and O 0 4.945858478322407e-08
always O 0 1.5770065431297553e-07
biased O 0 7.675511142224423e-07
towards O 0 4.4147103039904323e-07
further O 0 5.114432610753283e-07
expansion O 0 1.3690817468159366e-05
. O 0 8.715213880350348e-06

Attempts O 0 7.682221621507779e-05
to O 0 4.71648263555835e-06
mathematically O 0 1.1387962331355084e-05
model O 0 2.5523042950226227e-06
the O 0 3.060311541958072e-07
dynamics O 0 6.257298809941858e-05
have O 0 2.30078001095535e-07
proved O 0 1.2518975154307554e-06
only O 0 2.9202695372987364e-08
partially O 0 7.623867759321001e-07
successful O 0 4.829634008274297e-07
suggesting O 0 1.275953422918974e-06
that O 0 4.5544005899955664e-08
individual O 0 1.0241206638283984e-07
specific O 0 2.6337144731769513e-07
genetic O 0 8.05153922556201e-06
and O 0 1.108703258978494e-06
/ O 0 0.0030336417257785797
or O 0 1.522213096905034e-06
environmental O 0 6.817464964115061e-06
factors O 0 3.777200561216887e-07
also O 0 4.033413247839235e-08
play O 0 7.011163205561388e-08
a O 0 1.2489705625284842e-07
role O 0 3.4942561910611403e-07
in O 0 4.869198733103985e-07
somatic O 0 0.00037529724068008363
mosaicism O 0 0.10636918991804123
. O 0 4.532641469268128e-06
. O 0 1.2261378287803382e-05

Aspartylglucosaminuria B-Disease 1 0.957587480545044
among O 0 0.0003003923047799617
Palestinian O 0 0.00044569355668500066
Arabs O 0 0.00051970622735098
. O 0 9.613356814952567e-05

Aspartylglucosaminuria B-Disease 1 0.999208390712738
( O 0 0.0008109477930702269
AGU B-Disease 1 0.9991449117660522
) O 0 4.6974232645879965e-06
is O 0 1.3788098840450402e-06
a O 0 4.056415036757244e-06
rare O 0 0.000725570076610893
disorder B-Disease 0 0.02653740905225277
of I-Disease 0 9.675945875642356e-07
glycoprotein I-Disease 0 0.06966778635978699
metabolism I-Disease 0 0.0016251301858574152
caused O 0 2.6099683964275755e-05
by O 0 7.786551350363879e-07
the O 0 8.212909961002879e-06
deficiency B-Disease 0 0.07662537693977356
of I-Disease 0 1.5712838319359435e-07
the I-Disease 0 1.1975163261013222e-06
lysosomal I-Disease 0 0.15021556615829468
enzyme I-Disease 0 1.8468057533027604e-05
aspartylglucosaminidase I-Disease 0 0.0018960373708978295
( O 0 2.1976325115247164e-06
AGA O 0 0.0002964298182632774
) O 0 2.396950549155008e-06
. O 0 6.885094990138896e-06

AGU B-Disease 1 0.999769389629364
is O 0 0.000984569313004613
inherited O 1 0.7932692170143127
as O 0 1.8412032659398392e-05
an O 0 1.8309476217837073e-05
autosomal O 1 0.948815107345581
recessive O 1 0.9508187770843506
trait O 0 0.0028777841944247484
and O 0 9.604689694242552e-06
occurs O 0 3.5290318010083865e-06
with O 0 1.5180103218881413e-07
a O 0 2.712889966005605e-07
high O 0 3.0999422051536385e-06
frequency O 0 1.007145328912884e-06
in O 0 1.663713788957466e-07
Finland O 0 2.1817158994963393e-06
because O 0 1.6497595822784206e-07
of O 0 9.633411224285737e-08
a O 0 1.0267175412081997e-06
founder O 0 6.578316970262676e-05
effect O 0 6.947120709810406e-06
. O 0 8.688897651154548e-06

While O 0 8.516196248820052e-05
very O 0 1.894335036922712e-05
few O 0 2.2867476218380034e-05
patients O 0 0.0018060988513752818
with O 0 1.7189737263834104e-05
AGU B-Disease 1 0.9998757839202881
have O 0 7.987900403350068e-07
been O 0 3.797600811594748e-07
reported O 0 5.345606837181549e-07
from O 0 1.356710868094524e-07
non O 0 2.3251147922564996e-06
- O 0 0.00019687711028382182
Finnish O 0 3.356073284521699e-05
origin O 0 3.8329892504407326e-07
, O 0 7.261257337631832e-07
we O 0 4.820407866645837e-06
diagnosed O 0 0.49434894323349
the O 0 3.460259449639125e-06
disorder O 0 0.14316724240779877
in O 0 6.85314660131553e-07
8 O 0 5.386510383686982e-05
patients O 0 2.662259248609189e-05
originating O 0 2.301833461615388e-07
from O 0 1.270311003054303e-07
3 O 0 9.931776503435685e-07
unrelated O 0 7.254609499796061e-06
families O 0 7.493533757951809e-07
, O 0 8.977460197456821e-08
all O 0 2.6241366413159994e-08
Palestinian O 0 7.368750516434375e-07
Arabs O 0 5.684797201865877e-07
from O 0 6.997056090085607e-08
the O 0 4.543182186012018e-08
region O 0 4.3864747567567974e-07
of O 0 4.014985108824476e-07
Jerusalem O 0 6.957987352507189e-05
. O 0 1.3518922969524283e-05

The O 0 6.81969613651745e-05
clinical O 0 0.12519879639148712
diagnosis O 1 0.9086537957191467
of O 0 5.670184691553004e-05
AGU B-Disease 1 0.9999785423278809
is O 0 6.274888164625736e-06
often O 0 1.4777523347220267e-06
difficult O 0 1.666743446548935e-05
, O 0 2.0196625882817898e-07
in O 0 4.059074143469843e-08
particular O 0 5.990118268073275e-08
early O 0 1.3938922904799256e-07
in O 0 3.550951177544448e-08
the O 0 3.815329918666066e-08
course O 0 9.962313924916089e-07
of O 0 7.340310759218482e-08
the O 0 1.054029553415603e-06
disease O 0 0.000152172680827789
, O 0 1.7610605596019013e-07
and O 0 7.734480078624983e-08
most O 0 3.25168798553932e-08
of O 0 5.8994896079411774e-08
the O 0 1.4513983614961035e-06
patients O 0 0.002446052385494113
are O 0 2.902311962316162e-06
diagnosed O 0 0.3876631259918213
after O 0 6.231737756934308e-07
the O 0 7.703694393512706e-08
age O 0 5.350977403395518e-07
of O 0 1.589076532582112e-07
5 O 0 3.297278453828767e-06
years O 0 5.410055109678069e-06
. O 0 1.0767394996946678e-05

However O 0 4.1421262721996754e-05
, O 0 5.245076408755267e-06
since O 0 2.2144843114801915e-06
these O 0 6.936058412065904e-07
patients O 0 5.212416726863012e-05
excrete O 0 1.7453405234846286e-05
early O 0 6.670323386970267e-07
large O 0 3.8490810538860387e-07
amounts O 0 2.931498954694689e-07
of O 0 8.261736894610294e-08
aspartylglucosamine O 0 0.00017736353038344532
in O 0 1.4962554928388272e-07
urine O 0 2.784989646897884e-06
, O 0 1.3043879221186216e-07
biochemical O 0 1.9768312995438464e-06
screening O 0 3.7684931157855317e-06
is O 0 1.423218236595858e-07
easy O 0 2.185547828048584e-06
by O 0 7.882695740590862e-07
urine O 0 4.8942791181616485e-05
chromatography O 0 0.01731801964342594
. O 0 3.224357897124719e-06
. O 0 1.2073312973370776e-05

Detection O 0 0.00041277369018644094
of O 0 8.841076123644598e-06
heterozygous O 0 3.2749579986557364e-05
carriers O 0 1.0533701242820825e-05
of O 0 8.795350936452451e-07
the O 0 2.7053481971961446e-05
ataxia B-Disease 1 0.9999849796295166
- I-Disease 1 0.9994539618492126
telangiectasia I-Disease 1 0.9997852444648743
( O 0 2.289521262355265e-06
ATM O 0 5.605983824352734e-05
) O 0 3.3265530419157585e-07
gene O 0 1.0123115998794674e-06
by O 0 4.552081804831687e-07
G2 O 0 0.0006187114049680531
phase O 0 4.973629620508291e-05
chromosomal O 0 0.001285487785935402
radiosensitivity O 0 0.0007250903290696442
of O 0 4.629529939847998e-06
peripheral O 0 0.03741677477955818
blood O 0 0.006744896527379751
lymphocytes O 0 0.059462450444698334
. O 0 2.6054049158119597e-05

In O 0 0.0006802388816140592
ataxia B-Disease 1 0.9999629259109497
- I-Disease 1 0.9997641444206238
telangiectasia I-Disease 1 0.9999638795852661
( O 0 4.079132486367598e-05
A B-Disease 0 0.004625270608812571
- I-Disease 1 0.9994974136352539
T I-Disease 1 0.9999916553497314
) O 0 5.1757747314695735e-06
patients O 0 0.00027393962955102324
, O 0 7.227487230920815e-07
mutations O 0 1.2924390375701478e-06
in O 0 3.8110751887643346e-08
a O 0 6.933896656846628e-08
single O 0 2.5767783995434e-07
gene O 0 5.812070753563603e-07
, O 0 1.7857388456832268e-07
ATM O 0 4.54669316241052e-05
, O 0 3.143734375044005e-07
result O 0 9.032573871081695e-07
in O 0 1.3574788226833334e-06
an O 0 0.00015966522914823145
autosomal B-Disease 1 0.999994158744812
recessive I-Disease 1 0.999995231628418
syndrome I-Disease 1 0.9999954700469971
that O 0 1.302431655858527e-06
embraces O 0 3.200280116288923e-05
a O 0 7.256273875100305e-07
variety O 0 7.097381171661254e-07
of O 0 2.0990634652662266e-07
clinical O 0 9.79667529463768e-05
features O 0 3.0970848001743434e-06
and O 0 2.7198323095944943e-06
manifests O 0 5.893230263609439e-05
extreme O 0 0.00015376636292785406
radiosensitivity O 0 0.017612768337130547
and O 0 2.395510136921075e-07
a O 0 1.853636462101349e-07
strong O 0 7.339595526900666e-07
pre O 0 0.00016413051343988627
- O 0 0.00213544350117445
disposition O 0 0.0006464422913268209
to O 0 7.825276952644344e-06
malignancy B-Disease 1 0.5767788290977478
. O 0 1.8495837139198557e-05

Heterozygotes O 0 0.001633948995731771
for O 0 4.038219685753575e-06
the O 0 8.831332820591342e-07
ATM O 0 0.00013932990259490907
gene O 0 4.491448635235429e-06
have O 0 1.8866141715534468e-07
no O 0 3.006075530720409e-07
clinical O 0 1.0391211617388763e-05
expression O 0 2.506038185856596e-07
of O 0 2.3017190642349306e-07
A B-Disease 0 0.006338545586913824
- I-Disease 1 0.9998646974563599
T I-Disease 1 0.9999939203262329
but O 0 8.088079994195141e-06
may O 0 1.5198475921351928e-05
be O 0 1.215077190863667e-05
cancer B-Disease 1 0.9074370861053467
prone O 0 0.004391103982925415
with O 0 2.948399924207479e-07
a O 0 7.054260890981823e-07
moderate O 0 0.00011424291733419523
increase O 0 7.064891747177171e-07
in O 0 2.2973989644015091e-07
in O 0 1.1022638091162662e-06
vitro O 0 0.0007966848206706345
radiosensitivity O 0 0.018871955573558807
. O 0 2.1600981199298985e-05

We O 0 2.9283653930178843e-05
performed O 0 1.5577716112602502e-05
a O 0 3.0078701911406824e-06
blind O 0 5.505844092112966e-05
chromosomal O 0 0.0004385912325233221
analysis O 0 3.310802412670455e-06
on O 0 2.3983657229109667e-06
G2 O 0 0.057925909757614136
- O 0 0.0005855351337231696
phase O 0 0.00021483752061612904
lymphocytes O 0 0.0011425616685301065
from O 0 1.3561624712110643e-07
7 O 0 1.0699994845708716e-06
unrelated O 0 1.2669534953602124e-05
A B-Disease 0 0.001435919082723558
- I-Disease 1 0.9999182224273682
T I-Disease 1 0.9999980926513672
patients O 0 0.008356102742254734
, O 0 9.449802291783271e-07
13 O 0 1.0396328207207262e-06
obligate O 0 8.201905075111426e-06
A B-Disease 0 0.002125981729477644
- I-Disease 1 0.9996378421783447
T I-Disease 1 0.9999784231185913
heterozygotes O 0 0.0007578477379865944
( O 0 2.2136090649382822e-07
parents O 0 2.6533081154411775e-07
of O 0 4.663338870614098e-08
the O 0 7.266314696607878e-07
patients O 0 5.3743297030450776e-05
) O 0 7.695514625538635e-08
, O 0 9.605798112488628e-08
and O 0 5.024779170526017e-08
14 O 0 1.6394112378748105e-07
normal O 0 1.5945902021030633e-07
controls O 0 5.071719897387084e-07
following O 0 2.0638420039631455e-07
X O 0 4.675204399973154e-05
- O 0 1.798761877580546e-05
irradiation O 0 3.3802707548602484e-06
with O 0 7.248928568515112e-08
1 O 0 2.5007093995554897e-07
Gy O 0 7.688340701861307e-05
in O 0 3.0777496107248226e-08
order O 0 3.1746605344551426e-08
to O 0 2.3482353839199277e-08
evaluate O 0 7.976801157383306e-07
this O 0 4.746326354165831e-08
cytogenetic O 0 5.846423300681636e-05
method O 0 2.7949892000833643e-07
as O 0 3.530730907641555e-08
a O 0 7.149841252385158e-08
tool O 0 9.855003781922278e-07
for O 0 1.7696804377465014e-07
detection O 0 6.7087821662425995e-06
of O 0 9.377274068356201e-07
ATM O 0 0.0004161478136666119
carriers O 0 4.612695556716062e-05
. O 0 1.1294569048914127e-05

Both O 0 0.00010679708793759346
A B-Disease 0 0.0006573738646693528
- I-Disease 1 0.956773579120636
T I-Disease 1 0.9997257590293884
homozygotes O 0 0.005620681215077639
and O 0 3.979122539021773e-06
heterozygotes O 0 0.00017143890727311373
showed O 0 5.224423603067407e-06
significantly O 0 2.0854924969171407e-06
increased O 0 5.471131316880928e-07
levels O 0 3.4315732477807614e-07
of O 0 2.0292367253205157e-07
radiation O 0 0.001269446685910225
- O 0 0.017626982182264328
induced O 0 0.00909870769828558
chromatid O 1 0.9184491038322449
damage O 0 0.003350614570081234
relative O 0 8.15058228909038e-06
to O 0 1.245581842113097e-07
that O 0 9.3617558150072e-08
of O 0 3.697267914049007e-07
normal O 0 6.238907189981546e-06
controls O 0 2.2149968572193757e-05
. O 0 1.0041377208835911e-05

These O 0 1.1833723874588031e-05
results O 0 5.063202934252331e-06
show O 0 1.1375482245057356e-06
that O 0 1.1328114624120644e-07
the O 0 2.6771547823045694e-07
G2 O 0 0.004416660871356726
- O 0 0.00012922675523441285
phase O 0 4.609748793882318e-05
chromosomal O 0 0.0029944158159196377
radiosensitivity O 0 0.002334298798814416
assay O 0 2.562463123467751e-05
can O 0 1.254567081332425e-07
be O 0 2.3675150728763583e-08
used O 0 2.0388284838190884e-08
for O 0 2.4559824396419572e-08
the O 0 6.602692081969508e-08
detection O 0 3.4676129416766344e-06
of O 0 3.1271747502614744e-07
A B-Disease 0 0.00046234941692091525
- I-Disease 1 0.9959263801574707
T I-Disease 1 0.9998177886009216
heterozygotes O 0 0.0025540131609886885
. O 0 2.399786353635136e-05

In O 0 2.3005564798950218e-05
combination O 0 2.7304924515192397e-05
with O 0 1.4884309393892181e-06
molecular O 0 6.06158391747158e-05
genetic O 0 1.3727594705414958e-05
analyses O 0 1.0501854376343545e-05
, O 0 4.698713098605367e-07
this O 0 5.572169925471826e-08
test O 0 8.364684617845342e-06
may O 0 1.555426365484891e-07
be O 0 5.753456822077396e-09
of O 0 1.2645812397238387e-08
value O 0 5.416123372015136e-08
in O 0 3.9952599450998605e-08
studies O 0 9.273501433426645e-08
of O 0 1.0228595215266978e-07
familial B-Disease 0 0.000914251257199794
and I-Disease 0 2.467470721967402e-06
sporadic I-Disease 0 0.00030145407072268426
cancers I-Disease 0 0.08153610676527023
aimed O 0 4.987682132195914e-06
at O 0 1.3890953596273903e-06
determination O 0 1.4591536228181212e-06
of O 0 3.701628159546999e-08
the O 0 7.559001602430726e-08
potential O 0 4.250645702086331e-07
involvement O 0 6.612982019760238e-07
of O 0 1.4468554354607477e-07
ATM O 0 0.0005666744546033442
mutations O 0 8.381109182664659e-06
in O 0 2.434404450468719e-06
tumor B-Disease 1 0.9256800413131714
risk O 0 6.996324373176321e-05
or O 0 9.073531828107662e-07
development O 0 3.18746174343687e-06
. O 0 2.6223062832286814e-06
. O 0 1.021707612380851e-05

Ataxia B-Disease 1 0.9999592304229736
- I-Disease 1 0.9994779229164124
telangiectasia I-Disease 1 0.9997672438621521
: O 0 1.8394885046291165e-05
identification O 0 6.663052317890106e-06
and O 0 6.887170229674666e-07
detection O 0 5.8105133575736545e-06
of O 0 2.2099222007909702e-07
founder O 0 6.363872671499848e-05
- O 0 0.0013806259958073497
effect O 0 9.65379740591743e-07
mutations O 0 5.164869776308478e-07
in O 0 3.835701889443044e-08
the O 0 8.550698282761005e-08
ATM O 0 2.332493750145659e-05
gene O 0 1.40215468036331e-06
in O 0 2.83844059367766e-07
ethnic O 0 2.1584421574516455e-06
populations O 0 6.279653462115675e-06
. O 0 3.886204467562493e-06

To O 0 8.03077364253113e-06
facilitate O 0 7.197743798315059e-06
the O 0 5.446252657748119e-07
evaluation O 0 2.5820349947025534e-06
of O 0 3.9209081137414614e-07
ATM O 0 0.00012438453268259764
heterozygotes O 0 3.1620314985048026e-05
for O 0 3.597259023990773e-07
susceptibility O 0 6.633923476329073e-05
to O 0 2.74041696002314e-07
other O 0 1.0292301340086851e-06
diseases O 0 0.010625126771628857
, O 0 3.622728570462641e-07
such O 0 8.436936127509398e-07
as O 0 1.7307993402937427e-05
breast B-Disease 1 0.9999805688858032
cancer I-Disease 1 0.9776907563209534
, O 0 2.0555501123453723e-06
we O 0 2.7171103056389256e-07
have O 0 7.564293724726667e-08
attempted O 0 1.493041168032505e-06
to O 0 8.631992187702053e-08
define O 0 1.0441150379847386e-06
the O 0 6.316769685099644e-08
most O 0 1.0497676328213856e-07
common O 0 3.2267433880406315e-07
mutations O 0 6.750322540938214e-07
and O 0 5.1689095670326424e-08
their O 0 4.5202682485978585e-08
frequencies O 0 1.0497631137695862e-06
in O 0 2.905363771787961e-06
ataxia B-Disease 1 0.9999157190322876
- I-Disease 1 0.9988407492637634
telangiectasia I-Disease 1 0.9999217987060547
( O 0 2.907789166783914e-06
A B-Disease 0 0.0003584898076951504
- I-Disease 1 0.9951289892196655
T I-Disease 1 0.9999125003814697
) O 0 1.0339100526834955e-06
homozygotes O 0 4.9603866500547156e-05
from O 0 2.571213144619833e-07
10 O 0 6.554722062901419e-07
ethnic O 0 2.205840246460866e-06
populations O 0 8.139785677485634e-06
. O 0 5.736448201787425e-06

Both O 0 4.526562406681478e-05
genomic O 0 0.00033788179280236363
mutations O 0 6.828181358287111e-05
and O 0 1.2933575135321007e-06
their O 0 2.680041291114321e-07
effects O 0 1.7670188299234724e-06
on O 0 4.033710183648509e-07
cDNA O 0 1.0957427548419219e-05
were O 0 2.933825044237892e-06
characterized O 0 6.813357322243974e-05
. O 0 1.589754901942797e-05

Protein O 0 0.00010569229198154062
- O 0 0.0001502739469287917
truncation O 0 4.523736424744129e-05
testing O 0 5.707597210857784e-06
of O 0 1.5976239353676647e-07
the O 0 1.5815126630513987e-07
entire O 0 7.133018584681849e-07
ATM O 0 4.961532340530539e-06
cDNA O 0 4.811479811905883e-06
detected O 0 2.6557913770375308e-06
92 O 0 1.0943097095150733e-06
( O 0 1.3067210602457635e-07
66 O 0 1.0588585155346664e-06
% O 0 1.0170699482614509e-07
) O 0 1.2072246136085596e-07
truncating O 0 7.2020211518974975e-06
mutations O 0 1.2742863191306242e-06
in O 0 1.5718504187134386e-07
140 O 0 1.4383616644408903e-06
mutant O 0 1.04371947600157e-05
alleles O 0 9.329273780167568e-06
screened O 0 3.701605965034105e-05
. O 0 1.751655145199038e-05

The O 0 1.6454760043416172e-05
haplotyping O 0 0.002998381620272994
of O 0 9.694801519799512e-06
patients O 0 0.004089144989848137
with O 0 2.3540326310467208e-06
identical O 0 0.00011112634820165113
mutations O 0 2.0396670151967555e-05
indicates O 0 2.9764469218207523e-06
that O 0 3.6725836594087014e-08
almost O 0 4.7613141873625864e-08
all O 0 1.0435606156988797e-08
of O 0 1.6616233722288598e-08
these O 0 3.457352093505506e-08
represent O 0 1.5334101988173643e-07
common O 0 4.288590389478486e-07
ancestry O 0 1.0266519439028343e-06
and O 0 2.2086284445776982e-07
that O 0 9.731233063803302e-08
very O 0 6.002940153848613e-07
few O 0 8.61339685798157e-07
spontaneously O 0 1.2949031770403963e-05
recurring O 0 1.9878925741068088e-05
ATM O 0 0.0005283579812385142
mutations O 0 2.8091892090742476e-05
exist O 0 4.320019343140302e-06
. O 0 7.20823982192087e-06

Assays O 0 0.0007581351674161851
requiring O 0 0.00013874734577257186
minimal O 0 5.310257256496698e-05
amounts O 0 5.290924491418991e-06
of O 0 4.775921524924343e-07
genomic O 0 1.7021322491928004e-05
DNA O 0 1.2980906831216998e-05
were O 0 1.479642008916926e-07
designed O 0 9.85693077382166e-07
to O 0 1.3400750731307198e-07
allow O 0 5.407364369602874e-07
rapid O 0 1.2758178854710422e-05
screening O 0 3.574456422938965e-05
for O 0 1.1377977671145345e-06
common O 0 3.7937454635539325e-06
ethnic O 0 7.136807653296273e-06
mutations O 0 4.595505743054673e-05
. O 0 1.0103034583153203e-05

These O 0 2.5115698008448817e-05
rapid O 0 5.9134570619789883e-05
assays O 0 0.0001647795579629019
detected O 0 7.774089317535982e-05
mutations O 0 8.573463674110826e-06
in O 0 2.303996637920136e-07
76 O 0 5.617663646262372e-06
% O 0 1.4200415421328216e-07
of O 0 1.1502929453399702e-07
Costa O 0 0.00010742984159151092
Rican O 0 0.0004376436409074813
patients O 0 0.0001669637276791036
( O 0 7.560558401564776e-08
3 O 0 1.813295966712758e-07
) O 0 3.542947624168846e-08
, O 0 3.419126670678452e-08
50 O 0 6.945346342490666e-08
% O 0 3.606292153790491e-08
of O 0 3.634674072827693e-08
Norwegian O 0 0.00021263335656840354
patients O 0 7.622587872901931e-05
( O 0 7.159516712818004e-08
1 O 0 2.385219772804703e-07
) O 0 3.945567073060374e-08
, O 0 4.3651954939605275e-08
25 O 0 7.781905964066027e-08
% O 0 3.0973833275993456e-08
of O 0 6.065561564128075e-08
Polish O 0 0.0028784791938960552
patients O 0 8.481799159199e-05
( O 0 9.455773408717505e-08
4 O 0 2.7832322757603833e-07
) O 0 3.269056136900872e-08
, O 0 3.249170532626522e-08
and O 0 3.328265663071761e-08
14 O 0 1.1191526283482744e-07
% O 0 5.105553313455857e-08
of O 0 9.221239594126018e-08
Italian O 0 0.0006159271579235792
patients O 0 0.00023935985518619418
( O 0 1.1981133241079078e-07
1 O 0 2.470170841206709e-07
) O 0 5.833895855289484e-08
, O 0 6.51022844522231e-08
as O 0 2.0668746714136432e-08
well O 0 4.115405616289536e-08
as O 0 4.995385083361725e-08
in O 0 2.6895224891632097e-07
patients O 0 3.377418806849164e-06
of O 0 8.157857678270375e-08
Amish O 0 4.501461808104068e-05
/ O 0 0.00025292669306509197
Mennonite O 0 6.388711335603148e-05
and O 0 2.0879158455500146e-06
Irish O 0 5.309651442075847e-06
English O 0 2.5367494345118757e-06
backgrounds O 0 4.6931654651416466e-05
. O 0 2.269718788738828e-05

Additional O 0 5.5768119636923075e-05
mutations O 0 4.843965143663809e-05
were O 0 1.082598714674532e-06
observed O 0 9.442532586945163e-07
in O 0 1.1884132078421317e-07
Japanese O 0 9.212139957526233e-07
, O 0 2.4659223640810524e-07
Utah O 0 1.658590463193832e-06
Mormon O 0 1.366781134493067e-06
, O 0 1.8120478273431218e-07
and O 0 3.089141955570085e-07
African O 0 1.2554364730021916e-06
American O 0 7.862756319809705e-06
patients O 0 0.0004306851769797504
. O 0 1.4792012734687887e-05

These O 0 9.082796168513596e-06
assays O 0 3.128462049062364e-05
should O 0 9.274515377910575e-07
facilitate O 0 2.046080226136837e-06
screening O 0 2.119472628692165e-05
for O 0 1.0346517456127913e-06
A B-Disease 0 0.00015687312406953424
- I-Disease 1 0.9956252574920654
T I-Disease 1 0.999933123588562
heterozygotes O 0 0.00023150601191446185
in O 0 2.1328530408482038e-07
the O 0 2.0409241585639393e-07
populations O 0 1.8603356011226424e-06
studied O 0 1.809980290090607e-06
. O 0 1.382176264996815e-06
. O 0 7.777514838380739e-06

The O 0 0.00010057262988993898
von B-Disease 1 0.8766019940376282
Hippel I-Disease 1 0.9946225881576538
- I-Disease 1 0.8110935091972351
Lindau I-Disease 1 0.995261549949646
tumor I-Disease 1 0.7228705883026123
suppressor O 0 0.0005435259081423283
gene O 0 7.079358510964084e-06
is O 0 2.360648352350836e-07
required O 0 1.4235439493859303e-07
for O 0 9.288902447224245e-08
cell O 0 9.200944077747408e-06
cycle O 0 3.2601915336272214e-06
exit O 0 1.1896419891854748e-05
upon O 0 2.1182390810281504e-06
serum O 0 0.0008950397605076432
withdrawal O 0 0.00016343570314347744
. O 0 1.0350443517381791e-05

The O 0 2.966654756164644e-05
inactivation O 0 0.0013097579358145595
of O 0 5.036801667301916e-06
the O 0 9.014330316858832e-06
von B-Disease 1 0.9883062243461609
Hippel I-Disease 1 0.9975374937057495
- I-Disease 1 0.8585601449012756
Lindau I-Disease 1 0.9777656197547913
( I-Disease 0 7.039730462565785e-06
VHL I-Disease 0 0.0018124498892575502
) I-Disease 0 2.2155657006805995e-06
tumor I-Disease 0 0.0015032220399007201
suppressor O 0 9.569464600645006e-05
gene O 0 1.4320955415314529e-05
predisposes O 0 0.00020613943343050778
affected O 0 3.192109943483956e-06
individuals O 0 2.1405087125003774e-07
to O 0 1.784737833077088e-07
the O 0 8.989057960206992e-07
human O 0 0.0018828792963176966
VHL B-Disease 1 0.9999979734420776
cancer I-Disease 1 0.9999996423721313
syndrome I-Disease 1 0.9999605417251587
and O 0 4.294817699701525e-06
is O 0 1.559100610393216e-06
associated O 0 4.800987881026231e-06
with O 0 6.111810307629639e-06
sporadic B-Disease 1 0.8040695190429688
renal I-Disease 1 0.9999996423721313
cell I-Disease 1 0.9998890161514282
carcinomas I-Disease 1 0.9999984502792358
( O 0 5.182845416129567e-05
RCC B-Disease 1 0.8765628337860107
) O 0 3.3137780519609805e-06
and O 0 1.0021583875641227e-05
brain B-Disease 0 0.003196514444425702
hemangioblastomas I-Disease 0 0.01610625721514225
. O 0 3.4982600482180715e-05

VHL O 0 0.048762038350105286
- O 0 0.0007557731587439775
negative O 0 3.284209378762171e-05
786 O 0 0.00021031135111115873
- O 0 0.00044612542842514813
0 O 0 1.2917605999973603e-05
RCC B-Disease 0 0.00934661366045475
cells O 0 3.4762288123602048e-06
are O 0 7.758696796145159e-08
tumorigenic O 0 0.00011213278776267543
in O 0 5.909546416660305e-07
nude O 0 0.00031672240584157407
mice O 0 2.67729556071572e-05
which O 0 1.1394249810336987e-07
is O 0 1.7291375797867659e-07
suppressed O 0 1.087282839762338e-06
by O 0 8.282989938379615e-08
the O 0 1.977888359760982e-07
reintroduction O 0 2.5549599740770645e-05
of O 0 5.233928732195636e-06
VHL B-Disease 0 0.008144237101078033
. O 0 2.5051707780221477e-05

Remarkably O 0 0.0063443598337471485
, O 0 7.540635579061927e-06
this O 0 6.274237875913968e-07
occurs O 0 1.002013163997617e-06
without O 0 1.7897313853154628e-07
affecting O 0 5.143737666912784e-07
the O 0 4.979489176548668e-08
growth O 0 5.417305715127441e-07
rate O 0 2.9815217317263887e-07
and O 0 1.260132052038898e-07
cell O 0 4.6365066737052985e-06
cycle O 0 9.940816880771308e-07
profile O 0 1.2331599918979919e-06
of O 0 3.872323972586855e-08
these O 0 1.2626367151824525e-07
cells O 0 1.5182578181338613e-06
in O 0 2.864738064545236e-07
culture O 0 5.770549705630401e-06
. O 0 8.316696948895697e-06

The O 0 1.4543283214152325e-05
786 O 0 0.0003339005052112043
- O 0 0.000847193063236773
0 O 0 8.82852964423364e-06
cell O 0 1.7058699086192064e-05
line O 0 1.7953641417989274e-06
, O 0 2.7323949325364083e-07
like O 0 5.898431822970451e-07
many O 0 5.547418595597264e-07
cancer B-Disease 0 0.16035258769989014
cells O 0 9.19715421332512e-06
, O 0 4.4018167955073295e-07
fails O 0 8.412492206844036e-06
to O 0 9.087459318379842e-08
exit O 0 3.936647772206925e-06
the O 0 2.361486082236297e-07
cell O 0 1.1496505067043472e-05
cycle O 0 4.8860460992727894e-06
upon O 0 2.17311094274919e-06
serum O 0 0.00032160666887648404
withdrawal O 0 0.0001068652345566079
. O 0 1.8049790014629252e-05

Here O 0 3.387459582882002e-05
, O 0 2.426560740786954e-06
it O 0 1.4142720772269968e-07
is O 0 6.142822428500949e-08
shown O 0 8.02196566951352e-08
that O 0 1.7420905606968518e-08
reintroduction O 0 7.378109785349807e-07
of O 0 1.9480294710660928e-08
the O 0 7.591235373638483e-08
wild O 0 1.662709792071837e-06
- O 0 0.0004249163903295994
type O 0 1.3882656276109628e-05
VHL B-Disease 0 8.311044803122059e-05
gene O 0 7.691822361266532e-07
restores O 0 1.4479778656095732e-06
the O 0 6.391814366679682e-08
ability O 0 3.12542454139475e-07
of O 0 1.80661601234533e-07
VHL O 0 0.0008061885600909591
- O 0 0.002507517347112298
negative O 0 4.246719254297204e-05
RCC B-Disease 1 0.9966526627540588
cancer I-Disease 1 0.6749191284179688
cells O 0 3.3896778859343613e-06
to O 0 1.7929876605649042e-07
exit O 0 3.931245373678394e-06
the O 0 2.1692005702789174e-07
cell O 0 1.299227551498916e-05
cycle O 0 2.4320675038325135e-06
and O 0 4.3633647806018416e-07
enter O 0 6.8809267759206705e-06
G0 O 0 0.04325622320175171
/ O 0 9.413997031515464e-05
quiescence O 0 0.00150209735147655
in O 0 4.58931253888295e-06
low O 0 0.00037295997026376426
serum O 0 0.0011328199179843068
. O 0 2.7902060537599027e-05

Both O 0 9.523910557618365e-05
VHL O 0 0.006245906930416822
- O 0 0.0002500026603229344
positive O 0 4.360679213277763e-06
and O 0 1.471905420658004e-06
VHL O 0 0.0007096183253452182
- O 0 0.00016092590522021055
negative O 0 7.215604910015827e-06
RCC B-Disease 0 0.015302919782698154
cells O 0 9.624357517168391e-06
exit O 0 6.001634119456867e-06
the O 0 4.0846302340469265e-07
cell O 0 3.558759271982126e-05
cycle O 0 7.046071004879195e-06
by O 0 1.8569146504887613e-06
contact O 0 2.243991184514016e-05
inhibition O 0 8.243895717896521e-05
. O 0 1.619996692170389e-05

The O 0 2.4641791242174804e-05
cyclin O 0 0.013843447901308537
- O 0 0.00021991458197589964
dependent O 0 1.7763706637197174e-05
kinase O 0 7.286976324394345e-05
inhibitor O 0 3.749680035980418e-05
, O 0 7.710014529038745e-07
p27 O 0 3.229093999834731e-05
, O 0 2.6443706246936927e-07
accumulates O 0 2.0479349132074276e-06
upon O 0 1.8647854460596136e-07
serum O 0 2.4250144633697346e-05
withdrawal O 0 1.1468024240457453e-05
, O 0 1.4637346623658232e-07
only O 0 2.4795969721935762e-08
in O 0 3.057510511439432e-08
the O 0 2.6230457805809237e-08
presence O 0 6.183766743106389e-08
of O 0 8.950122065698451e-08
VHL B-Disease 0 0.0006837141118012369
, O 0 1.3102187779168162e-07
as O 0 2.3320197328757786e-08
a O 0 5.3601041827278095e-08
result O 0 4.739505143902534e-08
of O 0 1.4180286278531185e-08
the O 0 2.3326025555547858e-08
stabilization O 0 2.212662366218865e-06
of O 0 1.2082152522907563e-07
the O 0 5.36691175057058e-07
protein O 0 7.991176971700042e-06
. O 0 4.0901172724261414e-06

We O 0 1.7134480003733188e-05
propose O 0 2.4179063984774984e-05
that O 0 5.142702548255329e-07
the O 0 1.946124825735751e-07
loss O 0 2.4252051389339613e-06
of O 0 1.4265569348026474e-07
wild O 0 5.750064701715019e-06
- O 0 0.0034205217380076647
type O 0 3.740383544936776e-05
VHL B-Disease 0 0.00024067338381428272
gene O 0 1.358231202175375e-06
results O 0 5.970396728116611e-07
in O 0 4.9005880242702915e-08
a O 0 1.1319971093826098e-07
specific O 0 5.159217835171148e-07
cellular O 0 0.00013391059474088252
defect O 0 0.00028006863431073725
in O 0 2.8659923145823996e-07
serum O 0 9.696946654003114e-05
- O 0 9.435818355996162e-05
dependent O 0 1.7115024775193888e-06
growth O 0 4.3948281813754875e-07
control O 0 3.0132281381156645e-07
, O 0 1.0244351500432458e-07
which O 0 9.529753697279375e-08
may O 0 1.679569436419115e-06
initiate O 0 0.00023087557929102331
tumor B-Disease 0 0.3965797424316406
formation O 0 0.00012142592458985746
. O 0 1.2664763744396623e-05

This O 0 9.023025995702483e-06
is O 0 2.3725770006421953e-06
corrected O 0 7.680844646529295e-06
by O 0 1.8038097948647192e-07
the O 0 1.2727495857234317e-07
reintroduction O 0 2.28754606723669e-06
of O 0 2.0780819909305137e-07
wild O 0 1.2788779713446274e-05
- O 0 0.00507708266377449
type O 0 0.00016061592032201588
VHL B-Disease 0 0.0020960953552275896
, O 0 1.299353698414052e-06
implicating O 0 0.00027149662491865456
VHL B-Disease 0 0.0007727811462245882
as O 0 1.206379920404288e-07
the O 0 4.544811815776484e-08
first O 0 2.618602366055711e-07
tumor B-Disease 0 0.0018265758408233523
suppressor O 0 1.7676558854873292e-05
involved O 0 2.0886758989036025e-07
in O 0 3.238967494212375e-08
the O 0 1.7084476056083986e-08
regulation O 0 1.1855718895503742e-07
of O 0 5.23476906266751e-08
cell O 0 1.3246905837149825e-05
cycle O 0 2.8328693133516936e-06
exit O 0 1.1701570656441618e-05
, O 0 1.8357241060584784e-07
which O 0 4.072024140100439e-08
is O 0 4.755142413159774e-08
consistent O 0 1.9801133532837412e-07
with O 0 5.64419053716847e-08
its O 0 1.2973004004379618e-07
gatekeeper O 0 0.00025303015718236566
function O 0 3.9435323628822516e-07
in O 0 1.8357310693772888e-07
the O 0 2.4945645691332174e-06
kidney O 0 0.46628835797309875
. O 0 2.513575736884377e-06
. O 0 1.3956821021565702e-05

Piebaldism B-Disease 1 0.9989951252937317
with O 0 0.00694645568728447
deafness B-Disease 1 0.9999898672103882
: O 0 8.594613609602675e-05
molecular O 0 0.0002966469619423151
evidence O 0 2.0937797671649605e-05
for O 0 4.558964974421542e-06
an O 0 9.72913494479144e-06
expanded O 0 0.011111323721706867
syndrome O 1 0.998660683631897
. O 0 4.494938184507191e-05

In O 0 1.9091976355412044e-05
a O 0 5.218856131250504e-06
South O 0 3.816432581515983e-06
African O 0 1.251301910087932e-06
girl O 0 9.607355423213448e-06
of O 0 1.1393319709895877e-06
Xhosa O 0 0.021547716110944748
stock O 0 6.53886454529129e-05
with O 0 4.633589469449362e-06
severe O 0 0.004866078030318022
piebaldism B-Disease 1 0.8878058195114136
and O 0 0.000566745235119015
profound O 1 0.9940544962882996
congenital O 1 0.9999997615814209
sensorineural B-Disease 1 0.9999997615814209
deafness I-Disease 1 0.9999997615814209
we O 0 0.00045624026097357273
identified O 0 4.277389234630391e-05
a O 0 1.0237237120236387e-06
novel O 0 2.71067574431072e-06
missense O 0 1.5407118553412147e-05
substitution O 0 5.06878905071062e-07
at O 0 3.4025021022898727e-07
a O 0 8.198772860623649e-08
highly O 0 1.535675835384609e-07
conserved O 0 1.4874387943564216e-07
residue O 0 3.0118604854578734e-07
in O 0 1.3145124100333305e-08
the O 0 1.1061938920420289e-08
intracellular O 0 2.7760540888266405e-07
kinase O 0 6.170353685774899e-07
domain O 0 7.445714089726607e-08
of O 0 1.7936883978109108e-08
the O 0 9.115287014083151e-08
KIT O 0 0.0004011602432001382
proto O 0 0.0005936090601608157
- O 0 0.0011646710336208344
oncogene O 0 0.0008848591824062169
, O 0 3.562698566383915e-06
R796G O 0 0.0003547860833350569
. O 0 1.2194269402243663e-05

Though O 0 0.00017726783698890358
auditory B-Disease 0 0.00426897406578064
anomalies I-Disease 0 0.09745018184185028
have O 0 1.3512659506886848e-06
been O 0 2.825832723374333e-07
observed O 0 1.0819928775163135e-06
in O 0 2.3159077500167768e-07
mice O 0 1.57089380081743e-05
with O 0 5.797953690489521e-07
dominant O 0 1.3833796401740983e-05
white O 0 0.00024307009880430996
spotting O 0 0.06454290449619293
( O 0 3.5270602438686183e-06
W O 0 0.2034951001405716
) O 0 1.4867028141907213e-07
due O 0 3.941941884022526e-07
to O 0 4.5031006834506115e-07
KIT O 0 0.36235928535461426
mutations O 0 0.00025486762751825154
, O 0 3.501019818941131e-05
deafness B-Disease 1 0.999967098236084
is O 0 6.65890809159464e-07
not O 0 2.5646403400969575e-07
typical O 0 4.060448191012256e-06
in O 0 6.297305503721873e-07
human O 0 4.231093498674454e-06
piebaldism B-Disease 0 0.027043526992201805
. O 0 2.809628495015204e-05

Thus O 0 3.785096851061098e-05
, O 0 2.842760977728176e-06
the O 0 4.639611006496125e-07
occurrence O 0 7.307814030355075e-06
of O 0 1.2805095138901379e-05
sensorineural B-Disease 1 0.9999969005584717
deafness I-Disease 1 0.9999994039535522
in O 0 1.5323665138566867e-05
this O 0 2.094357569148997e-06
patient O 0 0.000481157359899953
extends O 0 8.521621566615067e-06
considerably O 0 3.610095745898434e-06
the O 0 8.107907945031911e-08
phenotypic O 0 1.8035826769846608e-06
range O 0 1.2254516832399531e-06
of O 0 1.4759352495730127e-07
piebaldism B-Disease 0 0.0003069776576012373
due O 0 7.919519475763082e-07
to O 0 2.762684800927673e-07
KIT O 0 0.004230028484016657
gene O 0 3.839263172267238e-06
mutation O 0 1.3637071560879122e-06
in O 0 9.771873266117836e-08
humans O 0 3.184102865816385e-07
and O 0 4.292137987249589e-07
tightens O 0 0.00018063960305880755
the O 0 5.109957328386372e-07
clinical O 0 5.532660725293681e-05
similarity O 0 2.2585013539355714e-06
between O 0 6.207922069734195e-07
piebaldism B-Disease 0 0.0027142714243382215
and O 0 2.4878951876416977e-07
the O 0 8.093553560684086e-08
various O 0 1.3777213325738558e-07
forms O 0 2.6380159852124052e-06
of O 0 0.0005407329881563783
Waardenburg B-Disease 1 0.9999979734420776
syndrome I-Disease 1 0.9997852444648743
. O 0 8.916025763028301e-06
. O 0 2.9633461963385344e-05

Cycloheximide O 0 0.008400408551096916
facilitates O 0 0.00011368358536856249
the O 0 2.3658574264118215e-06
identification O 0 2.8155886866443325e-06
of O 0 5.193492143007461e-07
aberrant O 0 0.0001616172812646255
transcripts O 0 7.204587745945901e-05
resulting O 0 4.029894626000896e-06
from O 0 3.771916112782492e-07
a O 0 3.564248061138642e-07
novel O 0 1.7297671774940682e-06
splice O 0 5.892263652640395e-05
- O 0 0.00018019853450823575
site O 0 4.5609781409439165e-06
mutation O 0 7.371766059804941e-07
in O 0 1.0733019450981374e-07
COL17A1 O 0 0.0013740335125476122
in O 0 4.4721156200466794e-07
a O 0 3.055959268749575e-06
patient O 0 0.0002299921470694244
with O 0 2.0145422240602784e-05
generalized O 0 0.41756191849708557
atrophic B-Disease 1 0.9999028444290161
benign I-Disease 1 0.9991281628608704
epidermolysis I-Disease 1 0.9992080330848694
bullosa I-Disease 1 0.9970711469650269
. O 0 0.00044171942863613367

Patients O 1 0.7690737843513489
with O 0 0.00022393993276637048
generalized O 1 0.6254148483276367
atrophic B-Disease 1 0.9999305009841919
benign I-Disease 1 0.9994820952415466
epidermolysis I-Disease 1 0.999795138835907
bullosa I-Disease 1 0.9992423057556152
often O 0 3.455036130617373e-05
show O 0 6.57354803479393e-06
decreased O 0 8.546222488803323e-06
expression O 0 5.689433919542353e-07
of O 0 3.0254022931330837e-07
type O 0 4.484213059186004e-05
XVII O 1 0.6434569358825684
collagen O 0 0.006481977179646492
, O 0 7.656276466150302e-07
a O 0 3.9634360859963635e-07
transmembrane O 0 3.0403141863644123e-05
hemidesmosomal O 0 0.00013234086509328336
protein O 0 1.5088149893927039e-06
encoded O 0 1.5072215546751977e-06
by O 0 1.363322098768549e-06
COL17A1 O 0 0.0007724181632511318
. O 0 1.3374440641200636e-05

This O 0 1.1682369404297788e-05
report O 0 9.115936336456798e-06
documents O 0 4.30636737291934e-06
a O 0 1.019872570395819e-06
novel O 0 6.027410563547164e-06
splice O 0 0.00015888220514170825
- O 0 0.00031194297480396926
site O 0 6.835087333456613e-06
mutation O 0 2.230231302746688e-06
in O 0 2.780961381176894e-07
COL17A1 O 0 0.0005980271962471306
in O 0 4.869950771535514e-07
a O 0 1.8507269032852491e-06
patient O 0 0.00011545942834345624
with O 0 5.084473741590045e-06
generalized O 0 0.07835439592599869
atrophic B-Disease 1 0.9999740123748779
benign I-Disease 1 0.9986250400543213
epidermolysis I-Disease 1 0.9998897314071655
bullosa I-Disease 1 0.9995298385620117
, O 0 2.091975875373464e-05
and O 0 1.1336105671944097e-06
applies O 0 7.772314347676001e-07
a O 0 1.0716491516404858e-07
new O 0 1.261191187040822e-07
methodology O 0 3.525630631884269e-07
to O 0 5.1706059878142696e-08
define O 0 6.614988592446025e-07
and O 0 1.5509353090692457e-07
characterize O 0 7.157357231335482e-06
the O 0 2.2809599897755106e-07
resulting O 0 2.093055627483409e-06
mRNA O 0 3.997835392510751e-06
splice O 0 5.0803955673472956e-05
variants O 0 1.086054999177577e-05
. O 0 1.3018421668675728e-05

Mutational O 0 0.0033544059842824936
analysis O 0 4.266032192390412e-05
of O 0 5.0868843572970945e-06
COL17A1 O 0 0.054428353905677795
identified O 0 1.033524313243106e-05
a O 0 1.6388561334679252e-06
maternally O 0 0.0006625247187912464
inherited O 0 0.009022653102874756
G O 0 0.012595629319548607
- O 0 0.00024070045037660748
to O 0 1.3304282902026898e-06
- O 0 0.009001178666949272
T O 0 0.10800689458847046
transversion O 0 0.00012923071335535496
at O 0 1.893700130040088e-07
the O 0 6.006111874512499e-08
- O 0 4.0956165321404114e-06
1 O 0 1.2984564534690435e-07
position O 0 8.014930585886759e-08
of O 0 1.6530573532236303e-07
exon O 0 2.5743545847944915e-05
32 O 0 4.619651008397341e-06
. O 0 5.314748250384582e-06

This O 0 1.3151417078915983e-05
acceptor O 0 8.432340109720826e-05
splice O 0 0.00020355152082629502
- O 0 0.000302940490655601
site O 0 5.434881586552365e-06
mutation O 0 1.499915924796369e-06
led O 0 3.061053064357111e-07
to O 0 3.566603723470507e-08
the O 0 3.500582579363254e-08
formation O 0 4.522079279922764e-07
of O 0 7.5736629412404e-08
aberrant O 0 1.4756393284187652e-05
transcripts O 0 6.817874236730859e-06
present O 0 7.207155476862681e-07
at O 0 2.004818270506803e-06
extremely O 0 2.285958362335805e-05
low O 0 3.744045534403995e-05
levels O 0 8.494391295243986e-06
. O 0 6.099814982007956e-06

Based O 0 3.063162512262352e-05
on O 0 2.882369471990387e-06
our O 0 1.2084726677130675e-06
recent O 0 9.34008312469814e-07
finding O 0 1.3483464726959937e-06
that O 0 2.5576011353223294e-07
cycloheximide O 0 0.0002765175304375589
stabilized O 0 0.00011148978228447959
mutant O 0 1.126688948716037e-05
COL17A1 O 0 0.0003050224913749844
transcripts O 0 6.695768206554931e-06
in O 0 3.6917080592502316e-07
keratinocytes O 0 6.1514598201029e-05
homozygous O 0 6.784199285903014e-06
for O 0 4.093767529411707e-07
a O 0 2.6310085559089202e-06
frameshift O 0 0.01172643806785345
mutation O 0 6.450248292821925e-06
, O 0 2.0742545814300684e-07
the O 0 8.49946175662808e-08
effects O 0 4.5478338961402187e-07
of O 0 4.444224543931341e-08
the O 0 1.4076999832468573e-07
splice O 0 4.3376458052080125e-05
- O 0 7.232052303152159e-05
site O 0 1.5661106544939685e-06
mutation O 0 2.881660918774287e-07
on O 0 5.8234117972233435e-08
splicing O 0 4.4866658299724804e-07
of O 0 1.0667690020227383e-07
COL17A1 O 0 0.0002807161072269082
transcripts O 0 4.25603820985998e-06
were O 0 1.0127087790579026e-07
determined O 0 2.393075817508361e-07
using O 0 1.3496956796643644e-07
reverse O 0 3.5398011277720798e-06
transcriptase O 0 2.0255534764146432e-05
polymerase O 0 2.2440253815148026e-05
chain O 0 2.7977437184745213e-06
reaction O 0 1.5839880518342397e-07
of O 0 1.8206389285069235e-08
total O 0 6.718153855445053e-08
RNA O 0 3.2787826853564184e-07
from O 0 1.3539629151182453e-07
keratinocytes O 0 1.1722747331077699e-05
incubated O 0 6.946286248421529e-06
for O 0 5.618197747025988e-07
2 O 0 7.605649898323463e-06
. O 0 8.720742698642425e-06

5 O 0 0.00011108937178505585
h O 0 0.0003831064095720649
in O 0 8.58853468344023e-07
the O 0 2.1413826800653624e-07
presence O 0 6.84096846725879e-07
or O 0 1.6386579204663576e-07
absence O 0 4.581724226682127e-07
of O 0 1.5500776839871833e-07
10 O 0 2.0014790607092436e-06
microg O 0 0.00111956219188869
cycloheximide O 0 0.0009494685218669474
per O 0 9.234700883098412e-06
ml O 0 0.0004216453817207366
. O 0 9.071681233763229e-06

Using O 0 9.612277608539443e-06
this O 0 7.431384005940345e-07
approach O 0 2.1447233393701026e-06
, O 0 4.943679527968925e-07
an O 0 1.8221994935174735e-07
abnormally O 0 7.097221532603726e-05
spliced O 0 1.9466222511255182e-05
transcript O 0 1.7521964764455333e-05
was O 0 1.0651043567122542e-06
identified O 0 5.58957367502444e-07
that O 0 1.8745202723380316e-08
contains O 0 3.1400514188817397e-08
an O 0 9.808712952974474e-09
extra O 0 8.071477708426755e-08
264 O 0 3.216215134216327e-07
bases O 0 8.283732455538484e-08
upstream O 0 1.0904327751859455e-07
from O 0 3.406452719900699e-08
exon O 0 1.2058178526785923e-06
32 O 0 5.321232947608223e-07
, O 0 6.903952964876225e-08
resulting O 0 1.2096818124973652e-07
in O 0 3.521993718891281e-08
a O 0 2.015070208472025e-07
premature O 0 4.351118695922196e-05
termination O 0 1.149767831520876e-05
codon O 0 1.4687926750411862e-06
27 O 0 6.665007390438404e-07
bp O 0 3.24094094139582e-06
downstream O 0 7.309963621082716e-07
from O 0 6.454035883507458e-08
the O 0 1.8408256607926887e-07
cryptic O 0 1.8084749171976e-05
splice O 0 0.00010630582983139902
site O 0 2.315172787348274e-05
. O 0 1.4580933566321619e-05

Three O 0 8.17384079709882e-06
other O 0 1.5761780787215685e-06
splice O 0 5.986502947052941e-05
variants O 0 4.73862837679917e-06
, O 0 3.57503608938714e-07
including O 0 1.209847937388986e-07
one O 0 4.68941969700154e-08
derived O 0 2.907908402960402e-08
from O 0 1.5397869645994433e-08
the O 0 1.525218884523838e-08
skipping O 0 4.5650631363969296e-07
of O 0 5.0701235210226514e-08
exon O 0 6.6491629695519805e-06
32 O 0 1.1482569561849232e-06
, O 0 2.3508351887358003e-07
were O 0 1.5731490066173137e-07
also O 0 6.004531769576715e-07
identified O 0 6.403079623851227e-06
. O 0 9.003298146126326e-06

These O 0 1.1578641533560585e-05
results O 0 1.3391044376476202e-05
indicate O 0 3.3212697871931596e-06
the O 0 1.8927647715827334e-07
usefulness O 0 4.247372999088839e-06
of O 0 2.842552646598051e-07
cycloheximide O 0 0.08090737462043762
treatment O 0 5.93947661400307e-05
in O 0 1.337853205995998e-07
evaluating O 0 2.142462335541495e-06
the O 0 9.135146683547646e-08
abnormal O 0 2.7065377707913285e-06
processing O 0 3.490742130907165e-07
of O 0 2.4486062955020316e-08
mRNA O 0 1.3750933192113735e-07
due O 0 8.799825224059532e-08
to O 0 5.891337551133802e-08
splice O 0 1.0499940799491014e-05
- O 0 0.00012103473272873089
site O 0 4.196193003735971e-06
mutations O 0 1.4633427554144873e-06
, O 0 1.047843198875853e-07
because O 0 1.2407019767124439e-07
( O 0 8.416542129907612e-08
i O 0 2.822167459726188e-07
) O 0 4.813158938077322e-08
aberrant O 0 1.4045328953216085e-06
splicing O 0 9.546761248202529e-07
often O 0 1.4940113146622025e-07
generates O 0 4.385634042591846e-07
a O 0 2.9332494477785076e-07
premature O 0 4.302496017771773e-05
termination O 0 2.0836811017943546e-05
codon O 0 3.214174512322643e-06
, O 0 1.972971261920975e-07
( O 0 1.0878464706820523e-07
ii O 0 1.657483517192304e-05
) O 0 9.642253218089536e-08
transcripts O 0 1.4086604096519295e-06
with O 0 3.633815026660159e-07
premature O 0 0.000247313262661919
termination O 0 4.175989670329727e-05
codons O 0 2.6168825115746586e-06
can O 0 1.478567099866268e-07
occur O 0 1.1668284827237585e-07
at O 0 2.9666711043319083e-07
low O 0 6.940518687770236e-06
or O 0 5.832704346175888e-07
undetectable O 0 5.531083297682926e-05
levels O 0 3.7160174315431505e-07
due O 0 9.586140237161089e-08
to O 0 3.3434790935871206e-08
nonsense O 0 2.312329115738976e-06
- O 0 5.224184405960841e-06
mediated O 0 1.4436318451771513e-06
mRNA O 0 2.5892452981679526e-07
decay O 0 1.0065481319543323e-06
, O 0 7.07985918779741e-08
and O 0 3.866308873057278e-08
( O 0 3.832893469279952e-08
iii O 0 1.5593190255458467e-05
) O 0 2.1413249839952186e-08
the O 0 1.6225222054799815e-08
levels O 0 5.1232877495976936e-08
of O 0 7.312749961130294e-09
these O 0 1.484206091362239e-08
transcripts O 0 1.3971517773825326e-06
can O 0 7.28732914012653e-08
be O 0 4.030498601537147e-08
increased O 0 2.1748928702436388e-07
by O 0 8.198098271350318e-07
cycloheximide O 0 0.0006917296559549868
. O 0 1.0073498742713127e-05

A O 0 0.00011722946510417387
deletion O 0 0.0006176119786687195
mutation O 0 4.564086702885106e-05
in O 0 2.44019656747696e-06
COL17A1 O 0 0.006726129446178675
in O 0 6.529665483867575e-07
five O 0 8.351487963409454e-07
Austrian O 0 6.241493247216567e-05
families O 0 4.155596343480283e-06
with O 0 4.361228093330283e-06
generalized O 0 0.07199124991893768
atrophic B-Disease 1 0.9999606609344482
benign I-Disease 1 0.9986999034881592
epidermolysis I-Disease 1 0.9998359680175781
bullosa I-Disease 1 0.9986540079116821
represents O 0 3.5612240026239306e-05
propagation O 0 1.0933126759482548e-05
of O 0 8.928823831411137e-07
an O 0 1.7332383777102223e-06
ancestral O 0 0.00010155048221349716
allele O 0 0.0001201905615744181
. O 0 1.758535836415831e-05

Patients O 1 0.9131801724433899
with O 0 0.00022291505592875183
generalized O 1 0.5594239830970764
atrophic B-Disease 1 0.9999691247940063
benign I-Disease 1 0.9998372793197632
epidermolysis I-Disease 1 0.9999351501464844
bullosa I-Disease 1 0.9998465776443481
, O 0 7.650638144696131e-05
a O 0 4.113830527785467e-06
usually O 0 2.3622660592081957e-06
nonlethal O 0 5.1944189181085676e-05
form O 0 1.5921042404443142e-06
of O 0 5.054431767348433e-06
junctional B-Disease 1 0.9909699559211731
epidermolysis I-Disease 1 0.9991911053657532
bullosa I-Disease 1 0.9964281916618347
, O 0 9.033469723362941e-06
have O 0 1.0429833992020576e-06
generalized O 0 4.019568223156966e-05
blistering B-Disease 0 0.007226661313325167
, O 0 5.230630995356478e-05
nail B-Disease 1 0.9998596906661987
dystrophy I-Disease 1 0.9996954202651978
, O 0 0.00047761001042090356
patchy B-Disease 1 0.999923825263977
alopecia I-Disease 1 0.9999943971633911
, O 0 0.00017331411072518677
and O 0 0.0006223859381861985
dental B-Disease 1 0.9994723200798035
abnormalities I-Disease 1 0.998150110244751
. O 0 0.0001537346834084019

Skin B-Disease 1 0.9907903671264648
fragility I-Disease 1 0.5861904621124268
in O 0 7.932559128676075e-06
most O 0 1.7313665239271359e-06
cases O 0 2.9893819828430424e-06
is O 0 2.2343584760164958e-07
due O 0 8.641453064228699e-07
to O 0 2.1190157895034645e-07
mutations O 0 1.817499423850677e-06
in O 0 3.8917235656299454e-08
the O 0 4.6334779568724116e-08
gene O 0 9.157491263067641e-07
encoding O 0 1.8377050992057775e-06
type O 0 2.7877964384970255e-05
XVII O 1 0.5582132935523987
collagen O 0 0.021334871649742126
( O 0 7.283677859959425e-06
COL17A1 O 0 0.0051724836230278015
) O 0 4.283479029254522e-06
. O 0 8.76537524163723e-06

Recently O 0 0.00044397113379091024
, O 0 1.0266998287988827e-05
we O 0 1.6789706478448352e-06
reported O 0 2.355995547986822e-06
five O 0 8.739156101000845e-07
Austrian O 0 5.4236479627434164e-05
families O 0 4.278172127669677e-06
with O 0 3.815297077380819e-06
generalized O 0 0.11249948292970657
atrophic B-Disease 1 0.9999748468399048
benign I-Disease 1 0.9991599321365356
epidermolysis I-Disease 1 0.9998283386230469
bullosa I-Disease 1 0.9996498823165894
who O 0 3.737894439836964e-05
share O 0 4.418730441102525e-06
the O 0 7.784925060150272e-07
same O 0 2.5691224436741322e-06
COL17A1 O 0 0.05312449112534523
mutation O 0 0.00012508415966294706
. O 0 1.5973442714312114e-05

Affected O 0 0.0005885251448489726
individuals O 0 1.0840145478141494e-05
in O 0 7.309656666620867e-07
three O 0 4.439031897618406e-07
families O 0 6.633820817114611e-07
are O 0 6.113006634222984e-08
homozygous O 0 1.4422281537918025e-06
for O 0 2.507778731342114e-07
4003delTC O 0 0.0007165559800341725
, O 0 3.079893247104337e-07
whereas O 0 9.82593064691173e-07
those O 0 9.740127637769547e-08
in O 0 6.428689403037424e-08
two O 0 1.6780775524694036e-07
others O 0 6.601118229809799e-07
are O 0 4.846257297685952e-07
compound O 0 1.8563072444521822e-05
heterozygotes O 0 0.00014553456276189536
. O 0 1.2047159543726593e-05

To O 0 2.277641760883853e-05
determine O 0 2.3043266992317513e-05
if O 0 1.1475772225821856e-06
the O 0 1.924325090385537e-07
occurrence O 0 1.4676193131890614e-06
of O 0 1.8097836118613486e-07
4003delTC O 0 0.0002778478665277362
in O 0 1.1806660182855921e-07
these O 0 7.596970874601539e-08
unrelated O 0 8.909668395062909e-06
families O 0 9.397568874192075e-07
signifies O 0 1.8218291870653047e-06
propagation O 0 1.065671312971972e-06
of O 0 6.673339925100663e-08
an O 0 1.0768945912786876e-07
ancestral O 0 5.693402727047214e-06
allele O 0 1.509500179963652e-06
or O 0 1.4063019193599757e-07
a O 0 2.6313645662412455e-07
mutational O 0 0.00014417046622838825
hot O 0 3.259360892116092e-05
spot O 0 1.213284758705413e-05
, O 0 4.861255433752376e-07
haplotypes O 0 3.796300461544888e-06
were O 0 8.885893976184889e-08
determined O 0 7.145935114749591e-07
for O 0 2.7380423262002296e-07
polymorphisms O 0 2.6459587388671935e-05
both O 0 1.8912437838025653e-07
within O 0 2.852478360182431e-07
and O 0 1.5729556253063492e-06
flanking O 0 0.00165868632029742
COL17A1 O 0 0.08566773682832718
. O 0 1.755786252033431e-05

Five O 0 7.155221828725189e-05
intragenic O 0 0.005114224273711443
polymorphisms O 0 0.00022226094733923674
were O 0 7.710286240580899e-07
chosen O 0 6.290462692959409e-07
based O 0 3.7158756072130927e-07
on O 0 4.426966313531011e-07
their O 0 1.3266260339150904e-06
informativeness O 0 0.002143080113455653
. O 0 1.684633389231749e-05

One O 0 9.071698514162563e-06
of O 0 9.549802371111582e-07
these O 0 3.278742042311933e-07
, O 0 3.26785993820522e-07
not O 0 9.342865325834282e-08
previously O 0 4.563426614367927e-07
reported O 0 1.2718301150016487e-06
, O 0 1.388590504802778e-07
was O 0 2.229649993523708e-07
2988 O 0 6.794276123400778e-05
A O 0 3.840372926333657e-07
or O 0 3.344544836636487e-07
C O 0 1.547455758554861e-05
that O 0 2.388574671385868e-08
introduces O 0 2.5570011530362535e-07
a O 0 6.44619930767476e-08
new O 0 1.693387048362638e-07
restriction O 0 7.297787760762731e-07
site O 0 9.83435938906041e-07
for O 0 4.010121585906745e-07
Eco0109 O 0 0.00012269880971871316
I O 0 1.2563618838612456e-05
. O 0 6.538759862451116e-06

All O 0 7.135766281862743e-06
the O 0 3.548541599229793e-06
4003delTC O 0 0.00014237183495424688
alleles O 0 1.4984967492637224e-05
showed O 0 7.329842446779367e-06
the O 0 2.593708643416903e-07
same O 0 4.0148165680875536e-07
haplotype O 0 1.7306325389654376e-05
for O 0 2.3071143573361041e-07
these O 0 3.063074132114707e-07
five O 0 1.1977562053289148e-06
polymorphic O 0 0.00031714027863927186
markers O 0 0.00015555339632555842
. O 0 1.8564878700999543e-05

Fourteen O 0 0.0003504243795759976
microsatellite O 0 0.008791067637503147
polymorphisms O 0 0.0004366470966488123
were O 0 1.7422986502424465e-06
selected O 0 4.7446877715628943e-07
based O 0 3.0081747581789386e-07
on O 0 1.5054705215789e-07
their O 0 1.3995347103445965e-07
high O 0 4.837728283746401e-06
heterozygosity O 0 0.00011762687063310295
and O 0 6.93261412720858e-08
their O 0 4.8621821235883544e-08
location O 0 4.3459971266202047e-07
within O 0 3.3599795301597624e-07
10q23 O 0 4.409746179590002e-05
- O 0 8.72769087436609e-05
q25 O 0 0.0002807677665259689
near O 0 2.5871033358271234e-05
COL17A1 O 0 0.001072772080078721
. O 0 1.5350271496572532e-05

Three O 0 5.052426422480494e-05
families O 0 3.9209244278026745e-05
shared O 0 1.666107891651336e-05
microsatellite O 0 0.001963398652151227
polymorphisms O 0 0.00017422922246623784
covering O 0 2.17964898183709e-05
at O 0 1.5793829106769408e-06
most O 0 2.1025735463808815e-07
19 O 0 2.276894520036876e-06
cM O 0 8.074919605860487e-05
, O 0 2.650869816989143e-07
whereas O 0 3.5461732750263764e-07
the O 0 5.291931159945307e-08
others O 0 1.8795027756368654e-07
shared O 0 1.97205139329526e-07
smaller O 0 5.963824492027925e-07
regions O 0 2.3927975689730374e-07
consistent O 0 1.9172361476194055e-07
with O 0 2.2604355365274387e-07
cross O 0 1.7670037095740554e-06
- O 0 3.309304156573489e-05
over O 0 2.3152034600570914e-07
events O 0 1.2742421517941693e-07
during O 0 1.552104151869571e-07
passage O 0 4.852500978813623e-07
of O 0 5.386063151036069e-08
this O 0 9.532044487059466e-08
mutation O 0 6.869203730275331e-07
through O 0 1.7634100402119657e-07
several O 0 4.5635917444997176e-07
generations O 0 9.591143680154346e-06
. O 0 1.0392777767265216e-05

These O 0 1.633460669836495e-05
results O 0 1.6379111912101507e-05
indicate O 0 4.7512990022369195e-06
that O 0 4.0203951812145533e-07
4003delTC O 0 0.0003473853867035359
occurs O 0 8.354531360055262e-07
on O 0 1.2568699503390235e-07
a O 0 1.5396761909869383e-07
single O 0 6.439164508265094e-07
ancestral O 0 6.781333468097728e-06
allele O 0 9.869019777397625e-06
. O 0 1.2975606296095066e-06
. O 0 6.4843679865589365e-06

The O 0 6.0593305533984676e-05
haptoglobin O 0 0.009579600766301155
- O 0 0.0007610643515363336
gene O 0 5.913964196224697e-05
deletion O 0 0.00010186715371673927
responsible O 0 1.647046155994758e-05
for O 0 7.887156243668869e-06
anhaptoglobinemia B-Disease 0 0.027985991910099983
. O 0 5.989518467686139e-05

We O 0 2.855470302165486e-05
have O 0 1.7927533235706505e-06
found O 0 7.821367375981936e-07
an O 0 1.8941877044653666e-07
allelic O 0 3.6468656617216766e-05
deletion O 0 7.6293176789477e-06
of O 0 2.0649092391522572e-07
the O 0 3.6876684816888883e-07
haptoglobin O 0 0.0011468437733128667
( O 0 3.0245428206399083e-07
Hp O 0 1.4985117786636692e-06
) O 0 9.10324615688296e-08
gene O 0 2.52914475140642e-07
from O 0 2.9058179862317957e-08
an O 0 4.025059396894903e-08
individual O 0 2.1715767672958464e-07
with O 0 1.5457096651516622e-06
anhaptoglobinemia B-Disease 0 0.007340025622397661
. O 0 1.9601427993620746e-05

The O 0 2.461834992573131e-05
Hp O 0 0.00011042443657061085
gene O 0 1.821640216803644e-05
cluster O 0 2.186973870266229e-05
consists O 0 5.493948833645845e-07
of O 0 1.4024513461663446e-07
coding O 0 6.877036412333837e-06
regions O 0 1.9288891905944183e-07
of O 0 2.952681654733169e-08
the O 0 5.37996456273504e-08
alpha O 0 1.5074285784066888e-06
chain O 0 1.5929167602735106e-06
and O 0 7.462362816568202e-08
beta O 0 8.154930242199043e-07
chain O 0 3.5689384958459414e-07
of O 0 1.2456739639787884e-08
the O 0 3.7460331725469587e-08
haptoglobin O 0 2.817958011291921e-05
gene O 0 6.172513735691609e-07
( O 0 6.52163762993041e-08
Hp O 0 5.631382578030752e-07
) O 0 1.8845726756921977e-08
and O 0 1.0993305821216381e-08
of O 0 1.0904322778060305e-08
the O 0 2.2156783074933628e-08
alpha O 0 1.25882911561348e-06
chain O 0 1.3933382660979987e-06
and O 0 1.1859665960400889e-07
beta O 0 8.530731747669051e-07
chain O 0 4.476164860989229e-07
of O 0 2.527412945596552e-08
the O 0 6.970388710669795e-08
haptoglobin O 0 0.0002476265945006162
- O 0 6.194336310727522e-05
related O 0 2.0191150724713225e-06
gene O 0 1.2205193797854008e-06
( O 0 1.383873495797161e-07
Hpr O 0 3.438103158259764e-05
) O 0 6.00938960815256e-08
, O 0 6.663749729796109e-08
in O 0 4.900905636873176e-08
tandem O 0 3.030602556464146e-06
from O 0 8.046453814358756e-08
the O 0 1.4121884817086539e-07
5 O 0 1.2119014627387514e-06
side O 0 4.444311798579292e-06
. O 0 4.717760475614341e-06

Southern O 0 0.0001224729639943689
blot O 0 0.0005262751365080476
and O 0 5.125876668898854e-06
PCR O 0 4.366219582152553e-05
analyses O 0 1.0887067219300661e-05
have O 0 3.5991979530081153e-07
indicated O 0 8.520381697962875e-07
that O 0 2.6814825915266738e-08
the O 0 3.280624483181782e-08
individual O 0 7.389716216721354e-08
with O 0 2.2111449027306662e-07
anhaptoglobinemia B-Disease 0 0.0036151439417153597
was O 0 4.945283080814988e-07
homozygous O 0 8.367464943148661e-07
for O 0 3.929390146595324e-08
the O 0 5.754315779427088e-08
gene O 0 8.314352726301877e-07
deletion O 0 3.7228348901408026e-06
and O 0 1.078454729963596e-07
that O 0 3.477583376820803e-08
the O 0 3.710661999889453e-08
gene O 0 8.543963190277282e-07
deletion O 0 1.7100145441872883e-06
was O 0 1.5641045081338234e-07
included O 0 1.9804382134225307e-07
at O 0 2.6984167789123603e-07
least O 0 4.77674149124141e-08
from O 0 2.728305936727793e-08
the O 0 4.1422676844149464e-08
promoter O 0 6.090712304285262e-06
region O 0 3.309825444830494e-07
of O 0 6.070087010812131e-08
Hp O 0 2.3593054265802493e-06
to O 0 1.2573399033044552e-07
Hpr O 0 5.413850522018038e-05
alpha O 0 7.127497383407899e-07
but O 0 5.3013064160722934e-08
not O 0 3.385957114687699e-08
to O 0 1.689688104988818e-07
Hpr O 0 0.00027851646882481873
beta O 0 7.77173863752978e-06
( O 0 9.798018254514318e-07
Hpdel O 0 0.0001859420444816351
) O 0 1.6500380297657102e-06
. O 0 6.002429472573567e-06

In O 0 1.2279387192393187e-05
addition O 0 5.02129114465788e-06
, O 0 9.397587632520299e-07
we O 0 1.5607638204073737e-07
found O 0 1.8654613143098686e-07
seven O 0 1.24538459544965e-07
individuals O 0 7.085736086764882e-08
with O 0 1.4882489551837352e-07
hypohaptoglobinemia B-Disease 0 0.001496681710705161
in O 0 2.0235069086993462e-07
three O 0 1.8742849761110847e-07
families O 0 6.198173423399567e-07
, O 0 1.503327098362206e-07
and O 0 1.0741006661874053e-07
the O 0 3.8309494243549125e-08
genotypes O 0 2.1407813619589433e-06
of O 0 1.873580401934305e-08
six O 0 6.838777011353159e-08
of O 0 4.40146372682193e-08
the O 0 7.512947775012435e-08
seven O 0 2.9007520652157837e-07
individuals O 0 1.3297594136929547e-07
were O 0 5.1645344001371996e-08
found O 0 9.160724800949538e-08
to O 0 1.089434888967844e-07
be O 0 5.893415959690174e-07
Hp2 O 0 0.009376812726259232
/ O 0 0.0009470120421610773
Hpdel O 0 0.003763743443414569
. O 0 2.003963163588196e-05

The O 0 1.526049163658172e-05
phenotypes O 0 0.0003214245953131467
and O 0 4.243895091349259e-06
genotypes O 0 0.00012452458031475544
in O 0 2.2747774153231148e-07
one O 0 6.285425513397058e-08
of O 0 4.036314749100711e-08
these O 0 4.89870970454831e-08
three O 0 1.1613774830721013e-07
families O 0 7.8265236425068e-07
showed O 0 1.0554609843893559e-06
the O 0 8.238322379838792e-08
father O 0 1.9092710772383725e-06
to O 0 8.996383371595584e-08
be O 0 8.86255264731517e-08
hypohaptoglobinemic B-Disease 0 0.00053634331561625
( O 0 2.3440338736691047e-07
Hp2 O 0 7.303449092432857e-05
) O 0 7.49029780422461e-08
and O 0 1.5936855390918936e-07
Hp2 O 0 0.00017156418471131474
/ O 0 4.2814539483515546e-05
Hpdel O 0 0.00024245835084002465
, O 0 1.6177762063307455e-07
the O 0 6.151264386744515e-08
mother O 0 1.7452354086344712e-06
to O 0 2.9186884020759862e-08
be O 0 5.523252610828422e-08
Hp2 O 0 7.174447819124907e-05
- O 0 2.8056447263224982e-05
1 O 0 2.7462851903692354e-07
and O 0 1.5215671567148092e-07
Hp1 O 0 0.00011224459012737498
/ O 0 2.2255899239098653e-05
Hp2 O 0 8.731627895031124e-05
, O 0 6.1891476832443e-08
one O 0 1.2145547678699131e-08
of O 0 1.2914032510025208e-08
the O 0 2.0295011893267656e-08
two O 0 4.363231198567519e-08
children O 0 1.291849685003399e-07
to O 0 5.847631356914462e-08
be O 0 1.42402598157787e-07
hypohaptoglobinemic B-Disease 0 0.0008299247710965574
( O 0 2.3333060994445987e-07
Hp2 O 0 6.37029079371132e-05
) O 0 6.740923907955221e-08
and O 0 1.3788016417493054e-07
Hp2 O 0 0.00034201255766674876
/ O 0 6.617799226660281e-05
Hpdel O 0 0.001428081188350916
, O 0 2.3288001216315024e-07
and O 0 7.644108279691864e-08
the O 0 4.0886785512839197e-08
other O 0 5.836978544948579e-08
child O 0 1.0285746157023823e-06
to O 0 6.481013770098798e-08
be O 0 1.5785593632244854e-07
Hp1 O 0 8.395528129767627e-05
and O 0 3.884389627728524e-07
Hp1 O 0 0.0021718349307775497
/ O 0 0.00033694025478325784
Hpdel O 0 0.0015362361446022987
, O 0 3.1395009614243463e-07
showing O 0 7.804118808962812e-07
an O 0 5.5874746607287307e-08
anomalous O 0 1.5682218872825615e-05
inheritance O 0 7.124492185539566e-06
of O 0 4.1483960444566037e-07
Hp O 0 6.673554889857769e-05
phenotypes O 0 5.286131636239588e-05
in O 0 3.55668959173272e-07
the O 0 6.518329769278353e-07
child O 0 2.849703378160484e-05
with O 0 6.362413387250854e-06
Hp1 O 0 0.021221663802862167
. O 0 2.166382000723388e-05

The O 0 3.196379111614078e-05
Hp2 O 0 0.027695830911397934
/ O 0 0.0018175719305872917
Hpdel O 0 0.019349562004208565
individuals O 0 3.1407275855599437e-06
had O 0 4.579688663852721e-07
an O 0 9.253606236825362e-08
extremely O 0 2.327155698367278e-06
low O 0 3.6758117403223878e-06
level O 0 1.7332618540422118e-07
of O 0 5.689728155289231e-08
Hp O 0 2.3154627797339344e-06
( O 0 9.242705090173331e-08
mean O 0 4.3768764612650557e-07
+ O 0 7.947718586365227e-06
/ O 0 7.896247552707791e-06
- O 0 2.6546658773440868e-05
SD O 0 0.0002672679256647825
= O 0 4.008426003565546e-06
0 O 0 4.804661557500367e-07
. O 0 1.0869442945704577e-07
049 O 0 1.752129537635483e-05
+ O 0 4.978776360076154e-06
/ O 0 2.3837560547690373e-06
- O 0 3.0995047382020857e-06
0 O 0 2.50658786171698e-07
. O 0 6.95043524956418e-08
043 O 0 5.2305554163467605e-06
mg O 0 1.3029637557337992e-05
/ O 0 9.174709703074768e-06
ml O 0 3.14439857902471e-05
; O 0 3.272591015957005e-07
n O 0 6.364932232827414e-06
= O 0 7.55595863211056e-07
6 O 0 1.3690819855582959e-07
) O 0 2.0427521008059557e-08
, O 0 1.7040052924244264e-08
compared O 0 7.722908179630394e-08
with O 0 8.07501621125084e-09
the O 0 9.790842803170108e-09
level O 0 5.2072646639089726e-08
( O 0 8.832814479831086e-09
1 O 0 1.8842348126213437e-08
. O 0 1.1810349143104304e-08
64 O 0 2.3231436330206634e-07
+ O 0 1.9122269350191345e-06
/ O 0 1.8140930251320242e-06
- O 0 3.1526712973573012e-06
1 O 0 6.76930795862063e-08
. O 0 1.7164204280106787e-08
07 O 0 5.942629854871484e-07
mg O 0 6.928912625880912e-06
/ O 0 5.067182883067289e-06
ml O 0 9.168167707684916e-06
) O 0 3.77305262588834e-08
obtained O 0 4.259093344671783e-08
from O 0 4.377986684289681e-08
52 O 0 6.403456040970923e-07
healthy O 0 5.78169249365601e-07
volunteers O 0 5.784262384622707e-07
having O 0 2.9079646424179373e-07
phenotype O 0 7.572971298941411e-06
Hp2 O 0 0.00012995807628612965
, O 0 1.6142779202255042e-07
whereas O 0 2.560612699653575e-07
the O 0 7.791961564862504e-08
serum O 0 1.5635643649147823e-05
Hp O 0 1.3059478760624188e-06
level O 0 9.98684868136479e-08
of O 0 2.7236371380467972e-08
an O 0 3.100315026927092e-08
individual O 0 5.960509241731415e-08
with O 0 2.1442639308588696e-07
Hp1 O 0 0.003397547174245119
/ O 0 0.0001548705477034673
Hpdel O 0 0.0003660981310531497
was O 0 2.52997506322572e-06
0 O 0 7.729790013399906e-06
. O 0 4.883652309217723e-06

50 O 0 7.414139690808952e-05
mg O 0 0.0005135480896569788
/ O 0 0.00020884943660348654
ml O 0 0.0002598589926492423
, O 0 3.889564652581612e-07
which O 0 4.4672901822195854e-08
was O 0 4.198800596100227e-08
approximately O 0 2.464377146793595e-08
half O 0 3.848496987757244e-08
the O 0 1.7989405520779655e-08
level O 0 3.676571580513155e-08
of O 0 2.4090812900112724e-08
Hp O 0 1.3428223155642627e-06
in O 0 6.750651238007777e-08
control O 0 4.936513846587331e-07
sera O 0 1.2577691450132988e-05
from O 0 6.184863821090403e-08
the O 0 1.6982987460778531e-07
Hp1 O 0 0.0014586352044716477
phenotype O 0 8.750450433581136e-06
( O 0 6.081211978425927e-08
1 O 0 1.3474991078510357e-07
. O 0 3.3246745800852295e-08
26 O 0 2.5137671855191e-07
+ O 0 3.497870920909918e-06
/ O 0 2.275307679155958e-06
- O 0 2.5862000256893225e-06
0 O 0 1.2258615811333584e-07
. O 0 2.1389002569094373e-08
33 O 0 1.9102388648661872e-07
mg O 0 4.158875071880175e-06
/ O 0 5.860969395143911e-06
ml O 0 2.2710784833179787e-05
; O 0 1.8964145453992387e-07
n O 0 3.938720510632265e-06
= O 0 1.048645458467945e-06
9 O 0 1.4612911058975442e-07
) O 0 2.4325093050947544e-08
, O 0 2.1613615786009177e-08
showing O 0 1.7736391555445152e-07
a O 0 1.4109390633620933e-07
gene O 0 2.5907963845384074e-06
- O 0 0.0003360769769642502
dosage O 0 0.0001812087430153042
effect O 0 5.53157269678195e-06
. O 0 5.868967491551302e-06

The O 0 6.596249932044884e-06
other O 0 1.431687223885092e-06
allele O 0 9.822934771364089e-06
( O 0 5.736616799367766e-07
Hp2 O 0 0.00010927043331321329
) O 0 1.728287060132061e-07
of O 0 5.613110332092219e-08
individuals O 0 2.6101304229086963e-07
with O 0 2.1898529212194262e-07
Hp2 O 0 0.013864155858755112
/ O 0 0.0007260382990352809
Hpdel O 0 0.005183075089007616
was O 0 8.142387173393217e-07
found O 0 8.843522181223307e-08
to O 0 2.57075658538497e-08
have O 0 1.9635290726682797e-08
, O 0 2.8272982177668382e-08
in O 0 1.3510988772225119e-08
all O 0 1.9799106354412288e-08
exons O 0 2.5217175334546482e-06
, O 0 2.2186074488672602e-07
no O 0 1.765852033486226e-07
mutation O 0 7.213893695734441e-07
, O 0 1.1304091884767331e-07
by O 0 1.5787009033374488e-07
DNA O 0 5.681124093825929e-06
sequencing O 0 1.797614459064789e-05
. O 0 8.775554306339473e-06

On O 0 7.4925787885149475e-06
the O 0 4.352276619101758e-07
basis O 0 2.7177944161849155e-07
of O 0 7.045643002356883e-08
the O 0 6.145084086028874e-08
present O 0 1.3977152946154092e-07
study O 0 1.8101340515386255e-07
, O 0 5.4336105392849277e-08
the O 0 1.70314748970668e-08
mechanism O 0 6.764532400893586e-08
of O 0 4.797788122345992e-08
anhaptoglobinemia B-Disease 0 0.0001508220302639529
and O 0 6.063618229745771e-08
the O 0 2.8570704913022382e-08
mechanism O 0 1.58904470026755e-07
of O 0 6.503291416493084e-08
anomalous O 0 2.5717632524902e-05
inheritance O 0 1.0208671483269427e-05
of O 0 5.994118623675604e-07
Hp O 0 0.00014231374370865524
phenotypes O 0 5.689141835318878e-05
were O 0 8.176438655027596e-07
well O 0 1.5071325378812617e-06
explained O 0 1.0364261470385827e-05
. O 0 9.61737532634288e-06

However O 0 3.1044964998727664e-05
, O 0 2.6084085220645647e-06
the O 0 7.62003764975816e-07
mechanism O 0 2.4200851385103306e-06
of O 0 1.9957683434768114e-06
hypohaptoglobinemia B-Disease 0 0.05564051866531372
remains O 0 0.00012556194269564003
unknown O 0 0.00010724550520535558

ATM O 0 0.011029397137463093
mutations O 0 0.0009536262950859964
and O 0 1.7923697669175453e-05
phenotypes O 0 0.0014810936991125345
in O 0 6.997885793680325e-05
ataxia B-Disease 1 0.9999874830245972
- I-Disease 1 0.999816358089447
telangiectasia I-Disease 1 0.9999526739120483
families O 0 2.2272461137617938e-05
in O 0 2.7514576572684746e-07
the O 0 1.0235152814175308e-07
British O 0 5.678127195096749e-07
Isles O 0 7.893371730460785e-06
: O 0 1.3357497152810538e-07
expression O 0 6.59734240571197e-08
of O 0 3.385408220424324e-08
mutant O 0 3.3382050332875224e-06
ATM O 0 1.9161379896104336e-05
and O 0 9.207899864804858e-08
the O 0 1.49660962733833e-07
risk O 0 1.5465588148799725e-05
of O 0 9.481665074417833e-06
leukemia B-Disease 1 0.9999876022338867
, O 0 0.05548851937055588
lymphoma B-Disease 1 0.9999998807907104
, O 0 0.0001748729991959408
and O 0 0.005623312201350927
breast B-Disease 1 0.9999873638153076
cancer I-Disease 1 0.9987112283706665
. O 0 5.862339821760543e-05

We O 0 1.1282501873211004e-05
report O 0 1.5446988754774793e-06
the O 0 1.8827336134563666e-07
spectrum O 0 3.388539880688768e-06
of O 0 2.570799040313432e-07
59 O 0 2.6889943910646252e-05
ATM O 0 0.00018976717547047883
mutations O 0 7.309772627195343e-06
observed O 0 5.9458211580931675e-06
in O 0 8.721807716938201e-06
ataxia B-Disease 1 0.9999783039093018
- I-Disease 1 0.9998323917388916
telangiectasia I-Disease 1 0.9999582767486572
( O 0 9.309286724601407e-06
A B-Disease 0 0.007268149871379137
- I-Disease 1 0.9998264908790588
T I-Disease 1 0.9999949932098389
) O 0 8.451862413494382e-06
patients O 0 2.1752011889475398e-05
in O 0 1.6968385807558661e-07
the O 0 2.877678468848899e-07
British O 0 5.6022286116785835e-06
Isles O 0 0.00015607342356815934
. O 0 2.1195455701672472e-05

Of O 0 2.6194111342192627e-05
51 O 0 0.0002525006711948663
ATM O 0 0.0029216588009148836
mutations O 0 0.0001268291671294719
identified O 0 8.1208900155616e-06
in O 0 2.8570332233357476e-07
families O 0 6.345564429466322e-07
native O 0 2.289629748020161e-07
to O 0 5.8929558122144954e-08
the O 0 5.392827517880505e-08
British O 0 3.8743709751543065e-07
Isles O 0 8.501571755914483e-06
, O 0 2.3723886499738e-07
11 O 0 2.1356028412355954e-07
were O 0 8.91480382847476e-08
founder O 0 7.021928468020633e-06
mutations O 0 6.378661510098027e-07
, O 0 4.5685908389714314e-08
and O 0 3.974798445938177e-08
2 O 0 6.745862890511489e-08
of O 0 1.7582506117719277e-08
these O 0 3.934024661589319e-08
11 O 0 6.38062033431197e-07
conferred O 0 2.182061507483013e-06
a O 0 1.4393455103345332e-06
milder O 0 0.020507317036390305
clinical O 0 0.006868450436741114
phenotype O 0 0.0001828886743169278
with O 0 3.000000958763849e-07
respect O 0 4.795391532752546e-07
to O 0 5.358305656955054e-07
both O 0 7.010233275650535e-06
cerebellar B-Disease 1 0.9950961470603943
degeneration I-Disease 1 0.962084949016571
and O 0 1.2931780474900734e-05
cellular O 0 0.0011593998642638326
features O 0 5.861467798240483e-05
. O 0 2.6152731152251363e-05

We O 0 2.2881220502313226e-05
report O 0 6.125762411102187e-06
, O 0 6.679605348836049e-07
in O 0 1.6915647904625075e-07
two O 0 2.1674243555480643e-07
A B-Disease 0 0.00020815776952076703
- I-Disease 1 0.9967526793479919
T I-Disease 1 0.9999790191650391
families O 0 4.674751835409552e-06
, O 0 2.644360677095392e-07
an O 0 1.0169845410246126e-07
ATM O 0 6.038990250090137e-05
mutation O 0 1.3643548300024122e-06
( O 0 2.247285095791085e-07
7271T O 0 3.832898801192641e-05
- O 0 0.00043645399273373187
- O 0 0.007716529071331024
> O 0 0.0003028861538041383
G O 0 0.00031177885830402374
) O 0 5.4593524367874124e-08
that O 0 3.26104760972612e-08
may O 0 1.9748065938074433e-07
be O 0 2.8252175710008487e-08
associated O 0 1.5451274748556898e-07
with O 0 6.456609469296382e-08
an O 0 3.914459156817429e-08
increased O 0 2.2070460090617416e-06
risk O 0 4.085812906851061e-05
of O 0 1.1495967555674724e-05
breast B-Disease 1 0.999976396560669
cancer I-Disease 1 0.9708132743835449
in O 0 9.868556389847072e-07
both O 0 8.104805147013394e-07
homozygotes O 0 0.0010147008579224348
and O 0 2.4176031274691923e-06
heterozygotes O 0 0.00013717480760533363
( O 0 5.487120802172285e-07
relative O 0 1.2494961083575618e-05
risk O 0 3.5485854823491536e-06
12 O 0 1.3365040274493367e-07
. O 0 6.020058407329998e-08
7 O 0 6.03802106979856e-07
; O 0 6.358000064210501e-07
P O 0 0.0017085169674828649
= O 0 1.79144751655258e-06
. O 0 6.674154207075844e-08
0025 O 0 1.327109566773288e-05
) O 0 4.9142538927071655e-08
, O 0 3.598830033979539e-08
although O 0 2.55821035466397e-08
there O 0 2.0063007255544107e-08
is O 0 3.176071672328362e-08
a O 0 1.6114384493448597e-07
less O 0 2.803250481520081e-06
severe O 0 0.0003666807897388935
A B-Disease 0 0.00452135456725955
- I-Disease 1 0.9999107122421265
T I-Disease 1 0.9999953508377075
phenotype O 0 0.00029176034149713814
in O 0 1.6404153768689866e-07
terms O 0 2.3047965669320547e-07
of O 0 7.117797906630585e-08
the O 0 1.4749616639164742e-07
degree O 0 7.2188195190392435e-06
of O 0 1.762005740602035e-05
cerebellar B-Disease 1 0.9992109537124634
degeneration I-Disease 1 0.9983918070793152
. O 0 0.00018844081205315888

This O 0 1.0549343642196618e-05
mutation O 0 3.420815119170584e-05
( O 0 1.922250476127374e-06
7271T O 0 0.0001442763750674203
- O 0 0.0013657229719683528
- O 0 0.007497540675103664
> O 0 0.0002077899407595396
G O 0 8.757878822507337e-05
) O 0 4.969280098521267e-08
also O 0 1.0602955846650275e-08
allows O 0 2.005275412386709e-08
expression O 0 2.1744112288502038e-08
of O 0 8.842894416716263e-09
full O 0 1.9290989428100147e-07
- O 0 2.6734433049568906e-05
length O 0 1.493183731327008e-06
ATM O 0 1.7607308109290898e-05
protein O 0 2.8437432320060907e-07
at O 0 6.32590868576699e-08
a O 0 4.687139210091118e-08
level O 0 1.237983582313973e-07
comparable O 0 6.929044502612669e-07
with O 0 6.530002139015778e-08
that O 0 1.2795003101473412e-07
in O 0 7.420520091727667e-07
unaffected O 0 0.00013799250882584602
individuals O 0 3.7286085898813326e-06
. O 0 7.505151188524906e-06

In O 0 1.0448657121742144e-05
addition O 0 2.922819248851738e-06
, O 0 8.97512904884934e-07
we O 0 1.299300009804938e-07
have O 0 5.585172857536236e-08
studied O 0 1.939177423082583e-07
18 O 0 7.778320423312834e-07
A B-Disease 0 0.0005256086587905884
- I-Disease 1 0.9998024106025696
T I-Disease 1 0.9999986886978149
patients O 0 0.0012003020383417606
, O 0 1.7484261150002567e-07
in O 0 7.556867842595238e-08
15 O 0 3.024531167739042e-07
families O 0 6.463016006819089e-07
, O 0 5.37491189334105e-07
who O 0 5.5102227634051815e-06
developed O 0 0.0014678157167509198
leukemia B-Disease 1 0.9999486207962036
, O 0 0.002654664684087038
lymphoma B-Disease 1 0.9999997615814209
, O 0 2.552266414568294e-05
preleukemic O 1 0.8686693906784058
T O 1 0.988684356212616
- O 0 0.01970876194536686
cell O 0 0.0010816463036462665
proliferation O 0 0.00189352931920439
, O 0 1.44811983773252e-05
or O 0 0.0037684377748519182
Hodgkin B-Disease 1 0.9999991655349731
lymphoma I-Disease 1 0.9999997615814209
, O 0 4.763548986375099e-06
mostly O 0 1.3309295354702044e-06
in O 0 2.5461779387114802e-06
childhood O 0 0.0008294912404380739
. O 0 3.3722040825523436e-05

A O 0 7.488777191611007e-05
wide O 0 4.059538332512602e-05
variety O 0 3.678041821331135e-06
of O 0 7.72540431626112e-07
ATM O 0 0.00032677018316462636
mutation O 0 7.29630983187235e-06
types O 0 2.912454419856658e-06
, O 0 2.564681835792726e-07
including O 0 5.28179668890516e-07
missense O 0 9.04399566934444e-05
mutations O 0 1.8265088783664396e-06
and O 0 1.1425959911548489e-07
in O 0 9.785787824512227e-08
- O 0 0.0001305608602706343
frame O 0 1.7689728338154964e-05
deletions O 0 2.0277646399335936e-05
, O 0 3.2142281725100474e-07
were O 0 8.872683565641637e-08
seen O 0 4.802439548257098e-07
in O 0 2.0032499037370144e-07
these O 0 1.3638865539178369e-06
patients O 0 0.00021478695271071047
. O 0 1.2145048458478414e-05

We O 0 1.4155840290186461e-05
also O 0 8.269318527709402e-07
show O 0 8.595262102062406e-07
that O 0 9.50684224676479e-08
25 O 0 1.60369026502849e-07
% O 0 5.030389260696211e-08
of O 0 2.9282903213356803e-08
all O 0 9.060028816065824e-08
A B-Disease 0 0.0028424705378711224
- I-Disease 1 0.9999459981918335
T I-Disease 1 0.9999990463256836
patients O 0 0.001254735398106277
carried O 0 7.102608492459694e-07
in O 0 1.7208400038271066e-07
- O 0 0.0002746004902292043
frame O 0 5.2918203437002376e-05
deletions O 0 3.917668800568208e-05
or O 0 1.8889974171543145e-06
missense O 0 7.158373773563653e-05
mutations O 0 2.232836322946241e-06
, O 0 8.100565196400566e-08
many O 0 1.3482003957676625e-08
of O 0 1.839214291976532e-08
which O 0 6.234098037793956e-08
were O 0 6.918757122775787e-08
also O 0 6.727283619056834e-08
associated O 0 2.837136321431899e-07
with O 0 5.898240829083079e-08
expression O 0 1.360681096684857e-07
of O 0 1.6102325162137276e-07
mutant O 0 1.8488095520297065e-05
ATM O 0 9.293635957874358e-05
protein O 0 9.075643902178854e-06
. O 0 7.007593012531288e-06

The O 0 2.5463416022830643e-05
DMPK O 0 0.0026103437412530184
gene O 0 6.35472169960849e-05
of O 0 1.6013158528949134e-05
severely O 0 0.2844597399234772
affected O 0 0.3549320101737976
myotonic B-Disease 1 0.9999991655349731
dystrophy I-Disease 1 0.9999995231628418
patients O 1 0.9653053879737854
is O 0 9.799197869142517e-06
hypermethylated O 0 0.4508194327354431
proximal O 0 0.052149176597595215
to O 0 1.7460213257436408e-06
the O 0 8.193690064217662e-07
largely O 0 3.1452957500732737e-06
expanded O 0 8.12471716926666e-06
CTG O 0 0.0018965968629345298
repeat O 0 0.00011136026296298951
. O 0 1.6791271264082752e-05

Using O 0 2.24090508709196e-05
methylation O 0 9.85926017165184e-05
- O 0 0.00021179426403250545
sensitive O 0 2.9068911317153834e-05
restriction O 0 3.273473112130887e-06
enzymes O 0 2.4430141820630524e-06
, O 0 2.9715585014855606e-07
we O 0 1.1986642789452162e-07
characterized O 0 7.976261144904129e-07
the O 0 6.169523913968078e-08
methylation O 0 3.410527142477804e-06
pattern O 0 6.556671792168345e-07
on O 0 1.0494913027514485e-07
the O 0 5.2717620491193884e-08
5 O 0 2.66201169552005e-07
side O 0 1.443806496581601e-07
of O 0 2.1746807021827408e-08
the O 0 8.83915447502659e-08
CTG O 0 0.0003716464270837605
repeat O 0 2.835250370480935e-06
in O 0 6.785155903799023e-08
the O 0 5.8739459518619697e-08
DMPK O 0 5.9637794038280845e-05
gene O 0 2.954789692921622e-07
of O 0 3.4094103540383e-08
normal O 0 5.823155788675649e-07
individuals O 0 7.978690064192051e-08
and O 0 1.0655671900394736e-07
of O 0 5.571935730586119e-07
patients O 0 0.0030292070005089045
affected O 0 2.918256723205559e-05
with O 0 0.0015309820882976055
myotonic B-Disease 1 0.9999994039535522
dystrophy I-Disease 1 0.9999868869781494
, O 0 7.6229757723922376e-06
showing O 0 1.1561780411284417e-05
expansions O 0 2.068941103061661e-05
of O 0 4.82084431041585e-07
the O 0 1.5451068975380622e-06
repetitive O 0 0.000293376186164096
sequence O 0 1.964107832463924e-05
. O 0 1.6217712982324883e-05

The O 0 1.4697183360112831e-05
gene O 0 2.5188808649545535e-05
segment O 0 1.6077365216915496e-05
analyzed O 0 4.523305506154429e-06
corresponds O 0 2.316739482921548e-06
to O 0 1.4656259850198694e-07
the O 0 2.025416421247428e-07
genomic O 0 7.374111646640813e-06
SacI O 0 0.00010200216638622805
- O 0 4.5763114030705765e-05
HindIII O 0 4.677800097852014e-05
fragment O 0 2.8129877591709374e-06
carrying O 0 1.5543691915809177e-06
exons O 0 5.711643098038621e-06
11 O 0 1.7692261735646753e-06
- O 0 6.283878610702232e-05
15 O 0 4.782156793226022e-06
. O 0 5.251758011581842e-06

There O 0 1.9023149434360676e-05
is O 0 1.7999294641413144e-06
constitutive O 0 6.970667982386658e-06
methylation O 0 1.3093374946038239e-05
in O 0 7.807877864252077e-07
intron O 0 0.0004230572085361928
12 O 0 9.122171604758478e-07
at O 0 4.6049501634115586e-07
restriction O 0 4.410867973092536e-07
sites O 0 2.422400484647369e-07
of O 0 6.099507743329013e-08
SacII O 0 4.128788714297116e-05
and O 0 3.177762835093745e-07
HhaI O 0 9.272462193621323e-05
, O 0 1.3636221751767152e-07
localized O 0 1.3724654763791477e-06
1 O 0 1.1544933897766896e-07
, O 0 1.051025790843596e-07
159 O 0 1.7119629092121613e-06
- O 0 3.4946886444231495e-05
1 O 0 1.8564882964255958e-07
, O 0 4.1487037805154614e-08
232 O 0 5.062422019364021e-07
bp O 0 1.748347358443425e-06
upstream O 0 1.7318491529749735e-07
of O 0 2.6862124968829448e-08
the O 0 6.181301870356037e-08
CTG O 0 0.000809224380645901
repeat O 0 5.8840428209805395e-06
, O 0 1.3603541049178602e-07
whereas O 0 3.4725400155366515e-07
most O 0 4.728462243974718e-08
, O 0 9.822270641279829e-08
if O 0 5.6927241587345634e-08
not O 0 1.2158504425485717e-08
all O 0 9.800596778575255e-09
, O 0 2.9891054964537034e-08
of O 0 1.0354375135079863e-08
the O 0 1.2058319676100382e-08
other O 0 1.3906413798281392e-08
sites O 0 8.6821223987954e-08
of O 0 2.5953657001309693e-08
SacII O 0 0.00010534735338296741
, O 0 2.708391662054055e-07
HhaI O 0 0.00012085943308193237
, O 0 1.4627647715315106e-07
and O 0 1.6462705332287442e-07
HpaII O 0 6.484703772002831e-05
in O 0 7.304361560045436e-08
this O 0 3.275697224580654e-08
region O 0 2.747136420566676e-07
are O 0 6.676076935718811e-08
unmethylated O 0 0.00016235513612627983
, O 0 1.2325409670665977e-07
in O 0 5.0973216758620765e-08
normal O 0 5.151852633389353e-07
individuals O 0 1.0164067276718924e-07
and O 0 7.239809463044367e-08
most O 0 5.54988552892155e-08
of O 0 2.2873054206229426e-07
the O 0 2.912593345172354e-06
patients O 0 0.0006695983465760946
. O 0 1.1474390703369863e-05

In O 0 1.1465640454844106e-05
a O 0 2.2732990601070924e-06
number O 0 2.1000806782467407e-07
of O 0 1.79713040893148e-07
young O 0 5.936540219408926e-06
and O 0 3.154138767058612e-06
severely O 0 0.015688518062233925
affected O 0 4.2512248910497874e-05
patients O 0 0.00014148445916362107
, O 0 3.516238678002992e-07
however O 0 1.3485197314366815e-07
, O 0 4.9179856631553776e-08
complete O 0 2.353807531108032e-07
methylation O 0 8.947951641857799e-07
of O 0 3.6315558560318095e-08
these O 0 3.3969993040727786e-08
restriction O 0 2.4861188308022975e-07
sites O 0 3.510860722144571e-07
was O 0 1.6758161791585735e-07
found O 0 1.280879899923093e-07
in O 0 8.939596085610901e-08
the O 0 2.699201786526828e-07
mutated O 0 1.8319100490771234e-05
allele O 0 2.5192990506184287e-05
. O 0 9.534710443404038e-06

In O 0 7.252354862430366e-06
most O 0 6.540834078805347e-07
of O 0 3.494919553759246e-07
these O 0 7.143665925468667e-07
patients O 0 8.21995417936705e-05
, O 0 1.6501277855240915e-07
the O 0 1.332798831299442e-07
onset O 0 0.0016841550823301077
of O 0 1.027204234560486e-06
the O 0 8.128156332531944e-05
disease O 1 0.7959632873535156
was O 0 0.0027956499252468348
congenital O 1 0.9999504089355469
. O 0 0.00021903839660808444

Preliminary O 0 0.00013791740639135242
in O 0 1.6420524843852036e-05
vivo O 0 0.001663197297602892
footprinting O 0 0.26784804463386536
data O 0 7.93385970609961e-06
gave O 0 1.9659555619000457e-06
evidence O 0 5.393422952693072e-07
for O 0 1.4355575217450678e-07
protein O 0 1.2500292996264761e-06
- O 0 8.603304740972817e-05
DNA O 0 5.006625542591792e-06
contact O 0 3.871685692047322e-07
in O 0 5.213525611225123e-08
normal O 0 3.409222415484692e-07
genes O 0 2.327876273966467e-07
at O 0 1.1266863708669916e-07
an O 0 2.277585764431933e-08
Sp1 O 0 9.972161024052184e-06
consensus O 0 1.0666204985909644e-07
binding O 0 1.8316811178920034e-07
site O 0 2.0818190193949704e-07
upstream O 0 1.3702549495064886e-07
of O 0 1.5693183641474207e-08
the O 0 3.8538594537840254e-08
CTG O 0 7.141786045394838e-05
repeat O 0 1.4779623143112985e-06
and O 0 3.6566191852216434e-08
for O 0 3.403757631303961e-08
a O 0 9.410540968701753e-08
significant O 0 2.4799714992695954e-07
reduction O 0 3.745919627817784e-07
of O 0 2.6253481166804704e-08
this O 0 2.1633494995398905e-08
interaction O 0 1.044172250885822e-07
in O 0 1.1417419187864652e-07
cells O 0 1.0548028512857854e-06
with O 0 7.586849193330636e-08
a O 0 5.523573349819344e-07
hypermethylated O 0 0.003989590797573328
DMPK O 0 0.016237309202551842
gene O 0 6.523343472508714e-06
. O 0 1.359377961307473e-06
. O 0 6.560715064551914e-06

The O 0 0.0001827145169954747
hemochromatosis B-Disease 1 0.9994219541549683
gene O 0 0.00011627614730969071
product O 0 2.9855627872166224e-05
complexes O 0 1.84408163477201e-05
with O 0 2.196152308897581e-07
the O 0 1.8805731372140144e-07
transferrin O 0 0.00010469782137079164
receptor O 0 4.2212550397380255e-06
and O 0 2.929573383880779e-07
lowers O 0 1.2012843399133999e-05
its O 0 1.22712592087737e-07
affinity O 0 8.925129577619373e-07
for O 0 2.9183692618062196e-07
ligand O 0 1.9953056835220195e-05
binding O 0 1.880636773421429e-05
. O 0 7.982821443874855e-06

We O 0 4.392379560158588e-05
recently O 0 2.6143354261876084e-05
reported O 0 2.350799832129269e-06
the O 0 1.1313927217315722e-07
positional O 0 1.8712108840190922e-06
cloning O 0 6.888970801810501e-06
of O 0 1.8987454097896261e-07
a O 0 8.906108632800169e-07
candidate O 0 3.622661461122334e-05
gene O 0 3.880822623614222e-05
for O 0 0.0001512056333012879
hereditary B-Disease 1 0.9999735355377197
hemochromatosis I-Disease 1 0.9999986886978149
called O 0 0.017023345455527306
HFE O 1 0.9594349265098572
. O 0 9.083842451218516e-05

The O 0 7.992411156010348e-06
gene O 0 1.5567884474876337e-05
product O 0 4.918932972941548e-06
, O 0 4.676753633248154e-07
a O 0 1.561669051852732e-07
member O 0 1.3371887064295152e-07
of O 0 5.34798267892711e-08
the O 0 1.4046210594642616e-07
major O 0 3.6697028917842545e-06
histocompatibility O 1 0.7993529438972473
complex O 0 2.485434197296854e-05
class O 0 4.546365289570531e-06
I O 0 4.786368208442582e-06
- O 0 6.0613532696152106e-05
like O 0 1.1778931821027072e-06
family O 0 7.709182909820811e-07
, O 0 1.2552911243801645e-07
was O 0 1.126732556144816e-07
found O 0 5.5377253005417515e-08
to O 0 1.952024142326536e-08
have O 0 9.945368084629536e-09
a O 0 6.716001621498435e-08
mutation O 0 4.1863179944812146e-07
, O 0 1.1991970438884891e-07
Cys O 0 0.00022543140221387148
- O 0 3.3738189813448116e-05
282 O 0 7.01722274243366e-06
- O 0 0.00022355100372806191
- O 0 0.0006829898920841515
> O 0 5.48151510884054e-05
Tyr O 0 0.00016923362272791564
( O 0 1.240096452193029e-07
C282Y O 0 6.840806690888712e-06
) O 0 4.570482303734025e-08
, O 0 3.1774835207443175e-08
in O 0 2.3194258957914826e-08
85 O 0 4.691615913543501e-07
% O 0 1.9218089164496632e-07
of O 0 3.286142202796327e-07
patient O 0 0.00011683865886880085
chromosomes O 0 8.42524241306819e-05
. O 0 2.915664117608685e-05

This O 0 8.995113603305072e-06
mutation O 0 2.6086470825248398e-05
eliminates O 0 1.9197503206669353e-05
the O 0 6.497822937490128e-07
ability O 0 6.530736982313101e-07
of O 0 2.4005069576560345e-07
HFE O 0 0.001813975046388805
to O 0 3.953786347210553e-07
associate O 0 1.018350531012402e-06
with O 0 4.5975997409186675e-07
beta2 O 0 0.003061736701056361
- O 0 0.005797096062451601
microglobulin O 0 0.009350743144750595
( O 0 4.1611625078985526e-07
beta2m O 0 7.812385592842475e-05
) O 0 9.702654324428295e-08
and O 0 2.396140814653336e-07
prevents O 0 3.4757115372485714e-06
cell O 0 5.749594856752083e-05
- O 0 0.0003669300931505859
surface O 0 0.00010471737914485857
expression O 0 1.0870549886021763e-05
. O 0 6.141186077002203e-06

A O 0 3.8683891034452245e-05
second O 0 1.0054706763185095e-05
mutation O 0 1.9174651242792606e-05
that O 0 2.286757876390766e-07
has O 0 1.445274904199323e-07
no O 0 9.666467803981504e-08
effect O 0 1.4895127264935581e-07
on O 0 2.797308980007074e-07
beta2m O 0 0.0017099817050620914
association O 0 9.326838039669383e-07
, O 0 3.909057966211549e-07
H63D O 0 0.02287266030907631
, O 0 4.7178770046230056e-07
was O 0 2.4095737671814277e-07
found O 0 1.2676002825173782e-07
in O 0 1.9412528473594648e-08
eight O 0 5.644028888696084e-08
out O 0 3.3566802670748075e-08
of O 0 4.4374402818903036e-08
nine O 0 2.237914259239915e-06
patients O 0 2.7604259230429307e-05
heterozygous O 0 1.1350082331773592e-06
for O 0 2.297997099276472e-07
the O 0 7.542373623437015e-07
C282Y O 0 0.00040916120633482933
mutant O 0 8.711394184501842e-05
. O 0 2.4588036467321217e-05

In O 0 1.4721367733727675e-05
this O 0 1.4379638741957024e-06
report O 0 1.8818445823853835e-06
, O 0 3.018525944753492e-07
we O 0 1.6171114225471683e-07
demonstrate O 0 3.9964496068023436e-07
in O 0 1.4259978797781514e-07
cultured O 0 6.297152594925137e-06
293 O 0 1.9066430468228646e-05
cells O 0 7.6012188401364256e-06
overexpressing O 0 0.00017127553292084485
wild O 0 3.3090821034420514e-06
- O 0 5.4670126701239496e-05
type O 0 2.274277221658849e-06
or O 0 2.2217729167550715e-07
mutant O 0 4.824685220228275e-06
HFE O 0 0.0002817771746776998
proteins O 0 2.7964821924797434e-07
that O 0 2.2257083287513524e-08
both O 0 1.677228844698675e-08
the O 0 3.073303034284436e-08
wild O 0 7.048619181659888e-07
- O 0 0.00010033477883553132
type O 0 4.3497975639184006e-06
and O 0 6.797973242100852e-07
H63D O 0 0.009377743117511272
HFE O 0 0.0026269948575645685
proteins O 0 3.4564101270007086e-07
form O 0 1.89233531955324e-07
stable O 0 1.4213736676538247e-06
complexes O 0 2.5942529191524955e-06
with O 0 1.6743113917527808e-07
the O 0 3.992575159372791e-07
transferrin O 0 0.003793431678786874
receptor O 0 0.0001011249260045588
( O 0 2.8299232326389756e-06
TfR O 0 0.00013109804422128946
) O 0 1.8475651586413733e-06
. O 0 5.322630386217497e-06

The O 0 2.904075699916575e-05
C282Y O 0 0.0008103804429993033
mutation O 0 2.302613211213611e-05
nearly O 0 2.0914014839945594e-06
completely O 0 2.4267458229587646e-06
prevents O 0 2.142448010999942e-06
the O 0 1.0708318853858145e-07
association O 0 3.176187135522923e-07
of O 0 7.119331968397091e-08
the O 0 1.5209694481654878e-07
mutant O 0 2.568133822933305e-05
HFE O 0 0.008177638053894043
protein O 0 2.5080612431338523e-06
with O 0 3.936719963348878e-07
the O 0 3.2524060316063697e-06
TfR O 0 0.0016197205986827612
. O 0 2.581326407380402e-05

Studies O 0 4.73999280075077e-05
on O 0 1.0326612937205937e-05
cell O 0 0.00024833399220369756
- O 0 0.00034957504249177873
associated O 0 2.2822553091828013e-06
transferrin O 0 2.9289154554135166e-05
at O 0 3.470580054454331e-07
37 O 0 5.977040018478874e-07
degrees O 0 1.0045295084637473e-06
C O 0 6.150458830234129e-06
suggest O 0 1.2768502699600504e-07
that O 0 1.6744671427204594e-08
the O 0 3.6265301872617783e-08
overexpressed O 0 1.6084526578197256e-05
wild O 0 1.442876055079978e-06
- O 0 8.62756569404155e-05
type O 0 7.590947006974602e-06
HFE O 0 0.00016707280883565545
protein O 0 5.28071893768356e-07
decreases O 0 6.717108931297844e-07
the O 0 3.266351455977201e-08
affinity O 0 3.803653783052141e-07
of O 0 7.191488293756265e-08
the O 0 3.763433085168799e-07
TfR O 0 0.00010657571692718193
for O 0 4.9396171561966185e-06
transferrin O 0 0.0030846584122627974
. O 0 1.721472290228121e-05

The O 0 4.3407741031842306e-05
overexpressed O 0 0.0022012724075466394
H63D O 0 0.014351497404277325
protein O 0 1.3117772141413298e-05
does O 0 1.0875803582166554e-06
not O 0 5.895856247661868e-08
have O 0 1.5378352813399943e-08
this O 0 9.112589793858206e-09
effect O 0 1.0225805624486384e-07
, O 0 3.8091059195721755e-08
providing O 0 3.627201294875704e-08
the O 0 9.420019431161109e-09
first O 0 1.6579193129473424e-08
direct O 0 8.072755974808388e-08
evidence O 0 2.700952848044835e-07
for O 0 8.59592859114855e-08
a O 0 2.8443994892768387e-07
functional O 0 2.730761480052024e-06
consequence O 0 7.734494147371151e-07
of O 0 2.228642301815853e-07
the O 0 1.388033297189395e-06
H63D O 0 0.16288167238235474
mutation O 0 6.241326627787203e-05
. O 0 9.430479622096755e-06

Addition O 0 3.168216426274739e-05
of O 0 5.121049525769195e-06
soluble O 0 0.0001492765441071242
wild O 0 8.558236913813744e-06
- O 0 0.00026896476629190147
type O 0 3.551737972884439e-05
HFE O 0 0.016474997624754906
/ O 0 9.114854037761688e-05
beta2m O 0 0.001101355068385601
heterodimers O 0 0.00013748122728429735
to O 0 4.0589819150227413e-07
cultured O 0 3.311517139081843e-05
cells O 0 5.175779278943082e-06
also O 0 1.2950604855177517e-07
decreased O 0 9.791274351300672e-07
the O 0 8.758231473393607e-08
apparent O 0 2.031860049100942e-06
affinity O 0 4.005614755442366e-07
of O 0 2.808422649991371e-08
the O 0 4.566569700159562e-08
TfR O 0 8.303461981995497e-06
for O 0 4.056705549260187e-08
its O 0 4.2158450952456406e-08
ligand O 0 1.067222342499008e-06
under O 0 2.1434216534998995e-07
steady O 0 7.796949830662925e-06
- O 0 9.954095003195107e-05
state O 0 4.0076781715470133e-07
conditions O 0 3.21161587635288e-06
, O 0 6.58711982737259e-08
both O 0 2.1574610542529626e-08
in O 0 6.819070108576852e-08
293 O 0 4.88875002702116e-06
cells O 0 2.663819714143756e-06
and O 0 2.515205892450467e-07
in O 0 1.5235316368489293e-06
HeLa O 0 0.1213398203253746
cells O 0 5.16374348080717e-05
. O 0 8.749916560191195e-06

Furthermore O 0 0.00013788203068543226
, O 0 4.465324309421703e-06
at O 0 1.3428043530439027e-06
4 O 0 1.003488705464406e-06
degrees O 0 1.3897273447582847e-06
C O 0 1.4034647392691113e-05
, O 0 6.792718920678453e-08
the O 0 4.0352830410483875e-08
added O 0 2.0163524538929778e-07
soluble O 0 4.209934104437707e-06
complex O 0 1.0854955689865164e-06
of O 0 2.7667769586514623e-07
HFE O 0 0.008892116136848927
/ O 0 3.183313674526289e-05
beta2m O 0 0.00010586437565507367
inhibited O 0 1.7845228512669564e-06
binding O 0 4.809410825146188e-07
of O 0 1.1781027353663376e-07
transferrin O 0 7.320505392272025e-05
to O 0 8.311902774948976e-07
HeLa O 0 0.011454127728939056
cell O 0 8.689308015163988e-05
TfR O 0 4.286061812308617e-05
in O 0 1.9645766258236108e-07
a O 0 4.871614009971381e-07
concentration O 0 7.87765602581203e-05
- O 0 0.0002789560239762068
dependent O 0 1.4038502740731928e-05
manner O 0 1.654189509281423e-05
. O 0 1.2014390449621715e-05

Scatchard O 0 0.0006117660668678582
plots O 0 4.839970642933622e-05
of O 0 1.4231437717171502e-06
these O 0 3.8900392951290996e-07
data O 0 1.0117634019479738e-06
indicate O 0 4.707989091912168e-07
that O 0 2.2514461406331066e-08
the O 0 4.788162044633282e-08
added O 0 2.730659787175682e-07
heterodimer O 0 3.69856134057045e-05
substantially O 0 3.2938842196017504e-06
reduced O 0 5.446984800983046e-07
the O 0 9.245667342838715e-08
affinity O 0 1.378834895149339e-06
of O 0 4.512016289481835e-07
TfR O 0 0.0001739380822982639
for O 0 3.356390834596823e-06
transferrin O 0 0.002492660190910101
. O 0 1.7933682102011517e-05

These O 0 1.5065697880345397e-05
results O 0 8.42681674839696e-06
establish O 0 2.7497023893374717e-06
a O 0 1.0006599495682167e-06
molecular O 0 3.4420394513290375e-05
link O 0 9.23930656426819e-06
between O 0 1.3057062915322604e-06
HFE O 0 0.043887365609407425
and O 0 5.911862785978883e-07
a O 0 2.53404124350709e-07
key O 0 1.0792525699798716e-06
protein O 0 2.6808848474502156e-07
involved O 0 2.0649525822591386e-07
in O 0 1.1124530630013396e-07
iron O 0 1.1738420653273351e-05
transport O 0 3.374016159796156e-06
, O 0 1.2087313905340125e-07
the O 0 6.322024859173325e-08
TfR O 0 2.2810128939454444e-05
, O 0 9.806059608763462e-08
and O 0 6.334215640890761e-08
raise O 0 2.632765188081976e-07
the O 0 3.728782260736807e-08
possibility O 0 3.5547193988350045e-07
that O 0 2.290594380838229e-08
alterations O 0 2.388297843936016e-06
in O 0 5.5355183548044806e-08
this O 0 4.248213869573192e-08
regulatory O 0 3.7995530419721035e-06
mechanism O 0 3.8258895074250177e-07
may O 0 1.0449193155182002e-07
play O 0 3.054439190464109e-08
a O 0 6.04659504688243e-08
role O 0 1.318837519193039e-07
in O 0 8.312887445072192e-08
the O 0 3.43972516247959e-07
pathogenesis O 0 0.002725079655647278
of O 0 0.00010405564535176381
hereditary B-Disease 1 0.9999926090240479
hemochromatosis I-Disease 1 0.9999992847442627
. O 0 7.273798837559298e-05
. O 0 6.763487181160599e-05

Genomic O 0 0.0006205221870914102
organization O 0 3.295617352705449e-05
of O 0 1.7435552308597835e-06
the O 0 2.525471927583567e-06
UBE3A O 0 0.006970588117837906
/ O 0 0.00015261619410011917
E6 O 0 0.003000607481226325
- O 0 0.029999608173966408
AP O 0 0.00019083845836576074
gene O 0 1.1076823284383863e-05
and O 0 2.493018655513879e-06
related O 0 3.563939026207663e-05
pseudogenes O 0 0.0008211612002924085
. O 0 3.029148865607567e-05

The O 0 1.856957169366069e-05
UBE3A O 0 0.0012859004782512784
gene O 0 1.4021376046002842e-05
encodes O 0 3.555597686499823e-06
the O 0 6.529814982059179e-07
E6 O 0 0.0003684634866658598
- O 0 0.0016051448183134198
AP O 0 2.2727424948243424e-05
ubiquitin O 0 1.4881944480293896e-05
- O 0 3.747270966414362e-05
protein O 0 5.523046411326504e-07
ligase O 0 3.197832256773836e-06
and O 0 1.374280458321664e-07
has O 0 7.373819954636929e-08
recently O 0 2.877294491554494e-07
been O 0 3.122986669268357e-08
shown O 0 7.57158318265283e-08
to O 0 7.441993687962167e-08
be O 0 3.369960097643343e-07
mutated O 0 0.00034533810685388744
in O 0 0.05452118441462517
Angelman B-Disease 1 1.0
syndrome I-Disease 1 0.9999998807907104
patients O 0 0.39755895733833313
who O 0 3.4867007343564183e-06
lack O 0 6.087680958444253e-06
15q11 O 0 0.008270024321973324
- O 0 0.030334068462252617
q13 O 0 0.0007397558656521142
deletions O 0 6.0883427067892626e-05
or O 0 2.545706820455962e-06
chromosome O 0 4.6044329792493954e-05
15 O 0 9.65089384408202e-06
paternal O 0 0.0005642152391374111
uniparental B-Disease 1 0.5366751551628113
disomy I-Disease 0 0.10207738727331161
. O 0 9.008929191622883e-05

Previous O 0 0.000135503985802643
UBE3A O 0 0.0020324953366070986
cDNA O 0 0.00011812638695118949
analysis O 0 1.811188121791929e-05
has O 0 1.488297471041733e-06
shown O 0 7.565843702650454e-07
a O 0 8.6249866626531e-07
coding O 0 1.8648153854883276e-05
region O 0 1.2060340850439388e-06
of O 0 1.8353846087393322e-07
approximately O 0 1.3879035805075546e-06
2 O 0 6.011492587276734e-06
. O 0 9.018191121867858e-06

6 O 0 0.00020109119941480458
kb O 0 0.0012490596855059266
and O 0 2.6818029255082365e-06
a O 0 1.0187100087932777e-06
3 O 0 3.195515091647394e-06
- O 0 0.00033258015173487365
untranslated O 0 0.00035899473004974425
region O 0 1.692842602096789e-06
( O 0 1.2382882630390668e-07
UTR O 0 5.64051651963382e-06
) O 0 2.150165023806494e-08
of O 0 2.2768301022324522e-08
< O 0 8.06796560937073e-06
50 O 0 1.1275000844079841e-07
bp O 0 1.4295357004812104e-06
, O 0 3.040193163883487e-08
whereas O 0 7.106010002644325e-08
Northern O 0 6.530475360477794e-08
analysis O 0 8.915348104210352e-08
has O 0 3.506342949322061e-08
indicated O 0 1.217085383586891e-07
mRNA O 0 1.4525404878895642e-07
sizes O 0 3.685555611809832e-07
of O 0 4.3307380792612094e-08
5 O 0 4.5454274300027464e-07
- O 0 1.5477391571039334e-05
8 O 0 2.599285153337405e-06
kb O 0 0.0001675637176958844
. O 0 5.2356258493091445e-06

We O 0 2.037530612142291e-05
have O 0 1.822190483835584e-06
analyzed O 0 1.8262144294567406e-06
additional O 0 5.202737725085171e-07
cDNA O 0 7.839283171051648e-06
clones O 0 2.5945450033759698e-05
and O 0 2.8568425136654696e-07
provide O 0 2.9139445700820943e-07
evidence O 0 2.2948827904656355e-07
for O 0 4.9106933630582716e-08
an O 0 6.099403293546857e-08
additional O 0 8.42866143102583e-07
0 O 0 1.173181772173848e-05
. O 0 6.819448117312277e-06

5 O 0 3.15328361466527e-05
kb O 0 8.695682481629774e-05
of O 0 8.978262258096947e-07
5 O 0 2.5045667371159652e-06
- O 0 0.00012132974370615557
UTR O 0 6.613844016101211e-05
and O 0 3.9653832573094405e-07
> O 0 5.3518160711973906e-06
2 O 0 6.330947712740453e-07
kb O 0 1.3495040548150428e-05
of O 0 2.2661357945708005e-07
3 O 0 4.23130677518202e-06
- O 0 0.00028673376073129475
UTR O 0 0.0008587827323935926
. O 0 1.0601463145576417e-05

We O 0 2.6576017262414098e-05
have O 0 7.753458248771494e-07
established O 0 2.9561172709691164e-07
the O 0 8.971708354010843e-08
genomic O 0 1.9122048797726166e-06
organization O 0 2.428620575756213e-07
of O 0 1.2690904327428143e-07
UBE3A O 0 0.0007180263055488467
and O 0 1.905330009321915e-07
the O 0 6.432909316345103e-08
sequence O 0 1.7639533211877279e-07
of O 0 2.54888391282293e-07
intron O 0 0.0015094645787030458
- O 0 0.0004722202429547906
exon O 0 0.00013184017734602094
borders O 0 1.9803164832410403e-05
. O 0 8.651102689327672e-06

We O 0 2.6401039576740004e-05
have O 0 2.0721900000353344e-06
also O 0 3.3301427038168185e-07
mapped O 0 3.059747541556135e-06
two O 0 1.2459963727451395e-07
highly O 0 4.3979898123325256e-07
homologous O 0 2.5912411274475744e-06
processed O 0 1.6047198414526065e-06
pseudogenes O 0 1.5583287677145563e-05
, O 0 3.6854888207926706e-07
UBE3AP1 O 0 0.0004192364576738328
and O 0 3.3528863241372164e-07
UBE3AP2 O 0 0.002846159739419818
, O 0 8.185959643469687e-08
to O 0 2.546123489821639e-08
chromosomes O 0 4.100824355646182e-07
2 O 0 1.6155699711362104e-07
and O 0 4.70147405451371e-08
21 O 0 1.768966768622704e-07
, O 0 9.894776553664997e-08
respectively O 0 1.9307793763800873e-07
, O 0 1.0174871079016157e-07
and O 0 9.892362129448884e-08
determined O 0 4.899185910289816e-07
their O 0 2.917729204909847e-07
genomic O 0 2.2093683583079837e-05
organization O 0 9.187843716063071e-06
. O 0 1.1717337656591553e-05

These O 0 9.359911018691491e-06
results O 0 1.0489292435522657e-05
will O 0 4.987221586816304e-07
form O 0 1.32848924749851e-07
the O 0 2.644521224226537e-08
basis O 0 3.916191460007212e-08
for O 0 4.506322426323095e-08
studies O 0 1.3159429101960995e-07
of O 0 7.884096220323045e-08
mutation O 0 2.2305630409391597e-06
and O 0 2.396250522451737e-07
imprinting O 0 4.7043049562489614e-05
of O 0 4.032397100672824e-06
UBE3A O 0 0.1027926504611969
. O 0 3.631928120739758e-05

Mutation O 0 0.0009624683298170567
spectrum O 0 0.0004456272872630507
and O 0 1.5321867977036163e-05
genotype O 0 0.0011297528399154544
- O 0 0.011595388874411583
phenotype O 0 0.0002381515223532915
analyses O 0 3.9202364860102534e-05
in O 0 2.6165003873757087e-05
Cowden B-Disease 1 0.9996745586395264
disease I-Disease 0 0.017290297895669937
and O 0 3.460051448200829e-05
Bannayan B-Disease 1 0.999404788017273
- I-Disease 1 0.9999831914901733
Zonana I-Disease 1 0.9999961853027344
syndrome I-Disease 1 0.9999122619628906
, O 0 9.473892532696482e-06
two O 0 2.4374487111344934e-05
hamartoma B-Disease 1 0.9995237588882446
syndromes I-Disease 1 0.9844845533370972
with O 0 8.63022287376225e-05
germline O 1 0.9701518416404724
PTEN O 1 0.9327465891838074
mutation O 0 0.0006430154899135232
. O 0 7.299884600797668e-05

The O 0 9.325222345069051e-05
tumour B-Disease 1 0.9961058497428894
suppressor O 0 0.0020011046435683966
gene O 0 0.00011208886280655861
PTEN O 0 0.010267231613397598
, O 0 2.2532369712280342e-06
which O 0 4.809874099009903e-07
maps O 0 6.228741312952479e-06
to O 0 2.652592002050369e-06
10q23 O 0 0.0006772089982405305
. O 0 2.095745730912313e-05

3 O 0 2.436428621876985e-05
and O 0 1.1665719057418755e-06
encodes O 0 2.057947085631895e-06
a O 0 3.668268391265883e-07
403 O 0 2.3351478830591077e-06
amino O 0 4.599411056460667e-07
acid O 0 3.6248124501980783e-07
dual O 0 2.2560355716905178e-07
specificity O 0 2.188215376008884e-06
phosphatase O 0 4.190514300717041e-05
( O 0 9.721141225327301e-08
protein O 0 2.7608149366642465e-07
tyrosine O 0 1.717644067866786e-06
phosphatase O 0 2.2772659576730803e-05
; O 0 2.5004280246321287e-07
PTPase O 0 4.208744576317258e-05
) O 0 6.205660696423365e-08
, O 0 6.17604598573962e-08
was O 0 5.553305371108763e-08
shown O 0 8.075897284243183e-08
recently O 0 1.2735507937122748e-07
to O 0 1.7310970434891715e-08
play O 0 3.252214852977886e-08
a O 0 1.0431649855036085e-07
broad O 0 4.748445007862756e-06
role O 0 6.568952244379034e-07
in O 0 1.2080001852154965e-06
human O 0 2.1614996512653306e-05
malignancy B-Disease 1 0.637414276599884
. O 0 3.2733467378420755e-05

Somatic O 0 0.012320910580456257
PTEN O 0 0.19524770975112915
deletions O 0 0.0018115226412191987
and O 0 2.109074739564676e-05
mutations O 0 3.8696551200700924e-05
were O 0 6.384833000083745e-07
observed O 0 1.2152357840022887e-06
in O 0 3.5064772418991197e-07
sporadic B-Disease 0 0.00035507383290678263
breast I-Disease 1 0.9917445778846741
, I-Disease 0 4.040004569105804e-05
brain I-Disease 0 0.09715564548969269
, I-Disease 0 8.525083831045777e-05
prostate I-Disease 1 0.999969482421875
and I-Disease 0 0.3788471221923828
kidney I-Disease 1 0.9999983310699463
cancer I-Disease 1 0.9998756647109985
cell O 0 0.017107145860791206
lines O 0 1.251681078429101e-05
and O 0 3.614111676597531e-07
in O 0 1.806781426694215e-07
several O 0 4.0768506437416363e-07
primary O 0 0.00020805200620088726
tumours B-Disease 1 0.9992048144340515
such O 0 4.241504029778298e-06
as O 0 6.17282566963695e-05
endometrial B-Disease 1 0.9999649524688721
carcinomas I-Disease 1 0.9999994039535522
, O 1 0.9969689249992371
malignant B-Disease 1 1.0
melanoma I-Disease 1 0.9999998807907104
and O 1 0.9974779486656189
thyroid B-Disease 1 0.9999988079071045
tumours I-Disease 1 0.9999845027923584
. O 0 0.00044172490015625954

In O 0 1.6176161807379685e-05
addition O 0 7.977228051458951e-06
, O 0 1.8795936966853333e-06
PTEN O 0 0.0019404994091019034
was O 0 9.422428206562472e-07
identified O 0 7.094958505149407e-07
as O 0 3.527082625964795e-08
the O 0 1.0168390929266025e-07
susceptibility O 0 3.221776569262147e-05
gene O 0 1.3988129694553209e-06
for O 0 1.0027883945440408e-06
two O 0 3.763479253393598e-05
hamartoma B-Disease 1 0.9999780654907227
syndromes I-Disease 1 0.9999858140945435
Cowden B-Disease 1 0.9999923706054688
disease I-Disease 1 0.5189825296401978
( O 0 9.770091082828003e-07
CD B-Disease 0 3.4333621442783624e-05
; O 0 5.992780643282458e-06
MIM O 0 0.003099011955782771
158350 O 0 0.00010530036524869502
) O 0 2.435297687952698e-07
and O 0 5.896947072869807e-07
Bannayan B-Disease 0 0.0029182101134210825
- I-Disease 0 0.11358700692653656
Zonana I-Disease 1 0.5514991283416748
( I-Disease 0 1.299786163144745e-06
BZS I-Disease 0 0.0001360474998364225
) I-Disease 0 3.0334626899275463e-07
or I-Disease 0 6.971358743612655e-07
Ruvalcaba I-Disease 0 0.0006215997855179012
- I-Disease 0 0.0006877282285131514
Riley I-Disease 0 0.0002888459130190313
- I-Disease 1 0.9744881987571716
Smith I-Disease 1 0.8664026856422424
syndrome I-Disease 1 0.9958795309066772
( O 0 3.5804102935799165e-06
MIM O 0 0.014929908327758312
153480 O 0 0.0006785139557905495
) O 0 3.3357416668877704e-06
. O 0 9.045607839652803e-06

Constitutive O 0 0.0007351373205892742
DNA O 0 0.00020153650257270783
from O 0 3.1691752155893482e-06
37 O 0 6.15921089774929e-06
CD B-Disease 0 1.166096353699686e-05
families O 0 1.4643478607467841e-06
and O 0 3.181522743034293e-07
seven O 0 9.96021412902337e-07
BZS B-Disease 0 0.0028512717690318823
families O 0 2.226612195954658e-06
was O 0 9.702151828605565e-07
screened O 0 1.582399090693798e-05
for O 0 6.479830517491791e-06
germline O 0 0.26259949803352356
PTEN O 1 0.6484138369560242
mutations O 0 0.00020040481467731297
. O 0 2.2928337784833275e-05

PTEN O 1 0.7947108149528503
mutations O 0 0.00104920519515872
were O 0 4.976326636096928e-06
identified O 0 6.854101684439229e-06
in O 0 2.1292031249231513e-07
30 O 0 1.799193540819033e-07
of O 0 7.50329576248987e-08
37 O 0 1.341786514785781e-06
( O 0 1.4386165503310622e-07
81 O 0 3.307394081275561e-06
% O 0 1.6934920665789832e-07
) O 0 5.514021239605427e-08
CD B-Disease 0 2.1505584300030023e-06
families O 0 4.088788898570783e-07
, O 0 1.3611743554520217e-07
including O 0 2.409762203114951e-07
missense O 0 1.8081023881677538e-05
and O 0 3.231572236472857e-07
nonsense O 0 1.3327584383659996e-05
point O 0 1.4066990843275562e-06
mutations O 0 1.9836168121400988e-06
, O 0 1.299342216043442e-07
deletions O 0 3.308561190351611e-06
, O 0 3.3555224376868864e-07
insertions O 0 1.460656858398579e-05
, O 0 3.8788849110460433e-07
a O 0 5.477782565321831e-07
deletion O 0 2.972814763779752e-05
/ O 0 3.875401307595894e-05
insertion O 0 1.1787205949076451e-05
and O 0 2.5682577415864216e-06
splice O 0 0.0004287079500500113
site O 0 6.10662464168854e-05
mutations O 0 4.969362998963334e-05
. O 0 1.4184245628712233e-05

These O 0 2.0279579985071905e-05
mutations O 0 3.596613532863557e-05
were O 0 9.873979252006393e-07
scattered O 0 2.6690863705880474e-06
over O 0 3.5878065318684094e-07
the O 0 7.357424891552e-08
entire O 0 3.3059959037018416e-07
length O 0 6.378253942784795e-07
of O 0 3.7612835512845777e-07
PTEN O 0 0.030814144760370255
, O 0 3.651497024748096e-07
with O 0 9.020834568218561e-08
the O 0 3.981430296562394e-08
exception O 0 1.3881853533348476e-07
of O 0 1.6584127848773278e-08
the O 0 2.791099440457856e-08
first O 0 6.335278612823458e-08
, O 0 2.474075131431164e-07
fourth O 0 1.979311946342932e-06
and O 0 5.997601419949206e-07
last O 0 3.878921233990695e-06
exons O 0 7.678435213165358e-05
. O 0 1.487005556555232e-05

A O 0 8.991387585410848e-05
hot O 0 0.00011445893323980272
spot O 0 3.084011405007914e-05
for O 0 3.502230356389191e-06
PTEN O 0 0.0019966871477663517
mutation O 0 5.4145557442097925e-06
in O 0 2.5019019744831894e-07
CD B-Disease 0 7.345418907789281e-06
was O 0 6.184887979543419e-07
identified O 0 5.204965987104515e-07
in O 0 3.1262526789532785e-08
exon O 0 3.254897819715552e-06
5 O 0 8.574837551122982e-08
that O 0 1.0778847148174009e-08
contains O 0 3.211990318163771e-08
the O 0 3.719831553894437e-08
PTPase O 0 1.900161078083329e-05
core O 0 7.001661401773163e-07
motif O 0 3.071715184432833e-07
, O 0 2.9155335923292114e-08
with O 0 1.4298183970140599e-08
13 O 0 3.302648465819402e-08
of O 0 1.4711315721172014e-08
30 O 0 1.3717036040361563e-07
( O 0 6.770857652327322e-08
43 O 0 5.691821911568695e-07
% O 0 1.0658538229790793e-07
) O 0 4.577601231403605e-08
CD B-Disease 0 4.1849270928651094e-06
mutations O 0 2.30462364925188e-06
identified O 0 2.937429144367343e-07
in O 0 8.620310865126157e-08
this O 0 3.606282632517832e-07
exon O 0 0.000213733030250296
. O 0 1.621871706447564e-05

Seven O 0 1.5801566405571066e-05
of O 0 2.4841472168191103e-06
30 O 0 2.446049393256544e-06
( O 0 2.663382758782973e-07
23 O 0 9.330148031949648e-07
% O 0 1.38724814746638e-07
) O 0 4.699904820881784e-08
were O 0 2.5135005188303694e-08
within O 0 1.855581466259082e-08
the O 0 2.616834215984909e-08
core O 0 1.2276907455088804e-06
motif O 0 4.064067695708218e-07
, O 0 5.8871588493047966e-08
the O 0 4.415269927449117e-08
majority O 0 6.007533102092566e-07
( O 0 2.3700136964066587e-08
five O 0 2.2666043264507607e-08
of O 0 1.6811876335509623e-08
seven O 0 5.912049516609841e-08
) O 0 1.379724512418079e-08
of O 0 1.0163366148674413e-08
which O 0 2.5700554573404588e-08
were O 0 1.0421328511256434e-07
missense O 0 3.3318312489427626e-05
mutations O 0 1.359064299322199e-06
, O 0 1.0749983658797646e-07
possibly O 0 3.652437499113148e-07
pointing O 0 8.527933914592722e-07
to O 0 3.988316166214645e-08
the O 0 3.1605953410007714e-08
functional O 0 5.948980970060802e-07
significance O 0 2.88170468820681e-07
of O 0 9.450922533460471e-08
this O 0 3.804517234584637e-07
region O 0 9.57304200710496e-06
. O 0 1.0365033631387632e-05

Germline O 1 0.9093771576881409
PTEN O 1 0.7775121331214905
mutations O 0 0.0011069804895669222
were O 0 4.647494279197417e-06
identified O 0 5.012879682908533e-06
in O 0 1.4231611089599028e-07
four O 0 5.5060130677020425e-08
of O 0 7.737947527175493e-08
seven O 0 3.236670522710483e-07
( O 0 2.608485658583959e-07
57 O 0 4.8936240091279615e-06
% O 0 6.835255703663279e-07
) O 0 6.578079592145514e-07
BZS B-Disease 0 0.0004773667315021157
families O 0 2.9957718652440235e-06
studied O 0 6.813863819843391e-06
. O 0 7.706692485953681e-06

Interestingly O 0 0.0011111494386568666
, O 0 1.0325066796212923e-05
none O 0 2.061056420643581e-06
of O 0 2.2151931489133858e-07
these O 0 2.240655447849349e-07
mutations O 0 3.1912027225189377e-06
was O 0 4.5346203592089296e-07
observed O 0 8.773376976023428e-07
in O 0 1.4902218481438467e-07
the O 0 4.871307623943721e-07
PTPase O 0 0.0002938800898846239
core O 0 2.406019120826386e-05
motif O 0 1.623747630219441e-05
. O 0 9.28559347812552e-06

It O 0 9.215328645950649e-06
is O 0 1.117168608288921e-06
also O 0 2.0963906877113914e-07
worthy O 0 1.1219273119422724e-06
of O 0 8.323168287915905e-08
note O 0 7.981922180988477e-07
that O 0 2.5146320581370674e-08
a O 0 6.218244408273677e-08
single O 0 2.0911809883727983e-07
nonsense O 0 5.4490133152285125e-06
point O 0 6.746969347659615e-07
mutation O 0 6.427329708458274e-07
, O 0 1.2724534315111669e-07
R233X O 0 2.6423276722198352e-05
, O 0 1.7306621202806127e-07
was O 0 1.341875730531683e-07
observed O 0 1.9822522290269262e-07
in O 0 4.055862490304207e-08
the O 0 9.825043179034765e-08
germline O 0 0.00011376394832041115
DNA O 0 1.6845791606101557e-06
from O 0 4.39628706772055e-08
two O 0 4.843549916699885e-08
unrelated O 0 1.3321829328560852e-06
CD B-Disease 0 1.2485812476370484e-05
families O 0 1.3546826949095703e-06
and O 0 7.138776254578261e-07
one O 0 1.7722894654070842e-06
BZS B-Disease 0 0.11427867412567139
family O 0 5.810534275951795e-05
. O 0 3.0429535399889573e-05

Genotype O 0 0.07033216953277588
- O 0 0.07243520021438599
phenotype O 0 0.0008192690438590944
studies O 0 7.465055205102544e-06
were O 0 4.289711341698421e-07
not O 0 1.1768057106564811e-07
performed O 0 4.0034035464486806e-07
on O 0 9.626413088881236e-08
this O 0 4.378303941621198e-08
small O 0 3.686019454107736e-07
group O 0 3.5891787319997093e-07
of O 0 3.991033565853286e-07
BZS B-Disease 0 0.006152505055069923
families O 0 1.002212957246229e-05
. O 0 1.156965663540177e-05

However O 0 3.450044823694043e-05
, O 0 8.186760169337504e-06
genotype O 0 0.0003883762692566961
- O 0 0.0009506670176051557
phenotype O 0 4.4070558942621574e-05
analysis O 0 1.5690856116634677e-06
inthe O 0 9.374313231091946e-05
group O 0 5.975051067252934e-07
of O 0 1.0076817602566734e-07
CD B-Disease 0 2.2607406208408065e-05
families O 0 2.4091102659440367e-06
revealed O 0 2.251486421300797e-06
two O 0 9.985324567196585e-08
possible O 0 3.172000901940919e-07
associations O 0 1.1268809174680428e-07
worthy O 0 2.712690729822498e-07
of O 0 2.637785989634267e-08
follow O 0 3.6822635252065083e-07
- O 0 3.623486918513663e-05
up O 0 4.006134588507848e-07
in O 0 1.2421701001130714e-07
independent O 0 1.1566703506105114e-06
analyses O 0 1.0053805453935638e-05
. O 0 6.502585620182799e-06

The O 0 9.659372153691947e-06
first O 0 2.0329318886069814e-06
was O 0 8.115873697533971e-07
an O 0 1.3467641224451654e-07
association O 0 1.0285373264196096e-06
noted O 0 3.316549168630445e-07
in O 0 4.107822348942136e-08
the O 0 3.879931398387271e-08
group O 0 1.3311830571183236e-07
of O 0 5.6089366040623645e-08
CD B-Disease 0 6.369064067257568e-05
families O 0 2.7166666768607683e-05
with O 0 0.0007698169210925698
breast B-Disease 1 0.9999879598617554
disease I-Disease 1 0.5208819508552551
. O 0 4.86965109303128e-05

A O 0 5.5039545259205624e-05
correlation O 0 4.175727008259855e-05
was O 0 1.5062603324622614e-06
observed O 0 1.1584985486479127e-06
between O 0 1.3479025540164002e-07
the O 0 7.839560112188337e-08
presence O 0 5.766884214608581e-07
/ O 0 1.4830148757027928e-05
absence O 0 2.76301676649382e-07
of O 0 4.8522416307150706e-08
a O 0 1.102465603253222e-06
PTEN O 0 0.004723876249045134
mutation O 0 9.970800647352007e-07
and O 0 8.500921211407331e-08
the O 0 5.057171748035216e-08
type O 0 2.5709975943755126e-06
of O 0 1.4219255035641254e-06
breast O 1 0.891002357006073
involvement O 0 7.145771087380126e-05
( O 0 2.535484554755385e-06
unaffected O 0 0.0002745237434282899
versus O 0 0.018189484253525734
benign O 1 0.865443229675293
versus O 1 0.6054881811141968
malignant O 1 0.9998140931129456
) O 0 1.5953180991346017e-05
. O 0 2.0190023860777728e-05

Specifically O 0 3.850469147437252e-05
and O 0 2.1821365407959092e-06
more O 0 2.643619154696353e-07
directly O 0 4.640854456283705e-07
, O 0 1.3305078994108044e-07
an O 0 3.6231149636023474e-08
association O 0 2.9300539949872473e-07
was O 0 1.7438200927699654e-07
also O 0 6.987067280306292e-08
observed O 0 4.549833647615742e-07
between O 0 7.350117670057443e-08
the O 0 5.3678284928082576e-08
presence O 0 9.984601234691581e-08
of O 0 7.021374415216997e-08
a O 0 1.5226092955344939e-06
PTEN O 0 0.15678909420967102
mutation O 0 0.00013613184273708612
and O 0 0.0052806478925049305
malignant B-Disease 1 0.9999985694885254
breast I-Disease 1 0.9999938011169434
disease I-Disease 1 0.9561817049980164
. O 0 6.157304596854374e-05

Secondly O 0 0.005057529080659151
, O 0 1.3258609214972239e-05
there O 0 1.2620939742191695e-06
appeared O 0 8.635332164885767e-07
to O 0 9.185500005060021e-08
be O 0 3.5236265460980576e-08
an O 0 4.0789736033275403e-08
interdependent O 0 1.1359372365404852e-05
association O 0 6.389377062987478e-07
between O 0 2.8708149102385505e-07
mutations O 0 1.5445441476913402e-06
upstream O 0 7.341542413996649e-07
and O 0 5.7856809121403785e-08
within O 0 2.9594136918831282e-08
the O 0 3.66263606110806e-08
PTPase O 0 6.239548383746296e-05
core O 0 1.8441202200847329e-06
motif O 0 6.261965950216108e-07
, O 0 5.6354448219053666e-08
the O 0 2.5747658227714965e-08
core O 0 9.403863145962532e-07
motif O 0 3.7179029277467635e-07
containing O 0 6.66233859192289e-08
the O 0 2.8512891603327262e-08
majority O 0 1.6540066383186058e-07
of O 0 7.44773132055343e-08
missense O 0 6.884225877001882e-05
mutations O 0 6.677829787804512e-06
, O 0 1.6403059532876796e-07
and O 0 6.929018070422899e-08
the O 0 2.9719998906330147e-08
involvement O 0 3.48148631701406e-07
of O 0 4.1889936852612664e-08
all O 0 7.828712256241488e-08
major O 0 2.7422101993579417e-06
organ O 0 4.2030049371533096e-05
systems O 0 1.748305840010289e-05
( O 0 2.4671808773746307e-07
central O 0 2.380266153068078e-07
nervous O 0 1.9004508430953138e-05
system O 0 6.083043899707263e-06
, O 0 2.8769383789040148e-05
thyroid O 1 0.9996241331100464
, O 0 6.8081688368693e-05
breast O 1 0.998940646648407
, O 0 6.75766495987773e-05
skin O 1 0.9675217270851135
and O 0 0.029455680400133133
gastrointestinal O 1 0.9999823570251465
tract O 1 0.9897446036338806
) O 0 2.866498653020244e-05
. O 0 3.328903403598815e-05

However O 0 3.132121855742298e-05
, O 0 1.447583031222166e-06
these O 0 6.817119668767191e-08
observations O 0 4.7397222147083085e-07
would O 0 1.087597496507442e-07
need O 0 8.786441441088755e-08
to O 0 5.350859666464203e-08
be O 0 4.442046730446236e-08
confirmed O 0 1.7203247182351333e-07
by O 0 4.260531838440329e-08
studying O 0 1.1253344212036609e-07
a O 0 4.6584226254253736e-08
larger O 0 1.6198326591165824e-07
number O 0 3.2662764937185784e-08
of O 0 7.004613422623152e-08
CD B-Disease 0 2.9326134608709253e-05
families O 0 5.826461347169243e-06
. O 0 5.4488209570990875e-06

Molecular O 1 0.7996655106544495
defects O 1 0.9934681057929993
leading O 0 2.982557452924084e-05
to O 0 1.2184224260636256e-06
human O 0 2.025056346610654e-06
complement B-Disease 0 3.656320404843427e-05
component I-Disease 0 0.1111309826374054
C6 I-Disease 1 0.9999984502792358
deficiency I-Disease 1 0.9999779462814331
in O 0 6.989705525484169e-07
an O 0 1.6278016801152262e-07
African O 0 1.2122657153668115e-06
- O 0 0.0007938785129226744
American O 0 2.4888638563425047e-06
family O 0 1.5093926776899025e-05
. O 0 1.163072283816291e-05

Complement B-Disease 0 0.001454444951377809
component I-Disease 1 0.5786072015762329
C6 I-Disease 1 0.99998939037323
deficiency I-Disease 1 0.9999895095825195
( O 0 1.2698286809609272e-05
C6D B-Disease 0 0.1774071604013443
) O 0 2.3624979803571478e-06
was O 0 2.000995482376311e-05
diagnosed O 0 0.08455304056406021
in O 0 9.287432334303958e-08
a O 0 1.3624237737985823e-07
16 O 0 5.346503826331173e-07
- O 0 2.1450961867230944e-05
year O 0 5.268641416478204e-07
- O 0 0.00010227039456367493
old O 0 5.805694399896311e-06
African O 0 7.8101271583364e-07
- O 0 0.0003261038800701499
American O 0 2.0812524326174753e-06
male O 0 9.249347385775764e-06
with O 0 0.00018592360720504075
meningococcal B-Disease 1 0.9999271631240845
meningitis I-Disease 1 0.998771607875824
. O 0 4.7261455620173365e-05

The O 0 9.657110786065459e-05
patients O 0 0.020257320255041122
father O 0 5.475454963743687e-05
and O 0 7.501470236093155e-07
two O 0 4.161289837156801e-07
brothers O 0 2.1010509954066947e-05
also O 0 2.1980400788379484e-07
had O 0 1.0306632702850038e-06
C6D B-Disease 0 0.07144364714622498
, O 0 5.961930469311483e-07
but O 0 2.3615174882252177e-07
gave O 0 3.7700283428421244e-07
no O 0 8.741975676684888e-08
history O 0 3.223418616471463e-07
of O 0 3.317221398901893e-06
meningitis B-Disease 1 0.9698541760444641
or O 0 3.986799129052088e-06
other O 0 5.611607321043266e-06
neisserial B-Disease 1 0.9729217290878296
infection I-Disease 0 0.038093697279691696
. O 0 3.825084786512889e-05

By O 0 1.2320173482294194e-05
using O 0 6.048503109923331e-06
exon O 0 7.995674968697131e-05
- O 0 5.190908268559724e-05
specific O 0 1.1225031357753323e-06
polymerase O 0 6.178373587317765e-05
chain O 0 3.546296284184791e-05
reaction O 0 1.7184011085191742e-06
( O 0 1.469708763579547e-07
PCR O 0 4.101734248251887e-06
) O 0 1.0293101126990223e-07
/ O 0 1.0724788808147423e-06
single O 0 1.574163519535432e-07
- O 0 1.0334257240174338e-05
strand O 0 2.4106891487463145e-06
conformation O 0 1.3454640566123999e-06
polymorphism O 0 1.3846288311469834e-06
as O 0 3.0737250966694774e-08
a O 0 5.092423904784482e-08
screening O 0 9.539089660393074e-07
step O 0 3.528112415551732e-07
and O 0 3.9309494326289496e-08
nucleotide O 0 2.3509336699589767e-07
sequencing O 0 2.5041651952051325e-07
of O 0 3.5948168886079657e-08
target O 0 2.429208620924328e-07
exons O 0 9.886510952128447e-07
, O 0 6.323496393179084e-08
we O 0 3.45435324788923e-08
determined O 0 7.851022587601619e-08
that O 0 1.0280187368039151e-08
the O 0 5.8439074024363435e-08
proband O 0 0.00019105437968391925
was O 0 2.7289885906611744e-07
a O 0 2.2062518212351279e-07
compound O 0 3.4523850445111748e-06
heterozygote O 0 1.2546568541438319e-05
for O 0 3.1568484359922877e-07
two O 0 1.129023075918667e-06
C6 O 0 0.037772055715322495
gene O 0 4.763179094879888e-05
mutations O 0 5.0744976761052385e-05
. O 0 1.390587021887768e-05

The O 0 8.232381333073135e-06
first O 0 2.659289066286874e-06
, O 0 7.767779379719286e-07
1195delC O 0 2.9436809199978597e-05
located O 0 1.1569219395823893e-06
in O 0 1.4881014465117914e-07
exon O 0 9.448789569432847e-06
7 O 0 2.0068191588507034e-06
, O 0 1.743071749160663e-07
is O 0 7.714810834613672e-08
a O 0 1.1598523030897923e-07
novel O 0 8.929743557928305e-07
mutation O 0 7.784331614857365e-07
, O 0 8.381395133483238e-08
while O 0 4.8685947717785893e-08
the O 0 1.6310798045537922e-08
second O 0 5.787237356003061e-08
, O 0 1.064100771941412e-07
1936delG O 0 1.103930117096752e-05
in O 0 5.571936156911761e-08
exon O 0 5.66142080060672e-06
12 O 0 3.422539691655402e-07
, O 0 1.3871145654320571e-07
has O 0 6.356314941058372e-08
been O 0 5.034583594465403e-08
described O 0 3.237158239244309e-07
before O 0 1.999097065663591e-07
to O 0 1.5558120480818616e-07
cause O 0 2.791983661154518e-06
C6D B-Disease 0 0.0023057260550558567
in O 0 1.2810851046651806e-07
an O 0 9.382957699699546e-08
unrelated O 0 3.7684176277252845e-06
African O 0 1.293521563638933e-06
- O 0 0.00022023078054189682
American O 0 1.9124968275718857e-06
individual O 0 1.8179067637902335e-06
. O 0 7.11657366991858e-06

Both O 0 8.018565858947113e-05
mutations O 0 0.0002169371146010235
result O 0 1.616220652067568e-05
in O 0 4.17418550568982e-06
premature O 0 0.0024844736326485872
termination O 0 0.0011782348155975342
codons O 0 6.702830432914197e-05
and O 0 9.025513463711832e-06
C6 O 0 0.19601628184318542
null O 0 0.0014153980882838368
alleles O 0 0.0001204173531732522
. O 0 1.9279126718174666e-05

Allele O 0 0.0007058507762849331
- O 0 0.0004025101661682129
specific O 0 7.893296242400538e-06
PCR O 0 4.669719055527821e-05
indicated O 0 3.815814125118777e-06
that O 0 5.084465470872601e-08
the O 0 7.269115087638056e-08
probands O 0 9.418882109457627e-05
two O 0 1.8592558603813814e-07
brothers O 0 1.2174038602097426e-05
also O 0 2.4272125642710307e-07
inherited O 0 1.5905312466202304e-05
the O 0 1.880314783875292e-07
1195delC O 0 0.00018585236102808267
mutation O 0 2.056059884125716e-06
from O 0 1.0821781160075261e-07
their O 0 1.5152045307331719e-07
heterozygous O 0 2.9026384709140984e-06
mother O 0 1.000863267108798e-05
and O 0 2.467919557602727e-07
the O 0 2.6693587074078096e-07
1936delG O 0 0.0003466118942014873
mutation O 0 2.159681798730162e-06
from O 0 1.7769626481367595e-07
their O 0 2.573335393663001e-07
homozygous O 0 1.0644194844644517e-05
father O 0 7.074478617141722e-06
. O 0 1.3460044101520907e-06
. O 0 8.436336429440416e-06

PAX6 O 1 0.957279622554779
mutations O 0 0.025258691981434822
reviewed O 0 0.0026701625902205706
. O 0 0.00044160702964290977

Mutations O 0 0.0010484103113412857
in O 0 1.2428434274625033e-05
PAX6 O 0 0.02206151932477951
are O 0 1.0054505992229679e-06
responsible O 0 1.979104581550928e-06
for O 0 4.360927050583996e-07
human O 0 2.5674667085695546e-06
aniridia B-Disease 1 0.9994022846221924
and O 0 2.828296146617504e-06
have O 0 2.0651731347243185e-07
also O 0 9.344771711994326e-08
been O 0 8.946025786826795e-08
found O 0 4.4071470028939075e-07
in O 0 1.1135733757328126e-06
patients O 0 0.000293112825602293
with O 0 8.048814379435498e-06
Peters B-Disease 1 0.9966546297073364
anomaly I-Disease 1 0.9993925094604492
, O 0 0.0013364058686420321
with O 1 0.5932499766349792
congenital B-Disease 1 0.9999998807907104
cataracts I-Disease 1 0.9999988079071045
, O 0 0.0004169914755038917
with O 0 0.0001581901597091928
autosomal B-Disease 0 0.30015015602111816
dominant I-Disease 0 0.0009728390723466873
keratitis I-Disease 1 0.9481087327003479
, O 0 8.790505489741918e-06
and O 0 4.836570496991044e-06
with O 0 6.086456050979905e-05
isolated B-Disease 0 0.4775657057762146
foveal I-Disease 1 0.9999241828918457
hypoplasia I-Disease 1 0.9998846054077148
. O 0 0.000199368383619003

No O 0 6.460409349529073e-05
locus O 0 9.412237704964355e-05
other O 0 2.1739544990850845e-06
than O 0 1.2352634257695172e-06
chromosome O 0 8.54106547194533e-05
11p13 O 0 0.0005294683505780995
has O 0 5.999963832437061e-07
been O 0 3.132705614916631e-07
implicated O 0 1.868209983513225e-05
in O 0 6.786196991015458e-07
aniridia B-Disease 1 0.9807385802268982
, O 0 7.290608436960611e-07
and O 0 6.287560267992376e-07
PAX6 O 0 0.006642874795943499
is O 0 1.6860533946783107e-07
clearly O 0 3.3125570553238504e-07
the O 0 6.915498573789591e-08
major O 0 7.604740517308528e-07
, O 0 2.1671826289093588e-07
if O 0 1.0173474151997652e-07
not O 0 3.7364998206612654e-08
only O 0 7.918683309071639e-08
, O 0 5.170591634851007e-07
gene O 0 4.340800842328463e-06
responsible O 0 6.963332452869508e-06
. O 0 1.034233264363138e-05

Twenty O 0 0.00015987946244422346
- O 0 0.00018682671361602843
eight O 0 4.719650405604625e-06
percent O 0 5.342963049770333e-06
of O 0 5.174404122954002e-07
identified O 0 7.5233679126540665e-06
PAX6 O 0 0.006884539499878883
mutations O 0 6.909512194397394e-06
are O 0 2.120811046779636e-07
C O 0 0.0006003257585689425
- O 0 0.029205061495304108
T O 0 0.02683296985924244
changes O 0 4.6513378038071096e-07
at O 0 7.772218282298127e-07
CpG O 0 3.355951776029542e-05
dinucleotides O 0 3.245911284466274e-05
, O 0 9.245455601103458e-08
20 O 0 4.8517236450607015e-08
% O 0 2.6271212760775597e-08
are O 0 1.0434391128910647e-08
splicing O 0 4.122665870909259e-07
errors O 0 1.4550154219250544e-06
, O 0 5.119263590813716e-08
and O 0 2.43107134423326e-08
more O 0 1.5899686900411325e-08
than O 0 4.71428762693904e-08
30 O 0 1.952091537305023e-07
% O 0 1.1882318773359657e-07
are O 0 4.9076220420829486e-08
deletion O 0 4.257990894984687e-06
or O 0 4.328203431214206e-07
insertion O 0 8.66959453560412e-06
events O 0 3.5696298255061265e-06
. O 0 1.116618932428537e-05

There O 0 1.276679540751502e-05
is O 0 9.208969231622177e-07
a O 0 1.1275102451691055e-06
noticeably O 0 3.322509292047471e-05
elevated O 0 2.5632230972405523e-05
level O 0 3.334423581691226e-07
of O 0 8.244122540190801e-08
mutation O 0 1.1195203342140303e-06
in O 0 6.626170545587229e-08
the O 0 6.20414652985346e-08
paired O 0 8.954037866715225e-07
domain O 0 2.7283223857921257e-07
compared O 0 5.434366130430135e-07
with O 0 3.2449033682269146e-08
the O 0 2.7682908410042728e-08
rest O 0 1.4549777915817685e-07
of O 0 5.6333387732365736e-08
the O 0 5.578943955697468e-07
gene O 0 1.0941095752059482e-05
. O 0 9.076206879399251e-06

Increased O 0 0.00013472915452439338
mutation O 0 4.817030639969744e-05
in O 0 8.323420956912742e-07
the O 0 2.5709485385050357e-07
homeodomain O 0 4.989743683836423e-05
is O 0 2.3696254913829762e-07
accounted O 0 1.6542558114451822e-06
for O 0 9.888777441346974e-08
by O 0 1.698395948324105e-07
the O 0 4.2533056898719224e-07
hypermutable O 0 0.005860169418156147
CpG O 0 0.0006069447845220566
dinucleotide O 0 0.00018276837363373488
in O 0 1.3152518931747181e-06
codon O 0 1.6846735888975672e-05
240 O 0 1.7514346836833283e-05
. O 0 1.1701994480972644e-05

Very O 0 3.344239667057991e-05
nearly O 0 6.67190352032776e-06
all O 0 6.2358697050513e-07
mutations O 0 7.636451300641056e-06
appear O 0 1.1925495755349402e-06
to O 0 4.668019926157285e-07
cause O 0 1.5930907466099598e-05
loss O 0 1.4412614291359205e-05
of O 0 1.0803302785689084e-07
function O 0 1.7388711626153963e-07
of O 0 2.4694164935112894e-08
the O 0 5.21817149490289e-08
mutant O 0 2.4537500848964555e-06
allele O 0 7.438360398737132e-07
, O 0 5.5010161759128096e-08
and O 0 1.659191184444353e-08
more O 0 1.3108570229292127e-08
than O 0 3.633135392533404e-08
80 O 0 2.6032915911855525e-07
% O 0 7.319535200167593e-08
of O 0 7.148560143832583e-08
exonic O 0 0.000105774772237055
substitutions O 0 2.814573690557154e-06
result O 0 1.196661287394818e-06
in O 0 6.130416068117484e-07
nonsense O 0 4.299276042729616e-05
codons O 0 5.995764149702154e-05
. O 0 1.0287492841598578e-05

In O 0 1.006292768579442e-05
a O 0 2.3621535092388513e-06
gene O 0 4.53939856015495e-06
with O 0 2.2513781061661575e-07
such O 0 2.4943452103798336e-07
extraordinarily O 0 0.00021992276015225798
high O 0 2.566903731349157e-06
sequence O 0 3.1590647608936706e-07
conservation O 0 6.439765911636641e-07
throughout O 0 8.815229790570811e-08
evolution O 0 2.0682124102222588e-07
, O 0 1.0566861163852082e-07
there O 0 6.045971900903169e-08
are O 0 1.2621104872323485e-07
presumed O 0 6.411158392438665e-05
undiscovered O 0 0.0012054513208568096
missense O 0 0.00025120715145021677
mutations O 0 5.904086719965562e-06
, O 0 1.4132946546396852e-07
these O 0 3.713685359230112e-08
are O 0 3.64249572726294e-08
hypothesized O 0 6.996694992267294e-07
to O 0 4.93543588220291e-08
exist O 0 1.252487038527761e-07
in O 0 6.415619679955853e-08
as O 0 1.6303528127536993e-07
- O 0 0.0005370976286940277
yet O 0 9.951422725862358e-06
unidentified O 0 3.2380488846683875e-05
phenotypes O 0 6.228549318620935e-05
. O 0 2.179939883717452e-06
. O 0 1.0437891432957258e-05

Genetic O 0 0.004219237249344587
heterogeneity O 0 0.0013037651078775525
and O 0 1.1340732271492016e-05
penetrance O 0 0.00048437234363518655
analysis O 0 1.4454806205321802e-06
of O 0 2.5219290478162293e-07
the O 0 7.101443770807236e-07
BRCA1 O 0 0.0005206128116697073
and O 0 3.922280029655667e-06
BRCA2 O 0 0.0016173243056982756
genes O 0 1.4975851627241354e-05
in O 0 0.00012087649520253763
breast B-Disease 1 0.9999924898147583
cancer I-Disease 1 0.9995239973068237
families O 0 9.319408127339557e-05
. O 0 5.142980444361456e-05

The O 0 0.010681339539587498
Breast B-Disease 1 0.9999936819076538
Cancer I-Disease 1 0.9999618530273438
Linkage O 0 0.062229663133621216
Consortium O 0 0.0036309596616774797
. O 0 0.0001829976827139035

The O 0 1.1172814993187785e-05
contribution O 0 9.498108738625888e-06
of O 0 1.7706203152556554e-06
BRCA1 O 0 0.0005355168250389397
and O 0 6.241787559702061e-06
BRCA2 O 0 0.06309252977371216
to O 0 0.0007340760203078389
inherited B-Disease 1 0.9999985694885254
breast I-Disease 1 0.9999995231628418
cancer I-Disease 1 0.9999972581863403
was O 0 3.549597749952227e-05
assessed O 0 6.468442006735131e-05
by O 0 7.075066150719067e-07
linkage O 0 2.754703746177256e-05
and O 0 5.011265216126048e-07
mutation O 0 5.003499836675473e-07
analysis O 0 2.7241753741691355e-07
in O 0 1.0502502334475139e-07
237 O 0 9.901552402880043e-06
families O 0 7.06108608028444e-07
, O 0 1.0748220802270225e-07
each O 0 2.887960270925305e-08
with O 0 6.437242205947769e-08
at O 0 2.0574317716182122e-07
least O 0 5.4214257971807456e-08
four O 0 5.829368632248588e-08
cases O 0 3.29542558574758e-07
of O 0 5.134688308316981e-06
breast B-Disease 1 0.99996018409729
cancer I-Disease 1 0.9698306322097778
, O 0 5.135017886459536e-07
collected O 0 3.5114098295707663e-07
by O 0 8.686832870807848e-07
the O 0 0.00018065821495838463
Breast B-Disease 1 0.9999982118606567
Cancer I-Disease 1 0.9999157190322876
Linkage O 0 0.002356802113354206
Consortium O 0 0.00037857310962863266
. O 0 3.0651994165964425e-05

Families O 0 0.00022233386698644608
were O 0 3.179337454639608e-06
included O 0 1.4220447610568954e-06
without O 0 5.004478111914068e-07
regard O 0 6.385100732586579e-07
to O 0 8.969809783820892e-08
the O 0 1.1702340430019831e-07
occurrence O 0 6.132303042249987e-06
of O 0 7.413923867716221e-06
ovarian B-Disease 1 0.999956488609314
or I-Disease 0 1.7132209904957563e-05
other I-Disease 0 1.1497426385176368e-05
cancers I-Disease 1 0.9715383648872375
. O 0 3.948304583900608e-05

Overall O 0 0.0024080066941678524
, O 0 0.0006372236530296504
disease O 0 0.12673720717430115
was O 0 2.631174083944643e-06
linked O 0 2.480088187439833e-05
to O 0 5.139564791534212e-07
BRCA1 O 0 0.00032029947033151984
in O 0 1.6556637660869455e-07
an O 0 5.794073842935177e-08
estimated O 0 6.744994038854202e-07
52 O 0 1.575737655912235e-06
% O 0 8.474533075286672e-08
of O 0 5.104404365852133e-08
families O 0 4.205381003430375e-07
, O 0 1.0147408602279029e-07
to O 0 1.5105327122455492e-07
BRCA2 O 0 2.0659741494455375e-05
in O 0 3.856138874880344e-08
32 O 0 4.6990311375338933e-07
% O 0 9.881574669634574e-08
of O 0 5.659357782406005e-08
families O 0 5.108787490826217e-07
, O 0 2.177196449792973e-07
and O 0 7.141581903624683e-08
to O 0 5.5215778616002353e-08
neither O 0 3.445243521582597e-07
gene O 0 2.0323568605817854e-07
in O 0 2.6426505428389646e-08
16 O 0 1.981190109745512e-07
% O 0 1.3172059709631867e-07
( O 0 4.082732729671079e-08
95 O 0 2.648954193773534e-07
% O 0 9.389384558744496e-08
confidence O 0 4.7466340902246884e-07
interval O 0 1.3095670965412864e-06
[ O 0 1.6289491213683505e-06
CI O 0 0.00011107136378996074
] O 0 7.419770327032893e-07
6 O 0 2.930939899670193e-07
% O 0 8.505916326839724e-08
- O 0 1.688356678641867e-05
28 O 0 4.4573494051292073e-07
% O 0 3.933776682174539e-08
) O 0 3.153261118882256e-08
, O 0 5.685074100370002e-08
suggesting O 0 6.619513328587345e-07
other O 0 3.4551379712866037e-07
predisposition O 0 0.00034583196975290775
genes O 0 1.3380666132434271e-05
. O 0 1.347819033981068e-05

The O 0 2.128143205482047e-05
majority O 0 1.994162448681891e-05
( O 0 1.5458291500181076e-06
81 O 0 4.993693437427282e-06
% O 0 2.459020436162973e-07
) O 0 2.758945250036504e-08
of O 0 3.550626104242838e-08
the O 0 1.8284782754562912e-06
breast B-Disease 1 0.9999667406082153
- I-Disease 1 0.9999992847442627
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999973773956299
families O 0 1.4083720088819973e-05
were O 0 2.7187329010303074e-07
due O 0 1.7194010979437735e-06
to O 0 4.04392125119557e-07
BRCA1 O 0 0.0018343717092648149
, O 0 4.3771603941422654e-07
with O 0 2.1281434214870387e-07
most O 0 1.4276757553943753e-07
others O 0 3.806803761108313e-07
( O 0 8.004648321957575e-08
14 O 0 2.430891470339702e-07
% O 0 1.7513933414647909e-07
) O 0 8.69606040510007e-08
due O 0 6.089714474910579e-07
to O 0 1.2875242418886046e-06
BRCA2 O 0 0.0006458821590058506
. O 0 1.3100219803163782e-05

Conversely O 0 0.001210609683766961
, O 0 7.1594326982449275e-06
the O 0 8.99696487977053e-07
majority O 0 1.1561321571207372e-06
of O 0 3.274614073234261e-07
families O 0 1.7645012349021272e-06
with O 0 5.22128289048851e-07
male B-Disease 0 6.138979642855702e-06
and I-Disease 0 1.146686372521799e-05
female I-Disease 0 0.0037699241656810045
breast I-Disease 1 0.9999758005142212
cancer I-Disease 1 0.9932326078414917
were O 0 1.5726376432212419e-06
due O 0 3.5285809190099826e-06
to O 0 1.617819293642242e-06
BRCA2 O 0 0.0038013579323887825
( O 0 1.49031848195591e-06
76 O 0 6.772903725504875e-05
% O 0 2.218561803601915e-06
) O 0 1.0911709296124172e-06
. O 0 5.432731086330023e-06

The O 0 9.62258673098404e-06
largest O 0 1.7324737200397067e-05
proportion O 0 7.87154112913413e-06
( O 0 6.297305503721873e-07
67 O 0 4.310265921958489e-06
% O 0 2.2901058116531203e-07
) O 0 3.3103866314831976e-08
of O 0 3.441095941525418e-08
families O 0 5.205795332585694e-07
due O 0 3.6952059190298314e-07
to O 0 6.633568006009227e-08
other O 0 5.4934250925953165e-08
genes O 0 3.525502734191832e-07
was O 0 1.8400956491859688e-07
found O 0 2.3332883358762047e-07
in O 0 8.982804189372473e-08
families O 0 2.0232349129400973e-07
with O 0 5.91084301504452e-08
four O 0 1.0030412056494242e-07
or O 0 9.850450055637339e-08
five O 0 9.864928074421186e-08
cases O 0 4.1160032537845836e-07
of O 0 1.1108284070360241e-06
female O 0 0.008966897614300251
breast B-Disease 1 0.9999858140945435
cancer I-Disease 1 0.9865447878837585
only O 0 3.7784038795507513e-06
. O 0 2.5854655177681707e-05

These O 0 1.0400759492767975e-05
estimates O 0 1.7726069927448407e-05
were O 0 6.646473025284649e-07
not O 0 1.6304959160606813e-07
substantially O 0 3.24240295412892e-06
affected O 0 3.1821721790947777e-07
either O 0 7.900143117467451e-08
by O 0 6.451549694475034e-08
changing O 0 3.4799296599885565e-07
the O 0 6.154761678089926e-08
assumed O 0 1.7177096651721513e-06
penetrance O 0 7.696937973378226e-05
model O 0 7.874731409174274e-07
for O 0 3.3136407751044317e-07
BRCA1 O 0 0.0001651592756388709
or O 0 2.1257297078136617e-07
by O 0 1.198673373892234e-07
including O 0 3.0109930548860575e-07
or O 0 1.0686604809961864e-06
excluding O 0 8.672371041029692e-05
BRCA1 O 0 0.01739734224975109
mutation O 0 3.081274917349219e-05
data O 0 8.807716767478269e-06
. O 0 1.1716980225173756e-05

Among O 0 7.17330549377948e-05
those O 0 7.956872650538571e-06
families O 0 3.9617349102627486e-05
with O 0 5.695737127098255e-05
disease O 0 0.020035192370414734
due O 0 4.221456492814468e-06
to O 0 1.5636197758794879e-06
BRCA1 O 0 0.0050096092745661736
that O 0 2.387800748238078e-07
were O 0 2.3313219799092622e-07
tested O 0 1.9312153654027497e-06
by O 0 4.0801403144996584e-08
one O 0 1.4311499541008743e-08
of O 0 1.3786355168576847e-08
the O 0 2.5088496613534517e-08
standard O 0 3.28215520539743e-07
screening O 0 1.5961177268764004e-06
methods O 0 6.432468353523291e-07
, O 0 1.6307633643464214e-07
mutations O 0 4.827165298593172e-07
were O 0 6.945478503439517e-08
detected O 0 1.0336990499126841e-06
in O 0 2.710887336832002e-08
the O 0 2.6259490581992395e-08
coding O 0 8.996955784823513e-07
sequence O 0 1.537944598339891e-07
or O 0 5.945918246652582e-08
splice O 0 1.2121338386350544e-06
sites O 0 1.6041337858041516e-07
in O 0 1.9205259604859748e-08
an O 0 9.83914283381182e-09
estimated O 0 3.100398657807091e-07
63 O 0 1.819941530811775e-06
% O 0 1.0942142125713872e-07
( O 0 2.8213833047630033e-08
95 O 0 2.811717081385723e-07
% O 0 2.039727462488372e-07
CI O 0 0.00020301698532421142
51 O 0 2.0637155557778897e-06
% O 0 4.1813066786744457e-07
- O 0 6.646219844697043e-05
77 O 0 9.693581887404434e-06
% O 0 8.092965231298876e-07
) O 0 6.59186412121926e-07
. O 0 3.5027749163418775e-06

The O 0 1.2547897313197609e-05
estimated O 0 1.1936594091821462e-05
sensitivity O 0 1.5644160157535225e-05
was O 0 8.443738579444471e-07
identical O 0 1.0871241329368786e-06
for O 0 7.501135002030423e-08
direct O 0 1.5718323709279503e-07
sequencing O 0 1.8892568505179952e-06
and O 0 3.148910252548376e-07
other O 0 2.80952718867411e-07
techniques O 0 5.9768503888335545e-06
. O 0 6.471159849752439e-06

The O 0 3.471904346952215e-05
penetrance O 0 0.001897600945085287
of O 0 6.3701963881612755e-06
BRCA2 O 0 0.0016713747754693031
was O 0 2.6705426989792613e-06
estimated O 0 1.4636958667324507e-06
by O 0 1.5917930795694701e-07
maximizing O 0 3.3891346902237274e-06
the O 0 2.201335860263498e-07
LOD O 0 0.0003588616382330656
score O 0 5.319035949469253e-07
in O 0 4.4014765876454476e-07
BRCA2 O 0 0.000252959958743304
- O 0 0.0024368634913116693
mutation O 0 5.055786459706724e-06
families O 0 5.955139954494371e-07
, O 0 2.731529775701347e-07
over O 0 2.5626061983530235e-07
all O 0 2.5466144393249124e-07
possible O 0 4.550876383291325e-06
penetrance O 0 0.0004237235407344997
functions O 0 4.548858669295441e-06
. O 0 7.936932888696902e-06

The O 0 1.809023342502769e-05
estimated O 0 1.505185355199501e-05
cumulative O 0 3.4846252674469724e-05
risk O 0 7.259967969730496e-05
of O 0 7.127121989469742e-06
breast B-Disease 1 0.9999606609344482
cancer I-Disease 1 0.9923604130744934
reached O 0 1.568977313581854e-05
28 O 0 7.646931408089586e-06
% O 0 2.9688959557461203e-07
( O 0 8.665611517244542e-08
95 O 0 4.851450512433075e-07
% O 0 3.032687629911379e-07
CI O 0 0.00011242873006267473
9 O 0 6.264946819101169e-07
% O 0 1.1115664477756582e-07
- O 0 1.2896445696242154e-05
44 O 0 5.107326614961494e-07
% O 0 5.067822428372892e-08
) O 0 1.3859543734895396e-08
by O 0 2.2226455342888585e-08
age O 0 1.6635013366794738e-07
50 O 0 6.915630024195707e-08
years O 0 4.1864613109510174e-08
and O 0 4.825053068202578e-08
84 O 0 1.1366893204467488e-06
% O 0 5.811073577888237e-08
( O 0 2.3945228022625997e-08
95 O 0 3.057237165648985e-07
% O 0 1.529076172346322e-07
CI O 0 6.44814208499156e-05
43 O 0 4.250142922046507e-07
% O 0 1.0230780844722176e-07
- O 0 1.0868610843317583e-05
95 O 0 7.86701434662973e-07
% O 0 1.2949604411005566e-07
) O 0 4.750102533535028e-08
by O 0 9.67153965802936e-08
age O 0 1.232588601851603e-06
70 O 0 1.3425711813397356e-06
years O 0 2.4588850919826655e-06
. O 0 8.199058356694877e-06

The O 0 0.0002078069665003568
corresponding O 1 0.9573580622673035
ovarian B-Disease 1 0.9999998807907104
cancer I-Disease 1 0.999997615814209
risks O 0 0.018092148005962372
were O 0 6.213475899130572e-06
0 O 0 5.359313581720926e-05
. O 0 2.916473567893263e-05

4 O 0 8.429502486251295e-05
% O 0 5.988079010421643e-06
( O 0 5.856705911355675e-07
95 O 0 1.0407637773823808e-06
% O 0 4.3860356413460977e-07
CI O 0 0.0005871466128155589
0 O 0 6.923495448063477e-07
% O 0 1.2840280305681517e-07
- O 0 1.1306068699923344e-05
1 O 0 1.415991448538989e-07
% O 0 4.314454926657163e-08
) O 0 1.0975812259061968e-08
by O 0 2.0813697432231493e-08
age O 0 1.0750394352498915e-07
50 O 0 3.859479136281152e-08
years O 0 4.5291834283034405e-08
and O 0 4.7062560071253756e-08
27 O 0 3.938687598292745e-07
% O 0 4.848171286653269e-08
( O 0 2.4697886402691438e-08
95 O 0 1.5048101431602845e-07
% O 0 1.1517484921341747e-07
CI O 0 6.188438419485465e-05
0 O 0 4.0378051835432416e-07
% O 0 7.686404757123455e-08
- O 0 1.0959496648865752e-05
47 O 0 1.9065855667577125e-06
% O 0 7.499933474264253e-08
) O 0 3.42322437063558e-08
by O 0 5.631190092003635e-08
age O 0 5.343603675100894e-07
70 O 0 9.944506018655375e-07
years O 0 1.8855740790968412e-06
. O 0 5.702912858396303e-06

The O 0 2.7307269192533568e-05
lifetime O 0 0.0004916408215649426
risk O 0 0.000511379272211343
of O 0 0.0001081916198018007
breast B-Disease 1 0.9999964237213135
cancer I-Disease 1 0.9999281167984009
appears O 0 4.80829257867299e-05
similar O 0 1.1450605370555422e-06
to O 0 2.1872108391107759e-07
the O 0 2.7329187446412107e-07
risk O 0 2.2279811673797667e-05
in O 0 5.122985271555081e-07
BRCA1 O 0 0.0010242874268442392
carriers O 0 1.5276698832167313e-05
, O 0 3.0287597496680974e-07
but O 0 9.338607043218872e-08
there O 0 5.12507654093497e-08
was O 0 7.33074045911053e-08
some O 0 1.6823456405745674e-08
suggestion O 0 3.0494973657368973e-07
of O 0 3.926603042714305e-08
a O 0 4.593081541770516e-07
lower O 0 4.998164513381198e-05
risk O 0 1.4288160855358e-05
in O 0 4.2403374322930176e-07
BRCA2 O 0 0.00011092646309407428
carriers O 0 8.593225174990948e-06
< O 0 0.00016602055984549224
50 O 0 8.708971677151567e-07
years O 0 6.447723990277154e-07
of O 0 4.7288412474699726e-07
age O 0 1.217343560711015e-05
. O 0 1.4084404938330408e-05

Eye B-Disease 1 0.7459269762039185
movement I-Disease 0 0.004729300271719694
abnormalities I-Disease 1 0.9821051359176636
correlate O 0 0.0013038053875789046
with O 0 3.684592229546979e-05
genotype O 0 0.09766747802495956
in O 0 5.903686542296782e-05
autosomal O 1 0.5298172831535339
dominant O 0 0.1328808069229126
cerebellar B-Disease 1 0.999795138835907
ataxia I-Disease 1 0.9998261332511902
type I-Disease 0 0.03855989873409271
I I-Disease 0 0.0006983933853916824
. O 0 5.766187678091228e-05

We O 0 5.3204959840513766e-05
compared O 0 6.103655323386192e-05
horizontal O 0 0.0003001678560394794
eye O 0 0.0008750476990826428
movements O 0 1.1349594387866091e-05
( O 0 5.812541985505959e-07
visually O 0 5.472359589475673e-06
guided O 0 5.532928298634943e-06
saccades O 0 0.0015704541001468897
, O 0 7.188312451944512e-07
antisaccades O 0 0.00023034258629195392
, O 0 2.6421221832606534e-07
and O 0 1.338998316668949e-07
smooth O 0 9.996422704716679e-06
pursuit O 0 2.1173756977077574e-05
) O 0 1.0051383014797466e-07
in O 0 4.141169185345461e-08
control O 0 3.0090927793935407e-07
subjects O 0 6.203270572768815e-07
( O 0 1.3583810698492016e-07
n O 0 2.68900203082012e-05
= O 0 2.151050694010337e-06
14 O 0 1.3880766402962763e-07
) O 0 5.024251947816083e-08
and O 0 3.532617540713545e-07
patients O 0 1.6947544281720184e-05
with O 0 1.0393319627155506e-07
three O 0 1.5360799920927093e-07
forms O 0 1.4174278248901828e-06
of O 0 1.7462909909227164e-06
autosomal O 0 0.0029205894097685814
dominant O 0 0.0001228247710969299
cerebellar B-Disease 1 0.7805251479148865
ataxias I-Disease 1 0.6432594060897827
type I-Disease 0 0.00019769011123571545
I I-Disease 0 8.325728413183242e-05
spinocerebellar B-Disease 0 0.4551340937614441
ataxias I-Disease 0 0.001170265837572515
1 I-Disease 0 7.226508387248032e-07
and I-Disease 0 1.364069674991697e-07
2 I-Disease 0 5.30516047092533e-07
( O 0 1.890160064021984e-07
SCA1 B-Disease 0 0.0006136256852187216
, O 0 4.505428705670056e-07
n O 0 2.5851300961221568e-05
= O 0 2.7180794859305024e-06
11 O 0 3.1648184517507616e-07
; O 0 2.387942004133947e-07
SCA2 B-Disease 0 0.00014585713506676257
, O 0 2.0534525901894085e-07
n O 0 7.828793059161399e-06
= O 0 9.373366651743709e-07
10 O 0 4.930571506633896e-08
) O 0 2.794114273285686e-08
and O 0 1.0997756305641815e-07
SCA3 B-Disease 0 0.3580375611782074
/ O 0 5.269431494525634e-05
Machado B-Disease 0 0.0007714523817412555
- I-Disease 0 0.2453845739364624
Joseph I-Disease 0 0.32862210273742676
disease I-Disease 0 0.0022096268367022276
( O 0 9.528451982987463e-07
MJD B-Disease 1 0.978981077671051
) O 0 6.625512583013915e-07
( O 0 3.64668068186802e-07
n O 0 2.1273866877891123e-05
= O 0 5.265584604785545e-06
16 O 0 8.727479325898457e-07
) O 0 6.793222837586654e-07
. O 0 1.862165731836285e-06

In O 0 5.506442903424613e-05
SCA1 B-Disease 0 0.0030077381525188684
, O 0 5.143578619026812e-06
saccade O 0 0.0001093225582735613
amplitude O 0 1.195971344714053e-05
was O 0 8.267189173238876e-07
significantly O 0 1.5868230320847942e-06
increased O 0 3.7535292563006806e-07
, O 0 2.2247158426580427e-07
resulting O 0 1.0940781294266344e-06
in O 0 1.0080793799716048e-06
hypermetria B-Disease 0 0.001390693592838943
. O 0 2.5925543013727292e-05

The O 0 2.2313452063826844e-05
smooth O 0 0.00012915124534629285
pursuit O 0 0.00019132965826429427
gain O 0 0.0001196816228912212
was O 0 2.2655538487015292e-05
decreased O 0 0.00012861346476711333
. O 0 2.0088136807316914e-05

In O 0 4.4636741222348064e-05
SCA2 B-Disease 0 0.0038044038228690624
, O 0 1.1177313353982754e-05
saccade O 0 0.0003008267958648503
velocity O 0 6.099500387790613e-05
was O 0 1.1152174010931049e-05
markedly O 0 0.00018055109831038862
decreased O 0 8.870675810612738e-05
. O 0 2.420437340333592e-05

The O 0 1.8462036678101867e-05
percentage O 0 2.8625185223063454e-05
of O 0 7.579522502965119e-07
errors O 0 1.0432846465846524e-05
in O 0 6.126401217443345e-07
antisaccades O 0 0.0008323970250785351
was O 0 9.338176596429548e-07
greatly O 0 1.0833557553269202e-06
increased O 0 1.9198489553673426e-07
and O 0 1.402685541052051e-07
was O 0 2.5680373028080794e-07
significantly O 0 1.6643089111312293e-06
correlated O 0 3.3240203265449964e-06
with O 0 5.301685632730369e-07
age O 0 2.0408637283253483e-05
at O 0 0.0001813594572013244
disease O 0 0.07848325371742249
onset O 0 0.22464147210121155
. O 0 5.849055014550686e-05

In O 0 1.0284285053785425e-05
addition O 0 3.0797984891250962e-06
, O 0 4.997601195100287e-07
a O 0 1.8401972567971825e-07
correlation O 0 9.782863799046027e-07
between O 0 2.980924591611256e-07
smooth O 0 1.5061358681123238e-05
pursuit O 0 4.934287062496878e-05
gain O 0 1.722660817904398e-05
and O 0 1.9144809471072222e-07
the O 0 6.817795394908899e-08
number O 0 1.0590387944375834e-07
of O 0 5.711157200494199e-07
trinucleotide O 0 0.006515442859381437
repeats O 0 2.418183248664718e-05
was O 0 4.038643510284601e-06
found O 0 5.044122644903837e-06
. O 0 7.028112122497987e-06

In O 0 3.7335521483328193e-05
SCA3 B-Disease 1 0.9699497818946838
, O 0 6.89609578330419e-06
gaze B-Disease 0 7.922653458081186e-05
- I-Disease 0 0.00041699997382238507
evoked I-Disease 0 0.00044964486733078957
nystagmus I-Disease 0 0.006867035757750273
was O 0 1.8299733710591681e-06
often O 0 2.738152033998631e-07
present O 0 9.991783400664644e-08
as O 0 5.797710755928165e-08
was O 0 3.0397848149732454e-07
saccade O 0 4.7464476665481925e-05
hypometria O 0 0.00010019155160989612
and O 0 2.455927017308568e-07
smooth O 0 5.342754320736276e-06
pursuit O 0 2.4162469344446436e-05
gain O 0 1.7816741092246957e-05
was O 0 6.301645953499246e-06
markedly O 0 7.459726475644857e-05
decreased O 0 4.098828139831312e-05
. O 0 1.3507285075320397e-05

Three O 0 2.764158671197947e-05
major O 0 2.052034869848285e-05
criteria O 0 7.679936061322223e-06
, O 0 9.62716285357601e-07
saccade O 0 4.0053339034784585e-05
amplitude O 0 2.6165505460085114e-06
, O 0 1.966466101066544e-07
saccade O 0 1.3508045412891079e-05
velocity O 0 3.394322902749991e-06
, O 0 1.155447222345174e-07
and O 0 3.084554833776565e-08
presence O 0 9.080269336436686e-08
of O 0 5.8134574487667123e-08
gaze B-Disease 0 1.1013476068910677e-05
- I-Disease 0 0.0003517687728162855
evoked I-Disease 0 0.0001456720201531425
nystagmus I-Disease 0 0.002651811810210347
, O 0 2.490475594640884e-07
permitted O 0 1.9965668229815492e-07
the O 0 5.680706038901917e-08
correct O 0 1.01445209566009e-06
assignment O 0 5.448902129501221e-07
of O 0 4.762349448128589e-08
90 O 0 2.222277259988914e-07
% O 0 4.244666129693542e-08
of O 0 1.5834769939715443e-08
the O 0 5.2618069901200215e-08
SCA1 B-Disease 0 0.00020023767137899995
, O 0 7.775022226041983e-08
90 O 0 1.2500348134381056e-07
% O 0 2.5869443476267406e-08
of O 0 1.2054065301470018e-08
the O 0 7.51770627971382e-08
SCA2 B-Disease 0 0.0007246807799674571
, O 0 1.4872048836878093e-07
and O 0 6.639821492626652e-08
93 O 0 7.891044333518948e-07
% O 0 5.7828788868619085e-08
of O 0 3.388832325867952e-08
the O 0 3.4448987662472064e-07
patients O 0 5.721502748201601e-05
with O 0 8.64711694248399e-07
SCA3 B-Disease 1 0.9984501600265503
to O 0 2.2490647211270698e-07
their O 0 1.2974699359347142e-07
genetically O 0 9.993906132876873e-06
confirmed O 0 4.121857728023315e-06
patient O 0 3.9118676795624197e-05
group O 0 6.873974598420318e-07
and O 0 1.9572925680222397e-07
, O 0 1.702031227068801e-07
therefore O 0 1.346240310340363e-07
, O 0 1.4767969958029425e-07
may O 0 3.127526611024223e-07
help O 0 6.693340424135386e-07
orient O 0 0.00013789004879072309
diagnoses O 0 0.00018495078256819397
of O 0 2.6555153453955427e-07
SCA1 B-Disease 0 0.05797040835022926
, O 0 1.8380853816779563e-06
SCA2 B-Disease 0 0.002806355245411396
, O 0 4.1462524791313626e-07
and O 0 5.143241992300318e-07
SCA3 B-Disease 1 0.9693976640701294
at O 0 9.859638794296188e-07
early O 0 1.1921732721020817e-06
clinical O 0 2.1424382794066332e-05
stages O 0 5.570720531977713e-06
of O 0 4.267184579020977e-07
the O 0 7.432017355313292e-06
diseases O 0 0.06306236982345581
. O 0 3.253904651501216e-06
. O 0 1.5673427697038278e-05

Genetic O 0 0.0005308607942424715
basis O 0 1.1435389751568437e-05
and O 0 5.303356829244876e-06
molecular O 0 0.00018220546189695597
mechanism O 0 0.00012591996346600354
for O 0 0.0016808408545330167
idiopathic B-Disease 1 0.9999974966049194
ventricular I-Disease 1 0.9999501705169678
fibrillation I-Disease 1 0.9999431371688843
. O 0 0.0008637270657345653

Ventricular B-Disease 1 0.9991031885147095
fibrillation I-Disease 1 0.9991832375526428
causes O 0 0.000626235909294337
more O 0 2.0636564386222744e-06
than O 0 8.939047688727442e-07
300 O 0 1.592930516380875e-06
, O 0 3.5632794492812536e-07
000 O 0 1.647886733735504e-06
sudden O 0 2.173059510823805e-05
deaths O 0 2.1379739791882457e-06
each O 0 6.725987589106808e-08
year O 0 1.6499642185863195e-07
in O 0 7.714119476531778e-08
the O 0 2.1771381852886407e-07
USA O 0 6.874479367979802e-06
alone O 0 5.78962726649479e-06
. O 0 5.820329988637241e-06

In O 0 5.984738891129382e-06
approximately O 0 3.828535682259826e-06
5 O 0 2.1993812424625503e-06
- O 0 5.001687532057986e-05
12 O 0 5.734926844525035e-07
% O 0 5.062035768332862e-08
of O 0 2.2772383090341464e-08
these O 0 7.965005721644047e-08
cases O 0 1.037329184327973e-06
, O 0 3.102960306478053e-07
there O 0 8.119808825313157e-08
are O 0 9.728709216005882e-08
no O 0 1.3049119615970994e-06
demonstrable O 0 0.012330316007137299
cardiac O 1 0.5716660618782043
or O 0 3.760232630156679e-06
non O 0 0.0002065553708234802
- O 1 0.9883480668067932
cardiac O 1 0.9707177877426147
causes O 0 1.2797563613275997e-05
to O 0 1.8140605106964358e-07
account O 0 1.6200273478261806e-07
for O 0 6.878428138179515e-08
the O 0 6.073051395105722e-08
episode O 0 9.385227599523205e-07
, O 0 1.593412122247173e-07
which O 0 6.706400768052845e-08
is O 0 1.0198341726663784e-07
therefore O 0 8.36263041037455e-07
classified O 0 7.936543988762423e-05
as O 0 9.174246224574745e-05
idiopathic B-Disease 1 0.9999980926513672
ventricular I-Disease 1 0.999955415725708
fibrillation I-Disease 1 0.9999805688858032
( O 0 0.0002145239559467882
IVF B-Disease 1 0.9991752505302429
) O 0 3.519135862006806e-05
. O 0 3.2282841857522726e-05

A O 0 5.96086829318665e-05
distinct O 0 1.7545142327435315e-05
group O 0 6.245444183150539e-06
of O 0 3.3298520065727644e-06
IVF B-Disease 1 0.9999769926071167
patients O 0 0.3456478416919708
has O 0 1.3522405879484722e-06
been O 0 3.6396900782165176e-07
found O 0 3.6455818985814403e-07
to O 0 1.2425991258169233e-07
present O 0 2.750869896317454e-07
with O 0 2.939856074135605e-07
a O 0 1.572691530782322e-06
characteristic O 0 2.81225293292664e-05
electrocardiographic O 0 0.025828439742326736
pattern O 0 0.00013147083518560976
. O 0 1.8586721125757322e-05

Because O 0 2.1861253117094748e-05
of O 0 7.829262926861702e-07
the O 0 2.7474143848849053e-07
small O 0 7.626587148479302e-07
size O 0 6.461882549047004e-07
of O 0 4.8336382008074e-08
most O 0 7.692403158898742e-08
pedigrees O 0 6.2171211538952775e-06
and O 0 1.1669285981952271e-07
the O 0 1.0179568477042267e-07
high O 0 2.5293013095506467e-05
incidence O 0 7.674971857341006e-05
of O 0 2.602035635845823e-07
sudden B-Disease 0 0.0028034825809299946
death I-Disease 0 9.202769433613867e-06
, O 0 3.24526610029352e-07
however O 0 1.3693666289782414e-07
, O 0 1.1885038730952147e-07
molecular O 0 6.840343303338159e-06
genetic O 0 8.737630992072809e-07
studies O 0 1.7546835806570016e-07
of O 0 2.9995976547070313e-07
IVF B-Disease 1 0.9941914677619934
have O 0 4.225239820243587e-07
not O 0 1.7757700732090598e-07
yet O 0 9.490995580563322e-07
been O 0 3.762970095522178e-07
done O 0 3.622981466833153e-06
. O 0 8.250001883425284e-06

Because O 0 0.0011889660963788629
IVF B-Disease 1 0.9995834231376648
causes O 0 0.3187665343284607
cardiac O 1 0.9922919869422913
rhythm O 0 0.011924754828214645
disturbance O 0 0.008185856975615025
, O 0 1.9191877527191537e-06
we O 0 3.0185779564817494e-07
investigated O 0 3.8107336877146736e-06
whether O 0 8.218560765271832e-07
malfunction O 0 0.0001427925017196685
of O 0 1.5265234765138302e-07
ion O 0 9.111846884479746e-05
channels O 0 3.738806526598637e-06
could O 0 2.862506107703666e-06
cause O 0 1.0561744602455292e-05
the O 0 9.710250878924853e-07
disorder O 0 0.0033367276191711426
by O 0 2.210887686260321e-07
studying O 0 1.8596296058603912e-06
mutations O 0 2.643864036144805e-06
in O 0 2.4601135351076664e-07
the O 0 1.1101071777375182e-06
cardiac O 0 0.002825550502166152
sodium O 0 4.0495593566447496e-05
channel O 0 2.9778109819744714e-05
gene O 0 3.217087942175567e-05
SCN5A O 0 0.0027377696242183447
. O 0 2.7443780709290877e-05

We O 0 3.124595241388306e-05
have O 0 3.0993512609711615e-06
now O 0 1.8597058897285024e-06
identified O 0 2.0582710931194015e-06
a O 0 7.585039156765561e-07
missense O 0 0.00016653792408760637
mutation O 0 4.439045824256027e-06
, O 0 1.9917287374937587e-07
a O 0 2.398060985342454e-07
splice O 0 7.433324208250269e-05
- O 0 0.011749249882996082
donor O 0 5.9825364587595686e-05
mutation O 0 2.9517634629883105e-06
, O 0 1.7294081544605433e-07
and O 0 1.8833189585620858e-07
a O 0 1.044573082253919e-06
frameshift O 0 0.0011313077993690968
mutation O 0 1.8832574824045878e-06
in O 0 7.634550058810419e-08
the O 0 5.8971611593960915e-08
coding O 0 5.973283350613201e-06
region O 0 3.7008379649705603e-07
of O 0 1.5038389733490476e-07
SCN5A O 0 0.0023013337049633265
in O 0 4.780250151270593e-07
three O 0 2.803584948196658e-06
IVF B-Disease 1 0.9951680898666382
families O 0 4.4365307985572144e-05
. O 0 1.6094149032142013e-05

We O 0 1.4238037692848593e-05
show O 0 2.767869091258035e-06
that O 0 1.7405966445949161e-07
sodium O 0 1.6319936548825353e-06
channels O 0 5.380630341278447e-07
with O 0 1.1305557734431204e-07
the O 0 1.4527205394188059e-07
missense O 0 6.450049113482237e-05
mutation O 0 4.348245965957176e-06
recover O 0 1.508251534687588e-05
from O 0 2.0074955386917281e-07
inactivation O 0 0.0004538964421954006
more O 0 1.0885667478532923e-07
rapidly O 0 5.460013312585943e-07
than O 0 5.11940037029035e-08
normal O 0 2.2080556050241285e-07
and O 0 5.721505402789262e-08
that O 0 3.013123972550602e-08
the O 0 1.3252069663849397e-07
frameshift O 0 0.0012122251791879535
mutation O 0 1.6432570646429667e-06
causes O 0 2.8515347594293416e-07
the O 0 4.1934541172850004e-08
sodium O 0 6.213252845554962e-07
channel O 0 3.432620587773272e-07
to O 0 4.636015304981811e-08
be O 0 7.028060622360499e-08
non O 0 1.8914345218945527e-06
- O 0 0.0002261034242110327
functional O 0 2.578762905613985e-05
. O 0 7.732179255981464e-06

Our O 0 3.4532902645878494e-05
results O 0 1.1074731446569785e-05
indicate O 0 4.751190317620058e-06
that O 0 3.4947825611197914e-07
mutations O 0 2.788303618217469e-06
in O 0 2.9005030910411733e-07
cardiac O 0 0.0013982539530843496
ion O 0 0.0005994904204271734
- O 0 6.405621388694271e-05
channel O 0 1.2152347608207492e-06
genes O 0 2.9993287853358197e-07
contribute O 0 8.961531960949287e-08
to O 0 4.719469970382306e-08
the O 0 1.1447511383266828e-07
risk O 0 1.542876020721451e-06
of O 0 4.260698460711865e-07
developing O 0 7.415737491101027e-05
IVF B-Disease 1 0.9784418940544128
. O 0 9.113371561397798e-06
. O 0 1.4927942174836062e-05

Molecular O 0 0.0009423640440218151
heterogeneity O 0 0.000988977961242199
in O 0 1.4831845874141436e-05
mucopolysaccharidosis B-Disease 0 0.24518339335918427
IVA I-Disease 1 0.7933173775672913
in O 0 1.231716737493116e-06
Australia O 0 3.9481798808083113e-07
and O 0 1.6643741673760815e-07
Northern O 0 5.490167040989036e-07
Ireland O 0 4.366628445495735e-07
: O 0 1.5177845114067168e-07
nine O 0 2.0023179558847914e-07
novel O 0 1.0126215101990965e-06
mutations O 0 1.5216759265967994e-06
including O 0 4.5448075525200693e-07
T312S O 0 0.0002965590392705053
, O 0 2.2698019108702283e-07
a O 0 2.1066801991764805e-07
common O 0 6.782554464734858e-07
allele O 0 3.855484465020709e-06
that O 0 6.251863737816166e-07
confers O 0 3.676316191558726e-05
a O 0 1.7059952369891107e-05
mild O 0 0.29187309741973877
phenotype O 0 0.0034524896182119846
. O 0 3.210104114259593e-05

Mucopolysaccharidosis B-Disease 1 0.9647018313407898
IVA I-Disease 1 0.9977321624755859
( O 0 0.0005270306719467044
MPS B-Disease 1 0.9914552569389343
IVA I-Disease 1 0.9999657869338989
) O 0 8.130840797093697e-06
is O 0 1.8127424254998914e-06
an O 0 7.840800208214205e-06
autosomal B-Disease 1 0.9712381362915039
recessive I-Disease 1 0.9992856383323669
lysosomal I-Disease 1 0.9999915361404419
storage I-Disease 1 0.9999785423278809
disorder I-Disease 1 0.9996926784515381
caused O 0 6.174644659040496e-05
by O 0 2.535791736590909e-06
a O 0 3.68383334716782e-05
genetic B-Disease 1 0.9732038974761963
defect I-Disease 1 0.9751071333885193
in O 0 1.6208570059461636e-06
N O 0 0.0013308438938111067
- O 0 0.0007821456529200077
acetylgalactosamine O 0 0.0010046116076409817
- O 0 0.0005170107469893992
6 O 0 1.5835479644010775e-05
- O 0 0.02675538882613182
sulfate O 0 0.029471568763256073
sulfatase O 0 0.013262899592518806
( O 0 1.7068797433239524e-06
GALNS O 0 0.0004463415243662894
) O 0 2.373543338762829e-06
. O 0 6.0899164964212105e-06

Previous O 0 5.669216989190318e-05
studies O 0 1.1529234143381473e-05
of O 0 3.548565246092039e-06
patients O 0 0.0005822467501275241
from O 0 4.616928208633908e-07
a O 0 4.434276377196511e-07
British O 0 2.461085614413605e-06
- O 0 0.004031401593238115
Irish O 0 3.3267795060965e-06
population O 0 1.6832980520575802e-07
showed O 0 6.24768006218801e-07
that O 0 3.224986144800823e-08
the O 0 1.1955748391301313e-07
I113F O 0 0.00030733697349205613
mutation O 0 2.7695591597876046e-06
is O 0 4.213417525988916e-08
the O 0 3.5708922041521873e-08
most O 0 8.621707792144662e-08
common O 0 1.7751368375229504e-07
single O 0 4.912726581096649e-07
mutation O 0 9.518847036815714e-06
among O 0 1.6001098629203625e-05
MPS B-Disease 1 0.9900122880935669
IVA I-Disease 1 0.9999974966049194
patients O 0 0.08419486880302429
and O 0 4.323023858887609e-06
produces O 0 5.6913067965069786e-05
a O 0 6.453039532061666e-05
severe O 1 0.6870519518852234
clinical O 0 0.24119490385055542
phenotype O 0 0.05483952909708023
. O 0 7.81010530772619e-05

We O 0 3.233661118429154e-05
studied O 0 2.3616810722160153e-05
mutations O 0 1.4114390978647862e-05
in O 0 3.9815751051719417e-07
the O 0 4.04075223059408e-07
GALNS O 0 0.0018294713227078319
gene O 0 2.673720473467256e-06
from O 0 2.629703885759227e-07
23 O 0 8.041710088946274e-07
additional O 0 1.3949722870165715e-06
MPS B-Disease 1 0.7390235662460327
IVA I-Disease 1 0.9999977350234985
patients O 0 0.10147786140441895
( O 0 2.5519290147713036e-07
15 O 0 1.422737767597937e-07
from O 0 3.19440083274003e-08
Australia O 0 4.3987444797721764e-08
, O 0 2.6729802371505684e-08
8 O 0 7.336502960697544e-08
from O 0 2.4263695053150514e-08
Northern O 0 9.401157541333305e-08
Ireland O 0 8.935947448662773e-08
) O 0 3.571906859178853e-08
, O 0 2.7777426581110376e-08
with O 0 3.573031293058193e-08
various O 0 1.340830664275927e-07
clinical O 0 0.0018981228349730372
phenotypes O 0 0.00545455701649189
( O 0 5.756945483881282e-06
severe O 0 0.001361318863928318
, O 0 4.198960823487141e-07
16 O 0 1.3047850870862021e-06
cases O 0 6.025463790138019e-07
; O 0 3.922299640635174e-07
intermediate O 0 2.0495056105573894e-06
, O 0 1.3449543700971844e-07
4 O 0 1.335900492449582e-06
cases O 0 1.5726286619610619e-06
; O 0 2.268755224577035e-06
mild O 0 0.0009040315053425729
, O 0 9.902958026941633e-07
3 O 0 7.839708814572077e-06
cases O 0 4.005750724900281e-06
) O 0 1.6785751313364017e-06
. O 0 8.452177098661195e-06

We O 0 3.2054816983873025e-05
found O 0 5.178806077310583e-06
two O 0 5.080307232674386e-07
common O 0 1.323677679465618e-06
mutations O 0 1.808869114938716e-06
that O 0 3.9604728385711496e-08
together O 0 1.1800716492871288e-07
accounted O 0 4.769904080603737e-07
for O 0 6.006467145880379e-08
32 O 0 4.180500923212094e-07
% O 0 4.4541366150951944e-08
of O 0 1.7773992055936105e-08
the O 0 6.045153355671573e-08
44 O 0 1.0630849374138052e-06
unrelated O 0 4.92433082399657e-06
alleles O 0 2.2857338990434073e-06
in O 0 4.4519035213852476e-07
these O 0 2.00668910110835e-06
patients O 0 0.0003513620758894831
. O 0 1.375667670799885e-05

One O 0 1.438287381461123e-05
is O 0 1.7116756225732388e-06
the O 0 7.770209435875586e-07
T312S O 0 0.000239371249335818
mutation O 0 6.803759788454045e-06
, O 0 4.983423309568025e-07
a O 0 3.6164323091725237e-07
novel O 0 2.7831154056912055e-06
mutation O 0 4.635936420527287e-06
found O 0 4.4810599320044275e-07
exclusively O 0 7.472438596778375e-07
in O 0 2.3251634502230445e-06
milder O 0 0.10507473349571228
patients O 0 0.005346490535885096
. O 0 2.6591153073241003e-05

The O 0 1.1365666978235822e-05
other O 0 1.9847370822390076e-06
is O 0 4.333473668793886e-07
the O 0 1.8464274376128742e-07
previously O 0 1.7032764390023658e-06
described O 0 8.414232979703229e-06
I113F O 0 0.00024343862605746835
that O 0 3.4589490383041266e-07
produces O 0 1.1006452041328885e-05
a O 0 1.5531406461377628e-05
severe O 0 0.02717185579240322
phenotype O 0 0.0024216242600232363
. O 0 4.7524757974315435e-05

The O 0 3.364597796462476e-05
I113F O 0 0.000475429929792881
and O 0 5.504497494257521e-06
T312S O 0 0.00038331205723807216
mutations O 0 1.2352702469797805e-05
accounted O 0 3.138320380458026e-06
for O 0 1.576558474880585e-07
8 O 0 6.382567789842142e-07
( O 0 6.115711670418023e-08
18 O 0 1.4695251593366265e-07
% O 0 6.258413520754402e-08
) O 0 3.2783724179807905e-08
and O 0 4.455912616663227e-08
6 O 0 3.0600054401475063e-07
( O 0 4.8300254462674275e-08
14 O 0 9.8096329281816e-08
% O 0 4.4573916113677114e-08
) O 0 1.826060902487825e-08
of O 0 4.075823767379916e-08
44 O 0 1.5394323327200254e-06
unrelated O 0 7.687894139962737e-06
alleles O 0 5.115864951221738e-06
, O 0 1.6905339634831762e-06
respectively O 0 9.870214853435755e-06
. O 0 7.94055904407287e-06

The O 0 2.2760694264434278e-05
relatively O 0 4.221563722239807e-05
high O 0 1.4488809028989635e-05
residual O 0 9.583921928424388e-05
GALNS O 0 0.001169444527477026
activity O 0 2.7588089324126486e-06
seen O 0 1.13238854737574e-06
when O 0 1.5610169157298515e-07
the O 0 6.218172643457365e-08
T312S O 0 4.313741101213964e-06
mutant O 0 9.093022868000844e-07
cDNA O 0 2.098998265864793e-06
is O 0 9.133543699135771e-08
overexpressed O 0 4.8197139221883845e-06
in O 0 1.0547872619781629e-07
mutant O 0 6.518219379358925e-06
cells O 0 2.2568435724679148e-06
provides O 0 1.7286859588239167e-07
an O 0 2.4092697614719327e-08
explanation O 0 2.7071291697211564e-07
for O 0 1.2707907615094882e-07
the O 0 1.0652790933818324e-06
mild O 0 0.3821631073951721
phenotype O 0 0.010542845353484154
in O 0 6.6804286689148284e-06
patients O 0 0.00020140435663051903
with O 0 4.905535320176568e-07
this O 0 1.5917655673547415e-06
mutation O 0 6.199218478286639e-05
. O 0 1.4497322808892932e-05

The O 0 4.821042693947675e-06
distribution O 0 3.526538876030827e-06
and O 0 6.127353344709263e-07
relative O 0 1.0504481906536967e-06
frequencies O 0 1.9875997736562567e-07
of O 0 4.765148275964748e-08
the O 0 6.759746895568242e-08
I113F O 0 3.055440174648538e-05
and O 0 3.314639229756722e-07
T312S O 0 9.374937508255243e-05
mutations O 0 9.213062526214344e-07
in O 0 3.8384097678090257e-08
Australia O 0 3.5752126592569766e-08
corresponded O 0 1.9557327846086991e-07
to O 0 3.1617950924101024e-08
those O 0 5.061668773009842e-08
observed O 0 1.233112385534696e-07
in O 0 4.181625357091434e-08
Northern O 0 1.1840814551078438e-07
Ireland O 0 1.7961913556518994e-07
and O 0 7.254572409465254e-08
are O 0 2.1295376129160104e-08
unique O 0 5.4390543624549537e-08
to O 0 2.5394982117177278e-08
these O 0 1.5793627738958094e-08
two O 0 2.6664675800702753e-08
populations O 0 2.784251762477652e-07
, O 0 1.1041138492373648e-07
suggesting O 0 4.581636687817081e-07
that O 0 3.124166170209719e-08
both O 0 6.618806480673811e-08
mutations O 0 7.513233981626399e-07
were O 0 5.1880814311289214e-08
probably O 0 1.5464306102330738e-07
introduced O 0 7.394142897965139e-08
to O 0 3.950958671339322e-08
Australia O 0 6.732648927254559e-08
by O 0 6.23532230292767e-08
Irish O 0 2.4923596697590256e-07
migrants O 0 1.5463140812244092e-07
during O 0 1.228262789254586e-07
the O 0 1.3426027578589128e-07
19th O 0 3.703507218233426e-06
century O 0 5.959684131084941e-06
. O 0 1.405532930220943e-05

Haplotype O 0 0.0007518549682572484
analysis O 0 2.541436333558522e-05
using O 0 4.4387115849531256e-06
6 O 0 7.434484814439202e-06
RFLPs O 0 8.418528159381822e-05
provides O 0 4.532977300186758e-07
additional O 0 1.4873197073939082e-07
data O 0 1.479932620895852e-07
that O 0 2.9538082202407168e-08
the O 0 7.635118492999027e-08
I113F O 0 0.00011160370195284486
mutation O 0 1.4280013829193194e-06
originated O 0 2.536047816192877e-07
from O 0 1.121370516443676e-07
a O 0 4.860225999436807e-07
common O 0 3.150206794089172e-06
ancestor O 0 2.0139159460086375e-05
. O 0 2.0459963707253337e-05

The O 0 6.1857354012317955e-06
other O 0 7.847083338674565e-07
9 O 0 2.175935378545546e-06
novel O 0 2.512449327696231e-06
mutations O 0 1.1521859050844796e-05
identified O 0 9.84677399173961e-07
in O 0 7.675227209347213e-08
these O 0 1.0823535490089853e-07
23 O 0 2.018586383201182e-05
patients O 0 2.3375130695058033e-05
were O 0 4.0791448441268585e-08
each O 0 1.7717637135206132e-08
limited O 0 1.3993877701068413e-07
to O 0 7.291472314818748e-08
a O 0 5.101426268083742e-07
single O 0 2.782011279123253e-06
family O 0 8.837914720061235e-06
. O 0 1.115982377086766e-05

These O 0 9.390775630890857e-06
data O 0 3.7823874663445167e-06
provide O 0 6.058693884369859e-07
further O 0 2.388124187291396e-07
evidence O 0 3.1106486630960717e-07
for O 0 1.9476992463296483e-07
extensive O 0 6.040513198968256e-06
allelic O 0 0.0005284153739921749
heterogeneity O 0 0.0006198587361723185
in O 0 5.589271040662425e-06
MPS B-Disease 0 0.4453005790710449
IVA I-Disease 1 0.9995878338813782
in O 0 2.2034037101548165e-06
British O 0 8.267684279417153e-06
- O 0 0.17539533972740173
Irish O 0 0.00029180984711274505
patients O 0 0.0002463810669723898
and O 0 3.173522600263823e-07
provide O 0 2.500914604297577e-07
evidence O 0 2.397260630004894e-07
for O 0 6.247393713465499e-08
their O 0 5.160556071359679e-08
transmission O 0 1.0531604175412212e-06
to O 0 7.186153538896178e-08
Australia O 0 1.3235221274499054e-07
by O 0 1.178355546471721e-07
British O 0 1.2307468750805128e-06
- O 0 0.0020784838125109673
Irish O 0 4.357935267762514e-06
migrants O 0 2.207791112596169e-06
. O 0 1.0087815098813735e-06
. O 0 6.226650839380454e-06

Identification O 0 8.874077320797369e-05
of O 0 7.997253305802587e-06
constitutional O 0 0.00010666295565897599
WT1 O 1 0.7352566123008728
mutations O 0 0.0001626014563953504
, O 0 2.8390138595568715e-06
in O 0 2.862052951968508e-06
patients O 0 0.0002832709869835526
with O 0 6.859352197352564e-06
isolated O 0 0.10089584439992905
diffuse B-Disease 1 0.9996793270111084
mesangial I-Disease 1 0.9999998807907104
sclerosis I-Disease 1 0.9999992847442627
, O 0 4.881515451415908e-06
and O 0 3.524954763634014e-07
analysis O 0 6.965988177398685e-07
of O 0 7.960135235407506e-07
genotype O 0 0.0182915311306715
/ O 0 0.0014089199248701334
phenotype O 0 4.063152300659567e-05
correlations O 0 1.148871160694398e-05
by O 0 1.0502662917133421e-07
use O 0 9.220588736980062e-08
of O 0 1.1049437631527326e-07
a O 0 1.8957667862196104e-06
computerized O 0 0.0007910972344689071
mutation O 0 6.793512147851288e-05
database O 0 2.640171987877693e-05
. O 0 1.2180345038359519e-05

Constitutional O 0 0.00020793004659935832
mutations O 0 0.00012541271280497313
of O 0 1.4166088249112363e-06
the O 0 1.2902665957881254e-06
WT1 O 0 0.0023257036227732897
gene O 0 7.746312803647015e-06
, O 0 2.7405476998865197e-07
encoding O 0 1.0891394595091697e-06
a O 0 9.695131666376255e-07
zinc O 0 0.00023832981241866946
- O 0 0.00013400716125033796
finger O 0 1.0334297257941216e-05
transcription O 0 7.944747721921885e-07
factor O 0 3.124774821117171e-07
involved O 0 3.032655797596817e-07
in O 0 1.237074229720747e-06
renal O 1 0.9996291399002075
and O 0 3.472981234153849e-06
gonadal O 0 0.3983713984489441
development O 0 2.4004345959838247e-06
, O 0 4.133208619805373e-07
are O 0 4.33301039493017e-08
found O 0 7.144538471948181e-08
in O 0 6.6158655442905e-08
most O 0 6.132357839305769e-07
patients O 0 5.904159479541704e-05
with O 0 6.093547654018039e-06
Denys B-Disease 1 0.9992923736572266
- I-Disease 1 0.9999810457229614
Drash I-Disease 1 0.9999939203262329
syndrome I-Disease 1 0.9999890327453613
( O 0 2.9081331376801245e-05
DDS B-Disease 1 0.9997723698616028
) O 0 1.4004040167492349e-06
, O 0 2.1023040517320624e-06
or O 0 2.029587085417006e-05
diffuse B-Disease 1 0.9978426694869995
mesangial I-Disease 1 0.9999995231628418
sclerosis I-Disease 1 0.9999994039535522
( O 0 8.669865928823128e-05
DMS B-Disease 1 0.9588293433189392
) O 0 8.138443376992655e-07
associated O 0 9.705520369607257e-07
with O 0 1.0168250810238533e-06
pseudohermaphroditism B-Disease 1 0.987733006477356
and O 0 7.0736628003942315e-06
/ O 0 0.007476390339434147
or O 0 0.0006493692053481936
Wilms B-Disease 1 0.999982476234436
tumor I-Disease 1 0.9967001080513
( O 0 2.647440487635322e-05
WT B-Disease 1 0.9834893941879272
) O 0 6.376238161465153e-06
. O 0 1.693214835540857e-05

Most O 0 6.009553908370435e-05
mutations O 0 0.00035850980202667415
in O 0 5.777988917543553e-05
DDS B-Disease 1 0.9999954700469971
patients O 1 0.887818455696106
lie O 0 0.00038279060390777886
in O 0 5.750579248342547e-07
exon O 0 3.5696739359991625e-05
8 O 0 1.6559337154831155e-06
or O 0 2.4270460130537685e-07
exon O 0 6.186307473399211e-06
9 O 0 8.093535939224239e-07
, O 0 1.483711287164624e-07
encoding O 0 5.027679321756295e-07
zinc O 0 5.4905023716855794e-05
finger O 0 9.371120540890843e-06
2 O 0 6.778474244129029e-07
or O 0 3.577430049972463e-07
zinc O 0 3.3025826269295067e-05
finger O 0 6.947690962988418e-06
3 O 0 2.365236468904186e-07
, O 0 7.663085455078544e-08
respectively O 0 1.4446452212268923e-07
, O 0 3.936561654427351e-08
with O 0 2.91213773095933e-08
a O 0 1.6344127118372853e-07
hot O 0 1.0415042197564617e-05
spot O 0 2.527946662667091e-06
( O 0 1.4465601338997658e-07
R394W O 0 8.431302376266103e-06
) O 0 1.1140816269517018e-07
in O 0 1.311403963200064e-07
exon O 0 1.680336572462693e-05
9 O 0 6.106427008489845e-06
. O 0 4.897952294413699e-06

We O 0 1.4168482266541105e-05
analyzed O 0 9.166549716610461e-06
a O 0 4.791812102666881e-07
series O 0 5.403802560977056e-07
of O 0 4.0537520362704527e-07
24 O 0 1.4696607649966609e-05
patients O 0 0.00021566114446613938
, O 0 4.6674236386934354e-07
10 O 0 5.030332204114529e-07
with O 0 2.004565885727061e-06
isolated B-Disease 0 0.0012366198934614658
DMS I-Disease 1 0.8758186101913452
( O 0 1.1570675724215107e-06
IDMS B-Disease 0 0.0188110563904047
) O 0 8.180621335895921e-08
, O 0 6.750960324097832e-08
10 O 0 7.269129298492771e-08
with O 0 3.599160152134573e-07
DDS B-Disease 1 0.9989393353462219
, O 0 4.6926047048145847e-07
and O 0 1.6311271622271306e-07
4 O 0 2.668182787601836e-06
with O 0 6.6380880525684915e-06
urogenital B-Disease 1 0.9971067309379578
abnormalities I-Disease 1 0.9579083323478699
and O 0 1.9584966139518656e-05
/ O 0 0.06816942244768143
or O 0 0.0001009712359518744
WT B-Disease 1 0.9988194108009338
. O 0 4.48214377684053e-05

We O 0 7.285038009285927e-05
report O 0 5.020137541578151e-05
WT1 O 0 0.0059187281876802444
heterozygous O 0 0.0001025451929308474
mutations O 0 2.89551135210786e-05
in O 0 1.460083581150684e-06
16 O 0 1.4077113519306295e-05
patients O 0 0.00023852419690229
, O 0 5.216649014982977e-07
4 O 0 1.3175518915886641e-06
of O 0 5.936835236752813e-07
whom O 0 1.59291139425477e-05
presented O 0 1.1012909453711472e-05
with O 0 1.4110260053712409e-05
IDMS B-Disease 1 0.9365831613540649
. O 0 3.1768660846864805e-05

One O 0 4.89412086608354e-05
male O 0 2.9486373023246415e-05
and O 0 1.976682369786431e-06
two O 0 1.0708262152547832e-06
female O 0 0.000116804672870785
IDMS B-Disease 1 0.9995076656341553
patients O 0 0.0050946432165801525
with O 0 2.1282812667777762e-05
WT1 O 1 0.9650519490242004
mutations O 0 0.0007491508149541914
underwent O 0 0.013897716999053955
normal O 0 0.00012475420953705907
puberty O 0 0.0041649253107607365
. O 0 4.4802458432968706e-05

Two O 0 4.755087138619274e-05
mutations O 0 0.00040726957377046347
associated O 0 2.301576932950411e-05
with O 0 4.593274752551224e-06
IDMS B-Disease 1 0.5983437299728394
are O 0 2.449602050091926e-07
different O 0 9.655190780222256e-08
from O 0 2.1366417968238238e-07
those O 0 3.523344958011876e-07
described O 0 2.4380135073442943e-05
in O 0 3.744227433344349e-05
DDS B-Disease 1 0.9999877214431763
patients O 0 0.07025465369224548
. O 0 4.0899922169046476e-05

No O 0 0.0001378842571284622
WT1 O 0 0.051022786647081375
mutations O 0 9.399518603459e-05
were O 0 1.4253550943976734e-06
detected O 0 1.1395731235097628e-05
in O 0 1.3146133426289452e-07
the O 0 8.881098523261244e-08
six O 0 5.588976250692212e-07
other O 0 2.6452153178979643e-06
IDMS B-Disease 1 0.9994927644729614
patients O 0 0.005668932106345892
, O 0 2.5592510155547643e-06
suggesting O 0 2.6722022084868513e-05
genetic O 0 2.5666160581749864e-05
heterogeneity O 0 5.6906126701505855e-05
of O 0 1.7916645447257906e-06
this O 0 2.1581667169812135e-05
disease O 0 0.02171468921005726
. O 0 1.7336751625407487e-05

We O 0 3.60242192982696e-05
analyzed O 0 0.00011038000229746103
genotype O 0 0.0009481754386797547
/ O 0 0.0005465379799716175
phenotype O 0 0.00012347931624390185
correlations O 0 5.927939128014259e-05
, O 0 3.119546363450354e-07
on O 0 6.331993063213304e-08
the O 0 2.2789588882687895e-08
basis O 0 3.1997917204762416e-08
of O 0 2.872227256034421e-08
the O 0 6.244200534410993e-08
constitution O 0 9.202123862905864e-08
of O 0 5.8737327890412416e-08
a O 0 9.724792562337825e-07
WT1 O 0 0.009055147878825665
mutation O 0 1.20525112379255e-06
database O 0 4.535649793524499e-07
of O 0 7.957261516366998e-08
84 O 0 7.030686447251355e-06
germ O 0 0.0007629654137417674
- O 0 0.00045011640759184957
line O 0 6.740056505805114e-06
mutations O 0 1.5201529777186806e-06
, O 0 5.6074927812233e-08
to O 0 2.8138918750642006e-08
compare O 0 8.061767289291311e-07
the O 0 3.020673489118053e-08
distribution O 0 2.2993015136307804e-07
and O 0 9.37456761107569e-08
type O 0 8.5948033756722e-07
of O 0 1.0838533626156277e-07
mutations O 0 5.560778845392633e-06
, O 0 3.0184338584149373e-07
according O 0 1.0382085235960403e-07
to O 0 9.796861633049048e-08
the O 0 4.037947576307488e-07
different O 0 1.8856926544685848e-06
symptoms O 0 0.00020092196064069867
. O 0 1.1554428965609986e-05

This O 0 1.186238932859851e-05
demonstrated O 0 1.408831485605333e-05
( O 0 7.460739084308443e-07
1 O 0 7.496199714296381e-07
) O 0 6.458235191075801e-08
the O 0 3.813176263633977e-08
association O 0 2.257049089848806e-07
between O 0 1.7539774432862032e-07
mutations O 0 7.184748369581939e-07
in O 0 4.7193797314548647e-08
exons O 0 1.4936066463633324e-06
8 O 0 3.7270191910465655e-07
and O 0 1.1274441646946798e-07
9 O 0 1.2799839623767184e-06
and O 0 9.351009566671564e-07
DMS B-Disease 1 0.5499979853630066
; O 0 6.126581979515322e-07
( O 0 8.43023073571203e-08
2 O 0 3.5210908322369505e-07
) O 0 1.0341274503389286e-07
among O 0 5.434863510345167e-07
patients O 0 2.3220491129904985e-05
with O 0 6.728232619934715e-07
DMS B-Disease 0 0.37130287289619446
, O 0 1.9096559356057696e-07
a O 0 7.130271484356854e-08
higher O 0 1.2456625597678794e-07
frequency O 0 1.5428864230671024e-07
of O 0 3.864156283839293e-08
exon O 0 6.591740657313494e-06
8 O 0 9.293010521105316e-07
mutations O 0 1.387454972245905e-06
among O 0 2.1923207782492682e-07
46 O 0 9.228960152540822e-06
, O 0 9.850505193753634e-06
XY O 1 0.9943515062332153
patients O 0 0.004397708922624588
with O 0 1.1571029290280421e-06
female O 0 2.76621722150594e-06
phenotype O 0 1.6104511814774014e-05
than O 0 3.1481414453082834e-07
among O 0 4.3584324771472893e-07
46 O 0 1.7715423382469453e-05
, O 0 1.2997790690860711e-05
XY O 1 0.9936087131500244
patients O 0 0.012655960395932198
with O 0 1.0360993201175006e-06
sexual O 0 6.71359430270968e-06
ambiguity O 0 3.251404268667102e-05
or O 0 7.09421237843344e-06
male O 0 1.1968179933319334e-05
phenotype O 0 0.00015910294314380735
; O 0 1.3444738442558446e-06
and O 0 3.8241535094130086e-07
( O 0 1.5317074542053888e-07
3 O 0 3.1268496059055906e-07
) O 0 5.662078805812598e-08
statistically O 0 5.411842494140728e-07
significant O 0 1.4543479665007908e-07
evidence O 0 2.3584836128520692e-07
that O 0 4.6390756125447297e-08
mutations O 0 4.22012561784868e-07
in O 0 2.419608335912926e-08
exons O 0 6.205684712767834e-07
8 O 0 1.5998469393707637e-07
and O 0 4.029622147072587e-08
9 O 0 4.7062741259651375e-07
preferentially O 0 1.246393935616652e-06
affect O 0 2.6407667519379174e-07
amino O 0 1.0244273340731525e-07
acids O 0 7.00194249247943e-08
with O 0 1.8459868300624294e-08
different O 0 2.86981247654694e-08
functions O 0 1.8343136787279946e-07
. O 0 3.5875123671758047e-07
. O 0 3.745351705219946e-06

The O 0 4.7065801481949165e-05
185delAG O 0 0.004321379121392965
BRCA1 O 0 0.002168192295357585
mutation O 0 3.138784450129606e-05
originated O 0 1.9881924799847184e-06
before O 0 4.1446156728852657e-07
the O 0 7.97820263187532e-08
dispersion O 0 3.251667976655881e-06
of O 0 1.327721719235342e-07
Jews O 0 5.197817927182768e-07
in O 0 6.400451724175582e-08
the O 0 4.974002365543129e-08
diaspora O 0 1.3975022739032283e-06
and O 0 2.0200054962060676e-07
is O 0 6.784832606854252e-08
not O 0 6.132695773430896e-08
limited O 0 5.344337523638387e-07
to O 0 2.0360323560453253e-06
Ashkenazim O 0 0.0012465388281270862
. O 0 1.2476813935791142e-05

The O 0 4.0799764974508435e-05
185delAG O 0 0.002302496926859021
mutation O 0 9.344102727482095e-05
in O 0 2.7205301194044296e-06
BRCA1 O 0 0.0009640468051657081
is O 0 1.399683128511242e-06
detected O 0 1.8782171537168324e-05
in O 0 3.202643483746215e-07
Ashkenazi O 0 7.300385914277285e-05
Jews O 0 9.91652996162884e-07
both O 0 1.5765402849865495e-07
in O 0 1.6975293419818627e-06
familial B-Disease 1 0.9959015250205994
breast I-Disease 1 0.9999865293502808
and I-Disease 1 0.9967923760414124
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999970197677612
and O 0 3.6705991988128517e-06
in O 0 4.0797328892949736e-07
the O 0 2.6713527745414467e-07
general O 0 3.1847177979216212e-06
population O 0 2.7373398552299477e-06
. O 0 8.289868674182799e-06

All O 0 3.2106152502819896e-05
tested O 0 0.0001986179850064218
Ashkenazi O 0 0.000988990650512278
mutation O 0 3.352123167132959e-05
carriers O 0 1.0035127161245327e-05
share O 0 9.371980809191882e-07
the O 0 1.789456689493818e-07
same O 0 4.7485627874266356e-07
allelic O 0 3.2494695915374905e-05
pattern O 0 5.266855168883922e-06
at O 0 1.9625763343356084e-06
the O 0 2.041168727373588e-06
BRCA1 O 0 0.0008150292560458183
locus O 0 0.00022355784312821925
. O 0 2.9166207241360098e-05

Our O 0 2.4931208827183582e-05
previous O 0 7.83222094469238e-06
study O 0 3.51601124748413e-06
showed O 0 3.916109108104138e-06
that O 0 1.2148147732204961e-07
this O 0 1.3674691956566676e-07
Ashkenazi O 0 0.00033010615152306855
mutation O 0 3.5712539556698175e-06
also O 0 1.1705198232903058e-07
occurs O 0 2.2608018923619966e-07
in O 0 7.87888012609983e-08
Iraqi O 0 8.943694638219313e-07
Jews O 0 1.1920971019208082e-06
with O 0 2.753373564701178e-07
a O 0 9.966599918698194e-07
similar O 0 7.515565812354907e-06
allelic O 0 0.0005833608447574079
pattern O 0 6.294385821092874e-05
. O 0 1.964645525731612e-05

We O 0 1.3233634490461554e-05
extended O 0 3.670367959784926e-06
our O 0 7.434941835526843e-07
analysis O 0 4.5235242396302056e-07
to O 0 7.032820548147356e-08
other O 0 6.6936216569502e-08
non O 0 1.565520733493031e-06
- O 0 0.00013438310998026282
Ashkenazi O 0 1.8346952856518328e-05
subsets O 0 3.5119901440339163e-06
354 O 0 1.955212155735353e-06
of O 0 5.8901687083334764e-08
Moroccan O 0 1.0406168939880445e-06
origin O 0 1.192114922332621e-07
, O 0 1.159095859293302e-07
200 O 0 3.885997728048096e-07
Yemenites O 0 2.3744176360196434e-05
and O 0 2.246903676450529e-07
150 O 0 9.680671837486443e-07
Iranian O 0 2.097521701216465e-06
Jews O 0 5.875156148249516e-06
. O 0 6.449743978009792e-06

Heteroduplex O 0 0.00877471175044775
analysis O 0 6.760978430975229e-05
complemented O 0 5.0679114792728797e-05
by O 0 1.6020377415770781e-06
direct O 0 9.998243513109628e-07
DNA O 0 3.1892739116301527e-06
sequencing O 0 3.5934504012402613e-06
of O 0 9.185901035380084e-07
abnormally O 0 0.00015302302199415863
migrating O 0 3.4412350942147896e-06
bands O 0 3.27964085045096e-06
were O 0 6.947246333766088e-07
employed O 0 5.925533059780719e-06
. O 0 6.9202546910673846e-06

Four O 0 7.937992450024467e-06
of O 0 1.4940510482119862e-06
Moroccan O 0 1.0599087545415387e-05
origin O 0 4.894124003840261e-07
( O 0 1.6801369895347307e-07
1 O 0 2.159635386078662e-07
. O 0 4.074277271115534e-08
1 O 0 1.6098502442218887e-07
% O 0 8.146925978280706e-08
) O 0 2.506195251328336e-08
and O 0 3.7283697906786983e-08
none O 0 4.478841830746205e-08
of O 0 1.2883968558696779e-08
the O 0 9.316368476675052e-08
Yemenites O 0 0.00010953353921649978
or O 0 1.614077689282567e-07
Iranians O 0 3.701035780068196e-07
was O 0 1.0851317711058073e-07
a O 0 8.983849397736776e-08
carrier O 0 3.307608494651504e-06
of O 0 1.0102220215912894e-07
the O 0 7.863924338380457e-07
185delAG O 0 0.0008095044177025557
mutation O 0 3.1841576856095344e-05
. O 0 7.808756890881341e-06

BRCA1 O 0 0.1311468929052353
allelic O 0 0.006529637612402439
patterns O 0 9.767339361133054e-05
were O 0 1.898350319606834e-06
determined O 0 1.932001850946108e-06
for O 0 1.1666682553368446e-07
four O 0 9.492094221741354e-08
of O 0 5.682981552013189e-08
these O 0 4.236497019860508e-08
individuals O 0 5.6591630936964066e-08
and O 0 3.40514034746775e-08
for O 0 2.5298341199686547e-08
12 O 0 1.237719118307723e-07
additional O 0 1.4008620041749964e-07
non O 0 3.2663253932696534e-06
- O 0 0.01060517504811287
Ashkenazi O 0 0.0007026520906947553
185delAG O 0 0.0005466650472953916
mutation O 0 8.415517186222132e-06
carriers O 0 1.164794866781449e-05
who O 0 3.805003188972478e-06
had O 0 0.00012405241432134062
breast B-Disease 1 0.9999786615371704
/ I-Disease 1 0.9999892711639404
ovarian I-Disease 1 0.9999998807907104
cancer I-Disease 1 0.9999852180480957
. O 0 0.00024141109315678477

Six O 0 4.750717562274076e-05
non O 0 0.00013714916713070124
- O 0 0.06315500289201736
Ashkenazi O 0 0.019475441426038742
individuals O 0 1.9219148725824198e-06
shared O 0 1.1257085361648933e-06
the O 0 3.1948889045452233e-07
common O 0 3.4636402688192902e-06
Ashkenazi O 0 0.000393648020690307
haplotype O 0 0.00027529196813702583
, O 0 8.282150929517229e-07
four O 0 2.1117531900927133e-07
had O 0 1.7511227667910134e-07
a O 0 1.242172515958373e-07
closely O 0 7.979357405929477e-07
related O 0 3.094017529292614e-06
pattern O 0 7.673069376323838e-06
, O 0 2.262825233856347e-07
and O 0 8.070630741485729e-08
the O 0 4.923354168795413e-08
rest O 0 5.069442181593331e-07
( O 0 1.9344619772709848e-07
n O 0 3.7563870137091726e-05
= O 0 4.833038474316709e-06
6 O 0 3.6946525483472215e-07
) O 0 7.549203218104594e-08
displayed O 0 2.6305065148335416e-07
a O 0 4.4035127189090417e-07
distinct O 0 2.4919679617596557e-06
BRCA1 O 0 0.00031736076925881207
allelic O 0 0.00030561164021492004
pattern O 0 0.00010329341603210196
. O 0 3.233941606595181e-05

We O 0 3.009181637025904e-05
conclude O 0 3.498096339171752e-05
that O 0 5.616981297862367e-07
the O 0 5.673244913850795e-07
185delAG O 0 0.0018962195608764887
BRCA1 O 0 0.007610027678310871
mutation O 0 2.8710373953799717e-05
occurs O 0 1.2672680895775557e-06
in O 0 1.0818107654131381e-07
some O 0 8.901958636897689e-08
non O 0 2.2716392322763568e-06
- O 0 0.006788086146116257
Ashkenazi O 0 0.0009315236820839345
populations O 0 1.3615382385978592e-06
at O 0 4.90343950332317e-07
rates O 0 1.0532357919146307e-06
comparable O 0 1.5210027868306497e-06
with O 0 9.027013447848731e-08
that O 0 8.532630602076097e-08
of O 0 1.0953120863632648e-06
Ashkenazim O 0 0.001631869818083942
. O 0 2.1064053726149723e-05

The O 0 1.738582614052575e-05
majority O 0 1.5822617569938302e-05
of O 0 1.1591495194807067e-06
Jewish O 0 3.014958019775804e-05
185delAG O 0 0.016091441735625267
mutation O 0 5.788108319393359e-05
carriers O 0 1.6380423403461464e-05
have O 0 2.187861696256732e-07
a O 0 3.584201806461351e-07
common O 0 9.921060382112046e-07
allelic O 0 0.00018750953313428909
pattern O 0 2.708079045987688e-05
, O 0 4.27566959615433e-07
supporting O 0 7.46716011690296e-07
the O 0 1.2959785067323537e-07
founder O 0 5.236704510025447e-06
effect O 0 4.30294136322118e-07
notion O 0 3.731343838353496e-07
, O 0 1.6589449103321385e-07
but O 0 8.315440425121778e-08
dating O 0 9.125565156864468e-07
the O 0 9.764923447619367e-08
mutations O 0 5.79814184220595e-07
origin O 0 1.882574984790608e-08
to O 0 1.595025977962905e-08
an O 0 1.9331794831600746e-08
earlier O 0 3.159597952162585e-07
date O 0 6.221280841600674e-07
than O 0 2.4718960389691347e-07
currently O 0 6.482794105977518e-07
estimated O 0 4.8089473239087965e-06
. O 0 6.037806087988429e-06

However O 0 4.200212788418867e-05
, O 0 2.0994129954488017e-06
the O 0 2.2517903630614455e-07
different O 0 1.3030090428856056e-07
allelic O 0 2.140843207598664e-05
pattern O 0 3.099463356193155e-06
at O 0 8.47776504997455e-07
the O 0 3.730148421254853e-07
BRCA1 O 0 6.765330908820033e-05
locus O 0 9.364839570480399e-06
even O 0 6.798446179345774e-07
in O 0 9.21473528592287e-08
some O 0 6.957490938930277e-08
Jewish O 0 1.3520717629944556e-06
mutation O 0 2.3415032046614215e-06
carriers O 0 3.1869387839833507e-06
, O 0 2.618832297685003e-07
might O 0 4.678796869939106e-07
suggest O 0 4.424754536103137e-07
that O 0 4.631949224176424e-08
the O 0 1.656383972203912e-07
mutation O 0 4.850728601013543e-06
arose O 0 2.1248408756946446e-06
independently O 0 8.710284191693063e-07
. O 0 1.1987058314844035e-06
. O 0 9.559886166243814e-06

Crystal O 0 0.005711683537811041
structure O 0 1.8021239156951196e-05
of O 0 1.5655282368243206e-06
the O 0 7.2508337325416505e-06
hemochromatosis B-Disease 1 0.9998687505722046
protein O 0 2.0901392417727038e-05
HFE O 0 0.002531280741095543
and O 0 3.3650977115939895e-07
characterization O 0 3.6293581615609583e-06
of O 0 7.462490714260639e-08
its O 0 1.8722144545790798e-07
interaction O 0 8.525373118573043e-07
with O 0 2.27654254558729e-06
transferrin O 0 0.007517457939684391
receptor O 0 0.00012578963651321828
. O 0 1.6230167602770962e-05

HFE O 0 0.4195764362812042
is O 0 1.9798897483269684e-05
an O 0 3.890457719535334e-06
MHC O 0 0.29106926918029785
- O 0 0.0018154088174924254
related O 0 7.533843472629087e-06
protein O 0 8.647891718283063e-07
that O 0 5.9274729125036174e-08
is O 0 9.622043961599047e-08
mutated O 0 1.0553260381129803e-06
in O 0 1.3717063040985522e-07
the O 0 1.7418235529476078e-06
iron B-Disease 0 0.4927928149700165
- I-Disease 1 0.999703586101532
overload I-Disease 1 0.9999628067016602
disease I-Disease 1 0.9998108744621277
hereditary B-Disease 1 0.9999827146530151
hemochromatosis I-Disease 1 0.9999978542327881
. O 0 0.0016843915218487382

HFE O 0 0.019105369225144386
binds O 0 0.00016693872748874128
to O 0 1.2628280273929704e-05
transferrin O 0 0.0015106730861589313
receptor O 0 5.857120777363889e-05
( O 0 1.1583283594518434e-06
TfR O 0 2.441345168335829e-05
) O 0 1.6795441126760124e-07
and O 0 7.801092039017021e-08
reduces O 0 9.620912351238076e-07
its O 0 6.52439950954431e-08
affinity O 0 8.130313631227182e-07
for O 0 2.6036889266833896e-07
iron O 0 6.325120921246707e-05
- O 0 7.755074329907075e-05
loaded O 0 1.857079223555047e-05
transferrin O 0 0.00018981838366016746
, O 0 7.990246331246453e-07
implicating O 0 0.00018123308836948127
HFE O 0 0.014015925116837025
in O 0 4.893404820904834e-06
iron O 0 0.0012250281870365143
metabolism O 0 0.0002614080731291324
. O 0 1.449208411941072e-05

The O 0 5.693075945600867e-05
2 O 0 0.00013040730846114457
. O 0 7.021515193628147e-05

6 O 0 0.0002468473103363067
A O 0 2.7004814910469577e-05
crystal O 0 0.00034697659430094063
structure O 0 3.9841079342295416e-06
of O 0 1.1036228215743904e-06
HFE O 0 0.057072680443525314
reveals O 0 1.262354817299638e-05
the O 0 3.206953067547147e-07
locations O 0 2.045572728093248e-06
of O 0 5.335702098818729e-06
hemochromatosis B-Disease 1 0.9999858140945435
mutations O 0 8.214446279453114e-05
and O 0 9.249544632439211e-07
a O 0 2.1358953290473437e-06
patch O 0 0.14185643196105957
of O 0 8.913229407880863e-07
histidines O 0 0.05060770735144615
that O 0 1.6991573659197456e-07
could O 0 2.1049910969850316e-07
be O 0 2.7024054105595496e-08
involved O 0 2.4978825763355417e-07
in O 0 8.00353234353679e-07
pH O 0 0.02878652699291706
- O 0 0.0005337928305380046
dependent O 0 7.215012828964973e-06
interactions O 0 3.3589590202609543e-06
. O 0 8.39192398416344e-06

We O 0 2.429815322102513e-05
also O 0 2.2065430584916612e-06
demonstrate O 0 4.4952666939934716e-06
that O 0 4.420849109010305e-07
soluble O 0 0.00011782646470237523
TfR O 0 9.826174937188625e-05
and O 0 8.212120405914902e-07
HFE O 0 0.020031334832310677
bind O 0 4.194801022094907e-06
tightly O 0 3.658102514236816e-06
at O 0 3.72068740261966e-07
the O 0 3.3397057563888666e-08
basic O 0 3.9242601701516833e-07
pH O 0 1.7308255337411538e-05
of O 0 3.563897266189997e-08
the O 0 5.637165045868642e-08
cell O 0 8.336883183801547e-06
surface O 0 1.1496833394630812e-05
, O 0 1.3508649487903313e-07
but O 0 3.7365854410609245e-08
not O 0 2.0680221979318958e-08
at O 0 1.0405518224843036e-07
the O 0 1.5773824202369724e-07
acidic O 0 0.0005148272612132132
pH O 0 0.00010911664867307991
of O 0 5.885013365514169e-07
intracellular O 0 7.767522765789181e-05
vesicles O 0 0.0006211891304701567
. O 0 1.639564652577974e-05

TfR O 0 0.07534528523683548
HFE O 0 0.40136730670928955
stoichiometry O 0 0.0011679037706926465
( O 0 8.179143151210155e-06
2 O 0 2.3629215775144985e-06
1 O 0 6.415363600353885e-07
) O 0 1.4552331606410007e-07
differs O 0 3.4965194117830833e-07
from O 0 1.1669352772969432e-07
TfR O 0 2.3347593014477752e-05
transferrin O 0 6.762886914657429e-05
stoichiometry O 0 9.142114322457928e-06
( O 0 1.0109101111765995e-07
2 O 0 1.3710263147004298e-07
2 O 0 1.2878763300250284e-07
) O 0 2.0116038612627563e-08
, O 0 3.358473676939866e-08
implying O 0 1.544608920767132e-07
a O 0 2.049675629223202e-08
different O 0 9.115352916921893e-09
mode O 0 1.1491329132695682e-07
of O 0 1.413279093753772e-08
binding O 0 3.0410345175369e-07
for O 0 1.7586471301456186e-07
HFE O 0 0.0027398562524467707
and O 0 8.279844792014046e-07
transferrin O 0 0.00032635204843245447
to O 0 4.467030692012486e-07
TfR O 0 0.00013179266534280032
, O 0 3.221193765057251e-07
consistent O 0 3.773942012230691e-07
with O 0 3.77816569141487e-08
our O 0 8.633622172737887e-08
demonstration O 0 1.5092094827195979e-06
that O 0 1.58514268377985e-07
HFE O 0 0.001156723010353744
, O 0 6.09753044500394e-07
transferrin O 0 0.0002476123918313533
, O 0 4.850182904192479e-07
and O 0 5.802522764497553e-07
TfR O 0 0.00020037346985191107
form O 0 4.816593559553439e-07
a O 0 1.7808387156037497e-06
ternary O 0 0.0001360249298159033
complex O 0 6.828708865214139e-05
. O 0 1.4787611689826008e-05

Identification O 0 3.642027877504006e-05
of O 0 1.3797122164760367e-06
three O 0 6.819336135777121e-07
novel O 0 5.156796305527678e-06
mutations O 0 3.6320730032457504e-06
and O 0 1.0612145473487544e-07
a O 0 1.0040326969829039e-07
high O 0 5.252091455076879e-07
frequency O 0 2.093723452389895e-07
of O 0 3.878207621710317e-08
the O 0 1.3810995369567536e-07
Arg778Leu O 0 0.00025675148935988545
mutation O 0 2.955352101707831e-06
in O 0 8.365214512195962e-07
Korean O 0 0.0001353188417851925
patients O 0 0.0009942614706233144
with O 0 5.092453648103401e-05
Wilson B-Disease 1 0.8105275630950928
disease I-Disease 0 0.1971118301153183
. O 0 6.145454972283915e-05

Four O 0 3.428300260566175e-05
mutations O 0 7.40242685424164e-05
- O 0 0.00046006462071090937
- O 0 0.0003080636088270694
R778L O 0 8.739958866499364e-05
, O 0 6.189951022861351e-07
A874V O 0 3.4948949178215116e-05
, O 0 3.8529594803549116e-07
L1083F O 0 1.3031003618380055e-05
, O 0 1.2593174858466227e-07
and O 0 9.857178184802251e-08
2304delC O 0 3.4107331885024905e-05
- O 0 7.215044752229005e-05
- O 0 2.1136718714842573e-05
in O 0 7.577217786547408e-08
the O 0 6.264910723530193e-08
copper O 0 6.0327643041091505e-06
- O 0 1.0644174835761078e-05
transporting O 0 2.3146635612647515e-06
enzyme O 0 7.374015922323451e-07
, O 0 1.358637575776811e-07
P O 0 5.474541467265226e-05
- O 0 5.587422492681071e-06
type O 0 1.0089488569064997e-06
ATPase O 0 2.0488765585469082e-05
( O 0 1.567921827927421e-07
ATP7B O 0 7.708198245381936e-05
) O 0 3.779520696411964e-08
, O 0 3.9677239271895814e-08
were O 0 4.8790994355840667e-08
identified O 0 5.944206122876494e-07
in O 0 2.922895134815917e-07
Korean O 0 8.96047058631666e-05
Patients O 0 0.0003996322921011597
with O 0 1.885043275251519e-05
Wilson B-Disease 0 0.336269736289978
disease I-Disease 0 0.006526075303554535
. O 0 1.6892005078261718e-05

Arg778Leu O 0 0.059648800641298294
, O 0 1.8694110622163862e-05
the O 0 9.908816309689428e-07
most O 0 3.091384428444144e-07
frequently O 0 6.03356568262825e-07
reported O 0 1.0770800145110115e-06
mutation O 0 3.008846078955685e-07
of O 0 2.3351976352614656e-08
this O 0 3.527143022097334e-08
enzyme O 0 9.504972808827006e-07
, O 0 1.7639885641074216e-07
was O 0 2.0001554901227792e-07
found O 0 9.06810200262953e-08
in O 0 1.8394143097566484e-08
six O 0 4.255577579215242e-08
of O 0 3.966543360434116e-08
eight O 0 1.741845153446775e-06
unrelated O 0 0.00041266708285547793
patients O 0 0.00024373708583880216
studied O 0 1.6109619309645495e-06
, O 0 2.0163139424766996e-07
an O 0 4.158019706324012e-08
allele O 0 1.0193728030571947e-06
frequency O 0 3.7336076275096275e-07
of O 0 3.065581211103563e-07
37 O 0 8.275035725091584e-06
. O 0 8.249246093328111e-06

5 O 0 3.0354121918207966e-05
% O 0 2.8948788894922473e-06
, O 0 2.1859365517684637e-07
which O 0 5.1570829384672834e-08
is O 0 5.4040810937294737e-08
considerably O 0 6.274088946156553e-07
higher O 0 1.5257577956617752e-07
than O 0 5.4468920041017554e-08
those O 0 4.960359945016535e-08
in O 0 5.873968333958146e-08
other O 0 1.203059554200081e-07
Asian O 0 2.033021019087755e-06
populations O 0 7.023328635114012e-06
. O 0 7.446476502082078e-06

The O 0 1.3647839296027087e-05
novel O 0 8.355124919035006e-06
single O 0 1.300965550399269e-06
nucleotide O 0 4.175782123638783e-06
deletion O 0 8.194228030333761e-06
, O 0 4.358989258435031e-07
2304delC O 0 6.536301953019574e-05
, O 0 3.697733461649477e-07
was O 0 4.5354767053140677e-07
found O 0 6.881182912366057e-07
in O 0 2.632004623137618e-07
one O 0 1.4738748177478556e-06
patient O 0 0.0002077917306451127
. O 0 1.3226632290752605e-05

Since O 0 6.971336551941931e-05
a O 0 9.178297659673262e-06
mutation O 0 1.5710120351286605e-05
at O 0 2.485225422788062e-06
cDNA O 0 1.5472462109755725e-05
nucleotide O 0 2.1190220650169067e-05
2302 O 0 0.0023856472689658403
( O 0 5.775602858193452e-07
2302insC O 0 2.1600921172648668e-05
) O 0 1.0296086117023151e-07
had O 0 5.916403722494579e-08
been O 0 2.9605089935103024e-08
previously O 0 1.1389361986857693e-07
described O 0 8.837938594297157e-07
, O 0 7.471891194654745e-08
this O 0 1.988570019761937e-08
region O 0 1.8181133043526643e-07
of O 0 3.046921293048399e-08
the O 0 8.62970352955017e-08
ATP7B O 0 0.006221923045814037
gene O 0 2.4750099782977486e-06
may O 0 3.7247664863571117e-07
be O 0 5.999127949962713e-08
susceptible O 0 5.231558134255465e-06
to O 0 3.3688161238387693e-07
gene O 0 2.169708750443533e-05
rearrangements O 0 0.02556159719824791
causing O 0 0.006658531259745359
Wilson B-Disease 0 0.24073252081871033
disease I-Disease 0 0.013514680787920952
. O 0 2.8473807105910964e-05

Disruption O 0 0.00033788793371059
of O 0 4.257690306985751e-06
splicing O 0 2.806677730404772e-05
regulated O 0 7.15338592272019e-06
by O 0 6.37540154002636e-07
a O 0 1.6682340628904058e-06
CUG O 0 0.01783958077430725
- O 0 0.0004986637504771352
binding O 0 1.4853105312795378e-05
protein O 0 1.4325845768325962e-05
in O 0 3.0701139621669427e-05
myotonic B-Disease 1 0.999921441078186
dystrophy I-Disease 1 0.9998842477798462
. O 0 0.00023659983708057553

Myotonic B-Disease 1 0.999981164932251
dystrophy I-Disease 1 0.9999866485595703
( O 0 0.003485361346974969
DM B-Disease 1 0.9999867677688599
) O 0 1.6347619748557918e-05
is O 0 2.1685439151042374e-06
caused O 0 1.7633389006732614e-06
by O 0 1.2822243888876983e-07
a O 0 1.9011660867818136e-07
CTG O 0 6.146926170913503e-05
expansion O 0 8.381161364923173e-07
in O 0 5.626895571708701e-08
the O 0 5.831525839994356e-08
3 O 0 5.87457861911389e-07
untranslated O 0 6.38001729384996e-05
region O 0 6.529578513436718e-07
of O 0 2.997144292748999e-07
the O 0 2.1026810372859472e-06
DM B-Disease 1 0.9996976852416992
gene O 0 4.8615082050673664e-05
. O 0 1.6888847312657163e-05

One O 0 1.7858108549262397e-05
model O 0 1.6653293641866185e-05
of O 0 1.116479415941285e-05
DM B-Disease 1 0.9999722242355347
pathogenesis O 0 0.19358982145786285
suggests O 0 9.593101822247263e-06
that O 0 4.2338075445513823e-07
RNAs O 0 1.812857408367563e-05
from O 0 1.0695887198153287e-07
the O 0 6.448843237194524e-08
expanded O 0 2.9061848749734054e-07
allele O 0 5.616354883386521e-07
create O 0 2.1078055567613774e-07
a O 0 1.4192835351423128e-07
gain O 0 2.133845100615872e-06
- O 0 1.5270463336491957e-05
of O 0 2.1477553957538476e-07
- O 0 0.0006113735144026577
function O 0 5.976788770567509e-07
mutation O 0 2.8557636255754915e-07
by O 0 2.604972237918446e-08
the O 0 3.331905418235692e-08
inappropriate O 0 4.772042530021281e-07
binding O 0 1.4552247762367188e-07
of O 0 2.7812733449650295e-08
proteins O 0 1.092977299776976e-07
to O 0 1.1265585442288284e-07
the O 0 1.0075277714349795e-06
CUG O 0 0.003129536984488368
repeats O 0 5.314030568115413e-05
. O 0 1.644735675654374e-05

Data O 0 7.225186709547415e-05
presented O 0 1.798098128347192e-05
here O 0 2.0928459889546502e-06
indicate O 0 1.2397562159094377e-06
that O 0 7.277174773889783e-08
the O 0 6.6467649162405e-08
conserved O 0 1.0203200417890912e-06
heterogeneous O 0 1.1831341907964088e-05
nuclear O 0 3.356780871399678e-05
ribonucleoprotein O 0 0.0001477400801377371
, O 0 3.2409823802481696e-07
CUG O 0 0.0002936339005827904
- O 0 4.269149212632328e-05
binding O 0 1.4823298215560499e-06
protein O 0 2.796775504521065e-07
( O 0 1.2532385085251008e-07
CUG O 0 6.624454545089975e-05
- O 0 3.042100797756575e-05
BP O 0 4.226251985528506e-05
) O 0 6.337938174283408e-08
, O 0 6.149305420422024e-08
may O 0 6.991385959054242e-08
mediate O 0 1.2681506404987886e-06
the O 0 1.4823167759914213e-07
trans O 0 1.4350978744914755e-05
- O 0 0.0003084280469920486
dominant O 0 2.2185215584613616e-06
effect O 0 1.2097071078187582e-07
of O 0 4.855463231479007e-08
the O 0 4.349770392764185e-07
RNA O 0 9.28983627090929e-06
. O 0 5.781191248388495e-06

CUG O 0 0.15967082977294922
- O 0 0.009068031795322895
BP O 0 0.0014621912268921733
was O 0 1.882909032246971e-06
found O 0 3.381233568688913e-07
to O 0 6.167970667547706e-08
bind O 0 5.47935542272171e-07
to O 0 4.9590543227395756e-08
the O 0 1.1321461101942987e-07
human O 0 2.732540451688692e-06
cardiac O 1 0.5190549492835999
troponin O 1 0.9998348951339722
T O 1 0.9184949398040771
( O 0 7.576812208753836e-07
cTNT O 0 3.3879019611049443e-05
) O 0 1.5268904007825768e-07
pre O 0 7.930372703413013e-06
- O 0 1.945918847923167e-05
messenger O 0 1.733767362566141e-06
RNA O 0 2.646383734372648e-07
and O 0 6.567623955788804e-08
regulate O 0 4.767125290072727e-07
its O 0 1.739654180710204e-07
alternative O 0 2.142817720596213e-06
splicing O 0 3.146354356431402e-05
. O 0 9.89695490716258e-06

Splicing O 0 0.0002738169569056481
of O 0 9.074804438569117e-06
cTNT O 0 0.0005446703871712089
was O 0 5.627540758723626e-06
disrupted O 0 3.2525793358217925e-05
in O 0 3.4568229239084758e-06
DM B-Disease 1 0.9999834299087524
striated O 1 0.5363534092903137
muscle O 0 0.00032954238122329116
and O 0 5.572753707383526e-07
in O 0 2.4347986027351e-07
normal O 0 3.17869466925913e-06
cells O 0 7.4163135650451295e-06
expressing O 0 2.611380296002608e-06
transcripts O 0 8.821535629977006e-06
that O 0 7.532332233495254e-07
contain O 0 1.2964663255843334e-05
CUG O 0 0.009473158977925777
repeats O 0 0.00010318237036699429
. O 0 2.6433408493176103e-05

Altered O 0 8.036004874156788e-05
expression O 0 9.440089343115687e-06
of O 0 7.725264481450722e-07
genes O 0 3.9524584281025454e-06
regulated O 0 6.073357326386031e-06
posttranscriptionally O 0 8.597908890806139e-05
by O 0 8.182742021745071e-07
CUG O 0 0.025658341124653816
- O 0 0.0016990173608064651
BP O 0 0.00015265081310644746
therefore O 0 5.288177931106475e-07
may O 0 3.221003339604067e-07
contribute O 0 9.32650038976135e-07
to O 0 3.5295802263135556e-06
DM B-Disease 1 0.999992847442627
pathogenesis O 0 0.3557138442993164
. O 0 5.077108653495088e-06
. O 0 1.3520418178813998e-05

Identification O 0 0.00010457757889525965
of O 0 3.4092850000888575e-06
a O 0 2.629097025419469e-06
novel O 0 1.00897468655603e-05
nonsense O 0 8.024280396057293e-05
mutation O 0 9.372738531965297e-06
and O 0 2.8526497430902964e-07
a O 0 5.396370852395194e-07
missense O 0 1.0715949429140892e-05
substitution O 0 3.2575917430222034e-07
in O 0 7.729686757329546e-08
the O 0 9.742895912268068e-08
vasopressin O 0 5.050895197200589e-06
- O 0 0.00015127890219446272
neurophysin O 0 0.0008580047870054841
II O 0 0.0002768565318547189
gene O 0 1.337710841653461e-06
in O 0 9.16385332061509e-08
two O 0 1.0424489005345094e-07
Spanish O 0 1.5862209465922206e-06
kindreds O 0 0.00023975495423655957
with O 0 9.321146535512526e-06
familial B-Disease 1 0.9866756796836853
neurohypophyseal I-Disease 1 0.9998980760574341
diabetes I-Disease 1 0.9999802112579346
insipidus I-Disease 1 0.9995909333229065
. O 0 0.0003423152957111597

Familial B-Disease 1 0.998559296131134
neurohypophyseal I-Disease 1 0.9998605251312256
diabetes I-Disease 1 0.9999938011169434
insipidus I-Disease 1 0.9999489784240723
( O 0 0.002415938302874565
FNDI B-Disease 1 0.9999277591705322
) O 0 8.823782991385087e-06
is O 0 1.921594275700045e-06
an O 0 4.239995632815408e-06
autosomal B-Disease 1 0.878011167049408
dominant I-Disease 1 0.8128942847251892
disease I-Disease 1 0.9001838564872742
caused O 0 0.0005176271661184728
by O 0 0.0005131842335686088
deficiency O 1 0.9728606939315796
in O 0 4.686549175403343e-07
the O 0 8.409599558945047e-07
antidiuretic O 0 0.0035508754663169384
hormone O 0 1.1340732271492016e-05
arginine O 0 7.471949629689334e-06
vasopressin O 0 1.0602474503684789e-05
( O 0 3.9833827258917154e-07
AVP O 0 2.5320863642264158e-05
) O 0 5.372827516225698e-08
encoded O 0 7.579328098472615e-08
by O 0 2.4161773026776245e-08
the O 0 6.947439601390215e-08
AVP O 0 0.00018364425341133028
- O 0 0.0004789361555594951
neurophysin O 0 0.0011711724800989032
II O 0 0.0008650440722703934
( O 0 7.280569320755603e-07
AVP O 0 0.0002659101446624845
- O 0 0.0005864151171408594
NPII O 0 0.004077657591551542
) O 0 3.216543120743154e-07
gene O 0 9.454291785004898e-07
on O 0 7.030157576082274e-07
chromosome O 0 7.573702168883756e-05
20p13 O 0 0.0006132187554612756
. O 0 1.2790938853868283e-05

In O 0 6.929976279934635e-06
this O 0 7.971493118930084e-07
study O 0 1.016423766486696e-06
, O 0 2.5744986942299874e-07
we O 0 1.1524868881451766e-07
analyzed O 0 7.802221375641238e-07
two O 0 7.48981179299335e-08
families O 0 4.1453904486843385e-07
with O 0 2.9967813475195726e-07
FNDI B-Disease 0 0.3437727093696594
using O 0 7.98953294633975e-08
direct O 0 7.522842082607895e-08
automated O 0 1.6358238781322143e-06
fluorescent O 0 6.407807632058393e-06
, O 0 8.872683565641637e-08
solid O 0 9.265948506254063e-07
phase O 0 3.2932557587628253e-06
, O 0 1.263115905203449e-07
single O 0 1.2496950319018651e-07
- O 0 1.0865979675145354e-05
stranded O 0 7.824612566764699e-07
DNA O 0 3.6951425386178016e-07
sequencing O 0 2.834856331901392e-07
of O 0 7.704444016098932e-08
PCR O 0 9.005900210468099e-06
- O 0 1.1908781743841246e-05
amplified O 0 8.96729306987254e-06
AVP O 0 0.0005186158232390881
- O 0 0.0007032689754851162
NPII O 0 0.0072756120935082436
DNA O 0 0.00011506881128298119
. O 0 2.026666516030673e-05

In O 0 9.002731530927122e-06
one O 0 5.303865009409492e-07
of O 0 1.732775984919499e-07
the O 0 2.578806572728354e-07
families O 0 2.31619151236373e-06
, O 0 8.663807875564089e-07
affected O 0 2.353747504457715e-06
individuals O 0 2.283197204633325e-07
presented O 0 8.206656048059813e-07
a O 0 4.037243002130708e-07
novel O 0 3.1621016205463093e-06
nonsense O 0 2.631388997542672e-05
mutation O 0 9.947655144060263e-07
in O 0 9.61890620487793e-08
exon O 0 3.0581925329897786e-06
3 O 0 2.0170062953184242e-07
of O 0 2.3519065805999162e-08
the O 0 3.333520126602707e-08
gene O 0 2.2447277103765373e-07
, O 0 5.213525611225123e-08
consisting O 0 1.0789938187372172e-07
in O 0 4.396337160983421e-08
a O 0 1.8866987261390022e-07
G O 0 0.00032212433870881796
to O 0 2.698784840049484e-07
T O 0 0.0014112788485363126
transition O 0 1.2411935585987521e-06
at O 0 3.417953564621712e-07
nucleotide O 0 1.5972567553035333e-06
2101 O 0 4.749776053358801e-05
, O 0 4.9703988480587213e-08
which O 0 2.1884954293227565e-08
produces O 0 1.0847964659888021e-07
a O 0 4.600472180982251e-08
stop O 0 1.671580065476519e-07
signal O 0 1.5597430547131808e-07
in O 0 4.494991046044561e-08
codon O 0 1.1626179912127554e-06
82 O 0 1.8194018593931105e-06
( O 0 2.728715458033548e-07
Glu O 0 0.0001889184641186148
) O 0 1.9328537348428654e-07
of O 0 5.571329779741063e-07
NPII O 0 0.0012589613907039165
. O 0 1.1040627214242704e-05

The O 0 5.48124335182365e-05
premature O 0 0.006650965660810471
termination O 0 0.0013456156011670828
eliminates O 0 9.830138151301071e-05
part O 0 2.1515820662898477e-06
of O 0 4.007980010101164e-07
the O 0 3.3542679034326284e-07
C O 0 0.00038032696465961635
- O 0 0.00013557093916460872
terminal O 0 6.655329343630001e-06
domain O 0 1.313928947865861e-07
of O 0 6.010341024875743e-08
NPII O 0 0.0009791734628379345
, O 0 1.3237733753612702e-07
including O 0 6.446936851034479e-08
a O 0 7.698714910020499e-08
cysteine O 0 2.931426195118547e-07
residue O 0 6.266070045057859e-07
in O 0 3.18888560002506e-08
position O 0 1.1228109286776089e-07
85 O 0 3.137303963285376e-07
, O 0 5.515767398378557e-08
which O 0 1.837401519821924e-08
could O 0 4.4280216826564356e-08
be O 0 9.776549347861874e-09
involved O 0 4.772570605382498e-08
in O 0 3.0198787470681054e-08
the O 0 9.549168566991284e-08
correct O 0 3.5141679290973116e-06
folding O 0 2.2810587324784137e-05
of O 0 4.3908065094910853e-07
the O 0 2.5624794943723828e-06
prohormone O 0 0.01204563956707716
. O 0 2.9919183361926116e-05

In O 0 8.989503839984536e-06
the O 0 1.049012553266948e-06
second O 0 1.7104256357924896e-06
family O 0 1.8283421923115384e-06
, O 0 1.4422128913338383e-07
a O 0 1.198396688550929e-07
G279A O 0 5.807798970636213e-06
substitution O 0 2.982079081448319e-07
at O 0 2.5105350687226746e-07
position O 0 1.4102261047810316e-07
- O 0 2.2185004127095453e-06
1 O 0 4.623642979595388e-08
of O 0 7.525622791604292e-09
the O 0 1.3879146720796598e-08
signal O 0 2.6422429755257326e-07
peptide O 0 5.506043976311048e-07
was O 0 8.456319733340933e-08
observed O 0 1.2952470740401623e-07
in O 0 2.546040711592923e-08
all O 0 6.232706795117338e-08
affected O 0 2.04353727895068e-06
individuals O 0 1.8349538777329144e-06
. O 0 6.742756340827327e-06

This O 0 1.981393143068999e-05
missense O 0 0.0013480116613209248
mutation O 0 6.164614023873582e-05
, O 0 1.967857315321453e-06
which O 0 6.435978434637946e-07
replaces O 0 0.00012611581769306213
Ala O 0 0.048335932195186615
with O 0 2.5249300961149856e-06
Thr O 0 0.038056399673223495
, O 0 7.158902235460118e-07
is O 0 1.5146814291711053e-07
frequent O 0 2.369296225879225e-06
among O 0 1.0063800800708123e-05
FNDI B-Disease 1 0.9999929666519165
patients O 0 0.01757265068590641
and O 0 3.406797759453184e-07
is O 0 1.3396930853559752e-07
thought O 0 1.4593719299682562e-07
to O 0 2.859665393373234e-08
reduce O 0 4.4252146835788153e-07
the O 0 3.6941095515885536e-08
efficiency O 0 7.654977025595144e-07
of O 0 1.0329446809009823e-07
cleavage O 0 0.0003612487926147878
by O 0 8.502086643602524e-07
signal O 0 8.247602636402007e-06
peptidases O 0 0.00022233830532059073
. O 0 2.899393621191848e-06
. O 0 8.115114724205341e-06

Genetic O 0 0.0017470106249675155
heterogeneity O 0 0.000290398282231763
of O 0 1.6211142792599276e-05
Saethre B-Disease 1 0.9474831223487854
- I-Disease 1 0.9997581839561462
Chotzen I-Disease 1 0.9999732971191406
syndrome I-Disease 1 0.9998555183410645
, O 0 2.3642357973585604e-06
due O 0 1.6595303122812766e-06
to O 0 5.465155368256092e-07
TWIST O 0 0.00015364002319984138
and O 0 1.37342340167379e-05
FGFR O 1 0.5873998403549194
mutations O 0 0.00014757887402083725
. O 0 2.3391499780700542e-05

Thirty O 0 0.00020374591986183077
- O 0 0.0013461769558489323
two O 0 5.220025741436984e-06
unrelated O 0 0.0010126110864803195
patients O 0 0.00018187481327913702
with O 0 2.6035075961772236e-07
features O 0 6.225844799701008e-07
of O 0 1.3407735650616814e-06
Saethre B-Disease 1 0.9713265299797058
- I-Disease 1 0.9999111890792847
Chotzen I-Disease 1 0.9999927282333374
syndrome I-Disease 1 0.9999556541442871
, O 0 4.5816377678420395e-06
a O 0 1.0294853382220026e-05
common O 0 0.00014411439769901335
autosomal B-Disease 0 0.014304748736321926
dominant I-Disease 0 0.0004068146226927638
condition I-Disease 0 0.000496900815051049
of O 0 5.368132860894548e-06
craniosynostosis B-Disease 1 0.9996546506881714
and O 0 0.00011814238678198308
limb B-Disease 1 0.9793429374694824
anomalies I-Disease 1 0.8859942555427551
, O 0 1.4932876410966855e-06
were O 0 2.071856499696878e-07
screened O 0 3.0075145787122892e-06
for O 0 3.4178393093498016e-07
mutations O 0 3.2613233997835778e-06
in O 0 1.9456794575489766e-07
TWIST O 0 2.4591579858679324e-05
, O 0 9.420774631507811e-07
FGFR2 O 0 0.0032682460732758045
, O 0 1.3077599305688636e-06
and O 0 4.9837876758829225e-06
FGFR3 O 0 0.02745908685028553
. O 0 2.3181242795544676e-05

Nine O 0 6.541790207847953e-05
novel O 0 2.1712239686166868e-05
and O 0 2.4658945676492294e-06
three O 0 1.7750263623383944e-06
recurrent O 0 0.004868397023528814
TWIST O 0 0.0014019354712218046
mutations O 0 3.63918807124719e-05
were O 0 3.007732800597296e-07
found O 0 7.089412292771158e-07
in O 0 5.231440241004748e-07
12 O 0 3.0513378987961914e-06
families O 0 7.72979728935752e-06
. O 0 1.1020578313036822e-05

Seven O 0 6.382306310115382e-05
families O 0 2.994147507706657e-05
were O 0 1.476764737162739e-06
found O 0 5.844531756338256e-07
to O 0 7.5105269559117e-08
have O 0 4.6752283822115714e-08
the O 0 1.1511995268165265e-07
FGFR3 O 0 0.00459968950599432
P250R O 0 0.0004928327980451286
mutation O 0 1.777753709575336e-06
, O 0 1.071553086262611e-07
and O 0 4.7932605440337284e-08
one O 0 2.973661139549222e-08
individual O 0 4.864937253046264e-08
was O 0 1.494960599757178e-07
found O 0 9.63622284189114e-08
to O 0 2.969863288626584e-08
have O 0 3.1092810104382806e-08
an O 0 7.867662077387649e-08
FGFR2 O 0 0.0013748666970059276
VV269 O 0 0.0002938988618552685
- O 0 0.0003112170088570565
270 O 0 2.2263882783590816e-05
deletion O 0 8.627079660072923e-05
. O 0 1.0688086149457376e-05

To O 0 6.774650046281749e-06
date O 0 7.918508345028386e-06
, O 0 9.17411682621605e-07
our O 0 3.099266052686289e-07
detection O 0 5.521026650967542e-06
rate O 0 2.135370635869549e-07
for O 0 6.6753514715856e-08
TWIST O 0 6.4075143200170714e-06
or O 0 4.520962306742149e-07
FGFR O 0 0.002882374217733741
mutations O 0 1.7224587054442964e-06
is O 0 1.035935781601438e-07
68 O 0 1.456000973121263e-06
% O 0 1.46054134120277e-07
in O 0 7.109508004532472e-08
our O 0 1.1827842172351666e-06
Saethre B-Disease 0 0.4151443839073181
- I-Disease 1 0.9996447563171387
Chotzen I-Disease 1 0.9999897480010986
syndrome I-Disease 1 0.9999901056289673
patients O 0 0.012167918495833874
, O 0 7.262676717800787e-07
including O 0 3.111215391982114e-07
our O 0 8.898196028894745e-07
five O 0 5.828784196637571e-06
patients O 0 0.001430406584404409
elsewhere O 0 3.972486865677638e-06
reported O 0 3.5893713175028097e-06
with O 0 1.6319003179887659e-06
TWIST O 0 0.0010184345301240683
mutations O 0 0.00019229459576308727
. O 0 1.3903018952987622e-05

More O 0 9.620971468393691e-06
than O 0 1.956564346983214e-06
35 O 0 1.5982776631062734e-06
different O 0 1.676150276352928e-07
TWIST O 0 8.662850632390473e-06
mutations O 0 3.4454810702300165e-06
are O 0 9.048768134789498e-08
now O 0 4.2563530655570503e-07
known O 0 3.832850552498712e-07
in O 0 1.070027408900387e-07
the O 0 4.695330915183149e-07
literature O 0 6.02877298661042e-06
. O 0 1.4552675565937534e-05

The O 0 1.0984808795910794e-05
most O 0 1.6256807384706917e-06
common O 0 1.235475451721868e-06
phenotypic O 0 9.95223945210455e-06
features O 0 1.8987740304510226e-06
, O 0 6.904024871801084e-07
present O 0 2.087723913746231e-07
in O 0 6.640885175102085e-08
more O 0 2.891686179395947e-08
than O 0 4.794247843165067e-08
a O 0 4.287146992965063e-08
third O 0 9.152395108458222e-08
of O 0 3.8294444948405726e-08
our O 0 9.423191613677773e-07
patients O 0 2.806008342304267e-05
with O 0 2.1532333960294636e-07
TWIST O 0 7.231817289721221e-05
mutations O 0 7.431196081597591e-06
, O 0 8.417585206643707e-08
are O 0 4.081907434283494e-08
coronal B-Disease 0 0.00033123407047241926
synostosis I-Disease 0 0.0029819905757904053
, O 0 1.116546627599746e-06
brachycephaly B-Disease 0 0.0007184506976045668
, O 0 2.0703448626591126e-06
low B-Disease 0 0.0008639023872092366
frontal I-Disease 1 0.9988445043563843
hairline I-Disease 1 0.9999098777770996
, O 0 2.6989035177393816e-05
facial B-Disease 0 0.19429995119571686
asymmetry I-Disease 0 0.0035586566664278507
, O 0 3.370802369317971e-05
ptosis B-Disease 1 0.9981314539909363
, O 0 1.3787158422928769e-05
hypertelorism B-Disease 1 0.6566921472549438
, O 0 3.716240598805598e-06
broad B-Disease 0 0.00010475692397449166
great I-Disease 0 1.3773346836387645e-05
toes I-Disease 0 0.00043234287295490503
, O 0 1.4895414324200829e-06
and O 0 3.0655160117021296e-06
clinodactyly B-Disease 0 0.00564461387693882
. O 0 2.0757339370902628e-05

Significant O 0 6.843461596872658e-05
intra O 0 0.00020253282855264843
- O 0 0.0007741197478026152
and O 0 5.236384822637774e-06
interfamilial O 0 0.0042153396643698215
phenotypic O 0 0.0001579892123118043
variability O 0 0.0007861493504606187
is O 0 5.20054527441971e-07
present O 0 3.7676596775781945e-07
for O 0 3.2250605386252573e-07
either O 0 1.1262185353189125e-06
TWIST O 0 0.0003320257819723338
mutations O 0 8.717535820323974e-05
or O 0 6.523188403662061e-06
FGFR O 0 0.23296768963336945
mutations O 0 0.000138242743560113
. O 0 1.976267776626628e-05

The O 0 6.897648290760117e-06
overlap O 0 1.704216265352443e-05
in O 0 1.422374452886288e-06
clinical O 0 3.939214366255328e-05
features O 0 1.0534628245295607e-06
and O 0 2.995538466166181e-07
the O 0 1.0891855595218658e-07
presence O 0 2.516012216347008e-07
, O 0 1.0072820799678084e-07
in O 0 3.241247981122797e-08
the O 0 1.892349210663724e-08
same O 0 3.1060206850952454e-08
genes O 0 1.3346661376090196e-07
, O 0 4.3550663519908994e-08
of O 0 4.294095035106693e-08
mutations O 0 5.026217309023195e-07
for O 0 2.1923810322732606e-08
more O 0 1.7746417668718095e-08
than O 0 5.7100361772199903e-08
one O 0 1.4409781101676344e-07
craniosynostotic B-Disease 0 0.008071988821029663
condition I-Disease 0 5.581355799222365e-05
- O 0 4.5773809688398615e-05
such O 0 1.0487428880878724e-07
as O 0 1.0258312244104673e-07
Saethre B-Disease 0 0.00017374612798448652
- I-Disease 0 0.0004452544671948999
Chotzen I-Disease 0 0.0002791486622299999
, I-Disease 0 2.6219734650112514e-07
Crouzon I-Disease 0 9.900656004901975e-05
, I-Disease 0 5.167485710444453e-07
and I-Disease 0 6.680409569526091e-06
Pfeiffer I-Disease 1 0.800097644329071
syndromes I-Disease 0 0.29733219742774963
- O 0 0.00022541098587680608
support O 0 4.3139118588442216e-07
the O 0 6.044403733085346e-08
hypothesis O 0 6.411913204829034e-07
that O 0 3.700343498280745e-08
TWIST O 0 2.205817054345971e-06
and O 0 2.4036683043959783e-07
FGFRs O 0 8.670751412864774e-05
are O 0 2.2041838576569717e-08
components O 0 1.7274416563850536e-07
of O 0 1.8629187081842247e-08
the O 0 2.9317886784951952e-08
same O 0 4.77155133182805e-08
molecular O 0 9.211955784849124e-07
pathway O 0 2.0928928279317915e-07
involved O 0 1.1403817268273997e-07
in O 0 3.436950279933626e-08
the O 0 4.347265303294989e-08
modulation O 0 9.412099757355463e-07
of O 0 5.510246410267428e-07
craniofacial O 1 0.9914871454238892
and O 0 1.0578074579825625e-05
limb O 0 0.15755321085453033
development O 0 5.544337454921333e-06
in O 0 1.1971212643402396e-06
humans O 0 2.940098738690722e-06
. O 0 1.976731482500327e-06
. O 0 8.870119017956313e-06

Mutation O 0 0.00046169274719431996
analysis O 0 7.094061584211886e-05
of O 0 4.0381866710959e-05
UBE3A O 1 0.9991113543510437
in O 1 0.9894471168518066
Angelman B-Disease 1 0.9999998807907104
syndrome I-Disease 1 0.9999997615814209
patients O 1 0.9966551065444946
. O 0 0.0006450802320614457

Angelman B-Disease 1 0.9999994039535522
syndrome I-Disease 1 0.9999991655349731
( O 0 0.00041211629286408424
AS B-Disease 0 0.00019359379075467587
) O 0 1.140597419180267e-06
is O 0 5.839895607095968e-07
caused O 0 2.9948864721518476e-06
by O 0 3.175148322043242e-07
chromosome O 0 3.0208118914742954e-05
15q11 O 0 0.0006433657836169004
- O 0 0.00035285146441310644
q13 O 0 4.8240824980894104e-05
deletions O 0 5.025880909670377e-06
of O 0 3.4388918379590905e-07
maternal O 0 1.4108939467405435e-05
origin O 0 3.796891121510271e-07
, O 0 4.112150122637104e-07
by O 0 9.147435662271164e-07
paternal O 0 0.00024555789423175156
uniparental B-Disease 1 0.9178608059883118
disomy I-Disease 1 0.9098320603370667
( O 0 1.1619769793469459e-05
UPD B-Disease 1 0.9968745708465576
) O 0 3.6261988611840934e-07
15 O 0 3.1572699299431406e-07
, O 0 9.297498593241471e-08
by O 0 1.614841380614962e-07
imprinting O 0 0.027700265869498253
defects O 1 0.5903023481369019
, O 0 6.153248364171304e-07
and O 0 2.5304089490418846e-07
by O 0 2.9913704224782123e-07
mutations O 0 2.2139477096061455e-06
in O 0 1.1900282004262408e-07
the O 0 6.695281058455294e-07
UBE3A O 0 0.007343497592955828
gene O 0 2.1041687432443723e-05
. O 0 1.1002579412888736e-05

UBE3A O 0 0.009754694998264313
encodes O 0 8.80738371051848e-05
a O 0 1.0024518815043848e-05
ubiquitin O 0 7.93462895671837e-05
- O 0 9.277565550291911e-05
protein O 0 2.0448862869670847e-06
ligase O 0 9.442079317523167e-06
and O 0 4.4364671225594066e-07
shows O 0 1.7538413885631599e-06
brain O 0 0.00016697966202627867
- O 0 7.76636807131581e-05
specific O 0 2.6051816348626744e-06
imprinting O 0 0.0002569162752479315
. O 0 1.645736483624205e-05

Here O 0 4.419774631969631e-05
we O 0 6.770825621060794e-06
describe O 0 1.9927403627661988e-05
UBE3A O 0 0.005742294248193502
coding O 0 0.0003613725712057203
- O 0 0.0010395942954346538
region O 0 7.103480584191857e-06
mutations O 0 5.2602745199692436e-06
detected O 0 1.5438976106452174e-06
by O 0 9.567618519668031e-08
SSCP O 0 0.00010023055074270815
analysis O 0 5.893876959817135e-07
in O 0 1.2854187048105814e-07
13 O 0 1.3670274938704097e-06
AS B-Disease 0 5.715773568226723e-06
individuals O 0 4.348269158072071e-07
or O 0 1.0546500561758876e-06
families O 0 5.349249931896338e-06
. O 0 9.093785592995118e-06

Two O 0 2.289927397214342e-05
identical O 0 3.600621857913211e-05
de O 0 4.4281958253122866e-05
novo O 0 3.169047340634279e-05
5 O 0 4.543504473986104e-06
- O 0 3.7376699765445665e-05
bp O 0 1.6643069102428854e-05
duplications O 0 1.1165742762386799e-05
in O 0 4.784578777616844e-07
exon O 0 2.536658757890109e-05
16 O 0 1.928579649757012e-06
were O 0 7.79004267315031e-07
found O 0 3.2865070807019947e-06
. O 0 6.731558187311748e-06

Among O 0 2.6097319278051145e-05
the O 0 1.458360657125013e-06
other O 0 3.1109840392673505e-07
11 O 0 7.565988084934361e-07
unique O 0 5.992152978251397e-07
mutations O 0 4.328288014221471e-06
, O 0 2.2732507432010607e-07
8 O 0 3.683626346173696e-07
were O 0 4.142512111116048e-08
small O 0 1.6431867777555453e-07
deletions O 0 1.5741832157800673e-06
or O 0 1.4065754783132434e-07
insertions O 0 3.8467619560833555e-06
predicted O 0 7.666142664675135e-06
to O 0 1.8515110866701434e-07
cause O 0 7.185473805293441e-06
frameshifts O 0 0.005746487993746996
, O 0 4.995966378373851e-07
1 O 0 4.090738912054803e-07
was O 0 1.8515410715735925e-07
a O 0 1.6666866997638863e-07
mutation O 0 3.6527754332382756e-07
to O 0 3.336242215823404e-08
a O 0 3.703817341715876e-08
stop O 0 2.4470216430927394e-07
codon O 0 2.9810951218678383e-07
, O 0 4.7372907374665374e-08
1 O 0 6.166653321315607e-08
was O 0 5.329531305164892e-08
a O 0 7.535321344676049e-08
missense O 0 2.163831959478557e-05
mutation O 0 6.36186371139047e-07
, O 0 7.681831704076103e-08
and O 0 4.6926139418701496e-08
1 O 0 1.7642813077145547e-07
was O 0 2.1152784768219135e-07
predicted O 0 5.616650923911948e-06
to O 0 4.699250766293517e-08
cause O 0 4.593769347138732e-07
insertion O 0 6.33299521268782e-07
of O 0 2.796652331937821e-08
an O 0 6.168841082399013e-08
isoleucine O 0 3.8047695852583274e-05
in O 0 5.81883732309052e-08
the O 0 2.8392683759648207e-08
hect O 0 7.490256848541321e-06
domain O 0 5.791499546603518e-08
of O 0 1.3043948143831585e-08
the O 0 3.08087386713396e-08
UBE3A O 0 9.93011926766485e-05
protein O 0 2.2714584702043794e-07
, O 0 3.1571005365549354e-08
which O 0 1.404132987659068e-08
functions O 0 2.845030877551835e-08
in O 0 3.642982093765568e-08
E2 O 0 1.4466002539847977e-05
binding O 0 1.641144422137586e-06
and O 0 4.851075345868594e-07
ubiquitin O 0 6.032336750649847e-05
transfer O 0 1.235057061421685e-05
. O 0 8.854103725752793e-06

Eight O 0 3.0768263968639076e-05
of O 0 1.4244554904507822e-06
the O 0 1.3113342447468312e-06
cases O 0 4.1927214624593034e-06
were O 0 1.135584170697257e-06
familial O 0 0.06358671188354492
, O 0 1.986384404517594e-06
and O 0 4.695510256169655e-07
five O 0 5.916448913012573e-07
were O 0 1.332219767391507e-06
sporadic O 0 3.157126411679201e-05
. O 0 1.114528549805982e-05

In O 0 4.013045327155851e-05
two O 0 8.561975846532732e-06
familial O 0 0.47818511724472046
cases O 0 2.6336989321862347e-05
and O 0 8.539042255506502e-07
one O 0 3.3190269732585875e-07
sporadic O 0 1.908638841996435e-05
case O 0 5.375197360990569e-06
, O 0 1.1601790674831136e-06
mosaicism O 0 0.0038414648734033108
for O 0 6.155543132990715e-07
UBE3A O 0 0.08526387810707092
mutations O 0 7.42099746275926e-06
was O 0 3.6712535234073584e-07
detected O 0 2.302953816979425e-06
in O 0 5.0845915922081986e-08
the O 0 6.331002566639654e-08
mother O 0 2.2458013972936897e-06
of O 0 5.227286337117221e-08
three O 0 1.9590927990975615e-07
AS B-Disease 0 1.6994446923490614e-05
sons O 0 0.00027040153509005904
, O 0 2.184667380333849e-07
in O 0 3.085378708078679e-08
the O 0 7.561727244365102e-08
maternal O 0 7.013857157289749e-06
grandfather O 0 9.08665060705971e-06
of O 0 3.2621798595755536e-08
two O 0 6.289383236435242e-08
AS B-Disease 0 6.978576152505411e-07
first O 0 7.834822213226289e-08
cousins O 0 1.1182079106220044e-05
, O 0 1.6797875446172839e-07
and O 0 7.862006867753735e-08
in O 0 3.298027806408754e-08
the O 0 6.717897349517443e-08
mother O 0 5.048612365499139e-06
of O 0 8.039626919753573e-08
an O 0 4.635970753952279e-07
AS B-Disease 0 9.387148747919127e-05
daughter O 0 0.010595583356916904
. O 0 3.5400174965616316e-05

The O 0 4.882776920567267e-06
frequencies O 0 4.235982032696484e-06
with O 0 3.92875364241263e-07
which O 0 1.5984529966317496e-07
we O 0 2.56961754985241e-07
detected O 0 4.703941613115603e-06
mutations O 0 9.446216040487343e-07
were O 0 4.4814655097979994e-08
5 O 0 1.923099546274898e-07
( O 0 6.948022956976274e-08
14 O 0 1.5898996252872166e-07
% O 0 6.09820460795163e-08
) O 0 1.3321808545185831e-08
of O 0 1.2760659195976132e-08
35 O 0 1.5931233576793602e-07
in O 0 4.572418177417603e-08
sporadic O 0 3.7928555229882477e-06
cases O 0 2.769585591977375e-07
and O 0 1.3335133530745225e-07
8 O 0 7.433247901644791e-07
( O 0 5.79190810867658e-08
80 O 0 2.3878189381321135e-07
% O 0 5.3858578041854344e-08
) O 0 1.880220956707035e-08
of O 0 2.515154839954903e-08
10 O 0 3.3624800721554493e-07
in O 0 7.578395297969109e-07
familial O 0 0.05993276461958885
cases O 0 1.060810791386757e-05
. O 0 2.3726674953650218e-06
. O 0 1.5735942724859342e-05

The O 0 0.00016439883620478213
hemochromatosis B-Disease 1 0.9993394017219543
845 O 0 0.02020782046020031
G O 0 0.06761953979730606
- O 0 0.005249794106930494
- O 0 0.00030779061489738524
> O 0 6.738674983353121e-06
A O 0 1.1927527054922393e-07
and O 0 6.661360885118484e-08
187 O 0 1.944642008311348e-06
C O 0 3.410756107768975e-05
- O 0 0.0001452063152100891
- O 0 0.0012725479900836945
> O 0 0.00010766038030851632
G O 0 0.0004739089636132121
mutations O 0 4.938637175655458e-06
: O 0 5.857348241988802e-07
prevalence O 0 2.2739130145055242e-05
in O 0 2.8404744512045e-07
non O 0 1.2634050108317751e-05
- O 0 0.03179273009300232
Caucasian O 0 0.0006632395088672638
populations O 0 1.6185282220249064e-05
. O 0 8.367724149138667e-06

Hemochromatosis B-Disease 1 0.9991996884346008
, O 0 0.0003585388185456395
the O 0 0.00033455563243478537
inherited B-Disease 1 0.9999885559082031
disorder I-Disease 1 0.999902606010437
of I-Disease 0 8.129274647217244e-06
iron I-Disease 0 0.16265077888965607
metabolism I-Disease 0 0.0003544436185620725
, O 0 2.1892528820899315e-06
leads O 0 1.131484896177426e-05
, O 0 1.2212575484227273e-06
if O 0 2.669526793397381e-06
untreated O 0 0.0010982376988977194
, O 0 2.476157021646941e-07
to O 0 6.27359213467571e-07
progressive O 0 0.0012814428191632032
iron B-Disease 0 0.04382062703371048
overload I-Disease 0 0.04194856807589531
and O 0 1.531077032268513e-05
premature B-Disease 0 0.045946162194013596
death I-Disease 0 0.00014544438454322517
. O 0 2.8334145099506713e-05

The O 0 0.0002490579499863088
hemochromatosis B-Disease 1 0.9992673993110657
gene O 0 0.00029199995333328843
, O 0 1.6771826267358847e-05
HFE O 0 0.18317151069641113
, O 0 2.79983100881509e-06
recently O 0 4.7902908590913285e-06
has O 0 2.266548619900277e-07
been O 0 2.1923227677689283e-07
identified O 0 1.6221218857026543e-06
, O 0 1.1612889494472256e-07
and O 0 9.829354041812621e-08
characterization O 0 2.8367135200824123e-06
of O 0 3.2646138237169e-08
this O 0 4.301242739757072e-08
gene O 0 4.1326211430714466e-07
has O 0 3.454544028613782e-08
shown O 0 6.478863667780388e-08
that O 0 1.1076379813346193e-08
it O 0 9.69528812788667e-09
contains O 0 5.251530055261355e-08
two O 0 6.547137587631369e-08
mutations O 0 7.226274192362325e-07
that O 0 1.9987227872775293e-08
result O 0 8.695462838659296e-08
in O 0 2.8943125229830002e-08
amino O 0 1.223142902517793e-07
acid O 0 1.596136058878983e-07
substitutions O 0 2.6936655217468797e-07
- O 0 7.219193207674834e-07
cDNA O 0 8.352874374395469e-07
nucleotides O 0 6.120006901255692e-07
845 O 0 5.965529908280587e-06
G O 0 2.0611623767763376e-05
- O 0 3.225920590921305e-05
- O 0 0.0001019737683236599
> O 0 6.449030479416251e-06
A O 0 1.3408281063220784e-07
( O 0 5.604637465239648e-08
C282Y O 0 2.0588265670085093e-06
) O 0 1.495173762577906e-08
and O 0 1.843351427055495e-08
187 O 0 5.938579192843463e-07
C O 0 1.1818633538496215e-05
- O 0 0.00011796947364928201
- O 0 0.0015828892355784774
> O 0 0.0001475634053349495
G O 0 0.00011109679326182231
( O 0 3.984849286098324e-07
H63D O 0 0.00012739373778458685
) O 0 8.393374741899606e-07
. O 0 2.2503679701912915e-06

Although O 0 0.0027769552543759346
hemochromatosis B-Disease 1 0.9999200105667114
is O 0 3.409658802411286e-06
common O 0 1.5233138128678547e-06
in O 0 5.128108000462817e-07
Caucasians O 0 5.7413264585193247e-05
, O 0 5.800166036351584e-07
affecting O 0 6.768708317395067e-06
> O 0 0.0003387487377040088
= O 0 1.5802364941919222e-05
1 O 0 4.539210749499034e-07
/ O 0 3.4671138564590365e-06
300 O 0 1.3416365618468262e-07
individuals O 0 3.460505837438177e-08
of O 0 1.4743337217737462e-08
northern O 0 9.009347934352263e-08
European O 0 5.464300656399246e-08
origin O 0 3.724020203321743e-08
, O 0 1.0099773106730936e-07
it O 0 3.319428287795745e-08
has O 0 2.9624068531575176e-08
not O 0 3.08584944264112e-08
been O 0 5.0277510155183336e-08
recognized O 0 1.5791736984738236e-07
in O 0 1.09502217071622e-07
other O 0 4.6048268131926307e-07
populations O 0 5.603831596090458e-06
. O 0 6.224204298632685e-06

The O 0 8.820871698844712e-06
present O 0 3.7828563108632807e-06
study O 0 1.3304688764037564e-06
used O 0 5.052920073467249e-07
PCR O 0 6.837994988018181e-06
and O 0 2.0678849921296205e-07
restriction O 0 8.685995567248028e-07
- O 0 9.20097045309376e-06
enzyme O 0 6.415583584384876e-07
digestion O 0 2.616740175653831e-06
to O 0 6.867743707061891e-08
analyze O 0 3.8960612869232136e-07
the O 0 1.714287201082243e-08
frequency O 0 5.5212304062024486e-08
of O 0 1.2811089966646705e-08
the O 0 4.547925058773217e-08
845 O 0 1.6089590644696727e-05
G O 0 0.0005436019855551422
- O 0 0.0002671871625352651
- O 0 0.00016470038099214435
> O 0 5.742327175539685e-06
A O 0 9.488654484357539e-08
and O 0 5.2025587393700334e-08
187 O 0 1.995817910938058e-06
C O 0 1.9807019270956516e-05
- O 0 7.368213118752465e-05
- O 0 0.00023405904357787222
> O 0 3.205527536920272e-05
G O 0 2.6445461116963997e-05
mutations O 0 4.291659365662781e-07
in O 0 8.629456971220861e-08
HLA O 0 0.00034860093728639185
- O 0 1.5804807844688185e-05
typed O 0 1.1067974128309288e-06
samples O 0 2.7201335228710377e-07
from O 0 6.325064560996907e-08
non O 0 5.786938572782674e-07
- O 0 0.00011531486234162003
Caucasian O 0 1.4107191418588627e-05
populations O 0 4.111185489819036e-07
, O 0 6.303397981355374e-08
comprising O 0 1.8113118471774214e-07
Australian O 0 1.4151841298826184e-07
Aboriginal O 0 2.485900552073872e-07
, O 0 6.899529836346119e-08
Chinese O 0 3.341961729574905e-08
, O 0 1.2868770227214554e-07
and O 0 4.3155662865501654e-07
Pacific O 0 1.2069110198353883e-05
Islanders O 0 3.235030817450024e-05
. O 0 9.30893929762533e-06

Results O 0 0.00011762765643652529
showed O 0 1.7351156202494167e-05
that O 0 4.190495985767484e-07
the O 0 2.607567637369357e-07
845 O 0 9.218831110047176e-05
G O 0 0.004805753007531166
- O 0 0.004030920565128326
- O 0 0.0036862113047391176
> O 0 2.7396083169151098e-05
A O 0 3.3091751561187266e-07
mutation O 0 7.192913926701294e-07
was O 0 6.224414761391017e-08
present O 0 5.329104624252068e-08
in O 0 2.919840902393389e-08
these O 0 2.894263140262865e-08
populations O 0 9.646336707191949e-08
( O 0 2.4273878906910795e-08
allele O 0 1.324992240370193e-07
frequency O 0 1.4155229166590289e-07
0 O 0 2.3475597288324934e-07
. O 0 3.788809621596556e-08
32 O 0 9.355847652159355e-08
% O 0 4.293841016078659e-08
) O 0 2.772623908242622e-08
, O 0 4.382272678071786e-08
and O 0 4.2324991511577537e-08
, O 0 8.014991692562035e-08
furthermore O 0 4.299868976431753e-07
, O 0 5.174493011850245e-08
it O 0 2.2430109325455305e-08
was O 0 1.084362111214432e-07
always O 0 1.7661668039181677e-07
seen O 0 1.7500107674095489e-07
in O 0 5.2778894144012156e-08
conjunction O 0 1.2907318023280823e-06
with O 0 1.1733221754184342e-06
HLA O 1 0.5543426275253296
haplotypes O 0 0.00020952777413185686
common O 0 1.2649111340579111e-06
in O 0 2.5194697172992164e-07
Caucasians O 0 2.0906834834022447e-05
, O 0 2.8975006216569454e-07
suggesting O 0 4.5903402678959537e-07
that O 0 7.351084718720813e-08
845 O 0 6.806610326748341e-05
G O 0 0.009281008504331112
- O 0 0.006119889207184315
- O 0 0.01620527356863022
> O 0 4.976921991328709e-05
A O 0 4.1388133809050487e-07
may O 0 2.149095337244944e-07
have O 0 2.343729477161105e-08
been O 0 2.012409971996476e-08
introduced O 0 5.01347336978597e-08
into O 0 4.560781263762692e-08
these O 0 6.094158777614211e-08
populations O 0 4.517570744155819e-07
by O 0 4.787066245626193e-07
Caucasian O 0 8.93829928827472e-05
admixture O 0 0.00025147292762994766
. O 0 2.169820618291851e-05

187 O 0 0.00045427418081089854
C O 0 0.0007749212090857327
- O 0 0.0004026281530968845
- O 0 0.00035810054396279156
> O 0 0.00010795706475619227
G O 0 7.677329267608002e-05
was O 0 2.485063816948241e-07
present O 0 7.697862969280322e-08
at O 0 8.216149183226662e-08
an O 0 2.599145609849529e-08
allele O 0 4.809135134564713e-07
frequency O 0 2.0311205162215629e-07
of O 0 1.4117682667347253e-07
2 O 0 2.7640705866360804e-06
. O 0 6.228165148058906e-06

68 O 0 0.0005059686955064535
% O 0 7.184535206761211e-06
in O 0 5.188413183532248e-07
the O 0 1.7935553842107765e-07
two O 0 1.9139022811032191e-07
populations O 0 9.228838848684973e-07
analyzed O 0 1.5303248801501468e-06
( O 0 1.303538539332294e-07
Australian O 0 2.787524806535657e-07
Aboriginal O 0 6.895609203638742e-07
and O 0 2.460221537603502e-07
Chinese O 0 2.0296528191465768e-07
) O 0 7.112802791198192e-07
. O 0 2.7334267542755697e-06

In O 0 1.1434409316279925e-05
the O 0 1.2708455869869795e-06
Australian O 0 1.6253908370345016e-06
Aboriginal O 0 1.3604128525912529e-06
samples O 0 9.200840054290893e-07
, O 0 1.5291197996702977e-07
187 O 0 1.7686121509541408e-06
C O 0 1.5555879144812934e-05
- O 0 8.072455966612324e-05
- O 0 0.0006783122662454844
> O 0 7.182217086665332e-05
G O 0 3.253904287703335e-05
was O 0 1.2225132195453625e-07
found O 0 5.9478470149088025e-08
to O 0 1.5687556143006987e-08
be O 0 3.1262228361583766e-08
associated O 0 3.801434615979815e-07
with O 0 7.228583172036451e-07
HLA O 0 0.18219086527824402
haplotypes O 0 3.91889079764951e-05
common O 0 5.538506684388267e-07
in O 0 1.937705889076824e-07
Caucasians O 0 2.3195858375402167e-05
, O 0 4.7023442562021955e-07
suggesting O 0 1.1334440159771475e-06
that O 0 5.58735742117733e-08
it O 0 6.649681694170795e-08
was O 0 1.9238002835209045e-07
introduced O 0 3.298261503914546e-07
by O 0 1.8012948999057699e-07
recent O 0 2.6498057650314877e-06
admixture O 0 0.00010349376680096611
. O 0 1.2515115486166906e-05

In O 0 1.3046087588008959e-05
the O 0 1.1810121804955998e-06
Chinese O 0 3.491654467779881e-07
samples O 0 6.754192440894258e-07
analyzed O 0 6.548268061123963e-07
, O 0 1.0728516741664862e-07
187 O 0 1.6464209693367593e-06
C O 0 2.861186658265069e-05
- O 0 0.00016604954726062715
- O 0 0.0009400522685609758
> O 0 0.00010508538252906874
G O 0 7.679833652218804e-05
was O 0 1.5426010691044212e-07
present O 0 8.503321424768728e-08
in O 0 7.069792928859897e-08
association O 0 1.6965391580470168e-07
with O 0 5.505697941998733e-08
a O 0 9.290213398571723e-08
wide O 0 1.210048026223376e-06
variety O 0 2.07222015546904e-07
of O 0 1.7558819820351346e-07
HLA O 0 0.14610455930233002
haplotypes O 0 2.8140584618085995e-05
, O 0 2.989043537127145e-07
showing O 0 9.499353836872615e-07
this O 0 5.825400251069368e-08
mutation O 0 6.017314717610134e-07
to O 0 2.7526954937684422e-08
be O 0 2.436878965283995e-08
widespread O 0 7.967358328642149e-07
and O 0 3.1439833492186153e-07
likely O 0 7.104566179805261e-07
to O 0 9.706929660069363e-08
predate O 0 8.582430382375605e-06
the O 0 5.764267996255512e-08
more O 0 9.462070238441811e-08
genetically O 0 1.0289691090292763e-06
restricted O 0 6.074001817069075e-07
845 O 0 6.571138510480523e-05
G O 0 0.010994215495884418
- O 0 0.010539533570408821
- O 0 0.014687801711261272
> O 0 0.0001605666329851374
A O 0 2.8162223770777928e-06
mutation O 0 1.628985228308011e-05
. O 0 5.542688086279668e-06

Genotype O 0 0.07246758043766022
- O 0 0.05053042992949486
phenotype O 0 0.007018093019723892
correlations O 0 0.0036157947033643723
in O 0 0.00030777414212934673
attenuated B-Disease 1 0.9942919015884399
adenomatous I-Disease 1 0.9999738931655884
polyposis I-Disease 1 0.9999685287475586
coli I-Disease 1 0.9992884397506714
. O 0 0.0008612468955107033

Germ O 0 0.061155132949352264
- O 0 0.001368620665743947
line O 0 3.179612394887954e-05
mutations O 0 7.327396360778948e-06
of O 0 3.460585560333129e-07
the O 0 8.138979410432512e-07
tumor B-Disease 0 0.006076511461287737
suppressor O 0 0.0002675049763638526
APC O 0 5.5335422075586393e-05
are O 0 3.309573060050752e-07
implicated O 0 6.790325278416276e-05
in O 0 1.4385178474185523e-05
attenuated B-Disease 1 0.9823552966117859
adenomatous I-Disease 1 0.999997615814209
polyposis I-Disease 1 0.9999954700469971
coli I-Disease 1 0.9998375177383423
( O 0 0.00010330543591408059
AAPC B-Disease 1 0.9996689558029175
) O 0 2.1904429559072014e-06
, O 0 4.437322047579073e-07
a O 0 9.808675258682342e-07
variant O 0 2.961069912998937e-05
of O 0 8.937361417338252e-05
familial B-Disease 1 0.9999896287918091
adenomatous I-Disease 1 0.999996542930603
polyposis I-Disease 1 0.9999979734420776
( O 0 0.0003801704151555896
FAP B-Disease 0 0.27332204580307007
) O 0 1.2000923561572563e-05
. O 0 2.4891012799344026e-05

AAPC B-Disease 1 0.998849630355835
is O 0 4.409956090967171e-05
recognized O 0 6.261987437028438e-06
by O 0 4.851982566833613e-07
the O 0 1.7472993363298883e-07
occurrence O 0 1.3158767160348361e-06
of O 0 4.237770099280169e-07
< O 0 0.0014576195972040296
100 O 0 3.40317137670354e-06
colonic B-Disease 1 0.5959603786468506
adenomas I-Disease 0 0.44157978892326355
and O 0 5.202837201068178e-07
a O 0 3.2496637913936866e-07
later O 0 1.1494632872199873e-06
onset O 0 0.4765618145465851
of O 0 0.11056966334581375
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999988079071045
( O 0 9.962503099814057e-06
age O 0 3.949799793190323e-05
> O 0 0.0003904789627995342
40 O 0 2.7965804747509537e-06
years O 0 1.4947595445846673e-06
) O 0 1.2572694458867772e-06
. O 0 4.154621819907334e-06

The O 0 6.771807420591358e-06
aim O 0 6.409555680875201e-06
of O 0 3.2489916179656575e-07
this O 0 1.226479042770734e-07
study O 0 3.121683107565332e-07
was O 0 2.801177174660552e-07
to O 0 2.0633717667806195e-07
assess O 0 3.298207593616098e-05
genotype O 0 0.00035442167427390814
- O 0 0.007356564048677683
phenotype O 0 0.0001273118978133425
correlations O 0 5.578801210504025e-05
in O 0 8.662157597427722e-06
AAPC B-Disease 1 0.9991113543510437
families O 0 8.365519170183688e-05
. O 0 3.085038042627275e-05

By O 0 1.5133909982978366e-05
protein O 0 1.6087151379906572e-05
- O 0 4.6066819777479395e-05
truncation O 0 2.4552609829697758e-05
test O 0 2.6754294140118873e-06
( O 0 2.3154485973009287e-07
PTT O 0 2.1564815142482985e-06
) O 0 6.350582992808995e-08
assay O 0 1.0306622471034643e-06
, O 0 3.319276231650292e-08
the O 0 1.7895910531251502e-08
entire O 0 2.1111651449245983e-07
coding O 0 1.5393413832498481e-06
region O 0 1.0089510737998353e-07
of O 0 2.2710267444381316e-08
the O 0 6.211771363950902e-08
APC B-Disease 0 8.093890755844768e-06
gene O 0 4.6090667638054583e-07
was O 0 1.5692920385390607e-07
screened O 0 2.2901240299688652e-06
in O 0 1.704836734006676e-07
affected O 0 7.681816214244463e-07
individuals O 0 1.3045320201854338e-07
from O 0 1.9418607166699076e-07
11 O 0 6.242978543014033e-06
AAPC B-Disease 1 0.9975003600120544
kindreds O 0 0.005442391615360975
, O 0 5.522277319869318e-07
and O 0 1.946510934658363e-07
their O 0 2.1920908466199762e-07
phenotypic O 0 2.0119348846492358e-05
differences O 0 1.1108474609500263e-05
were O 0 1.9821247860818403e-06
examined O 0 0.0002077388489851728
. O 0 2.1854853912373073e-05

Five O 0 5.730080738430843e-05
novel O 0 7.821717736078426e-05
germ O 0 0.007252346724271774
- O 0 0.001844628481194377
line O 0 3.014106914633885e-05
APC B-Disease 0 0.00017869319708552212
mutations O 0 6.048474006092874e-06
were O 0 3.6123992686043493e-07
identified O 0 1.7549958784002229e-06
in O 0 3.333275628847332e-07
seven O 0 3.601286152843386e-06
kindreds O 0 0.0013581957900896668
. O 0 1.7778280380298384e-05

Mutations O 0 0.0006169054540805519
were O 0 4.7998755690059625e-06
located O 0 2.263132500956999e-06
in O 0 1.760461003641467e-07
three O 0 6.550759934498274e-08
different O 0 3.325492770045457e-08
regions O 0 9.16857416655148e-08
of O 0 2.096390083750066e-08
the O 0 7.008288349652503e-08
APC B-Disease 0 6.861079327791231e-06
gene O 0 4.596350322572107e-07
( O 0 5.213545506421724e-08
1 O 0 1.1941959598971152e-07
) O 0 2.5973168504833666e-08
at O 0 3.8111114264438584e-08
the O 0 1.1671841271265748e-08
5 O 0 4.4595598325258834e-08
end O 0 7.567483351067494e-08
spanning O 0 5.136487857271277e-07
exons O 0 8.8008971488307e-07
4 O 0 2.421021463305806e-07
and O 0 6.268400909448246e-08
5 O 0 1.547280419345043e-07
, O 0 7.347930619516774e-08
( O 0 3.035829720943184e-08
2 O 0 4.571720424451087e-08
) O 0 1.1909655484032555e-08
within O 0 1.7643783323251228e-08
exon O 0 1.1833143389594625e-06
9 O 0 4.2142215761487023e-07
, O 0 4.0659237754425703e-08
and O 0 2.373537633104661e-08
( O 0 2.1603929312163928e-08
3 O 0 8.217622848860628e-08
) O 0 1.987637254785568e-08
at O 0 2.04373424850246e-08
the O 0 1.0362673386055121e-08
3 O 0 1.9300080111861462e-07
distal O 0 3.6747809645021334e-05
end O 0 7.115951348168892e-07
of O 0 7.559880543794861e-08
the O 0 4.165820257640007e-07
gene O 0 8.57392205944052e-06
. O 0 6.418131761165569e-06

Variability O 0 0.0050795841962099075
in O 0 7.091047791618621e-06
the O 0 7.895772000665602e-07
number O 0 1.0066911499961861e-06
of O 0 0.00014350583660416305
colorectal B-Disease 1 1.0
adenomas I-Disease 1 0.9999973773956299
was O 0 2.9855000320822e-05
most O 0 1.3671852912011673e-06
apparent O 0 4.8781712393974885e-05
in O 0 5.806442118228006e-07
individuals O 0 4.705681817540608e-07
with O 0 3.1274788625523797e-07
mutations O 0 3.685942374431761e-06
in O 0 9.531481026670008e-08
region O 0 2.7772563271355466e-07
1 O 0 3.1950807510838786e-07
, O 0 1.5210636661322496e-07
and O 0 5.20313449214882e-07
upper O 0 0.009777798317372799
- O 1 0.9778586030006409
gastrointestinal O 1 0.9734009504318237
manifestations O 0 2.5832621759036556e-05
were O 0 3.087327513640048e-07
more O 0 4.7283270987463766e-07
severe O 0 7.708771590841934e-05
in O 0 2.891493977585924e-07
them O 0 7.557025014648389e-07
. O 0 5.5402147154381964e-06

In O 0 4.151110624661669e-05
individuals O 0 9.170195880869869e-06
with O 0 2.0168959053989965e-06
mutations O 0 1.670282472332474e-05
in O 0 2.3038121810259327e-07
either O 0 3.2351798040508584e-07
region O 0 6.669439471806982e-07
2 O 0 6.506156751129311e-07
or O 0 2.4239648155344184e-07
region O 0 3.1775473985362623e-07
3 O 0 2.831203289588302e-07
, O 0 3.758816191634651e-08
the O 0 1.53195962582231e-08
average O 0 1.245695813167913e-07
number O 0 1.6681108050420335e-08
of O 0 6.749144887407965e-08
adenomas B-Disease 0 0.02584107592701912
tended O 0 2.53920370596461e-06
to O 0 7.686375624871289e-08
be O 0 3.715477703281067e-08
lower O 0 5.988473503748537e-07
than O 0 7.0298568743965e-08
those O 0 4.527654340336085e-08
in O 0 4.104618867017962e-08
individuals O 0 5.869824093451825e-08
with O 0 7.057855100356392e-08
mutations O 0 9.530332931717567e-07
in O 0 6.022791865234467e-08
region O 0 6.082581194277736e-07
1 O 0 3.385777063158457e-07
, O 0 1.911365075102367e-07
although O 0 2.109514838366522e-07
age O 0 3.10163068206748e-06
at O 0 1.862950921349693e-05
diagnosis O 0 0.10814306139945984
was O 0 3.2313919291482307e-06
similar O 0 7.282671049324563e-06
. O 0 9.971266990760341e-06

In O 0 3.053730324609205e-05
all O 0 1.3099882380629424e-05
AAPC B-Disease 1 0.9919664859771729
kindreds O 0 0.00665561156347394
, O 0 3.923170424968703e-06
a O 0 1.5230334611260332e-06
predominance O 0 2.9591499696834944e-05
of O 0 1.8464289723851834e-06
right O 0 0.000767455087043345
- O 1 0.9991928935050964
sided O 1 0.9999877214431763
colorectal B-Disease 1 1.0
adenomas I-Disease 1 0.9999959468841553
and O 0 0.0478360690176487
rectal B-Disease 1 0.9999922513961792
polyp I-Disease 1 0.9996953010559082
sparing O 0 0.0032580657862126827
was O 0 4.301474473322742e-05
observed O 0 8.147844346240163e-05
. O 0 2.834668521245476e-05

No O 0 0.00045476542436517775
desmoid B-Disease 1 0.9970766305923462
tumors I-Disease 1 0.9999450445175171
were O 0 4.567468295135768e-06
found O 0 2.646136408657185e-06
in O 0 6.332886641757796e-07
these O 0 2.959357061627088e-06
kindreds O 0 0.0011300789192318916
. O 0 3.112716876785271e-05

Our O 0 3.110102625214495e-05
data O 0 1.2929980584885925e-05
suggest O 0 4.5122974370315205e-06
that O 0 1.8423361325403675e-07
, O 0 3.4208494525955757e-07
in O 0 7.400336130558571e-07
AAPC B-Disease 1 0.9994877576828003
families O 0 6.540556114487117e-06
, O 0 3.1000317335383443e-07
the O 0 4.411364074030644e-08
location O 0 3.7162971011639456e-07
of O 0 4.909157524934926e-08
the O 0 1.8563218873168807e-07
APC B-Disease 0 0.000251396675594151
mutation O 0 9.629489795770496e-06
may O 0 1.188613282465667e-06
partially O 0 5.158684871275909e-06
predict O 0 1.276858620258281e-05
specific O 0 1.6956137187662534e-06
phenotypic O 0 2.8257618396310136e-05
expression O 0 1.1454513696662616e-05
. O 0 1.5281142623280175e-05

This O 0 8.62343586049974e-06
should O 0 1.7498384750069818e-06
help O 0 8.233058110818092e-07
in O 0 1.1979408043316653e-07
the O 0 8.504521531449427e-08
design O 0 5.176684680918697e-07
of O 0 1.6819902270981402e-07
tailored O 0 0.000564795802347362
clinical O 0 0.003878440707921982
- O 0 0.06488586217164993
management O 0 2.5067743990803137e-05
protocols O 0 5.554476956604049e-06
in O 0 6.978542899105378e-08
this O 0 4.252469665289027e-08
subset O 0 3.6528106193145504e-06
of O 0 1.5684048548791907e-06
FAP B-Disease 1 0.8382568359375
patients O 0 0.0016146785346791148
. O 0 3.503680090943817e-06
. O 0 2.3037795472191647e-05

Wilms B-Disease 1 0.9988089799880981
' I-Disease 0 0.002563179936259985
tumor I-Disease 0 0.008806854486465454
1 O 0 3.0076148505031597e-06
and O 0 7.808108648532652e-07
Dax O 0 0.001186403795145452
- O 0 5.2586390665965155e-05
1 O 0 3.2130327554114047e-07
modulate O 0 1.371629423374543e-06
the O 0 1.0599360678043013e-07
orphan O 0 9.718165529193357e-06
nuclear O 0 8.412515853706282e-06
receptor O 0 3.4222955491713947e-06
SF O 0 0.005496825557202101
- O 0 2.1886302420170978e-05
1 O 0 1.7101501725846902e-07
in O 0 6.591883305873125e-08
sex O 0 1.259411533283128e-06
- O 0 4.023322253488004e-05
specific O 0 7.943360742501682e-07
gene O 0 3.1816368846193654e-06
expression O 0 2.891898702728213e-06
. O 0 5.797124686068855e-06

Products O 0 4.573602564050816e-05
of O 0 2.9368873128987616e-06
steroidogenic O 0 0.0033206644002348185
factor O 0 6.519543603644706e-06
1 O 0 1.4788055295866798e-06
( O 0 4.723675885998091e-07
SF O 0 0.011022279970347881
- O 0 3.807975008385256e-05
1 O 0 4.1159049146699545e-07
) O 0 1.1595359694638319e-07
and O 0 6.894267130519438e-07
Wilms B-Disease 1 0.9909075498580933
tumor I-Disease 0 0.012914065271615982
1 O 0 1.0821198657140485e-06
( O 0 3.5790137076219253e-07
WT1 O 0 0.0001485866232542321
) O 0 8.008680651983013e-08
genes O 0 1.1792504039931373e-07
are O 0 1.553024553402338e-08
essential O 0 4.816244825178728e-08
for O 0 5.814210979337986e-08
mammalian O 0 3.399713477847399e-06
gonadogenesis O 0 0.0001891522406367585
prior O 0 8.722237225811114e-07
to O 0 5.744741429225542e-07
sexual O 0 1.0926486538664903e-05
differentiation O 0 9.719184163259342e-05
. O 0 1.4776065654587e-05

In O 0 2.746875907178037e-05
males O 0 1.927434823301155e-05
, O 0 3.3987537335633533e-06
SF O 0 0.10277286171913147
- O 0 0.00012467644410207868
1 O 0 6.383651793839817e-07
participates O 0 6.490341775133857e-07
in O 0 5.409970427194821e-08
sexual O 0 2.1080667522710428e-07
development O 0 1.0958078178191499e-07
by O 0 4.76815777972206e-08
regulating O 0 4.3057247012256994e-07
expression O 0 1.1170775593427607e-07
of O 0 4.4595857673357386e-08
the O 0 2.3087321210368827e-07
polypeptide O 0 0.00018766263383440673
hormone O 0 4.876975799561478e-05
Mullerian O 0 0.001016033929772675
inhibiting O 0 9.459565626457334e-05
substance O 0 3.981247209594585e-05
( O 0 1.944521500263363e-06
MIS O 0 0.00046335181104950607
) O 0 2.6670963961805683e-06
. O 0 4.566388270177413e-06

Here O 0 5.1281411288073286e-05
, O 0 3.0715912089362973e-06
we O 0 4.398769704039296e-07
show O 0 1.1968860462729936e-06
that O 0 3.413106526295451e-07
WT1 O 0 0.0007777546416036785
- O 0 0.00015666833496652544
KTS O 0 0.000994376023299992
isoforms O 0 1.9730230178538477e-06
associate O 0 1.7510052430225187e-06
and O 0 4.1628337044130603e-07
synergize O 0 0.0010941894724965096
with O 0 2.007906459766673e-06
SF O 1 0.603236734867096
- O 0 0.00021518112043850124
1 O 0 1.2577168035932118e-06
to O 0 4.0449972971146053e-07
promote O 0 3.940520400647074e-06
MIS O 0 0.0006761900731362402
expression O 0 1.0080110769195016e-05
. O 0 1.1478670785436407e-05

In O 0 6.576214946107939e-05
contrast O 0 0.00025473887217231095
, O 0 2.7243409931543283e-05
WT1 O 0 0.23546621203422546
missense O 0 0.007276845630258322
mutations O 0 0.00014164982712827623
, O 0 3.146909875795245e-06
associated O 0 4.531911145022605e-06
with O 0 1.1142872153868666e-06
male B-Disease 0 1.1743783034035005e-05
pseudohermaphroditism I-Disease 1 0.9692823886871338
in O 0 9.171096280624624e-06
Denys B-Disease 1 0.9946532249450684
- I-Disease 1 0.9998739957809448
Drash I-Disease 1 0.9999828338623047
syndrome I-Disease 1 0.9996516704559326
, O 0 2.8372598990245024e-06
fail O 0 2.7423897336120717e-05
to O 0 8.014721402105351e-07
synergize O 0 0.01784469187259674
with O 0 7.3651854108902626e-06
SF O 1 0.9644979238510132
- O 0 0.005420004017651081
1 O 0 1.597973459865898e-05
. O 0 9.594858056516387e-06

Additionally O 0 9.319390665041283e-05
, O 0 3.6800556699745357e-06
the O 0 7.156485253290157e-07
X O 0 0.0008344674133695662
- O 0 0.0010221838019788265
linked O 0 1.3339907127374317e-05
, O 0 3.973601394591242e-07
candidate O 0 2.2020781216269825e-06
dosage O 0 3.125930379610509e-05
- O 0 4.7117988287936896e-05
sensitive O 0 1.1195641491212882e-05
sex O 0 1.6501985555805732e-06
- O 0 3.580058182706125e-05
reversal O 0 1.1405461009417195e-05
gene O 0 1.2169302863185294e-06
, O 0 2.467559738761338e-07
Dax O 0 0.0005642749601975083
- O 0 4.611054828274064e-05
1 O 0 4.2608775174812763e-07
, O 0 1.7324354928405228e-07
antagonizes O 0 6.454783488152316e-06
synergy O 0 1.3179263760321192e-06
between O 0 2.7697282689587155e-07
SF O 0 0.08763428777456284
- O 0 8.00455454736948e-05
1 O 0 4.357755187811563e-07
and O 0 2.845758899638895e-07
WT1 O 0 0.0004403696220833808
, O 0 1.1482674722174124e-07
most O 0 3.1150271695423726e-08
likely O 0 9.408279311173828e-08
through O 0 2.579435509630912e-08
a O 0 2.7526533941113485e-08
direct O 0 7.252580047634183e-08
interaction O 0 4.044989623253059e-07
with O 0 1.3510406233763206e-06
SF O 1 0.9746452569961548
- O 0 0.0023643148597329855
1 O 0 9.10240942175733e-06
. O 0 1.0053556252387352e-05

We O 0 3.904834375134669e-05
propose O 0 5.988946941215545e-05
that O 0 1.2868981684732717e-06
WT1 O 0 0.0007736152620054781
and O 0 3.719687356351642e-06
Dax O 0 0.12229841202497482
- O 0 0.0006399067351594567
1 O 0 1.412238475495542e-06
functionally O 0 4.229955720802536e-06
oppose O 0 9.042174724527285e-07
each O 0 1.9189513977835304e-08
other O 0 2.1278161455029476e-08
in O 0 7.147755809455703e-08
testis O 0 6.744165148120373e-05
development O 0 4.10378191872951e-07
by O 0 2.47022967414523e-07
modulating O 0 6.97182840667665e-05
SF O 0 0.442787230014801
- O 0 0.00034374307142570615
1 O 0 2.2556384919880657e-06
- O 0 0.00011267601075815037
mediated O 0 6.878911517560482e-05
transactivation O 0 0.0004112386086490005
. O 0 2.0496015622484265e-06
. O 0 7.0579617386101745e-06

A O 0 0.00030419157701544464
mouse O 0 0.0004504418175201863
model O 0 0.00011441963579272851
for O 0 0.00030418814276345074
Prader B-Disease 1 0.9999923706054688
- I-Disease 1 0.999985933303833
Willi I-Disease 1 0.9999974966049194
syndrome I-Disease 1 0.999900221824646
imprinting O 0 0.30423039197921753
- O 0 0.3555885851383209
centre O 0 0.0005977223627269268
mutations O 0 0.0002145022590411827
. O 0 2.384497202001512e-05

Imprinting O 0 0.0013890444533899426
in O 0 1.23930212794221e-05
the O 0 3.273975835327292e-06
15q11 O 0 0.0004050270945299417
- O 0 0.0006305720889940858
q13 O 0 0.00016197891090996563
region O 0 1.1399209824958234e-06
involves O 0 7.458306185981201e-07
an O 0 7.103435706312666e-08
imprinting O 0 4.7970392188290134e-05
centre O 0 4.439427357283421e-06
( O 0 2.0515399512532895e-07
IC O 0 3.1113188015297055e-05
) O 0 5.2757453516960595e-08
, O 0 3.148399230212817e-08
mapping O 0 6.681573836431198e-07
in O 0 2.5779403500791886e-08
part O 0 5.1949136548046226e-08
to O 0 3.250242741614784e-08
the O 0 6.04521090963317e-08
promoter O 0 6.618025054194732e-06
and O 0 1.2618974665201677e-07
first O 0 2.0256925381545443e-07
exon O 0 1.5783058188389987e-05
of O 0 1.9573762983782217e-06
SNRPN O 0 0.007956362329423428
. O 0 1.9592531316448003e-05

Deletion O 0 0.0005746962851844728
of O 0 5.3204785217531025e-06
this O 0 2.1565390397881856e-06
IC O 0 0.0002246887015644461
abolishes O 0 6.587563984794542e-05
local O 0 1.5570129789921339e-06
paternally O 0 4.547568823909387e-05
derived O 0 8.120054530991183e-07
gene O 0 1.00379986633925e-06
expression O 0 2.425606737688213e-07
and O 0 2.2968207247231476e-07
results O 0 3.86015335607226e-06
in O 0 5.5513322877231985e-05
Prader B-Disease 1 0.9999992847442627
- I-Disease 1 0.9999991655349731
Willi I-Disease 1 0.9999998807907104
syndrome I-Disease 1 0.9999963045120239
( O 0 0.00019737237016670406
PWS B-Disease 1 0.9998192191123962
) O 0 1.1115458619315177e-05
. O 0 2.3429718567058444e-05

We O 0 2.9041975722066127e-05
have O 0 8.630614729554509e-07
created O 0 8.520820529156481e-07
two O 0 2.1992374854562513e-07
deletion O 0 4.1014245653059334e-05
mutations O 0 8.598070053267293e-06
in O 0 2.727721550854767e-07
mice O 0 1.3266830137581564e-05
to O 0 5.573147063842043e-07
understand O 0 5.3246578318066895e-05
PWS B-Disease 1 0.9994115829467773
and O 0 6.205945055626216e-07
the O 0 1.2554156114674697e-07
mechanism O 0 4.421987398472993e-07
of O 0 2.2134211974389473e-07
this O 0 1.5499106211791513e-06
IC O 0 0.0013173222541809082
. O 0 1.8611714040162042e-05

Mice O 0 0.01123080588877201
harbouring O 0 0.004392500966787338
an O 0 4.18259332946036e-06
intragenic O 0 0.001168146263808012
deletion O 0 5.545999374589883e-05
in O 0 1.2274342680029804e-06
Snrpn O 0 0.000551752164028585
are O 0 4.125879513594555e-07
phenotypically O 0 4.000016633654013e-05
normal O 0 1.702651161394897e-06
, O 0 2.84765377500662e-07
suggesting O 0 1.1711646266121534e-06
that O 0 6.158941801004403e-08
mutations O 0 4.878359618487593e-07
of O 0 1.3772353213425959e-07
SNRPN O 0 0.014714007265865803
are O 0 1.2641162072668521e-07
not O 0 9.022503633104861e-08
sufficient O 0 1.0529164455874707e-06
to O 0 1.8007037851930363e-06
induce O 0 0.001214374671690166
PWS B-Disease 1 0.9991359114646912
. O 0 5.498640166479163e-05

Mice O 0 0.0023720429744571447
with O 0 7.338731393247144e-06
a O 0 2.3073287138686283e-06
larger O 0 4.524289124674397e-06
deletion O 0 1.651434286031872e-05
involving O 0 4.357336820248747e-06
both O 0 6.776839427402592e-07
Snrpn O 0 0.0007574672345072031
and O 0 6.829443464084761e-07
the O 0 7.716104732935491e-07
putative O 0 0.003520404454320669
PWS O 1 0.9997665286064148
- O 0 0.020065145567059517
IC O 0 0.0011719083413481712
lack O 0 8.646424021208077e-07
expression O 0 1.5402108033413242e-07
of O 0 3.364943168548962e-08
the O 0 1.6827506499339506e-07
imprinted O 0 3.153852230752818e-05
genes O 0 1.8104431092069717e-06
Zfp127 O 0 0.0001083822498912923
( O 0 1.4165208028771303e-07
mouse O 0 1.255630309060507e-06
homologue O 0 2.6053085093735717e-06
of O 0 2.6361470872870996e-07
ZNF127 O 0 0.001068580662831664
) O 0 3.69593550431091e-07
, O 0 4.072455794812413e-07
Ndn O 0 0.0002430446184007451
and O 0 4.447986157174455e-07
Ipw O 0 1.073004023055546e-05
, O 0 2.5997411512435065e-07
and O 0 2.890710959491116e-07
manifest O 0 4.294915925129317e-06
several O 0 1.0992782790708588e-06
phenotypes O 0 0.0001910644059535116
common O 0 7.868284228607081e-06
to O 0 7.59826143621467e-05
PWS B-Disease 1 0.9999574422836304
infants O 0 0.08705263584852219
. O 0 4.307833296479657e-05

These O 0 7.595589067932451e-06
data O 0 4.1712528400239535e-06
demonstrate O 0 1.5521324030487449e-06
that O 0 6.830564558413244e-08
both O 0 2.6884677595262474e-08
the O 0 2.1849293929676605e-08
position O 0 5.4498123347457295e-08
of O 0 1.7744556046750404e-08
the O 0 4.116441942869642e-08
IC O 0 1.6134856196003966e-05
and O 0 5.645729928005494e-08
its O 0 3.182754326758186e-08
role O 0 9.806920076016468e-08
in O 0 1.5733075287016618e-08
the O 0 1.2747789490674677e-08
coordinate O 0 3.7036556932434905e-07
expression O 0 8.356779801488301e-08
of O 0 2.160726708666516e-08
genes O 0 1.0262441207942175e-07
is O 0 2.075799443446158e-08
conserved O 0 1.4109485846347525e-07
between O 0 1.263257018990771e-07
mouse O 0 5.0991529860766605e-06
and O 0 2.302871990877975e-07
human O 0 1.6629667243250879e-07
, O 0 1.87589790812126e-07
and O 0 1.2042993091654353e-07
indicate O 0 1.982481023787841e-07
that O 0 1.4040687723593237e-08
the O 0 4.3516042325109083e-08
mouse O 0 3.775115374082816e-06
is O 0 4.585457347161537e-08
a O 0 6.828219767385235e-08
suitable O 0 1.8930351188828354e-06
model O 0 3.527150624904607e-07
system O 0 2.3130957060857327e-07
in O 0 2.3873857557532574e-08
which O 0 1.488239931290991e-08
to O 0 2.8785397176989136e-08
investigate O 0 4.2735459260256903e-07
the O 0 3.8147184966419445e-08
molecular O 0 2.0431707525858656e-06
mechanisms O 0 1.395695932160379e-07
of O 0 3.062156395117199e-08
imprinting O 0 1.9334402168169618e-05
in O 0 9.549332702363245e-08
this O 0 3.5119249730541924e-08
region O 0 1.540680898415303e-07
of O 0 2.8783805561261033e-08
the O 0 1.4835133299584413e-07
genome O 0 5.952146693743998e-06
. O 0 1.1204933798580896e-06
. O 0 6.3066722759685945e-06

Mutations O 0 0.0002794668835122138
of O 0 3.8835105442558415e-06
the O 0 2.2967731183598517e-06
ATM O 0 0.00013442733325064182
gene O 0 8.295151019410696e-06
detected O 0 6.662867690465646e-06
in O 0 5.808806804452615e-07
Japanese O 0 7.513140008086339e-05
ataxia B-Disease 1 0.9999814033508301
- I-Disease 1 0.9999735355377197
telangiectasia I-Disease 1 0.9999985694885254
patients O 0 0.24530334770679474
: O 0 1.3012707995585515e-06
possible O 0 1.7475871345595806e-06
preponderance O 0 5.585636245086789e-05
of O 0 1.9365717207620037e-07
the O 0 2.5100899847529945e-07
two O 0 6.083753305574646e-07
founder O 0 6.846549513284117e-05
mutations O 0 2.327991387574002e-05
4612del165 O 0 0.0001291359803872183
and O 0 4.594071924657328e-06
7883del5 O 0 0.000730416621081531
. O 0 2.001757275138516e-05

The O 0 4.322886888985522e-05
ATM O 0 0.0012301995884627104
( O 0 6.096738161431858e-06
A O 0 0.00014542802819050848
- O 1 0.9898143410682678
T O 1 0.9998169541358948
, O 0 1.2305554264457896e-06
mutated O 0 3.2936579827946844e-06
) O 0 1.5847359691179008e-07
gene O 0 6.061456474526494e-07
on O 0 3.588665435927396e-07
human O 0 3.2514635677216575e-06
chromosome O 0 0.0002780073555186391
11q22 O 0 0.0026987597811967134
. O 0 2.4575518182246014e-05

3 O 0 7.510275463573635e-05
has O 0 3.958905381296063e-06
recently O 0 5.752269771619467e-06
been O 0 3.594128372697014e-07
identified O 0 9.383222732139984e-07
as O 0 4.273268316978829e-08
the O 0 4.465254122010265e-08
gene O 0 5.860281930836209e-07
responsible O 0 4.5072295051795663e-07
for O 0 1.8867886808493495e-07
the O 0 7.662309826628189e-07
human O 0 9.956469148164615e-05
recessive B-Disease 1 0.9989092350006104
disease I-Disease 1 0.9990026354789734
ataxia B-Disease 1 0.999994158744812
- I-Disease 1 0.9999661445617676
telangiectasia I-Disease 1 0.9999860525131226
( O 0 3.134153666906059e-05
A B-Disease 0 0.002982867183163762
- I-Disease 1 0.9980290532112122
T I-Disease 1 0.9998481273651123
) O 0 6.978941200941335e-06
. O 0 1.0974097676808015e-05

In O 0 1.1087730854342226e-05
order O 0 2.5235747216356685e-06
to O 0 3.4770701518027636e-07
define O 0 1.056230303220218e-06
the O 0 1.3155688804999954e-07
types O 0 1.1963908264078782e-06
of O 0 1.0106601848747232e-06
disease O 0 0.0016856678994372487
- O 0 0.010176822543144226
causing O 0 5.770147981820628e-05
ATM O 0 0.00047346510109491646
mutations O 0 3.116946118097985e-06
in O 0 8.863803202530107e-08
Japanese O 0 1.3248585446490324e-06
A B-Disease 0 0.0004721302248071879
- I-Disease 1 0.9999244213104248
T I-Disease 1 0.9999985694885254
patients O 0 0.000396101240767166
as O 0 5.7041802392632235e-08
well O 0 9.549222568239202e-08
as O 0 2.454226333270526e-08
to O 0 3.709367391024898e-08
look O 0 4.6459206259896746e-07
for O 0 6.925173323679701e-08
possible O 0 7.670133186366002e-07
mutational O 0 0.0001358519948553294
hotspots O 0 3.12026240862906e-05
, O 0 3.9210652857946116e-07
reverse O 0 4.511759470915422e-06
- O 0 3.20874823955819e-05
transcribed O 0 1.1855826187456842e-06
RNA O 0 4.782375526701799e-07
derived O 0 7.104871713181637e-08
from O 0 5.360553956279546e-08
ten O 0 3.5113896501570707e-07
patients O 0 3.172096057824092e-06
belonging O 0 3.8608527574979234e-07
to O 0 6.59836132399505e-08
eight O 0 1.49530279713872e-07
unrelated O 0 2.5723268208821537e-06
Japanese O 0 3.5101115827274043e-06
A B-Disease 0 0.00028170726727694273
- I-Disease 1 0.999146580696106
T I-Disease 1 0.9999779462814331
families O 0 3.4594545468280558e-06
was O 0 2.973534378725162e-07
analyzed O 0 1.456963559576252e-06
for O 0 1.3328076420293655e-07
mutations O 0 1.0251666253680014e-06
by O 0 8.414407659529388e-08
the O 0 1.3745898286288138e-07
restriction O 0 1.85095439064753e-06
endonuclease O 0 0.00014375893806573004
fingerprinting O 0 0.00011070760956499726
method O 0 1.0117844794876873e-05
. O 0 1.2634555787371937e-05

As O 0 1.937770502991043e-05
has O 0 2.1883156477997545e-06
been O 0 3.8238908928178716e-07
reported O 0 1.21605205549713e-06
by O 0 2.28139512614689e-07
others O 0 6.962893621675903e-07
, O 0 3.133010579858819e-07
mutations O 0 7.807013844285393e-07
that O 0 2.9375820886912152e-08
lead O 0 2.414583661902725e-07
to O 0 1.106314542198561e-07
exon O 0 2.8864715204690583e-05
skipping O 0 3.1766270694788545e-05
or O 0 1.097875383493374e-06
premature O 0 4.9465455958852544e-05
protein O 0 4.947273737343494e-07
truncation O 0 3.74106775780092e-06
were O 0 1.4980746243509202e-07
also O 0 5.760948695865409e-08
predominant O 0 4.488330489493819e-07
in O 0 1.155702946675774e-07
our O 0 1.533952854515519e-06
mutants O 0 5.57713137823157e-05
. O 0 1.5004156921349932e-05

Six O 0 2.9685594199690968e-05
different O 0 3.86193869417184e-06
mutations O 0 1.757650898071006e-05
were O 0 4.502533670347475e-07
identified O 0 8.436679195256147e-07
on O 0 1.794063422266845e-07
12 O 0 1.84633933031364e-07
of O 0 6.703843524746844e-08
the O 0 1.7002759022943792e-07
16 O 0 1.7499553450761596e-06
alleles O 0 9.534192031424027e-06
examined O 0 4.3799816921819e-05
. O 0 1.6135501937242225e-05

Four O 0 2.334089185751509e-05
were O 0 2.706847453737282e-06
deletions O 0 2.1434601876535453e-05
involving O 0 7.493621978937881e-06
a O 0 2.3332379441853845e-06
loss O 0 1.435301783203613e-05
of O 0 1.8667837764496653e-07
a O 0 2.3185883435417054e-07
single O 0 9.058444447873626e-07
exon O 0 1.949912439158652e-05
exon O 0 2.2039936084183864e-05
7 O 0 1.2056661944370717e-06
, O 0 1.8636512777447933e-07
exon O 0 5.417505235527642e-06
16 O 0 3.985343539625319e-07
, O 0 2.399099514605041e-07
exon O 0 7.905357051640749e-06
33 O 0 2.6369921215518843e-06
or O 0 7.312445973184367e-07
exon O 0 2.535575367801357e-05
35 O 0 7.682456271140836e-06
. O 0 6.515217592095723e-06

The O 0 1.6304928067256697e-05
others O 0 4.411198005982442e-06
were O 0 3.4303496931897826e-07
minute O 0 1.2881199609182659e-06
deletions O 0 1.0694029697333463e-05
, O 0 5.387079227148206e-07
4649delA O 0 1.9028735550818965e-05
in O 0 1.5735272995698324e-07
exon O 0 8.517420610587578e-06
33 O 0 1.1350363138262765e-06
and O 0 2.032903410054132e-07
7883del5 O 0 2.5336221369798295e-05
in O 0 7.693664088037622e-07
exon O 0 5.681084803654812e-05
55 O 0 2.510626109142322e-05
. O 0 1.428336418030085e-05

The O 0 1.9173718101228587e-05
mutations O 0 5.608320498140529e-05
4612del165 O 0 0.0003728604642674327
and O 0 2.5000658752105664e-06
7883del5 O 0 0.00034183068783022463
were O 0 5.349145908439823e-07
found O 0 4.1302570252810256e-07
in O 0 3.6490806820665966e-08
more O 0 1.9185781852115724e-08
than O 0 3.967496908785506e-08
two O 0 5.055030882772371e-08
unrelated O 0 4.389183686726028e-06
families O 0 6.219649435479369e-07
; O 0 2.6585206569507136e-07
44 O 0 1.2057029152856558e-06
% O 0 1.0100929159762018e-07
( O 0 3.184533525768529e-08
7 O 0 8.946793883524151e-08
of O 0 2.03180974267525e-08
16 O 0 1.237395821362952e-07
) O 0 2.0477765261261993e-08
of O 0 9.372972620269593e-09
the O 0 2.8255193740278628e-08
mutant O 0 1.5643745427951217e-06
alleles O 0 8.085467015916947e-07
had O 0 8.752287072866238e-08
one O 0 1.8651693522997448e-08
of O 0 3.678724880273876e-08
the O 0 1.2857925923981384e-07
two O 0 8.552326562494272e-07
mutations O 0 2.1772888430859894e-05
. O 0 7.439868113578996e-06

The O 0 2.232145197922364e-05
4612del165 O 0 0.0018462312873452902
mutations O 0 5.129026249051094e-05
in O 0 4.5564598849523463e-07
three O 0 1.1789602893941264e-07
different O 0 8.007076957028403e-08
families O 0 2.377700099032154e-07
were O 0 4.230279415651239e-08
all O 0 1.531500970486377e-08
ascribed O 0 4.259573245235515e-07
to O 0 4.668384789852098e-08
the O 0 4.5698197226329285e-08
same O 0 2.1002568928452092e-07
T O 0 0.08884269744157791
- O 0 0.00025502880453132093
- O 0 0.00015372352208942175
> O 0 3.6983615245844703e-06
A O 0 5.3904514629721234e-08
substitution O 0 1.545631533872438e-07
at O 0 1.270584846224665e-07
the O 0 5.0461299139215043e-08
splice O 0 4.790943876287201e-06
donor O 0 2.0919360395055264e-06
site O 0 1.2676765663854894e-06
in O 0 4.900513204120216e-07
intron O 0 0.0011520577827468514
33 O 0 3.221524821128696e-05
. O 0 1.3269918781588785e-05

Microsatellite O 0 0.009413438849151134
genotyping O 0 0.00224088947288692
around O 0 9.83551399258431e-06
the O 0 1.283094320569944e-06
ATM O 0 8.045497088460252e-05
locus O 0 2.0814050003536977e-05
also O 0 5.987034228382981e-07
indicated O 0 2.3348650302068563e-06
that O 0 6.822335762990406e-08
a O 0 2.6812071496351564e-07
common O 0 1.318427962360147e-06
haplotype O 0 0.00011704662756528705
was O 0 6.70846077355236e-07
shared O 0 3.6282537507759116e-07
by O 0 8.921183081156414e-08
the O 0 9.073586682006862e-08
mutant O 0 6.545897122123279e-06
alleles O 0 2.1854125407116953e-06
in O 0 2.2643406794031762e-07
both O 0 9.87130533758318e-07
mutations O 0 3.441501030465588e-05
. O 0 9.523440894554369e-06

This O 0 7.972147614054848e-06
suggests O 0 1.1994355190836359e-05
that O 0 2.576554720690183e-07
these O 0 8.565797315895907e-08
two O 0 1.9896329206403607e-07
founder O 0 0.0001287202030653134
mutations O 0 1.9353550669620745e-05
may O 0 7.770135539431067e-07
be O 0 8.212764868176237e-08
predominant O 0 7.056542585814896e-07
among O 0 3.744762011592684e-07
Japanese O 0 2.8368922357913107e-06
ATM O 0 7.689579797443002e-05
mutant O 0 3.27207671944052e-05
alleles O 0 1.9525175957824104e-05
. O 0 9.178586878988426e-06

W474C O 0 0.0037524746730923653
amino O 0 5.9701753343688324e-05
acid O 0 2.0726620277855545e-05
substitution O 0 2.6301831894670613e-06
affects O 0 2.2609535790252266e-06
early O 0 3.588114623198635e-07
processing O 0 5.353825827114633e-07
of O 0 2.2400394428245818e-08
the O 0 2.0088050334265972e-08
alpha O 0 3.2113538850353507e-07
- O 0 6.039115305611631e-07
subunit O 0 1.9611977108979772e-07
of O 0 1.7117388395604394e-08
beta O 0 7.632729079887213e-07
- O 0 9.920484444592148e-06
hexosaminidase O 0 2.8907248633913696e-05
A O 0 1.553321311575928e-07
and O 0 8.649923444181695e-08
is O 0 1.0894931534721763e-07
associated O 0 8.622930636192905e-07
with O 0 3.2343671136914054e-06
subacute O 1 0.9955436587333679
G B-Disease 0 0.43163833022117615
( I-Disease 0 4.3383506636018865e-06
M2 I-Disease 0 0.003862992627546191
) I-Disease 0 2.977815483973245e-06
gangliosidosis I-Disease 0 0.0003332171472720802
. O 0 9.746437171997968e-06

Mutations O 0 0.0008454585331492126
in O 0 6.1157984418969136e-06
the O 0 2.7120565846416866e-06
HEXA O 0 0.025677762925624847
gene O 0 8.800126124697272e-06
, O 0 2.672127266123425e-07
encoding O 0 4.569497491502261e-07
the O 0 4.8870255398014706e-08
alpha O 0 5.426975917544041e-07
- O 0 5.785868211205525e-07
subunit O 0 2.7411749670136487e-07
of O 0 5.8178052597668284e-08
beta O 0 1.1834983979497338e-06
- O 0 4.175105641479604e-05
hexosaminidase O 0 5.9302514273440465e-05
A O 0 3.057966182495875e-07
( O 0 1.2661480752740317e-07
Hex O 0 3.368396392033901e-06
A O 0 1.328927794475021e-07
) O 0 3.548770877159768e-08
, O 0 3.57427190067483e-08
that O 0 2.1136184358283572e-08
abolish O 0 1.4617581882703234e-06
Hex O 0 4.71648263555835e-06
A O 0 1.7371441174418578e-07
enzyme O 0 8.647726872368366e-07
activity O 0 1.920659769893973e-06
cause O 0 0.00017878077051136643
Tay B-Disease 1 0.99998939037323
- I-Disease 1 0.9999525547027588
Sachs I-Disease 1 0.9999921321868896
disease I-Disease 0 0.09571970999240875
( O 0 9.617381238058442e-07
TSD B-Disease 0 0.07997337728738785
) O 0 3.5469173553792643e-07
, O 0 3.182927912348532e-07
the O 0 3.5361634331820824e-07
fatal O 0 0.006173527799546719
infantile B-Disease 0 0.0024405803997069597
form I-Disease 0 6.028176358086057e-07
of I-Disease 0 5.053686322753492e-07
G I-Disease 0 0.002936476143077016
( I-Disease 0 6.396497838068171e-07
M2 I-Disease 0 0.0007565012783743441
) I-Disease 0 3.2608616606921714e-07
gangliosidosis I-Disease 0 0.00015906288172118366
, I-Disease 0 4.997505698156601e-07
Type I-Disease 0 2.8788310828531394e-06
1 I-Disease 0 2.6770603653858416e-06
. O 0 5.128516932018101e-06

Less O 0 0.0009823996806517243
severe O 0 0.18680158257484436
, O 0 6.724719423800707e-05
subacute O 1 0.9978152513504028
( O 0 3.411963189137168e-05
juvenile O 1 0.9316352605819702
- O 1 0.8894585371017456
onset O 1 0.9554395079612732
) O 0 5.098049314256059e-06
and O 0 4.661954881157726e-05
chronic O 1 0.9739670753479004
( O 0 8.498212196172972e-07
adult O 0 2.1530193407670595e-05
- O 1 0.8369230031967163
onset O 0 0.46387502551078796
) O 0 4.782329483532521e-07
variants O 0 9.139168923866237e-07
are O 0 9.293616187733278e-08
characterized O 0 1.3689048046217067e-06
by O 0 5.983152817634618e-08
a O 0 1.788284578196908e-07
broad O 0 1.790727947081905e-05
spectrum O 0 1.3292639778228477e-05
of O 0 5.064894708084466e-07
clinical O 0 0.0002792487503029406
manifestations O 0 2.5051660486496985e-05
and O 0 5.694275841960916e-07
are O 0 1.0665044669622148e-07
associated O 0 6.046422527106188e-07
with O 0 1.8129432532987266e-07
residual O 0 4.727677514893003e-05
levels O 0 5.523510253624409e-07
of O 0 8.839727883014348e-08
Hex O 0 9.876043804979417e-06
A O 0 4.854852022617706e-07
enzyme O 0 3.014587036886951e-06
activity O 0 3.4958500236825785e-06
. O 0 4.940917278872803e-06

We O 0 2.3181484721135348e-05
identified O 0 1.0276471584802493e-05
a O 0 1.852298396443075e-06
1422 O 0 0.00043928809463977814
G O 0 0.0015245337272062898
- O 0 0.000894600641913712
- O 0 0.0014861368108540773
> O 0 0.00014030448801349849
C O 0 2.3930901079438627e-05
( O 0 6.186019874121484e-08
amino O 0 6.500005156340194e-08
acid O 0 1.0327121913178416e-07
W474C O 0 5.879583113710396e-07
) O 0 8.630046011148806e-09
substitution O 0 1.9511791293780334e-08
in O 0 7.232104692889152e-09
the O 0 8.455928401929214e-09
first O 0 1.8548242053384456e-08
position O 0 5.585598827906324e-08
of O 0 2.7061139107331655e-08
exon O 0 3.430575816310011e-06
13 O 0 2.5987148433159746e-07
of O 0 1.0766563462993872e-07
HEXA O 0 0.0005821358063258231
of O 0 8.60347313391685e-08
a O 0 2.3821897343623277e-07
non O 0 2.408866748737637e-06
- O 0 0.00015890145732555538
Jewish O 0 8.104086191451643e-06
proband O 0 0.005235748831182718
who O 0 1.4167358131089713e-06
manifested O 0 2.6927998533210484e-06
a O 0 1.233682269230485e-06
subacute O 0 0.3079375922679901
variant O 0 7.043645837256918e-06
of O 0 1.1026770607713843e-06
G B-Disease 0 0.03639787808060646
( I-Disease 0 4.2459641917957924e-06
M2 I-Disease 0 0.003672931343317032
) I-Disease 0 4.331773197918665e-06
gangliosidosis I-Disease 0 0.00042951948125846684
. O 0 1.3596940334537067e-05

On O 0 1.6181036698981188e-05
the O 0 2.038134425674798e-06
second O 0 3.469644298093044e-06
maternally O 0 0.0008305596420541406
inherited O 0 0.0011697387089952826
allele O 0 1.0101107363880146e-05
, O 0 5.847430202265969e-07
we O 0 3.2674111594133137e-07
identified O 0 6.290810574682837e-07
the O 0 1.341677489108406e-07
common O 0 1.538283504487481e-05
infantile O 1 0.9898191094398499
disease O 0 0.05154802277684212
- O 0 0.01913733221590519
causing O 0 1.747993883327581e-05
4 O 0 1.7002902268359321e-06
- O 0 2.4945096811279655e-05
bp O 0 9.531473551760428e-06
insertion O 0 3.7477527712326264e-06
, O 0 4.3519281689441414e-07
+ O 0 1.8619224647409283e-05
TATC O 0 0.0010507616680115461
1278 O 0 0.0004134908667765558
, O 0 5.550562036660267e-07
in O 0 4.917535534332274e-07
exon O 0 6.149476394057274e-05
11 O 0 7.2152265602198895e-06
. O 0 9.38724770094268e-06

Pulse O 0 0.001133267767727375
- O 0 0.00046479926095344126
chase O 0 5.1914918003603816e-05
analysis O 0 2.6173643163929228e-06
using O 0 1.4346612715598894e-06
proband O 0 0.0002190525847254321
fibroblasts O 0 6.034350735717453e-05
revealed O 0 4.9962800403591245e-06
that O 0 9.430647196495556e-08
the O 0 1.2002038829450612e-07
W474C O 0 1.747080750647001e-05
- O 0 3.3958901894948212e-06
containing O 0 2.3185022257621313e-07
alpha O 0 3.663241159301833e-07
- O 0 1.4459824342338834e-06
subunit O 0 4.30201424705956e-07
precursor O 0 2.1227820923286345e-07
was O 0 4.453915636304373e-08
normally O 0 6.613078085138113e-08
synthesized O 0 1.285768007619481e-07
, O 0 2.2738616323181304e-08
but O 0 1.1814427658407567e-08
not O 0 1.2508213131923185e-08
phosphorylated O 0 4.0830764191923663e-07
or O 0 2.7181981110402376e-08
secreted O 0 2.0259824395907344e-07
, O 0 3.99030959385982e-08
and O 0 3.837999784650492e-08
the O 0 6.120519202568175e-08
mature O 0 2.04469142772723e-06
lysosomal O 0 6.125486106611788e-05
alpha O 0 1.3674421097675804e-06
- O 0 5.756451628258219e-06
subunit O 0 1.8240352801512927e-06
was O 0 3.1666598943047575e-07
not O 0 3.3470271887381386e-07
detected O 0 5.3062394727021456e-06
. O 0 3.7118097679922357e-06

When O 0 1.6633182895020582e-05
the O 0 1.6714953972041258e-06
W474C O 0 7.379345333902165e-05
- O 0 8.975139280664735e-06
containing O 0 4.253650445207313e-07
alpha O 0 7.480039130314253e-07
- O 0 1.8692114736040821e-06
subunit O 0 5.242202973931853e-07
was O 0 1.0990479637484896e-07
transiently O 0 6.17232308286475e-06
co O 0 4.0702025216887705e-06
- O 0 8.115765012917109e-06
expressed O 0 5.1153886460042486e-08
with O 0 1.4810699333622779e-08
the O 0 1.5406742548407237e-08
beta O 0 3.19388362868267e-07
- O 0 1.3606685342892888e-06
subunit O 0 3.147190170693648e-07
to O 0 2.7713552341879222e-08
produce O 0 1.9721416322227014e-07
Hex O 0 2.216702796431491e-06
A O 0 7.351869868443828e-08
( O 0 5.980973583064042e-08
alphabeta O 0 1.391869955114089e-05
) O 0 4.2734885852269144e-08
in O 0 5.172539019326905e-08
COS O 0 0.00033344054827466607
- O 0 0.00010157674114452675
7 O 0 1.7376340792907286e-06
cells O 0 7.710455065534916e-07
, O 0 2.3234596469023927e-08
the O 0 1.2756959044679661e-08
mature O 0 1.9395842798530794e-07
alpha O 0 2.567963974797749e-07
- O 0 1.2312505077716196e-06
subunit O 0 3.4172072105320694e-07
was O 0 8.498230386067007e-08
present O 0 4.8574548827673425e-08
, O 0 4.306972556378241e-08
but O 0 2.1795891314013716e-08
its O 0 1.5208904358132713e-08
level O 0 5.3650239806302125e-08
was O 0 2.7758096265984022e-08
much O 0 5.032192973430938e-08
lower O 0 4.9648275535219e-07
than O 0 1.9049988253527772e-08
that O 0 5.664062996402208e-09
from O 0 9.827307856369316e-09
normal O 0 7.300211279925861e-08
alpha O 0 3.063027236294147e-07
- O 0 1.4304876003734535e-06
subunit O 0 5.862685270585644e-07
transfections O 0 1.7663500329945236e-05
, O 0 9.153756508339939e-08
although O 0 3.589643782220264e-08
higher O 0 5.370839772922409e-08
than O 0 2.1452086329531994e-08
in O 0 3.0286695817949294e-08
those O 0 1.0582351706034387e-07
cells O 0 2.092021986754844e-06
transfected O 0 2.7535690605873242e-05
with O 0 6.777499095278472e-08
an O 0 3.349606814140316e-08
alpha O 0 1.4295152368504205e-06
- O 0 1.4372836631082464e-05
subunit O 0 4.1137641346722376e-06
associated O 0 1.5468096989934565e-06
with O 0 2.0435645637917332e-06
infantile O 0 0.05445418506860733
TSD B-Disease 1 0.6502799391746521
. O 0 5.047466038377024e-05

Furthermore O 0 0.00015196041204035282
, O 0 4.602290118782548e-06
the O 0 5.634433932755201e-07
precursor O 0 1.6128019524330739e-06
level O 0 2.530389906496566e-07
of O 0 4.325034197449895e-08
the O 0 7.028221205018781e-08
W474C O 0 2.550710632931441e-06
alpha O 0 5.247875947134162e-07
- O 0 1.1513503750393284e-06
subunit O 0 3.8269476476671116e-07
was O 0 6.784794237546521e-08
found O 0 4.99221357586066e-08
to O 0 3.964629868846714e-08
accumulate O 0 1.0431114787934348e-05
in O 0 4.77229704642923e-08
comparison O 0 2.8305689170338155e-07
to O 0 2.2518026554507742e-08
the O 0 2.1045432063715452e-08
normal O 0 1.9009414131687663e-07
alpha O 0 1.2173783261459903e-06
- O 0 4.612510110746371e-06
subunit O 0 2.695276407393976e-06
precursor O 0 3.915313754987437e-06
levels O 0 2.5098436253756518e-06
. O 0 3.207719146303134e-06

We O 0 2.4411916456301697e-05
conclude O 0 1.7303898857790045e-05
that O 0 4.6919424789848563e-07
the O 0 3.755863815513294e-07
1422 O 0 0.00046827204641886055
G O 0 0.0038285767659544945
- O 0 0.002441158751025796
- O 0 0.03747723996639252
> O 0 0.0007160938694141805
C O 0 0.0003129536926280707
mutation O 0 1.45307410548412e-06
is O 0 3.6288898996872376e-08
the O 0 4.972892853061239e-08
cause O 0 5.597020162895205e-07
of O 0 1.0943644923600004e-07
Hex B-Disease 0 0.0005912731285206974
A I-Disease 0 8.313240687130019e-05
enzyme I-Disease 1 0.9884459972381592
deficiency I-Disease 1 0.9972875118255615
in O 0 4.85087696233677e-07
the O 0 1.5654371736673056e-06
proband O 0 0.007009491324424744
. O 0 2.1185613150009885e-05

The O 0 1.704131682345178e-05
resulting O 0 3.464188557700254e-05
W474C O 0 0.00010186268627876416
substitution O 0 4.386664386402117e-06
clearly O 0 2.0324491742940154e-06
interferes O 0 3.504796268316568e-06
with O 0 1.3859681757821818e-07
alpha O 0 8.784277270024177e-07
- O 0 1.5289813291019527e-06
subunit O 0 4.4791286768486316e-07
processing O 0 5.708108119506505e-07
, O 0 8.513967486578622e-08
but O 0 4.347248605540699e-08
because O 0 3.935135239885312e-08
the O 0 1.7668432050754745e-08
base O 0 3.1574202807860274e-07
substitution O 0 5.019577997700253e-07
falls O 0 1.3975987712910865e-05
at O 0 8.754674496458392e-08
the O 0 1.6698107785373395e-08
first O 0 2.138557597675117e-08
position O 0 5.1024869662796846e-08
of O 0 3.556726113629338e-08
exon O 0 4.890348918706877e-06
13 O 0 2.5923881707967666e-07
, O 0 1.1442556058227638e-07
aberrant O 0 3.3846513360913377e-06
splicing O 0 4.121763595321681e-06
may O 0 4.7044522943906486e-07
also O 0 4.408235199093724e-08
contribute O 0 1.8925211975329148e-07
to O 0 2.627069477512123e-07
Hex B-Disease 0 0.0005874349153600633
A I-Disease 0 0.00014394739991985261
deficiency I-Disease 0 0.2613104581832886
in O 0 2.378605046260418e-07
this O 0 3.7191190926932904e-07
proband O 0 0.0015516673447564244
. O 0 2.816125515892054e-06
. O 0 6.85703662384185e-06

Two O 0 0.00013611769827548414
frequent O 0 0.00046645483234897256
missense O 0 0.0272454172372818
mutations O 0 0.015583888627588749
in O 0 0.0017983227735385299
Pendred B-Disease 1 0.9999868869781494
syndrome I-Disease 1 0.9999916553497314
. O 0 0.00036491380888037384

Pendred B-Disease 1 0.9999933242797852
syndrome I-Disease 1 0.9999986886978149
is O 0 0.01907981187105179
an O 0 0.37076935172080994
autosomal B-Disease 1 0.9999984502792358
recessive I-Disease 1 0.9999997615814209
disorder I-Disease 1 0.9999998807907104
characterized O 0 0.4598185420036316
by O 0 5.3384464990813285e-05
early O 0 0.007662240415811539
childhood O 1 0.9996945858001709
deafness B-Disease 1 0.999998927116394
and O 1 0.7551447153091431
goiter B-Disease 1 0.9999982118606567
. O 0 0.0011468115262687206

A O 0 2.5278930479544215e-05
century O 0 5.639828032144578e-06
after O 0 1.8343887404626003e-06
its O 0 4.968162556906464e-07
recognition O 0 9.308923267781211e-07
as O 0 5.039286747887672e-07
a O 0 1.1710781109286472e-05
syndrome O 1 0.6972522735595703
by O 0 4.59513216810592e-07
Vaughan O 0 0.0007600680692121387
Pendred O 0 0.01365472748875618
, O 0 9.548090247335494e-07
the O 0 1.6177714314835612e-06
disease O 0 0.0002978056436404586
gene O 0 3.5428640785539756e-06
( O 0 1.2743968227368896e-06
PDS O 0 0.0004932934534735978
) O 0 2.3919284330986557e-07
was O 0 3.122028147117817e-07
mapped O 0 4.5057568058837205e-06
to O 0 5.717130306948093e-07
chromosome O 0 6.0180584114277735e-05
7q22 O 0 0.0006718669319525361
- O 0 0.0011880039237439632
q31 O 0 0.0009781905682757497
. O 0 1.735461592033971e-05

1 O 0 5.35637118446175e-05
and O 0 5.943576070421841e-06
, O 0 2.3703969418420456e-06
recently O 0 3.6691151308332337e-06
, O 0 2.80611317293733e-07
found O 0 1.6087943777165492e-07
to O 0 7.356035780503589e-08
encode O 0 1.6704181007298757e-06
a O 0 3.449683163125883e-06
putative O 0 0.0015471420483663678
sulfate O 0 0.04185939580202103
transporter O 0 0.009996170178055763
. O 0 2.9410151910269633e-05

We O 0 2.5177569114021026e-05
performed O 0 9.685652912594378e-06
mutation O 0 2.8652291348407743e-06
analysis O 0 4.373233934984455e-07
of O 0 9.281534829597149e-08
the O 0 3.5992974289911217e-07
PDS B-Disease 0 0.0020885514095425606
gene O 0 1.0409630704089068e-05
in O 0 1.42177907491714e-06
patients O 0 3.989003744209185e-05
from O 0 1.9204202317268937e-07
14 O 0 1.6537148894713027e-06
Pendred B-Disease 0 0.001131769153289497
families O 0 4.7109892875596415e-07
originating O 0 1.426605962251415e-07
from O 0 4.9880920727218836e-08
seven O 0 1.2310972863360803e-07
countries O 0 5.8695778903938844e-08
and O 0 2.750229555203987e-07
identified O 0 1.0693139529394102e-06
all O 0 4.371995032670384e-07
mutations O 0 2.5462322810199112e-05
. O 0 6.3535426306771114e-06

The O 0 3.330916297272779e-05
mutations O 0 0.0001074073079507798
include O 0 2.5879492113745073e-06
three O 0 3.6281949178373907e-07
single O 0 6.034941293364682e-07
base O 0 2.164279749194975e-06
deletions O 0 1.1102713870059233e-05
, O 0 2.955330842269177e-07
one O 0 1.6706572125713137e-07
splice O 0 2.017776387219783e-05
site O 0 4.92572098664823e-06
mutation O 0 2.9171385449444642e-06
and O 0 5.152216431270062e-07
10 O 0 3.6594353787222644e-06
missense O 0 0.00023778146714903414
mutations O 0 4.041565262014046e-05
. O 0 1.3945299542683642e-05

One O 0 7.281516445800662e-05
missense O 0 0.0027177806477993727
mutation O 0 7.59569593355991e-05
( O 0 1.975559371203417e-06
L236P O 0 8.977233665063977e-05
) O 0 1.9365347725397442e-07
was O 0 2.2662891296931775e-07
found O 0 1.4085917143802362e-07
in O 0 4.0405200962823073e-08
a O 0 1.9413867846651556e-07
homozygous O 0 1.9137264644086827e-06
state O 0 9.606017670193978e-08
in O 0 5.379461498478122e-08
two O 0 1.1405730759861399e-07
consanguineous O 0 0.0038078969810158014
families O 0 1.5782476339154528e-06
and O 0 2.103833196542837e-07
in O 0 1.2569250884553185e-07
a O 0 2.9741411822215014e-07
heterozygous O 0 1.5679802345403004e-06
state O 0 1.0469022981851595e-07
in O 0 2.963593637161921e-08
five O 0 8.805886864138301e-08
additional O 0 5.213476015342167e-07
non O 0 1.0072712029796094e-05
- O 0 0.018924396485090256
consanguineous O 0 0.190565288066864
families O 0 5.6740580475889146e-05
. O 0 2.7372265321901068e-05

Another O 0 0.00017323331849183887
missense O 0 0.00687699019908905
mutation O 0 0.00015152721607591957
( O 0 2.8110650873713894e-06
T416P O 0 0.00017714906425680965
) O 0 4.284245278540766e-07
was O 0 3.8119262057989545e-07
found O 0 1.7264881080336636e-07
in O 0 3.1837441127891e-08
a O 0 1.201520944960066e-07
homozygous O 0 1.8474330545359408e-06
state O 0 1.1949001077482535e-07
in O 0 7.016139846882652e-08
one O 0 7.708074178935931e-08
family O 0 5.400432883106987e-07
and O 0 8.979549193099956e-08
in O 0 5.70166704960684e-08
a O 0 1.507007425516349e-07
heterozygous O 0 9.672837677499047e-07
state O 0 1.382775991487506e-07
in O 0 1.510590408315693e-07
four O 0 7.441326488333289e-07
families O 0 6.547145858348813e-06
. O 0 8.744043952901848e-06

Pendred B-Disease 1 0.993471622467041
patients O 0 0.2113335132598877
in O 0 3.875445145240519e-06
three O 0 1.371550979456515e-06
non O 0 2.6271591195836663e-05
- O 0 0.035950131714344025
consanguineous O 0 0.28937751054763794
families O 0 3.222239911337965e-06
were O 0 1.7943938246389735e-07
shown O 0 2.4750426064201747e-07
to O 0 9.20693423722696e-08
be O 0 1.1712523217966009e-07
compound O 0 3.599387127906084e-06
heterozygotes O 0 1.633156898606103e-05
for O 0 6.941345986888336e-07
L236P O 0 0.00017572680371813476
and O 0 3.1748654691909906e-06
T416P O 0 0.0003331539046484977
. O 0 1.2450321264623199e-05

In O 0 8.775612514000386e-06
total O 0 2.2274532511801226e-06
, O 0 4.3955995465694286e-07
one O 0 6.458186163627033e-08
or O 0 7.914545818721308e-08
both O 0 1.5803601982611326e-08
of O 0 1.4845062068502557e-08
these O 0 3.7189451518315764e-08
mutations O 0 6.589023087144597e-07
were O 0 5.765598487528223e-08
found O 0 8.207629065282163e-08
in O 0 2.654461361828453e-08
nine O 0 4.3523591841676534e-08
of O 0 3.728860420437741e-08
the O 0 1.049511340056597e-07
14 O 0 1.419697923665808e-06
families O 0 2.986632125612232e-06
analyzed O 0 1.8557975636213087e-05
. O 0 9.043563295563217e-06

The O 0 7.1975509854382835e-06
identification O 0 6.510937964776531e-06
of O 0 3.853183443425223e-07
two O 0 7.491047426810837e-07
frequent O 0 1.2268794307601638e-05
PDS B-Disease 0 0.008620794862508774
mutations O 0 4.7085823098313995e-06
will O 0 2.1682181738924555e-07
facilitate O 0 1.2652357099796063e-06
the O 0 1.1287646657365258e-06
molecular O 0 0.004306933376938105
diagnosis O 1 0.8177332878112793
of O 0 0.009212369099259377
Pendred B-Disease 1 0.9999972581863403
syndrome I-Disease 1 0.9999940395355225
. O 0 0.00018035169341601431

Insertional O 0 0.12502434849739075
mutation O 0 0.0005137291736900806
by O 0 1.3544459761760663e-05
transposable O 0 0.0007178220548667014
element O 0 1.3899054465582594e-05
, O 0 3.1449985726794694e-06
L1 O 0 0.0003409961354918778
, O 0 3.339502541166439e-07
in O 0 1.3529806608403305e-07
the O 0 3.4447018038008537e-07
DMD B-Disease 1 0.9939292669296265
gene O 0 2.398569449724164e-06
results O 0 1.1996629609711817e-06
in O 0 9.583961855241796e-07
X B-Disease 1 0.552312970161438
- I-Disease 1 0.9896752238273621
linked I-Disease 1 0.6204553842544556
dilated I-Disease 1 0.9984472393989563
cardiomyopathy I-Disease 1 0.9998326301574707
. O 0 9.356790542369708e-05

X B-Disease 1 0.7146157622337341
- I-Disease 1 0.8166914582252502
linked I-Disease 1 0.5764275789260864
dilated I-Disease 1 0.999704897403717
cardiomyopathy I-Disease 1 0.9999914169311523
( O 0 2.7974503609584644e-05
XLDCM B-Disease 0 0.3234386146068573
) O 0 6.921369504198083e-07
is O 0 1.9396028960727563e-07
a O 0 4.427228077474865e-07
clinical O 0 7.882675708970055e-05
phenotype O 0 2.4914737878134474e-05
of O 0 3.97997297341135e-07
dystrophinopathy B-Disease 0 0.016294794157147408
which O 0 4.4080633188059437e-07
is O 0 2.4679528110027604e-07
characterized O 0 6.451503395510372e-06
by O 0 1.2063343319823616e-06
preferential O 0 0.0007364162593148649
myocardial B-Disease 1 0.998714804649353
involvement I-Disease 0 4.29721076216083e-05
without O 0 6.842521429462067e-07
any O 0 4.39072692870468e-07
overt O 0 3.8964906707406044e-05
clinical O 0 0.00503655057400465
signs O 0 0.0003616531321313232
of O 0 0.000660615274682641
skeletal B-Disease 1 0.9999834299087524
myopathy I-Disease 1 0.9999948740005493
. O 0 0.0005606867489404976

To O 0 9.32806415221421e-06
date O 0 8.62281012814492e-06
, O 0 7.664407917218341e-07
several O 0 2.4556061362090986e-07
mutations O 0 2.020191686824546e-06
in O 0 3.3684304412417987e-07
the O 0 6.541946731886128e-06
Duchenne B-Disease 1 0.9999667406082153
muscular I-Disease 1 0.9996966123580933
dystrophy I-Disease 1 0.9982088804244995
gene O 0 0.0005145947216078639
, O 0 0.00010084662062581629
DMD O 1 0.9999778270721436
, O 0 7.137767170206644e-06
have O 0 2.503685152532853e-07
been O 0 3.5874063541996293e-07
identified O 0 5.013539521314669e-06
in O 0 1.1136784223708673e-06
patients O 0 4.9136779125547037e-05
with O 0 4.609435677593865e-07
XLDCM B-Disease 1 0.5727135539054871
, O 0 1.4652670188297634e-06
but O 0 1.222468881678651e-07
a O 0 9.818374735459656e-08
pathogenic O 0 3.1011910550660104e-07
correlation O 0 1.5444703649336589e-07
of O 0 2.4668603160193925e-08
these O 0 9.61648467523446e-08
cardiospecific O 0 0.0017363870283588767
mutations O 0 1.825898107199464e-05
in O 0 7.81666926741309e-07
DMD O 1 0.9963071346282959
with O 0 6.461352199949033e-07
the O 0 1.7950731034943601e-06
XLDCM B-Disease 1 0.7624449133872986
phenotype O 0 0.0002976875694002956
has O 0 6.19815580193972e-07
remained O 0 1.5702936480010976e-06
to O 0 2.3424473738486995e-07
be O 0 7.383150091300195e-07
elucidated O 0 6.227421545190737e-05
. O 0 1.48384960994008e-05

We O 0 2.8569331334438175e-05
report O 0 5.3945727813697886e-06
here O 0 4.8967666543831e-07
the O 0 6.850461176099998e-08
identification O 0 4.89275237214315e-07
of O 0 8.066014345331496e-08
a O 0 3.9547518326799036e-07
unique O 0 8.588198738834762e-07
de O 0 1.4870807717670687e-05
novo O 0 1.6536374459974468e-05
L1 O 0 7.290124631254002e-05
insertion O 0 3.352954763613525e-06
in O 0 1.7562705068030482e-07
the O 0 1.0671373473769563e-07
muscle O 0 7.240274953801418e-06
exon O 0 2.1574258425971493e-05
1 O 0 1.749818352436705e-06
in O 0 6.90172726081073e-07
DMD O 1 0.9864857196807861
in O 0 3.39014547989791e-07
three O 0 1.4393701803783188e-06
XLDCM B-Disease 1 0.9679592847824097
patients O 0 0.00036395262577570975
from O 0 2.4917630980780814e-07
two O 0 4.131352113745379e-07
unrelated O 0 2.7633021090878174e-05
Japanese O 0 1.247893123945687e-05
families O 0 1.7370992281939834e-05
. O 0 1.665599484113045e-05

The O 0 1.0135652701137587e-05
insertion O 0 3.141844354104251e-05
was O 0 1.207260766022955e-06
a O 0 6.85226439145481e-07
5 O 0 1.1036428304578294e-06
- O 0 3.340778130223043e-05
truncated O 0 2.4087357815005817e-06
form O 0 5.0131195195035616e-08
of O 0 3.324389297176822e-08
human O 0 2.7202111141377827e-07
L1 O 0 7.800719322403893e-05
inversely O 0 1.3322614904609509e-05
integrated O 0 2.9065997750876704e-06
in O 0 6.600475899176672e-08
the O 0 6.63027961422813e-08
5 O 0 4.0085421915136976e-07
- O 0 6.409311754396185e-05
untranslated O 0 8.617969433544204e-05
region O 0 3.575581786208204e-07
in O 0 4.752459048518176e-08
the O 0 4.8720597334295235e-08
muscle O 0 2.4997464151965687e-06
exon O 0 1.1062033081543632e-05
1 O 0 5.101679221297672e-07
, O 0 7.976286298116975e-08
which O 0 1.8460783124396585e-08
affected O 0 7.97814223574278e-08
the O 0 1.8292750425530357e-08
transcription O 0 3.4228040135531046e-07
or O 0 7.388518241668862e-08
the O 0 3.5715935098323826e-08
stability O 0 1.9552777530407184e-07
of O 0 4.469855596767047e-08
the O 0 1.4395264713584766e-07
muscle O 0 6.497936283267336e-06
form O 0 6.141440422879896e-08
of O 0 1.2808847316136962e-07
dystrophin O 0 0.00015467411139979959
transcripts O 0 8.020028872124385e-06
but O 0 2.2823743961453147e-07
not O 0 1.9001616280434064e-08
that O 0 1.0799631411373412e-08
of O 0 2.3164639983974666e-08
the O 0 2.9228507969492057e-07
brain O 0 0.001100216875784099
or O 0 1.924735897773644e-06
Purkinje O 0 0.12533211708068848
cell O 0 0.00017856681370176375
form O 0 5.515104248843272e-07
, O 0 3.806266306582984e-07
probably O 0 5.266034008855058e-07
due O 0 1.4185717134296283e-07
to O 0 2.8874975299686412e-08
its O 0 6.497290172546855e-08
unique O 0 1.6457116203127953e-07
site O 0 6.373018663907715e-07
of O 0 1.905422664094658e-07
integration O 0 1.7361087884637527e-05
. O 0 1.0779919648484793e-05

We O 0 1.940637048392091e-05
speculate O 0 2.7457548640086316e-05
that O 0 3.0419394647651643e-07
this O 0 9.693313529623993e-08
insertion O 0 1.5177222394413548e-06
of O 0 9.071960249684707e-08
an O 0 1.5321765545195376e-07
L1 O 0 9.640106873121113e-05
sequence O 0 9.463492460781708e-07
in O 0 7.155612138376455e-07
DMD O 1 0.9898253083229065
is O 0 2.673455412605108e-07
responsible O 0 4.7525224999844795e-07
for O 0 4.767129979654783e-08
some O 0 1.7530803475551693e-08
of O 0 1.9345774759926826e-08
the O 0 4.7170761519055304e-08
population O 0 3.401316917006625e-08
of O 0 7.600377216476772e-08
Japanese O 0 1.8711660231929272e-05
patients O 0 0.00014080239634495229
with O 0 2.456941729178652e-06
XLDCM B-Disease 0 0.18943031132221222
. O 0 4.183797955192858e-06
. O 0 1.0112153177033179e-05

Severe O 0 0.15025091171264648
early O 0 0.0008974744123406708
- O 1 0.9968574047088623
onset O 1 0.9999250173568726
obesity B-Disease 1 0.9999934434890747
, O 0 0.30271220207214355
adrenal B-Disease 1 0.9999974966049194
insufficiency I-Disease 1 0.9999945163726807
and O 0 0.00012218415213283151
red O 0 0.014779546298086643
hair O 1 0.7775015234947205
pigmentation O 1 0.6572687029838562
caused O 0 0.0001041380237438716
by O 0 1.6901673006941564e-05
POMC O 1 0.9733894467353821
mutations O 0 7.806806388543919e-05
in O 0 1.7040644024746143e-06
humans O 0 8.127437467919663e-06
. O 0 1.7186966942972504e-05

Sequential O 0 0.00018631972488947213
cleavage O 0 0.0008405019179917872
of O 0 1.2369101796139148e-06
the O 0 4.956936550115643e-07
precursor O 0 3.584188789318432e-06
protein O 0 1.2664320365729509e-06
pre O 0 2.0995867089368403e-05
- O 0 9.764638525666669e-05
pro O 0 2.437065268168226e-05
- O 0 0.00043013287358917296
opiomelanocortin O 0 0.0008895111386664212
( O 0 3.98921457644974e-07
POMC O 0 6.633696466451511e-05
) O 0 7.827532755300126e-08
generates O 0 2.3825599271276587e-07
the O 0 9.271167300539673e-08
melanocortin O 0 0.00016328616766259074
peptides O 0 6.977178145461949e-06
adrenocorticotrophin O 0 0.00011591249494813383
( O 0 2.752730381416768e-07
ACTH O 0 1.4272227417677641e-05
) O 0 9.524938349159129e-08
, O 0 1.1132149779768952e-07
melanocyte O 0 0.00011808077397290617
- O 0 5.481870539369993e-05
stimulating O 0 1.613011772860773e-05
hormones O 0 2.0021873297082493e-06
( O 0 2.8914112704114814e-07
MSH O 0 6.976364966249093e-05
) O 0 6.136124142130939e-08
alpha O 0 3.0437561804319557e-07
, O 0 4.801724529102103e-08
beta O 0 1.9754169500174612e-07
and O 0 2.4182888580526196e-08
gamma O 0 3.1616326623407076e-07
as O 0 1.4474840881462114e-08
well O 0 1.4192598207785068e-08
as O 0 1.7701962562455265e-08
the O 0 3.573821771851726e-08
opioid O 0 3.3452797651989385e-05
- O 0 6.550285615958273e-05
receptor O 0 1.2570221770147327e-05
ligand O 0 1.2622826034203172e-05
beta O 0 1.911163235490676e-05
- O 0 0.00012744319974444807
endorphin O 0 0.0009666037512943149
. O 0 1.1232751603529323e-05

While O 0 2.8783295419998467e-05
a O 0 3.2688340070308186e-06
few O 0 1.4615852705901489e-06
cases O 0 1.2586358479893534e-06
of O 0 2.976534915433149e-06
isolated O 1 0.6871842741966248
ACTH B-Disease 1 0.9999256134033203
deficiency I-Disease 1 0.9986635446548462
have O 0 4.850159598390746e-07
been O 0 6.071256848372286e-07
reported O 0 4.71517432742985e-06
( O 0 1.0908609056059504e-06
OMIM O 0 0.24980132281780243
201400 O 0 0.0011265063658356667
) O 0 3.122698331026186e-07
, O 0 3.4670799209379766e-07
an O 0 5.04181969063211e-07
inherited O 0 0.1583961546421051
POMC O 1 0.9981487989425659
defect O 0 0.09405161440372467
has O 0 5.150153015165415e-07
not O 0 1.3282030408845458e-07
been O 0 2.6757200544125226e-07
described O 0 4.134661139687523e-06
so O 0 9.852964240053552e-07
far O 0 5.311013410391752e-06
. O 0 8.844364856486209e-06

Recent O 0 8.524808072252199e-05
studies O 0 1.1392970918677747e-05
in O 0 9.379930361319566e-07
animal O 0 1.8527364318288164e-06
models O 0 5.314423560776049e-06
elucidated O 0 1.3023351129959337e-05
a O 0 2.6235517225359217e-07
central O 0 9.904596254273201e-08
role O 0 6.284442832793502e-08
of O 0 3.793806513385789e-08
alpha O 0 2.635827968333615e-06
- O 0 0.000596867292188108
MSH O 0 0.0012313202023506165
in O 0 5.7928694729980634e-08
the O 0 3.203724219247306e-08
regulation O 0 2.2937385324439674e-07
of O 0 5.67852858068818e-08
food O 0 3.755720854314859e-07
intake O 0 5.687199404746934e-07
by O 0 3.5906708717448055e-08
activation O 0 2.3105427260361466e-07
of O 0 4.491323579713935e-08
the O 0 1.7460067169849935e-07
brain O 0 3.391567224753089e-05
melanocortin O 0 0.0006951393443159759
- O 0 4.4956581405131146e-05
4 O 0 1.323358333138458e-06
- O 0 3.994363942183554e-05
receptor O 0 2.7747116746468237e-06
( O 0 1.6559701521146053e-07
MC4 O 0 0.0006471406668424606
- O 0 9.372847125632688e-05
R O 0 0.00015590502880513668
; O 0 1.7428956766707415e-07
refs O 0 1.152179493146832e-06
3 O 0 2.688932738692529e-07
- O 0 8.894692655303515e-06
5 O 0 1.3401198373230727e-07
) O 0 1.4891770483416167e-08
and O 0 1.3416846300629004e-08
the O 0 1.2195201293252467e-08
linkage O 0 3.7069983704896003e-07
of O 0 7.178318384148952e-08
human O 0 2.694785507628694e-06
obesity B-Disease 0 0.4208913743495941
to O 0 2.7003116542800853e-07
chromosome O 0 8.453063855995424e-06
2 O 0 3.2095596225190093e-07
in O 0 6.333152668958064e-08
close O 0 5.527710413844034e-07
proximity O 0 5.988976568005455e-07
to O 0 5.5618489369635427e-08
the O 0 1.2868819965206058e-07
POMC O 0 0.0006453545647673309
locus O 0 4.829748377233045e-06
, O 0 1.5759164284645522e-07
led O 0 2.0012296886307013e-07
to O 0 3.5258718611430595e-08
the O 0 4.154293975489054e-08
proposal O 0 4.69348663045821e-07
of O 0 4.6659632602086276e-08
an O 0 5.97309579575267e-08
association O 0 6.346514282995486e-07
of O 0 8.329932370543247e-07
POMC O 1 0.9050288200378418
with O 0 1.2030189282086212e-05
human O 0 7.94804873294197e-05
obesity B-Disease 1 0.9911118149757385
. O 0 6.826748722232878e-05

The O 0 1.0825929166458081e-05
dual O 0 6.939671493455535e-06
role O 0 1.2400992090988439e-06
of O 0 2.6329436764171987e-07
alpha O 0 1.1140577953483444e-05
- O 0 0.00021153048146516085
MSH O 0 0.0007262933067977428
in O 0 1.786655161595263e-07
regulating O 0 1.5818369547559996e-06
food O 0 5.954270818619989e-07
intake O 0 9.111677741202584e-07
and O 0 1.483714129335567e-07
influencing O 0 4.281608653400326e-06
hair O 0 0.0017402262892574072
pigmentation O 0 0.002941757906228304
predicts O 0 0.0008007624419406056
that O 0 1.3908223195358005e-07
the O 0 2.386628352724074e-07
phenotype O 0 0.00011180543515365571
associated O 0 1.6621581835352117e-06
with O 0 3.636130827544548e-07
a O 0 5.786878318758681e-06
defect O 0 0.016148462891578674
in O 0 6.126442144704924e-07
POMC O 0 0.05609838664531708
function O 0 9.340812994196313e-07
would O 0 3.762715152788587e-07
include O 0 1.2475755283958279e-05
obesity B-Disease 1 0.9949199557304382
, O 0 5.727789357479196e-06
alteration O 0 0.00014978554099798203
in O 0 5.2668951866508e-06
pigmentation O 1 0.634039044380188
and O 0 0.006795976776629686
ACTH B-Disease 1 0.9998788833618164
deficiency I-Disease 1 0.9988549947738647
. O 0 5.842304744874127e-05

The O 0 1.096925279853167e-05
observation O 0 2.8541666324599646e-05
of O 0 1.4854515484330477e-06
these O 0 1.3919622006142163e-06
symptoms O 0 0.00017730738909449428
in O 0 1.2479573285872902e-07
two O 0 2.0630196218007768e-07
probands O 0 0.0015398639952763915
prompted O 0 3.386750222489354e-06
us O 0 1.767727155765897e-07
to O 0 5.831603289152554e-08
search O 0 4.86017995626753e-07
for O 0 1.807862020086759e-07
mutations O 0 2.714483798627043e-06
within O 0 3.2402346050730557e-07
their O 0 1.394500031892676e-06
POMC O 0 0.028378764167428017
genes O 0 1.2172088645456824e-05
. O 0 7.323337285924936e-06

Patient O 0 0.013782978989183903
1 O 0 1.7311060219071805e-05
was O 0 2.4132332328008488e-06
found O 0 3.9957407693691493e-07
to O 0 4.4797477727342994e-08
be O 0 3.13936254769942e-08
a O 0 1.862457281731622e-07
compound O 0 1.5953719412209466e-06
heterozygote O 0 8.193711437343154e-06
for O 0 6.4925700371532e-08
two O 0 6.145740627516716e-08
mutations O 0 5.716192390536889e-07
in O 0 5.1509779552816326e-08
exon O 0 6.334834779408993e-06
3 O 0 4.7368934019687003e-07
( O 0 1.310744863758373e-07
G7013T O 0 1.932621671585366e-05
, O 0 1.532864928321942e-07
C7133delta O 0 3.650512735475786e-05
) O 0 3.25339399864788e-08
which O 0 1.0214476375836057e-08
interfere O 0 1.1080758355319631e-07
with O 0 3.133661508059049e-08
appropriate O 0 9.667574119021083e-08
synthesis O 0 2.742513913744915e-07
of O 0 2.4891102157198475e-07
ACTH O 0 0.00014508537424262613
and O 0 1.1660936252155807e-06
alpha O 0 2.6876052288571373e-05
- O 0 0.001427834271453321
MSH O 0 0.0039039948023855686
. O 0 1.4733444913872518e-05

Patient O 0 0.02975272946059704
2 O 0 2.532132202759385e-05
was O 0 2.602539552754024e-06
homozygous O 0 5.388839326769812e-06
for O 0 1.6193074259263085e-07
a O 0 2.590188898921042e-07
mutation O 0 1.3552926247939467e-06
in O 0 1.3750829452874314e-07
exon O 0 1.7026615751092322e-05
2 O 0 1.7653361510383547e-06
( O 0 3.3972332857956644e-07
C3804A O 0 4.340715895523317e-05
) O 0 3.015205720657832e-07
which O 0 5.615401050818036e-07
abolishes O 0 0.0001276831899303943
POMC O 0 0.0026032880414277315
translation O 0 1.2299205991439521e-05
. O 0 1.8843385987565853e-05

These O 0 2.0290994143579155e-05
findings O 0 1.4310592632682528e-05
represent O 0 9.289005333812383e-07
the O 0 1.8343942542742298e-07
first O 0 2.0495083674632042e-07
examples O 0 4.524404175754171e-07
of O 0 3.2260049920296296e-07
a O 0 3.2107993320096284e-05
genetic B-Disease 1 0.9933220744132996
defect I-Disease 1 0.9793033599853516
within O 0 6.478381919805543e-07
the O 0 6.116680992818146e-07
POMC O 0 0.029030069708824158
gene O 0 3.1958384170138743e-06
and O 0 3.306065252672852e-07
define O 0 3.220844973839121e-06
a O 0 1.1036280511689256e-06
new O 0 4.7061897930689156e-05
monogenic B-Disease 1 0.9997981190681458
endocrine I-Disease 1 0.9999229907989502
disorder I-Disease 0 0.46824607253074646
resulting O 0 2.9127545531082433e-06
in O 0 3.8845155359013006e-07
early O 0 2.9453152819769457e-05
- O 1 0.9938283562660217
onset O 1 0.9998869895935059
obesity B-Disease 1 0.9999842643737793
, O 0 0.08734025806188583
adrenal B-Disease 1 0.9999967813491821
insufficiency I-Disease 1 0.9999874830245972
and O 0 5.7979810662800446e-05
red O 0 0.01897609233856201
hair O 1 0.692238450050354
pigmentation O 0 0.41651102900505066
. O 0 1.1138304216729011e-05
. O 0 1.9007426089956425e-05

A O 0 4.953234383719973e-05
European O 0 1.4490812645817641e-05
multicenter O 0 0.015089569613337517
study O 0 1.995735874515958e-05
of O 0 2.4344335542991757e-05
phenylalanine B-Disease 1 0.9998784065246582
hydroxylase I-Disease 1 0.9999802112579346
deficiency I-Disease 1 0.9999808073043823
: O 0 4.373836418380961e-06
classification O 0 5.692860213457607e-06
of O 0 1.8251213873554661e-07
105 O 0 8.444168088317383e-06
mutations O 0 4.4428452383726835e-06
and O 0 1.4643015333604126e-07
a O 0 1.9027588393782935e-07
general O 0 4.203508296996006e-07
system O 0 1.8555996916802542e-07
for O 0 1.3077332994271273e-07
genotype O 0 7.461263157892972e-05
- O 0 9.837425022851676e-05
based O 0 1.7365805433655623e-06
prediction O 0 1.3457692148222122e-05
of O 0 2.592427563286037e-06
metabolic O 0 0.030555762350559235
phenotype O 0 0.00087091198656708
. O 0 3.2550058676861227e-05

Phenylketonuria B-Disease 1 0.9965381622314453
( O 0 0.0001818623422877863
PKU B-Disease 0 0.4488902688026428
) O 0 8.66438767843647e-06
and O 0 1.849564432632178e-05
mild B-Disease 1 0.8388493657112122
hyperphenylalaninemia I-Disease 1 0.9999855756759644
( O 0 0.0007293930975720286
MHP B-Disease 1 0.9999784231185913
) O 0 3.8236312320805155e-06
are O 0 2.3559730379929533e-06
allelic B-Disease 1 0.970840334892273
disorders I-Disease 1 0.998713493347168
caused O 0 2.692915586521849e-05
by O 0 5.595088055088127e-07
mutations O 0 2.9483480830094777e-06
in O 0 8.087828717862067e-08
the O 0 7.225462184123899e-08
gene O 0 1.1263592796240118e-06
encoding O 0 3.0936987513996428e-06
phenylalanine O 0 0.00024221089552156627
hydroxylase O 0 0.008998668752610683
( O 0 7.848288987588603e-06
PAH O 1 0.6983439326286316
) O 0 2.67292239186645e-06
. O 0 9.329808563052211e-06

Previous O 0 7.54524880903773e-05
studies O 0 1.8218555851490237e-05
have O 0 1.294794060413551e-06
suggested O 0 2.882440867324476e-06
that O 0 1.242717502236701e-07
the O 0 3.2886694611988787e-07
highly O 0 3.3496564810775453e-06
variable O 0 2.7312607926432975e-05
metabolic O 0 0.0024226463865488768
phenotypes O 0 0.00045653912820853293
of O 0 0.00030157456058077514
PAH B-Disease 1 0.9999974966049194
deficiency I-Disease 1 0.9984768033027649
correlate O 0 0.0006897449493408203
with O 0 9.505629714112729e-05
PAH O 1 0.9998387098312378
genotypes O 0 0.0030844544526189566
. O 0 1.9627857909654267e-05

We O 0 3.291687244200148e-05
identified O 0 2.2288311811280437e-05
both O 0 1.8183957308792742e-06
causative O 0 8.442147372988984e-05
mutations O 0 2.149908868886996e-05
in O 0 1.5844640302020707e-06
686 O 0 0.2722906768321991
patients O 0 0.003106457181274891
from O 0 4.619694209395675e-07
seven O 0 1.006283241622441e-06
European O 0 2.6173215701419394e-06
centers O 0 1.4699033272336237e-05
. O 0 1.2791610060958192e-05

On O 0 9.494983714830596e-06
the O 0 4.598472287398181e-07
basis O 0 1.8706812454638566e-07
of O 0 6.894176607374902e-08
the O 0 1.1880686656695616e-07
phenotypic O 0 5.332985438144533e-06
characteristics O 0 5.070926363259787e-07
of O 0 1.609738262686733e-07
297 O 0 4.184807767160237e-05
functionally O 0 0.00020103597489651293
hemizygous O 1 0.6044231057167053
patients O 0 0.00010867304808925837
, O 0 1.518236274478113e-07
105 O 0 4.3039142383349827e-07
of O 0 5.556611171186887e-08
the O 0 9.289610858331798e-08
mutations O 0 5.792200568066619e-07
were O 0 2.4128336661988214e-08
assigned O 0 8.731245060289439e-08
to O 0 1.4679305770926021e-08
one O 0 1.6144896974878975e-08
of O 0 2.7499666543917556e-08
four O 0 2.376115730839956e-07
arbitrary O 0 4.27952272730181e-06
phenotype O 0 0.00014302045747172087
categories O 0 1.80371444002958e-05
. O 0 1.1549494047358166e-05

We O 0 1.4909817764419131e-05
proposed O 0 1.4738516256329603e-05
and O 0 2.3430914097843925e-06
tested O 0 4.088737114216201e-06
a O 0 1.8941118185011874e-07
simple O 0 6.902503741912369e-07
model O 0 7.507117061322788e-07
for O 0 1.710362340645588e-07
correlation O 0 1.963388740477967e-06
between O 0 8.804792628325231e-07
genotype O 0 7.439763430738822e-05
and O 0 1.5517357496719342e-06
phenotypic O 0 4.591362448991276e-05
outcome O 0 0.00011341398203512654
. O 0 3.4722852433333173e-05

The O 0 1.7830370779847726e-05
observed O 0 3.067936995648779e-05
phenotype O 0 0.00010262912110192701
matched O 0 7.729649951215833e-06
the O 0 2.636881220041687e-07
predicted O 0 5.243936175247654e-05
phenotype O 0 1.4206392734195106e-05
in O 0 1.5857732194035634e-07
79 O 0 7.515988727391232e-06
% O 0 6.868844337759583e-08
of O 0 2.224935968797581e-08
the O 0 1.301722249991144e-07
cases O 0 1.0005636568166665e-06
, O 0 1.9710171272890875e-07
and O 0 8.722189903664912e-08
in O 0 2.2920715991858742e-08
only O 0 1.4898475342306483e-08
5 O 0 6.302484223397187e-08
of O 0 3.414180227423458e-08
184 O 0 2.4032857254496776e-05
patients O 0 4.8509540647501126e-05
was O 0 1.0742932232687963e-07
the O 0 5.828101024007992e-08
observed O 0 5.775619342784921e-07
phenotype O 0 1.943298002515803e-06
more O 0 2.4725224534449808e-08
than O 0 2.4605446569125888e-08
one O 0 2.7377517142213037e-08
category O 0 4.386972420888924e-07
away O 0 1.3703829893074726e-07
from O 0 5.685909343355888e-08
that O 0 1.1953378020734817e-07
expected O 0 2.9540954074036563e-06
. O 0 5.253260496829171e-06

Among O 0 2.3186194084701128e-05
the O 0 9.07076355360914e-07
seven O 0 6.525482376673608e-07
contributing O 0 1.1978384009125875e-06
centers O 0 7.394339718302945e-07
, O 0 7.925649470053031e-08
the O 0 4.0592677663653376e-08
proportion O 0 8.819920367386658e-07
of O 0 3.626350917329546e-07
patients O 0 7.436266605509445e-05
for O 0 3.816494995589892e-07
whom O 0 2.072201596092782e-06
the O 0 1.2459382503493543e-07
observed O 0 5.53777454115334e-06
phenotype O 0 2.9581229682662524e-05
did O 0 2.3448299657502503e-07
not O 0 3.465386910761481e-08
match O 0 1.749133105022338e-07
the O 0 5.295929383919429e-08
predicted O 0 8.115664968499914e-06
phenotype O 0 2.08019287128991e-06
was O 0 8.56377226909899e-08
4 O 0 2.583828404567612e-07
% O 0 1.049321127766234e-07
- O 0 4.20214346377179e-05
23 O 0 1.8739325469141477e-06
% O 0 2.423352327696193e-07
( O 0 2.508965053493739e-07
P O 0 0.0007248312467709184
< O 0 5.04509371239692e-05
. O 0 8.961104924765095e-08
0001 O 0 1.655392043176107e-05
) O 0 5.335532193839754e-08
, O 0 6.251374884413963e-08
suggesting O 0 2.163471606309031e-07
that O 0 3.398872294724242e-08
differences O 0 3.5757318528339965e-07
in O 0 5.181850681879041e-08
methods O 0 1.122280011145449e-07
used O 0 8.242125915103315e-08
for O 0 1.6997003626784135e-07
mutation O 0 3.8120567751320777e-06
detection O 0 1.8493208699510433e-05
or O 0 1.7662017626207671e-06
phenotype O 0 0.0002242046466562897
classification O 0 7.52453415771015e-05
may O 0 1.2164858844698756e-06
account O 0 1.7650756944931345e-07
for O 0 6.46533422354878e-08
a O 0 1.764658321690149e-07
considerable O 0 9.352954180030792e-07
proportion O 0 1.4933673355699284e-06
of O 0 5.586929887613223e-07
genotype O 0 0.0012543554184958339
- O 0 0.08010189980268478
phenotype O 0 0.0008777998154982924
inconsistencies O 0 0.0003598496550694108
. O 0 4.984398765373044e-05

Our O 0 2.2119105778983794e-05
data O 0 6.132174348749686e-06
indicate O 0 2.1960529466014123e-06
that O 0 2.191079175872801e-07
the O 0 9.314589419773256e-07
PAH O 1 0.9992851614952087
- O 0 0.011022555641829967
mutation O 0 1.1205276678083465e-05
genotype O 0 8.00436464487575e-06
is O 0 5.513537360002374e-08
the O 0 4.641544748551496e-08
main O 0 3.09646821960996e-07
determinant O 0 2.76749710792501e-06
of O 0 5.300801149132894e-07
metabolic O 0 0.0033971467055380344
phenotype O 0 9.038591088028625e-05
in O 0 1.1561156725292676e-06
most O 0 1.4939820175641216e-05
patients O 0 0.10933458060026169
with O 0 0.05799210071563721
PAH B-Disease 1 0.9999994039535522
deficiency I-Disease 1 0.9997879862785339
. O 0 9.562267950968817e-05

In O 0 7.114402706065448e-06
the O 0 1.3860610579286003e-06
present O 0 8.879013080331788e-07
study O 0 1.1043661061194143e-06
, O 0 2.8184746270198957e-07
the O 0 1.1972065294685308e-07
classification O 0 2.3887671432021307e-06
of O 0 2.0198167760554497e-07
105 O 0 0.00034125696402043104
PAH O 1 0.9999314546585083
mutations O 0 1.669462290010415e-05
may O 0 2.346172038869554e-07
allow O 0 1.046127806603181e-07
the O 0 5.008140036011355e-08
prediction O 0 1.6273761502816342e-06
of O 0 4.4264343301847475e-08
the O 0 1.376178317968879e-07
biochemical O 0 1.1015577001671772e-05
phenotype O 0 7.686449862376321e-06
in O 0 1.1231986007942396e-07
> O 0 2.5362693122588098e-05
10 O 0 3.002276400820847e-07
, O 0 1.523762733768308e-07
000 O 0 5.458753093989799e-07
genotypes O 0 7.460294000338763e-06
, O 0 1.0534903793768535e-07
which O 0 2.658560660506737e-08
may O 0 8.215694435875776e-08
be O 0 1.0318789378516158e-08
useful O 0 5.859600094026973e-08
for O 0 3.172378626459249e-08
the O 0 5.7703292810629137e-08
management O 0 6.957497475923446e-07
of O 0 5.174295552023978e-07
hyperphenylalaninemia B-Disease 1 0.9913832545280457
in O 0 8.292043276014738e-06
newborns O 0 0.023556716740131378
. O 0 1.85423359653214e-05

Somatic O 0 0.0017160082934424281
instability O 0 0.0001821693585952744
of O 0 2.0242146092641633e-06
the O 0 2.120820226991782e-06
CTG O 0 0.007632069289684296
repeat O 0 3.168503462802619e-05
in O 0 7.000313075877784e-07
mice O 0 1.15014954644721e-05
transgenic O 0 1.0363965884607751e-05
for O 0 7.871067282394506e-07
the O 0 3.8244063034653664e-05
myotonic B-Disease 1 0.999998927116394
dystrophy I-Disease 1 0.9999908208847046
region O 0 8.173914102371782e-05
is O 0 1.0023715049101156e-06
age O 0 3.861334789689863e-06
dependent O 0 2.815894731611479e-06
but O 0 1.5648863893602538e-07
not O 0 5.445915363111453e-08
correlated O 0 8.333396408488625e-07
to O 0 5.043877848720513e-08
the O 0 9.808117340526223e-08
relative O 0 2.5238300622731913e-06
intertissue O 0 8.144853927660733e-05
transcription O 0 4.556865405902499e-06
levels O 0 3.3134492696262896e-06
and O 0 3.445224820097792e-06
proliferative O 1 0.7598533034324646
capacities O 0 0.0001801045727916062
. O 0 2.0721459804917686e-05

A O 0 9.652525477577001e-05
( O 0 8.342274668393657e-06
CTG O 0 0.00048337262705899775
) O 0 1.1066201750509208e-06
nexpansion O 0 5.388082718127407e-05
in O 0 9.263813183224556e-08
the O 0 1.1557271761830634e-07
3 O 0 1.1181322179254494e-06
- O 0 0.0002211440005339682
untranslated O 0 0.000451867061201483
region O 0 1.445855559722986e-06
( O 0 2.4906179874051304e-07
UTR O 0 9.2716300059692e-06
) O 0 2.18055387080085e-08
of O 0 1.9021305419641976e-08
the O 0 1.3028511602897197e-07
DM O 1 0.9817185401916504
protein O 0 1.5392841987704742e-06
kinase O 0 4.8875517677515745e-06
gene O 0 1.0367209597461624e-06
( O 0 1.8060164563848957e-07
DMPK O 0 0.00011665240890579298
) O 0 1.1154892121112425e-07
is O 0 1.2243940261669195e-07
responsible O 0 2.319467512279516e-06
for O 0 9.228370799974073e-06
causing O 0 0.49522510170936584
myotonic B-Disease 1 0.999998927116394
dystrophy I-Disease 1 0.9999967813491821
( O 0 0.0008994339732453227
DM B-Disease 1 0.9999896287918091
) O 0 2.8601281883311458e-05
. O 0 3.2783140341052786e-05

Major O 0 0.00025862237089313567
instability O 0 0.00039487099274992943
, O 0 3.134055305054062e-06
with O 0 4.906237336399499e-07
very O 0 3.9768011106389167e-07
large O 0 5.358888301998377e-07
expansions O 0 3.049158976864419e-06
between O 0 1.8548247737726342e-07
generations O 0 6.416617566173954e-07
and O 0 1.6761295285050437e-07
high O 0 1.3174035302654374e-06
levels O 0 2.010162347687583e-07
of O 0 6.435855226527565e-08
somatic O 0 4.32251144957263e-05
mosaicism O 0 0.06743951886892319
, O 0 8.572177421228844e-07
is O 0 2.9156902314753097e-07
observed O 0 4.007596544397529e-06
in O 0 5.377248726290418e-06
patients O 0 0.0006022186134941876
. O 0 1.840211552917026e-05

There O 0 2.0676752683357336e-05
is O 0 1.2813433158953558e-06
a O 0 7.18605065230804e-07
good O 0 1.2290390714042587e-06
correlation O 0 2.5556144009897253e-06
between O 0 4.778636935043323e-07
repeat O 0 1.7624815882300027e-05
size O 0 6.011262939864537e-06
( O 0 1.5339338688136195e-07
at O 0 1.7689364995021606e-07
least O 0 4.726514646336e-08
in O 0 5.4437347074554054e-08
leucocytes O 0 0.0001543710386613384
) O 0 2.0011952983622905e-07
, O 0 4.186988746823772e-07
clinical O 0 9.874549868982285e-05
severity O 0 0.00014946781448088586
and O 0 1.0107344223797554e-06
age O 0 3.5250895962235518e-06
of O 0 2.613520564409555e-06
onset O 0 0.3981303572654724
. O 0 4.335656558396295e-05

The O 0 6.452830712078139e-05
trinucleotide O 0 0.023931968957185745
repeat O 0 0.0002598871651571244
instability O 0 6.795455556130037e-05
mechanisms O 0 6.351640422508353e-06
involved O 0 4.266620635462459e-06
in O 0 5.491835054272087e-06
DM B-Disease 1 0.999992847442627
and O 0 1.2375765436445363e-05
other O 0 4.941850420436822e-06
human O 0 0.0010618494125083089
genetic B-Disease 1 0.9998884201049805
diseases I-Disease 1 0.9998745918273926
are O 0 4.278441338101402e-06
unknown O 0 3.5707696952158585e-05
. O 0 2.168837636418175e-05

We O 0 3.7542704376392066e-05
studied O 0 2.9574601285276003e-05
somatic O 0 0.00016951803991105407
instability O 0 6.006751937093213e-05
by O 0 1.8996705648532952e-06
measuring O 0 2.3354428776656277e-05
the O 0 5.485791803039319e-07
CTG O 0 0.0005571324145421386
repeat O 0 6.775043857487617e-06
length O 0 1.58102409386629e-06
at O 0 2.809179022733588e-07
several O 0 4.302350120610754e-08
ages O 0 4.5017179672868224e-07
in O 0 3.266618975317215e-08
various O 0 3.798803049903654e-08
tissues O 0 9.282532005272515e-07
of O 0 5.1604772011160094e-08
transgenic O 0 1.703062662272714e-05
mice O 0 8.60232648847159e-06
carrying O 0 9.300440524384612e-07
a O 0 3.5059153447036806e-07
( O 0 3.3733940085767244e-07
CTG O 0 0.00010743076563812792
) O 0 2.9012306868025917e-07
55expansion O 0 2.853859041351825e-05
surrounded O 0 1.302988266616012e-06
by O 0 7.224689824170127e-08
45 O 0 2.547396604768437e-07
kb O 0 3.7548793443420436e-06
of O 0 3.02664844298306e-08
the O 0 7.398474366482333e-08
human O 0 1.316758016400854e-06
DM B-Disease 1 0.9999282360076904
region O 0 2.358511210331926e-06
, O 0 1.7459166201660992e-07
using O 0 2.4140953769347107e-07
small O 0 1.9987930954812327e-06
- O 0 0.0001568327279528603
pool O 0 5.919527029618621e-05
PCR O 0 8.16907559055835e-05
. O 0 9.932829016179312e-06

These O 0 4.1436072933720425e-05
mice O 0 0.00019862517365254462
have O 0 1.0472582516740658e-06
been O 0 2.5495450017842813e-07
shown O 0 3.6424822269509605e-07
to O 0 2.1096556679367495e-07
reproduce O 0 2.614056256788899e-06
the O 0 1.2126341175644484e-07
intergenerational O 0 4.166716826148331e-05
and O 0 4.0249065591524413e-07
somatic O 0 1.5214774066407699e-05
instability O 0 3.2209986784437206e-06
of O 0 7.542625723999663e-08
the O 0 1.4451343588461896e-07
55 O 0 3.5129814932588488e-06
CTG O 0 0.0013813244877383113
repeat O 0 1.4169562746246811e-05
suggesting O 0 1.9010589085155516e-06
that O 0 5.7337626202524916e-08
surrounding O 0 6.44589192688727e-07
sequences O 0 3.108569899268332e-07
and O 0 4.802796382818997e-08
the O 0 3.934760073320831e-08
chromatin O 0 1.5221639841911383e-05
environment O 0 2.9479883778549265e-06
are O 0 7.657855150000614e-08
involved O 0 5.914880034652015e-07
in O 0 7.860610367060872e-07
instability O 0 7.901271601440385e-05
mechanisms O 0 3.207132613169961e-05
. O 0 1.6710153431631625e-05

As O 0 1.5269037248799577e-05
observed O 0 1.4125312191026751e-05
in O 0 3.414428420001059e-07
some O 0 5.663234503572312e-08
of O 0 7.32502414280134e-08
the O 0 2.0009511558782833e-07
tissues O 0 1.3143117030267604e-05
of O 0 3.783491592912469e-06
DM B-Disease 1 0.9999995231628418
patients O 0 0.37798503041267395
, O 0 1.1467391232145019e-06
there O 0 1.7662055995515402e-07
is O 0 1.0329071642445342e-07
a O 0 1.914373228828481e-07
tendency O 0 8.473529078401043e-07
for O 0 1.09224160382837e-07
repeat O 0 2.9079724299663212e-06
length O 0 4.776385935656435e-07
and O 0 9.897816255488578e-08
somatic O 0 7.138549790397519e-06
mosaicism O 0 0.0010430187685415149
to O 0 1.3941129850536527e-07
increase O 0 2.7396592372497253e-07
with O 0 8.682652463676277e-08
the O 0 5.800177405035356e-08
age O 0 3.4578047802824585e-07
of O 0 8.86405757682951e-08
the O 0 7.079393071762752e-07
mouse O 0 8.370594150619581e-05
. O 0 9.791089723876212e-06

Furthermore O 0 0.00011123459989903495
, O 0 2.6604736831359332e-06
we O 0 6.785776918150077e-07
observed O 0 8.54895858992677e-07
no O 0 1.5959609811488917e-07
correlation O 0 4.369469195353304e-07
between O 0 9.538482714788188e-08
the O 0 8.182119870525639e-08
somatic O 0 4.6792403736617416e-05
mutation O 0 7.516784080507932e-06
rate O 0 1.6693543329893146e-06
and O 0 2.3550205696665216e-06
tissue O 0 0.003200798761099577
proliferation O 0 0.000601728621404618
capacity O 0 2.5872610422084108e-05
. O 0 9.43377108342247e-06

The O 0 1.0479143384145573e-05
somatic O 0 0.0004649320035241544
mutation O 0 0.00015173367864917964
rates O 0 6.876708539493848e-06
in O 0 1.6266409375020885e-07
different O 0 1.3448851632347214e-07
tissues O 0 5.575110662903171e-06
were O 0 9.420327984344112e-08
also O 0 2.825196077083092e-08
not O 0 2.8200920709764432e-08
correlated O 0 3.457741684087523e-07
to O 0 2.1601950450644836e-08
the O 0 3.3306726265891484e-08
relative O 0 1.846217628553859e-06
inter O 0 9.03103227756219e-06
- O 0 0.004266019910573959
tissue O 0 4.3598491174634546e-05
difference O 0 2.9499469178517757e-07
in O 0 3.2879597711144015e-08
transcriptional O 0 4.119679033465218e-07
levels O 0 6.759012904922201e-08
of O 0 1.0004537642771538e-08
the O 0 1.6438914229865986e-08
three O 0 3.624573352567495e-08
genes O 0 2.1237701730569825e-07
( O 0 8.054714584204703e-08
DMAHP O 0 0.00012588418030645698
, O 0 2.3608464516655658e-07
DMPK O 0 0.0003506897483021021
and O 0 3.067312661642063e-07
59 O 0 3.78985055249359e-06
) O 0 8.073325830082467e-08
surrounding O 0 4.901672241430788e-07
the O 0 1.7800631724185223e-07
repeat O 0 1.8599648683448322e-05
. O 0 1.5543128029094078e-06
. O 0 9.01319526747102e-06

A O 0 5.960618000244722e-05
novel O 0 4.422312485985458e-05
missense O 0 0.0015483114402741194
mutation O 0 0.00011252729018451646
in O 0 6.769909305148758e-06
patients O 0 0.0002502876741345972
from O 0 5.954441348876571e-07
a O 0 3.5459572700347053e-06
retinoblastoma B-Disease 0 0.2962782382965088
pedigree O 0 0.0012980728643015027
showing O 0 2.4138700609910302e-05
only O 0 5.037667278884328e-07
mild O 0 0.00016463332576677203
expression O 0 6.615726420022838e-07
of O 0 4.1573943576622696e-07
the O 0 1.3152470273780636e-05
tumor B-Disease 1 0.8875815868377686
phenotype O 0 0.000925026077311486
. O 0 3.51029411831405e-05

We O 0 1.3687670616491232e-05
have O 0 8.277800134237623e-07
used O 0 2.1451762677315855e-07
single O 0 2.6072495984408306e-07
strand O 0 1.7847848994279047e-06
conformation O 0 1.4253904510042048e-06
polymorphism O 0 1.5494377976210671e-06
analysis O 0 2.843865161139547e-07
to O 0 7.37230152481061e-08
study O 0 1.3599468218217226e-07
the O 0 3.3794535170272866e-08
27 O 0 1.915629610493852e-07
exons O 0 3.1247984111359983e-07
of O 0 2.774835472507675e-08
the O 0 1.885044014215964e-07
RB1 O 0 0.005964420735836029
gene O 0 1.4147416322884965e-06
in O 0 8.339011259295148e-08
individuals O 0 1.2479073063786927e-07
from O 0 5.411765968688087e-08
a O 0 4.194710356841824e-07
family O 0 4.7017083488754e-06
showing O 0 4.9051996029447764e-05
mild O 0 0.0012306348653510213
expression O 0 9.027958185470197e-07
of O 0 4.108300970528944e-07
the O 0 5.421236892289016e-06
retinoblastoma B-Disease 1 0.5763599872589111
phenotype O 0 0.00199502008035779
. O 0 2.5355946490890346e-05

In O 0 2.1414944058051333e-05
this O 0 1.919346914291964e-06
family O 0 7.993973667907994e-06
affected O 0 5.472083557833685e-06
individuals O 0 1.2613780882020365e-06
developed O 0 7.023716989351669e-06
unilateral B-Disease 0 0.20009642839431763
tumors I-Disease 1 0.999992847442627
and O 0 4.225806605973048e-06
, O 0 7.489732638532587e-07
as O 0 4.8157485110778e-08
a O 0 1.1724324622264248e-07
result O 0 1.1971950186762115e-07
of O 0 5.2353485102685227e-08
linkage O 0 6.077674242987996e-06
analysis O 0 2.264898739667842e-06
, O 0 1.2844557204516605e-06
unaffected O 0 4.875343802268617e-05
mutation O 0 2.7621181288850494e-06
carriers O 0 2.266465344291646e-06
were O 0 1.4205468801264942e-07
also O 0 1.9079338642313814e-07
identified O 0 1.4148604350339156e-06
within O 0 2.3134509774536127e-07
the O 0 1.2453791669031489e-06
pedigree O 0 0.0003023241588380188
. O 0 1.602399061084725e-05

A O 0 2.2669391910312697e-05
single O 0 3.5883788314095e-06
band O 0 1.3598707937489962e-06
shift O 0 1.3187020613258937e-06
using O 0 6.204217015692848e-07
SSCP O 0 0.0003372544306330383
was O 0 7.644697461728356e-07
identified O 0 4.903374701825669e-07
in O 0 6.377214134545284e-08
exon O 0 4.411206191434758e-06
21 O 0 3.5991223512610304e-07
which O 0 4.2282223944312136e-08
resulted O 0 3.80394425292252e-07
in O 0 4.830873123751189e-08
a O 0 2.6279741405232926e-07
missense O 0 1.3769905308436137e-05
mutation O 0 6.16500756223104e-07
converting O 0 3.39461337262037e-07
a O 0 3.6135847381046915e-07
cys O 0 0.001396171748638153
- O 0 0.00024904010933823884
- O 0 0.00026593805523589253
> O 0 2.0588482584571466e-05
arg O 0 1.5874522432568483e-05
at O 0 3.2791297144285636e-07
nucleotide O 0 9.622922334528994e-07
position O 0 2.4059869474513107e-07
28 O 0 2.455685716995504e-07
in O 0 9.772525544349264e-08
the O 0 4.5877757770540484e-07
exon O 0 0.00011490991892060265
. O 0 1.0982608728227206e-05

The O 0 3.632063453551382e-05
mutation O 0 7.590482709929347e-05
destroyed O 0 2.3554637664346956e-05
an O 0 9.702632723929128e-07
NdeI O 0 0.0003179710474796593
restriction O 0 1.5819208783796057e-05
enzyme O 0 2.322868567716796e-05
site O 0 3.2503838156117126e-05
. O 0 1.1225802154513076e-05

Analysis O 0 5.317412069416605e-05
of O 0 2.7081848656962393e-06
all O 0 1.2853136013291078e-06
family O 0 3.5102420952171087e-06
members O 0 4.78053323149652e-07
demonstrated O 0 1.7346075082969037e-06
that O 0 6.616787118218781e-08
the O 0 1.3041365320987097e-07
missense O 0 0.00010413067502668127
mutation O 0 9.086875252251048e-06
co O 0 3.570766421034932e-05
- O 0 0.0020045472774654627
segregated O 0 0.00013481538917403668
with O 0 1.326651454292005e-05
patients O 0 0.00822521187365055
with O 0 4.618580351234414e-05
tumors B-Disease 1 0.9999914169311523
or O 0 9.404443517269101e-06
who O 0 2.1821613245265326e-06
, O 0 2.2063801452532061e-07
as O 0 4.766366146213841e-08
a O 0 7.652043620964832e-08
result O 0 9.504793752057594e-08
of O 0 4.072668602361773e-08
linkage O 0 4.38743018094101e-06
analysis O 0 5.320938498698524e-07
had O 0 2.263131761992554e-07
been O 0 1.3013151090035535e-07
predicted O 0 2.387664835623582e-06
to O 0 1.2626244938473974e-07
carry O 0 1.064672801476263e-06
the O 0 2.2490055471280357e-06
predisposing O 0 0.0009492586250416934
mutation O 0 4.107346467208117e-05
. O 0 1.5478601198992692e-05

These O 0 5.370939106796868e-06
observations O 0 8.868012628227007e-06
point O 0 2.5214769721060293e-06
to O 0 2.3294042250654456e-07
another O 0 2.6739346026261046e-07
region O 0 2.5637402245592966e-07
of O 0 5.912984946121469e-08
the O 0 2.5221189048352244e-07
RB1 O 0 0.011863742023706436
gene O 0 2.0600834886863595e-06
where O 0 4.305010179450619e-07
mutations O 0 1.005130343401106e-06
only O 0 2.7428528781570094e-08
modify O 0 7.307126566047373e-07
the O 0 2.3741170807056733e-08
function O 0 2.988906189216323e-08
of O 0 1.3539547261132157e-08
the O 0 2.9165459380919856e-08
gene O 0 3.4682307159528136e-07
and O 0 1.0702866859446658e-07
raise O 0 3.938537247449858e-07
important O 0 1.0867493926980387e-07
questions O 0 4.6440021606031223e-07
for O 0 4.377907600883191e-07
genetic O 0 2.202319046773482e-05
counseling O 0 8.36826438899152e-05
in O 0 5.957213033980224e-07
families O 0 1.8638784240465611e-06
with O 0 3.769251861740486e-07
these O 0 4.2777537601068616e-07
distinctive O 0 1.784762389434036e-05
phenotypes O 0 8.505505684297532e-05
. O 0 2.7886280804523267e-06
. O 0 9.105648132390343e-06

Maternal B-Disease 0 0.03404052555561066
disomy I-Disease 1 0.6417168974876404
and O 0 0.00873011164367199
Prader B-Disease 1 0.9999953508377075
- I-Disease 1 0.9999964237213135
Willi I-Disease 1 0.9999996423721313
syndrome I-Disease 1 0.9999773502349854
consistent O 0 5.498828977579251e-05
with O 0 2.933796849902137e-06
gamete O 0 0.0010818573646247387
complementation O 1 0.6950159072875977
in O 0 6.949326802896394e-07
a O 0 5.100404791846813e-07
case O 0 1.77969104697695e-06
of O 0 3.491914242204075e-07
familial O 0 0.00362241524271667
translocation O 0 0.00047296806587837636
( O 0 6.355908226396423e-07
3 O 0 1.0529676046644454e-06
; O 0 2.6664019969757646e-07
15 O 0 1.8204242735464504e-07
) O 0 6.700992116748239e-08
( O 0 5.0656190353493e-08
p25 O 0 7.4960234996979125e-06
; O 0 2.3780789604188612e-07
q11 O 0 1.3305703760124743e-05
. O 0 1.156584943373673e-07
2 O 0 6.885791208333103e-07
) O 0 5.350640890355862e-07
. O 0 2.8357803785183933e-06

Maternal B-Disease 0 0.12894673645496368
uniparental I-Disease 1 0.9871690273284912
disomy I-Disease 1 0.9455792307853699
( I-Disease 0 0.00015549911768175662
UPD I-Disease 1 0.9984447360038757
) I-Disease 0 1.818586497392971e-06
for I-Disease 0 4.234869379615702e-07
chromosome I-Disease 0 9.360999683849514e-06
15 I-Disease 0 5.818204726892873e-07
is O 0 8.66025757773059e-08
responsible O 0 2.867072339540755e-07
for O 0 7.094620713132826e-08
an O 0 5.5999148429464185e-08
estimated O 0 4.170355509813817e-07
30 O 0 2.2081398753925896e-07
% O 0 8.401786288914082e-08
of O 0 9.959799029957139e-08
cases O 0 3.1879239941190463e-06
of O 0 4.239197005517781e-05
Prader B-Disease 1 0.9999994039535522
- I-Disease 1 0.9999992847442627
Willi I-Disease 1 0.9999997615814209
syndrome I-Disease 1 0.9999945163726807
( O 0 0.0002956443640869111
PWS B-Disease 1 0.9997217059135437
) O 0 1.377958687953651e-05
. O 0 2.017681981669739e-05

We O 0 1.691586476226803e-05
report O 0 2.1985215425956994e-06
on O 0 3.4870024023803126e-07
an O 0 9.192054761797408e-08
unusual O 0 1.04749506135704e-06
case O 0 6.814876201133302e-07
of O 0 1.7895438020332222e-07
maternal B-Disease 0 5.6345983466599137e-05
disomy I-Disease 0 0.03014487400650978
15 I-Disease 0 3.0454216357611585e-06
in O 0 1.989599923035712e-06
PWS B-Disease 1 0.9993570446968079
that O 0 1.5677110809519945e-07
is O 0 1.0562851571194187e-07
most O 0 6.915946926255856e-08
consistent O 0 2.857044023585331e-07
with O 0 7.355109943318894e-08
adjacent O 0 2.257000687677646e-06
- O 0 5.901896292925812e-05
1 O 0 5.550842843149439e-07
segregation O 0 1.3599732255897834e-06
of O 0 5.2829957297717556e-08
a O 0 4.818178922505467e-07
paternal O 0 0.0001659444678807631
t O 0 0.03316999971866608
( O 0 1.4169208384373633e-07
3 O 0 3.956577643293713e-07
; O 0 1.166354479664733e-07
15 O 0 8.190176714606423e-08
) O 0 3.797100589508773e-08
( O 0 3.989396546444368e-08
p25 O 0 4.080435701325769e-06
; O 0 1.3375891683153895e-07
q11 O 0 7.3442979555693455e-06
. O 0 4.764311967164758e-08
2 O 0 1.1999040339105704e-07
) O 0 3.479248533722057e-08
with O 0 3.870123421734206e-08
simultaneous O 0 9.65964545684983e-07
maternal O 0 1.613199492567219e-05
meiotic O 0 0.009618740528821945
nondisjunction O 0 0.0032313815318048
for O 0 2.437049943182501e-06
chromosome O 0 8.651911048218608e-05
15 O 0 1.3438531823339872e-05
. O 0 1.351429455098696e-05

The O 0 7.648902101209387e-05
patient O 0 0.001923062838613987
( O 0 7.158470452850452e-06
J O 0 0.0762871652841568
. O 0 1.0794029776661773e-06
B O 0 7.723915041424334e-05
. O 0 1.1327703930419375e-07
) O 0 5.345922460264774e-08
, O 0 3.753686073082463e-08
a O 0 5.854874629562801e-08
17 O 0 3.46759918556927e-07
- O 0 3.802470018854365e-05
year O 0 1.1220461146876914e-06
- O 0 0.003568431595340371
old O 0 0.0002656987926457077
white O 0 0.0001420168555341661
male O 0 2.614579898363445e-06
with O 0 3.5348250548850046e-06
PWS B-Disease 1 0.9997033476829529
, O 0 1.3336701840671594e-06
was O 0 4.401371427320555e-07
found O 0 1.6520550616405671e-07
to O 0 4.3074166455880913e-08
have O 0 4.342259884992927e-08
47 O 0 1.678386297498946e-06
chromosomes O 0 1.4045771195014822e-06
with O 0 1.173806296606017e-07
a O 0 8.665526252116251e-07
supernumerary O 0 0.0001488559355493635
, O 0 2.5038621060957666e-06
paternal O 0 0.00010246493911836296
der O 0 0.0010009085526689887
( O 0 2.0285769153360889e-07
15 O 0 1.5270825315383263e-07
) O 0 2.4698545431078855e-08
consisting O 0 4.700514821820434e-08
of O 0 2.123380760110649e-08
the O 0 6.969644061882718e-08
short O 0 2.4606019906059373e-06
arm O 0 3.067091529374011e-05
and O 0 1.2129555670981063e-07
the O 0 1.509383622533278e-07
proximal O 0 0.0023098611272871494
long O 0 4.702497972175479e-05
arm O 0 7.471159915439785e-05
of O 0 2.0675989276242035e-07
chromosome O 0 2.6247676942148246e-05
15 O 0 1.9199583221052308e-06
, O 0 7.163327495618432e-07
and O 0 2.6973127660312457e-06
distal O 0 0.15200483798980713
chromosome O 0 0.00583778228610754
arm O 0 0.050427377223968506
3p O 1 0.6146425008773804
. O 0 5.826525011798367e-05

The O 0 3.472185926511884e-05
t O 0 0.02132566273212433
( O 0 8.028736715459672e-07
3 O 0 7.434090889546496e-07
; O 0 2.0063319539076474e-07
15 O 0 1.3570965506914945e-07
) O 0 3.503120638015389e-08
was O 0 3.630488976114066e-08
present O 0 2.9397906331496415e-08
in O 0 1.1205084859966519e-08
the O 0 1.552526995851622e-08
balanced O 0 3.849279437417863e-07
state O 0 7.733299867140886e-08
in O 0 7.837542170818779e-08
the O 0 3.8143045344440907e-07
patients O 0 0.00017484399722889066
father O 0 9.475247679802123e-06
and O 0 6.766848059669428e-07
a O 0 4.171439286437817e-06
sister O 0 0.0004942363011650741
. O 0 2.2193016775418073e-05

Fluorescent O 0 0.0007834563730284572
in O 0 9.142297130892985e-06
situ O 0 6.126894004410133e-05
hybridization O 0 1.6230153050855733e-05
analysis O 0 5.8760801948665176e-06
demonstrated O 0 3.960045887652086e-06
that O 0 1.292098517069462e-07
the O 0 8.534589142072946e-07
PWS B-Disease 1 0.9911371469497681
critical O 0 9.907966159516945e-06
region O 0 4.756671387440292e-06
resided O 0 3.669982788778725e-06
on O 0 1.7698442889013677e-07
the O 0 7.540641178138685e-08
derivative O 0 4.9343061618856154e-06
chromosome O 0 8.203649485949427e-06
3 O 0 6.393936473614303e-07
and O 0 1.209933202517277e-07
that O 0 2.44599220877717e-08
there O 0 4.3158870255410875e-08
was O 0 1.2211569355713436e-07
no O 0 1.0258489169245877e-07
deletion O 0 7.909782766546414e-07
of O 0 5.459154550635503e-08
the O 0 6.600041615456576e-07
PWS B-Disease 1 0.9923354983329773
region O 0 9.907199682857026e-07
on O 0 1.261144291220262e-07
the O 0 7.208653585166758e-08
normal O 0 4.5287339389687986e-07
pair O 0 7.51086929540179e-07
of O 0 2.054598269296548e-07
15s O 0 7.308815111173317e-05
present O 0 8.756225042816368e-07
in O 0 1.4124458402875462e-06
J O 0 0.0023976133670657873
. O 0 1.1754583283618558e-05

B O 0 0.029210368171334267
. O 0 0.0009995802538469434

Methylation O 0 0.00038411683635786176
analysis O 0 1.778248588379938e-05
at O 0 3.7602862903440837e-06
exon O 0 2.5577779524610378e-05
alpha O 0 2.7417631827120204e-06
of O 0 1.659267780951268e-07
the O 0 1.583519946279921e-07
small O 0 1.0035786317530437e-06
nuclear O 0 4.079891004948877e-05
ribonucleoprotein O 0 0.0002915356890298426
- O 0 5.796079130959697e-05
associated O 0 1.4462719946095604e-06
polypeptide O 0 1.0027014468505513e-05
N O 0 2.80105432466371e-05
( O 0 1.7261916696043045e-07
SNRPN O 0 6.041133019607514e-05
) O 0 7.534444534940121e-08
gene O 0 3.910828922926157e-07
showed O 0 6.056591246306198e-07
a O 0 1.3006538779336552e-07
pattern O 0 1.722286128824635e-06
characteristic O 0 4.1057901967178623e-07
of O 0 3.4485204025713756e-08
only O 0 4.6437321543635335e-08
the O 0 1.828888400723372e-07
maternal O 0 4.197934322291985e-05
chromosome O 0 3.436670886003412e-05
15 O 0 3.637639792941627e-06
in O 0 3.1274478260456817e-06
J O 0 0.017481133341789246
. O 0 1.839620017562993e-05

B O 0 0.02226337045431137
. O 0 0.0008640334126539528

Maternal B-Disease 0 0.0050543625839054585
disomy I-Disease 0 0.033595938235521317
was O 0 1.2839480405091308e-05
confirmed O 0 3.639818942247075e-06
by O 0 8.033554195208126e-07
polymerase O 0 6.854891398688778e-05
chain O 0 1.089980378310429e-05
reaction O 0 5.552118977902865e-07
analysis O 0 2.0722319504784537e-07
of O 0 9.979765280831998e-08
microsatellite O 0 6.620772182941437e-05
repeats O 0 2.229486881333287e-06
at O 0 3.3218481121366494e-07
the O 0 1.2884119371392444e-07
gamma O 0 4.97071550853434e-06
- O 0 2.3373235308099538e-05
aminobutyric O 0 0.00013529921125154942
acid O 0 5.65550089959288e-06
receptor O 0 4.577296749630477e-06
beta3 O 0 4.5258675527293235e-05
subunit O 0 1.0246056262985803e-05
( O 0 1.3806295555696124e-06
GABRB3 O 0 0.00019344784959685057
) O 0 1.5925385241644108e-06
locus O 0 5.2619499911088496e-05
. O 0 1.603574310138356e-05

A O 0 9.185354429064319e-05
niece O 0 0.020625675097107887
( O 0 3.4266390684933867e-06
B O 0 7.267732871696353e-05
. O 0 2.6176462597504724e-07
B O 0 1.4171766451909207e-05
. O 0 3.937537940146285e-08
) O 0 2.3418035510758273e-08
with O 0 2.242959595832872e-08
45 O 0 9.69425570929161e-08
chromosomes O 0 4.220406992772041e-07
and O 0 4.8603371993749533e-08
the O 0 1.8290307934876182e-08
derivative O 0 1.0437425999043626e-06
3 O 0 1.7871801105684426e-07
but O 0 7.738523066791458e-08
without O 0 6.918941863887085e-08
the O 0 9.999180861086643e-08
der O 0 8.81262676557526e-05
( O 0 8.173961418833642e-08
15 O 0 1.529151916201954e-07
) O 0 7.580961636222128e-08
demonstrated O 0 7.666293413421954e-07
a O 0 3.828452008747263e-07
phenotype O 0 1.632805106055457e-05
consistent O 0 7.292367740774353e-07
with O 0 1.210075168955882e-07
that O 0 6.945187180917856e-08
reported O 0 5.897284154343652e-07
for O 0 1.9218548175103933e-07
haploinsufficiency O 0 0.0004501262737903744
of O 0 1.2109622957723332e-06
distal O 0 0.07663358002901077
3 O 0 7.09177547832951e-05
p O 0 0.003444741712883115
. O 0 1.49330398926395e-05

Uniparental B-Disease 1 0.9992052912712097
disomy I-Disease 1 0.9989809393882751
associated O 0 0.0007943711243569851
with O 0 9.560423677612562e-06
unbalanced O 0 0.00021590084361378103
segregation O 0 2.9673507015104406e-05
of O 0 4.831702540286642e-07
non O 0 1.2873872947238851e-05
- O 0 0.013152440078556538
Robertsonian O 0 0.0030361369717866182
translocations O 0 0.00018534551782067865
has O 0 6.073932468098064e-07
been O 0 2.8465839818636596e-07
reported O 0 1.2450727808754891e-06
previously O 0 4.6800192876617075e-07
but O 0 9.709967230264738e-08
has O 0 4.0144023216726055e-08
not O 0 2.1330091470872503e-08
, O 0 2.9047873439935756e-08
to O 0 1.9137026185944706e-08
our O 0 5.2771138570051335e-08
knowledge O 0 9.876110595996579e-08
, O 0 1.0549924667202504e-07
been O 0 5.7845113587973174e-08
observed O 0 3.4440907370481e-07
in O 0 1.0649169723819796e-07
a O 0 5.71801365367719e-07
case O 0 6.171234417706728e-06
of O 0 1.2421015526342671e-05
PWS B-Disease 1 0.9997501969337463
. O 0 0.0001213818250107579

Furthermore O 0 0.0001673087535891682
, O 0 6.329351890599355e-06
our O 0 1.4257275324780494e-06
findings O 0 2.0155923721176805e-06
are O 0 1.2193089560241788e-07
best O 0 4.863364893026301e-07
interpreted O 0 4.5271147541825485e-07
as O 0 1.3985753355427732e-07
true O 0 2.269714059366379e-06
gamete O 0 0.00012282982061151415
complementation O 0 0.2092272937297821
resulting O 0 1.6926416719798e-05
in O 0 3.0487867661577184e-06
maternal B-Disease 0 0.002790934406220913
UPD I-Disease 1 0.9993935823440552
15 I-Disease 0 0.00013478079927153885
and O 0 0.00020652935199905187
PWS B-Disease 1 0.9985985159873962

Schwartz B-Disease 1 0.742373526096344
- I-Disease 1 0.9977090358734131
Jampel I-Disease 1 0.9996292591094971
syndrome I-Disease 1 0.9994227886199951
type I-Disease 0 4.1511779272696e-05
2 I-Disease 0 8.620787411928177e-06
and O 0 1.0587237738945987e-05
Stuve B-Disease 1 0.9879432320594788
- I-Disease 1 0.9999569654464722
Wiedemann I-Disease 1 0.9999951124191284
syndrome I-Disease 1 0.9999451637268066
: O 0 3.095446118095424e-06
a O 0 1.6216022231674287e-06
case O 0 4.1288922147941776e-06
for O 0 4.615866942003777e-07
" O 0 2.541866706451401e-06
lumping O 0 0.00033924839226529
" O 0 8.324339432874694e-06
. O 0 9.438126653549261e-06

Recent O 0 7.464023656211793e-05
studies O 0 2.3729782697046176e-05
demonstrated O 0 1.3199213753978256e-05
the O 0 3.073027983191423e-07
existence O 0 4.4525148723550956e-07
of O 0 2.1075763356748212e-07
a O 0 1.050984224093554e-06
genetically O 0 8.521799827576615e-06
distinct O 0 6.746274721081136e-07
, O 0 3.45766949294557e-07
usually O 0 2.9595079809041636e-07
lethal O 0 8.158601758623263e-07
form O 0 3.3028879187213533e-08
of O 0 2.53136409611443e-08
the O 0 2.671681329502462e-07
Schwartz B-Disease 0 0.0038411931600421667
- I-Disease 1 0.9900366067886353
Jampel I-Disease 1 0.9999029636383057
syndrome I-Disease 1 0.9978342652320862
( O 0 2.852665375030483e-06
SJS B-Disease 1 0.704585611820221
) O 0 1.6790140477951354e-07
of O 0 6.361954660860647e-07
myotonia B-Disease 1 0.967712938785553
and O 0 0.0001476111210649833
skeletal B-Disease 1 0.9952065348625183
dysplasia I-Disease 1 0.999971866607666
, O 0 2.2560257093573455e-06
which O 0 2.7211868314225285e-07
we O 0 6.038354740667273e-07
called O 0 2.0329283870523795e-05
SJS B-Disease 1 0.9528352618217468
type I-Disease 0 1.883474578789901e-05
2 I-Disease 0 4.884663212578744e-06
. O 0 8.49176649353467e-06

This O 0 0.00014919057139195502
disorder O 1 0.8301883339881897
is O 0 1.7070101421268191e-06
reminiscent O 0 4.392454866319895e-05
of O 0 6.530836458296108e-07
another O 0 8.03944840299664e-06
rare O 0 0.00015625001105945557
condition O 0 0.0001116474304581061
, O 0 7.961441497172927e-07
the O 0 1.7353703469780157e-06
Stuve B-Disease 1 0.9893885254859924
- I-Disease 1 0.9999749660491943
Wiedemann I-Disease 1 0.9999953508377075
syndrome I-Disease 1 0.9998342990875244
( O 0 2.276774921483593e-06
SWS B-Disease 0 0.027994448319077492
) O 0 1.9694221009558532e-07
, O 0 8.798684092425901e-08
which O 0 2.9178256255590895e-08
comprises O 0 3.778980612878513e-07
campomelia B-Disease 0 0.0008566431351937354
at O 0 4.637598976842128e-06
birth O 0 4.23891433456447e-05
with O 0 1.3450891856336966e-05
skeletal B-Disease 1 0.9929977655410767
dysplasia I-Disease 1 0.9999755620956421
, O 0 6.206706166267395e-05
contractures B-Disease 1 0.9668898582458496
, O 0 4.271803845767863e-06
and O 0 1.390102511322766e-06
early B-Disease 0 1.289060583076207e-05
death I-Disease 0 3.8685368053847924e-05
. O 0 1.1067088053096086e-05

To O 0 1.5687393897678703e-05
test O 0 9.386038982484024e-06
for O 0 8.007196470316558e-07
possible O 0 3.630923174569034e-06
nosologic O 0 0.017365343868732452
identity O 0 3.0180879093677504e-06
between O 0 1.5091071645656484e-06
these O 0 3.421740757403313e-06
disorders O 1 0.7666342258453369
, O 0 7.590184054606652e-07
we O 0 1.038361077121408e-07
reviewed O 0 4.500533350437763e-07
the O 0 3.037399309846478e-08
literature O 0 8.84772290987712e-08
and O 0 8.403116424915424e-08
obtained O 0 1.0416141549285385e-07
a O 0 4.4054701220375136e-08
follow O 0 1.9271129758635652e-07
- O 0 9.176057574222796e-06
up O 0 7.99535655460204e-08
of O 0 1.0895654156684031e-08
the O 0 1.1549818879075247e-08
only O 0 1.0972525998909077e-08
two O 0 7.343335539644613e-08
surviving O 0 0.00016812868125271052
patients O 0 0.00013345717161428183
, O 0 1.0993079513355042e-07
one O 0 7.102175203499428e-08
with O 0 4.641341320166248e-07
SJS B-Disease 1 0.6835548281669617
type I-Disease 0 2.046181634796085e-06
2 I-Disease 0 3.9205829693855776e-07
at O 0 3.583306238397199e-07
age O 0 2.7854787276737625e-07
10 O 0 7.776223753808154e-08
years O 0 9.468569572845809e-08
and O 0 4.890465987728021e-08
another O 0 1.5937312980440765e-07
with O 0 2.722557610468357e-07
SWS B-Disease 0 0.012318572960793972
at O 0 1.6918048686420661e-06
age O 0 1.9461951978883008e-06
7 O 0 3.5842781471728813e-06
years O 0 3.1158465390035417e-06
. O 0 1.0194262358709238e-05

Patients O 1 0.9357879161834717
reported O 0 0.00017066451255232096
as O 0 2.1253840714052785e-06
having O 0 2.659154688444687e-06
either O 0 9.961382602341473e-06
neonatal O 1 0.9997350573539734
SJS B-Disease 1 0.9998983144760132
or O 0 3.568618558347225e-05
SWS B-Disease 0 0.3897894322872162
presented O 0 5.3286134971131105e-06
a O 0 8.592778613092378e-07
combination O 0 2.0522772956610424e-06
of O 0 4.299811564578704e-07
a O 0 8.692627488926519e-06
severe O 0 0.004195490851998329
, O 0 1.4954245671106037e-05
prenatal O 1 0.9981449842453003
- O 1 0.9999775886535645
onset O 1 0.9999961853027344
neuromuscular B-Disease 1 0.9999991655349731
disorder I-Disease 1 0.9999393224716187
( O 0 5.0717506383080035e-05
with O 0 0.0004045879759360105
congenital B-Disease 1 0.9999953508377075
joint I-Disease 1 0.9257461428642273
contractures I-Disease 1 0.999985933303833
, O 0 0.021970150992274284
respiratory O 0 0.4642467200756073
and O 0 5.243515715847025e-06
feeding O 0 0.0001289105712203309
difficulties O 0 0.00010739318531705067
, O 0 1.318155113949615e-06
tendency O 0 3.577134066290455e-06
to O 0 1.8081412918036222e-06
hyperthermia B-Disease 1 0.9245789647102356
, O 0 1.124016762332758e-06
and O 0 3.813995306245488e-07
frequent O 0 5.1041156439168844e-06
death O 0 8.801419426163193e-06
in O 0 8.631981245343923e-07
infancy O 0 0.0003087507502641529
) O 0 1.9675184148582048e-07
with O 0 1.850407755910055e-07
a O 0 6.249061925700516e-07
distinct O 0 3.8273201425909065e-06
campomelic B-Disease 0 0.140605166554451
- I-Disease 1 0.8726325631141663
metaphyseal I-Disease 1 0.9897568821907043
skeletal I-Disease 1 0.9843252897262573
dysplasia I-Disease 1 0.9996802806854248
. O 0 0.0001488204434281215

The O 0 1.1021230420737993e-05
similarity O 0 1.284725840378087e-05
of O 0 4.361916978723457e-07
the O 0 3.8551758052562946e-07
clinical O 0 6.872307130834088e-05
and O 0 1.962471515071229e-06
radiographic O 0 0.3745800256729126
findings O 0 3.427264164201915e-05
is O 0 2.5989206164922507e-07
so O 0 1.8070846863338375e-07
extensive O 0 1.7870297597255558e-06
that O 0 3.889846311722067e-07
these O 0 3.8077366752986563e-06
disorders O 1 0.8367419838905334
appear O 0 3.046261099370895e-06
to O 0 1.992215032942113e-07
be O 0 1.5034531486435299e-07
a O 0 5.701410827896325e-07
single O 0 3.0740527563466458e-06
entity O 0 2.4691755243111402e-05
. O 0 9.626074643165339e-06

The O 0 1.201102259074105e-05
follow O 0 1.4586649740522262e-05
- O 0 7.203350105555728e-05
up O 0 1.5540755384790828e-06
observation O 0 2.089991994580487e-06
of O 0 1.1504509700444032e-07
an O 0 1.1336933880556899e-07
identical O 0 3.778991185754421e-06
and O 0 1.46855995808437e-07
unique O 0 2.2154212331315648e-07
pattern O 0 1.8212731447420083e-06
of O 0 4.983157282367756e-07
progressive O 0 0.3475779891014099
bone B-Disease 1 0.9994872808456421
dysplasia I-Disease 1 0.9999110698699951
in O 0 6.172231223899871e-07
the O 0 4.245152069870528e-07
two O 0 3.0845601486362284e-06
patients O 0 0.0005419906810857356
( O 0 1.4403104842131143e-07
one O 0 8.232620274384317e-08
with O 0 9.722834874992259e-07
SJS B-Disease 1 0.9694865942001343
type I-Disease 0 6.675989425275475e-06
2 I-Disease 0 5.804758984595537e-07
, O 0 1.36223277991121e-07
one O 0 8.514357574540554e-08
with O 0 2.9385245170487906e-07
SWS B-Disease 0 0.002964096376672387
) O 0 1.9843761833726603e-07
surviving O 0 9.437644052923133e-07
beyond O 0 9.559279305904056e-07
infancy O 0 3.9681246562395245e-05
adds O 0 1.184667098641512e-06
to O 0 7.184249284364341e-08
the O 0 5.536975322684157e-08
evidence O 0 4.4858910541734076e-07
in O 0 1.6556195703287813e-07
favor O 0 2.733392648224253e-06
of O 0 1.3697837175641325e-06
identity O 0 1.6012516425689682e-05
. O 0 1.2609085388248786e-05

The O 0 2.713352660066448e-05
hypothesis O 0 3.619204289861955e-05
that O 0 1.5352056834672112e-06
SWS B-Disease 0 0.004166734870523214
and O 0 7.716480467934161e-06
SJS B-Disease 1 0.968834638595581
type I-Disease 0 1.2380935913824942e-05
2 I-Disease 0 6.656330810983491e-07
are O 0 3.833332229419284e-08
the O 0 1.1701771995831223e-07
same O 0 3.1295842291001463e-06
disorder O 0 0.01998012699186802
should O 0 1.596484651145147e-07
be O 0 4.930082653231693e-08
testable O 0 2.4938224214565707e-06
by O 0 1.7563812093612796e-07
molecular O 0 6.05113427809556e-06
methods O 0 2.516845142963575e-06
. O 0 1.7052105931725237e-06
. O 0 8.791880645730998e-06

A O 0 8.518103277310729e-05
mouse O 0 0.0001873781584436074
model O 0 2.626936293381732e-05
of O 0 7.32364715076983e-05
severe O 1 0.9998517036437988
von B-Disease 1 0.9999997615814209
Willebrand I-Disease 1 0.9999996423721313
disease I-Disease 1 0.9999938011169434
: O 0 0.00978007074445486
defects O 1 0.998786985874176
in O 0 8.655509009258822e-05
hemostasis O 1 0.9994636178016663
and O 0 0.00298696244135499
thrombosis B-Disease 1 0.9998190999031067
. O 0 0.0003235669282730669

von B-Disease 1 0.9964286684989929
Willebrand I-Disease 1 0.9961676001548767
factor I-Disease 0 0.0015802899142727256
( I-Disease 0 0.00010656728409230709
vWf I-Disease 1 0.9763389825820923
) I-Disease 0 0.009482242166996002
deficiency I-Disease 1 0.9999375343322754
causes O 1 0.935374915599823
severe O 1 0.9999592304229736
von B-Disease 1 0.9999998807907104
Willebrand I-Disease 1 0.9999995231628418
disease I-Disease 1 0.9999613761901855
in O 0 3.531982292770408e-05
humans O 0 3.773527714656666e-05
. O 0 3.296245267847553e-05

We O 0 1.1073422683693934e-05
generated O 0 4.415882358443923e-06
a O 0 1.153695848188363e-06
mouse O 0 1.4941131667001173e-05
model O 0 2.184918457714957e-06
for O 0 6.913512606843142e-07
this O 0 2.211504124716157e-06
disease O 0 0.0001021651187329553
by O 0 2.0611395257219556e-07
using O 0 6.55542805816367e-07
gene O 0 5.294341463013552e-06
targeting O 0 1.5847354006837122e-05
. O 0 1.2159998732386157e-05

vWf B-Disease 1 0.7409235835075378
- I-Disease 1 0.8266831040382385
deficient I-Disease 1 0.6684420108795166
mice O 0 0.00024195168225560337
appeared O 0 5.8453674682823475e-06
normal O 0 2.7426758606452495e-06
at O 0 2.767388878055499e-06
birth O 0 1.461446845496539e-05
; O 0 5.161147100807284e-07
they O 0 8.674111029449705e-08
were O 0 1.7285836406699673e-07
viable O 0 6.369134098349605e-06
and O 0 1.726133859847323e-06
fertile O 0 0.0003663289244286716
. O 0 1.6925287127378397e-05

Neither O 0 0.0014963240828365088
vWf O 0 0.014099441468715668
nor O 0 0.00042686270899139345
vWf O 0 0.018609484657645226
propolypeptide O 0 0.12059836834669113
( O 0 6.274328188737854e-05
von B-Disease 1 0.984128475189209
Willebrand I-Disease 1 0.9980633854866028
antigen O 0 0.32652032375335693
II O 0 0.021697895601391792
) O 0 9.30405974486348e-07
were O 0 2.2174356217874447e-07
detectable O 0 2.868318688342697e-06
in O 0 8.264274242719694e-08
plasma O 0 2.582301567599643e-05
, O 0 3.86241822525335e-07
platelets O 0 0.0017725114012137055
, O 0 3.8216739994823e-07
or O 0 6.973273798394075e-07
endothelial O 0 0.00024380447575822473
cells O 0 1.4974018540669931e-06
of O 0 6.595605839265772e-08
the O 0 5.427866085483402e-07
homozygous O 0 2.807973032759037e-05
mutant O 0 0.0001748156500980258
mice O 0 0.0001955130137503147
. O 0 2.643819789227564e-05

The O 0 5.8285706472815946e-05
mutant O 0 0.001376244705170393
mice O 0 0.01243538036942482
exhibited O 0 0.0021338409278541803
defects O 1 0.9793255925178528
in O 0 8.406500455748755e-06
hemostasis O 1 0.9645410776138306
with O 0 2.6237869406031677e-06
a O 0 6.259222573135048e-06
highly O 0 4.506057666731067e-05
prolonged O 0 0.41107454895973206
bleeding O 1 0.5618887543678284
time O 0 1.0284923064318718e-06
and O 0 6.853774152659753e-07
spontaneous O 0 5.938615868217312e-05
bleeding O 0 0.011268384754657745
events O 0 4.246042806244077e-07
in O 0 1.3174270918625552e-07
approximately O 0 4.487679916564957e-07
10 O 0 3.4955127148350584e-07
% O 0 3.778429231715563e-07
of O 0 1.091679905584897e-06
neonates O 0 0.00435794610530138
. O 0 2.470758590789046e-05

As O 0 1.2898474778921809e-05
in O 0 1.526256937722792e-06
the O 0 1.2038209433740121e-06
human O 0 2.4135822968673892e-05
disease O 0 0.0017295206198468804
, O 0 1.910706970420506e-07
the O 0 1.0840766151432035e-07
factor O 0 1.597395339558716e-06
VIII O 0 0.0005283456994220614
level O 0 8.497069075019681e-07
in O 0 7.82389051323662e-08
these O 0 6.374830263666809e-08
mice O 0 3.195393446731032e-06
was O 0 2.1413620743260253e-07
reduced O 0 1.2928273918078048e-06
strongly O 0 4.2681813283707015e-07
as O 0 3.0724240929203006e-08
a O 0 7.02915983197272e-08
result O 0 9.597354733159591e-08
of O 0 4.2258442078946246e-08
the O 0 1.2331560128586716e-07
lack O 0 7.901783192210132e-07
of O 0 1.4209993537406262e-07
protection O 0 4.717553565569688e-06
provided O 0 9.195883876600419e-07
by O 0 2.7608198251982685e-06
vWf O 0 0.0028463383205235004
. O 0 1.646662894927431e-05

Defective O 1 0.993739128112793
thrombosis B-Disease 1 0.9991544485092163
in O 0 3.966811709688045e-05
mutant O 0 0.0008301489870063961
mice O 0 0.0004847153031732887
was O 0 2.0421889530553017e-06
also O 0 3.328586899442598e-07
evident O 0 1.126069264500984e-06
in O 0 5.254264934251296e-08
an O 0 4.5547999150130636e-08
in O 0 1.5243733741954202e-07
vivo O 0 6.826514436397702e-05
model O 0 3.677333324958454e-06
of O 0 1.202370913233608e-05
vascular B-Disease 1 0.9998430013656616
injury I-Disease 0 0.06076139956712723
. O 0 9.248116111848503e-05

In O 0 9.738761946209706e-06
this O 0 7.786009632582136e-07
model O 0 2.810395017149858e-06
, O 0 3.2534626370761544e-07
the O 0 2.0076068096841482e-07
exteriorized O 0 0.00016664943541400135
mesentery O 0 0.0003346152661833912
was O 0 1.2986747606191784e-06
superfused O 0 0.00024552299873903394
with O 0 1.5020086721051484e-06
ferric O 0 0.17826376855373383
chloride O 0 6.0406371630961075e-05
and O 0 1.9875581358519412e-07
the O 0 8.872243739688201e-08
accumulation O 0 2.908396481871023e-06
of O 0 2.8617509428841004e-07
fluorescently O 0 0.03007730282843113
labeled O 0 0.00019200053066015244
platelets O 0 0.0019243701826781034
was O 0 7.640426815669343e-07
observed O 0 1.5908095747363404e-06
by O 0 6.93852655331284e-07
intravital O 0 0.0005049434257671237
microscopy O 0 0.00013884423242416233
. O 0 2.304021290910896e-05

We O 0 2.5386772904312238e-05
conclude O 0 7.019474287517369e-05
that O 0 1.0385634823251166e-06
these O 0 7.583686851830862e-07
mice O 0 3.174322409904562e-05
very O 0 2.865016085706884e-06
closely O 0 4.076110781170428e-05
mimic O 0 0.14675062894821167
severe O 0 0.2551901638507843
human O 0 0.05257679894566536
von B-Disease 1 0.9999998807907104
Willebrand I-Disease 1 0.9999996423721313
disease I-Disease 1 0.9993013143539429
and O 0 3.2829641440912383e-06
will O 0 1.0086987458635122e-06
be O 0 1.4930654401723586e-07
very O 0 2.478269038874714e-07
useful O 0 2.5451527108089067e-07
for O 0 5.746879594425991e-08
investigating O 0 1.0344396059736027e-06
the O 0 2.2690612055953352e-08
role O 0 8.405921647636205e-08
of O 0 6.031655175320338e-08
vWf O 0 7.706059113843367e-05
in O 0 1.1507560770951386e-07
normal O 0 1.2998320926271845e-06
physiology O 0 1.2716077435470652e-05
and O 0 1.840019990595465e-06
in O 0 8.908282325137407e-06
disease O 0 0.00040508346864953637
models O 0 1.5690176951466128e-05
. O 0 3.978943823312875e-06
. O 0 1.410354525432922e-05

Oral O 0 0.007623868063092232
contraceptives O 0 0.09299065917730331
and O 0 9.046832929016091e-06
the O 0 4.720082415587967e-06
risk O 0 0.0009495707927271724
of O 0 0.0009758952655829489
hereditary B-Disease 1 0.9999971389770508
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999958276748657
. O 0 0.0005792424781247973

Hereditary B-Disease 1 0.9999709129333496
Ovarian I-Disease 1 0.9999990463256836
Cancer I-Disease 1 0.9999841451644897
Clinical O 1 0.9223921895027161
Study O 0 0.0007814022246748209
Group O 0 0.0003171986318193376
. O 0 7.710837235208601e-05

BACKGROUND O 0 0.0007563981926068664
Women O 0 2.365950604144018e-05
with O 0 2.8909914817631943e-06
mutations O 0 1.5240027096297126e-05
in O 0 2.9648950317096023e-07
either O 0 3.298437718513014e-07
the O 0 2.7267668656349997e-07
BRCA1 O 0 0.0009409133926965296
or O 0 7.706250357841782e-07
the O 0 3.578620919597597e-07
BRCA2 O 0 6.218614726094529e-05
gene O 0 1.3928253110861988e-06
have O 0 8.340538215634297e-08
a O 0 4.753891573727742e-07
high O 0 2.793974090309348e-05
lifetime O 0 0.00039716027094982564
risk O 0 0.007432966027408838
of O 0 0.02380858175456524
ovarian B-Disease 1 0.9999998807907104
cancer I-Disease 1 0.9999877214431763
. O 0 0.00022862393234390765

Oral O 0 0.019869765266776085
contraceptives O 1 0.680889904499054
protect O 0 0.02407727763056755
against O 1 0.8877114057540894
ovarian B-Disease 1 1.0
cancer I-Disease 1 0.9999942779541016
in O 0 2.968028638861142e-06
general O 0 1.32460718305083e-05
, O 0 1.856806534306088e-06
but O 0 1.8513662780605955e-07
it O 0 4.493062633059708e-08
is O 0 5.226468502428361e-08
not O 0 3.4810209825764105e-08
known O 0 1.3668407916611613e-07
whether O 0 1.6927380386277946e-07
they O 0 8.441848109441707e-08
also O 0 1.751079281575585e-07
protect O 0 4.029287083540112e-06
against O 0 6.061437943571946e-06
hereditary B-Disease 0 0.01860356330871582
forms I-Disease 0 0.0001049102793331258
of I-Disease 0 0.07307171076536179
ovarian I-Disease 1 0.9999998807907104
cancer I-Disease 1 0.9999850988388062
. O 0 0.00022621707466896623

METHODS O 0 0.00011658924631774426
We O 0 1.0064003618026618e-05
enrolled O 0 2.855892489606049e-05
207 O 0 4.503050513449125e-05
women O 0 1.846730083343573e-05
with O 0 0.0003695347986649722
hereditary B-Disease 1 0.9999938011169434
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999961853027344
and O 0 4.542980150290532e-06
161 O 0 2.3512873667641543e-05
of O 0 2.0167024672446132e-07
their O 0 2.632127689139452e-07
sisters O 0 5.786762358184205e-06
as O 0 5.796970015126135e-08
controls O 0 7.40561688417074e-07
in O 0 8.121868688704126e-08
a O 0 3.6197516806169006e-07
case O 0 4.600486136041582e-06
- O 0 0.0003099729947280139
control O 0 6.910750926181208e-06
study O 0 5.347908427211223e-06
. O 0 8.997249096864834e-06

All O 0 1.3260239938972518e-05
the O 0 6.8642207224911544e-06
patients O 0 0.00037548583350144327
carried O 0 2.360315875193919e-06
a O 0 1.2019796713502728e-06
pathogenic O 0 6.27572626399342e-06
mutation O 0 1.9747681108128745e-06
in O 0 2.3177594243861677e-07
either O 0 1.0780778438856942e-06
BRCA1 O 0 0.0002081397396977991
( O 0 4.003273943453678e-07
179 O 0 1.4675208149128594e-05
women O 0 1.3304511412570719e-06
) O 0 2.3875139731899253e-07
or O 0 2.400280891379225e-06
BRCA2 O 0 0.0002333226439077407
( O 0 4.661018238039105e-07
28 O 0 2.2572203306481242e-06
women O 0 1.280048650187382e-06
) O 0 1.491069156145386e-06
. O 0 7.1598492468183395e-06

The O 0 1.4842116797808558e-05
control O 0 1.621043156774249e-05
women O 0 2.2269223336479627e-06
were O 0 5.117154842082527e-07
enrolled O 0 4.4068415263609495e-06
regardless O 0 1.3572224588642712e-06
of O 0 1.3161411516193766e-07
whether O 0 6.387890607584268e-07
or O 0 1.7981881228479324e-07
not O 0 5.6903900258475915e-08
they O 0 8.849242760788911e-08
had O 0 5.116100965096848e-07
either O 0 2.191358362324536e-06
mutation O 0 1.2771740330208559e-05
. O 0 4.943863586959196e-06

Lifetime O 0 0.0010411314433440566
histories O 0 0.00015869189519435167
of O 0 5.469073130370816e-06
oral O 0 0.0003892643435392529
- O 0 0.14176425337791443
contraceptive O 0 0.039201825857162476
use O 0 8.228332717408193e-07
were O 0 1.3921439290243143e-07
obtained O 0 2.3587266184676992e-07
by O 0 1.9596123479459493e-07
interview O 0 1.3206214134697802e-05
or O 0 3.0986811339062115e-07
by O 0 1.0142493778175776e-07
written O 0 1.3644626051245723e-07
questionnaire O 0 5.0020676098938566e-06
and O 0 1.903237887290743e-07
were O 0 1.621452412337021e-07
compared O 0 7.466337137884693e-06
between O 0 2.220752776338486e-06
patients O 0 8.406399138038978e-05
and O 0 3.029701645118621e-07
control O 0 2.330484903723118e-06
women O 0 4.82307029869844e-07
, O 0 1.9682278207255877e-07
after O 0 3.1371004638458544e-07
adjustment O 0 9.376746561429172e-07
for O 0 4.903421313429135e-08
year O 0 2.3599821474817873e-07
of O 0 2.2288440959528089e-07
birth O 0 2.1106483472976834e-05
and O 0 1.8902948113463935e-06
parity O 0 3.592178472899832e-05
. O 0 1.0680006198526826e-05

RESULTS O 0 0.00013731574290432036
The O 0 6.281767582549946e-06
adjusted O 0 6.433819362428039e-05
odds O 0 0.0005552452057600021
ratio O 0 0.00012977392179891467
for O 0 0.018377255648374557
ovarian B-Disease 1 1.0
cancer I-Disease 1 0.9999986886978149
associated O 0 4.661692582885735e-05
with O 0 5.041877670919348e-07
any O 0 2.3220161438075593e-07
past O 0 3.059879816191824e-07
use O 0 9.658561594960702e-08
of O 0 1.446728532528141e-07
oral O 0 7.378479494946077e-05
contraceptives O 0 0.012542582117021084
was O 0 1.2236217116878834e-05
0 O 0 3.400895366212353e-05
. O 0 1.3786790077574551e-05

5 O 0 2.787129233183805e-05
( O 0 2.350555632801843e-06
95 O 0 3.2437762911285972e-06
percent O 0 2.902732603615732e-06
confidence O 0 6.202424174261978e-07
interval O 0 5.215067062636081e-07
, O 0 5.45462697232324e-08
0 O 0 7.426920944908488e-08
. O 0 1.0352064094831803e-08
3 O 0 4.077674375935203e-08
to O 0 1.694919582462262e-08
0 O 0 2.1075943834603095e-07
. O 0 4.13272651655916e-08
8 O 0 6.718871077282529e-07
) O 0 5.261817364043964e-07
. O 0 2.2017611627234146e-06

The O 0 5.482968845171854e-05
risk O 0 0.0005258754827082157
decreased O 0 2.3941745894262567e-05
with O 0 3.472407570370706e-07
increasing O 0 4.399621502670925e-07
duration O 0 1.4246782029658789e-06
of O 0 5.719563134221062e-08
use O 0 2.2244931585646555e-07
( O 0 1.9094848369149986e-07
P O 0 3.6832709156442434e-05
for O 0 6.13850019703932e-08
trend O 0 1.1776156725318287e-06
, O 0 1.4914630241946725e-07
< O 0 3.98261436203029e-05
0 O 0 3.368652130575356e-07
. O 0 3.6270837000529355e-08
001 O 0 3.0126846013445174e-06
) O 0 2.8088619430377548e-08
; O 0 1.3950008259655533e-08
use O 0 1.0630373026287998e-08
for O 0 2.1280555984048988e-08
six O 0 4.250515672765687e-08
or O 0 3.9139962382250815e-08
more O 0 2.02537115967516e-08
years O 0 1.2069115484791837e-07
was O 0 1.199396137963049e-07
associated O 0 1.5953126819567842e-07
with O 0 4.653946561461453e-08
a O 0 7.728787920768809e-08
60 O 0 5.360329851100687e-07
percent O 0 3.502624394968734e-06
reduction O 0 1.2099614650651347e-05
in O 0 2.1275641302054282e-06
risk O 0 7.161514804465696e-05
. O 0 8.363392225874122e-06

Oral O 0 0.007339709438383579
- O 0 0.16765928268432617
contraceptive O 0 0.053719375282526016
use O 0 1.4945022485335357e-05
protected O 0 0.001974022015929222
against O 0 0.47596579790115356
ovarian B-Disease 1 1.0
cancer I-Disease 1 0.9999902248382568
both O 0 1.3021671065871487e-06
for O 0 6.354568995448062e-07
carriers O 0 3.873731657222379e-06
of O 0 1.8083430575188686e-07
the O 0 9.393250479661219e-07
BRCA1 O 0 0.0062439097091555595
mutation O 0 9.473043064645026e-06
( O 0 2.9465925877047994e-07
odds O 0 2.1286039554979652e-05
ratio O 0 7.684483307457413e-07
, O 0 8.072000667880275e-08
0 O 0 1.5253097274126048e-07
. O 0 1.0704067854305777e-08
5 O 0 5.395564173227285e-08
; O 0 3.128662484641609e-08
95 O 0 1.31240611267458e-07
percent O 0 3.837312192445097e-07
confidence O 0 3.580881013931503e-07
interval O 0 3.424217709380173e-07
, O 0 2.6004448372418665e-08
0 O 0 7.117933620293115e-08
. O 0 6.813658970372671e-09
3 O 0 1.2620197331614236e-08
to O 0 6.9693886217692125e-09
0 O 0 9.053378136059109e-08
. O 0 1.758263934448223e-08
9 O 0 1.6142993786161242e-07
) O 0 1.4227291345036974e-08
and O 0 1.376223668358989e-08
for O 0 1.4721700303255147e-08
carriers O 0 2.026913961117316e-07
of O 0 1.9730308054022316e-08
the O 0 2.1243981507268472e-07
BRCA2 O 0 0.0003854965034406632
mutation O 0 2.3327017970586894e-06
( O 0 1.2612778732545848e-07
odds O 0 9.116022738453466e-06
ratio O 0 4.5085494093655143e-07
, O 0 5.0770808002198464e-08
0 O 0 1.510731522103015e-07
. O 0 1.6710661299157437e-08
4 O 0 6.899425386563962e-08
; O 0 4.180046531132575e-08
95 O 0 1.2523089765181794e-07
percent O 0 2.2086854301051062e-07
confidence O 0 1.567555472092863e-07
interval O 0 2.178536107066975e-07
, O 0 3.02510159144731e-08
0 O 0 7.673309454503396e-08
. O 0 8.090942138494484e-09
2 O 0 2.0594452365685356e-08
to O 0 1.186876907866008e-08
1 O 0 6.748913250476107e-08
. O 0 3.01909537370193e-08
1 O 0 2.9018866598562454e-07
) O 0 3.3490385931145283e-07
. O 0 1.6876473409865866e-06

CONCLUSIONS O 0 0.0005949654150754213
Oral O 0 0.0015719300135970116
- O 0 0.022750280797481537
contraceptive O 0 0.008652979508042336
use O 0 1.8582537677502842e-06
may O 0 1.3849656852471526e-06
reduce O 0 2.767668547676294e-06
the O 0 4.345723709775484e-07
risk O 0 0.00014005773118697107
of O 0 0.002046663546934724
ovarian B-Disease 1 1.0
cancer I-Disease 1 0.9999960660934448
in O 0 5.306618731992785e-06
women O 0 3.88363287129323e-06
with O 0 8.694291295796575e-07
pathogenic O 0 1.5819388863747008e-05
mutations O 0 2.2671483748126775e-06
in O 0 1.8666662526811706e-07
the O 0 1.3383921668719267e-06
BRCA1 O 0 0.005350595340132713
or O 0 4.2623229091987014e-05
BRCA2 O 0 0.0036749509163200855
gene O 0 0.00044597129453904927

A O 0 8.750383858568966e-05
Japanese O 0 0.000124369835248217
family O 0 0.00010893024591496214
with O 0 2.750393468886614e-05
adrenoleukodystrophy B-Disease 1 0.9999465942382812
with O 0 1.441246581634914e-06
a O 0 6.743071025994141e-07
codon O 0 4.279032964404905e-06
291 O 0 8.047071787586901e-06
deletion O 0 1.3554267752624582e-05
: O 0 6.079629315536295e-07
a O 0 6.925945967850566e-07
clinical O 0 7.00146410963498e-05
, O 0 1.2586683624249417e-06
biochemical O 0 5.638538277707994e-05
, O 0 3.6727699352923082e-06
pathological O 0 0.0004930613795295358
, O 0 1.7268781675738865e-06
and O 0 1.7813941894928575e-06
genetic O 0 5.333328226697631e-05
report O 0 5.301359124132432e-06
. O 0 1.2715955563180614e-05

We O 0 2.1495725377462804e-05
report O 0 3.913723503501387e-06
a O 0 1.0518776889512083e-06
Japanese O 0 5.744906957261264e-06
family O 0 2.870243406505324e-05
with O 0 0.0002683901693671942
adrenoleukodystrophy B-Disease 1 0.9999991655349731
( O 0 0.0004682510334532708
ALD B-Disease 1 0.9999978542327881
) O 0 1.9062383671553107e-06
with O 0 1.8418003833176044e-07
a O 0 2.077527057053885e-07
three O 0 1.0204821165871181e-07
base O 0 1.7224601833731867e-06
pair O 0 2.713049980229698e-06
deletion O 0 7.748211828584317e-06
( O 0 3.971570947669534e-07
delGAG O 0 3.811102578765713e-05
291 O 0 3.6889596231048927e-06
) O 0 1.926587458456197e-07
in O 0 2.7118500156575465e-07
the O 0 3.1347788080893224e-06
ALD B-Disease 1 0.999817430973053
gene O 0 8.048282325034961e-05
. O 0 2.8790815122192726e-05

A O 0 2.7991822207695805e-05
variety O 0 9.994497304433025e-06
of O 0 1.5459307860510307e-06
phenotypes O 0 9.141558984993026e-05
were O 0 7.565765258732426e-07
observed O 0 2.0547524854919175e-06
within O 0 7.582804641970142e-07
this O 0 7.495034992643923e-07
family O 0 1.2510640772234183e-05
. O 0 2.1332496544346213e-05

While O 0 2.4286893676617183e-05
the O 0 4.537705990514951e-06
proband O 0 0.009045197628438473
( O 0 3.4728157061181264e-06
patient O 0 9.82366400421597e-05
1 O 0 1.5099695929166046e-06
) O 0 1.8504536569707852e-07
was O 0 3.788362334944395e-07
classified O 0 3.00258511742868e-06
as O 0 7.520890932255497e-08
having O 0 1.6621977749764483e-07
a O 0 1.8982494509600656e-07
rare O 0 1.8075429579766933e-06
intermediate O 0 1.6487559832967236e-06
type O 0 6.200502298270294e-07
of O 0 6.766184412754228e-08
adult O 0 1.2151698683737777e-05
cerebral O 0 0.011890290305018425
and O 0 2.343113692404586e-06
cerebello O 0 0.28190967440605164
- O 1 0.7476212978363037
brain O 0 0.035082388669252396
stem O 0 7.8669807408005e-05
forms O 0 7.515168363170233e-07
, O 0 3.766524514503544e-07
his O 0 6.001829433444072e-07
younger O 0 3.3718501072144136e-05
brother O 0 5.310009146342054e-05
( O 0 5.336865456229134e-07
patient O 0 1.2080223314114846e-05
2 O 0 7.22643960671121e-07
) O 0 1.5678828901855013e-07
and O 0 5.685978976543993e-07
nephew O 0 0.0019955975003540516
( O 0 8.705758318683365e-07
patient O 0 4.43932440248318e-05
3 O 0 1.6017551160985022e-06
) O 0 3.765073586237122e-07
had O 0 6.718198051203217e-07
a O 0 5.793604032078292e-06
childhood O 0 0.3955185115337372
ALD B-Disease 1 0.9999887943267822
type O 0 0.001711016520857811
. O 0 3.399514389457181e-05

Another O 0 0.00013627718726638705
nephew O 0 0.03264092653989792
( O 0 1.3962119737698231e-05
patient O 0 0.0002717568713705987
4 O 0 3.100400590483332e-06
) O 0 1.609497246590763e-07
of O 0 1.6111373213334446e-07
patient O 0 0.00011133561929455027
1 O 0 2.423683554297895e-06
was O 0 1.891005240395316e-06
classified O 0 4.748698756884551e-06
as O 0 8.007550178490419e-08
having O 0 2.1422016516225995e-07
an O 0 2.2086305762059055e-07
adolescent O 0 0.0003410952922422439
form O 0 5.748091098212171e-06
. O 0 1.314564906351734e-05

The O 0 1.2292147403059062e-05
tau O 0 5.3851850680075586e-05
level O 0 1.929790414578747e-06
in O 0 1.706570742499025e-07
the O 0 1.8343835961331934e-07
cerebrospinal O 0 0.0002053335920209065
fluid O 0 6.961531471461058e-05
( O 0 1.2992272786505055e-06
CSF O 0 0.1209300085902214
) O 0 2.162832259955394e-07
in O 0 1.3963563105789945e-07
patient O 0 1.811493893910665e-05
1 O 0 5.692810418622685e-07
was O 0 1.4516153612476046e-07
as O 0 4.6752195004273744e-08
high O 0 5.767632842434978e-07
as O 0 2.2428482182590415e-08
that O 0 1.7412533637184424e-08
of O 0 3.824802661256399e-07
patients O 0 0.005003152880817652
with O 0 0.0028634772170335054
Alzheimers B-Disease 1 0.9999995231628418
disease I-Disease 0 0.47707468271255493
( O 0 2.11433757613122e-06
AD B-Disease 0 0.00014943460701033473
) O 0 4.025354428449646e-06
. O 0 1.180538583867019e-05

His O 0 0.0001160294923465699
brain O 0 0.001364034367725253
magnetic O 0 9.253973985323682e-05
resonance O 0 0.00017841959197539836
image O 0 9.873843373497948e-05
( O 0 2.365002501392155e-06
MRI O 0 0.0062233624048531055
) O 0 1.6136665408339468e-06
showed O 0 8.158200944308192e-05
abnormalities B-Disease 0 0.026676181703805923
in I-Disease 0 2.739855062827701e-07
the I-Disease 0 2.22981356046148e-07
bilateral I-Disease 0 4.120932862861082e-05
cerebellar I-Disease 0 0.49385547637939453
hemispheres I-Disease 0 0.0002101528225466609
and O 0 1.1184819413756486e-05
brain O 0 0.01368371769785881
stem O 0 0.00010415232827654108
, O 0 4.6810373532935046e-07
but O 0 9.475615314613606e-08
not O 0 2.8277028718548536e-08
in O 0 3.662286829353434e-08
the O 0 1.448332653808393e-07
cerebral O 0 0.09372448921203613
white O 0 0.00012026794865960255
matter O 0 2.031602434726665e-06
, O 0 3.491980749004142e-07
where O 0 1.456324270066034e-07
marked O 0 1.1825393357867142e-06
reductions O 0 2.310503987246193e-06
of O 0 5.4950810124410054e-08
the O 0 4.1041460008273134e-07
cerebral O 0 0.020978983491659164
blood O 0 1.352571871393593e-05
flow O 0 8.415721026722167e-07
and O 0 1.8449664196396043e-07
oxygen O 0 2.5494141482340638e-06
metabolism O 0 2.1467656097229337e-06
were O 0 8.181947919183585e-08
clearly O 0 3.1244320553014404e-07
demonstrated O 0 5.281005996948807e-07
by O 0 2.106322511963299e-07
positron O 0 2.6329051252105273e-05
emission O 0 6.301387657003943e-06
tomography O 0 2.5578436179785058e-05
( O 0 1.3712278814637102e-06
PET O 0 5.351179061108269e-05
) O 0 2.620536179165356e-06
. O 0 4.712921509053558e-06

In O 0 5.142073132446967e-05
patients O 0 0.0005465129506774247
2 O 0 3.772315494643408e-06
and O 0 4.535653772563819e-07
3 O 0 1.3437510233416106e-06
, O 0 1.8679644142594043e-07
the O 0 1.2071382116118912e-07
autopsy O 0 0.00016734751989133656
findings O 0 4.781577445100993e-06
showed O 0 1.3415303328656591e-05
massive O 0 0.0006812852807343006
demyelination B-Disease 1 0.985270619392395
of I-Disease 0 8.110163776109403e-07
the I-Disease 0 2.7831949864776107e-06
cerebral I-Disease 1 0.5282072424888611
white I-Disease 0 7.754490070510656e-05
matter I-Disease 0 9.870439043879742e-07
with O 0 1.3628186934511177e-07
sparing O 0 1.8255963141200482e-06
of O 0 1.2034084306833392e-07
the O 0 3.042722767077066e-07
U O 0 0.0294245183467865
- O 0 0.016419535502791405
fibers O 0 0.00023173459339886904
, O 0 3.6830152794209425e-07
compatible O 0 1.9496521872497397e-06
with O 0 1.2791171855042194e-07
the O 0 1.457975287166846e-07
findings O 0 2.2087199340603547e-06
of O 0 3.6335798085929127e-06
childhood O 1 0.565633237361908
ALD B-Disease 1 0.9999829530715942
. O 0 0.0001861105702118948

Oleic O 0 0.00949164666235447
and O 0 3.257633215980604e-05
erucic O 0 0.022609632462263107
acids O 0 1.0057650797534734e-05
( O 0 8.595671943112393e-07
Lorenzos O 0 3.688797005452216e-05
Oil O 0 1.1212052868359024e-06
) O 0 5.065010455496122e-08
were O 0 3.422604066827262e-08
administered O 0 1.374791764874317e-07
to O 0 7.86802232255468e-08
patients O 0 4.97612745675724e-06
1 O 0 2.1202933453423611e-07
and O 0 1.3508390850347496e-07
4 O 0 8.009166663214273e-07
, O 0 1.8392113076970418e-07
but O 0 1.6589291362834047e-07
sufficient O 0 9.058617251866963e-07
effectiveness O 0 4.408737368066795e-06
was O 0 5.551626145461341e-07
not O 0 1.9804041073712142e-07
obtained O 0 2.5617048322601477e-06
. O 0 3.972437752963742e-06

The O 0 1.5864350643823855e-05
findings O 0 1.677676846156828e-05
in O 0 5.922748300690728e-07
this O 0 1.9296803088764136e-07
family O 0 1.8605343257149798e-06
suggest O 0 9.614539067115402e-07
that O 0 1.3054095404640975e-07
delGAG291 O 0 6.654503522440791e-05
is O 0 6.183672951465269e-08
part O 0 9.388040922431173e-08
of O 0 4.9607194796408294e-08
the O 0 1.9539467643880926e-07
cause O 0 1.3347657841222826e-06
of O 0 6.114231609899434e-07
Japanese O 0 0.00023640409926883876
ALD B-Disease 1 0.9999861717224121
with O 0 1.1606290172494482e-05
phenotypic O 0 0.00020993693033233285
variations O 0 0.00010920554632321
. O 0 3.1277908419724554e-05

Moreover O 0 0.00026679536676965654
, O 0 5.178495030122576e-06
although O 0 4.763448941957904e-07
the O 0 9.443030535294383e-08
scale O 0 3.151240434817737e-06
of O 0 7.627796350107019e-08
the O 0 6.975017186050536e-08
study O 0 3.987875913935568e-07
is O 0 1.4042487350707233e-07
limited O 0 8.207469477383711e-07
, O 0 3.0982997145656554e-07
there O 0 7.432149118358211e-08
is O 0 5.703853389604774e-08
a O 0 1.483595326590148e-07
possibility O 0 9.182957683151471e-07
that O 0 1.0444750131455294e-07
PET O 0 3.282959733041935e-05
can O 0 3.7989192946952244e-07
detect O 0 9.98775358311832e-05
an O 0 2.137187919970529e-07
insidious B-Disease 0 0.0017242316389456391
lesion I-Disease 0 0.11119435727596283
which O 0 1.6496620958150743e-07
is O 0 1.957787389983423e-07
undetectable O 0 1.3994713299325667e-05
by O 0 9.484945451276872e-08
computed O 0 1.7375546121911611e-06
tomogram O 0 0.00012996539589948952
( O 0 3.545814877270459e-07
CT O 0 0.001115186489187181
) O 0 7.844885629992859e-08
or O 0 1.2302498930694128e-07
MRI O 0 2.4089993530651554e-05
analysis O 0 3.724865962340118e-07
, O 0 1.5528461005942518e-07
and O 0 7.206193686215556e-08
that O 0 1.4841806006415936e-08
the O 0 2.1275400996501048e-08
higher O 0 9.236766373987848e-08
level O 0 4.5540183180037275e-08
of O 0 2.2180715930630868e-08
tau O 0 1.1113539812868112e-06
reflects O 0 1.1292195978285235e-07
the O 0 2.1028098373676585e-08
process O 0 2.051843210892912e-07
of O 0 3.3574556823623425e-07
neuronal B-Disease 0 0.0006514296401292086
degeneration I-Disease 1 0.9462263584136963
in O 0 0.00016529980348423123
ALD B-Disease 1 0.9999728202819824
. O 0 0.00017953636415768415

Lorenzos O 0 0.005225011147558689
Oil O 0 9.211264841724187e-05
should O 0 1.96773521565774e-06
be O 0 1.2497105217335047e-07
given O 0 1.1147023570856618e-07
in O 0 3.658335501199872e-08
the O 0 5.4087735179564334e-08
early O 0 7.261160703819769e-07
stage O 0 1.5222277397697326e-05
. O 0 1.1607744454522617e-06
. O 0 5.7724869293451775e-06

Nonsense O 0 0.0010845268843695521
mutation O 0 6.640500214416534e-05
in O 0 1.621595970391354e-06
exon O 0 3.4885117202065885e-05
4 O 0 1.8020677998720203e-06
of O 0 2.1840693875674333e-07
human O 0 4.902387900074245e-07
complement O 0 4.734174581244588e-06
C9 O 0 0.07155982404947281
gene O 0 6.277832653722726e-06
is O 0 1.0930482119420049e-07
the O 0 1.0741702993755098e-07
major O 0 1.865123181232775e-06
cause O 0 1.4530962744174758e-06
of O 0 4.540202382941061e-07
Japanese O 0 3.568335887393914e-05
complement B-Disease 0 0.0016900041373446584
C9 I-Disease 1 0.9998694658279419
deficiency I-Disease 1 0.9946304559707642
. O 0 3.5759258025791496e-05

Deficiency B-Disease 1 0.998393714427948
of I-Disease 0 7.717974767729174e-06
the I-Disease 0 1.3470920521285734e-06
ninth I-Disease 0 7.372480013145832e-06
component I-Disease 0 2.503188625269104e-06
of I-Disease 0 1.8424239556225075e-07
human I-Disease 0 4.2446626480341365e-07
complement I-Disease 0 2.1999580894771498e-06
( O 0 8.656704721943242e-07
C9 O 0 0.025194335728883743
) O 0 1.5110629192349734e-07
is O 0 4.4043272140470435e-08
the O 0 4.1189551325260254e-08
most O 0 3.11784503992385e-07
common O 0 9.84000780590577e-06
complement B-Disease 1 0.8677307367324829
deficiency I-Disease 1 0.9998364448547363
in O 0 2.6132735797546047e-07
Japan O 0 1.531608290861186e-06
but O 0 4.0105268794832227e-07
is O 0 3.2912043934629764e-07
rare O 0 1.9514602627168642e-06
in O 0 1.669886273703014e-07
other O 0 1.9817834129298717e-07
countries O 0 6.504940870399878e-07
. O 0 7.77551940700505e-06

We O 0 7.590215773234377e-06
studied O 0 4.053758402733365e-06
the O 0 3.70938550986466e-07
molecular O 0 3.655493856058456e-06
basis O 0 8.319373705489852e-07
of O 0 8.04607589088846e-06
C9 B-Disease 1 0.999968409538269
deficiency I-Disease 1 0.9817712306976318
in O 0 4.6136446485434135e-07
four O 0 4.965220909980417e-07
Japanese O 0 5.95909341427614e-06
C9 B-Disease 1 0.9364811778068542
- I-Disease 1 0.9961997866630554
deficient I-Disease 1 0.995378851890564
patients O 0 0.02881564386188984
who O 0 1.984808659472037e-05
had O 0 5.717924432246946e-05
suffered O 1 0.604830801486969
from O 0 0.0008749443804845214
meningococcal B-Disease 1 0.9999707937240601
meningitis I-Disease 1 0.9995889067649841
. O 0 0.00018775821081362665

Direct O 0 2.726867751334794e-05
sequencing O 0 2.8335116439848207e-05
of O 0 1.4132085652818205e-06
amplified O 0 1.461303236283129e-05
C9 O 0 0.0011018426157534122
cDNA O 0 1.9502769646351226e-05
and O 0 1.5633423799954471e-06
DNA O 0 1.7582528016646393e-05
revealed O 0 4.102594630239764e-06
a O 0 3.979350537974824e-07
nonsense O 0 3.157344053761335e-06
substitution O 0 7.271291906363331e-07
( O 0 2.1985287901316042e-07
CGA O 0 6.6874340518552344e-06
- O 0 0.00013912412396166474
- O 0 0.0003367809986229986
> O 0 2.3866265109973028e-05
TGA O 0 7.262951839948073e-05
) O 0 4.5194060049880136e-08
at O 0 4.127432973177747e-08
codon O 0 1.6366649902010977e-07
95 O 0 6.452373924048516e-08
in O 0 1.977774388706166e-08
exon O 0 1.1843835636682343e-06
4 O 0 2.2206246796940832e-07
in O 0 3.623723188184158e-08
the O 0 6.005631547623125e-08
four O 0 1.4956365248508519e-06
C9 B-Disease 1 0.8945919871330261
- I-Disease 1 0.9049962162971497
deficient I-Disease 0 0.20491072535514832
individuals O 0 5.139528639119817e-06
. O 0 1.340434482699493e-05

An O 0 1.7859983927337453e-05
allele O 0 6.499321170849726e-05
- O 0 8.552296640118584e-05
specific O 0 1.7380202734784689e-06
polymerase O 0 6.269333971431479e-05
chain O 0 1.0197296433034353e-05
reaction O 0 9.503077649242186e-07
system O 0 2.186770586831699e-07
designed O 0 5.390481305767025e-07
to O 0 5.532794844498312e-08
detect O 0 3.7367603908933233e-06
exclusively O 0 1.0909695191685387e-07
only O 0 1.155484330439549e-08
one O 0 1.2555204875752679e-08
of O 0 8.881094082369145e-09
the O 0 1.8034892690366178e-08
normal O 0 1.4288376348758902e-07
and O 0 7.455647477172533e-08
mutant O 0 2.765491899481276e-06
alleles O 0 8.233545258917729e-07
indicated O 0 7.434601343447866e-07
that O 0 1.6075881958954596e-08
all O 0 1.0249174842158482e-08
the O 0 3.257777336784784e-08
four O 0 3.5422050359557034e-07
patients O 0 1.8310174709768035e-05
were O 0 9.973199865953575e-08
homozygous O 0 9.907446383294882e-07
for O 0 6.00537930495193e-08
the O 0 9.495027342154572e-08
mutation O 0 4.138698841416044e-07
in O 0 4.912388718025795e-08
exon O 0 2.9198938591434853e-06
4 O 0 5.265792992759089e-07
and O 0 7.121301592860618e-08
that O 0 2.4005039733765443e-08
the O 0 4.4071590821204154e-08
parents O 0 2.839415458311123e-07
of O 0 1.4899021039127547e-07
patient O 0 5.217732541495934e-05
2 O 0 1.854781771726266e-06
were O 0 6.431051247091091e-07
heterozygous O 0 1.7097901945817284e-05
. O 0 1.0803773875522893e-05

The O 0 1.4164861568133347e-05
common O 0 5.772079930466134e-06
mutation O 0 5.537193828786258e-06
at O 0 6.814402127020003e-07
codon O 0 1.3769084716841462e-06
95 O 0 5.802301643598184e-07
in O 0 1.0630215996343395e-07
exon O 0 4.730104137706803e-06
4 O 0 1.0036858384410152e-06
might O 0 2.277447350707007e-07
be O 0 1.6602326624592934e-08
responsible O 0 9.130147304858838e-08
for O 0 8.728264333512925e-08
most O 0 3.636463645761978e-07
Japanese O 0 0.00011373931920388713
C9 B-Disease 1 0.9999346733093262
deficiency I-Disease 1 0.9932273030281067
. O 0 3.877748440572759e-06
. O 0 1.3863921594747808e-05

BRCA1 O 0 0.0038522572722285986
required O 0 2.400583070993889e-05
for O 0 2.6484970021556364e-06
transcription O 0 1.3663803656527307e-05
- O 0 0.0003576632007025182
coupled O 0 5.5359225370921195e-05
repair O 0 0.0025512909051030874
of O 0 4.405807430885034e-06
oxidative O 0 0.3684929609298706
DNA O 0 0.07723592966794968
damage O 0 0.04580822214484215
. O 0 4.898112820228562e-05

The O 0 0.00022161217930261046
breast B-Disease 1 0.999733030796051
and I-Disease 1 0.9695455431938171
ovarian I-Disease 1 0.9999998807907104
cancer I-Disease 1 0.9999984502792358
susceptibility O 1 0.9515281915664673
gene O 0 0.00022223679115995765
BRCA1 O 0 0.0005910737090744078
encodes O 0 5.87536305829417e-06
a O 0 6.499150913441554e-06
zinc O 0 0.0011423444375395775
finger O 0 4.0703620470594615e-05
protein O 0 1.5421052239616984e-06
of O 0 4.043951946641755e-07
unknown O 0 5.1739930313488e-06
function O 0 6.638581908191554e-06
. O 0 7.664702025067527e-06

Association O 0 5.574876195169054e-05
of O 0 2.250670377179631e-06
the O 0 1.0194642072747229e-06
BRCA1 O 0 0.00014317779277916998
protein O 0 1.3501878584065707e-06
with O 0 1.7503414539987716e-07
the O 0 1.810296339499473e-07
DNA O 0 1.6349802535842173e-05
repair O 0 0.0027625663205981255
protein O 0 3.6420271953829797e-06
Rad51 O 0 0.0004737151903100312
and O 0 1.4785543100970244e-07
changes O 0 8.846036081422426e-08
in O 0 1.966167495481841e-08
the O 0 1.439044172713011e-08
phosphorylation O 0 1.8860869488435128e-07
and O 0 5.6637745160514896e-08
cellular O 0 2.3336317553912522e-06
localization O 0 7.108083082130179e-07
of O 0 2.5839854700393516e-08
the O 0 3.736870368697964e-08
protein O 0 2.416302038454887e-07
after O 0 2.010202564406427e-07
exposure O 0 1.9948056433349848e-06
to O 0 7.368533516682874e-08
DNA O 0 2.7561911338125356e-05
- O 0 0.0026839503552764654
damaging O 0 0.0002150879881810397
agents O 0 1.3847187574356212e-06
are O 0 4.820352828005525e-08
consistent O 0 2.43679153300036e-07
with O 0 4.617835003273285e-08
a O 0 1.015302260043427e-07
role O 0 2.2182203451848181e-07
for O 0 5.276983756630216e-07
BRCA1 O 0 0.0005771665601059794
in O 0 2.150874252038193e-06
DNA O 0 0.0004472303844522685
repair O 0 0.10714744031429291
. O 0 3.1976534955902025e-05

Here O 0 3.8218757254071534e-05
, O 0 3.211594730601064e-06
it O 0 1.7970549492929422e-07
is O 0 8.555478814287198e-08
shown O 0 1.5312006951262447e-07
that O 0 6.766377680378355e-08
mouse O 0 1.624395008548163e-05
embryonic O 0 0.00019057007739320397
stem O 0 0.0009604484657756984
cells O 0 0.00018336973153054714
deficient B-Disease 0 0.00040254549821838737
in I-Disease 0 4.442822501005139e-07
BRCA1 I-Disease 0 0.00032579872640781105
are O 0 3.081626971379592e-07
defective O 0 0.00012709671864286065
in O 0 1.1098207863824427e-07
the O 0 7.918668387674188e-08
ability O 0 2.4591636815785023e-07
to O 0 4.1034759590274916e-08
carry O 0 1.8701247483932093e-07
out O 0 9.430377190255967e-08
transcription O 0 7.847187930565269e-07
- O 0 2.0076493456144817e-05
coupled O 0 2.811759486576193e-06
repair O 0 8.197198621928692e-05
of O 0 2.5652076374171884e-07
oxidative O 0 0.0015137625159695745
DNA O 0 0.003373686922714114
damage O 0 0.0018993952544406056
, O 0 5.993912850499328e-07
and O 0 1.4768603762149723e-07
are O 0 1.1214262229941596e-07
hypersensitive O 0 0.00019238262029830366
to O 0 8.755039289098931e-07
ionizing O 0 0.00399514427408576
radiation O 0 0.0001863680372480303
and O 0 1.2527024182418245e-06
hydrogen O 0 5.163655077922158e-05
peroxide O 0 0.0025898381136357784
. O 0 1.4228983673092443e-05

These O 0 1.221628008352127e-05
results O 0 1.0573253348411527e-05
suggest O 0 4.0882064240577165e-06
that O 0 4.135451945330715e-07
BRCA1 O 0 0.000125350066809915
participates O 0 5.061073807155481e-06
, O 0 3.6586777696356876e-07
directly O 0 1.7068067847958446e-07
or O 0 1.8360567821673612e-07
indirectly O 0 8.371303579224332e-07
, O 0 8.59143725051581e-08
in O 0 5.259418855985132e-08
transcription O 0 1.6286228401440894e-06
- O 0 0.00011424291733419523
coupled O 0 2.358053097850643e-05
repair O 0 0.0005436144419945776
of O 0 1.2895826557723922e-06
oxidative O 0 0.08062224090099335
DNA O 0 0.014738871715962887
damage O 0 0.0018230833811685443
. O 0 3.549174607542227e-06
. O 0 1.7464044503867626e-05

Truncation O 0 0.003325841622427106
mutations O 0 0.0005528534529730678
in O 0 4.314490070100874e-06
the O 0 1.6991117490761098e-06
transactivation O 0 0.00015392934437841177
region O 0 2.1775920231448254e-06
of O 0 6.405551289390132e-07
PAX6 O 0 0.010981057770550251
result O 0 2.1437538180180127e-06
in O 0 4.1798435290729685e-07
dominant O 0 1.3223050700617023e-05
- O 0 0.00039671003469266
negative O 0 1.3513559679267928e-05
mutants O 0 7.954304601298645e-05
. O 0 1.1128143341920804e-05

PAX6 O 0 0.1694292575120926
is O 0 6.432869213313097e-06
a O 0 1.529891505924752e-06
transcription O 0 2.2004303446010454e-06
factor O 0 1.25032499909139e-06
with O 0 1.1062786597904051e-07
two O 0 8.11558180657812e-08
DNA O 0 1.2977391634194646e-05
- O 0 0.0002261747868033126
binding O 0 4.0493227970728185e-06
domains O 0 1.7710593738229363e-06
( O 0 9.953208746082964e-08
paired O 0 1.2703621905529872e-06
box O 0 3.827998625638429e-06
and O 0 4.283632222268352e-07
homeobox O 0 6.03580083406996e-05
) O 0 1.072252260314599e-07
and O 0 6.472564706427875e-08
a O 0 1.3343428406642488e-07
proline O 0 1.5831674318178557e-05
- O 0 5.635828711092472e-05
serine O 0 1.9487528334138915e-05
- O 0 3.646956247393973e-05
threonine O 0 1.943846837093588e-05
( O 0 4.6657811481054523e-07
PST O 0 7.567602006020024e-05
) O 0 3.4815991512004985e-07
- O 0 1.8202561477664858e-05
rich O 0 6.769269930373412e-06
transactivation O 0 0.0001131104800151661
domain O 0 8.25027655082522e-06
. O 0 7.467661362170475e-06

PAX6 O 0 0.25539252161979675
regulates O 0 0.0013832149561494589
eye O 0 0.002653127536177635
development O 0 1.557009636599105e-05
in O 0 9.604888191461214e-07
animals O 0 4.980581707059173e-07
ranging O 0 4.294289283279795e-06
from O 0 2.7337242158864683e-07
jellyfish O 0 3.2644072689436143e-06
to O 0 1.5090296301423223e-07
Drosophila O 0 1.8398585552859004e-06
to O 0 5.177000730327563e-07
humans O 0 3.2979892239382025e-06
. O 0 6.047609076631488e-06

Heterozygous O 0 0.001473359763622284
mutations O 0 0.00022143263777252287
in O 0 2.343125061088358e-06
the O 0 5.496893891177024e-07
human O 0 1.7445066760046757e-06
PAX6 O 0 0.022306371480226517
gene O 0 1.452374090149533e-05
result O 0 8.896219014786766e-07
in O 0 1.4619823218708916e-07
various O 0 2.8680292984972766e-07
phenotypes O 0 2.1014417143305764e-05
, O 0 1.06572929325921e-06
including O 0 1.1013140465365723e-05
aniridia B-Disease 1 0.999854564666748
, O 0 0.0008145339088514447
Peters B-Disease 1 0.9991143345832825
anomaly I-Disease 1 0.9996399879455566
, O 0 0.00017144186131190509
autosomal B-Disease 0 0.04844650253653526
dominant I-Disease 0 0.0010554110631346703
keratitis I-Disease 1 0.9668542146682739
, O 0 2.119559758284595e-05
and O 0 0.00011556362005649135
familial B-Disease 1 0.99903404712677
foveal I-Disease 1 0.9998281002044678
dysplasia I-Disease 1 0.9999414682388306
. O 0 0.0004343138716649264

It O 0 1.2957852050021756e-05
is O 0 3.413279955566395e-06
believed O 0 1.42056205731933e-06
that O 0 8.699029763192812e-08
the O 0 1.1237815300546572e-07
mutated O 0 1.6943398577495827e-06
allele O 0 1.1441414926594007e-06
of O 0 1.5028912514480908e-07
PAX6 O 0 0.0009783725254237652
produces O 0 7.959603749441158e-07
an O 0 9.408727663640093e-08
inactive O 0 1.4927195479685906e-06
protein O 0 5.07774927882565e-07
and O 0 3.8849896100146e-07
aniridia B-Disease 1 0.9350032806396484
is O 0 6.526602760459355e-07
caused O 0 3.166531769238645e-06
due O 0 1.5924504168651765e-06
to O 0 1.4133082686385023e-06
genetic O 0 0.00012363720452412963
haploinsufficiency O 0 0.03194192424416542
. O 0 2.6435123800183646e-05

However O 0 2.7306616175337695e-05
, O 0 2.364522288189619e-06
several O 0 6.589016834368522e-07
truncation O 0 4.2762188968481496e-05
mutations O 0 2.9201861252659e-05
have O 0 2.1482593126620486e-07
been O 0 1.2223442524827988e-07
found O 0 9.987687121792987e-08
to O 0 4.760378757850958e-08
occur O 0 9.053395189084767e-08
in O 0 2.1840252273364058e-08
the O 0 8.312395749499046e-08
C O 0 0.0001425546797690913
- O 0 0.00010533390013733879
terminal O 0 9.503508408670314e-06
half O 0 8.049477884242151e-08
of O 0 1.2388197490054154e-07
PAX6 O 0 0.011184525676071644
in O 0 1.9641922790469835e-06
patients O 0 0.00014422438107430935
with O 0 8.755156386541785e-07
Aniridia B-Disease 1 0.9821180105209351
resulting O 0 2.6821585379366297e-06
in O 0 1.5573441203287075e-07
mutant O 0 1.07915684566251e-06
proteins O 0 8.350885138952435e-08
that O 0 2.9729749329021615e-08
retain O 0 3.025982096005464e-07
the O 0 6.900398830111953e-08
DNA O 0 7.585324055980891e-06
- O 0 5.1049159083049744e-05
binding O 0 1.8296190091859899e-06
domains O 0 6.024826006978401e-07
but O 0 8.96570426789367e-08
have O 0 7.087993481036392e-08
lost O 0 1.13155624603678e-06
most O 0 3.504604251247656e-08
of O 0 9.590565497319403e-08
the O 0 5.179514346309588e-07
transactivation O 0 0.00013176791253499687
domain O 0 8.404273103224114e-06
. O 0 9.332745321444236e-06

It O 0 8.002700269571505e-06
is O 0 1.2249587371115922e-06
not O 0 3.270541242272884e-07
clear O 0 6.00356997892959e-07
whether O 0 3.0363457881321665e-07
such O 0 1.987139199854937e-07
mutants O 0 1.734075522108469e-05
really O 0 4.523012194113107e-06
behave O 0 1.3680630672752159e-06
as O 0 7.825890691037785e-08
loss O 0 2.918643986049574e-06
- O 0 2.9053748221485876e-05
of O 0 1.689739548282887e-07
- O 0 0.00015770581376273185
function O 0 6.573382620445045e-07
mutants O 0 3.334968823764939e-06
as O 0 2.008518151797034e-07
predicted O 0 7.760643711662851e-06
by O 0 9.84111352408945e-07
haploinsufficiency O 0 0.0005588881322182715
. O 0 9.436444088350981e-06

Contrary O 0 8.149227505782619e-05
to O 0 1.8894081676990027e-06
this O 0 2.0785616072771518e-07
theory O 0 5.385533086155192e-07
, O 0 1.417314052787333e-07
our O 0 1.0883466217137538e-07
data O 0 2.842317030626873e-07
showed O 0 4.516278124810924e-07
that O 0 1.828817985938258e-08
these O 0 2.866617343499911e-08
mutants O 0 1.3080655207886593e-06
are O 0 6.229640803212533e-08
dominant O 0 1.019379624267458e-06
- O 0 1.4660701708635315e-05
negative O 0 5.436579613160575e-07
in O 0 9.07465960153786e-08
transient O 0 5.871570920135127e-06
transfection O 0 0.0002000611275434494
assays O 0 5.725856226490578e-06
when O 0 2.7642028044283506e-07
they O 0 7.218023512223226e-08
are O 0 6.717820610901981e-08
coexpressed O 0 6.158690666779876e-05
with O 0 3.1144867307375534e-07
wild O 0 8.228087608586065e-06
- O 0 0.0018347498262301087
type O 0 0.00015770025493111461
PAX6 O 0 0.011395174078643322
. O 0 1.9866796719725244e-05

We O 0 2.6312385671189986e-05
found O 0 2.4107903300318867e-06
that O 0 1.7574316757418273e-07
the O 0 1.7144498087873217e-07
dominant O 0 2.726940692809876e-06
- O 0 9.289011359214783e-05
negative O 0 1.993714022319182e-06
effects O 0 1.6837216207932215e-06
result O 0 1.8717645389187965e-07
from O 0 6.067644164886588e-08
the O 0 6.182788325759248e-08
enhanced O 0 3.2671230201231083e-06
DNA O 0 6.603677320526913e-06
binding O 0 9.881138112177723e-07
ability O 0 3.053862656088313e-07
of O 0 1.1309914782486885e-07
these O 0 3.7432837984852085e-07
mutants O 0 4.608245944837108e-05
. O 0 1.226471158588538e-05

Kinetic O 0 0.00015494557737838477
studies O 0 1.049163347488502e-05
of O 0 1.112191625907144e-06
binding O 0 1.0750597539299633e-05
and O 0 1.1474895700303023e-06
dissociation O 0 4.792032632394694e-05
revealed O 0 3.979179382440634e-06
that O 0 5.9267382113148415e-08
various O 0 4.306414425059302e-08
truncation O 0 5.148511263541877e-06
mutants O 0 5.319047886587214e-06
have O 0 6.077397074477631e-08
3 O 0 3.3916234087882913e-07
- O 0 1.2745287676807493e-05
5 O 0 2.461526378283452e-07
- O 0 4.964300842402736e-06
fold O 0 6.021798526489874e-07
higher O 0 1.3500574880254135e-07
affinity O 0 1.1367831831421427e-07
to O 0 1.3543085763956242e-08
various O 0 2.0419184565412252e-08
DNA O 0 1.1165593605255708e-06
- O 0 6.73396016281913e-06
binding O 0 5.223723178460205e-07
sites O 0 1.6945647018928867e-07
when O 0 6.257960194488987e-08
compared O 0 2.1799431237923272e-07
with O 0 4.077449133887967e-08
the O 0 8.199038603606823e-08
wild O 0 3.1438983114639996e-06
- O 0 0.0006529779639095068
type O 0 0.00010083027154905722
PAX6 O 0 0.017664359882473946
. O 0 1.6377331121475436e-05

These O 0 1.2617338143172674e-05
results O 0 1.0098950042447541e-05
provide O 0 1.1124960792585625e-06
a O 0 2.3915816882436047e-07
new O 0 3.3956200695683947e-07
insight O 0 1.088427097784006e-06
into O 0 7.87257050660628e-08
the O 0 6.269237928790972e-08
role O 0 2.4875367898857803e-07
of O 0 2.0563587099786673e-07
mutant O 0 4.001488923677243e-05
PAX6 O 0 0.03481123968958855
in O 0 4.053375505463919e-06
causing O 0 0.00016628547746222466
aniridia B-Disease 1 0.9841078519821167
. O 0 1.2295054148125928e-05
. O 0 2.2898902898305096e-05

Reversal O 0 0.03840237110853195
of O 0 0.0012136265868321061
severe O 1 0.9998713731765747
hypertrophic B-Disease 1 0.9999887943267822
cardiomyopathy I-Disease 1 0.999992847442627
and O 0 3.60962949343957e-05
excellent O 0 0.00016497513570357114
neuropsychologic O 0 0.0470125675201416
outcome O 0 4.6952296543167904e-05
in O 0 5.720511921936122e-07
very B-Disease 0 2.2948288460611366e-06
- I-Disease 0 0.0017668246291577816
long I-Disease 0 6.651761941611767e-05
- I-Disease 0 0.005318437237292528
chain I-Disease 0 0.000108098000055179
acyl I-Disease 0 8.095242083072662e-05
- I-Disease 0 0.0004951180890202522
coenzyme I-Disease 0 0.00034606613917276263
A I-Disease 0 8.33664380479604e-05
dehydrogenase I-Disease 1 0.7223539352416992
deficiency I-Disease 1 0.7133506536483765
. O 0 2.0872928871540353e-05

Very B-Disease 0 9.348540334030986e-05
- I-Disease 0 0.001920114504173398
long I-Disease 0 7.832084520487115e-05
- I-Disease 0 0.0006473470130003989
chain I-Disease 0 4.4928761781193316e-05
acyl I-Disease 0 2.375092481088359e-05
- I-Disease 0 5.440815948531963e-05
coenzyme I-Disease 0 1.4772332178836223e-05
A I-Disease 0 1.3546026593758143e-06
dehydrogenase I-Disease 0 7.377043948508799e-05
( I-Disease 0 1.1011227343260543e-06
VLCAD I-Disease 1 0.6007319092750549
) I-Disease 0 3.35440672643017e-05
deficiency I-Disease 0 0.06887882202863693
is O 0 1.6584672835051606e-07
a O 0 3.015765969394124e-06
disorder O 0 0.0029702612664550543
of O 0 3.3028035772986186e-07
fatty O 0 0.0002388895081821829
acid O 0 1.4951422599551734e-05
beta O 0 3.156245156787918e-06
oxidation O 0 1.2381281067064265e-06
that O 0 6.85132377498121e-08
reportedly O 0 1.7326980241705314e-06
has O 0 6.061906532295325e-08
high O 0 1.199969574372517e-06
rates O 0 4.0895454844758206e-07
of O 0 3.534370023317024e-07
morbidity O 0 0.037274450063705444
and O 0 2.572965604485944e-05
mortality O 0 0.003276619827374816
. O 0 2.920261431427207e-05

We O 0 2.371089067310095e-05
describe O 0 9.934212357620709e-06
the O 0 4.4746752791979816e-07
outcome O 0 1.779507670107705e-06
of O 0 1.0978538256267711e-07
a O 0 4.274833713679982e-07
5 O 0 1.0272502777297632e-06
- O 0 9.845288877841085e-05
year O 0 1.6329651089108665e-06
- O 0 0.000644670391920954
old O 0 3.826230386039242e-05
girl O 0 0.00023559090914204717
with O 0 0.00011433304462116212
VLCAD B-Disease 1 0.9999991655349731
deficiency I-Disease 1 0.9999833106994629
who O 0 1.2900931096737622e-06
was O 0 2.0948758105987508e-07
first O 0 9.975521209071303e-08
seen O 0 5.798993356620485e-07
at O 0 2.0055246352512768e-07
5 O 0 1.9257755923263176e-07
months O 0 2.502875702248275e-07
of O 0 1.2425694251305686e-07
age O 0 8.053812962316442e-06
with O 0 4.753174289362505e-05
severe O 1 0.9972187280654907
hypertrophic B-Disease 1 0.9999839067459106
cardiomyopathy I-Disease 1 0.9999978542327881
, O 0 0.04667441174387932
hepatomegaly B-Disease 1 0.9999990463256836
, O 0 0.07478483021259308
encephalopathy B-Disease 1 0.9785163402557373
, O 0 8.028491720324382e-06
and O 0 3.1837324058869854e-05
hypotonia B-Disease 1 0.9671024680137634
. O 0 8.05421732366085e-05

Biochemical O 0 0.004777710884809494
studies O 0 0.0010745483450591564
indicated O 1 0.9660824537277222
VLCAD B-Disease 1 0.9999985694885254
deficiency I-Disease 1 0.9999982118606567
caused O 0 0.00038545954157598317
by O 0 2.6188872652710415e-06
a O 0 4.341852218203712e-06
stable O 0 0.00016133121971506625
yet O 0 1.251491266884841e-05
inactive O 0 6.495763955172151e-05
enzyme O 0 2.9238142815302126e-05
. O 0 1.1381319382053334e-05

Molecular O 0 0.0018076966516673565
genetic O 0 0.00014685021596960723
analysis O 0 7.37059599487111e-06
of O 0 1.6121545058922493e-06
her O 0 1.6376268831663765e-05
VLCAD O 0 0.1985132396221161
gene O 0 1.8281807570019737e-05
revealed O 0 9.95953905658098e-06
a O 0 1.6338187833753182e-06
T1372C O 0 0.0006849115015938878
( O 0 7.372342452072189e-07
F458L O 0 9.036445408128202e-05
) O 0 3.8415521430579247e-07
missense O 0 2.1900752471992746e-05
mutation O 0 1.6129157529576332e-06
and O 0 3.6932186731064576e-07
a O 0 3.0849428185319994e-06
1668 O 0 0.0034108413383364677
ACAG O 0 0.07247453927993774
1669 O 0 0.0019432554254308343
splice O 0 0.0007421495392918587
site O 0 7.275839743670076e-05
mutation O 0 7.265451858984306e-05
. O 0 1.5850906493142247e-05

After O 0 0.00010143532563233748
initial O 0 0.00018383680435363203
treatment O 0 0.0002883553388528526
with O 0 1.9647786757559516e-06
intravenous O 0 6.365607987390831e-05
glucose O 0 9.490258526057005e-05
and O 0 1.2916909781779395e-06
carnitine O 0 0.021644510328769684
, O 0 7.08083121025993e-07
the O 0 1.8442170812704717e-07
patient O 0 2.4863822545739822e-05
has O 0 1.333892356569777e-07
thrived O 0 3.109754970864742e-06
on O 0 1.2145368089022668e-07
a O 0 1.8838022697309498e-07
low O 0 1.1874216397700366e-05
- O 0 0.00015149253886193037
fat O 0 8.307580174005125e-06
diet O 0 7.427522064062941e-07
supplemented O 0 3.753607984435803e-07
with O 0 7.315878036706636e-08
medium O 0 3.069395006605191e-06
- O 0 1.6899079128052108e-05
chain O 0 4.004406491731061e-06
triglyceride O 0 5.443949248729041e-06
oil O 0 5.062876198280719e-07
and O 0 1.4004666581968195e-07
carnitine O 0 9.798935934668407e-05
and O 0 2.1352852286327106e-07
avoidance O 0 1.2544511264422908e-05
of O 0 1.2427594811015297e-06
fasting O 0 7.134427141863853e-05
. O 0 1.4410690710064955e-05

Her O 0 0.0017857542261481285
ventricular O 1 0.9796873331069946
hypertrophy O 1 0.8557623028755188
resolved O 0 0.0007108261343091726
significantly O 0 2.6179803171544336e-05
over O 0 9.712584869703278e-07
1 O 0 7.24822257325286e-07
year O 0 5.202757620281773e-07
, O 0 3.50801258264255e-07
and O 0 6.499577125396172e-07
cognitively O 0 0.003653849009424448
, O 0 6.737234343745513e-07
she O 0 4.027137379125634e-07
is O 0 5.803574509855025e-08
in O 0 7.461409268216812e-08
the O 0 1.3631100159727794e-07
superior O 0 2.9972159609314986e-05
range O 0 4.884946974925697e-06
for O 0 6.699764867335034e-07
age O 0 7.134609859349439e-06
. O 0 5.745279850088991e-06

Clinical O 0 0.004883225075900555
recognition O 0 7.968775025801733e-05
of O 0 0.0005228673689998686
VLCAD B-Disease 1 0.9999995231628418
deficiency I-Disease 1 0.9999982118606567
is O 0 3.2323382583854254e-06
important O 0 9.529097155791533e-07
because O 0 4.6543820531042e-07
it O 0 4.850576118542449e-08
is O 0 2.823208333779803e-08
one O 0 9.543174250836728e-09
of O 0 1.7502003402114497e-08
the O 0 1.0292924912391754e-07
few O 0 1.0222817081739777e-06
directly O 0 1.0058734915219247e-05
treatable O 1 0.9742856025695801
causes O 0 1.9982286175945774e-05
of O 0 1.8411628843750805e-05
cardiomyopathy B-Disease 1 0.999974250793457
in O 0 8.491087100992445e-06
children O 0 1.6435438737971708e-05
. O 0 4.174081823293818e-06
. O 0 1.7066917280317284e-05

Cloning O 0 0.00048226898070424795
of O 0 5.468546078191139e-06
a O 0 2.6114253159903456e-06
novel O 0 1.9382339360163314e-06
member O 0 3.0975789400145004e-07
of O 0 6.462646950922135e-08
the O 0 1.370492839214421e-07
low O 0 7.071518211887451e-06
- O 0 7.300908328033984e-05
density O 0 2.2102429284132086e-05
lipoprotein O 0 0.1980946809053421
receptor O 0 3.4239550586789846e-05
family O 0 1.133997557190014e-05
. O 0 9.207421499013435e-06

A O 0 2.5204979465343058e-05
gene O 0 1.9319140847073868e-05
encoding O 0 5.158129170013126e-06
a O 0 1.807692910915648e-06
novel O 0 3.3289472867181757e-06
transmembrane O 0 3.004014797625132e-05
protein O 0 1.4496607718683663e-06
was O 0 3.963329788803094e-07
identified O 0 3.886857484758366e-07
by O 0 3.501871503885923e-08
DNA O 0 6.239492336135299e-07
sequence O 0 8.901499626290388e-08
analysis O 0 1.0627397273310635e-07
within O 0 4.646088669346682e-08
the O 0 9.4286690455192e-08
insulin B-Disease 0 0.0001673074730206281
- I-Disease 1 0.919605553150177
dependent I-Disease 1 0.8680387139320374
diabetes I-Disease 1 0.9999996423721313
mellitus I-Disease 1 0.9999933242797852
( O 0 1.3338875760382507e-05
IDDM B-Disease 0 0.11793401092290878
) O 0 2.53812891060079e-06
locus O 0 5.0337283028056845e-05
IDDM4 O 0 0.0015885857865214348
on O 0 6.116731583460933e-06
chromosome O 0 0.00033431430347263813
11q13 O 0 0.0012066017370671034
. O 0 2.137923911504913e-05

Based O 0 2.3872002202551812e-05
on O 0 2.1654193460562965e-06
its O 0 1.0719737701947452e-06
chromosomal O 0 0.0008437647484242916
position O 0 1.3577467825598433e-06
, O 0 2.2108244479568384e-07
this O 0 5.120083912402151e-08
gene O 0 4.4564697532223363e-07
is O 0 4.172550660541674e-08
a O 0 9.823338587011676e-08
candidate O 0 1.6233182122959988e-06
for O 0 4.0109014776135155e-07
conferring O 0 0.00016619986854493618
susceptibility O 0 0.02919975481927395
to O 0 6.864710303489119e-05
diabetes B-Disease 1 0.998950719833374
. O 0 4.597403676598333e-05

The O 0 1.0146136446564924e-05
gene O 0 1.8864100638893433e-05
, O 0 9.445432169741252e-07
termed O 0 6.971890798013192e-06
low O 0 9.35255957301706e-06
- O 0 4.939786231261678e-05
density O 0 4.703694685304072e-06
lipoprotein O 0 0.027329096570611
receptor O 0 2.758530172286555e-06
related O 0 4.0288543345923244e-07
protein O 0 1.966509159956331e-07
5 O 0 1.828147162541427e-07
( O 0 6.636707183815815e-08
LRP5 O 0 3.538242890499532e-05
) O 0 3.926221125993834e-08
, O 0 1.821090478415499e-08
encodes O 0 4.7463892371979455e-08
a O 0 1.9133377548996577e-08
protein O 0 6.046813894045044e-08
of O 0 2.4072440041322807e-08
1615 O 0 3.924682005163049e-06
amino O 0 6.5025346884795e-08
acids O 0 3.729102360239267e-08
that O 0 5.9259326334881735e-09
contains O 0 1.8790665023971087e-08
conserved O 0 4.195206315671385e-08
modules O 0 1.383562135970351e-07
which O 0 1.563408957849788e-08
are O 0 7.2303940612528095e-09
characteristic O 0 4.469974967946655e-08
of O 0 1.3792088360276011e-08
the O 0 5.636562860900085e-08
low O 0 4.019922016595956e-06
- O 0 5.320267882780172e-05
density O 0 2.8322094294708222e-05
lipoprotein O 1 0.5938315987586975
( O 0 2.1486703190021217e-06
LDL O 0 0.00035307739744894207
) O 0 8.405286280321889e-07
receptor O 0 1.458959832234541e-05
family O 0 5.7267461670562625e-06
. O 0 7.120932423276827e-06

These O 0 9.155393854598515e-06
modules O 0 2.5314971935586073e-05
include O 0 2.1250434656394646e-06
a O 0 8.047848041314865e-07
putative O 0 1.3481918358593248e-05
signal O 0 1.338530069006083e-06
peptide O 0 8.818279866318335e-07
for O 0 5.2432127972679154e-08
protein O 0 1.1042717318332507e-07
export O 0 1.0376206205364724e-07
, O 0 3.349753896486618e-08
four O 0 7.299138360394863e-08
epidermal O 0 1.3688245417142753e-05
growth O 0 7.89528257882921e-07
factor O 0 1.121630930356332e-06
( O 0 2.8729238010782865e-07
EGF O 0 3.0814393539913e-05
) O 0 9.771332543095923e-08
repeats O 0 8.693942845638958e-07
with O 0 1.2561558548895846e-07
associated O 0 3.892184281539812e-07
spacer O 0 9.06696732272394e-06
domains O 0 1.1037469676011824e-06
, O 0 1.725368719007747e-07
three O 0 2.3101284796211985e-07
LDL O 0 0.002005059737712145
- O 0 8.502214041072875e-05
receptor O 0 5.523233085114043e-06
( O 0 1.6281060766232258e-07
LDLR O 0 6.270649464568123e-05
) O 0 1.0582109410961493e-07
repeats O 0 5.422624553830246e-07
, O 0 6.80389575791196e-08
a O 0 5.9109783734356824e-08
single O 0 1.8955178404667095e-07
transmembrane O 0 2.5280839963670587e-06
spanning O 0 1.2162759048806038e-06
domain O 0 4.551665142571437e-07
, O 0 1.004308529672926e-07
and O 0 7.37435428277422e-08
a O 0 5.451963716041064e-07
cytoplasmic O 0 2.7032900106860325e-05
domain O 0 5.4213969633565284e-06
. O 0 5.281119683786528e-06

The O 0 4.659947535401443e-06
encoded O 0 2.9148718567739706e-06
protein O 0 1.4487430917142774e-06
has O 0 1.5271874076461245e-07
a O 0 1.0500720293293853e-07
unique O 0 1.739564510216951e-07
organization O 0 1.8861770456624072e-07
of O 0 1.6483379283727118e-07
EGF O 0 0.0001076453918358311
and O 0 7.887056767685863e-07
LDLR O 0 0.014708130620419979
repeats O 0 6.576701707672328e-06
; O 0 5.514630743164162e-07
therefore O 0 2.0908402120767278e-07
, O 0 2.3054846565173648e-07
LRP5 O 0 0.004056030884385109
likely O 0 2.013989615079481e-06
represents O 0 4.3445135133879376e-07
a O 0 8.883046831442698e-08
new O 0 2.0600666061909578e-07
category O 0 9.723048606247175e-07
of O 0 1.1233721863845858e-07
the O 0 1.2460266134439735e-06
LDLR O 0 0.11248745769262314
family O 0 3.7290010368451476e-05
. O 0 1.9903700376744382e-05

Both O 0 2.8482172638177872e-05
human O 0 7.559457117167767e-06
and O 0 2.219831912952941e-06
mouse O 0 0.00012085712660336867
LRP5 O 0 0.051540471613407135
cDNAs O 0 0.0025283147115260363
have O 0 5.134773459758435e-07
been O 0 3.6037832273905224e-07
isolated O 0 2.7878065793629503e-06
and O 0 5.1738908268816886e-08
the O 0 2.0667288325171285e-08
encoded O 0 8.447130994682084e-08
mature O 0 3.772563843540411e-07
proteins O 0 4.2378545117571775e-08
are O 0 1.3992805136808784e-08
95 O 0 1.9338474999130995e-07
% O 0 1.268304004042875e-07
identical O 0 4.91849277750589e-07
, O 0 9.182907234617232e-08
indicating O 0 5.241003009359702e-07
a O 0 9.756303853691861e-08
high O 0 1.8276361970492871e-06
degree O 0 3.743058982763614e-07
of O 0 1.428777665068992e-07
evolutionary O 0 4.330426236265339e-06
conservation O 0 8.998827979667112e-06
. O 0 1.563540877214109e-06
. O 0 5.744463123846799e-06

The O 0 1.8950397134176455e-05
APC B-Disease 0 0.0002082520950352773
variants O 0 1.989436350413598e-05
I1307K O 0 0.0001525270054116845
and O 0 1.7774655134417117e-06
E1317Q O 0 0.0002190730592701584
are O 0 7.704456947976723e-07
associated O 0 7.542687671957538e-05
with O 0 0.4079292416572571
colorectal B-Disease 1 1.0
tumors I-Disease 1 1.0
, O 0 9.061642049346119e-05
but O 0 2.669974719538004e-06
not O 0 1.9871677636729146e-07
always O 0 5.660295983034302e-07
with O 0 2.495315811756882e-07
a O 0 9.596711834092275e-07
family O 0 5.796467121399473e-06
history O 0 9.534528544463683e-06
. O 0 2.5085324523388408e-05

Classical O 0 0.024677537381649017
familial B-Disease 1 0.9998992681503296
adenomatous I-Disease 1 0.9999659061431885
polyposis I-Disease 1 0.9999914169311523
( O 0 0.0011211299570277333
FAP B-Disease 0 0.3356783390045166
) O 0 4.1910780055332e-06
is O 0 1.1757663287426112e-06
a O 0 2.803170445986325e-06
high O 0 0.0009787966264411807
- O 1 0.9962279796600342
penetrance O 1 0.9991717338562012
autosomal B-Disease 1 0.8902711868286133
dominant I-Disease 0 0.04220353066921234
disease I-Disease 0 0.004604866728186607
that O 0 3.232345875403553e-07
predisposes O 0 0.00010339759319322184
to O 0 4.0143530100067437e-07
hundreds O 0 1.6804908682388486e-06
or O 0 5.235628464106412e-07
thousands O 0 5.66652488487307e-06
of O 0 0.0006150103872641921
colorectal B-Disease 1 1.0
adenomas I-Disease 1 0.9999997615814209
and I-Disease 0 0.486298531293869
carcinoma I-Disease 1 0.9999998807907104
and O 0 5.516258170246147e-06
that O 0 3.4554639682937704e-07
results O 0 2.4871437744877767e-06
from O 0 5.374804459279403e-07
truncating O 0 0.00036114733666181564
mutations O 0 5.4099778026284184e-06
in O 0 1.9671993811698485e-07
the O 0 6.500265499198576e-07
APC B-Disease 0 0.00018656434258446097
gene O 0 2.1838706743437797e-05
. O 0 1.3185524949221872e-05

A O 0 9.340208634966984e-05
variant O 0 0.00013703516742680222
of O 0 1.2258351489435881e-05
FAP B-Disease 0 0.07470797002315521
is O 0 8.875650382833555e-05
attenuated B-Disease 1 0.9898617267608643
adenomatous I-Disease 1 0.9999971389770508
polyposis I-Disease 1 0.9999971389770508
coli I-Disease 1 0.9989857077598572
, O 0 3.5164941891707713e-06
which O 0 2.2542656097357394e-07
results O 0 8.977620495898009e-07
from O 0 1.932754258859859e-07
germ O 0 0.0012436130782589316
- O 0 0.0007565435371361673
line O 0 5.325860001903493e-06
mutations O 0 5.043397663939686e-07
in O 0 2.006717814140302e-08
the O 0 1.650999159608091e-08
5 O 0 9.765109609816136e-08
and O 0 5.460977092752728e-08
3 O 0 1.5006268938577705e-07
regions O 0 7.967238957462541e-08
of O 0 4.267639752697505e-08
the O 0 4.156661077558965e-07
APC B-Disease 0 0.00012334634084254503
gene O 0 1.6700802007107995e-05
. O 0 7.043444384180475e-06

Attenuated B-Disease 1 0.9973894953727722
adenomatous I-Disease 1 0.9999827146530151
polyposis I-Disease 1 0.999995231628418
coli I-Disease 1 0.9999821186065674
patients O 1 0.9961137771606445
have O 0 9.74464273895137e-06
" O 0 7.3735204750846606e-06
multiple O 0 0.00011505959264468402
" O 1 0.5847119092941284
colorectal B-Disease 1 1.0
adenomas I-Disease 1 0.9999994039535522
( O 0 6.17219984633266e-06
typically O 0 1.3254600617074175e-06
fewer O 0 3.576856784093252e-07
than O 0 7.48435695641092e-08
100 O 0 7.634025678271428e-08
) O 0 3.125197522990675e-08
without O 0 8.0031526294988e-08
the O 0 1.3864308812117088e-07
florid O 0 0.00023203504679258913
phenotype O 0 1.0808988918142859e-05
of O 0 5.388178578868974e-07
classical O 0 1.2225322279846296e-05
FAP B-Disease 0 0.00211612437851727
. O 0 1.9344435713719577e-05

Another O 0 0.00012990727555006742
group O 0 3.3364736736984923e-05
of O 0 8.460112439934164e-06
patients O 0 0.004775285255163908
with O 0 5.9118679018865805e-06
multiple O 0 0.000291709991870448
adenomas B-Disease 1 0.9993472695350647
has O 0 4.4757689465768635e-06
no O 0 8.260325330411433e-07
mutations O 0 2.5167755666188896e-06
in O 0 4.835076694575946e-08
the O 0 1.0956406271134256e-07
APC B-Disease 0 2.7993426556349732e-05
gene O 0 1.2782968497049296e-06
, O 0 1.0387314119952862e-07
and O 0 1.4227609312911227e-07
their O 0 1.318691573715114e-07
phenotype O 0 9.376940397487488e-06
probably O 0 5.137996481607843e-07
results O 0 2.443502751248161e-07
from O 0 4.713685441970483e-08
variation O 0 6.30990541594656e-07
at O 0 2.694991394491808e-07
a O 0 1.4434320405598555e-07
locus O 0 4.122377049498027e-06
, O 0 2.843127617779828e-07
or O 0 1.6076624831384834e-07
loci O 0 1.0600750783851254e-06
, O 0 1.3345744775961066e-07
elsewhere O 0 4.388780325825792e-07
in O 0 1.1360354790213023e-07
the O 0 5.616531666419178e-07
genome O 0 3.1128860427998006e-05
. O 0 1.2308135410421528e-05

Recently O 0 0.0004902812652289867
, O 0 6.269558070925996e-06
however O 0 9.618188414606266e-07
, O 0 3.431844675105822e-07
a O 0 3.89196884498233e-07
missense O 0 3.5944769479101524e-05
variant O 0 1.971646270249039e-06
of O 0 3.5214637250646774e-07
APC B-Disease 0 0.00016018783207982779
( O 0 6.489685802080203e-07
I1307K O 0 0.00012219439668115228
) O 0 2.0075894724413956e-07
was O 0 2.086382409061116e-07
described O 0 4.977054004484671e-07
that O 0 5.2800135819097704e-08
confers O 0 1.5955210983520374e-06
an O 0 1.0692296825709491e-07
increased O 0 7.894471309555229e-06
risk O 0 0.00042757458868436515
of O 0 0.014821361750364304
colorectal B-Disease 1 1.0
tumors I-Disease 1 1.0
, O 0 1.9046890884055756e-05
including O 0 7.520498002122622e-06
multiple O 0 0.00011043801350751892
adenomas B-Disease 1 0.9492512345314026
, O 0 4.469065061130095e-06
in O 0 6.076543741073692e-06
Ashkenazim O 0 0.0054550329223275185
. O 0 3.5725748602999374e-05

We O 0 2.254174614790827e-05
have O 0 1.5992960697985836e-06
studied O 0 9.97841198113747e-07
a O 0 1.907209821183642e-07
set O 0 2.881957357203646e-07
of O 0 2.4521472141714185e-07
164 O 0 0.0005920346593484282
patients O 0 0.002115717390552163
with O 0 3.407154144952074e-05
multiple O 1 0.9489015936851501
colorectal B-Disease 1 1.0
adenomas I-Disease 1 0.9999992847442627
and I-Disease 0 0.0017240247689187527
/ I-Disease 1 0.8544397950172424
or I-Disease 0 0.003242022357881069
carcinoma I-Disease 1 0.9999973773956299
and O 0 1.9836129467876162e-06
analyzed O 0 5.9135704759682994e-06
codons O 0 1.01355562946992e-05
1263 O 0 0.00019060024351347238
- O 0 0.00015282706590369344
1377 O 0 0.00046908558579161763
( O 0 4.4232527329768345e-07
exon O 0 1.5181453818513546e-05
15G O 0 5.967931792838499e-05
) O 0 8.796938288924139e-08
of O 0 3.0818728902204384e-08
the O 0 7.584577588204411e-08
APC B-Disease 0 9.752666301210411e-06
gene O 0 8.781814813119126e-07
for O 0 4.644498403649777e-07
germ O 0 0.0012241009389981627
- O 0 0.000618947553448379
line O 0 1.8788188754115254e-05
variants O 0 1.886933750938624e-05
. O 0 9.250662515114527e-06

Three O 0 0.00018343563715461642
patients O 0 0.005136603489518166
with O 0 1.387224642712681e-06
the O 0 6.926837272658304e-07
I1307K O 0 0.00014887495490256697
allele O 0 6.031993052602047e-06
were O 0 2.482096022049518e-07
detected O 0 3.609083705669036e-06
, O 0 7.484885600206326e-08
each O 0 4.102912498638034e-08
of O 0 3.189458084307262e-07
Ashkenazi O 0 0.00014558315160684288
descent O 0 6.0235186538193375e-05
. O 0 1.544779479445424e-05

Four O 0 0.00025117862969636917
patients O 0 0.016889361664652824
had O 0 3.624467126428499e-06
a O 0 2.3010484255792107e-06
germ O 0 0.012849755585193634
- O 0 0.001310882274992764
line O 0 2.091154055960942e-05
E1317Q O 0 0.0001712079392746091
missense O 0 2.7641666747513227e-05
variant O 0 1.0845849374163663e-06
of O 0 1.9470270729016192e-07
APC O 0 1.6611009414191358e-05
that O 0 6.336354374525399e-08
was O 0 1.1360007334815236e-07
not O 0 2.2467402160941674e-08
present O 0 3.975784323984044e-08
in O 0 4.483859328274775e-08
controls O 0 9.706186574476305e-07
; O 0 1.200824328861927e-07
one O 0 1.7373819716226535e-08
of O 0 2.905274953945991e-08
these O 0 4.2353899942781936e-08
individuals O 0 1.2281130068458879e-07
had O 0 8.041620702670116e-08
an O 0 3.4921928460107665e-08
unusually O 0 8.52703487908002e-06
large O 0 2.0519783561212535e-07
number O 0 5.2121933435955725e-08
of O 0 2.871693993711233e-07
metaplastic B-Disease 0 0.21776869893074036
polyps I-Disease 0 0.01241556741297245
of I-Disease 0 3.160291441872687e-07
the I-Disease 0 2.723881607380463e-06
colorectum I-Disease 0 0.011846850626170635
. O 0 2.423835394438356e-05

There O 0 2.167617822124157e-05
is O 0 2.345913117096643e-06
increasing O 0 2.4809912702039583e-06
evidence O 0 1.2496478802859201e-06
that O 0 8.25425487960274e-08
there O 0 1.4217951616046776e-07
exist O 0 6.228107736205857e-07
germ O 0 0.0006681048544123769
- O 0 0.00030006025917828083
line O 0 1.551698687762837e-06
variants O 0 2.2797509302563412e-07
of O 0 2.7523594070544277e-08
the O 0 8.717400135083153e-08
APC B-Disease 0 1.5195272681012284e-05
gene O 0 9.955978157449863e-07
that O 0 8.127152995029974e-08
predispose O 0 3.0522253382514464e-06
to O 0 5.914936807016602e-08
the O 0 5.893495114150937e-08
development O 0 6.848971452200203e-07
of O 0 4.67343261334463e-06
multiple O 1 0.9375522136688232
colorectal B-Disease 1 1.0
adenomas I-Disease 1 0.9999997615814209
and I-Disease 1 0.8681648969650269
carcinoma I-Disease 1 0.9999998807907104
, O 0 3.0356815841514617e-05
but O 0 1.0709478601711453e-06
without O 0 3.5649927099257184e-07
the O 0 3.40961918254834e-07
florid O 0 0.000941690057516098
phenotype O 0 1.3365756785788108e-05
of O 0 1.5208853199055739e-07
classical O 0 1.3203921298554633e-06
FAP B-Disease 0 0.0005401369999162853
, O 0 4.847006493946537e-07
and O 0 1.9539280060598685e-07
possibly O 0 3.4006305327238806e-07
with O 0 1.7920184802733274e-07
importance O 0 4.127100964979036e-06
for O 0 0.434063583612442
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
risk O 0 0.014535537920892239
in O 0 2.528590243855433e-07
the O 0 1.5911858497474896e-07
general O 0 3.2999776067299535e-06
population O 0 6.566559136444994e-07
. O 0 9.725384870762355e-07
. O 0 9.845555723586585e-06

Genomic O 0 0.0005351027357392013
structure O 0 1.6529877029825002e-05
of O 0 3.101615902778576e-06
the O 0 1.0810638741531875e-05
human O 0 0.0792253315448761
congenital B-Disease 1 0.9999996423721313
chloride I-Disease 1 0.9999897480010986
diarrhea I-Disease 1 0.9999990463256836
( O 0 0.0005794054013676941
CLD B-Disease 1 0.9981456995010376
) O 0 6.598137133551063e-06
gene O 0 2.2545164028997533e-05
. O 0 1.3711213796341326e-05

Congenital B-Disease 1 0.9999967813491821
chloride I-Disease 1 0.9999439716339111
diarrhea I-Disease 1 0.9999967813491821
( O 0 0.0006345857982523739
CLD B-Disease 1 0.9988763928413391
) O 0 5.365629931475269e-06
is O 0 1.0902888334385352e-06
caused O 0 3.237570581404725e-06
by O 0 3.889850006544293e-07
mutations O 0 3.98930887968163e-06
in O 0 6.247417871918515e-08
a O 0 2.0172871018075966e-07
gene O 0 6.471613573921786e-07
which O 0 7.318697470282132e-08
encodes O 0 1.1276102895863005e-06
an O 0 1.528721895738272e-06
intestinal O 1 0.9057893753051758
anion O 0 0.015550428070127964
transporter O 0 0.010153100825846195
. O 0 4.6223030949477106e-05

We O 0 2.5673281925264746e-05
report O 0 5.771710675617214e-06
here O 0 1.0168114386033267e-06
the O 0 7.654496414488676e-08
complete O 0 8.507374786859145e-07
genomic O 0 8.880843779479619e-06
organization O 0 5.52432652511925e-07
of O 0 6.686067877126334e-08
the O 0 1.5238529726957495e-07
human O 0 1.6257024526566966e-06
CLD B-Disease 0 0.12579463422298431
gene O 0 2.539518618505099e-06
which O 0 1.5348324211572617e-07
spans O 0 2.891722260756069e-06
approximately O 0 5.678002708009444e-07
39kb O 0 0.00033543561585247517
, O 0 4.73717335580659e-07
and O 0 3.093478539994976e-07
comprises O 0 1.976007752091391e-06
21 O 0 5.626182883133879e-06
exons O 0 4.824620555154979e-05
. O 0 1.3930145541962702e-05

All O 0 2.3881930246716365e-05
exon O 0 0.0003818076802417636
/ O 0 0.00016873767890501767
intron O 0 0.0003637830086518079
boundaries O 0 3.118474296570639e-06
conform O 0 2.8759743599948706e-06
to O 0 3.5846565538122377e-07
the O 0 9.076742912839109e-07
GT O 0 0.002142531331628561
/ O 0 0.02414378710091114
AG O 1 0.9335102438926697
rule O 0 1.9790062651736662e-05
. O 0 1.7698741430649534e-05

An O 0 5.7589554671722e-06
analysis O 0 3.6041276416654e-06
of O 0 4.0066080941869586e-07
the O 0 3.974529931838333e-07
putative O 0 3.600505442591384e-05
promoter O 0 7.442886271746829e-05
region O 0 1.266547997147427e-06
sequence O 0 7.536161206189718e-07
shows O 0 5.230991746429936e-07
a O 0 3.765461542570847e-07
putative O 0 5.2421859436435625e-05
TATA O 0 0.008579550310969353
box O 0 1.699863059911877e-05
and O 0 4.190044364804635e-07
predicts O 0 1.903559677884914e-05
multiple O 0 1.2476210713430191e-06
transcription O 0 3.8119878809084184e-06
factor O 0 3.1122115160542307e-06
binding O 0 4.810750397155061e-06
sites O 0 8.001357855391689e-06
. O 0 8.949999937613029e-06

The O 0 1.441371477994835e-05
genomic O 0 9.358306851936504e-05
structure O 0 8.958625585364643e-06
was O 0 1.0985969538523932e-06
determined O 0 8.190861535695149e-07
using O 0 1.7976927324525604e-07
DNA O 0 1.567192271068052e-06
from O 0 5.715244455473112e-08
several O 0 5.957224757935364e-08
sources O 0 9.805947343011212e-08
including O 0 1.2971926821592206e-07
multiple O 0 6.603422662010416e-07
large O 0 1.2546727248263778e-06
- O 0 8.435025665676221e-05
insert O 0 1.2556204637803603e-05
libaries O 0 0.00014101291890256107
and O 0 4.958491786055674e-07
genomic O 0 1.1542215361259878e-05
DNA O 0 1.125377730204491e-05
from O 0 1.1363933936081594e-06
Finnish O 0 0.003247736720368266
CLD B-Disease 1 0.9991801381111145
patients O 0 0.00447159493342042
and O 0 3.7657052871509222e-06
controls O 0 4.396167423692532e-05
. O 0 2.1085075786686502e-05

Exon O 0 0.0016412078402936459
- O 0 0.0004544410912785679
specific O 0 8.217877621063963e-06
primers O 0 6.550241960212588e-05
developed O 0 2.958262257379829e-06
in O 0 1.1723184201173353e-07
this O 0 3.546131921439155e-08
study O 0 1.1997312299172336e-07
will O 0 8.485774571909133e-08
facilitate O 0 6.914099799359974e-07
mutation O 0 1.0929268228210276e-06
screening O 0 4.7255730351025704e-06
studies O 0 6.528420044560335e-07
of O 0 1.3412109183263965e-06
patients O 0 0.0016095832688733935
with O 0 3.497107172734104e-06
the O 0 4.568171425489709e-05
disease O 0 0.049625348299741745
. O 0 3.975097934016958e-05

Genomic O 0 0.0003438263665884733
sequencing O 0 7.291556539712474e-05
of O 0 4.1874782255035825e-06
a O 0 4.6067511902947444e-06
BAC O 0 0.00022551479924004525
clone O 0 0.019705194979906082
H O 1 0.9980449676513672
_ O 0 3.560901677701622e-05
RG364P16 O 0 0.0002188108628615737
revealed O 0 3.5318666959938128e-06
the O 0 8.530970774245361e-08
presence O 0 1.1186490667114413e-07
of O 0 2.146788524726162e-08
another O 0 1.7753349368376803e-07
, O 0 7.344203822867712e-08
highly O 0 1.4151787297578267e-07
homologous O 0 6.710124011988228e-07
gene O 0 2.4165649392671185e-07
3 O 0 6.426422061167614e-08
of O 0 2.0039296444451793e-08
the O 0 9.24626633036496e-08
CLD B-Disease 0 0.0640389546751976
gene O 0 2.1824132545589237e-06
, O 0 1.3505686524695193e-07
with O 0 1.0117453541624855e-07
a O 0 1.0813775475071452e-07
similar O 0 2.3525375070221344e-07
genomic O 0 3.436968199821422e-06
structure O 0 1.3753389112025616e-06
, O 0 2.7109862799079565e-07
recently O 0 2.3595753191330004e-06
identified O 0 1.0114160886587342e-06
as O 0 2.426828586976626e-07
the O 0 1.2808685823983978e-05
Pendred B-Disease 1 0.9999973773956299
syndrome I-Disease 1 0.9999957084655762
gene O 0 8.953799988375977e-05
( O 0 4.517546130955452e-06
PDS B-Disease 0 0.001589022926054895
) O 0 1.0136175205843756e-06
. O 0 1.7245707795154885e-06
. O 0 1.239740686287405e-05

The O 0 2.1411657144199125e-05
APCI1307K O 0 0.01029218640178442
allele O 0 0.00036441872362047434
and O 0 0.00031730360933579504
cancer B-Disease 1 0.9984281063079834
risk O 0 0.0003448317584116012
in O 0 2.902202140830923e-07
a O 0 5.19934474141337e-07
community O 0 8.202689514291706e-07
- O 0 0.00011626639752648771
based O 0 1.1886664879057207e-06
study O 0 7.97366737970151e-07
of O 0 1.2115917797927978e-06
Ashkenazi O 0 0.0010523138334974647
Jews O 0 2.4494564058841206e-05
. O 0 1.6772832168499008e-05

Mutations O 0 0.0015695512993261218
in O 0 2.1640486011165194e-05
APC O 0 0.0008739095646888018
are O 0 5.192940079723485e-06
classically O 0 0.008290547877550125
associated O 0 7.481210923288018e-05
with O 0 0.00019597008940763772
familial B-Disease 1 0.9999901056289673
adenomatous I-Disease 1 0.9999974966049194
polyposis I-Disease 1 0.999998927116394
( O 0 0.00012688044807873666
FAP B-Disease 0 0.3291564881801605
) O 0 2.545066081438563e-06
, O 0 9.79740093498549e-07
a O 0 6.269528512348188e-06
highly O 0 0.0006671472801826894
penetrant O 1 0.999177873134613
autosomal B-Disease 1 0.9998965263366699
dominant I-Disease 1 0.9890011548995972
disorder I-Disease 1 0.9999867677688599
characterized O 0 0.021688401699066162
by O 0 3.633210144471377e-05
multiple O 0 0.03303951025009155
intestinal O 1 0.9999836683273315
polyps B-Disease 1 0.9994275569915771
and O 0 1.0881119123951066e-05
, O 0 1.7094309896492632e-06
without O 0 9.132634772868187e-07
surgical O 0 0.03421632573008537
intervention O 0 3.0035932923055952e-06
, O 0 1.4212352539288986e-07
the O 0 6.948009456664295e-08
development O 0 8.318156687892042e-06
of O 0 0.0631275624036789
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999995231628418
( O 0 6.956580182304606e-05
CRC B-Disease 0 0.02538951113820076
) O 0 4.6239219955168664e-06
. O 0 1.2369629985187203e-05

APC B-Disease 0 0.0028106393292546272
is O 0 1.3906306776334532e-05
a O 0 2.21586087718606e-05
tumour O 1 0.9991532564163208
- O 0 0.0022449209354817867
suppressor O 0 0.00026822619838640094
gene O 0 6.0271572692727204e-06
, O 0 3.4295970863240655e-07
and O 0 5.589882903223042e-07
somatic O 0 0.0002882659900933504
loss O 0 0.0030878360848873854
occurs O 0 5.298147880239412e-05
in O 0 3.943427509511821e-05
tumours B-Disease 1 0.999799907207489
. O 0 5.72002463741228e-05

The O 0 4.147098297835328e-05
germline O 0 0.2072504311800003
T O 1 0.8101125955581665
- O 0 0.00027403165586292744
to O 0 9.473804993831436e-07
- O 0 5.2792751375818625e-05
A O 0 1.4032837043487234e-06
transversion O 0 0.00013150670565664768
responsible O 0 5.101217084302334e-07
for O 0 8.60539373093161e-08
the O 0 1.3486638295034936e-07
APC O 0 1.52442717080703e-05
I1307K O 0 9.842945473792497e-06
allele O 0 5.822300863655983e-07
converts O 0 1.9832751263493265e-07
the O 0 5.3296329127761055e-08
wild O 0 5.087793510938354e-07
- O 0 8.186760169337504e-06
type O 0 3.578546170501795e-07
sequence O 0 9.249458798876731e-08
to O 0 4.628822836139079e-08
a O 0 4.187004662981053e-07
homopolymer O 1 0.5509188175201416
tract O 0 0.046309199184179306
( O 0 1.3723280289923423e-06
A8 O 0 0.12717372179031372
) O 0 1.8836890092188696e-07
that O 0 4.859299096438008e-08
is O 0 1.8721982542047044e-07
genetically O 0 1.1548270776984282e-05
unstable O 0 0.0004465781385079026
and O 0 1.6195035641430877e-06
prone O 0 8.36476101540029e-05
to O 0 9.636386266720365e-07
somatic O 0 0.0007308226195164025
mutation O 0 9.279697405872867e-05
. O 0 1.9488494217512198e-05

The O 0 2.6595995223033242e-05
I1307K O 0 0.000390200613765046
allele O 0 7.128401921363547e-05
was O 0 3.0979651910456596e-06
found O 0 1.5160732118602027e-06
in O 0 1.1592810551519506e-06
6 O 0 1.7957469026441686e-05
. O 0 1.1556599929463118e-05

1 O 0 3.7339759728638455e-05
% O 0 3.245113020966528e-06
of O 0 8.166751968019526e-07
unselected O 0 0.0009955837158486247
Ashkenazi O 0 0.0002462762931827456
Jews O 0 2.1091921098559396e-06
and O 0 4.778176503350551e-07
higher O 0 1.1911619139937102e-06
proportions O 0 4.596810867951717e-06
of O 0 1.530686830619743e-07
Ashkenazim O 0 0.00048696831800043583
with O 0 1.6410317584814038e-06
family O 0 6.616548489546403e-06
or O 0 1.0195166169069125e-06
personal O 0 8.167497981048655e-06
histories O 0 1.735680052661337e-05
of O 0 1.3437228290058556e-06
CRC B-Disease 0 0.005514433607459068
( O 0 1.5396482240248588e-06
ref O 0 0.006581807043403387
. O 0 4.71743618390974e-07
2 O 0 1.2631836625587312e-06
) O 0 1.1378606359357946e-06
. O 0 5.01423755849828e-06

To O 0 1.062465162249282e-05
evaluate O 0 2.7710821086657234e-05
the O 0 3.5453683722153073e-07
role O 0 3.824313523637102e-07
of O 0 2.3071913801686605e-07
I1307K O 0 0.0017619760474190116
in O 0 6.075362307456089e-06
cancer B-Disease 0 0.05255813151597977
, O 0 2.0377210319111327e-07
we O 0 2.0512719345333608e-07
genotyped O 0 0.00015708536375313997
5 O 0 8.947286005422939e-07
, O 0 5.903564215259394e-07
081 O 0 0.0009182951180264354
Ashkenazi O 0 3.5973062040284276e-05
volunteers O 0 1.0235557965643238e-06
in O 0 1.7444071431782504e-07
a O 0 4.333861909344705e-07
community O 0 2.3426980533258757e-06
survey O 0 1.2692295968008693e-05
. O 0 1.1960043593717273e-05

Risk O 0 0.0016582931857556105
of O 0 2.5496679882053286e-05
developing O 0 0.048486411571502686
colorectal B-Disease 1 0.9999990463256836
, I-Disease 0 0.002319969469681382
breast I-Disease 1 0.9987366795539856
and I-Disease 0 1.870928826974705e-05
other I-Disease 0 7.635046131326817e-06
cancers I-Disease 1 0.7619755864143372
were O 0 5.644340603794262e-07
compared O 0 6.267680873861536e-06
between O 0 9.576424417900853e-07
genotyped O 0 0.005843314342200756
I1307K O 0 0.00067618751199916
carriers O 0 4.796516805072315e-06
and O 0 1.668397970888691e-07
non O 0 1.5472568293262157e-06
- O 0 0.00017109922191593796
carriers O 0 2.8781225864804583e-06
and O 0 5.468461239388489e-08
their O 0 5.2435829900332465e-08
first O 0 2.704974235712143e-07
- O 0 0.00031148322159424424
degree O 0 2.0968351236660965e-05
relatives O 0 3.398742774152197e-05
. O 0 1.124114260164788e-05

Sperm O 0 0.0006668344140052795
DNA O 0 0.0001430652046110481
analysis O 0 1.9157121641910635e-05
in O 0 2.521385567888501e-06
a O 0 1.609826176718343e-05
Friedreich B-Disease 1 0.9937587976455688
ataxia I-Disease 1 0.9965241551399231
premutation O 1 0.8797782063484192
carrier O 0 0.001980709144845605
suggests O 0 6.251623744901735e-06
both O 0 4.681224652358651e-07
meiotic O 0 0.0009961255127564073
and O 0 1.8038285816146526e-06
mitotic O 0 0.000315675773890689
expansion O 0 9.435624633624684e-06
in O 0 6.853741183476814e-07
the O 0 2.113642040058039e-06
FRDA B-Disease 0 0.003946482669562101
gene O 0 3.4284734283573925e-05
. O 0 1.649227851885371e-05

Friedreich B-Disease 1 0.9992461204528809
ataxia I-Disease 1 0.999496579170227
is O 0 7.278836710611358e-05
usually O 0 1.275915201404132e-05
caused O 0 1.0470791494299192e-05
by O 0 2.447038127684209e-07
an O 0 5.849527795476206e-08
expansion O 0 8.616756872470432e-07
of O 0 9.377178855629609e-08
a O 0 1.17414720079978e-06
GAA O 0 2.3696129574091174e-05
trinucleotide O 0 0.00038728260551579297
repeat O 0 5.7188594837498385e-06
in O 0 2.3856838993197016e-07
intron O 0 0.00016923007206059992
1 O 0 3.3575835800547793e-07
of O 0 1.2367173951588484e-07
the O 0 6.01512340381305e-07
FRDA B-Disease 0 0.0022913834545761347
gene O 0 2.8974700398975983e-05
. O 0 1.212158258567797e-05

Occasionally O 0 0.00011738115426851436
, O 0 5.3691674111178145e-06
a O 0 1.036829758049862e-06
fully O 0 8.941058808886737e-07
expanded O 0 2.987333687087812e-07
allele O 0 1.577486273163231e-06
has O 0 1.1508591768460974e-07
been O 0 7.813466140760283e-08
found O 0 1.2690965434103418e-07
to O 0 6.404530950021581e-08
arise O 0 6.294543481999426e-07
from O 0 3.0469909262365036e-08
a O 0 9.189512439888858e-08
premutation O 0 3.86877654818818e-05
of O 0 5.628377053312761e-08
100 O 0 2.474405391694745e-07
or O 0 2.509869716504909e-07
less O 0 8.701715614733985e-07
triplet O 0 0.0001452672586310655
repeats O 0 2.738453622441739e-05
. O 0 1.1355495189491194e-05

We O 0 1.5406589227495715e-05
have O 0 1.5826457229195512e-06
examined O 0 8.412660463363864e-06
the O 0 3.386293769835902e-07
sperm O 0 5.553121354751056e-06
DNA O 0 3.687250455186586e-06
of O 0 3.661784546693525e-07
a O 0 5.4681549954693764e-06
premutation O 0 0.040811337530612946
carrier O 0 0.001141309505328536
. O 0 2.877237602660898e-05

This O 0 1.802709994080942e-05
mans O 0 0.0002586203918326646
leucocyte O 0 0.023749398067593575
DNA O 0 0.0003593302972149104
showed O 0 1.1893641385540832e-05
one O 0 3.600169691253541e-07
normal O 0 8.616822810836311e-07
allele O 0 1.8109576558344997e-06
and O 0 1.3862484138371656e-07
one O 0 7.647432909152485e-08
allele O 0 9.625896382203791e-07
of O 0 1.8197160045474448e-07
approximately O 0 1.0982009825966088e-06
100 O 0 1.58996931531874e-06
repeats O 0 2.1060197468614206e-05
. O 0 8.88906197360484e-06

His O 0 5.4778567573521286e-05
sperm O 0 0.00014275273133534938
showed O 0 8.733575668884441e-06
an O 0 1.1789827425445765e-07
expanded O 0 5.116833108331775e-07
allele O 0 1.0070205007650657e-06
in O 0 7.471506791034699e-08
a O 0 2.964281407003e-07
tight O 0 9.396760106028523e-06
range O 0 1.4758171573703294e-06
centering O 0 1.7951056179299485e-06
on O 0 2.1476387246366357e-07
a O 0 1.547994799011576e-07
size O 0 1.1691691952364636e-06
of O 0 2.6771240868583845e-07
approximately O 0 3.0200831133697648e-06
320 O 0 4.201995034236461e-05
trinucleotide O 0 0.00248325546272099
repeats O 0 9.974076237995178e-05
. O 0 2.2594475012738258e-05

His O 0 8.942314889281988e-05
affected O 0 0.00012650642020162195
son O 0 0.000800031702965498
has O 0 2.71513113148103e-06
repeat O 0 1.9737175534828566e-05
sizes O 0 8.054081263253465e-06
of O 0 7.673066875213408e-07
1040 O 0 0.0001809357781894505
and O 0 3.9187016227515414e-06
540 O 0 9.082239557756111e-05
. O 0 2.5942874344764277e-05

These O 0 6.547689281433122e-06
data O 0 5.712721758754924e-06
suggest O 0 1.4708082289871527e-06
that O 0 9.825942726138237e-08
expansion O 0 1.36841015319078e-06
occurs O 0 4.6310037760122214e-07
in O 0 6.312578193501395e-08
two O 0 5.8595109209136353e-08
stages O 0 3.3530700420669746e-06
, O 0 8.332094125762524e-08
the O 0 2.2364064378166404e-08
first O 0 4.586200574863142e-08
during O 0 2.454760590353544e-07
meiosis O 0 1.1094934052380268e-05
followed O 0 4.298717044548539e-07
by O 0 1.480378699625362e-07
a O 0 4.771077897203213e-07
second O 0 3.574876473066979e-06
mitotic O 0 0.0008273898274637759
expansion O 0 7.85121155786328e-05
. O 0 3.320874384371564e-05

We O 0 2.1990161258145235e-05
also O 0 1.1517324765009107e-06
show O 0 7.530730385951756e-07
that O 0 5.781709688790215e-08
in O 0 4.677101372863035e-08
all O 0 2.319501390957157e-08
informative O 0 1.8528920691096573e-06
carrier O 0 4.4030653953086585e-05
father O 0 1.8865741822082782e-06
to O 0 1.7738507551712246e-07
affected O 0 2.446079633955378e-06
child O 0 5.685920314135728e-06
transmissions O 0 5.818864792672684e-06
, O 0 2.7132651325700863e-07
with O 0 4.8834568389111155e-08
the O 0 5.186666385270655e-08
notable O 0 3.4644688184926054e-07
exception O 0 1.4525349456562253e-07
of O 0 3.511777535436522e-08
the O 0 1.36806136197265e-07
premutation O 0 0.0007224218570627272
carrier O 0 3.4268559829797596e-05
, O 0 1.333727084329439e-07
the O 0 4.233685757526473e-08
expansion O 0 1.8193758251072722e-06
size O 0 1.0729047971835826e-05
decreases O 0 1.755163430061657e-05
. O 0 1.590695774211781e-06
. O 0 8.528677426511422e-06

The O 0 5.100964699522592e-05
R496H O 0 0.0007528307614848018
mutation O 0 4.386251021060161e-05
of O 0 2.3417555894411635e-06
arylsulfatase O 0 0.0032213127706199884
A O 0 4.609827556123491e-06
does O 0 3.921143161278451e-06
not O 0 3.8570033211726695e-06
cause O 0 0.0015230290591716766
metachromatic B-Disease 1 0.9998332262039185
leukodystrophy I-Disease 1 0.9998040795326233
. O 0 0.00015154556604102254

Deficiency B-Disease 1 0.9979008436203003
of I-Disease 0 4.395823270897381e-05
arylsulfatase I-Disease 0 0.17630670964717865
A I-Disease 0 2.4340040909009986e-05
( O 0 9.343038982478902e-06
ARSA O 0 0.22704842686653137
) O 0 1.5694732837800984e-06
enzyme O 0 8.142223123286385e-06
activity O 0 1.248764692718396e-05
causes O 0 0.0006444755708798766
metachromatic B-Disease 1 0.9999122619628906
leukodystrophy I-Disease 1 0.9999536275863647
( O 0 0.0001539250952191651
MLD B-Disease 1 0.9978000521659851
) O 0 2.116267387464177e-05
. O 0 3.2192641810979694e-05

A O 0 4.9767797463573515e-05
number O 0 2.8686440600722563e-06
of O 0 2.642959088916541e-06
ARSA O 1 0.5530213117599487
gene O 0 3.7965710362186655e-05
mutations O 0 1.607316517038271e-05
responsible O 0 3.8596231206611264e-06
for O 0 2.630968310768367e-06
MLD B-Disease 1 0.9997771382331848
have O 0 2.662108045115019e-06
been O 0 1.4892927993059857e-06
identified O 0 1.0774708243843634e-05
. O 0 1.0473449037817772e-05

Recently O 0 0.00026244594482704997
, O 0 3.3834573969215853e-06
the O 0 6.084693495722604e-07
R496H O 0 8.031920151552185e-05
mutation O 0 2.7572966700972756e-06
of O 0 4.0678017398931843e-07
ARSA O 0 0.11449547857046127
was O 0 8.349751965397445e-07
proposed O 0 8.030329468056152e-07
to O 0 1.1126461174626456e-07
be O 0 6.783694317391564e-08
a O 0 3.361155904713087e-07
cause O 0 1.981193008759874e-06
of O 0 6.11294296959386e-07
MLD B-Disease 1 0.9995250701904297
( O 0 3.0377004804904573e-06
Draghia O 0 0.012330274097621441
et O 0 0.00018933934916276485
al O 0 8.698900637682527e-05
. O 0 4.007311247278267e-07
, O 0 5.18693411777349e-07
1997 O 0 2.5272836410294985e-06
) O 0 1.0845022870853427e-06
. O 0 4.428175543580437e-06

We O 0 2.5327335606561974e-05
have O 0 1.2704397249763133e-06
investigated O 0 7.703040864726063e-06
the O 0 2.8165317189632333e-07
R496H O 0 0.00021747245045844465
mutation O 0 3.6279393498261925e-06
and O 0 2.1631477409300714e-07
found O 0 1.5512873119405413e-07
this O 0 4.185303836834464e-08
mutation O 0 5.120787136547733e-07
at O 0 1.3880581661851465e-07
a O 0 7.856400685568588e-08
relatively O 0 4.0188464822676906e-07
high O 0 4.0026745296017907e-07
frequency O 0 1.3765733797299617e-07
in O 0 1.7902362259292204e-08
an O 0 9.419965252277507e-09
African O 0 4.428908439990664e-08
American O 0 4.4500520601786775e-08
population O 0 4.31906563846951e-08
( O 0 4.445284673693095e-08
f O 0 6.179609044920653e-06
= O 0 1.6446068684672355e-06
0 O 0 1.5729629865290917e-07
. O 0 2.131443466169003e-08
09 O 0 5.089705155114643e-07
, O 0 8.345168822643245e-08
n O 0 5.4609890867141075e-06
= O 0 2.3405900719808415e-06
61 O 0 1.1705760698532686e-06
subjects O 0 1.0388577038611402e-06
) O 0 8.30585690891894e-07
. O 0 3.686884838316473e-06

The O 0 3.4041560866171494e-05
ARSA O 0 0.026577336713671684
enzyme O 0 2.3733808120596223e-05
activity O 0 5.252960363577586e-06
in O 0 3.365707641478366e-07
subjects O 0 1.0209761285295826e-06
with O 0 1.979118593453677e-07
and O 0 2.0737502381962258e-07
without O 0 1.2608136046310392e-07
the O 0 1.2835162976898573e-07
R496H O 0 7.13133267709054e-05
mutation O 0 6.709483955091855e-07
was O 0 1.5328033953210252e-07
determined O 0 7.240360559990222e-07
and O 0 1.0140578865502903e-07
found O 0 1.2217486755616846e-07
to O 0 8.369318038603524e-08
be O 0 2.1036726138845552e-07
normal O 0 4.031036041851621e-06
. O 0 7.466094757546671e-06

It O 0 1.1573386473173741e-05
is O 0 1.90462469618069e-06
therefore O 0 1.4754106132386369e-06
concluded O 0 1.8564295487522031e-06
that O 0 4.570839706730112e-08
the O 0 1.5334966008140327e-07
R496H O 0 0.00010643160931067541
mutation O 0 1.9479034563119058e-06
of O 0 3.7289925103323185e-07
ARSA O 0 0.44340208172798157
does O 0 5.144311785443278e-07
not O 0 5.2511293091583866e-08
negatively O 0 2.0634033148780873e-07
influence O 0 5.117623658179582e-08
the O 0 2.17049542783343e-08
activity O 0 9.82530536930426e-08
of O 0 1.044393300730917e-07
ARSA O 0 0.36636799573898315
and O 0 4.871084797741787e-07
is O 0 1.9214314761484275e-07
not O 0 1.1329368021506525e-07
a O 0 9.518687988929742e-07
cause O 0 1.2774712558893953e-05
of O 0 2.2806347260484472e-05
MLD B-Disease 1 0.9994410872459412

Down O 0 0.00030381890246644616
- O 0 0.00013496752944774926
regulation O 0 6.80854373058537e-06
of O 0 1.425254367859452e-06
transmembrane O 0 0.00010780595039250329
carbonic O 0 0.00025692314375191927
anhydrases O 0 0.022387661039829254
in O 0 0.00022912606073077768
renal B-Disease 1 0.9999990463256836
cell I-Disease 1 0.9999443292617798
carcinoma I-Disease 1 0.9999997615814209
cell O 0 0.022591620683670044
lines O 0 1.7675902199698612e-05
by O 0 5.617393981083296e-07
wild O 0 9.789623618416954e-06
- O 0 0.004365114960819483
type O 0 0.0002867015136871487
von B-Disease 1 0.5400846004486084
Hippel I-Disease 1 0.8674113750457764
- I-Disease 0 0.035259831696748734
Lindau I-Disease 0 0.22124744951725006
transgenes O 0 0.0016841312171891332
. O 0 3.9969967474462464e-05

To O 0 3.6208544770488515e-05
discover O 0 8.721675840206444e-05
genes O 0 1.1537416867213324e-05
involved O 0 5.834746843902394e-06
in O 0 6.8673243731609546e-06
von B-Disease 1 0.9324414730072021
Hippel I-Disease 1 0.9945695996284485
- I-Disease 1 0.7014399766921997
Lindau I-Disease 1 0.9303635358810425
( O 0 4.881538188783452e-06
VHL B-Disease 0 0.00032948830630630255
) O 0 8.127809678626363e-07
- O 0 4.8588935896987095e-05
mediated O 0 0.00010256397217744961
carcinogenesis O 0 0.021625801920890808
, O 0 1.3629244222101988e-06
we O 0 1.994830427065608e-06
used O 0 0.00016564471297897398
renal B-Disease 1 0.9999972581863403
cell I-Disease 1 0.9998494386672974
carcinoma I-Disease 1 0.9999997615814209
cell O 0 0.07931862026453018
lines O 0 8.747947140363976e-05
stably O 0 0.00048799708019942045
transfected O 0 0.0011547409230843186
with O 0 1.2017183053103508e-06
wild O 0 1.2852883628511336e-05
- O 0 0.0027793676126748323
type O 0 0.00016159031656570733
VHL O 0 0.002737105591222644
- O 0 0.00041794616845436394
expressing O 0 8.124909072648734e-05
transgenes O 0 0.0009103058255277574
. O 0 2.9483673642971553e-05

Large O 0 0.00011826671106973663
- O 0 0.00014904924319125712
scale O 0 2.7010170015273616e-05
RNA O 0 3.3491230624349555e-06
differential O 0 2.152760089302319e-06
display O 0 1.4172710507409647e-06
technology O 0 1.6033216070354683e-06
applied O 0 1.7296720500326046e-07
to O 0 8.126843198397182e-08
these O 0 1.0782758153027316e-07
cell O 0 1.6930405763559975e-05
lines O 0 1.786840584827587e-06
identified O 0 5.721581146644894e-07
several O 0 7.353735043125198e-08
differentially O 0 2.7337760002410505e-06
expressed O 0 2.9210951879576896e-07
genes O 0 4.907402058051957e-07
, O 0 1.1649560605064835e-07
including O 0 1.1408798883394411e-07
an O 0 1.7454671308314573e-07
alpha O 0 7.5322914199205115e-06
carbonic O 0 4.2327865230618045e-05
anhydrase O 0 8.93940741661936e-05
gene O 0 3.199293360012234e-06
, O 0 1.0341959750803653e-06
termed O 0 5.718012107536197e-05
CA12 O 0 0.0032708924263715744
. O 0 2.319869054190349e-05

The O 0 1.1850957889691927e-05
deduced O 0 1.6528616470168345e-05
protein O 0 2.658708353919792e-06
sequence O 0 1.2354613545539905e-06
was O 0 3.5789588537227246e-07
classified O 0 1.2145151231379714e-06
as O 0 5.593957652649806e-08
a O 0 1.5895236060714524e-07
one O 0 2.6287986543138686e-07
- O 0 0.0005557185504585505
pass O 0 1.3282300642458722e-05
transmembrane O 0 6.741213292116299e-05
CA O 0 1.7400623619323596e-05
possessing O 0 1.136138735091663e-06
an O 0 6.062369095616305e-08
apparently O 0 5.597917152044829e-07
intact O 0 1.028960241455934e-06
catalytic O 0 5.68447717341769e-07
domain O 0 1.9424757624619815e-07
in O 0 4.667013797643449e-08
the O 0 1.5092885519152333e-07
extracellular O 0 2.466925434418954e-05
CA O 0 0.0001023703080136329
module O 0 0.0003115462022833526
. O 0 1.3258279977890197e-05

Reintroduced O 0 0.0005382764502428472
wild O 0 0.00013012088311370462
- O 0 0.0014404667308554053
type O 0 6.450743967434391e-05
VHL B-Disease 0 0.0004678693658206612
strongly O 0 3.172256583638955e-06
inhibited O 0 3.606668542488478e-06
the O 0 1.4640390588738228e-07
overexpression O 0 2.3944371605466586e-06
of O 0 8.408599683207285e-08
the O 0 2.9734803774772445e-07
CA12 O 0 0.002048843540251255
gene O 0 1.9217666249460308e-06
in O 0 1.6083401987998514e-07
the O 0 1.501631913924939e-06
parental O 1 0.5774409174919128
renal B-Disease 1 0.9999992847442627
cell I-Disease 1 0.9999722242355347
carcinoma I-Disease 1 0.9999996423721313
cell O 1 0.6138641238212585
lines O 0 0.0008096849196590483
. O 0 6.103882333263755e-05

Similar O 0 5.693494313163683e-05
results O 0 2.0640422008000314e-05
were O 0 1.0042708709079307e-06
obtained O 0 8.875466050994874e-07
with O 0 1.0696453500713687e-06
CA9 O 1 0.6925572156906128
, O 0 4.2164043634329573e-07
encoding O 0 1.0060548447654583e-06
another O 0 1.1294474688838818e-06
transmembrane O 0 8.011030149646103e-05
CA O 0 2.0020606825710274e-05
with O 0 2.1892745394325175e-07
an O 0 2.5005567749758484e-07
intact O 0 9.715654414321762e-06
catalytic O 0 1.6047892131609842e-05
domain O 0 1.0895500963670202e-05
. O 0 7.790089512127452e-06

Although O 0 3.8168280298123136e-05
both O 0 1.7930440208147047e-06
domains O 0 1.8579579545985325e-06
of O 0 1.4366366940521402e-07
the O 0 1.9738520506962232e-07
VHL B-Disease 0 9.979157039197162e-05
protein O 0 5.911846301387413e-07
contribute O 0 1.683196870772008e-07
to O 0 3.1542597866973665e-08
regulation O 0 1.2074180233412335e-07
of O 0 8.194598422051058e-08
CA12 O 0 0.0018373565981164575
expression O 0 7.019813779152173e-07
, O 0 1.134710103656289e-07
the O 0 6.746300584836717e-08
elongin O 0 4.0371280192630365e-05
binding O 0 1.4819170246482827e-06
domain O 0 1.2794921531167347e-06
alone O 0 1.2776484936694033e-06
could O 0 3.614632362314296e-07
effectively O 0 4.172788521827897e-06
regulate O 0 3.4345179301453754e-05
CA9 O 0 0.22057516872882843
expression O 0 2.2867388906888664e-05
. O 0 1.0744734936452005e-05

We O 0 4.008654650533572e-05
mapped O 0 0.0002207833167631179
CA12 O 0 0.007707111071795225
and O 0 1.0092143384099472e-05
CA9 O 0 0.04706444591283798
loci O 0 3.34531141561456e-05
to O 0 1.0696912795538083e-06
chromosome O 0 2.6609139240463264e-05
bands O 0 8.623550456832163e-06
15q22 O 0 0.00022203940898180008
and O 0 7.685343916818965e-06
17q21 O 0 0.0008508517639711499
. O 0 1.8413666111882776e-05

2 O 0 0.00011722366616595536
respectively O 0 2.8115207896917127e-05
, O 0 2.37209974329744e-06
regions O 0 6.91816967446357e-06
prone O 0 0.00010768195352284238
to O 0 3.3529536835885665e-07
amplification O 0 2.6221207008347847e-05
in O 0 3.3259249221373466e-07
some O 0 6.609924412259716e-07
human O 0 2.591419433883857e-05
cancers B-Disease 1 0.7813125848770142
. O 0 4.45421646873001e-05

Additional O 0 2.2273437934927642e-05
experiments O 0 2.9642789741046727e-05
are O 0 5.487602265930036e-07
needed O 0 8.006899179235916e-07
to O 0 1.343129270026111e-07
define O 0 1.2628499916900182e-06
the O 0 6.911515981755656e-08
role O 0 1.6033322935982142e-07
of O 0 1.1308770808682311e-07
CA O 0 5.9926253015873954e-05
IX O 0 0.0007753726094961166
and O 0 2.785568767649238e-06
CA O 0 0.0002508502802811563
XII O 0 0.004638785030692816
enzymes O 0 1.4145136901788646e-06
in O 0 4.951332499558703e-08
the O 0 1.9264840389610072e-08
regulation O 0 1.169050563021301e-07
of O 0 7.547159697196548e-08
pH O 0 8.953518408816308e-05
in O 0 2.6029805866301103e-08
the O 0 3.090537958883033e-08
extracellular O 0 1.1187145219082595e-06
microenvironment O 0 4.260559944668785e-05
and O 0 5.850866813261746e-08
its O 0 7.645711974646474e-08
potential O 0 6.56960310152499e-07
impact O 0 1.2270936622371664e-06
on O 0 1.0862445378734265e-05
cancer B-Disease 1 0.9105663299560547
cell O 0 0.0008071920019574463
growth O 0 2.3099015379557386e-05
. O 0 1.598098606336862e-05

A O 0 3.15504330501426e-05
gene O 0 2.296888669661712e-05
encoding O 0 8.812321539153345e-06
a O 0 1.269895847144653e-06
transmembrane O 0 2.0468669390538707e-05
protein O 0 1.382695700158365e-06
is O 0 2.1813050921082322e-07
mutated O 0 5.508593858394306e-06
in O 0 2.544211611166247e-06
patients O 0 0.014366519637405872
with O 0 0.03597258776426315
diabetes B-Disease 1 0.9999997615814209
mellitus I-Disease 1 0.9999985694885254
and O 1 0.7372565269470215
optic B-Disease 1 0.9999986886978149
atrophy I-Disease 1 0.9999781847000122
( O 1 0.9176543951034546
Wolfram B-Disease 1 0.9999943971633911
syndrome I-Disease 1 0.9999924898147583
) O 0 2.7537265850696713e-05
. O 0 4.578481457429007e-05

Wolfram B-Disease 1 0.9999841451644897
syndrome I-Disease 1 0.9999947547912598
( O 0 0.0009183838847093284
WFS B-Disease 1 0.9935548901557922
; O 0 0.0009137190645560622
OMIM O 1 0.9967562556266785
222300 O 0 0.21731188893318176
) O 0 4.34784806202515e-06
is O 0 2.1460123207361903e-06
an O 0 7.459070729964878e-06
autosomal B-Disease 1 0.9974679946899414
recessive I-Disease 1 0.9999710321426392
neurodegenerative I-Disease 1 0.9999991655349731
disorder I-Disease 1 0.9990341663360596
defined O 0 1.5784698916831985e-05
by O 0 1.3667015537066618e-06
young O 0 2.1539679437410086e-05
- O 0 0.010191078297793865
onset O 0 0.08308319002389908
non O 0 8.837797940941527e-05
- O 0 0.1398249715566635
immune O 0 0.00289932987652719
insulin B-Disease 0 0.0015454760286957026
- I-Disease 1 0.9197349548339844
dependent I-Disease 1 0.610558271408081
diabetes I-Disease 1 0.9999986886978149
mellitus I-Disease 1 0.9999865293502808
and O 0 0.0011170017533004284
progressive O 1 0.9483692049980164
optic B-Disease 1 0.9999628067016602
atrophy I-Disease 1 0.9940117001533508
. O 0 0.00024091789964586496

Linkage O 0 0.0007334753172472119
to O 0 7.66114317229949e-06
markers O 0 5.2423409215407446e-05
on O 0 3.105090399913024e-06
chromosome O 0 0.0007040210766717792
4p O 1 0.998068630695343
was O 0 2.9557918423961382e-06
confirmed O 0 1.805184638214996e-06
in O 0 1.9812317475498276e-07
five O 0 9.31947624849272e-07
families O 0 6.477087026723893e-06
. O 0 6.9698166953457985e-06

On O 0 1.0415468750579748e-05
the O 0 7.197882041509729e-07
basis O 0 8.31627914976707e-07
of O 0 5.607171260635369e-07
meiotic O 0 0.3933771550655365
recombinants O 1 0.988658607006073
and O 0 0.0002319737832294777
disease O 0 0.15680162608623505
- O 0 0.10862606018781662
associated O 0 3.2033825846156105e-05
haplotypes O 0 0.00010650957119651139
, O 0 5.305524837240227e-07
the O 0 3.5603582659859967e-07
WFS B-Disease 0 0.0030821547843515873
gene O 0 1.962860778803588e-06
was O 0 4.303130083371798e-07
localized O 0 1.8414173155179014e-06
to O 0 1.2767260670898395e-07
a O 0 7.930833589853137e-07
BAC O 0 3.961682159570046e-05
/ O 0 1.7401316654286347e-05
P1 O 0 8.12681537354365e-05
contig O 0 2.8314612791291438e-05
of O 0 1.191559064750436e-07
less O 0 3.936104064905521e-07
than O 0 4.266134681074618e-07
250 O 0 6.304543148871744e-06
kb O 0 0.0002995914837811142
. O 0 1.4775755516893696e-05

Mutations O 0 0.0005558522534556687
in O 0 3.5585421755968127e-06
a O 0 1.1145082225993974e-06
novel O 0 4.77705134471762e-06
gene O 0 3.8066148135840194e-06
( O 0 3.895151223787252e-07
WFS1 O 0 0.00011587546759983525
) O 0 7.157687065273421e-08
encoding O 0 2.301903521129134e-07
a O 0 2.15517061974424e-07
putative O 0 6.719635166518856e-06
transmembrane O 0 4.5898245844000485e-06
protein O 0 2.6414116405248933e-07
were O 0 5.765400601376314e-08
found O 0 8.508708049248526e-08
in O 0 2.4967100387129904e-08
all O 0 2.063593385059903e-08
affected O 0 4.03684623506706e-07
individuals O 0 9.073638551626573e-08
in O 0 1.054543901091165e-07
six O 0 1.5994487512216438e-06
WFS B-Disease 0 0.280780166387558
families O 0 3.468860313660116e-06
, O 0 2.3435244145275647e-07
and O 0 8.665644202210387e-08
these O 0 4.9968619464380026e-08
mutations O 0 1.2430155038600788e-06
were O 0 1.1060381410743503e-07
associated O 0 1.4580560900867567e-06
with O 0 1.3429029195322073e-06
the O 0 4.5966058678459376e-05
disease O 0 0.4420287311077118
phenotype O 0 0.002305095549672842
. O 0 4.378181620268151e-05

WFS1 O 0 0.1645781695842743
appears O 0 9.221494838129729e-05
to O 0 1.7209562201969675e-06
function O 0 7.273857818290708e-07
in O 0 2.210971814520235e-07
survival O 0 1.23540339700412e-05
of O 0 4.2237894604113535e-07
islet O 0 0.32423147559165955
beta O 0 0.00019157280621584505
- O 0 0.00180122593883425
cells O 0 1.4125204870651942e-05
and O 0 5.883392191208259e-07
neurons O 0 8.709646863280796e-06
. O 0 1.0992362149409018e-06
. O 0 4.856417035625782e-06

Stable O 0 0.00020000756194349378
interaction O 0 9.256160410586745e-06
between O 0 1.1579816145967925e-06
the O 0 2.0907164355321584e-07
products O 0 3.9199511547849397e-07
of O 0 5.083204968059363e-08
the O 0 2.5317174845440604e-07
BRCA1 O 0 0.0004950336297042668
and O 0 5.192306161916349e-06
BRCA2 O 0 0.028631338849663734
tumor B-Disease 0 0.017909158021211624
suppressor O 0 5.7886220020009205e-05
genes O 0 1.1857996469188947e-06
in O 0 3.202472385055444e-07
mitotic O 0 0.0005080020055174828
and O 0 8.483397323288955e-06
meiotic O 1 0.8840551972389221
cells O 0 0.0008417980861850083
. O 0 3.3271640859311447e-05

BRCA1 O 0 0.04163864627480507
and O 0 2.7736938136513345e-05
BRCA2 O 0 0.0013065316015854478
account O 0 2.6747482024802594e-06
for O 0 5.054953930994088e-07
most O 0 4.650566154396074e-07
cases O 0 7.16131921763008e-07
of O 0 5.080811433799681e-07
familial O 0 0.031018821522593498
, O 0 4.3486361391842365e-06
early O 0 5.1852184697054327e-05
onset O 1 0.9892368912696838
breast B-Disease 1 0.9983637928962708
and I-Disease 0 0.00010861793998628855
/ I-Disease 1 0.9925646781921387
or I-Disease 1 0.9754043221473694
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999890327453613
and O 0 1.7602338857614086e-06
encode O 0 1.5616452628819388e-06
products O 0 1.0774242582556326e-06
that O 0 5.394966962057879e-08
each O 0 9.712985615806247e-08
interact O 0 5.979388788546203e-07
with O 0 1.4486671489066794e-06
hRAD51 O 0 0.0010423174826428294
. O 0 2.1188461687415838e-05

Results O 0 0.00011619689757935703
presented O 0 1.9639241145341657e-05
here O 0 2.673541985132033e-06
show O 0 1.9879196315741865e-06
that O 0 6.29724524969788e-07
BRCA1 O 0 0.0006915569538250566
and O 0 4.531716513156425e-06
BRCA2 O 0 0.016216998919844627
coexist O 0 4.0838804125087336e-05
in O 0 2.421852798306645e-07
a O 0 6.944782171558472e-07
biochemical O 0 1.2918468200950883e-05
complex O 0 7.646566700714175e-06
and O 0 5.919416707911296e-07
colocalize O 0 0.00030546917696483433
in O 0 3.9412427099705383e-07
subnuclear O 0 0.00045087849139235914
foci O 0 1.6237521776929498e-05
in O 0 1.7356603621010436e-07
somatic O 0 2.083436629618518e-05
cells O 0 3.2361999728891533e-06
and O 0 1.0260875882295295e-07
on O 0 9.195333916522941e-08
the O 0 5.7109950546418986e-08
axial O 0 1.0933167686744127e-06
elements O 0 2.4969679657260713e-07
of O 0 2.360945643431478e-07
developing O 0 1.6182519175345078e-05
synaptonemal O 0 0.00527474470436573
complexes O 0 0.00020979785767849535
. O 0 1.6733003576518968e-05

Like O 0 0.0003195476601831615
BRCA1 O 0 0.002766398247331381
and O 0 2.247788324893918e-05
RAD51 O 0 0.4111878573894501
, O 0 1.3244113688415382e-05
BRCA2 O 0 0.0003468669601716101
relocates O 0 5.881468314328231e-05
to O 0 2.3373022486339323e-06
PCNA O 0 0.004443457815796137
+ O 0 2.422120815026574e-05
replication O 0 3.356147772137774e-06
sites O 0 9.528788496027119e-07
following O 0 2.620960799504246e-07
exposure O 0 1.0042757594419527e-06
of O 0 1.0308446007911698e-07
S O 0 0.00019531624275259674
phase O 0 3.165486123180017e-05
cells O 0 5.965483978798147e-06
to O 0 7.597180342600041e-07
hydroxyurea O 0 0.0010925928363576531
or O 0 8.290548976219725e-06
UV O 0 0.05200283229351044
irradiation O 0 0.0005766881513409317
. O 0 1.9874923964380287e-05

Thus O 0 6.293041951721534e-05
, O 0 7.731073310424108e-06
BRCA1 O 0 0.00022214697673916817
and O 0 2.414584514554008e-06
BRCA2 O 0 0.0001482444495195523
participate O 0 1.0401108738733456e-06
, O 0 3.344867138821428e-07
together O 0 3.086950641773001e-07
, O 0 1.9402412476665631e-07
in O 0 4.805920994499502e-08
a O 0 1.6452942475098098e-07
pathway O 0 2.330433744646143e-06
( O 0 1.8151541780753178e-07
s O 0 0.0002958030963782221
) O 0 9.108647702760209e-08
associated O 0 1.0585461041046074e-07
with O 0 2.424519252031132e-08
the O 0 3.211445331885443e-08
activation O 0 4.64994514004502e-07
of O 0 3.769427436850492e-08
double O 0 1.6347133851013496e-06
- O 0 0.00011390440340619534
strand O 0 1.7581152860657312e-05
break O 0 4.821695256396197e-06
repair O 0 0.0016922116046771407
and O 0 1.6787961385489325e-06
/ O 0 6.966166984057054e-05
or O 0 1.395772073919943e-06
homologous O 0 3.729104355443269e-05
recombination O 0 0.0002707598905544728
. O 0 3.613552325987257e-05

Dysfunction O 1 0.5372223258018494
of O 0 3.6101714613323566e-06
this O 0 1.2382249678921653e-06
pathway O 0 2.3119600882637314e-05
may O 0 1.421452338945528e-06
be O 0 6.029986820976774e-08
a O 0 1.2694366091636766e-07
general O 0 9.05682952634379e-07
phenomenon O 0 2.56986004387727e-06
in O 0 4.7575195338822596e-08
the O 0 4.8681766173785945e-08
majority O 0 2.3155214989856177e-07
of O 0 7.334698182148713e-08
cases O 0 8.873519163898891e-07
of O 0 2.331852101633558e-06
hereditary B-Disease 1 0.9866530299186707
breast I-Disease 1 0.9984354376792908
and I-Disease 0 0.001181101892143488
/ I-Disease 1 0.9996792078018188
or I-Disease 1 0.9966182112693787
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999920129776001
. O 0 1.709729986032471e-05
. O 0 3.5680775908986107e-05

A O 0 0.00011737007298506796
novel O 0 0.00010197135270573199
Arg362Ser O 0 0.003926906269043684
mutation O 0 2.856404535123147e-05
in O 0 9.440002486371668e-07
the O 0 3.963889696478873e-07
sterol O 0 6.25701795797795e-05
27 O 0 5.614535893982975e-06
- O 0 0.00018643183284439147
hydroxylase O 0 0.00012365277507342398
gene O 0 1.7058318917406723e-06
( O 0 1.6749214637457044e-07
CYP27 O 0 7.339152944041416e-05
) O 0 5.304532635364012e-08
: O 0 4.301144329588169e-08
its O 0 3.108877777435737e-08
effects O 0 2.2929775411739683e-07
on O 0 1.185759614941162e-07
pre O 0 9.060743650479708e-06
- O 0 3.378375595275429e-06
mRNA O 0 2.702622339256777e-07
splicing O 0 8.464854204248695e-07
and O 0 1.9270100892754272e-07
enzyme O 0 3.1897909593681106e-06
activity O 0 2.9381619697232964e-06
. O 0 3.2000805276766187e-06

A O 0 5.580498691415414e-05
novel O 0 2.8944154109922238e-05
C O 0 0.0001339569571428001
to O 0 3.2326971677321126e-07
A O 0 5.668161406902072e-07
mutation O 0 7.913012041171896e-07
in O 0 4.9779981026176756e-08
the O 0 9.00737262554685e-08
sterol O 0 2.525309901102446e-05
27 O 0 2.6411321414343547e-06
- O 0 0.00011701414041453972
hydroxylase O 0 9.349334868602455e-05
gene O 0 6.624426305279485e-07
( O 0 1.123809383329899e-07
CYP27 O 0 5.479925675899722e-05
) O 0 6.277517883290784e-08
was O 0 5.6190664565747284e-08
identified O 0 6.194343882270914e-08
by O 0 2.0331897943037802e-08
sequencing O 0 7.005254474279354e-07
amplified O 0 1.0298820143361809e-06
CYP27 O 0 5.2034218242624775e-05
gene O 0 6.111806101216644e-07
products O 0 2.7492225740388676e-07
from O 0 9.093406561078154e-08
a O 0 7.720947792222432e-07
patient O 0 8.528044418198988e-05
with O 0 1.0141783604922239e-05
cerebrotendinous B-Disease 1 0.9996706247329712
xanthomatosis I-Disease 1 0.999797523021698
( O 0 2.1114979972480796e-05
CTX B-Disease 1 0.8324187994003296
) O 0 7.857710443204269e-06
. O 0 9.188097465084866e-06

The O 0 4.146311039221473e-05
mutation O 0 5.7797631598077714e-05
changed O 0 5.46241653864854e-06
the O 0 8.06968216693349e-07
adrenodoxin O 0 8.07206379249692e-05
cofactor O 0 6.089410817367025e-06
binding O 0 2.6200964384770487e-06
residue O 0 7.595197985210689e-06
362Arg O 0 4.0631832234794274e-05
to O 0 6.919844963704236e-07
362Ser O 0 0.0001061142174876295
( O 0 4.937832045470714e-07
CGT O 0 3.5682714951690286e-05
362Arg O 0 1.650242666073609e-05
to O 0 5.002832494938048e-07
AGT O 0 0.0015353492926806211
362Ser O 0 0.00013893243158236146
) O 0 1.8585892291866912e-07
, O 0 9.001326617408267e-08
and O 0 6.010879616269449e-08
was O 0 1.527024267033994e-07
responsible O 0 1.2282855550438398e-06
for O 0 3.6525459563563345e-06
deficiency O 0 0.02719937078654766
in O 0 4.7301853101089364e-08
the O 0 7.901167009549681e-08
sterol O 0 1.9551114746718667e-05
27 O 0 1.4751572052773554e-06
- O 0 4.292799349059351e-05
hydroxylase O 0 2.9337770683923736e-05
activity O 0 2.583138609679736e-07
, O 0 3.126908865169753e-08
as O 0 1.617115330532215e-08
confirmed O 0 4.802796382818997e-08
by O 0 2.0164133474054324e-08
expression O 0 3.558008643267385e-08
of O 0 2.2175768776833138e-08
mutant O 0 6.77418995564949e-07
cDNA O 0 1.8530793113313848e-06
into O 0 5.579156550084008e-07
COS O 0 0.0003570060071069747
- O 0 0.0001159757302957587
1 O 0 5.338369192031678e-06
cells O 0 2.018138002313208e-05
. O 0 6.399935500667198e-06

Quantitative O 0 0.0001447826944058761
analysis O 0 3.2156312954612076e-05
showed O 0 1.9984170648967847e-05
that O 0 1.5029284838874446e-07
the O 0 4.7775799316696066e-08
expression O 0 1.1502008590014157e-07
of O 0 4.600375902441556e-08
CYP27 O 0 0.00011625009210547432
gene O 0 4.797440738002479e-07
mRNA O 0 2.109527059701577e-07
in O 0 8.10292917208244e-08
the O 0 2.425861111987615e-07
patient O 0 2.333770680706948e-05
represented O 0 2.552693786128657e-06
52 O 0 2.8334847229416482e-05
. O 0 1.3063079677522182e-05

5 O 0 5.675453940057196e-05
% O 0 3.829831712209852e-06
of O 0 5.097900270811806e-07
the O 0 8.060037544055376e-07
normal O 0 6.113973086030455e-06
level O 0 7.303605798369972e-06
. O 0 1.0817630936799105e-05

As O 0 1.1431639904913027e-05
the O 0 1.4997414155004662e-06
mutation O 0 8.018667358555831e-06
occurred O 0 2.796882199618267e-06
at O 0 3.7042136113996094e-07
the O 0 8.57940136711477e-08
penultimate O 0 2.453502020216547e-06
nucleotide O 0 7.157761388043582e-07
of O 0 7.19443704610967e-08
exon O 0 5.293311460263794e-06
6 O 0 5.33227705545869e-07
( O 0 4.8459153134672306e-08
- O 0 1.3700841918762308e-06
2 O 0 4.9560664905357044e-08
position O 0 2.0154175217612647e-08
of O 0 1.873633870275171e-08
exon O 0 2.0621278054022696e-06
6 O 0 5.99589668581757e-07
- O 0 2.8789825591957197e-05
intron O 0 0.00014978283434174955
6 O 0 4.0535275047659525e-07
splice O 0 2.9482075660780538e-06
site O 0 3.2947340855571383e-07
) O 0 1.695417495284346e-08
of O 0 6.756110337846621e-09
the O 0 1.3169442425464695e-08
gene O 0 1.9861484190641931e-07
, O 0 4.68806895526086e-08
we O 0 3.7660495166846886e-08
hypothesized O 0 3.787466766880243e-07
that O 0 2.1135619476808643e-08
the O 0 9.453447091800626e-08
mutation O 0 2.4312491859745933e-06
may O 0 3.551398606305156e-07
partially O 0 8.601108447692241e-07
affect O 0 1.278663432913163e-07
the O 0 1.8063845530491562e-08
normal O 0 1.4910492041053658e-07
splicing O 0 7.334180054385797e-07
efficiency O 0 1.106197032640921e-06
in O 0 8.199179291068504e-08
exon O 0 9.012302143673878e-06
6 O 0 1.2919670098199276e-06
and O 0 1.7091295489990443e-07
cause O 0 3.690124117383675e-07
alternative O 0 3.230028653433692e-07
splicing O 0 2.2488618469651556e-06
elsewhere O 0 9.333120374321879e-07
, O 0 6.872631530541184e-08
which O 0 3.2375346847857145e-08
resulted O 0 4.574119145672739e-07
in O 0 2.129010141516119e-07
decreased O 0 3.5916211800213205e-06
transcript O 0 5.26335043105064e-06
in O 0 3.068295768571261e-07
the O 0 9.98417021946807e-07
patient O 0 0.00033659752807579935
. O 0 1.9503699149936438e-05

Transfection O 0 0.004946589004248381
of O 0 9.370628504257184e-06
constructed O 0 6.79750373819843e-05
minigenes O 0 0.03467883914709091
, O 0 2.606108409963781e-06
with O 0 3.525757961142517e-07
or O 0 3.1452219673155923e-07
without O 0 2.2931480714305508e-07
the O 0 7.69024666169571e-08
mutation O 0 6.550047828568495e-07
, O 0 4.071907611091774e-08
into O 0 8.934038220331786e-08
COS O 0 0.0003949278616346419
- O 0 0.00012776539369951934
1 O 0 9.102011517825304e-07
cells O 0 2.0044092252646806e-06
confirmed O 0 8.54543174000355e-08
that O 0 7.434088900026836e-09
the O 0 3.0613740875651274e-08
mutant O 0 3.7522661386901746e-06
minigene O 0 0.00018582613847684115
was O 0 2.0658309551890852e-07
responsible O 0 1.7715818501073954e-07
for O 0 4.228649785886773e-08
a O 0 8.693522346447935e-08
mRNA O 0 3.179611951509287e-07
species O 0 6.711391620228824e-08
alternatively O 0 4.307071606035606e-07
spliced O 0 2.256141897305497e-06
at O 0 2.626966590923985e-07
an O 0 4.67447947016808e-08
activated O 0 2.3716404484730447e-06
cryptic O 0 1.0891247939071036e-06
5 O 0 1.3580080349129275e-07
splice O 0 2.1572095647570677e-06
site O 0 3.9076638813639875e-07
88 O 0 3.456769377407909e-07
bp O 0 9.78472030510602e-07
upstream O 0 1.6867450369772996e-07
from O 0 1.8396740131265688e-08
the O 0 1.678739458554901e-08
3 O 0 9.18767213420324e-08
end O 0 1.701914413843042e-07
of O 0 1.379421092906341e-07
exon O 0 3.444249523454346e-05
6 O 0 8.863759831001516e-06
. O 0 6.424751973099774e-06

Our O 0 2.245990799565334e-05
data O 0 8.095295925159007e-06
suggest O 0 3.981688678322826e-06
that O 0 1.7562186371833377e-07
the O 0 1.1949205713790434e-07
C O 0 2.2599926523980685e-05
to O 0 1.1674718081167157e-07
A O 0 3.6604751585400663e-07
mutation O 0 7.998435194167541e-07
at O 0 9.62292503459139e-08
the O 0 2.138178345489905e-08
penultimate O 0 1.1913095931959106e-06
nucleotide O 0 4.4434455048758537e-07
of O 0 4.102451001131158e-08
exon O 0 2.755238256213488e-06
6 O 0 2.141202912753215e-07
of O 0 2.0679038925663917e-08
the O 0 4.810855358527988e-08
CYP27 O 0 0.0002143115270882845
gene O 0 2.869128934435139e-07
not O 0 3.139104975957707e-08
only O 0 4.4370001006655e-08
causes O 0 7.0645346568198875e-06
the O 0 3.1151691928243963e-06
deficiency B-Disease 0 0.1618107110261917
in I-Disease 0 5.25459604716616e-08
the I-Disease 0 6.456190249082283e-08
sterol I-Disease 0 1.8220780475530773e-05
27 I-Disease 0 1.5356376934505533e-06
- I-Disease 0 3.316494985483587e-05
hydroxylase I-Disease 0 2.769391176116187e-05
activity I-Disease 0 2.4992576186377846e-07
, O 0 5.230377908560513e-08
but O 0 2.9406821866473365e-08
also O 0 1.954352413235938e-08
partially O 0 5.558619591283787e-07
leads O 0 1.1167601599026966e-07
to O 0 1.7554425468802037e-08
alternative O 0 1.2771876356509893e-07
pre O 0 5.053930635767756e-06
- O 0 2.094335513902479e-06
mRNA O 0 1.9542653717508074e-07
splicing O 0 3.9150870634330204e-07
of O 0 5.178738504696412e-08
the O 0 2.535871317377314e-07
gene O 0 6.856729214632651e-06
. O 0 5.805162800243124e-06

To O 0 9.416854481969494e-06
our O 0 3.230036327295238e-06
knowledge O 0 1.885235974441457e-06
, O 0 3.823446093065286e-07
this O 0 3.770592371665771e-08
is O 0 2.992779712940319e-08
the O 0 2.2210647543374762e-08
first O 0 4.7068844821751554e-08
report O 0 1.6070738695361797e-07
regarding O 0 2.7113819101032277e-07
effects O 0 4.6762718852733087e-07
on O 0 1.353423328964709e-07
pre O 0 9.327673069492448e-06
- O 0 1.9024826087843394e-06
mRNA O 0 6.18698763332759e-08
splicing O 0 1.221774255100172e-07
of O 0 1.3660607756094123e-08
a O 0 7.291555448318832e-08
mutation O 0 3.3126610787803656e-07
at O 0 1.0196572475251742e-07
the O 0 2.510773988717574e-08
- O 0 1.4754225048818626e-05
2 O 0 2.8600862833627616e-07
position O 0 6.732263813091777e-08
of O 0 2.5858390984012658e-08
a O 0 2.379317436407291e-07
5 O 0 1.2869277270510793e-06
splice O 0 6.742827099515125e-05
site O 0 1.6841371689224616e-05
. O 0 8.673382581037004e-06

ATM O 0 0.01822427287697792
germline O 0 0.17950867116451263
mutations O 0 0.0006425271858461201
in O 0 1.0957009180856403e-05
classical O 0 0.0003841025463771075
ataxia B-Disease 1 0.9999926090240479
- I-Disease 1 0.999983549118042
telangiectasia I-Disease 1 0.9999979734420776
patients O 0 0.36234596371650696
in O 0 1.0080832453240873e-06
the O 0 1.3665738833879004e-06
Dutch O 0 4.831366095459089e-05
population O 0 4.925448592985049e-06
. O 0 7.886900675657671e-06

Germline O 1 0.7952153086662292
mutations O 0 0.0007078773924149573
in O 0 2.7640971893561073e-06
the O 0 7.376203257081215e-07
ATM O 0 4.571457247948274e-05
gene O 0 2.5591509711375693e-06
are O 0 1.211783171584102e-07
responsible O 0 1.5237366142173414e-06
for O 0 2.59766920862603e-06
the O 0 0.001314824796281755
autosomal B-Disease 1 0.9999955892562866
recessive I-Disease 1 0.9999997615814209
disorder I-Disease 1 1.0
ataxia B-Disease 1 0.9999996423721313
- I-Disease 1 0.9999945163726807
telangiectasia I-Disease 1 0.999995231628418
( O 0 5.171026714378968e-05
A B-Disease 0 0.032558925449848175
- I-Disease 1 0.9995347261428833
T I-Disease 1 0.9998855590820312
) O 0 6.662594842055114e-06
. O 0 1.2273123502382077e-05

In O 0 1.1069272659369744e-05
our O 0 2.1552066300500883e-06
study O 0 1.0732462669693632e-06
, O 0 3.984097247666796e-07
we O 0 1.0562126107060976e-07
have O 0 3.6602056496803925e-08
determined O 0 2.0166523029274686e-07
the O 0 4.3205485411590416e-08
ATM O 0 2.004591988225002e-05
mutation O 0 7.560997232758382e-07
spectrum O 0 1.3694781273443368e-06
in O 0 6.860399537345074e-08
19 O 0 3.546822711086861e-07
classical O 0 7.849852181607275e-07
A B-Disease 0 0.00017735727305989712
- I-Disease 1 0.9993875026702881
T I-Disease 1 0.9999969005584717
patients O 0 0.004822842311114073
, O 0 3.120736380424205e-07
including O 0 1.4950660442991648e-07
some O 0 7.04730922507224e-08
immigrant O 0 9.716645763546694e-06
populations O 0 6.358824862218171e-07
, O 0 6.636263805148701e-08
as O 0 1.9771482229202775e-08
well O 0 2.5546459170300295e-08
as O 0 2.136250110140736e-08
12 O 0 9.374048914878585e-08
of O 0 6.656966178297807e-08
Dutch O 0 3.3911132959474344e-06
ethnic O 0 1.3998231906953151e-06
origin O 0 2.4392334125877824e-06
. O 0 8.938135579228401e-06

Both O 0 7.384498530882411e-06
the O 0 8.47774060730444e-07
protein O 0 2.125610990333371e-06
truncation O 0 1.0707705769164022e-05
test O 0 2.6223613076581387e-06
( O 0 1.9955255936565663e-07
PTT O 0 2.239934019598877e-06
) O 0 6.917054662380906e-08
and O 0 2.867765935832267e-08
the O 0 4.2711253200877763e-08
restriction O 0 5.560066824727983e-07
endonuclease O 0 9.61529221967794e-05
fingerprinting O 0 0.0002809921570587903
( O 0 4.476510753192997e-07
REF O 0 0.00023252182290889323
) O 0 4.991289870304172e-08
method O 0 4.0296377790127735e-08
were O 0 1.2420771966503708e-08
used O 0 1.806915328472769e-08
and O 0 4.915987972253788e-08
compared O 0 3.296682962172781e-07
for O 0 2.484615357900566e-08
their O 0 5.103119349314511e-08
detection O 0 1.9859924123011297e-06
efficiency O 0 1.4221438959793886e-06
, O 0 6.22605327293968e-08
identifying O 0 5.082439429315855e-07
76 O 0 2.9193734008003958e-06
% O 0 5.8042164852167843e-08
and O 0 2.6033529110236486e-08
60 O 0 1.4446189311456692e-07
% O 0 4.676298459571626e-08
of O 0 3.680809612660596e-08
the O 0 2.869889783596591e-07
mutations O 0 1.0840785762411542e-05
, O 0 1.0576374052106985e-06
respectively O 0 8.449678716715425e-06
. O 0 1.3625548490381334e-05

Most O 0 0.00025034998543560505
patients O 0 0.020492611452937126
were O 0 2.6544671527517494e-06
found O 0 1.001693021862593e-06
to O 0 4.0500808040633274e-07
be O 0 1.0667683909559855e-06
compound O 0 2.9100476240273565e-05
heterozygote O 0 0.0002940412668976933
. O 0 1.5033334420877509e-05

Seventeen O 0 0.00023236246488522738
mutations O 0 0.00025624671252444386
were O 0 2.3251013772096485e-06
distinct O 0 1.1809198667833698e-06
, O 0 2.0448206328183005e-07
of O 0 4.890326366080444e-08
which O 0 6.367939420215407e-08
10 O 0 1.7288144249505422e-07
were O 0 8.384592575794159e-08
not O 0 1.9373290172097768e-07
reported O 0 2.2466540485766018e-06
previously O 0 2.4110595404636115e-06
. O 0 6.476530870713759e-06

Mutations O 0 0.000887740112375468
are O 0 2.532485495976289e-06
small O 0 5.289486580295488e-06
deletions O 0 4.797117435373366e-05
or O 0 2.7619364573183702e-06
point O 0 4.267178155714646e-06
mutations O 0 1.2594063264259603e-05
frequently O 0 1.522721163382812e-06
affecting O 0 8.791402251517866e-06
splice O 0 0.0002009121817536652
sites O 0 2.8992195439059287e-05
. O 0 1.5104164958756883e-05

Moreover O 0 0.0005469016614370048
, O 0 1.1896659088961314e-05
a O 0 5.0625844778551254e-06
16 O 0 1.758666621753946e-05
. O 0 1.4531915439874865e-05

7 O 0 0.00015472795348614454
- O 0 0.0004675659874919802
kb O 0 0.00048052091733552516
genomic O 0 2.602388121886179e-05
deletion O 0 9.115996363107115e-06
of O 0 1.9298313702620362e-07
the O 0 8.410235352585005e-08
3 O 0 2.2943642363770778e-07
end O 0 2.0670726996740996e-07
of O 0 2.4296157974390553e-08
the O 0 4.114354013040611e-08
gene O 0 5.442872179628466e-07
, O 0 8.630180303725865e-08
most O 0 3.7978178824005226e-08
likely O 0 1.604216350870047e-07
a O 0 5.68174627346707e-08
result O 0 5.826122517760268e-08
of O 0 2.9797931233588315e-08
recombination O 0 6.789027793274727e-06
between O 0 1.4541842574544717e-07
two O 0 7.922475475652391e-08
LINE O 0 1.8590409354146686e-06
elements O 0 3.497516445349902e-07
, O 0 3.737611962151277e-07
was O 0 1.0903761449299054e-06
identified O 0 4.482111762627028e-06
. O 0 6.000564098940231e-06

The O 0 1.5611401977366768e-05
most O 0 3.77538162865676e-06
frequently O 0 5.92258402321022e-06
found O 0 2.310100853719632e-06
mutation O 0 1.1639265721896663e-05
, O 0 7.959763479448156e-07
identified O 0 1.0394820719739073e-06
in O 0 5.678701953115706e-08
three O 0 6.05206338377684e-08
unrelated O 0 3.2753591767686885e-06
Turkish O 0 1.2003839628960122e-06
A B-Disease 0 0.00028034995193593204
- I-Disease 1 0.9971724152565002
T I-Disease 1 0.9999674558639526
individuals O 0 9.532078593110782e-07
, O 0 2.3462034448584745e-07
was O 0 2.4898747597035253e-07
previously O 0 7.263689099090698e-07
described O 0 6.952820967853768e-07
to O 0 5.068933717211621e-08
be O 0 4.2601900673844284e-08
a O 0 1.4489003774542653e-07
Turkish O 0 1.6990113635984017e-06
A B-Disease 0 0.00018336711218580604
- I-Disease 1 0.9980639815330505
T I-Disease 1 0.9999310970306396
founder O 0 0.0013060779310762882
mutation O 0 9.04546250239946e-05
. O 0 1.4409081813937519e-05

The O 0 1.562601391924545e-05
presence O 0 6.304519502009498e-06
of O 0 8.186816558009014e-07
a O 0 1.827062874326657e-06
founder O 0 0.00013191990728955716
mutation O 0 1.6228574168053456e-05
among O 0 8.023745863283693e-07
relatively O 0 2.1416267372842412e-06
small O 0 4.995404196961317e-07
ethnic O 0 2.2708736935328488e-07
population O 0 6.169182853454913e-08
groups O 0 6.201035063213567e-08
in O 0 3.882270860344761e-08
Western O 0 1.4871650932946068e-07
Europe O 0 1.775390785496711e-07
could O 0 1.1527286858381558e-07
indicate O 0 2.7083194709121017e-07
a O 0 1.8054481643048348e-07
high O 0 2.6913312467513606e-06
carrier O 0 5.035341473558219e-06
frequency O 0 3.5843319778905425e-07
in O 0 1.2524284898063343e-07
such O 0 3.7858200130358455e-07
communities O 0 2.63800825450744e-06
. O 0 6.600793312827591e-06

In O 0 0.0001661160495132208
patients O 0 0.0008016793872229755
of O 0 1.116080284191412e-06
Dutch O 0 1.8501130398362875e-05
ethnic O 0 9.837810921453638e-07
origin O 0 2.8664214823947987e-07
, O 0 4.472892101148318e-07
however O 0 1.5644386053281778e-07
, O 0 1.779228142595457e-07
no O 0 1.6271235381282168e-07
significant O 0 5.349839398149925e-07
founder O 0 1.9297578546684235e-05
effect O 0 1.4756863038201118e-06
could O 0 7.3365799835301e-07
be O 0 5.841388315275253e-07
identified O 0 1.0802126780617982e-05
. O 0 7.817504410922993e-06

The O 0 3.662078233901411e-05
observed O 0 0.00010123936226591468
genetic O 0 9.652083099354059e-05
heterogeneity O 0 0.0001126479692175053
including O 0 1.656334916333435e-06
the O 0 4.7479150566687167e-07
relative O 0 1.4392177945410367e-05
high O 0 3.883259068970801e-06
percentage O 0 9.682961490398156e-07
of O 0 7.580253225114575e-08
splice O 0 5.969810445094481e-05
- O 0 0.00048683141358196735
site O 0 1.0675485100364313e-05
mutations O 0 2.347271447433741e-06
had O 0 1.3134527421243547e-07
no O 0 8.225274683582029e-08
reflection O 0 8.35352750527818e-07
on O 0 5.696068683391786e-07
the O 0 1.9346291537658544e-06
phenotype O 0 0.00036082282895222306
. O 0 1.4769739209441468e-05

All O 0 5.385267286328599e-05
patients O 0 0.002552686957642436
manifested O 0 2.1227800971246324e-05
classical O 0 8.546736353309825e-06
A B-Disease 0 0.0004221511771902442
- I-Disease 1 0.981767475605011
T I-Disease 1 0.9991793036460876
and O 0 1.1883038268933888e-06
increased O 0 3.2409625418949872e-06
cellular O 0 6.646644760621712e-05
radioresistant O 0 0.0020822235383093357
DNA O 0 4.0038405131781474e-05
synthesis O 0 2.619526094349567e-05
. O 0 1.5404884834424593e-05

Determination O 0 7.475521124433726e-05
of O 0 1.9316039470140822e-06
the O 0 4.926064320898149e-07
genomic O 0 6.449282409448642e-06
structure O 0 7.178413170549902e-07
of O 0 6.251637074683458e-08
the O 0 1.3453777114591503e-07
COL4A4 O 0 0.00041162240086123347
gene O 0 1.0664165301932371e-06
and O 0 1.7651464645496162e-07
of O 0 5.728837209062476e-07
novel O 0 0.00018102479225490242
mutations O 0 0.010284485295414925
causing O 0 0.22936642169952393
autosomal B-Disease 1 0.9987205862998962
recessive I-Disease 1 0.9999270439147949
Alport I-Disease 1 0.9999960660934448
syndrome I-Disease 1 0.9999737739562988
. O 0 0.0005770417046733201

Autosomal B-Disease 1 0.999879002571106
recessive I-Disease 1 0.9999855756759644
Alport I-Disease 1 0.9999991655349731
syndrome I-Disease 1 0.9999943971633911
is O 0 4.8483823775313795e-05
a O 0 4.615652505890466e-05
progressive O 0 0.3919695019721985
hematuric B-Disease 1 0.9997138381004333
glomerulonephritis I-Disease 1 0.9999885559082031
characterized O 0 0.03216201066970825
by O 0 4.857115345657803e-05
glomerular B-Disease 1 0.9943761825561523
basement I-Disease 1 0.88507479429245
membrane I-Disease 0 0.24875585734844208
abnormalities I-Disease 1 0.9394389390945435
and O 0 2.870113576136646e-06
associated O 0 7.155139428505208e-06
with O 0 7.620349720127706e-07
mutations O 0 1.3572233910963405e-05
in O 0 1.2877241317710286e-07
either O 0 1.1120541643094839e-07
the O 0 5.4019583473063904e-08
COL4A3 O 0 0.005543401464819908
or O 0 1.8900051657055883e-07
the O 0 1.195303553913618e-07
COL4A4 O 0 0.0011403944808989763
gene O 0 8.667641964166251e-07
, O 0 4.6735344483295194e-08
which O 0 1.7903522220308332e-08
encode O 0 1.2416774097800953e-07
the O 0 5.6259192859897666e-08
alpha3 O 0 3.7404017348308116e-05
and O 0 5.279208608044428e-07
alpha4 O 0 0.0012327453587204218
type O 0 6.204221426742151e-05
IV O 0 0.3973653018474579
collagen O 0 0.025045063346624374
chains O 0 0.0001371359539916739
, O 0 3.2033447041612817e-06
respectively O 0 1.0798985385918058e-05
. O 0 1.0134087460755836e-05

To O 0 1.1844585060316604e-05
date O 0 1.0839793503691908e-05
, O 0 1.122581238632847e-06
mutation O 0 2.975275037897518e-06
screening O 0 4.563027232507011e-06
in O 0 6.329275947791757e-08
the O 0 2.9650410127146642e-08
two O 0 4.5054974862068775e-08
genes O 0 2.5718804863572586e-07
has O 0 5.71735974119747e-08
been O 0 1.1420817003227057e-07
hampered O 0 4.3517869926290587e-05
by O 0 1.057230463175074e-07
the O 0 6.426936494108304e-08
lack O 0 5.10890458826907e-07
of O 0 2.7338728614267893e-07
genomic O 0 6.541284528793767e-05
structure O 0 8.936712220020127e-06
information O 0 8.28816064313287e-06
. O 0 1.0981875675497577e-05

We O 0 2.487390156602487e-05
report O 0 3.917573394573992e-06
here O 0 4.38729045981745e-07
the O 0 1.367427415743805e-07
complete O 0 9.44210057696182e-07
characterization O 0 6.003975613566581e-06
of O 0 7.115082922837246e-08
the O 0 4.9738698493229094e-08
48 O 0 3.160764379117609e-07
exons O 0 5.655925860992284e-07
of O 0 2.9307209103990317e-08
the O 0 7.493884623954727e-08
COL4A4 O 0 0.0004049327108077705
gene O 0 8.730077070140396e-07
, O 0 6.638757810151219e-08
a O 0 4.6430415068243747e-08
comprehensive O 0 9.307200912189728e-07
gene O 0 7.70782321524166e-07
screen O 0 3.741025238923612e-06
, O 0 1.580942665668772e-07
and O 0 4.109993056999883e-08
the O 0 1.5687406929032477e-08
subsequent O 0 1.209922828593335e-07
detection O 0 7.78528942646517e-07
of O 0 3.325283515209776e-08
10 O 0 2.222681985131203e-07
novel O 0 9.751157676873845e-07
mutations O 0 2.7471783141663764e-06
in O 0 6.21023161784251e-07
eight O 0 0.00016648313612677157
patients O 1 0.9950873255729675
diagnosed O 1 0.9998664855957031
with O 0 0.10752102732658386
autosomal B-Disease 1 0.9999195337295532
recessive I-Disease 1 0.9999802112579346
Alport I-Disease 1 0.9999971389770508
syndrome I-Disease 1 0.9999639987945557
. O 0 0.0006559594767168164

Furthermore O 0 0.0002466790610924363
, O 0 5.821701506647514e-06
we O 0 6.726660899403214e-07
identified O 0 6.415130542336556e-07
a O 0 1.557501576598952e-07
glycine O 0 4.3097525121993385e-06
to O 0 9.709410875302638e-08
alanine O 0 1.8362544551564497e-06
substitution O 0 1.2415081585004373e-07
in O 0 3.461944686478091e-08
the O 0 5.387337154161287e-08
collagenous O 0 8.567936311010271e-05
domain O 0 2.380043753191785e-07
that O 0 2.9118377042891552e-08
is O 0 7.988222705535009e-08
apparently O 0 1.3850052482666797e-06
silent O 0 4.3111745071655605e-06
in O 0 5.177820128210442e-08
the O 0 9.374728904276708e-08
heterozygous O 0 2.637251100168214e-06
carriers O 0 1.831895701798203e-06
, O 0 1.778424092435671e-07
in O 0 3.1184754334390163e-07
11 O 0 3.57783687832125e-06
. O 0 6.481350737885805e-06

5 O 0 3.411455691093579e-05
% O 0 2.439777972540469e-06
of O 0 2.2384618603155104e-07
all O 0 1.216772034240421e-07
control O 0 9.002063166008156e-07
individuals O 0 1.9219372404677415e-07
, O 0 1.44627051668067e-07
and O 0 9.688341151559143e-08
in O 0 6.72211442065418e-08
one O 0 8.789291428001889e-08
control O 0 6.413741857613786e-07
individual O 0 9.345949081307481e-08
homozygous O 0 9.77733293439087e-07
for O 0 7.180454275612647e-08
this O 0 2.6780000439430296e-07
glycine O 0 5.327842882252298e-05
substitution O 0 8.46480907057412e-06
. O 0 6.755494268873008e-06

There O 0 2.5760886273928918e-05
has O 0 2.2942163013794925e-06
been O 0 2.96966589985459e-07
no O 0 1.3949428989690205e-07
previous O 0 1.544317314028376e-07
finding O 0 3.43536157743074e-07
of O 0 2.3660300385586197e-08
a O 0 8.781683646930105e-08
glycine O 0 4.036541213281453e-06
substitution O 0 2.1622030033086048e-07
that O 0 3.0866324607359275e-08
is O 0 3.7450476497724594e-08
not O 0 3.0787592919523377e-08
associated O 0 3.1498055363954336e-07
with O 0 8.623236880112017e-08
any O 0 1.8602561624447844e-07
obvious O 0 5.682131813955493e-06
phenotype O 0 3.3486310712760314e-05
in O 0 1.1822428405139362e-06
homozygous O 0 4.278633787180297e-05
individuals O 0 4.083156909473473e-06
. O 0 9.322648111265153e-06

Founder O 0 0.009249375201761723
BRCA1 O 0 0.029349401593208313
and O 0 5.4655894928146154e-05
BRCA2 O 0 0.006872405763715506
mutations O 0 5.7505709264660254e-05
in O 0 1.2133875770814484e-06
French O 0 1.4223013749870006e-05
Canadian O 0 0.00032170506892725825
breast B-Disease 1 0.9999489784240723
and I-Disease 1 0.9904449582099915
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999971389770508
families O 0 0.001011504209600389
. O 0 0.00012286013225093484

We O 0 2.6003313905675896e-05
have O 0 2.147342911484884e-06
identified O 0 2.612401658552699e-06
four O 0 2.7489343779052433e-07
mutations O 0 1.3202649142840528e-06
in O 0 2.815942856670972e-08
each O 0 1.3730668158018489e-08
of O 0 8.21354859681378e-08
the O 0 6.219944225449581e-06
breast B-Disease 1 0.9998958110809326
cancer I-Disease 1 0.9948400855064392
- O 1 0.5294376611709595
susceptibility O 0 0.005980001296848059
genes O 0 3.5828527416015277e-06
, O 0 8.627907277514169e-07
BRCA1 O 0 0.00016373518155887723
and O 0 1.78712684828497e-06
BRCA2 O 0 0.0001696755352895707
, O 0 3.030473010312562e-07
in O 0 1.251988948069993e-07
French O 0 4.345891738921637e-06
Canadian O 0 0.0005166488699615002
breast B-Disease 1 0.9999603033065796
cancer I-Disease 1 0.999799907207489
and O 0 0.07650488615036011
breast B-Disease 1 0.9999990463256836
/ I-Disease 1 0.9999991655349731
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999984502792358
families O 0 7.385356002487242e-05
from O 0 8.496489499520976e-06
Quebec O 0 0.0003635186585597694
. O 0 2.967775253637228e-05

To O 0 4.6499044401571155e-05
identify O 0 6.71425586915575e-05
founder O 0 0.00010013139399234205
effects O 0 2.9725169952143915e-05
, O 0 6.503352665276907e-07
we O 0 2.3367354629044712e-07
examined O 0 3.9224742067744955e-06
independently O 0 3.210144541299087e-07
ascertained O 0 2.909159320552135e-06
French O 0 3.566138730093371e-06
Canadian O 0 0.00013127543206792325
cancer B-Disease 1 0.9195747971534729
families O 0 9.297513656747469e-07
for O 0 1.0591984533903087e-07
the O 0 6.811296771047637e-08
distribution O 0 2.9782256660837447e-07
of O 0 5.86866022445065e-08
these O 0 1.7136603958078922e-07
eight O 0 2.3149327716964763e-06
mutations O 0 3.654057582025416e-05
. O 0 9.541232429910451e-06

Mutations O 0 0.0007846195949241519
were O 0 8.55302278068848e-06
found O 0 1.7242007288587047e-06
in O 0 2.9146281121938955e-07
41 O 0 1.3776965488432324e-06
of O 0 5.376593890105141e-07
97 O 0 2.3824470190447755e-05
families O 0 1.3855752513336483e-05
. O 0 1.556445386086125e-05

Six O 0 3.189360359101556e-05
of O 0 2.8118695354351075e-06
eight O 0 4.189259925624356e-06
mutations O 0 1.0714181371440645e-05
were O 0 4.2461482507860637e-07
observed O 0 1.663255375206063e-06
at O 0 9.092364052776247e-07
least O 0 1.1835153372885543e-06
twice O 0 6.71815496389172e-06
. O 0 1.0309394383511972e-05

The O 0 3.6254918086342514e-05
BRCA1 O 0 0.009970703162252903
C4446T O 0 0.006076162680983543
mutation O 0 9.600157500244677e-05
was O 0 1.1794309102697298e-06
the O 0 3.522175688885909e-07
most O 0 4.5688526029152854e-07
common O 0 1.7930132116816822e-06
mutation O 0 5.425487870525103e-06
found O 0 5.761645525126369e-07
, O 0 1.4195148878570762e-07
followed O 0 4.1066792277888453e-07
by O 0 2.8903085080855817e-07
the O 0 1.3311770317159244e-06
BRCA2 O 0 0.002084252890199423
8765delAG O 0 0.006697335280478001
mutation O 0 0.0001310018269577995
. O 0 2.3688719011261128e-05

Together O 0 8.118473488138989e-05
, O 0 5.28024838786223e-06
these O 0 4.73956845326029e-07
mutations O 0 2.4429023142147344e-06
were O 0 1.1061162297210103e-07
found O 0 1.757724987783149e-07
in O 0 4.1315601606584096e-08
28 O 0 2.9029439474470564e-07
of O 0 6.226456861213592e-08
41 O 0 8.881215762812644e-06
families O 0 8.343702688762278e-07
identified O 0 9.096839335143159e-07
to O 0 1.106257556671153e-07
have O 0 1.2253448744559137e-07
a O 0 1.4722003243150539e-06
mutation O 0 3.31693772750441e-05
. O 0 8.833389074425213e-06

The O 0 2.5534958695061505e-05
odds O 0 0.00012788496678695083
of O 0 6.821333045081701e-07
detection O 0 5.455559858091874e-06
of O 0 1.0084104218321954e-07
any O 0 8.693124442515909e-08
of O 0 4.669693964842736e-08
the O 0 1.0695091390289235e-07
four O 0 8.909183861760539e-07
BRCA1 O 0 0.0015261031221598387
mutations O 0 1.0665309673640877e-05
was O 0 1.5699223467890988e-06
18 O 0 4.549939149001148e-06
. O 0 9.387838872498833e-06

7x O 0 0.12522846460342407
greater O 0 7.967134297359735e-05
if O 0 5.442318979476113e-06
one O 0 2.8754402592312545e-07
or O 0 2.876888629543828e-07
more O 0 1.813584873389118e-07
cases O 0 4.697741132986266e-06
of O 0 0.006395849399268627
ovarian B-Disease 1 1.0
cancer I-Disease 1 0.9999957084655762
were O 0 2.527288415876683e-06
also O 0 4.5306435936254275e-07
present O 0 3.3848601788122323e-07
in O 0 2.117916864108338e-07
the O 0 5.851335345141706e-07
family O 0 1.189196336781606e-05
. O 0 1.0082649168907665e-05

The O 0 1.8010414351010695e-05
odds O 0 0.00012410175986588
of O 0 1.0758634516605525e-06
detection O 0 7.452841146005085e-06
of O 0 7.110457289627448e-08
any O 0 6.370806460154199e-08
of O 0 5.166524275068696e-08
the O 0 1.7604828883577284e-07
four O 0 1.5696080026827985e-06
BRCA2 O 0 0.0009604506776668131
mutations O 0 9.610884262656327e-06
was O 0 1.471828227295191e-06
5 O 0 6.764727004338056e-06
. O 0 1.255583356396528e-05

3x O 0 0.003533892333507538
greater O 0 5.7798130001174286e-05
if O 0 5.000627425033599e-06
there O 0 3.7670631058972504e-07
were O 0 1.7442724242755503e-07
at O 0 2.802163407977787e-07
least O 0 1.0284663432003072e-07
five O 0 8.394594175342718e-08
cases O 0 6.011269988448475e-07
of O 0 8.09068023954751e-06
breast B-Disease 1 0.9999902248382568
cancer I-Disease 1 0.9937334656715393
in O 0 1.418101192030008e-06
the O 0 3.4231572954013245e-06
family O 0 5.845024134032428e-05
. O 0 4.052441363455728e-05

Interestingly O 0 0.0007041656645014882
, O 0 5.793625859951135e-06
the O 0 3.9674708318671037e-07
presence O 0 4.907874995296879e-07
of O 0 2.02639981239372e-07
a O 0 5.033627530792728e-05
breast B-Disease 1 0.999962568283081
cancer I-Disease 1 0.9991579055786133
case O 0 4.399371755425818e-05
< O 0 0.013953439891338348
36 O 0 3.1193578706734115e-06
years O 0 2.5931151981239964e-07
of O 0 6.350038006530667e-08
age O 0 7.288689971574058e-07
was O 0 1.5621277782429388e-07
strongly O 0 2.742176263836882e-07
predictive O 0 6.059918860046309e-07
of O 0 4.0643421073127683e-08
the O 0 4.616267901269566e-08
presence O 0 1.0765413094304677e-07
of O 0 1.837380381175535e-08
any O 0 4.709255208013019e-08
of O 0 4.4609045346533094e-08
the O 0 1.7476824609730102e-07
eight O 0 1.8358360875936341e-06
mutations O 0 2.511876300559379e-05
screened O 0 4.327890201238915e-05
. O 0 2.1414129150798544e-05

Carriers O 0 0.00012826660531572998
of O 0 1.5406014881591545e-06
the O 0 5.609315962828987e-07
same O 0 5.833182967762696e-07
mutation O 0 2.787091261780006e-06
, O 0 2.2787162379245274e-07
from O 0 1.0973304398476103e-07
different O 0 5.146225134922133e-08
families O 0 4.7062562202881963e-07
, O 0 1.8571435589365137e-07
shared O 0 3.2950705985967943e-07
similar O 0 8.576421350880992e-07
haplotypes O 0 4.9750909965950996e-05
, O 0 4.0577432969257643e-07
indicating O 0 1.5031048405944603e-06
that O 0 3.1338228012600666e-08
the O 0 4.288823518550089e-08
mutant O 0 2.4004641545616323e-06
alleles O 0 5.248015781944559e-07
were O 0 6.064058055699206e-08
likely O 0 1.7200015633989096e-07
to O 0 2.6136566688705898e-08
be O 0 3.5112819318783295e-08
identical O 0 5.156866791367065e-07
by O 0 6.778532934959003e-08
descent O 0 1.6614892501820577e-06
for O 0 1.2872722265910852e-07
a O 0 3.244260255996778e-07
mutation O 0 1.3669075542566134e-06
in O 0 1.1319809090082344e-07
the O 0 3.149877727537387e-07
founder O 0 3.489193841232918e-05
population O 0 1.3784377870251774e-06
. O 0 4.786048521054909e-06

The O 0 8.66281789058121e-06
identification O 0 1.0641433618729934e-05
of O 0 1.6846258859004593e-06
common O 0 5.797174708277453e-06
BRCA1 O 0 0.0025467518717050552
and O 0 1.0903307156695519e-05
BRCA2 O 0 0.003634454682469368
mutations O 0 6.341841071844101e-06
will O 0 3.763013012303418e-07
facilitate O 0 3.6485560030996567e-06
carrier O 0 9.876536205410957e-05
detection O 0 7.741733497823589e-06
in O 0 1.3414982902304473e-07
French O 0 3.4026782032015035e-06
Canadian O 0 0.00014321465278044343
breast B-Disease 1 0.9999486207962036
cancer I-Disease 1 0.9998453855514526
and O 0 0.07284682244062424
breast B-Disease 1 0.9999986886978149
/ I-Disease 1 0.9999991655349731
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999979734420776
families O 0 0.0011879801750183105
. O 0 0.00010178141383221373

Are O 0 3.945548814954236e-05
Dp71 O 0 0.0015997346490621567
and O 0 1.339242317044409e-05
Dp140 O 0 0.005616354756057262
brain O 0 0.0007620378746651113
dystrophin O 0 0.0003140649641864002
isoforms O 0 5.549166871787747e-06
related O 0 7.91459115134785e-06
to O 0 4.627808721124893e-06
cognitive B-Disease 0 0.048255011439323425
impairment I-Disease 1 0.9904564023017883
in O 0 0.0030010314658284187
Duchenne B-Disease 1 0.9999872446060181
muscular I-Disease 1 0.9999233484268188
dystrophy I-Disease 1 0.9998699426651001
? O 0 0.1330200880765915

Molecular O 0 0.0004783576587215066
study O 0 1.5100851669558324e-05
and O 0 2.1477626432897523e-06
neuropsychological O 0 0.00010173212649533525
analysis O 0 1.3800872693536803e-06
were O 0 1.334864663249391e-07
performed O 0 3.9942892726685386e-07
concurrently O 0 2.9684315450140275e-07
on O 0 4.834818128074403e-07
49 O 0 0.00013912093709222972
patients O 0 0.001098995446227491
with O 0 6.843526352895424e-05
Duchenne B-Disease 1 0.9999938011169434
muscular I-Disease 1 0.9999805688858032
dystrophy I-Disease 1 0.9999839067459106
( O 0 0.0011346142273396254
DMD B-Disease 1 0.9999872446060181
) O 0 1.8277443132319604e-06
in O 0 1.493207832936605e-07
order O 0 1.6973176286683156e-07
to O 0 8.888826386055371e-08
find O 0 5.629105999105377e-07
a O 0 1.6871760522008117e-07
molecular O 0 2.991948804265121e-06
explanation O 0 3.404511232929508e-07
for O 0 7.889858011367323e-08
the O 0 4.557268198368547e-07
cognitive B-Disease 0 0.0008371027070097625
impairment I-Disease 0 0.08328709751367569
observed O 0 1.0052357538370416e-05
in O 0 2.428246034469339e-06
most O 0 7.348215876845643e-05
DMD B-Disease 1 0.9999908208847046
patients O 0 0.27542632818222046
. O 0 4.849756078328937e-05

Complete O 0 3.238756107748486e-05
analysis O 0 6.802948519180063e-06
of O 0 5.53835832306504e-07
the O 0 5.010796826354635e-07
dystrophin O 0 0.00018345523858442903
gene O 0 3.7240172332531074e-06
was O 0 5.40641053703439e-07
performed O 0 4.7670070557614963e-07
to O 0 5.842101913344777e-08
define O 0 5.247659942142491e-07
the O 0 3.38654508880154e-08
localization O 0 4.747738557853154e-07
of O 0 3.586988484016729e-08
deletions O 0 6.021750778018031e-06
and O 0 4.840691190111102e-07
duplications O 0 1.3963624041934963e-05
in O 0 2.7343290298631473e-07
relation O 0 8.779118729762558e-07
to O 0 2.2852928793781757e-07
the O 0 5.417342094915512e-07
different O 0 3.4485055948607624e-06
DMD B-Disease 1 0.9955036044120789
promoters O 0 0.000797862361650914
. O 0 3.235607800888829e-05

Qualitative O 0 0.00014294424909166992
analysis O 0 1.542440804769285e-05
of O 0 1.0037413176178234e-06
the O 0 6.85180680193298e-07
Dp71 O 0 0.0002570591459516436
transcript O 0 7.862756319809705e-06
and O 0 3.341490639741096e-07
testing O 0 1.6031060567911481e-06
for O 0 5.1756771313193894e-08
the O 0 4.635944250708235e-08
specific O 0 7.747546959535612e-08
first O 0 5.2350490165054e-08
exon O 0 2.836223984559183e-06
of O 0 1.560799489652709e-07
Dp140 O 0 7.91781276348047e-05
were O 0 2.0982227511012752e-07
also O 0 1.558928062195264e-07
carried O 0 6.241896812753112e-07
out O 0 1.0699544645831338e-06
. O 0 5.02953480463475e-06

Neuropsychological O 0 0.007963788695633411
analysis O 0 0.00011532353528309613
assessed O 0 0.00011525955778779462
verbal O 0 6.407393084373325e-05
and O 0 3.917158664989984e-06
visuospatial O 0 0.0012443477753549814
intelligence O 0 1.3386192222242244e-05
, O 0 1.1762418807848007e-06
verbal O 0 2.0414008758962154e-05
memory O 0 0.00012906371557619423
, O 0 4.373980573291192e-07
and O 0 6.26773157819116e-07
reading O 0 7.820972314220853e-06
skills O 0 2.3302194676944055e-05
. O 0 1.0488451152923517e-05

Comparison O 0 0.00011229672963963822
of O 0 3.878133156831609e-06
molecular O 0 8.115400851238519e-05
and O 0 5.172384589968715e-06
psychometric O 0 0.003052161540836096
findings O 0 1.2859552953159437e-05
demonstrated O 0 2.6304664970666636e-06
that O 0 1.4533580383613298e-07
deletions O 0 4.250736765243346e-06
and O 0 2.127922158479123e-07
duplications O 0 6.403898169082822e-06
that O 0 7.159735559980618e-08
were O 0 8.171981846771814e-08
localized O 0 2.429056621622294e-06
in O 0 7.007312774476304e-08
the O 0 8.115070926351109e-08
distal O 0 7.10101958247833e-05
part O 0 1.879898832157778e-07
of O 0 3.400344184001369e-08
the O 0 7.343027164097293e-08
gene O 0 5.183759412830113e-07
seemed O 0 5.246664613878238e-07
to O 0 5.366129229855687e-08
be O 0 8.944438434355106e-08
preferentially O 0 1.0569139703875408e-05
associated O 0 6.033610134181799e-06
with O 0 4.950434686179506e-06
cognitive B-Disease 0 0.00859900377690792
impairment I-Disease 1 0.5732028484344482
. O 0 5.5587064707651734e-05

Two O 0 2.00741760636447e-05
altered O 0 5.777294427389279e-05
Dp71 O 0 0.00045255632721818984
transcripts O 0 1.653085564612411e-05
and O 0 4.2753475781864836e-07
two O 0 1.8203408558292722e-07
deleted O 0 2.8322156140347943e-06
Dp140 O 0 4.972709939465858e-05
DNA O 0 1.733726094244048e-06
sequences O 0 2.861646919427585e-07
were O 0 1.0568574282387999e-07
found O 0 1.5743258074962796e-07
in O 0 8.76790906545466e-08
four O 0 1.9295455331302946e-06
patients O 0 0.010093593038618565
with O 0 0.00011747408279916272
severe O 1 0.9906547665596008
cerebral B-Disease 1 0.9998856782913208
dysfunction I-Disease 1 0.9946069121360779
. O 0 0.00020699226297438145

These O 0 1.2116797734051943e-05
findings O 0 2.077435055980459e-05
suggest O 0 4.157467628829181e-06
that O 0 1.3539913368276757e-07
some O 0 6.38214174841778e-08
sequences O 0 3.885775186063256e-07
located O 0 2.3127803672196023e-07
in O 0 3.038842422142807e-08
the O 0 3.509621393504858e-08
distal O 0 5.290841363603249e-05
part O 0 2.0624845831207494e-07
of O 0 4.20870271966578e-08
the O 0 6.808361519006212e-08
gene O 0 6.859482937215944e-07
and O 0 1.4687027771742578e-07
, O 0 1.3088899208923976e-07
in O 0 5.497345156868505e-08
particular O 0 1.3550352662150544e-07
, O 0 8.619159785894226e-08
some O 0 1.071217923254153e-07
DMD B-Disease 1 0.5440750122070312
isoforms O 0 6.8929267627027e-07
expressed O 0 2.678702344383055e-07
in O 0 9.480532270345066e-08
the O 0 4.0969780457089655e-07
brain O 0 0.012882011011242867
may O 0 1.5716690313638537e-06
be O 0 5.2666965899561546e-08
related O 0 7.988365382516349e-07
to O 0 1.473122779316327e-07
the O 0 1.25593453503825e-06
cognitive B-Disease 0 0.030409449711441994
impairment I-Disease 1 0.9542096853256226
associated O 0 0.00010076770558953285
with O 0 8.007165160961449e-05
DMD B-Disease 1 0.9999806880950928
. O 0 1.3469184523273725e-05
. O 0 2.5224144337698817e-05

I1307K O 0 0.009512650780379772
APC O 0 0.0018968007061630487
and O 0 1.857638926594518e-05
hMLH1 O 0 0.0015508226351812482
mutations O 0 3.2174164516618475e-05
in O 0 5.397714062382875e-07
a O 0 5.777861247224791e-07
non O 0 3.9657984416408e-06
- O 0 0.0003816112002823502
Jewish O 0 4.515668024396291e-06
family O 0 5.307646461005788e-06
with O 0 6.766333626728738e-06
hereditary B-Disease 1 0.7222703695297241
non I-Disease 1 0.6726191639900208
- I-Disease 1 0.9999969005584717
polyposis I-Disease 1 0.9999995231628418
colorectal I-Disease 1 1.0
cancer I-Disease 1 0.9999958276748657
. O 0 0.0009970435639843345

We O 0 4.624256325769238e-05
describe O 0 4.403275306685828e-05
a O 0 4.614762929122662e-06
French O 0 1.358042936772108e-05
Canadian O 0 2.1696403564419597e-05
hereditary B-Disease 0 0.07091604173183441
non I-Disease 0 0.348741739988327
- I-Disease 1 0.9999970197677612
polyposis I-Disease 1 0.9999998807907104
colorectal I-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
( O 0 0.014609661884605885
HNPCC B-Disease 1 0.9999278783798218
) O 0 9.65142680797726e-06
kindred O 0 0.00012455260730348527
which O 0 4.807658910976897e-07
carries O 0 1.8138508721676772e-06
a O 0 5.481043103827687e-07
novel O 0 5.004444119549589e-06
truncating O 0 0.0004384882340673357
mutation O 0 1.2727626199193764e-05
in O 0 2.4180849322874565e-06
hMLH1 O 0 0.0008119757403619587
. O 0 1.7387485058861785e-05

Interestingly O 0 0.0010009696707129478
, O 0 1.0547622878220864e-05
the O 0 2.1778887457912788e-06
I1307K O 0 0.0003530218964442611
APC O 0 0.00013910052075516433
polymorphism O 0 4.352708128863014e-05
, O 0 7.553797445325472e-07
associated O 0 7.302967901523516e-07
with O 0 1.0480111001243131e-07
an O 0 9.871872919120506e-08
increased O 0 8.185745173250325e-06
risk O 0 0.0011421464150771499
of O 0 0.007181919179856777
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999995231628418
, O 0 1.9943032384617254e-05
is O 0 4.2410167111484043e-07
also O 0 1.283412274233342e-07
present O 0 2.638964247125841e-07
in O 0 1.968058853663024e-07
this O 0 3.8292481008284085e-07
family O 0 8.799849638307933e-06
. O 0 1.0493024092284031e-05

The O 0 1.8905664546764456e-05
I1307K O 0 0.0007857457385398448
polymorphism O 0 0.00021918589482083917
has O 0 1.5099450365596567e-06
previously O 0 7.14256202627439e-07
only O 0 7.231322030065712e-08
been O 0 8.519994310063339e-08
identified O 0 5.885311225029e-07
in O 0 7.260884160587011e-08
individuals O 0 1.0007842377035558e-07
of O 0 1.3996067593780026e-07
self O 0 2.6750167307909578e-05
- O 0 0.18116585910320282
reported O 0 7.134073530323803e-05
Ashkenazi O 0 0.0004669940681196749
Jewish O 0 1.6422607586719096e-05
origins O 0 2.2252652343013324e-05
. O 0 1.9860886823153123e-05

In O 0 8.748163963900879e-06
addition O 0 3.1028230296215042e-06
, O 0 6.448984777307487e-07
in O 0 1.4982160223553365e-07
this O 0 1.0325349819595431e-07
family O 0 2.032476231761393e-06
, O 0 2.2935613230856688e-07
there O 0 1.0555359608588333e-07
appears O 0 4.773485215991968e-07
to O 0 5.4451263054033916e-08
be O 0 3.7605225600145786e-08
no O 0 7.363110654523553e-08
relationship O 0 3.962336165841407e-07
between O 0 7.363279053151928e-08
the O 0 7.396301526796378e-08
I1307K O 0 5.535927266464569e-05
polymorphism O 0 9.045418664754834e-06
and O 0 1.1645583697372786e-07
the O 0 6.800262752904018e-08
presence O 0 3.3760591122700134e-07
or O 0 2.452182457091112e-07
absence O 0 2.010953721764963e-06
of O 0 3.928636488126358e-06
cancer B-Disease 1 0.8791046142578125
. O 0 4.280183929949999e-06
. O 0 1.6162761312443763e-05

Identification O 0 8.218293078243732e-05
of O 0 3.233170673411223e-06
a O 0 2.1402975107776e-06
novel O 0 5.142651843925705e-06
mutation O 0 3.9855103750596754e-06
of O 0 1.3280207156185497e-07
the O 0 1.4790987279411638e-07
CPO O 0 3.4287448215764016e-05
gene O 0 1.1241239690207294e-06
in O 0 1.259491710925431e-07
a O 0 5.970009624434169e-07
Japanese O 0 2.0362213035696186e-05
hereditary B-Disease 0 0.1803385615348816
coproporphyria I-Disease 1 0.5918406844139099
family O 0 7.533486495958641e-05
. O 0 2.988462074426934e-05

Hereditary B-Disease 1 0.995434582233429
coproporphyria I-Disease 1 0.9919162392616272
( O 0 0.00013880756159778684
HCP B-Disease 1 0.9215124249458313
) O 0 4.590367097989656e-06
is O 0 1.3174023933970602e-06
an O 0 3.815413492702646e-06
autosomal B-Disease 1 0.828222393989563
dominant I-Disease 1 0.7750957012176514
disease I-Disease 1 0.7083072066307068
characterized O 0 0.0017398858908563852
by O 0 1.1450079000496771e-05
a O 0 0.00022667045413982123
deficiency B-Disease 1 0.563977062702179
of I-Disease 0 1.0903241900450666e-06
coproporphyrinogen I-Disease 0 0.1355285793542862
oxidase I-Disease 0 0.0003881627053488046
( O 0 5.30757404249016e-07
CPO O 0 6.225403194548562e-05
) O 0 2.9346682595132734e-07
caused O 0 5.316657620824117e-07
by O 0 6.866407886718662e-08
a O 0 2.602911592930468e-07
mutation O 0 1.035707100527361e-06
in O 0 1.0441562636742674e-07
the O 0 4.901635293208528e-07
CPO O 0 0.00019715400412678719
gene O 0 2.9528551749535836e-05
. O 0 1.2401120329741389e-05

Only O 0 1.028522638080176e-05
11 O 0 1.0378713341196999e-05
mutations O 0 4.060463652422186e-06
of O 0 1.6418944426277449e-07
the O 0 1.7315502987003129e-07
gene O 0 1.7071012052838341e-06
have O 0 1.225336774268726e-07
been O 0 2.5043129880941706e-07
reported O 0 6.386687346093822e-06
in O 0 8.826517841953319e-06
HCP B-Disease 1 0.9996404647827148
patients O 0 0.025165222585201263
. O 0 3.236811244278215e-05

We O 0 1.3386817045102362e-05
report O 0 3.573553840396926e-06
another O 0 1.49640254676342e-06
mutation O 0 3.859048774756957e-06
in O 0 1.477075954881002e-07
a O 0 5.19232855822338e-07
Japanese O 0 6.695066076645162e-06
family O 0 1.5193128092505503e-05
. O 0 1.4614914107369259e-05

Polymerase O 0 0.004493104759603739
chain O 0 0.0008929469040594995
reaction O 0 3.671211379696615e-05
- O 0 4.0451439417665824e-05
single O 0 1.1817298855021363e-06
strand O 0 6.3801608121139e-06
conformational O 0 3.4820782275346573e-06
polymorphism O 0 6.140144250821322e-06
and O 0 1.0366769487291094e-07
direct O 0 1.3183948510686605e-07
sequence O 0 3.362887355251587e-07
analyses O 0 1.0749209877758403e-06
demonstrated O 0 4.876406478615536e-07
a O 0 1.565429670336016e-07
C O 0 1.2074924597982317e-05
to O 0 1.1402968880247499e-07
T O 0 2.3732087356620468e-05
substitution O 0 8.439304366447686e-08
in O 0 2.258766862439643e-08
exon O 0 1.372781071040663e-06
1 O 0 7.103571419975196e-08
of O 0 8.102972515189322e-09
the O 0 1.9394358119484423e-08
CPO O 0 2.8206277420395054e-06
gene O 0 1.6771049615726952e-07
at O 0 3.94671069159358e-08
nucleotide O 0 1.4694242622681486e-07
position O 0 4.979631995638556e-08
85 O 0 1.4462084152455645e-07
, O 0 1.8917102551085918e-08
which O 0 1.6671693359171513e-08
lies O 0 2.6581707857076253e-07
in O 0 2.651617769799941e-08
the O 0 5.92211648609009e-08
putative O 0 6.94833352099522e-06
presequence O 0 3.499337253742851e-05
for O 0 1.073351114655452e-07
targeting O 0 9.517163448435895e-07
to O 0 6.149563773760747e-07
mitochondria O 0 2.6967731173499487e-05
. O 0 6.737318472005427e-06

This O 0 7.928920240374282e-06
mutation O 0 1.6112513549160212e-05
changes O 0 8.14011968941486e-07
the O 0 1.1715784609123148e-07
codon O 0 5.610594371319166e-07
for O 0 5.227984445355105e-08
glutamine O 0 8.020755331017426e-07
to O 0 1.0057250676709373e-07
a O 0 1.0905284852924524e-07
termination O 0 3.713406385941198e-06
codon O 0 1.5383626532639028e-06
at O 0 3.7647288309017313e-07
amino O 0 5.849666990798141e-07
acid O 0 1.1479689874249743e-06
position O 0 6.979407771723345e-07
29 O 0 4.454886038729455e-06
. O 0 4.279486347513739e-06

MaeI O 0 0.004514723550528288
restriction O 0 4.879566768067889e-05
analysis O 0 8.871363206708338e-06
showed O 0 4.77356297778897e-06
two O 0 1.3294778966610465e-07
other O 0 2.0647280507546384e-07
carriers O 0 2.5662698135420214e-06
in O 0 1.9352940228145599e-07
the O 0 6.497439244412817e-07
family O 0 1.2010770660708658e-05
. O 0 1.8345781427342445e-05

The O 0 3.733238918357529e-05
C O 0 0.024669302627444267
- O 0 0.41820502281188965
T O 1 0.7065731883049011
mutation O 0 5.44602653462789e-06
is O 0 1.0620548351880643e-07
located O 0 2.592581154203799e-07
within O 0 5.3389118903623967e-08
a O 0 1.6682294301517686e-07
recently O 0 1.080969695976819e-06
proposed O 0 6.854218668195244e-07
putative O 0 1.5326442053265055e-06
alternative O 0 2.1336893496481935e-07
translation O 0 1.288101145746623e-07
initiation O 0 6.970134904804581e-07
codon O 0 9.887454552881536e-07
( O 0 1.6498162835887342e-07
TIC O 0 1.7312084310106002e-05
- O 0 7.91156435298035e-06
1 O 0 1.653159955594674e-07
) O 0 3.941429937981411e-08
, O 0 3.7488209869707134e-08
supporting O 0 1.8945094382161187e-07
that O 0 7.073272456636914e-08
TIC O 0 0.0004065049288328737
- O 0 7.378880400210619e-05
1 O 0 3.335695737405331e-07
is O 0 3.6940743797231335e-08
the O 0 4.292146016382503e-08
real O 0 1.112344421017042e-06
TIC O 0 7.026412640698254e-05
rather O 0 3.3303811619589396e-07
than O 0 2.8438054755497433e-07
TIC O 0 0.00041677901754155755
- O 0 8.400212391279638e-05
2 O 0 2.45525279751746e-06
. O 0 8.515110039297724e-07
. O 0 4.595807240548311e-06

Human B-Disease 0 0.00036975540569983423
complement I-Disease 0 0.0006527176010422409
factor I-Disease 0 0.1935756653547287
H I-Disease 1 0.9999855756759644
deficiency I-Disease 1 0.9999489784240723
associated O 0 0.17322133481502533
with O 1 0.99299556016922
hemolytic B-Disease 1 0.9999998807907104
uremic I-Disease 1 0.9999998807907104
syndrome I-Disease 1 0.9999898672103882
. O 0 0.0015997529262676835

This O 0 7.90375179349212e-06
study O 0 5.605461865343386e-06
reports O 0 1.9800786503765266e-06
on O 0 5.462127887767565e-07
six O 0 1.1771968502216623e-06
cases O 0 9.481917913944926e-06
of O 0 2.449218118272256e-05
deficiency B-Disease 1 0.9829244017601013
in I-Disease 0 1.516488197239596e-07
the I-Disease 0 4.9284558656381705e-08
human I-Disease 0 1.2037561702982202e-07
complement I-Disease 0 3.05210988926774e-07
regulatory I-Disease 0 2.245510131615447e-06
protein I-Disease 0 1.182133473776048e-06
Factor I-Disease 0 2.735377393037197e-06
H I-Disease 0 0.13430628180503845
( O 0 2.950717714611528e-07
FH O 0 5.4163861932465807e-05
) O 0 3.5798393582808785e-08
in O 0 1.4550520788247923e-08
the O 0 1.7834745236200433e-08
context O 0 1.793935240357314e-07
of O 0 8.141175840137294e-07
an O 0 0.0006667242269031703
acute B-Disease 1 0.999993085861206
renal I-Disease 1 1.0
disease I-Disease 1 0.9999443292617798
. O 0 0.0003066696517635137

Five O 0 1.4584840755560435e-05
of O 0 1.5566387219223543e-06
the O 0 7.465094995495747e-07
cases O 0 1.109221443584829e-06
were O 0 1.9507629644976987e-07
observed O 0 1.637957780076249e-06
in O 0 2.2627322948665096e-07
children O 0 3.6193828236719128e-06
presenting O 0 0.0021363624837249517
with O 1 0.98612380027771
idiopathic O 1 0.9999998807907104
hemolytic B-Disease 1 1.0
uremic I-Disease 1 1.0
syndrome I-Disease 1 0.999998927116394
( O 0 0.00906421896070242
HUS B-Disease 1 0.9998989105224609
) O 0 4.566681673168205e-05
. O 0 4.048358096042648e-05

Two O 0 6.79054301144788e-06
of O 0 8.639484008199361e-07
the O 0 7.108517365850275e-07
children O 0 4.517339220910799e-06
exhibited O 0 2.8432126782718115e-05
a O 0 8.037184306886047e-05
homozygous O 1 0.9065725207328796
deficiency O 1 0.9993140697479248
characterized O 0 0.00012444636377040297
by O 0 3.431543973420048e-07
the O 0 1.1628470275582004e-07
absence O 0 3.883700685491931e-07
of O 0 3.0779901294408774e-08
the O 0 4.820527621518522e-08
150 O 0 3.575261189325829e-07
- O 0 3.8345471693901345e-05
kD O 0 4.749169238493778e-05
form O 0 4.9468962259879845e-08
of O 0 4.320499513710274e-08
Factor O 0 1.4294197399067343e-06
H O 0 0.07538964599370956
and O 0 8.947817775606381e-08
the O 0 1.8653720346151204e-08
presence O 0 9.380057974794909e-08
, O 0 2.6333772495945595e-08
upon O 0 5.076625697597592e-08
immunoblotting O 0 1.626278208277654e-05
, O 0 3.9332217482979104e-08
of O 0 9.898641906147532e-09
the O 0 3.459430075736236e-08
42 O 0 5.245653937890893e-07
- O 0 1.3806908100377768e-05
kD O 0 0.00012101604806957766
Factor O 0 2.0708189367724117e-06
H O 0 0.012713690288364887
- O 0 5.523191248357762e-06
like O 0 9.69396083405627e-08
protein O 0 1.0054854016061654e-07
1 O 0 7.41620524991049e-08
( O 0 4.570691203298338e-08
FHL O 0 2.3625074391020462e-05
- O 0 7.329234449571231e-06
1 O 0 1.6545968151149282e-07
) O 0 2.6597829716479282e-08
and O 0 2.7664963653251107e-08
other O 0 5.999014263124991e-08
FH O 0 0.0002949362969957292
- O 0 0.00011693896522046998
related O 0 3.7450015497597633e-06
protein O 0 2.6845791580853984e-06
( O 0 5.462210879159102e-07
FHR O 0 0.00044060329673811793
) O 0 9.153195037470141e-07
bands O 0 1.059824808180565e-05
. O 0 6.891651537443977e-06

Southern O 0 7.912430010037497e-05
blot O 0 0.00039858336094766855
and O 0 1.6367663420169265e-06
PCR O 0 7.3616247391328216e-06
analysis O 0 4.660058152694546e-07
of O 0 8.933272255262636e-08
DNA O 0 2.0328463961050147e-06
of O 0 1.4856567531751352e-07
one O 0 9.146266393145197e-07
patient O 0 0.0005717072635889053
with O 0 2.16478765651118e-05
homozygous O 1 0.6281859278678894
deficiency O 1 0.9864707589149475
ruled O 0 1.6768753994256258e-05
out O 0 1.9419033492340532e-07
the O 0 7.614118402443637e-08
presence O 0 9.344183382609117e-08
of O 0 2.8257241879714456e-08
a O 0 1.0434535369086007e-07
large O 0 3.827174168691272e-07
deletion O 0 7.961365326991654e-07
of O 0 3.9509892246769596e-08
the O 0 1.7661331241924927e-07
FH O 0 0.0005314544541761279
gene O 0 8.905803383640887e-07
as O 0 7.656788625354238e-08
the O 0 2.300446340086637e-07
underlying O 0 0.0004437540774233639
defect O 0 0.0026631117798388004
for O 0 3.372677838342497e-06
the O 0 0.00010448975808685645
deficiency O 1 0.9833276867866516
. O 0 2.8450220270315185e-05

The O 0 7.041053322609514e-06
other O 0 9.475214142184996e-07
four O 0 7.322557280531328e-07
children O 0 2.646186885613133e-06
presented O 0 4.159260242886376e-06
with O 0 1.577338480274193e-05
heterozygous O 0 0.02066492848098278
deficiency O 1 0.8402987122535706
and O 0 8.094239092315547e-07
exhibited O 0 3.2149987418961246e-06
a O 0 6.05029299549642e-07
normal O 0 5.748551757278619e-06
immunoblotting O 0 0.002265172079205513
pattern O 0 2.2622175492870156e-06
of O 0 6.9746846520502e-08
proteins O 0 2.166686527971251e-07
of O 0 1.200478578766706e-07
the O 0 1.756042138367775e-06
FH O 0 0.06006420776247978
family O 0 3.660782749648206e-05
. O 0 3.077553992625326e-05

Factor B-Disease 1 0.9428015351295471
H I-Disease 1 0.9999926090240479
deficiency I-Disease 1 0.9990881681442261
is O 0 1.3129935041433782e-06
the O 0 6.482306389443693e-07
only O 0 3.577557208700455e-06
complement B-Disease 1 0.9914849400520325
deficiency I-Disease 1 0.9999916553497314
associated O 0 0.00012856980902142823
with O 0 6.489313091151416e-05
HUS B-Disease 1 0.9996198415756226
. O 0 7.553426257800311e-05

These O 0 1.1788599294959567e-05
observations O 0 1.5350564353866503e-05
suggest O 0 6.640721949224826e-06
a O 0 9.751594234330696e-07
role O 0 7.346823167608818e-07
for O 0 8.711895702617767e-07
FH O 0 0.03938126936554909
and O 0 3.519533493090421e-06
/ O 0 0.00030521617736667395
or O 0 3.5865825793734984e-06
FH O 0 0.00366256688721478
receptors O 0 5.046359547122847e-06
in O 0 1.210895987924232e-07
the O 0 4.712552765795408e-07
pathogenesis O 0 0.0007795866695232689
of O 0 2.814364415826276e-05
idiopathic O 1 0.9999778270721436
HUS B-Disease 1 0.9999383687973022
. O 0 2.1390658730524592e-05
. O 0 4.844865543418564e-05

Further O 0 3.600944910431281e-05
evidence O 0 1.139309006248368e-05
for O 0 9.320071399088192e-07
a O 0 9.282257451559417e-07
major O 0 4.039999566884944e-06
ancient O 0 1.0064616617455613e-05
mutation O 0 0.0006433084490709007
underlying O 1 0.7024949789047241
myotonic B-Disease 1 0.9999985694885254
dystrophy I-Disease 1 0.9999735355377197
from O 0 5.869079814146971e-06
linkage O 0 0.00030443008290603757
disequilibrium O 0 0.0055700382217764854
studies O 0 2.1178229872020893e-06
in O 0 2.641109233536554e-07
the O 0 3.620317841068754e-07
Japanese O 0 5.3213921091810334e-06
population O 0 2.8574686439242214e-06
. O 0 9.491553100815509e-06

The O 0 0.0024281966034322977
myotonic B-Disease 1 0.9999759197235107
dystrophy I-Disease 1 0.9999885559082031
( O 0 0.015425290912389755
DM B-Disease 1 0.9999973773956299
) O 0 1.904040800582152e-05
mutation O 0 1.6627556760795414e-05
is O 0 2.0460477401229582e-07
an O 0 1.7432580534659792e-07
unstable O 0 0.001624868717044592
( O 0 4.5370771317720937e-07
CTG O 0 0.00101547222584486
) O 0 2.190981120975266e-07
n O 0 1.9201275790692307e-05
repeat O 0 3.240060095777153e-06
, O 0 7.656467460037675e-08
present O 0 4.187923252629844e-08
at O 0 8.81260717733312e-08
a O 0 4.469565695330857e-08
copy O 0 2.0242866582975694e-07
number O 0 1.516134595647145e-08
of O 0 1.1190369519908927e-08
5 O 0 1.2370701085728797e-07
- O 0 1.0412241863377858e-05
37 O 0 4.544404532680346e-07
repeats O 0 1.705261070128472e-07
on O 0 5.0979824806063334e-08
normal O 0 1.9267308459802734e-07
chromosomes O 0 5.43389433005359e-07
but O 0 5.03976238519499e-08
amplified O 0 2.422360978471261e-07
to O 0 4.125323727066643e-08
50 O 0 2.1860510912574682e-07
- O 0 9.546894034428988e-06
3000 O 0 2.5410231501155067e-06
copies O 0 9.568819905325654e-07
on O 0 4.518054538493743e-06
DM B-Disease 1 0.9974796175956726
chromosomes O 0 9.059361036634073e-05
. O 0 1.17367526399903e-05

Previous O 0 9.595269511919469e-05
findings O 0 5.4431093303719535e-05
in O 0 2.2957876808504807e-06
Caucasian O 0 7.309860666282475e-05
populations O 0 2.730896767388913e-06
of O 0 3.988681953615014e-07
a O 0 1.2862226867582649e-05
DM B-Disease 1 0.9999947547912598
founder O 0 0.0009758747182786465
chromosome O 0 7.506694964831695e-05
raise O 0 2.289514895892353e-06
a O 0 2.5197940090038173e-07
question O 0 3.415884179958084e-07
about O 0 6.194142798676694e-08
the O 0 4.827465005519116e-08
molecular O 0 1.4123435221335967e-06
events O 0 1.2793745440831117e-07
involved O 0 1.7597342605313315e-07
in O 0 7.837601856408583e-08
the O 0 2.292627527822333e-07
expansion O 0 1.3180747373553459e-05
mutation O 0 2.165419573429972e-05
. O 0 5.822783805342624e-06

To O 0 2.3974143914529122e-05
investigate O 0 4.346150308265351e-05
whether O 0 4.01681018047384e-06
a O 0 2.154846924895537e-06
founder O 0 4.8290858103428036e-05
chromosome O 0 1.993670048250351e-05
for O 0 7.234673375933198e-07
the O 0 3.4156732908741105e-06
DM B-Disease 1 0.9999934434890747
mutation O 0 2.401446363364812e-05
exists O 0 4.7454480522901576e-07
in O 0 3.68019890117921e-08
the O 0 4.1581785126254545e-08
Japanese O 0 7.652444082850707e-07
population O 0 6.348027881131202e-08
, O 0 7.28791249571259e-08
we O 0 9.799758515782742e-08
genotyped O 0 0.00024393724743276834
families O 0 5.080123059997277e-07
using O 0 2.52156326041586e-07
polymorphic O 0 2.7932945158681832e-05
markers O 0 1.5382658602902666e-05
near O 0 2.062100293187541e-06
the O 0 1.2969280760444235e-07
( O 0 2.3560600936889387e-07
CTG O 0 8.630502998130396e-05
) O 0 2.4973775225589634e-07
n O 0 1.2915782463096548e-05
repeat O 0 3.3873541269713314e-06
region O 0 1.0403499572930741e-06
and O 0 6.566909860339365e-07
constructed O 0 1.850146691140253e-05
haplotypes O 0 0.00017172326624859124
. O 0 1.1628925676632207e-05

Six O 0 3.562219353625551e-05
different O 0 5.658975624101004e-06
haplotypes O 0 9.929030056810006e-05
were O 0 2.0692357338703005e-06
found O 0 2.444190840833471e-06
and O 0 3.1376710012409603e-06
DM B-Disease 1 0.9999655485153198
alleles O 0 3.3695810998324305e-05
were O 0 1.3954659152659588e-06
always O 0 9.863393643172458e-06
haplotype O 0 0.0002991451183333993
A O 0 9.90775788523024e-06
. O 0 2.175860572606325e-05

To O 0 2.8153415769338608e-05
find O 0 1.3240312000561971e-05
an O 0 2.8644265626098786e-07
origin O 0 1.5908642581052845e-07
of O 0 8.978778254231656e-08
the O 0 1.0687322316016434e-07
( O 0 2.2889355477673234e-07
CTG O 0 0.00012172131391707808
) O 0 1.4115852309259935e-07
n O 0 1.9533856175257824e-05
repeat O 0 4.182106749794912e-06
mutation O 0 3.762381481919874e-07
and O 0 3.950679783315536e-08
to O 0 2.79389578139444e-08
investigate O 0 4.49988533546275e-07
the O 0 2.271659482744326e-08
mechanism O 0 5.8757386511842924e-08
of O 0 1.1884785600102532e-08
the O 0 1.7902976878758636e-08
expansion O 0 4.175289802788029e-07
mutation O 0 1.7793333029203495e-07
in O 0 1.15613900675271e-08
the O 0 1.825026707535926e-08
Japanese O 0 2.472633866545948e-07
population O 0 5.257523127966124e-08
we O 0 3.8287723214125435e-08
have O 0 1.5245092299664975e-08
studied O 0 1.178189137363006e-07
90 O 0 3.446495782100101e-07
Japanese O 0 3.831808498944156e-06
DM B-Disease 1 0.9996852874755859
families O 0 1.9419178443058627e-06
comprising O 0 5.511481617759273e-07
190 O 0 1.1778492989833467e-06
affected O 0 7.172275786615501e-07
and O 0 3.0456843091997143e-07
130 O 0 5.856080406374531e-06
unaffected O 0 4.9641817895462736e-05
members O 0 2.107927230099449e-06
. O 0 8.62499018694507e-06

The O 0 9.678340575192124e-06
results O 0 1.862759017967619e-05
suggest O 0 4.770841769641265e-06
that O 0 1.8286196734607074e-07
a O 0 3.2120462378770753e-07
few O 0 4.0028425019045244e-07
common O 0 6.049306193744997e-07
ancestral O 0 1.1161078873556107e-05
mutations O 0 2.0319530449341983e-06
in O 0 5.803076774668625e-08
both O 0 1.1699249569119274e-07
Caucasian O 0 1.1812041520897765e-05
and O 0 3.133918937692215e-07
Japanese O 0 1.4398575558516313e-06
populations O 0 3.875306049394567e-07
have O 0 2.7274266400922897e-08
originated O 0 5.01221144588726e-08
by O 0 1.7300012089549455e-08
expansion O 0 1.220019640868486e-07
of O 0 3.840167295265928e-08
an O 0 4.692148181106859e-08
ancestral O 0 6.381998900906183e-06
n O 0 4.8021516704466194e-05
= O 0 2.361369524805923e-06
5 O 0 1.0845606368548033e-07
repeat O 0 4.084501767920301e-07
to O 0 6.437905142320233e-08
n O 0 8.370533578272443e-06
= O 0 1.953948185473564e-06
19 O 0 4.209076394090516e-07
- O 0 4.006813014711952e-06
37 O 0 1.0998381867466378e-06
copies O 0 1.3742545661443728e-06
. O 0 3.2235029721050523e-06

These O 0 9.531019713904243e-06
data O 0 6.161107648949837e-06
support O 0 3.0201954359654337e-06
multistep O 0 4.79642185382545e-05
models O 0 1.7414497506251791e-06
of O 0 2.775267660126701e-07
triplet O 0 8.84649925865233e-05
repeat O 0 8.18004809843842e-06
expansion O 0 1.8751965171759366e-06
that O 0 5.880783859879557e-08
have O 0 4.196926894906028e-08
been O 0 3.397504499957904e-08
proposed O 0 1.9500933490235184e-07
for O 0 1.4553191363120277e-07
both O 0 1.5372376083178096e-06
DM B-Disease 1 0.999957799911499
and O 0 4.943932799506001e-05
Friedreichs B-Disease 1 0.8081034421920776
ataxia I-Disease 1 0.9090676307678223
. O 0 8.140251338772941e-06
. O 0 1.4609618119720835e-05

The O 0 2.394044349784963e-05
molecular O 0 5.982571019558236e-05
basis O 0 8.68248662300175e-06
of O 0 3.783834108617157e-05
C6 B-Disease 1 0.9999985694885254
deficiency I-Disease 1 0.9999840259552002
in O 0 8.67776577706536e-07
the O 0 2.382518999866079e-07
western O 0 1.543538360238017e-06
Cape O 0 0.0001262480509467423
, O 0 1.4335015521282912e-06
South O 0 3.0972414606367238e-06
Africa O 0 5.860388228029478e-06
. O 0 1.078380682884017e-05

Deficiency B-Disease 1 0.9949748516082764
of I-Disease 0 4.36674645243329e-06
the I-Disease 0 8.246024094660243e-07
sixth I-Disease 0 3.907085101673147e-06
component I-Disease 0 2.3507570858782856e-06
of I-Disease 0 1.1746103467658031e-07
human I-Disease 0 3.438108251430094e-07
complement I-Disease 0 1.761616090334428e-06
( O 0 3.315278149784717e-07
C6 O 0 0.0036119353026151657
) O 0 2.1799077387640864e-07
has O 0 8.38308906736529e-08
been O 0 5.304947592321696e-08
reported O 0 2.600976358735352e-07
in O 0 2.2709922831154472e-08
a O 0 2.8457908030077306e-08
number O 0 1.340195954213641e-08
of O 0 1.7383099404355562e-08
families O 0 1.0138200678966314e-07
from O 0 2.599006698744688e-08
the O 0 2.7363004306835137e-08
western O 0 2.6711768441600725e-07
Cape O 0 1.6668262105667964e-05
, O 0 4.806998390449735e-07
South O 0 1.506891067037941e-06
Africa O 0 2.8440488222258864e-06
. O 0 6.797059995733434e-06

Meningococcal B-Disease 1 0.9999254941940308
disease I-Disease 1 0.9973829388618469
is O 0 2.6184419766650535e-05
endemic O 0 0.0001163124106824398
in O 0 7.167413969000336e-07
the O 0 3.2950043760138215e-07
Cape O 0 0.00010255203960696235
and O 0 1.8978258253810054e-07
almost O 0 7.385263955939081e-08
all O 0 2.1716880738154032e-08
pedigrees O 0 2.385261495874147e-06
of O 0 2.8715021471725777e-07
total O 0 0.0002060278202407062
C6 B-Disease 1 0.9999994039535522
deficiency I-Disease 1 0.999991774559021
( O 0 2.914532842623885e-06
C6Q0 O 0 0.03409538418054581
) O 0 3.3722778880473925e-07
have O 0 1.1374686437193304e-07
been O 0 2.564860324127949e-07
ascertained O 0 9.705514457891695e-06
because O 0 1.0195896038567298e-06
of O 0 8.489216270390898e-06
recurrent O 1 0.9903296232223511
disease O 0 0.20750786364078522
. O 0 4.998812801204622e-05

We O 0 2.2234791686059907e-05
have O 0 1.2568548299896065e-06
sequenced O 0 4.774601165991044e-06
the O 0 1.70859834724979e-07
expressed O 0 3.694388510666613e-07
exons O 0 1.6542179537282209e-06
of O 0 9.478127793727253e-08
the O 0 1.8753684116745717e-07
C6 O 0 0.0003801138373091817
gene O 0 6.777162298021722e-07
from O 0 8.180387567335856e-08
selected O 0 2.959773155453149e-07
cases O 0 4.1445446186116897e-07
and O 0 2.2235302310491534e-07
have O 0 7.333817109156371e-08
found O 0 1.0833181107727796e-07
three O 0 1.9872170753387763e-07
molecular O 0 0.001254041213542223
defects O 0 0.08335962891578674
leading O 0 1.2826845932067954e-06
to O 0 1.6076333508863172e-07
total O 0 1.9464125216472894e-05
deficiency O 1 0.6156842708587646
879delG O 0 0.0023832162842154503
, O 0 4.2575263137223374e-07
which O 0 5.691638449434322e-08
is O 0 9.15466458195624e-08
the O 0 1.0830722629862066e-07
common O 0 1.6427571836175048e-06
defect O 0 0.00016440902254544199
in O 0 6.590612855461586e-08
the O 0 1.0025056695894818e-07
Cape O 0 4.451465792953968e-05
and O 0 3.591599693208991e-07
hitherto O 0 2.4086714347504312e-06
unreported O 0 2.1349258076952538e-06
, O 0 1.4076999832468573e-07
and O 0 1.1055657012093434e-07
1195delC O 0 2.8220723834238015e-05
and O 0 3.8908038391127775e-07
1936delG O 0 0.00015125250502023846
, O 0 1.8366873177910747e-07
which O 0 5.470276320806988e-08
have O 0 3.2554918760752116e-08
been O 0 4.9253547018679456e-08
previously O 0 3.573025253444939e-07
reported O 0 5.93379013480444e-07
in O 0 1.1002309463492566e-07
African O 0 1.459171699025319e-06
- O 0 0.002411654219031334
Americans O 0 1.7169568309327587e-05
. O 0 1.2339737622824032e-05

We O 0 1.9372233509784564e-05
also O 0 1.1906995496246964e-06
show O 0 9.265577318728901e-07
that O 0 1.0069593514572261e-07
the O 0 1.4623365984789416e-07
879delG O 0 0.00024603435304015875
and O 0 4.621519110514782e-06
1195delC O 1 0.8879050612449646
defects O 1 0.829166829586029
are O 0 2.0650982435199694e-07
associated O 0 3.304465053588501e-06
with O 0 1.0006256161432248e-06
characteristic O 0 5.498855534824543e-05
C6 O 1 0.5176376700401306
/ O 0 0.001071728765964508
C7 O 0 0.01316913589835167
region O 0 1.148741921497276e-05
DNA O 0 9.088867955142632e-05
marker O 0 7.246535096783191e-05
haplotypes O 0 4.0335027733817697e-05
, O 0 4.943660769640701e-07
although O 0 3.8280393255263334e-07
small O 0 1.2354825003058068e-06
variations O 0 4.809951860806905e-06
were O 0 1.8084947441820987e-06
observed O 0 1.2086261449439917e-05
. O 0 8.820399671094492e-06

The O 0 5.1164377509849146e-05
1936delG O 0 0.18808792531490326
defect O 0 0.042688824236392975
was O 0 3.019020368810743e-06
observed O 0 1.9227766188123496e-06
only O 0 7.488726794235845e-08
once O 0 3.004470556788874e-07
in O 0 5.2317147947178455e-08
the O 0 1.2762318135628448e-07
Cape O 0 7.89584155427292e-05
, O 0 2.3731489307010634e-07
but O 0 1.6135913938342128e-07
its O 0 3.386261369087151e-07
associated O 0 8.696715667610988e-06
haplotype O 0 0.0001015718953567557
could O 0 8.062328333835467e-07
be O 0 3.6382465395945474e-07
deduced O 0 8.849729965731967e-06
. O 0 6.529879556183005e-06

The O 0 6.257665972952964e-06
data O 0 4.211957730149152e-06
from O 0 4.375315540983138e-07
the O 0 2.824577336468792e-07
haplotypes O 0 1.5554365745629184e-05
indicate O 0 7.344987125179614e-07
that O 0 4.137814002547202e-08
these O 0 4.8872209390538046e-08
three O 0 2.1523321436234255e-07
molecular O 0 0.00230471626855433
defects O 0 0.19006794691085815
account O 0 6.97733128163236e-07
for O 0 5.949185037934512e-07
the O 0 3.8052498894103337e-06
defects O 0 0.37877610325813293
in O 0 7.585141759136604e-08
all O 0 3.064867470925492e-08
the O 0 6.950885733658652e-08
38 O 0 1.9339042864885414e-06
unrelated O 0 9.014321221911814e-06
C6Q0 O 0 0.017791785299777985
individuals O 0 1.95508008005163e-07
we O 0 6.197310398192712e-08
have O 0 2.9669534384879626e-08
studied O 0 1.626898438189528e-07
from O 0 1.2892932943486812e-07
the O 0 5.54841278699314e-07
Cape O 0 0.0001592598855495453
. O 0 1.145302849181462e-05

We O 0 2.52798454312142e-05
have O 0 1.956495225385879e-06
also O 0 3.063634892441769e-07
observed O 0 1.1425865977798821e-06
the O 0 4.512450857419026e-07
879delG O 0 0.01590888388454914
defect O 0 0.0007453144062310457
in O 0 2.1619804613237648e-07
two O 0 3.252742715176282e-07
Dutch O 0 0.00010105512774316594
C6 B-Disease 1 0.9997695088386536
- I-Disease 1 0.9943398833274841
deficient I-Disease 1 0.9842942357063293
kindreds O 0 0.0008568300982005894
, O 0 6.226320010682684e-07
but O 0 1.4283075699950132e-07
the O 0 1.2396753845678177e-07
879delG O 0 0.0025122377555817366
defect O 0 0.00017436135385651141
in O 0 7.647345512395987e-08
the O 0 1.0618178691856883e-07
Cape O 0 7.508521230192855e-05
probably O 0 9.5713573955436e-07
did O 0 1.2093622103748203e-07
not O 0 2.8252660655425643e-08
come O 0 9.596512740017715e-08
from O 0 5.237895095433487e-08
The O 0 1.0375276104923614e-07
Netherlands O 0 3.4879710710811196e-06
. O 0 7.787509730405873e-07
. O 0 5.517026693269145e-06

Complement B-Disease 1 0.819119393825531
C7 I-Disease 1 0.9999819993972778
deficiency I-Disease 1 0.9999843835830688
: O 0 2.0511113689281046e-05
seven O 0 4.667508619604632e-06
further O 0 5.08612265548436e-06
molecular O 0 0.009872143156826496
defects O 1 0.7055792808532715
and O 0 1.96347491510096e-06
their O 0 1.5022034176581656e-06
associated O 0 2.8701886549242772e-05
marker O 0 0.0006121349870227277
haplotypes O 0 0.0008051569457165897
. O 0 3.5620498238131404e-05

Seven O 0 2.9039485525572672e-05
further O 0 1.0906956958933733e-05
molecular O 0 3.9591894164914265e-05
bases O 0 1.4557298527506646e-05
of O 0 0.00011683820775942877
C7 B-Disease 1 0.9999971389770508
deficiency I-Disease 1 0.9999926090240479
are O 0 4.730077307613101e-06
described O 0 6.604924419661984e-05
. O 0 2.7658516046358272e-05

All O 0 9.87103339866735e-06
these O 0 2.258975200675195e-06
new O 0 4.92255594508606e-06
molecular O 0 0.002032608725130558
defects O 0 0.13271114230155945
involve O 0 4.14789974456653e-06
single O 0 1.1181514310010243e-06
- O 0 4.3135758460266516e-05
nucleotide O 0 1.437093374079268e-06
events O 0 1.9960147312758636e-07
, O 0 1.2483883438108023e-07
deletions O 0 1.4468542985923705e-06
and O 0 1.0986875054186385e-07
substitutions O 0 6.36789138752647e-07
, O 0 5.493991395155717e-08
some O 0 5.648398637703167e-09
of O 0 8.590236966199427e-09
which O 0 3.008358007150491e-08
alter O 0 1.8940013433166314e-06
splice O 0 8.485112630296499e-06
sites O 0 7.938870112411678e-07
, O 0 1.7827235865297553e-07
and O 0 2.3176444585715217e-07
others O 0 7.18439252977987e-07
codons O 0 1.0256526365992613e-05
. O 0 4.583884219755419e-06

They O 0 7.948362508614082e-06
are O 0 8.863564744387986e-07
distributed O 0 9.773519877853687e-07
along O 0 4.722811013380124e-07
the O 0 1.7548040887049865e-07
C7 O 0 0.0003039985313080251
gene O 0 3.08398375636898e-06
, O 0 2.361727098332267e-07
but O 0 8.942136275891244e-08
predominantly O 0 1.2035805241339403e-07
towards O 0 1.538843861226269e-07
the O 0 1.1428770818611156e-07
3 O 0 1.3698543170903577e-06
end O 0 7.039180218271213e-06
. O 0 9.708532161312178e-06

All O 0 9.58341024670517e-06
were O 0 3.093179657298606e-06
found O 0 1.7046951370502939e-06
in O 0 8.952014809437969e-07
compound O 0 1.970321318367496e-05
heterozygous O 0 1.9017090380657464e-05
individuals O 0 5.126038104208419e-06
. O 0 1.2369559044600464e-05

The O 0 8.373660239158198e-05
C6 O 0 0.36642733216285706
/ O 0 0.013955946080386639
C7 O 0 0.42308735847473145
marker O 0 0.009361660107970238
haplotypes O 0 0.0025715003721415997
associated O 0 2.52211593760876e-05
with O 0 2.2395047380996402e-06
most O 0 2.2331973013933748e-05
C7 B-Disease 1 0.999771773815155
defects I-Disease 1 0.9954612851142883
are O 0 1.830758719734149e-06
tabulated O 0 0.00012358863023109734
. O 0 3.1369199859909713e-06
. O 0 1.2940241504111327e-05

A O 0 4.437876486917958e-05
genome O 0 9.59870230872184e-05
- O 0 0.00020791283168364316
wide O 0 5.416255135060055e-06
search O 0 1.7419597497791983e-06
for O 0 4.79338893910608e-07
chromosomal O 0 0.001508852350525558
loci O 0 2.707738349272404e-05
linked O 0 3.546255538822152e-05
to O 0 4.034693574794801e-06
mental O 0 0.3886237144470215
health O 0 0.0014108378672972322
wellness O 0 0.0192412082105875
in O 0 1.4595725588151254e-06
relatives O 0 5.89834016864188e-05
at O 0 7.0341743594326545e-06
high O 0 0.0002929750771727413
risk O 0 0.0011767446994781494
for O 0 0.0004289702046662569
bipolar B-Disease 1 0.9999982118606567
affective I-Disease 1 0.9999746084213257
disorder I-Disease 1 0.992717981338501
among O 0 2.345398570469115e-06
the O 0 6.260049190132122e-07
Old O 0 2.163833960366901e-05
Order O 0 5.236005108599784e-06
Amish O 0 0.00019633796182461083
. O 0 2.720618067542091e-05

Bipolar B-Disease 1 0.9999738931655884
affective I-Disease 1 0.9999339580535889
disorder I-Disease 1 0.9998817443847656
( O 0 0.0006816168315708637
BPAD B-Disease 1 0.9998935461044312
; O 0 0.008543159812688828
manic B-Disease 1 0.9999630451202393
- I-Disease 1 0.9999899864196777
depressive I-Disease 1 0.9999990463256836
illness I-Disease 1 0.9937911629676819
) O 0 3.5574839785113e-06
is O 0 1.1422531542848446e-06
characterized O 0 2.2642554540652782e-05
by O 0 1.8629297926509025e-07
episodes O 0 1.1508979014251963e-06
of O 0 1.1714595302692032e-06
mania B-Disease 1 0.7863894104957581
and O 0 1.1131954124721233e-05
/ O 0 0.00410111527889967
or O 0 6.986806056374917e-06
hypomania B-Disease 0 0.2810453474521637
interspersed O 0 3.561529956641607e-05
with O 0 1.218359784616041e-06
periods O 0 1.4255549103836529e-05
of O 0 8.178433745342772e-06
depression B-Disease 0 0.1250854879617691
. O 0 6.285508425207809e-05

Compelling O 0 0.0003819834964815527
evidence O 0 9.033842798089609e-05
supports O 0 3.7763104046462104e-05
a O 0 3.3161204555653967e-06
significant O 0 8.615232218289748e-06
genetic O 0 3.671243030112237e-05
component O 0 8.469767635688186e-06
in O 0 3.2436417995995726e-07
the O 0 3.99517688265405e-07
susceptibility O 0 0.0001220988924615085
to O 0 2.071071548925829e-06
develop O 0 0.00012307539873290807
BPAD B-Disease 1 0.9955952763557434
. O 0 4.6201043005567044e-05

To O 0 1.1212032404728234e-05
date O 0 1.1064216778322589e-05
, O 0 1.1451413683971623e-06
however O 0 3.6684502902062377e-07
, O 0 1.8715503813382384e-07
linkage O 0 3.137841758871218e-06
studies O 0 2.8908488047818537e-07
have O 0 5.259549240577144e-08
attempted O 0 1.081663867807947e-06
only O 0 3.80890234907838e-08
to O 0 1.0561581831325384e-07
identify O 0 2.943369736385648e-06
chromosomal O 0 0.00026996518136002123
loci O 0 2.7124033294967376e-06
that O 0 1.4227785527509695e-07
cause O 0 1.8027571968559641e-06
or O 0 2.8133720775258553e-07
increase O 0 6.850585236861662e-07
the O 0 2.818861730702338e-07
risk O 0 9.673735803517047e-06
of O 0 1.5123026742003276e-06
developing O 0 0.00021140527678653598
BPAD B-Disease 1 0.9985458850860596
. O 0 3.7993166188243777e-05

To O 0 1.109901859308593e-05
determine O 0 7.668226317036897e-06
whether O 0 2.023363322223304e-06
there O 0 4.794001142727211e-07
could O 0 3.964823065416567e-07
be O 0 1.374322522451621e-07
protective O 0 4.351259849499911e-05
alleles O 0 1.1376371276128339e-06
that O 0 6.446175149221745e-08
prevent O 0 1.959617748070741e-06
or O 0 3.701229616126511e-07
reduce O 0 3.2627949622110464e-06
the O 0 1.9811126605873142e-07
risk O 0 3.964361440011999e-06
of O 0 1.6267867408714665e-07
developing O 0 3.745856156456284e-05
BPAD B-Disease 1 0.9998247027397156
, O 0 1.652428409215645e-06
similar O 0 4.9130733259517e-07
to O 0 8.570668086349542e-08
what O 0 1.0161701879951579e-07
is O 0 7.748123209694313e-08
observed O 0 6.567636319232406e-07
in O 0 3.256644447446888e-07
other O 0 1.040054121403955e-05
genetic B-Disease 1 0.9997898936271667
disorders I-Disease 1 0.9999896287918091
, O 0 4.9993159336736426e-06
we O 0 1.8409098174743121e-06
used O 0 2.3091946786735207e-05
mental O 1 0.9304071068763733
health O 0 0.024803396314382553
wellness O 0 0.11011236906051636
( O 0 1.3772341844742186e-06
absence O 0 2.610478986753151e-06
of O 0 6.446291536121862e-07
any O 0 0.00014680370804853737
psychiatric B-Disease 1 0.999981164932251
disorder I-Disease 1 0.988476037979126
) O 0 4.4674013111034583e-07
as O 0 7.213041186560076e-08
the O 0 7.335005847153298e-08
phenotype O 0 5.014840098738205e-06
in O 0 4.938213749028364e-08
our O 0 1.3927044051342818e-07
genome O 0 2.039129640252213e-06
- O 0 1.8446251488057896e-05
wide O 0 2.2571621229872108e-06
linkage O 0 3.613795342971571e-06
scan O 0 1.3339931683731265e-05
of O 0 4.6678415799306094e-08
several O 0 9.112749665973752e-08
large O 0 6.590990437871369e-07
multigeneration O 0 9.811334166442975e-05
Old O 0 1.221958882524632e-06
Order O 0 1.0245856429946798e-07
Amish O 0 4.247664946888108e-06
pedigrees O 0 1.3997329006087966e-05
exhibiting O 0 2.5447309326409595e-06
an O 0 1.7631947457630304e-07
extremely O 0 4.997864380129613e-05
high O 0 7.794651173753664e-05
incidence O 0 0.0017199984285980463
of O 0 6.427466814784566e-06
BPAD B-Disease 1 0.9996280670166016
. O 0 7.204230496427044e-05

We O 0 2.996664261445403e-05
have O 0 2.405602117505623e-06
found O 0 1.0825409617609694e-06
strong O 0 5.391360673456802e-07
evidence O 0 4.92600293000578e-07
for O 0 9.543597201400189e-08
a O 0 2.5039119577741076e-07
locus O 0 5.750383024860639e-06
on O 0 1.1618599273788277e-06
chromosome O 0 0.00017873475735541433
4p O 1 0.9790701866149902
at O 0 2.2950346192374127e-06
D4S2949 O 0 2.200077142333612e-05
( O 0 1.36048385002141e-07
maximum O 0 1.0797199365697452e-06
GENEHUNTER O 0 0.00012128613161621615
- O 0 8.875796993379481e-06
PLUS O 0 1.2773791695508407e-06
nonparametric O 0 5.3055109674460255e-06
linkage O 0 2.932191591753508e-06
score O 0 6.051060381651041e-07
= O 0 1.2269883882254362e-06
4 O 0 1.474726758488032e-07
. O 0 3.6184879093070776e-08
05 O 0 1.0484144468136947e-06
, O 0 8.035027576624998e-08
P O 0 5.0486742111388594e-05
= O 0 5.003185492569173e-07
5 O 0 3.630766087781012e-08
. O 0 9.143457546656464e-09
22 O 0 3.8986627259873785e-08
x O 0 1.0592141279630596e-06
10 O 0 3.976633777824645e-08
( O 0 2.1766934921174652e-08
- O 0 3.426358034630539e-06
4 O 0 1.8191539652434585e-07
) O 0 2.5031759776084073e-08
; O 0 8.095359760318388e-08
SIBPAL O 0 2.43190661421977e-05
Pempirical O 0 6.264562216529157e-06
value O 0 5.937532421285141e-08
< O 0 4.8816036724019796e-06
3 O 0 1.1322768500576785e-07
x O 0 1.7728845023157191e-06
10 O 0 5.063406760541511e-08
( O 0 2.8510605432074954e-08
- O 0 4.411046120367246e-06
5 O 0 8.456609634777124e-08
) O 0 1.302666863267632e-08
) O 0 8.829848852087707e-09
and O 0 3.602222520271425e-08
suggestive O 0 2.6432815047883196e-06
evidence O 0 1.6085733989257278e-07
for O 0 2.4987539148924043e-08
a O 0 1.521700596640585e-07
locus O 0 3.394743998796912e-06
on O 0 9.023051461554132e-07
chromosome O 0 0.00013552725431509316
4q O 0 0.10899421572685242
at O 0 2.207947090937523e-06
D4S397 O 0 4.23518504248932e-05
( O 0 1.2408841598698928e-07
maximum O 0 6.356066251100856e-07
GENEHUNTER O 0 0.0001938505592988804
- O 0 1.2086896276741754e-05
PLUS O 0 1.775056716724066e-06
nonparametric O 0 3.5454870612738887e-06
linkage O 0 1.4630650184699334e-06
score O 0 2.1846464903774176e-07
= O 0 5.138398364579189e-07
3 O 0 7.115151134939879e-08
. O 0 1.4077156329506124e-08
29 O 0 1.1156976853499145e-07
, O 0 4.559946376048174e-08
P O 0 1.898695518320892e-05
= O 0 2.485753611836117e-07
2 O 0 2.7047724060480505e-08
. O 0 9.429348857281639e-09
57 O 0 2.0861119764958858e-07
x O 0 1.7836771348811453e-06
10 O 0 4.3513136205319825e-08
( O 0 2.849462354959087e-08
- O 0 4.099380021216348e-06
3 O 0 1.6218081100305426e-07
) O 0 3.6419049109781554e-08
; O 0 8.902196668714168e-08
SIBPAL O 0 1.4465616914094426e-05
Pempirical O 0 9.02444571693195e-06
value O 0 1.0647545423125848e-07
< O 0 6.660803137492621e-06
1 O 0 1.6618110976196476e-07
x O 0 3.200071432729601e-06
10 O 0 6.980287281521669e-08
( O 0 3.5665966180431496e-08
- O 0 6.890481472510146e-06
3 O 0 1.5420243926200783e-07
) O 0 2.8074801150523854e-08
) O 0 1.0521265636498356e-08
that O 0 9.433918535250996e-09
are O 0 5.002736358505899e-08
linked O 0 5.717583917430602e-06
to O 0 3.3007518140948378e-06
mental O 0 0.46686267852783203
health O 0 0.004525217227637768
wellness O 0 0.15725764632225037
. O 0 7.539588114013895e-05

These O 0 1.8954353436129168e-05
findings O 0 1.3265464076539502e-05
are O 0 4.803011961485026e-07
consistent O 0 1.0947074997602613e-06
with O 0 1.5877223802363005e-07
the O 0 1.1456073423232738e-07
hypothesis O 0 1.384405663884536e-06
that O 0 4.571877099124322e-08
certain O 0 1.5564651789645723e-07
alleles O 0 6.58682438370306e-07
could O 0 1.5364712169230188e-07
prevent O 0 7.744347385596484e-07
or O 0 1.7844212152340333e-07
modify O 0 3.1840529572946252e-06
the O 0 2.3403215720918524e-07
clinical O 0 2.594582110759802e-05
manifestations O 0 5.013328973291209e-06
of O 0 1.5255498055921635e-06
BPAD B-Disease 1 0.9997591376304626
and O 0 4.2146621126448736e-06
perhaps O 0 7.152737907745177e-06
other O 0 2.8907350042572943e-06
related O 0 0.021255023777484894
affective B-Disease 1 0.9996634721755981
disorders I-Disease 1 0.999466598033905
. O 0 0.0001408468233421445

Segregation O 0 0.0160392876714468
distortion O 0 0.03522989898920059
in O 0 0.003952316008508205
myotonic B-Disease 1 0.9999573230743408
dystrophy I-Disease 1 0.9999405145645142
. O 0 0.002260443987324834

Myotonic B-Disease 1 0.9999768733978271
dystrophy I-Disease 1 0.9999841451644897
( O 0 0.01667032390832901
DM B-Disease 1 0.9999920129776001
) O 0 5.029999738326296e-05
is O 0 6.355069672281388e-06
an O 0 5.387529199651908e-06
autosomal B-Disease 1 0.6471023559570312
dominant I-Disease 0 0.1450480818748474
disease I-Disease 0 0.035608090460300446
which O 0 3.9569550835949485e-07
, O 0 7.82938229804131e-07
in O 0 1.1986048775725067e-07
the O 0 1.8367346399372764e-07
typical O 0 9.152967322734185e-06
pedigree O 0 6.450714136008173e-05
, O 0 1.2459690879040863e-07
shows O 0 9.933125255656705e-08
a O 0 1.091271286668416e-07
three O 0 2.512103947083233e-07
generation O 0 9.464545655646361e-06
anticipation O 0 4.7542122047161683e-05
cascade O 0 0.0005327758844941854
. O 0 1.015916950564133e-05

This O 0 1.555973540234845e-05
results O 0 4.390021786093712e-05
in O 0 3.3977576094912365e-05
infertility B-Disease 1 0.9998352527618408
and O 1 0.9633776545524597
congenital B-Disease 1 0.9999998807907104
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 0.9999995231628418
( O 0 0.0003748929884750396
CDM B-Disease 0 0.17847077548503876
) O 0 1.1388452776373015e-06
with O 0 2.4021514377636777e-07
the O 0 1.265134130790102e-07
disappearance O 0 1.5239867934724316e-05
of O 0 1.7288799654124887e-06
DM B-Disease 1 0.9999810457229614
in O 0 1.9080916899838485e-06
that O 0 1.9133817659167107e-06
pedigree O 0 0.0005607049097307026
. O 0 1.442024495190708e-05

The O 0 7.886268576839939e-06
concept O 0 7.049277428450296e-06
of O 0 1.5273286635419936e-06
segregation O 0 3.625505632953718e-05
distortion O 0 0.00019248850003350526
, O 0 1.6462121266158647e-06
where O 0 4.244755587023974e-07
there O 0 8.041436672101554e-08
is O 0 5.514242218396248e-08
preferential O 0 1.2740105148623115e-06
transmission O 0 1.2560639106595772e-06
of O 0 4.544491005731288e-08
the O 0 6.528631502078497e-08
larger O 0 3.386158198281919e-07
allele O 0 9.496908432993223e-07
at O 0 4.492351592944033e-07
the O 0 3.2950043760138215e-07
DM B-Disease 1 0.9997965693473816
locus O 0 3.538907549227588e-05
, O 0 4.3640142166623264e-07
has O 0 5.636713495960066e-08
been O 0 2.417864486403687e-08
put O 0 8.12442522146739e-08
forward O 0 1.01472927838131e-07
to O 0 3.937838144452144e-08
explain O 0 6.253115429899481e-07
partially O 0 5.456686835714208e-07
the O 0 3.666543335612005e-08
maintenance O 0 7.567954071419081e-06
of O 0 7.798188903507253e-07
DM B-Disease 1 0.9999728202819824
in O 0 8.423943995694572e-07
the O 0 7.871937555137265e-07
population O 0 2.7636490358418087e-06
. O 0 7.961016308399849e-06

In O 0 1.1417333553254139e-05
a O 0 4.844962859351654e-06
survey O 0 5.1864167289750185e-06
of O 0 1.7026301293299184e-06
DM B-Disease 1 0.9998694658279419
in O 0 1.8006729760600138e-06
Northern O 0 1.975188069991418e-06
Ireland O 0 1.7480738279118668e-06
, O 0 7.143740958781564e-07
59 O 0 1.2857724868808873e-05
pedigrees O 0 3.5864410165231675e-05
were O 0 2.4859057248249883e-06
ascertained O 0 7.833362178644165e-05
. O 0 1.4336151252791751e-05

Sibships O 0 0.027588998898863792
where O 0 1.688981501501985e-05
the O 0 1.1374462474122993e-06
status O 0 8.076442554738605e-07
of O 0 4.985362522802461e-08
all O 0 3.26004041539818e-08
the O 0 4.264523667529829e-08
members O 0 7.591105344317839e-08
had O 0 1.5844231882056192e-07
been O 0 1.2111892999655538e-07
identified O 0 3.165920077208284e-07
were O 0 4.5161833384099737e-08
examined O 0 2.182261141570052e-06
to O 0 3.9259440143268876e-08
determine O 0 2.5289375571446726e-07
the O 0 2.8356151204889102e-08
transmission O 0 4.0323871530745237e-07
of O 0 5.611825670825965e-08
the O 0 3.618591790655046e-07
DM B-Disease 1 0.9994840621948242
expansion O 0 4.6680606828886084e-06
from O 0 3.5423062172412756e-07
affected O 0 9.9934197805851e-07
parents O 0 3.383252931143943e-07
to O 0 2.1356396473493078e-07
their O 0 6.19199340690102e-07
offspring O 0 3.131459016003646e-05
. O 0 1.2472054550016765e-05

Where O 0 3.683106115204282e-05
the O 0 5.294165021041408e-06
transmitting O 0 0.0001849162217695266
parent O 0 5.933973807259463e-05
was O 0 2.742694050539285e-06
male O 0 6.836534794274485e-06
, O 0 3.389428911759751e-06
58 O 0 8.731761045055464e-05
. O 0 2.1702075173379853e-05

3 O 0 4.993595211999491e-05
% O 0 3.83868473363691e-06
of O 0 3.177017049438291e-07
the O 0 2.3356682277153595e-07
offspring O 0 4.287934643798508e-06
were O 0 2.148476596630644e-07
affected O 0 7.118842972886341e-07
, O 0 1.1279011857823207e-07
and O 0 6.537054986210933e-08
in O 0 3.38640937513901e-08
the O 0 4.5587984942585535e-08
case O 0 4.415994681039592e-07
of O 0 4.198472325356306e-08
a O 0 3.241418085053738e-07
female O 0 1.1846151437566732e-06
transmitting O 0 9.291049354942515e-05
parent O 0 2.2077128960518166e-05
, O 0 2.1769276372651802e-06
68 O 0 5.512716234079562e-05
. O 0 1.7004595065372996e-05

7 O 0 0.00046606286196038127
% O 0 6.518394366139546e-05
were O 0 1.3490241144609172e-05
affected O 0 4.945017644786276e-05
. O 0 2.599627259769477e-05

Studies O 0 4.874427759204991e-05
on O 0 7.226257821457693e-06
meiotic O 0 0.0013466295786201954
drive O 0 0.00014882540563121438
in O 0 6.2588887885794975e-06
DM B-Disease 1 0.9999587535858154
have O 0 4.871669716521865e-07
shown O 0 2.396922411662672e-07
increased O 0 1.8994916217707214e-07
transmission O 0 5.198739927436691e-07
of O 0 3.0673181328211285e-08
the O 0 5.5666358633743585e-08
larger O 0 5.349125444809033e-07
allele O 0 8.204652317544969e-07
at O 0 2.80985403833256e-07
the O 0 2.4717331825740985e-07
DM B-Disease 1 0.9982433319091797
locus O 0 1.2659812455240171e-05
in O 0 6.303422424025484e-07
non O 0 2.221285831183195e-05
- O 1 0.5923624038696289
DM O 1 0.9999518394470215
heterozygotes O 0 0.0007858490571379662
for O 0 7.8424909588648e-06
CTGn O 0 0.0034092271234840155
. O 0 2.313905679329764e-05

This O 0 5.894017249374883e-06
study O 0 2.805582653309102e-06
provides O 0 1.1290015891063376e-06
further O 0 3.4906156543002e-07
evidence O 0 5.811550067846838e-07
that O 0 5.379348877454504e-08
the O 0 2.8666673301813717e-07
DM B-Disease 1 0.9991990923881531
expansion O 0 6.925067737029167e-06
tends O 0 3.118200766039081e-06
to O 0 1.5467492175957887e-07
be O 0 2.1847007758424297e-07
transmitted O 0 3.6114042814006098e-06
preferentially O 0 1.9429589883657172e-05
. O 0 5.8857153817371e-06

Diagnosis O 1 0.9935799837112427
of O 0 0.000982276163995266
hemochromatosis B-Disease 1 0.999819815158844
. O 0 0.001335933688096702

If O 0 0.0017647275235503912
untreated O 1 0.9838069677352905
, O 0 0.001648453064262867
hemochromatosis B-Disease 1 0.9999966621398926
can O 0 0.00010619640670483932
cause O 0 0.008855053223669529
serious O 0 0.12362776696681976
illness O 0 0.11037595570087433
and O 0 2.48956416726287e-06
early B-Disease 0 1.6610945749562234e-05
death I-Disease 0 2.6017401978606358e-05
, O 0 1.0531111911404878e-06
but O 0 4.1260287275690644e-07
the O 0 1.5114593452381087e-06
disease O 0 0.00022093491861596704
is O 0 3.296120212326059e-07
still O 0 1.33980461214378e-06
substantially O 0 2.4562348698964342e-05
under O 0 1.653984327276703e-05
- O 1 0.9952098727226257
diagnosed O 1 0.9823134541511536
. O 0 2.6638133931555785e-05

The O 0 9.71523786574835e-06
cornerstone O 0 3.4724576835287735e-05
of O 0 1.0499333029656555e-06
screening O 0 9.073167893802747e-05
and O 0 2.162620830858941e-06
case O 0 5.5211844482983e-06
detection O 0 1.1437899047450628e-05
is O 0 8.730312117677386e-08
the O 0 5.518871759591093e-08
measurement O 0 9.684060842118924e-07
of O 0 2.282139206499778e-07
serum O 0 5.457277438836172e-05
transferrin O 0 4.968036228092387e-05
saturation O 0 6.5119688770209905e-06
and O 0 1.6969420357781928e-07
the O 0 4.05778990852923e-07
serum O 0 0.0001896559406304732
ferritin O 0 0.0005154244136065245
level O 0 6.042109362169867e-06
. O 0 7.393546184175648e-06

Once O 0 0.00022150717268232256
the O 0 1.1601897313084919e-05
diagnosis O 0 0.11053728312253952
is O 0 3.0400824471144006e-06
suspected O 0 8.031943434616551e-05
, O 0 1.4572289046554943e-06
physicians O 0 5.467904884426389e-06
must O 0 2.3546384397832298e-07
use O 0 2.839182684510888e-07
serum O 0 7.792585529386997e-05
ferritin O 0 0.00034994445741176605
levels O 0 1.1173475513714948e-06
and O 0 7.125975116650807e-07
hepatic O 0 0.06855370849370956
iron O 0 3.3299449569312856e-05
stores O 0 1.5497481626880472e-06
on O 0 3.0033959319553105e-06
liver O 0 0.12849539518356323
biopsy O 0 0.06444510817527771
specimens O 0 8.67655126057798e-06
to O 0 6.893327508805669e-07
assess O 0 0.0020056741777807474
patients O 0 8.613213140051812e-05
for O 0 1.5584777202093392e-07
the O 0 2.9868948558942066e-07
presence O 0 1.3159093441572622e-06
of O 0 2.083041636069538e-06
iron B-Disease 0 0.02463660016655922
overload I-Disease 0 0.020780067890882492
. O 0 2.0905499695800245e-05

Liver O 1 0.9992340803146362
biopsy O 1 0.9844953417778015
is O 0 3.639610667960369e-06
also O 0 1.8756279018816713e-07
used O 0 6.040796307615892e-08
to O 0 3.7020800647269425e-08
establish O 0 2.9767886644549435e-07
the O 0 8.854375010969306e-08
presence O 0 3.29003711385667e-07
or O 0 1.1848032244188289e-07
absence O 0 9.104294349526754e-07
of O 0 1.036524281516904e-06
cirrhosis B-Disease 1 0.9946473240852356
, O 0 4.4911351437804115e-07
which O 0 1.7174643573980575e-07
can O 0 1.0239160701530636e-06
affect O 0 5.7411238230997697e-05
prognosis O 1 0.8374253511428833
and O 0 4.538186658464838e-06
management O 0 7.822731276974082e-05
. O 0 1.5582396372337826e-05

A O 0 3.9747719711158425e-05
DNA O 0 0.00014714078861288726
- O 0 0.0001392467675032094
based O 0 1.194284095618059e-06
test O 0 1.1874881238327362e-06
for O 0 6.672411245745025e-08
the O 0 9.635487430159628e-08
HFE O 0 0.00040312609053216875
gene O 0 6.159436338748492e-07
is O 0 5.334077002316917e-08
commercially O 0 7.308429985641851e-07
available O 0 1.249820087423359e-07
, O 0 6.505759841957115e-08
but O 0 2.335687732113456e-08
its O 0 1.5288362575915926e-08
place O 0 7.825920533832686e-08
in O 0 6.539050190212947e-08
the O 0 3.042960941002093e-07
diagnosis O 0 0.020148035138845444
of O 0 9.807425158214755e-06
hemochromatosis B-Disease 1 0.9999914169311523
is O 0 1.973915232156287e-06
still O 0 1.6529689901290112e-06
being O 0 2.388994971624925e-06
evaluated O 0 3.893886969308369e-05
. O 0 1.0516627298784442e-05

Currently O 0 3.410264616832137e-05
, O 0 2.6128350327780936e-06
the O 0 1.9244131976847711e-07
most O 0 1.047691355893221e-07
useful O 0 2.2175603930918442e-07
role O 0 1.508792024651484e-07
for O 0 4.928521590841228e-08
this O 0 3.588356989325803e-08
test O 0 1.386175995321537e-06
is O 0 5.498047883634172e-08
in O 0 4.252461849318934e-08
the O 0 5.7331501324142664e-08
detection O 0 5.627401151286904e-06
of O 0 8.320341748913052e-07
hemochromatosis B-Disease 1 0.9998821020126343
in O 0 2.716900553423329e-07
the O 0 1.270936280661772e-07
family O 0 1.2902826256322442e-06
members O 0 1.633362529673832e-07
of O 0 6.569816832779907e-07
patients O 0 0.00046707550063729286
with O 0 5.977489649922063e-07
a O 0 3.815937816398218e-06
proven O 0 9.5728064479772e-05
case O 0 3.2178761557588587e-06
of O 0 7.023899115665699e-07
the O 0 1.9876080841640942e-05
disease O 0 0.006102303043007851
. O 0 1.7282574845012277e-05

It O 0 2.282329478475731e-05
is O 0 7.879458280513063e-06
crucial O 0 4.588315641740337e-05
to O 0 4.9614085583016276e-05
diagnose O 1 0.9999309778213501
hemochromatosis B-Disease 1 0.9999964237213135
before O 0 0.37046098709106445
hepatic B-Disease 1 0.9999948740005493
cirrhosis I-Disease 1 0.9999814033508301
develops O 0 0.017664657905697823
because O 0 2.3735890863463283e-05
phlebotomy O 1 0.8708121180534363
therapy O 0 0.002716907300055027
can O 0 1.1289992471574806e-05
avert O 1 0.9708036184310913
serious O 1 0.999887228012085
chronic O 1 0.9999995231628418
disease O 1 0.9248180389404297
and O 0 3.933630523533793e-06
can O 0 1.3384113799475017e-06
even O 0 7.566248427792743e-07
lead O 0 7.844815854696208e-07
to O 0 3.340413741170778e-07
normal O 0 2.9020684451097623e-06
life O 0 7.45244369682041e-06
expectancy O 0 0.00010755880066426471
. O 0 3.4923746170534287e-06
. O 0 1.4073771126277279e-05

Prevalence O 0 0.004730880726128817
of O 0 6.941160791029688e-06
the O 0 2.7659111765387934e-06
I1307K O 0 0.0004815982829313725
APC B-Disease 0 0.00013743089220952243
gene O 0 9.26407392398687e-06
variant O 0 4.1069474718824495e-06
in O 0 2.1087103618810943e-07
Israeli O 0 1.6889159724087222e-06
Jews O 0 7.605741529914667e-07
of O 0 1.577230648308614e-07
differing O 0 9.447000479667622e-07
ethnic O 0 4.7429642791030346e-07
origin O 0 3.279730265148828e-07
and O 0 5.586574843619019e-06
risk O 0 0.025061393156647682
for O 0 0.2007334679365158
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999934434890747
. O 0 0.0003475520061329007

BACKGROUND O 0 0.00032676206319592893
& O 0 0.00013304459571372718
AIMS O 0 2.2795626136939973e-05
Israeli O 0 6.307051080511883e-06
Jews O 0 1.7975879700316e-06
of O 0 1.895338783697298e-07
European O 0 1.1674155757646076e-06
birth O 0 1.8511560483602807e-05
, O 0 6.217200052560656e-07
i O 0 1.6962994777713902e-06
. O 0 1.565859690799698e-07
e O 0 6.6197676460433286e-06
. O 0 5.6696862316130137e-08
, O 0 1.5246406803726131e-07
Ashkenazim O 0 2.977845178975258e-05
, O 0 1.2257913795110653e-07
have O 0 8.347652169504727e-08
the O 0 2.385923380643362e-06
highest O 1 0.9946290850639343
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999996423721313
incidence O 0 0.16488116979599
of O 0 4.075890274179983e-07
any O 0 8.132407174343825e-07
Israeli O 0 1.0903462680289522e-05
ethnic O 0 4.67581776320003e-06
group O 0 1.4281103176472243e-05
. O 0 1.1055346476496197e-05

The O 0 3.3855023502837867e-05
I1307K O 0 0.0016443461645394564
APC B-Disease 0 0.0005227962974458933
gene O 0 3.8108337321318686e-05
variant O 0 2.4483400920871645e-05
was O 0 2.101397967635421e-06
found O 0 1.0884125458687777e-06
in O 0 5.089365231469856e-07
6 O 0 1.195275763166137e-05
. O 0 1.2367660019663163e-05

1 O 0 2.9374443329288624e-05
% O 0 2.5038646072061965e-06
of O 0 2.660283371369587e-07
American O 0 3.577860070436145e-07
Jews O 0 1.4627120208388078e-06
, O 0 2.6764246285893023e-07
28 O 0 5.461888008539972e-07
% O 0 6.312060207847026e-08
of O 0 1.0436684760861681e-07
their O 0 4.337575228419155e-05
familial O 1 0.9999978542327881
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
cases O 0 0.0008122887811623514
, O 0 2.1294335965649225e-06
but O 0 1.65980907240737e-07
not O 0 5.520103485423533e-08
in O 0 1.1750808681654235e-07
non O 0 6.215544544829754e-06
- O 0 0.013304850086569786
Jews O 0 3.8837701140437275e-05
. O 0 9.825352208281402e-06

We O 0 2.0610759747796692e-05
assessed O 0 4.206485391478054e-05
the O 0 1.776452222657099e-06
I1307K O 0 0.0025123069062829018
prevalence O 0 0.0003641291114035994
in O 0 4.499189856232988e-07
Israeli O 0 3.218928895876161e-06
Jews O 0 6.934438374628371e-07
of O 0 8.241685378607144e-08
differing O 0 4.951484129378514e-07
ethnic O 0 3.109317106009257e-07
origin O 0 3.4739048260234995e-07
and O 0 4.195241217530565e-06
risk O 0 0.004568977747112513
for O 0 0.1376972496509552
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999955892562866
. O 0 0.0004119827353861183

METHODS O 0 0.00013178210065234452
DNA O 0 0.000170040424563922
samples O 0 1.0015259249485098e-05
from O 0 7.623518740729196e-07
500 O 0 1.5656357845728053e-06
unrelated O 0 3.024876605195459e-06
Jews O 0 5.808846026411629e-07
of O 0 4.50200126067557e-08
European O 0 1.6623262411030737e-07
or O 0 2.242006331698576e-07
non O 0 2.38171310229518e-06
- O 0 0.00018377335800323635
European O 0 3.0335786505020224e-07
origin O 0 1.2733019616462116e-07
, O 0 1.5378945761312934e-07
with O 0 9.664440625556381e-08
or O 0 1.2100174728857382e-07
without O 0 8.843825582971476e-08
a O 0 1.8356384146045457e-07
personal O 0 4.866320068686036e-06
and O 0 2.0760626284754835e-06
/ O 0 0.000521915324497968
or O 0 4.853278596783639e-07
family O 0 4.5355719180406595e-07
history O 0 1.6769513422332238e-07
of O 0 4.93157301661995e-07
neoplasia B-Disease 1 0.8713224530220032
, O 0 6.101276994741056e-07
were O 0 1.5049364776587026e-07
examined O 0 4.759262537845643e-06
for O 0 7.428309345414164e-08
the O 0 1.18938380921918e-07
I1307K O 0 5.1342231017770246e-05
variant O 0 8.576012646699382e-07
by O 0 4.744959269942228e-08
the O 0 4.094906813634225e-08
allele O 0 9.219637036039785e-07
- O 0 8.999686542665586e-06
specific O 0 3.667397265871841e-07
oligonucleotide O 0 9.777813829714432e-05
( O 0 1.3564124401455047e-06
ASO O 0 0.0005203855689615011
) O 0 8.061205676312966e-07
method O 0 3.216630375391105e-06
. O 0 4.894179710390745e-06

RESULTS O 0 0.00019221613183617592
In O 0 4.642346993932733e-06
persons O 0 2.0994730220991187e-06
at O 0 2.660016889421968e-06
average O 0 2.855873572116252e-05
risk O 0 0.0008733792928978801
for O 0 0.017750918865203857
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999991655349731
, O 0 4.4718286517309025e-05
I1307K O 0 0.014161855913698673
was O 0 3.2196962820307817e-06
found O 0 1.4239623169487459e-06
in O 0 8.917718332668301e-07
5 O 0 9.687648343970068e-06
. O 0 1.0487181498319842e-05

0 O 0 5.9291603974998e-05
% O 0 1.8403078456685762e-06
of O 0 2.0457140692542453e-07
120 O 0 9.96070866676746e-07
European O 0 4.0698930092730734e-07
and O 0 4.351454947482125e-07
1 O 0 4.108420853299322e-06
. O 0 5.934191449341597e-06

6 O 0 6.993002898525447e-05
% O 0 2.2867914140078938e-06
of O 0 3.2222078516497277e-07
188 O 0 4.799001544597559e-06
non O 0 4.184129466011655e-06
- O 0 5.87140311836265e-05
European O 0 5.885681844119972e-07
Jews O 0 2.7888650038221385e-06
( O 0 7.918386586425186e-07
P O 0 0.0007331251981668174
= O 0 4.8385868467448745e-06
0 O 0 1.0203395959251793e-06
. O 0 2.6826805310520285e-07
08 O 0 3.255018782510888e-06
) O 0 6.924043987055484e-07
. O 0 3.419489758016425e-06

It O 0 4.60356823168695e-05
occurred O 0 7.111373270163313e-05
in O 0 4.798630470759235e-06
15 O 0 1.3334259165276308e-05
. O 0 1.5203997463686392e-05

4 O 0 5.684358984581195e-05
% O 0 3.5056589240411995e-06
of O 0 6.705658393002523e-07
52 O 0 1.4218918295227922e-05
Ashkenazi O 0 0.00014069126336835325
Israelis O 0 3.51938433595933e-05
with O 0 3.244382605771534e-05
familial O 1 0.9995294809341431
cancer B-Disease 1 0.99861741065979
( O 0 7.15344731361256e-06
P O 0 0.33085715770721436
= O 0 1.0891937563428655e-05
0 O 0 4.482021154217364e-07
. O 0 8.127710771077545e-08
02 O 0 4.410856945469277e-06
) O 0 2.5778222223493685e-08
and O 0 2.4080064164877513e-08
was O 0 5.94201878811873e-08
not O 0 2.6836213251613117e-08
detected O 0 3.907175596395973e-07
in O 0 3.602277587333447e-08
51 O 0 1.1565975910343695e-06
non O 0 5.888090299777105e-07
- O 0 1.3261479580251034e-05
European O 0 1.5415524501349864e-07
Jews O 0 9.099798035094864e-07
at O 0 3.169456249452196e-06
increased O 0 7.640600233571604e-05
cancer B-Disease 1 0.9084330797195435
risk O 0 0.00021178375754971057
. O 0 1.9845343558699824e-05

Colorectal B-Disease 1 0.9999370574951172
neoplasia I-Disease 1 0.998978853225708
occurred O 0 0.0010884678922593594
personally O 0 0.0006375453085638583
or O 0 2.535515932322596e-06
in O 0 2.550474107465561e-07
the O 0 9.620814722666182e-08
families O 0 1.0244410475479526e-07
of O 0 2.2683169120796265e-08
13 O 0 1.0692195218098277e-07
of O 0 3.810864512843182e-08
20 O 0 4.3482899059199553e-07
Ashkenazi O 0 2.467814920237288e-05
I1307K O 0 0.00011309355613775551
carriers O 0 2.6762154448078945e-06
, O 0 9.44908435940306e-08
8 O 0 2.1233225311334536e-07
of O 0 6.195276824882967e-08
whom O 0 2.2052054191590287e-06
also O 0 1.0292414032164743e-07
had O 0 1.133179878820556e-07
a O 0 1.7503013793884747e-07
personal O 0 3.078647296206327e-06
or O 0 5.718302418245003e-07
family O 0 9.298914847022388e-07
history O 0 1.021975663206831e-06
of O 0 5.171521479496732e-06
noncolonic O 1 0.926937460899353
neoplasia B-Disease 1 0.9901851415634155
. O 0 6.529766687890515e-05

CONCLUSIONS O 0 0.00048403197433799505
The O 0 1.836965930124279e-05
I1307K O 0 0.0029776785522699356
APC O 0 0.0012010008795186877
variant O 0 5.5937278375495225e-05
may O 0 2.235644387837965e-06
represent O 0 5.781201934951241e-07
a O 0 7.350249688897748e-07
susceptibility O 0 0.0001420599437551573
gene O 0 1.0960478903143667e-05
for O 0 4.250904748914763e-05
colorectal B-Disease 1 0.9999992847442627
, I-Disease 0 6.49809726382955e-06
or I-Disease 0 4.5705260731665476e-07
other I-Disease 0 1.0036038133875991e-07
, I-Disease 0 3.3404244277335238e-06
cancers I-Disease 0 0.1981881558895111
in O 0 4.870823886449216e-07
Ashkenazi O 0 0.00020427597337402403
Jews O 0 2.923549345723586e-06
, O 0 2.6086496518473723e-07
and O 0 1.3562375045239605e-07
partially O 0 1.6486065987919574e-06
explains O 0 4.2393952526253997e-07
the O 0 1.1434985225378114e-07
higher O 0 9.327975021733437e-06
incidence O 0 0.024649333208799362
of O 0 0.01127189677208662
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999947547912598
in O 0 4.27101758759818e-06
European O 0 8.769279702391941e-06
Israelis O 0 0.00014060032845009118
. O 0 2.983746526297182e-05

Systematic O 0 0.00013152012252248824
analysis O 0 1.7940761608770117e-05
of O 0 8.751669156481512e-06
coproporphyrinogen O 0 0.06529618799686432
oxidase O 0 0.024239346385002136
gene O 0 0.0005646946374326944
defects O 0 0.4763951897621155
in O 0 5.193752258492168e-06
hereditary B-Disease 0 0.24757139384746552
coproporphyria I-Disease 1 0.5554385781288147
and O 0 1.1000491213053465e-05
mutation O 0 7.034390000626445e-05
update O 0 7.430709956679493e-05
. O 0 2.275683254993055e-05

Hereditary B-Disease 1 0.9775198101997375
coproporphyria I-Disease 1 0.8673225045204163
( O 0 0.00012924143811687827
HC B-Disease 1 0.9982325434684753
) O 0 5.191959644434974e-06
is O 0 3.957063654524973e-06
an O 0 2.4053470042417757e-05
acute O 1 0.9997450709342957
hepatic B-Disease 1 0.9999910593032837
porphyria I-Disease 1 0.9999606609344482
with O 0 0.002325539942830801
autosomal O 1 0.7552638053894043
dominant O 0 0.0020493175834417343
inheritance O 0 0.022043753415346146
caused O 0 9.480898006586358e-05
by O 0 2.272978235851042e-06
deficient B-Disease 0 0.0007907365798018873
activity I-Disease 0 1.237443484569667e-06
of I-Disease 0 5.943072096670221e-07
coproporphyrinogen I-Disease 0 0.07559142261743546
III I-Disease 0 0.43986836075782776
oxidase I-Disease 0 0.0014740454498678446
( O 0 2.8536910576804075e-06
CPO O 0 0.00010468623804626986
) O 0 3.2450077469547978e-06
. O 0 5.112143753649434e-06

Clinical O 0 0.06569410860538483
manifestations O 0 0.000525455572642386
of O 0 6.7019082052866e-06
the O 0 5.46702831343282e-05
disease O 0 0.15493395924568176
are O 0 1.1894987892446807e-06
characterized O 0 0.0002978809061460197
by O 0 1.2999427781323902e-05
acute O 0 0.1565188318490982
attacks O 0 3.472841490292922e-05
of O 0 6.936251884326339e-05
neurological B-Disease 1 0.9999843835830688
dysfunction I-Disease 1 0.9911435842514038
often O 0 4.644698492484167e-06
precipitated O 0 0.0007375929853878915
by O 0 8.50185983836127e-07
drugs O 0 1.134503872890491e-05
, O 0 2.382982700055436e-07
fasting O 0 2.245623591079493e-06
, O 0 4.647989726436208e-07
cyclical O 0 0.003880850737914443
hormonal O 0 0.0005345440586097538
changes O 0 2.331465339011629e-06
, O 0 7.06973787600873e-06
or O 0 0.00021610903786495328
infectious B-Disease 1 0.8589251041412354
diseases I-Disease 1 0.6093478798866272
. O 0 3.644154276116751e-05

Skin O 1 0.9992827773094177
photosensitivity O 1 0.9993815422058105
may O 0 0.000375027593690902
also O 0 3.7495474316529e-06
be O 0 1.7422321434423793e-06
present O 0 1.091989270207705e-05
. O 0 2.5606432245695032e-05

The O 0 1.534263174107764e-05
seven O 0 5.882819550606655e-06
exons O 0 1.6910767953959294e-05
, O 0 5.951455364083813e-07
the O 0 1.8981299376719107e-07
exon O 0 1.3781032976112328e-05
/ O 0 2.5226188881788403e-05
intron O 0 0.00014167034532874823
boundaries O 0 4.565860081129358e-07
and O 0 7.197717621920674e-08
part O 0 7.385840916640518e-08
of O 0 4.0657067046367956e-08
3 O 0 5.105271156935487e-07
noncoding O 0 1.9398949007154442e-05
sequence O 0 1.4745297960416792e-07
of O 0 2.464640402877194e-08
the O 0 3.643913260020781e-08
CPO O 0 5.671076905855443e-06
gene O 0 4.629273178125004e-07
were O 0 7.655226141878302e-08
systematically O 0 1.2101979791623307e-06
analyzed O 0 7.6359032163964e-07
by O 0 7.85424347782282e-08
an O 0 6.374842342893317e-08
exon O 0 1.4564519005944021e-05
- O 0 2.425900129310321e-05
by O 0 3.8127151924527425e-07
- O 0 5.845960549777374e-05
exon O 0 7.174447819124907e-05
denaturing O 0 0.0009510747040621936
gradient O 0 0.0002647341461852193
gel O 0 0.002106299391016364
electrophoresis O 0 0.00022152300516609102
( O 0 3.110806119366316e-07
DGGE O 0 0.00011824460671050474
) O 0 1.184258735520416e-07
strategy O 0 5.294672291711322e-07
followed O 0 1.0686446216823242e-07
by O 0 2.8601947477113754e-08
direct O 0 5.03976238519499e-08
sequencing O 0 7.28222858015215e-07
in O 0 1.0159764229911161e-07
seven O 0 3.028493722467829e-07
unrelated O 0 1.5085463928699028e-05
heterozygous O 0 4.7979672672227025e-05
HC B-Disease 1 0.9998912811279297
patients O 0 0.009401222690939903
from O 0 7.566031854366884e-07
France O 0 7.87706085247919e-06
, O 0 1.868634058155294e-06
Holland O 0 0.00020311145635787398
, O 0 1.4248236084313248e-06
and O 0 1.723847390167066e-06
Czech O 0 5.432618490885943e-05
Republic O 0 6.730518634867622e-06
. O 0 1.1438182809797581e-05

Seven O 0 8.692142728250474e-05
novel O 0 4.823134440812282e-05
mutations O 0 3.204497625119984e-05
and O 0 8.167242526724294e-07
two O 0 3.9462562995140615e-07
new O 0 2.0754373508680146e-06
polymorphisms O 0 0.0001814296847442165
were O 0 2.585802803878323e-06
detected O 0 3.931651735911146e-05
. O 0 1.0473898328200448e-05

Among O 0 9.027694613905624e-05
these O 0 5.816834345750976e-06
mutations O 0 1.7273032426601276e-05
two O 0 6.283597713263589e-07
are O 0 3.8064371210566605e-07
missense O 0 4.691670983447693e-05
( O 0 8.60124771406845e-07
G197W O 0 0.00012536943540908396
, O 0 6.097914706515439e-07
W427R O 0 6.484462937805802e-05
) O 0 1.157712787858145e-07
, O 0 4.4717829439377965e-08
two O 0 2.7832847138142824e-08
are O 0 3.4872940091190685e-08
nonsense O 0 5.2842988225165755e-06
( O 0 1.5222870786146814e-07
Q306X O 0 1.937894194270484e-05
, O 0 2.653819137776736e-07
Q385X O 0 1.8446849935571663e-05
) O 0 4.180325419156361e-08
, O 0 3.5985284085882085e-08
two O 0 1.1772453234470959e-08
are O 0 2.311987934433546e-08
small O 0 2.1806665984058782e-07
deletions O 0 3.1728554859000724e-06
( O 0 2.0184612026241666e-07
662de14bp O 0 2.9091541364323348e-05
; O 0 2.8141127472736116e-07
1168del3bp O 0 2.889818097173702e-05
removing O 0 1.425647269570618e-06
a O 0 1.5824480215087533e-07
glycine O 0 1.3477470929501578e-05
at O 0 3.219115001229511e-07
position O 0 1.0484209411742995e-07
390 O 0 6.652668957940477e-07
) O 0 3.1116897503125074e-08
, O 0 2.9191168593456496e-08
and O 0 2.0402678657660545e-08
one O 0 1.3335001547432057e-08
is O 0 1.9643344728592638e-08
a O 0 7.420634062782483e-08
splicing O 0 2.0248344299034216e-06
mutation O 0 1.1440869229772943e-06
( O 0 9.604295314602496e-08
IVS1 O 0 0.00013388364459387958
- O 0 9.059274452738464e-05
15c O 0 0.00011037315562134609
- O 0 0.00027758520445786417
- O 0 0.002970946254208684
> O 0 0.00011239849118283018
g O 0 1.7631675291340798e-05
) O 0 5.570608152538625e-08
which O 0 3.4352396482972836e-08
creates O 0 2.609279192711256e-07
a O 0 1.0305969055934838e-07
new O 0 4.40862237383044e-07
acceptor O 0 2.657898403413128e-05
splice O 0 6.45825348328799e-05
site O 0 1.781037099135574e-05
. O 0 1.249504475708818e-05

The O 0 1.7834607206168585e-05
pathological O 0 0.0004818554443772882
significance O 0 3.856333478324814e-06
of O 0 3.812333488895092e-07
the O 0 2.6039768385999196e-07
point O 0 1.895996433631808e-06
mutations O 0 3.922111773135839e-06
G197W O 0 6.071222014725208e-05
, O 0 3.9090988934731286e-07
W427R O 0 0.0001232349022757262
, O 0 1.297675424893896e-07
and O 0 3.6858466501143994e-08
the O 0 1.9736141609882907e-08
in O 0 8.262430384320396e-08
- O 0 9.007383050629869e-05
frame O 0 3.1726489396533e-05
deletion O 0 2.8625951017602347e-05
390delGly O 0 0.00016952773148659617
were O 0 2.0351517093786242e-07
assessed O 0 1.4696333892061375e-06
by O 0 3.480629118257639e-08
their O 0 2.2757836504183615e-08
respective O 0 5.0927638994835434e-08
expression O 0 6.808114250134167e-08
in O 0 2.443809776764283e-08
a O 0 9.839371273301367e-08
prokaryotic O 0 2.097963943015202e-06
system O 0 4.0099340026245045e-07
using O 0 5.063880053057801e-07
site O 0 4.387401077110553e-06
- O 0 4.270664067007601e-05
directed O 0 1.1438204637670424e-05
mutagenesis O 0 0.000313952739816159
. O 0 1.5809677279321477e-05

These O 0 4.615841680788435e-05
mutations O 0 0.00011626051855273545
resulted O 0 1.8873566659749486e-05
in O 0 1.0331215207770583e-06
the O 0 5.239244273980148e-07
absence O 0 9.060829142981675e-06
or O 0 1.0233663942926796e-06
a O 0 6.496013611467788e-07
dramatic O 0 1.534709554107394e-05
decrease O 0 1.1474347047624178e-05
of O 0 1.106726699617866e-06
CPO O 0 0.00039211128023453057
activity O 0 2.4455421225866303e-05
. O 0 1.0460132216394413e-05

The O 0 1.0533038221183233e-05
two O 0 2.690494738999405e-06
polymorphisms O 0 3.471530362730846e-05
were O 0 4.136070970162109e-07
localized O 0 4.899022314930335e-06
in O 0 1.3233277229574014e-07
noncoding O 0 5.6887402024585754e-05
part O 0 9.860168859177065e-08
of O 0 2.041229052451854e-08
the O 0 2.2102502938992075e-08
gene O 0 1.9902135761640238e-07
1 O 0 8.406868090560238e-08
) O 0 2.4672932141811543e-08
a O 0 9.182609517210949e-08
C O 0 0.0001859140320448205
/ O 0 5.9787664213217795e-05
G O 0 6.922829925315455e-05
polymorphism O 0 3.1992049116524868e-06
in O 0 6.816937769826836e-08
the O 0 5.954305493105494e-08
promotor O 0 6.281601963564754e-05
region O 0 3.034278677205293e-07
, O 0 5.992404084054215e-08
142 O 0 4.7478746978413255e-07
bp O 0 3.0613293802161934e-06
upstream O 0 2.715931657348847e-07
from O 0 3.189110486800928e-08
the O 0 1.6163877347707967e-08
transcriptional O 0 5.356839096748445e-07
initiation O 0 6.70153497139836e-07
site O 0 5.537497713703488e-07
( O 0 1.2484598244100198e-07
- O 0 2.355459400860127e-05
142C O 0 0.00011265280772931874
/ O 0 1.885399251477793e-05
G O 0 2.9288681616890244e-05
) O 0 3.869614317864034e-08
, O 0 4.058269098550227e-08
and O 0 2.59447485717601e-08
2 O 0 1.2218033873523382e-07
) O 0 1.005799532549645e-08
a O 0 1.8239791899077318e-08
6 O 0 2.7317540229887527e-07
bp O 0 7.800690582371317e-06
deletion O 0 3.2916702821239596e-06
polymorphism O 0 2.6984396299667424e-06
in O 0 2.948730859486659e-08
the O 0 1.7998775803107492e-08
3 O 0 1.700045686447993e-07
noncoding O 0 1.643409086682368e-05
part O 0 6.042512978865489e-08
of O 0 1.3251483466092395e-08
the O 0 3.12633616772473e-08
CPO O 0 5.1428287406452e-06
gene O 0 3.8750064845771703e-07
, O 0 7.718755057339877e-08
574 O 0 1.4635869547419134e-06
bp O 0 2.4406156171608018e-06
downstream O 0 3.647630535397184e-07
of O 0 3.275122750778792e-08
the O 0 2.7301696903236916e-08
last O 0 1.0839960395969683e-07
base O 0 1.7367035809456866e-07
of O 0 2.064120963041205e-08
the O 0 4.6910386686249694e-08
normal O 0 4.2250505316587805e-07
termination O 0 4.848725438932888e-06
codon O 0 1.7813024442148162e-06
( O 0 5.170931558495795e-07
+ O 0 1.0054236554424278e-05
574 O 0 2.0325815057731234e-05
delATTCTT O 0 6.125416257418692e-05
) O 0 2.588307097539655e-06
. O 0 4.672822342399741e-06

Five O 0 5.710884215659462e-05
intragenic O 0 0.003457695711404085
dimorphisms O 0 0.004094661679118872
are O 0 1.0743235634436132e-06
now O 0 4.799124440069136e-07
well O 0 2.7891019271919504e-07
characterized O 0 4.7553603508276865e-06
and O 0 1.623504175540802e-07
the O 0 1.1926049126032012e-07
high O 0 3.2161610761249904e-06
degree O 0 4.5607509946421487e-07
of O 0 1.907781097543193e-07
allelic O 0 0.00013144576223567128
heterogeneity O 0 0.00017136667156592011
in O 0 2.7106420930067543e-06
HC B-Disease 1 0.9852373003959656
is O 0 1.056299765878066e-06
demonstrated O 0 2.402154223091202e-06
with O 0 8.915755955740678e-08
seven O 0 9.90497355246589e-08
new O 0 9.210710771867525e-08
different O 0 5.511687106718455e-08
mutations O 0 4.468658403311565e-07
making O 0 1.0096460556496822e-07
a O 0 6.044703582119837e-08
total O 0 5.3934549271161814e-08
of O 0 6.16855828639018e-08
nineteen O 0 4.04521961172577e-06
CPO O 0 0.0011530789779499173
gene B-Disease 0 0.00018608606478665024
defects I-Disease 0 0.3234884440898895
reported O 0 7.882433237682562e-06
so O 0 8.832200819597347e-07
far O 0 2.2738499865226913e-06
. O 0 1.0990087275786209e-06
. O 0 8.75030855240766e-06

Coincidence O 0 0.0001721639564493671
of O 0 3.804509788096766e-06
two O 0 1.2685691217484418e-06
novel O 0 6.726656010869192e-06
arylsulfatase O 0 0.0009756200015544891
A O 0 2.6530574359640013e-06
alleles O 0 3.3479861940577393e-06
and O 0 1.083410552382702e-06
mutation O 0 1.263221838598838e-05
459 O 0 0.00018277362687513232
+ O 0 0.0008098863763734698
1G O 0 0.06000089272856712
> O 0 0.00013404549099504948
A O 0 6.585310075024609e-07
within O 0 2.1707568009787792e-07
a O 0 4.3852324438375945e-07
family O 0 4.771078238263726e-06
with O 0 1.7317004676442593e-05
metachromatic B-Disease 1 0.9999754428863525
leukodystrophy I-Disease 1 0.9999550580978394
: O 0 2.1373602976382244e-06
molecular O 0 3.947346613131231e-06
basis O 0 5.89883654811274e-07
of O 0 9.475720048612857e-07
phenotypic O 0 0.0001836629817262292
heterogeneity O 0 0.0024528203066438437
. O 0 5.2943749324185774e-05

In O 0 2.6410452846903354e-05
a O 0 6.917251994309481e-06
family O 0 5.359784609026974e-06
with O 0 4.625182441486686e-07
three O 0 6.73087697578012e-07
siblings O 0 6.611579010495916e-05
, O 0 2.896417754527647e-07
one O 0 6.805426977507523e-08
developed O 0 6.253980586734542e-07
classical O 0 1.967932348634349e-06
late O 0 0.00017883279360830784
infantile O 1 0.9916685819625854
metachromatic B-Disease 1 0.9999662637710571
leukodystrophy I-Disease 1 0.9999674558639526
( O 0 2.1457344701047987e-05
MLD B-Disease 1 0.9980804920196533
) O 0 1.796525339159416e-06
, O 0 1.6746561186664621e-06
fatal O 0 0.0001676509709795937
at O 0 1.262852492800448e-06
age O 0 7.252717182382185e-07
5 O 0 3.1561378932565276e-07
years O 0 3.705376059315313e-07
, O 0 1.960337527862066e-07
with O 0 6.721069212289876e-07
deficient O 0 0.0010969458380714059
arylsulfatase O 0 0.000528504082467407
A O 0 1.0896047797359643e-06
( O 0 5.661937620971003e-07
ARSA O 0 0.0050134421326220036
) O 0 1.1381717968106386e-07
activity O 0 2.1683443662823265e-07
and O 0 1.2288650452774164e-07
increased O 0 1.1466320302133681e-06
galactosylsulfatide O 0 0.0011170374928042293
( O 0 2.7492174012877513e-06
GS O 1 0.6507711410522461
) O 0 3.1867716643319e-06
excretion O 0 4.6083205234026536e-05
. O 0 1.320582305197604e-05

The O 0 6.049045168765588e-06
two O 0 1.5420905583596323e-06
other O 0 7.1801048306952e-07
siblings O 0 5.130748468218371e-05
, O 0 1.020845729726716e-06
apparently O 0 4.504021035245387e-06
healthy O 0 1.696085973890149e-06
at O 0 2.7746986575039045e-07
12 O 0 9.398899436519059e-08
( O 0 2.584695302232376e-08
1 O 0 9.459597549721366e-08
/ O 0 2.7042001420340966e-06
2 O 0 8.743644031028452e-08
) O 0 1.2517521241761642e-08
and O 0 1.548593608902138e-08
15 O 0 5.559961380185996e-08
years O 0 9.445552962006332e-08
, O 0 4.685512422497595e-08
respectively O 0 1.6346996289939852e-07
, O 0 5.504018218971396e-08
and O 0 3.450731256293693e-08
their O 0 3.86976921618043e-08
father O 0 2.7708379093382973e-06
, O 0 2.905342455505888e-07
apparently O 0 9.726109055918641e-07
healthy O 0 1.1529193670867244e-06
as O 0 3.3499006235615525e-08
well O 0 7.2188356625702e-08
, O 0 9.076806151142591e-08
presented O 0 2.0606730686267838e-06
ARSA O 0 0.3887493312358856
and O 0 1.1168469882250065e-06
GS O 1 0.5184587240219116
values O 0 4.0673478451935807e-07
within O 0 1.0479131873353253e-07
the O 0 8.906577875222865e-08
range O 0 2.1131604626134504e-06
of O 0 6.2633666857436765e-06
MLD B-Disease 1 0.9999476671218872
patients O 0 0.01797342859208584
. O 0 2.7315212719258852e-05

Mutation O 0 0.0004959921934641898
screening O 0 0.00019777778652496636
and O 0 1.7613674572203308e-06
sequence O 0 1.363270257570548e-06
analysis O 0 1.3612383327199495e-06
disclosed O 0 9.565658729115967e-06
the O 0 1.0539265105080631e-07
involvement O 0 1.2110245961594046e-06
of O 0 6.62770034409732e-08
three O 0 1.2093056511730538e-07
different O 0 3.967489874412422e-07
ARSA O 0 0.4496850371360779
mutations O 0 3.7301558677427238e-06
being O 0 4.71464787210607e-08
the O 0 2.8309784738667076e-08
molecular O 0 6.358460495903273e-07
basis O 0 2.3558175143989502e-07
of O 0 7.306402380891086e-07
intrafamilial O 0 0.00721746077761054
phenotypic O 0 0.00020381099602673203
heterogeneity O 0 0.002402794547379017
. O 0 4.434652873896994e-05

The O 0 5.0151225877925754e-05
late O 0 0.00042026679147966206
infantile O 1 0.997831404209137
patient O 1 0.9808809757232666
inherited O 1 0.5081821084022522
from O 0 6.090468104957836e-06
his O 0 8.538573638361413e-06
mother O 0 6.428618507925421e-05
the O 0 2.0664221267452376e-07
frequent O 0 2.4368246158701368e-06
0 O 0 3.387570814084029e-06
- O 0 0.00012269413855392486
type O 0 3.1139038583205547e-06
mutation O 0 1.2368252555461368e-06
459 O 0 7.666895726288203e-06
+ O 0 2.1483718228409998e-05
1G O 0 0.00028677316731773317
> O 0 1.5678449926781468e-05
A O 0 2.737144200182229e-07
, O 0 8.864040523803851e-08
and O 0 3.807253534660049e-08
from O 0 6.186279222220037e-08
his O 0 1.8959589453970693e-07
father O 0 1.0021211664934526e-06
a O 0 1.1085894868756441e-07
novel O 0 3.8593694284827507e-07
, O 0 9.36857986744144e-08
single O 0 2.251375832429403e-07
basepair O 0 8.74737961567007e-05
microdeletion O 0 1.1283706044196151e-05
of O 0 4.904786621295898e-08
guanine O 0 1.4107307606536779e-06
at O 0 1.0625998925206659e-07
nucleotide O 0 2.5389613256265875e-07
7 O 0 9.494321062675226e-08
in O 0 3.2942622851805936e-08
exon O 0 3.4867305203079013e-06
1 O 0 5.982862489872787e-07
( O 0 1.8940613699669484e-07
7delG O 0 2.4633614884805866e-05
) O 0 7.637534622517705e-07
. O 0 2.193626869484433e-06

The O 0 2.491922896297183e-05
two O 0 8.258825801021885e-06
clinically O 0 0.006128293927758932
unaffected O 0 0.0005655058193951845
siblings O 0 5.169241921976209e-05
carried O 0 1.925997366925003e-06
the O 0 4.785920282301959e-07
maternal O 0 3.932225445169024e-05
mutation O 0 5.55786846234696e-06
459 O 0 5.21599140483886e-05
+ O 0 0.00010656016820576042
1G O 0 0.0018557512667030096
> O 0 3.581249984563328e-05
A O 0 3.4232348866680695e-07
and O 0 1.1607463079599256e-07
, O 0 8.587571187490539e-08
on O 0 6.321711509826855e-08
their O 0 6.489574388979236e-08
paternal O 0 4.131428795517422e-06
allele O 0 2.0985962692066096e-06
, O 0 1.1768618435326061e-07
a O 0 7.815389579945986e-08
novel O 0 3.635211953678663e-07
cytosine O 0 2.2438211999542546e-06
to O 0 5.978430550612757e-08
thymidine O 0 2.907420366682345e-06
transition O 0 9.168343808596546e-07
at O 0 3.446039045229554e-07
nucleotide O 0 1.9357346445758594e-06
2435 O 0 8.307083044201136e-05
in O 0 2.015548830058833e-07
exon O 0 5.803258773084963e-06
8 O 0 5.817927331008832e-07
, O 0 7.914273680853512e-08
resulting O 0 1.2682967565069703e-07
in O 0 3.796347414208867e-08
substitution O 0 1.624520251652939e-07
of O 0 9.431258973791046e-08
alanine O 0 1.608751881576609e-05
464 O 0 1.195388631458627e-05
by O 0 7.155121011237497e-07
valine O 0 0.00017350309644825757
( O 0 1.186400254482578e-06
A464V O 0 6.033896352164447e-05
) O 0 1.5952351759551675e-06
. O 0 4.523874849837739e-06

The O 0 4.673456714954227e-05
fathers O 0 0.00018293435277882963
genotype O 0 0.0004545117262750864
thus O 0 1.3278197911859024e-05
was O 0 1.2179090845165774e-05
7delG O 0 0.003031571162864566
/ O 0 0.0007954861503094435
A464V O 0 0.0014136240351945162
. O 0 2.4974038751679473e-05

Mutation O 0 0.0017285312060266733
A464V O 0 0.002326895482838154
was O 0 1.0407664376543835e-05
not O 0 6.98737324000831e-07
found O 0 6.169365178720909e-07
in O 0 2.4429854761365277e-07
18 O 0 4.282392637833254e-06
unrelated O 0 0.0015043598832562566
MLD B-Disease 1 0.9999839067459106
patients O 0 0.0581304170191288
and O 0 1.9049026604989194e-06
50 O 0 6.059241513867164e-06
controls O 0 2.3320575564866886e-05
. O 0 1.1289905160083435e-05

A464V O 0 0.0095403753221035
, O 0 2.636669341882225e-05
although O 0 2.240045205326169e-06
clearly O 0 3.0988721846370026e-06
modifying O 0 3.2726788049330935e-05
ARSA O 0 0.4593285322189331
and O 0 9.723263246996794e-06
GS O 1 0.9976255297660828
levels O 0 1.755163430061657e-05
, O 0 5.823739002153161e-07
apparently O 0 1.5087805422808742e-06
bears O 0 1.1993380439889734e-06
little O 0 3.8726864204363665e-07
significance O 0 4.68894540972542e-07
for O 0 2.898816262586479e-07
clinical O 0 6.0085167206125334e-05
manifestation O 0 2.98331979138311e-05
of O 0 3.6454534892982338e-06
MLD B-Disease 1 0.9995775818824768
, O 0 4.0736349546932615e-06
mimicking O 0 4.8610214435029775e-05
the O 0 2.578580279077869e-06
frequent O 0 4.418274329509586e-05
ARSA O 1 0.6574556231498718
pseudodeficiency O 0 0.009161043912172318
allele O 0 0.00022427176008932292
. O 0 3.0737232009414583e-05

Our O 0 3.668929639388807e-05
results O 0 2.0328607206465676e-05
demonstrate O 0 8.444522791251075e-06
that O 0 3.540151851666451e-07
in O 0 3.826794738870376e-07
certain O 0 1.0540104540268658e-06
genetic O 0 0.00011683375487336889
conditions O 0 0.0004777206340804696
MLD B-Disease 1 0.9996309280395508
- O 0 0.0737856850028038
like O 0 2.2909474864718504e-05
ARSA O 1 0.6445724964141846
and O 0 2.0232457700330997e-06
GS O 1 0.636565625667572
values O 0 8.872555099515012e-07
need O 0 2.66739419885198e-07
not O 0 3.854675156844678e-08
be O 0 4.677743703496162e-08
paralleled O 0 8.107015673886053e-06
by O 0 7.228367394418456e-06
clinical O 1 0.7641189694404602
disease O 0 0.07652854174375534
, O 0 1.2578043424582575e-06
a O 0 6.385691335708543e-07
finding O 0 1.2440694263204932e-05
with O 0 6.924387434992241e-06
serious O 0 0.0014683881308883429
diagnostic O 0 0.0879763513803482
and O 0 4.9068319640355185e-05
prognostic O 1 0.7501243948936462
implications O 0 0.0016265915473923087
. O 0 5.797991980216466e-05

Moreover O 0 0.000400473247282207
, O 0 9.010617759486195e-06
further O 0 3.90830791729968e-06
ARSA O 0 0.18040770292282104
alleles O 0 3.66021013178397e-05
functionally O 0 2.2013153284206055e-05
similar O 0 1.0535683259149664e-06
to O 0 3.4489420386307756e-07
A464V O 0 0.000470413506263867
might O 0 1.253522214028635e-06
exist O 0 1.085669936173872e-07
which O 0 2.91267649998872e-08
, O 0 4.5502151380105715e-08
together O 0 4.132214215246677e-08
with O 0 4.3711281705327565e-08
0 O 0 2.0885133835690795e-06
- O 0 0.0009702778188511729
type O 0 2.788431811495684e-05
mutations O 0 7.646172889508307e-06
, O 0 6.000524876981217e-07
may O 0 1.6170419030459016e-06
cause O 0 4.614859790308401e-06
pathological O 0 0.0001455970195820555
ARSA O 1 0.849220335483551
and O 0 6.614240191993304e-06
GS O 1 0.9967871904373169
levels O 0 4.4424809857446235e-06
, O 0 1.57273504441946e-07
but O 0 1.4480399102012598e-07
not O 0 2.661120674929407e-07
clinical O 0 7.759971776977181e-05
outbreak O 0 1.100453118851874e-05
of O 0 4.202590559998498e-07
the O 0 1.3585338820121251e-05
disease O 0 0.00794319249689579
. O 0 2.298425215485622e-06
. O 0 1.861093369370792e-05

Human O 0 0.04051920771598816
MLH1 O 1 0.9997205138206482
deficiency O 1 0.9996577501296997
predisposes O 0 0.26779237389564514
to O 0 0.0002683454367797822
hematological B-Disease 1 0.9998464584350586
malignancy I-Disease 1 0.9998260140419006
and O 0 0.0020768088288605213
neurofibromatosis B-Disease 1 0.9998782873153687
type I-Disease 0 0.0003767932066693902
1 I-Disease 0 2.7244188459008e-05
. O 0 2.7319980290485546e-05

Heterozygous O 0 0.0038603951688855886
germ O 0 0.10111091285943985
- O 0 0.008286705240607262
line O 0 4.5091954234521836e-05
mutations O 0 1.622421041247435e-05
in O 0 3.28435021401674e-07
the O 0 3.961625623105647e-07
DNA O 0 0.00014181672304403037
mismatch O 0 0.21243296563625336
repair O 0 0.1670185774564743
genes O 0 1.9945942767662928e-05
lead O 0 1.3208329619374126e-05
to O 0 2.7886684620170854e-05
hereditary B-Disease 1 0.9995902180671692
nonpolyposis I-Disease 1 0.9999943971633911
colorectal I-Disease 1 1.0
cancer I-Disease 1 0.9999954700469971
. O 0 0.0010330815566703677

The O 0 0.0002908943279180676
disease O 1 0.6997967958450317
susceptibility O 0 0.002261202549561858
of O 0 3.1412159842147958e-06
individuals O 0 1.1503128916956484e-05
who O 0 9.260522347176448e-06
constitutionally O 0 6.0172202211106196e-05
lack O 0 3.1638755899621174e-06
both O 0 4.3256324033791316e-07
wild O 0 1.309984418185195e-05
- O 0 0.013840815983712673
type O 0 5.424770279205404e-05
alleles O 0 4.417622221808415e-06
is O 0 9.555250244375202e-07
unknown O 0 7.89452315075323e-06
. O 0 1.0114853466802742e-05

We O 0 5.702052658307366e-05
have O 0 2.7293474431644427e-06
identified O 0 4.236075255903415e-06
three O 0 3.4601697507241624e-07
offspring O 0 6.878821295686066e-06
in O 0 4.787997909261321e-07
a O 0 2.14391402550973e-05
hereditary B-Disease 1 0.9996945858001709
nonpolyposis I-Disease 1 0.9999991655349731
colorectal I-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
family O 0 0.01309819146990776
who O 0 6.623228546231985e-05
developed O 0 0.0008485103608109057
hematological B-Disease 1 0.9998890161514282
malignancy I-Disease 1 0.9989131689071655
at O 0 1.1398979950172361e-05
a O 0 4.28883168979155e-07
very O 0 3.7052100765322393e-07
early O 0 7.590278414681961e-07
age O 0 1.495732021794538e-06
, O 0 1.2909605118238687e-07
and O 0 9.761590291645916e-08
at O 0 1.6939540614657744e-07
least O 0 2.4237099438551013e-08
two O 0 9.585880533791169e-09
of O 0 1.395173754303869e-08
them O 0 4.1655528804085407e-08
displayed O 0 6.167788910715899e-07
signs O 0 2.2484266537503572e-06
of O 0 1.1231273902012617e-06
neurofibromatosis B-Disease 1 0.9949032068252563
type I-Disease 0 2.7722815502784215e-05
1 I-Disease 0 3.957886292482726e-06
( O 0 2.2199712930159876e-06
NF1 B-Disease 0 0.002156245755031705
) O 0 2.702758820305462e-06
. O 0 6.2417047956842e-06

DNA O 0 0.000359635625500232
sequence O 0 1.898798655020073e-05
analysis O 0 7.294027909665601e-06
and O 0 9.863042578217573e-07
allele O 0 4.7694993554614484e-06
- O 0 4.737326889880933e-05
specific O 0 4.4166642965137726e-07
amplification O 0 1.3309434507391416e-05
in O 0 1.9406463991344935e-07
two O 0 2.8898838877466915e-07
siblings O 0 2.2497933969134465e-05
revealed O 0 6.259467681957176e-06
a O 0 1.998457719309954e-06
homozygous O 0 8.484152931487188e-05
MLH1 O 0 0.09766937047243118
mutation O 0 1.1998657100775745e-05
( O 0 8.372373372367292e-07
C676T O 0 0.00016038576723076403
- O 0 0.005295280367136002
- O 0 0.03458641469478607
> O 0 0.0006627901457250118
Arg226Stop O 0 0.0007806735811755061
) O 0 3.0396565762202954e-06
. O 0 6.053269316907972e-06

Thus O 0 0.00010973132884828374
, O 0 6.939757440704852e-06
a O 0 5.550230525841471e-06
homozygous O 0 4.445068407221697e-05
germ O 0 0.004269573837518692
- O 0 0.001934132189489901
line O 0 5.0193528295494616e-05
MLH1 O 0 0.10922058671712875
mutation O 0 1.5032946066639852e-05
and O 0 2.4883820515242405e-06
consequent O 0 0.011796338483691216
mismatch O 1 0.9999122619628906
repair O 1 0.999996542930603
deficiency O 1 0.9999545812606812
results O 0 3.1818723073229194e-05
in O 0 9.634345587983262e-07
a O 0 8.654064913571347e-06
mutator O 1 0.9749933481216431
phenotype O 0 0.00980927050113678
characterized O 0 0.0004642285348381847
by O 0 0.0001029270570143126
leukemia B-Disease 1 0.9999603033065796
and O 0 7.474223821191117e-05
/ O 1 0.9720056653022766
or O 0 0.2844735085964203
lymphoma B-Disease 1 0.9999998807907104
associated O 0 0.002840370638296008
with O 0 0.00011829174763988703
neurofibromatosis B-Disease 1 0.9998942613601685
type I-Disease 0 7.71446357248351e-05
1 I-Disease 0 4.882776920567267e-06
. O 0 1.8264792061017943e-06
. O 0 1.0409778951725457e-05

Missense O 0 0.02680051140487194
mutations O 0 0.000340760889230296
in O 0 1.821759610720619e-06
the O 0 3.208121484021831e-07
most O 0 1.1984882064552949e-07
ancient O 0 1.4885088717164763e-07
residues O 0 5.318554485711502e-07
of O 0 6.791655948745756e-08
the O 0 2.863880297354626e-07
PAX6 O 0 0.01202727947384119
paired O 0 4.448763775144471e-06
domain O 0 9.4473159606423e-07
underlie O 0 7.445226856361842e-06
a O 0 9.045314754985156e-07
spectrum O 0 2.8329794076853432e-05
of O 0 8.296243322547525e-06
human O 0 0.04410147666931152
congenital B-Disease 1 0.9999960660934448
eye I-Disease 1 0.9996390342712402
malformations I-Disease 1 0.9998201727867126
. O 0 0.00044806202640756965

Mutations O 0 0.00043349096085876226
of O 0 6.514409960800549e-06
the O 0 3.1534891604678705e-06
human O 0 1.248450280399993e-05
PAX6 O 0 0.19227127730846405
gene O 0 0.0005363840027712286
underlie O 1 0.5241917967796326
aniridia B-Disease 1 0.9999871253967285
( O 0 0.010537470690906048
congenital B-Disease 1 0.9999866485595703
absence I-Disease 0 4.5450025936588645e-05
of I-Disease 0 1.1301973472654936e-06
the I-Disease 0 4.6740124162170105e-06
iris I-Disease 1 0.9430533647537231
) O 0 8.818321930448292e-07
, O 0 5.748024136664753e-07
a O 0 1.1126667232019827e-06
rare O 0 5.412616883404553e-05
dominant O 0 0.0005704167997464538
malformation B-Disease 1 0.9859635233879089
of I-Disease 0 1.0573307918093633e-06
the I-Disease 0 3.6917963370797224e-06
eye I-Disease 0 0.0075011178851127625
. O 0 4.5694916479988024e-05

The O 0 1.2121744475734886e-05
spectrum O 0 6.372574716806412e-05
of O 0 3.933701918867882e-06
PAX6 O 1 0.5366676449775696
mutations O 0 0.00026011772570200264
in O 0 1.7555285012349486e-05
aniridia B-Disease 1 0.9999710321426392
patients O 0 0.05566589534282684
is O 0 7.657138212380232e-07
highly O 0 1.3604493460661615e-06
biased O 0 9.60192392085446e-06
, O 0 2.473928759627597e-07
with O 0 1.4698474615215673e-07
92 O 0 4.308724783186335e-06
% O 0 7.748123209694313e-08
of O 0 2.668624787816043e-08
all O 0 5.8869900954050536e-08
reported O 0 1.9248075204814086e-06
mutations O 0 1.4318155763248797e-06
leading O 0 2.7306106176183675e-07
to O 0 9.892833219282693e-08
premature O 0 1.2943154615641106e-05
truncation O 0 3.195606495864922e-06
of O 0 6.342230562950135e-08
the O 0 1.2068424837252678e-07
protein O 0 4.1199655242962763e-07
( O 0 8.888691382935576e-08
nonsense O 0 1.0866391448871582e-06
, O 0 5.0354671543573204e-08
splicing O 0 3.87971738291526e-07
, O 0 7.421808589924694e-08
insertions O 0 1.2771221236107522e-06
and O 0 9.700619330033078e-08
deletions O 0 1.8706506352828e-06
) O 0 4.625663052593154e-08
and O 0 1.9461724676261838e-08
just O 0 4.763639438465361e-08
2 O 0 1.3212319061040034e-07
% O 0 3.035609807966466e-08
leading O 0 3.171815876612527e-08
to O 0 6.6991749925193744e-09
substitution O 0 3.227694023166805e-08
of O 0 1.1425715484847387e-08
one O 0 2.658844522329673e-08
amino O 0 1.0669928229845027e-07
acid O 0 2.0612890239135595e-07
by O 0 5.6057174901980034e-08
another O 0 3.040912588403444e-07
( O 0 4.61352158254158e-07
missense O 0 2.699683500395622e-05
) O 0 1.6831131688377354e-06
. O 0 4.137903488299344e-06

The O 0 6.336635578918504e-06
extraordinary O 0 1.0246144483971875e-05
conservation O 0 2.4534997464797925e-06
of O 0 2.2798248267008603e-07
the O 0 4.167417557709996e-07
PAX6 O 0 0.0027855965308845043
protein O 0 1.9291996977699455e-06
at O 0 2.5013056870193395e-07
the O 0 5.953124215807293e-08
amino O 0 2.0512055698418408e-07
acid O 0 3.937602173209598e-07
level O 0 7.715149052955894e-08
amongst O 0 1.140729750659375e-07
vertebrates O 0 1.1646477560134372e-06
predicts O 0 2.2958705812925473e-05
that O 0 1.7282968656218145e-07
pathological O 0 0.00025228169397450984
missense O 0 0.0006726120482198894
mutations O 0 2.1187694073887542e-05
should O 0 4.3083124978693377e-07
in O 0 1.6141670755587256e-07
fact O 0 5.149519779479306e-07
be O 0 1.4618318289194576e-07
common O 0 3.055978083921218e-07
even O 0 5.751664957642788e-07
though O 0 2.8725705192300666e-07
they O 0 4.413830012595099e-08
are O 0 3.923870295352572e-08
hardly O 0 5.958508495496062e-07
ever O 0 5.370490612222056e-07
seen O 0 2.413969923509285e-06
in O 0 5.0060289140674286e-06
aniridia B-Disease 1 0.9998797178268433
patients O 0 0.017154110595583916
. O 0 2.0525358195300214e-05

This O 0 1.2047664313286077e-05
indicates O 0 1.6454416254418902e-05
that O 0 2.896798889651109e-07
there O 0 1.4525321034852823e-07
is O 0 9.81492860319122e-08
a O 0 2.669888203854498e-07
heavy O 0 8.789690036792308e-05
ascertainment O 0 0.0226910300552845
bias O 0 2.6126006559934467e-05
in O 0 9.739551387610845e-08
the O 0 2.7552589543233807e-08
selection O 0 2.2945174293909076e-07
of O 0 3.2030771990321227e-07
patients O 0 4.0474893467035145e-05
for O 0 7.448824135281029e-07
PAX6 O 0 0.48929592967033386
mutation O 0 5.375863565859618e-06
analysis O 0 9.651863592807786e-07
and O 0 2.3483771371957118e-07
that O 0 5.72268383791652e-08
the O 0 3.090329130372993e-07
missing O 0 2.1582078261417337e-05
PAX6 O 0 0.423054039478302
missense O 0 0.0032197011169046164
mutations O 0 5.421652167569846e-05
frequently O 0 5.99219174546306e-06
may O 0 5.37444384463015e-06
underlie O 0 0.00014363095397129655
phenotypes O 0 6.93037363816984e-05
distinct O 0 3.356336492288392e-06
from O 0 2.0624936496460577e-06
textbook O 0 0.00032151376944966614
aniridia B-Disease 1 0.9921616911888123
. O 0 5.729244730900973e-05

Here O 0 4.4600314140552655e-05
we O 0 3.2204793569690082e-06
present O 0 1.462076056668593e-06
four O 0 7.46790760786098e-07
novel O 0 1.0090960131492466e-05
PAX6 O 0 0.1265145093202591
missense O 0 0.0015615342417731881
mutations O 0 2.6764735594042577e-05
, O 0 6.541258699144237e-07
two O 0 9.436531200890386e-08
in O 0 2.874683389109123e-07
association O 0 1.1373485904186964e-06
with O 0 1.1038217735404032e-06
atypical O 0 0.00033413199707865715
phenotypes O 0 0.00047497174819000065
ectopia B-Disease 0 0.298491895198822
pupillae I-Disease 0 0.3950446546077728
( O 0 1.149309809989063e-06
displaced B-Disease 0 4.3571994865487795e-06
pupils I-Disease 0 3.0007474833837477e-06
) O 0 8.710300676284533e-07
and O 0 4.435507071320899e-05
congenital B-Disease 1 0.9999847412109375
nystagmus I-Disease 1 0.5220230221748352
( O 0 1.0131625458598137e-06
searching B-Disease 0 1.8934571926365606e-05
gaze I-Disease 0 3.2110256142914295e-05
) O 0 1.6791597090559662e-07
, O 0 8.530254547167715e-08
and O 0 4.697467659298127e-08
two O 0 3.370987755602073e-08
in O 0 9.668330136491932e-08
association O 0 3.134695987228042e-07
with O 0 1.9921961325053417e-07
more O 0 9.497768473920587e-07
recognizable O 0 0.00021599678439088166
aniridia B-Disease 1 0.9946278929710388
phenotypes O 0 0.0010589592857286334
. O 0 3.270345041528344e-05

Strikingly O 0 0.0014994206139817834
, O 0 6.2107328631100245e-06
all O 0 3.4181653063569684e-07
four O 0 2.8264042839509784e-07
mutations O 0 1.6805324776214547e-06
are O 0 3.407394899568317e-08
located O 0 1.1696003809902322e-07
within O 0 3.401615700227012e-08
the O 0 6.583954359484778e-08
PAX6 O 0 0.00037591971340589225
paired O 0 1.2603981076608761e-06
domain O 0 1.5445971257577185e-07
and O 0 5.855578066871203e-08
affect O 0 1.9734945055915887e-07
amino O 0 1.1948134215344908e-07
acids O 0 5.772916367163816e-08
which O 0 1.3529350972873999e-08
are O 0 6.763213988847383e-09
highly O 0 5.251670387451668e-08
conserved O 0 8.791370476046723e-08
in O 0 2.2664183418896755e-08
all O 0 3.3233686025369025e-08
known O 0 3.7793662954754836e-07
paired O 0 4.052548320032656e-06
domain O 0 2.7195703751203837e-06
proteins O 0 4.083082785655279e-06
. O 0 8.636133316031191e-06

Our O 0 4.2815765482373536e-05
results O 0 1.3494576705852523e-05
support O 0 2.523743205529172e-06
the O 0 2.9466374940056994e-07
hypothesis O 0 1.8068001281790202e-06
that O 0 4.770841144363658e-08
the O 0 4.8452314160840615e-08
under O 0 1.5064729552705103e-07
- O 0 1.0565269803919364e-05
representation O 0 2.46198652575913e-07
of O 0 1.832677156698992e-07
missense O 0 0.0002210630482295528
mutations O 0 1.0261447641823906e-05
is O 0 1.7371738181282126e-07
caused O 0 1.1471416883068741e-06
by O 0 3.252057183544821e-07
ascertainment O 0 0.03229625150561333
bias O 0 0.00010488347470527515
and O 0 9.895396715364768e-07
suggest O 0 1.843747327257006e-06
that O 0 6.227252669077643e-08
a O 0 2.91994751933089e-07
substantial O 0 3.4857496302720392e-06
burden O 0 1.5202285794657655e-05
of O 0 1.5497585081902798e-06
PAX6 B-Disease 1 0.9882900714874268
- I-Disease 1 0.9874880313873291
related I-Disease 0 0.4137515425682068
disease I-Disease 0 0.07280777394771576
remains O 0 3.868739895551698e-06
to O 0 3.3389710552000906e-07
be O 0 5.560342515309458e-07
uncovered O 0 0.00014008018479216844
. O 0 2.0863235477008857e-06
. O 0 9.359268005937338e-06

The O 0 4.1344857891090214e-05
chromosomal O 0 0.001798919402062893
order O 0 2.7412845611252123e-06
of O 0 5.550043624680256e-07
genes O 0 3.6803787679673405e-06
controlling O 0 1.2624125702132005e-05
the O 0 5.482569918058289e-07
major O 0 1.3102056072966661e-05
histocompatibility O 1 0.9338385462760925
complex O 0 2.310432682861574e-05
, O 0 5.660577357957663e-07
properdin O 0 0.00021506052871700376
factor O 0 5.040044925408438e-06
B O 0 0.00026389872073195875
, O 0 1.369404913020844e-06
and O 0 7.750495569780469e-06
deficiency B-Disease 0 0.007191547192633152
of I-Disease 0 5.318483076166558e-08
the I-Disease 0 5.9285806486286674e-08
second I-Disease 0 2.774883967049391e-07
component I-Disease 0 1.3214325917942915e-06
of I-Disease 0 2.549873556745297e-07
complement I-Disease 0 9.12741779757198e-06
. O 0 9.64016726356931e-06

The O 0 1.1754482329706661e-05
relationship O 0 9.69556003838079e-06
of O 0 4.167890779172012e-07
the O 0 3.6497635846899357e-07
genes O 0 1.3025012322032126e-06
coding O 0 9.621833669370972e-06
for O 0 4.2206690409329894e-07
HLA O 0 0.006168877240270376
to O 0 1.161561371532116e-07
those O 0 8.562464870465192e-08
coding O 0 9.276080277231813e-07
for O 0 6.377907624255386e-08
properdin O 0 2.8941063646925613e-05
Factor O 0 4.98483018418483e-07
B O 0 1.151131436927244e-05
allotypes O 0 0.0001276336406590417
and O 0 5.777591809419391e-07
for O 0 3.0482112833851716e-06
deficiency B-Disease 0 0.011052369140088558
of I-Disease 0 3.278897864333885e-08
the I-Disease 0 2.7467480734344463e-08
second I-Disease 0 1.1780566921970603e-07
component I-Disease 0 2.8265307605579437e-07
of I-Disease 0 3.392285563563746e-08
complement I-Disease 0 1.1377564987924416e-06
( O 0 2.5609890030864335e-07
C2 O 0 6.705117993988097e-05
) O 0 4.1509515824600385e-08
was O 0 3.550070815094841e-08
studied O 0 1.262501712062658e-07
in O 0 5.6947442317323294e-08
families O 0 3.484050523638871e-07
of O 0 1.090478008336504e-06
patients O 0 0.011982548981904984
with O 0 0.0003044565091840923
connective O 1 0.9999054670333862
tissue O 1 0.9998924732208252
disorders O 1 0.9989266991615295
. O 0 0.00012152738781878725

Patients O 0 0.10441004484891891
were O 0 2.6843308660318144e-06
selected O 0 2.4663813746883534e-06
because O 0 1.0240009942208417e-06
they O 0 2.598457342628535e-07
were O 0 2.909282272867131e-07
heterozygous O 0 3.8297112041618675e-06
or O 0 1.7462709820392774e-06
homozygous O 0 6.840812420705333e-05
for O 0 0.000579768093302846
C2 B-Disease 1 0.999997615814209
deficiency I-Disease 1 0.9999573230743408
. O 0 8.801533113000914e-05

12 O 0 8.24139715405181e-05
families O 0 1.497145331086358e-05
with O 0 1.3036892596574035e-06
15 O 0 2.2258202534430893e-06
matings O 0 0.0003618741757236421
informative O 0 0.0002088430628646165
for O 0 0.015224775299429893
C2 B-Disease 1 0.9999991655349731
deficiency I-Disease 1 0.9999831914901733
were O 0 4.564159098663367e-06
found O 0 9.50948287936626e-06
. O 0 8.005815288925078e-06

Of O 0 1.5272795280907303e-05
57 O 0 2.8417654903023504e-05
informative O 0 3.161476706736721e-05
meioses O 0 0.0023978082463145256
, O 0 9.900702480081236e-07
two O 0 8.909279358704225e-08
crossovers O 0 2.895055786211742e-06
were O 0 1.9102606074739015e-07
noted O 0 2.8775139071512967e-07
between O 0 3.842010301013943e-07
the O 0 1.9077779143117368e-05
C2 B-Disease 1 0.999996542930603
deficiency I-Disease 1 0.9993520379066467
gene O 0 2.0511677121248795e-06
and O 0 1.7678688379874075e-07
the O 0 2.0246149290414905e-07
HLA O 0 0.04403168708086014
- O 0 0.0008135123644024134
B O 0 3.8726269849576056e-05
gene O 0 5.130402200848039e-07
, O 0 5.682829851139104e-08
with O 0 4.089458727207784e-08
a O 0 1.1114010334267732e-07
recombinant O 0 3.1669032978243195e-06
fraction O 0 1.9380509002075996e-06
of O 0 4.4685177158498846e-07
0 O 0 1.1932609595532995e-05
. O 0 1.3679058611160144e-05

035 O 0 0.4227624535560608
. O 0 0.003787360619753599

A O 0 0.0001008272884064354
lod O 0 0.001256403629668057
score O 0 3.9101419133658055e-06
of O 0 3.399777597223874e-07
13 O 0 8.071752972682589e-07
was O 0 1.8721947014910256e-07
calculated O 0 3.4245249480591156e-07
for O 0 1.9601152700943203e-07
linkage O 0 7.701747381361201e-05
between O 0 0.00010932484292425215
C2 B-Disease 1 0.9999932050704956
deficiency I-Disease 1 0.99982750415802
and O 0 3.5462410323816584e-06
HLA O 0 0.16329103708267212
- O 0 0.008086471818387508
B O 0 4.437453389982693e-05
at O 0 1.8456721306847612e-07
a O 0 4.097907080335972e-08
maximum O 0 2.1574902575594024e-07
likelihood O 0 2.793955218294286e-07
value O 0 3.233282441783558e-08
of O 0 1.748638744913933e-08
the O 0 2.3826910222624065e-08
recombinant O 0 8.762983156884729e-07
fraction O 0 8.815152341412613e-07
of O 0 3.561750645530992e-07
0 O 0 6.63076161799836e-06
. O 0 5.106096978124697e-06

04 O 0 0.015966370701789856
. O 0 0.0013917575124651194

18 O 0 0.00011266419460298494
families O 0 1.813580274756532e-05
with O 0 1.0325718449166743e-06
21 O 0 1.8452390122547513e-06
informative O 0 4.40973008153378e-06
matings O 0 4.795292261405848e-05
for O 0 3.648962945135281e-07
both O 0 2.7979788796983485e-07
properdin O 0 8.427838474744931e-05
Factor O 0 2.6719233119365526e-06
B O 0 3.027956154255662e-05
allotype O 0 7.645103323739022e-05
and O 0 1.5256894130288856e-06
HLA O 0 0.0345783568918705
- O 0 0.0024954513646662235
B O 0 0.00012963960762135684
were O 0 6.990612178014999e-07
found O 0 2.6656698537408374e-06
. O 0 5.68335599382408e-06

Of O 0 1.6198886441998184e-05
72 O 0 3.677473068819381e-05
informative O 0 4.975067713530734e-05
meioses O 0 0.003410935401916504
, O 0 1.0167416348849656e-06
three O 0 2.9260885980875173e-07
recombinants O 0 0.00046759186079725623
were O 0 2.041786615336605e-07
found O 0 1.9102132853276999e-07
, O 0 4.460734004396727e-08
giving O 0 6.228369642258258e-08
a O 0 8.289912756254125e-08
recombinant O 0 1.7169072634715121e-06
fraction O 0 1.266235130970017e-06
of O 0 5.741362087974267e-07
0 O 0 1.1753866601793561e-05
. O 0 8.468862688459922e-06

042 O 0 0.07411990314722061
. O 0 0.0023598179686814547

A O 0 6.710222805850208e-05
lod O 0 0.0010219266405329108
score O 0 1.4052978940526373e-06
of O 0 1.806133553827749e-07
16 O 0 3.310886143026437e-07
between O 0 1.9480931712223537e-07
HLA O 0 0.0009050225489772856
- O 0 0.00010665124864317477
B O 0 1.8290507796336897e-05
and O 0 1.3004628840462829e-07
Factor O 0 4.632218519873277e-07
B O 0 4.8030074140115175e-06
allotypes O 0 2.5723620638018474e-05
was O 0 6.37744435039167e-08
calculated O 0 1.296876206424713e-07
at O 0 5.134675262752353e-08
a O 0 3.095658840379656e-08
maximum O 0 1.4919723412276653e-07
likelihood O 0 2.801564562560088e-07
value O 0 3.385731162097727e-08
of O 0 1.2503919677442354e-08
the O 0 4.123419827806174e-08
recombinant O 0 1.4202992133505177e-06
fraction O 0 1.2165113503215252e-06
of O 0 4.4909378971169645e-07
0 O 0 8.913415513234213e-06
. O 0 7.980248483363539e-06

04 O 0 0.010513844899833202
. O 0 0.0007792784599587321

A O 0 2.9315340725588612e-05
crossover O 0 6.601971836062148e-05
was O 0 4.3148274926352315e-06
shown O 0 1.0374775456511998e-06
to O 0 1.6333312657934584e-07
have O 0 7.176620187010485e-08
occurred O 0 2.14737255532782e-07
between O 0 4.5108372148661147e-08
genes O 0 9.547911616891724e-08
for O 0 3.036339535356092e-08
Factor O 0 3.0120560268187546e-07
B O 0 5.527222128876019e-06
and O 0 4.424045698669943e-07
HLA O 0 0.033953629434108734
- O 0 0.018910983577370644
D O 0 0.04324878007173538
, O 0 1.9432039266575885e-07
in O 0 9.471892781220959e-08
which O 0 2.977674569137889e-07
HLA O 0 0.02585771307349205
- O 0 0.014985368587076664
D O 0 0.21822935342788696
segregared O 0 0.00025053336867131293
with O 0 1.307069169342867e-06
HLA O 0 0.0093307513743639
- O 0 6.981982005527243e-05
A O 0 2.13384919334203e-06
and O 0 2.766512807284016e-06
B O 0 0.00023527890152763575
. O 0 8.028101547097322e-06

These O 0 1.2816957678296603e-05
studies O 0 8.633046491013374e-06
suggest O 0 3.0148485166137107e-06
that O 0 1.2555545936265844e-07
the O 0 3.3782161068529604e-08
genes O 0 1.3607225923806254e-07
for O 0 6.764867777064865e-08
Factor O 0 3.451690645306371e-06
B O 0 0.004141222219914198
and O 0 0.0005748344119638205
C2 B-Disease 1 0.9999983310699463
deficiency I-Disease 1 0.9997342228889465
are O 0 7.544597480091397e-08
located O 0 2.303087143218363e-07
outside O 0 2.0071108508545876e-07
those O 0 3.720498753523316e-08
for O 0 1.5181927892626845e-07
HLA O 0 0.2168823927640915
, O 0 3.0971770570431545e-07
that O 0 2.4018413924409288e-08
the O 0 2.1783755244086933e-08
order O 0 4.085092797367906e-08
of O 0 5.674738901007004e-08
genese O 0 8.72771634021774e-05
is O 0 3.207402698990336e-07
HLA O 0 0.0011704888893291354
- O 0 2.8226833819644526e-05
A O 0 2.5494284727756167e-07
, O 0 2.1395372584720462e-07
- O 0 8.075258665485308e-05
B O 0 2.8665015634032898e-05
, O 0 2.8976941734981665e-07
- O 0 0.0007417931919917464
D O 0 0.0030137128196656704
, O 0 1.7330205537291477e-07
Factor O 0 8.697757607478707e-07
B O 0 4.361366882221773e-05
allotype O 0 0.0655464231967926
, O 0 0.001502786297351122
C2 B-Disease 1 0.9999971389770508
deficiency I-Disease 1 0.9999611377716064
, O 0 3.740072429536667e-07
that O 0 3.2677597516794776e-08
the O 0 7.152924297315622e-08
genes O 0 1.001354917207209e-06
coding O 0 4.2991694499505684e-05
for O 0 7.456084131263196e-05
C2 B-Disease 1 0.9999948740005493
deficiency I-Disease 1 0.9996019005775452
and O 0 5.522756509890314e-07
Factor O 0 1.7240479337488068e-06
B O 0 3.0120727387838997e-05
allotypes O 0 3.8332313124556094e-05
are O 0 2.2385743037034445e-08
approximately O 0 4.214993154505464e-08
3 O 0 1.6698687943517143e-07
- O 0 1.3553374628827441e-05
- O 0 1.1730173355317675e-05
5 O 0 2.9757129027530027e-07
centimorgans O 0 6.186065547808539e-06
from O 0 2.6912076123153383e-08
the O 0 3.703654627429387e-08
HLA O 0 9.753350605024025e-05
- O 0 7.3289897954964545e-06
A O 0 1.8207263963176956e-07
and O 0 3.828086505563988e-07
HLA O 0 0.003362303599715233
- O 0 0.00026543039712123573
B O 0 3.2706760975997895e-05
loci O 0 1.1483982689242112e-06
, O 0 6.787641382288712e-08
and O 0 2.55879104571477e-08
that O 0 1.6137322589315772e-08
the O 0 5.041329131927341e-08
apparent O 0 3.6149192510492867e-06
lack O 0 1.688808453081947e-07
of O 0 6.155512721761625e-08
recombinants O 0 0.00015309777518268675
between O 0 9.253058408376091e-08
the O 0 3.331053832766884e-08
Factor O 0 5.159370743967884e-07
B O 0 4.6260960516519845e-05
gene O 0 5.33254797119298e-06
and O 0 0.00025021229521371424
C2 B-Disease 1 0.9999979734420776
deficiency I-Disease 1 0.9999765157699585
gene O 0 8.696856639289763e-06
suggests O 0 1.2265262512300978e-06
that O 0 3.818387384058042e-08
these O 0 2.9345580188078202e-08
two O 0 6.082255765704758e-08
genes O 0 6.001154133628006e-07
lie O 0 8.2714532254613e-06
in O 0 1.0238784398097778e-07
close O 0 1.1544948392838705e-06
proximity O 0 1.2917440699311555e-06
to O 0 1.0888864210301108e-07
one O 0 2.9769847742500133e-07
another O 0 2.89036847789248e-06
. O 0 9.271356248063967e-06

Distribution O 0 3.6135556001681834e-05
of O 0 3.985491275670938e-06
emerin O 0 0.0005450043827295303
and O 0 3.99434111386654e-06
lamins O 0 0.015559693798422813
in O 0 4.782831410921062e-07
the O 0 6.29807459517906e-07
heart O 0 6.401945574907586e-05
and O 0 7.532611903116049e-07
implications O 0 1.7040407328750007e-05
for O 0 2.6033883386844536e-06
Emery B-Disease 0 0.24273554980754852
- I-Disease 1 0.9990328550338745
Dreifuss I-Disease 1 0.9999176263809204
muscular I-Disease 1 0.9996304512023926
dystrophy I-Disease 1 0.9993636012077332
. O 0 0.00047040381468832493

Emerin O 0 0.017092404887080193
is O 0 7.337912848015549e-06
a O 0 2.956578555313172e-06
nuclear O 0 1.5264900866895914e-05
membrane O 0 4.7540547711832915e-06
protein O 0 3.472678997695766e-07
which O 0 5.748063358623767e-08
is O 0 1.1062681437579158e-07
missing O 0 6.838006925136142e-07
or O 0 3.3125317600024573e-07
defective O 0 4.367943620309234e-05
in O 0 8.324722671204654e-07
Emery B-Disease 0 0.1374489665031433
- I-Disease 1 0.9985529780387878
Dreifuss I-Disease 1 0.9999421834945679
muscular I-Disease 1 0.999903678894043
dystrophy I-Disease 1 0.9999301433563232
( O 0 0.0001719887222861871
EDMD B-Disease 1 0.999765932559967
) O 0 1.4882739378663246e-05
. O 0 2.1811916667502373e-05

It O 0 8.806843652564567e-06
is O 0 1.0090249134009355e-06
one O 0 1.4486089128240565e-07
member O 0 1.2197742194075545e-07
of O 0 5.1641993792372887e-08
a O 0 2.8247552563698264e-07
family O 0 7.317538575080107e-07
of O 0 3.632924574503704e-07
lamina O 1 0.9982883334159851
- O 0 0.03451951965689659
associated O 0 1.0915684924839297e-06
proteins O 0 7.925724077040286e-08
which O 0 2.523954023558872e-08
includes O 0 3.163074495660112e-07
LAP1 O 0 0.00022522233484778553
, O 0 4.1438647713221144e-07
LAP2 O 0 0.0002791350707411766
and O 0 1.489440478508186e-06
lamin O 1 0.5682181119918823
B O 0 0.004173259250819683
receptor O 0 0.00014952398487366736
( O 0 5.8502864703768864e-06
LBR O 0 0.015309207141399384
) O 0 3.677333324958454e-06
. O 0 1.2188212167529855e-05

A O 0 3.838377961074002e-05
panel O 0 2.1310312149580568e-05
of O 0 1.4114440318735433e-06
16 O 0 4.1437560867052525e-06
monoclonal O 0 0.00019491292187012732
antibodies O 0 8.366088877664879e-06
( O 0 2.840864397057885e-07
mAbs O 0 2.9427659683278762e-05
) O 0 1.1169986890990913e-07
has O 0 6.092299287274727e-08
been O 0 3.261713388269527e-08
mapped O 0 9.229859756487713e-07
to O 0 3.999354447614678e-08
six O 0 3.432338502307175e-08
specific O 0 5.649985368449961e-08
sites O 0 1.133939875330725e-07
throughout O 0 2.9338137252921115e-08
the O 0 2.8492124215517833e-08
emerin O 0 1.3133419088262599e-05
molecule O 0 7.377772135441774e-07
using O 0 7.59114868742472e-08
phage O 0 5.694119408872211e-06
- O 0 6.931152711331379e-06
displayed O 0 3.7551333775809326e-07
peptide O 0 3.30011800997454e-07
libraries O 0 6.572824418071832e-08
and O 0 2.8101803550839577e-08
has O 0 2.2441534852646328e-08
been O 0 1.347722111688654e-08
used O 0 2.1159701546480392e-08
to O 0 2.9708775883818817e-08
localize O 0 1.5440917195519432e-05
emerin O 0 0.0005199190345592797
in O 0 2.1720346410347702e-07
human O 0 8.534743756172247e-07
and O 0 2.4918110739236e-06
rabbit O 0 0.002616910496726632
heart O 0 0.0034991579595953226
. O 0 2.1902338630752638e-05

Several O 0 7.282009028131142e-05
mAbs O 0 0.001946018892340362
against O 0 1.0543489224801306e-05
different O 0 1.6524143120477675e-06
emerin O 0 0.0010291776852682233
epitopes O 0 0.0010259184055030346
did O 0 1.2365634347588639e-06
not O 0 1.3322180336672318e-07
recognize O 0 7.600912681482441e-07
intercalated O 0 1.1448386430856772e-05
discs O 0 3.4436681744409725e-05
in O 0 2.2670977273264725e-07
the O 0 3.067341651785682e-07
heart O 0 0.0002464595017954707
, O 0 5.570894359152589e-07
though O 0 2.441360038574203e-07
they O 0 5.47004646023197e-08
recognized O 0 1.1403229649431523e-07
cardiomyocyte O 0 2.4407074306509458e-05
nuclei O 0 2.8936974558746442e-06
strongly O 0 5.453955509437947e-07
, O 0 4.8732211155311234e-08
both O 0 3.486110244921292e-08
at O 0 1.0067576994288174e-07
the O 0 4.205164216841695e-08
rim O 0 5.681124093825929e-06
and O 0 1.3753530936355673e-07
in O 0 2.418566111828113e-07
intranuclear O 0 0.0004177910159341991
spots O 0 7.272245966305491e-06
or O 0 1.0197811661782907e-06
channels O 0 9.970316568796989e-06
. O 0 7.449971690220991e-06

A O 0 0.00019025163783226162
polyclonal O 0 0.003920986782759428
rabbit O 0 0.00044235275709070265
antiserum O 0 0.0013209071476012468
against O 0 1.7481741451774724e-05
emerin O 0 0.0018076057313010097
did O 0 3.4445547498762608e-06
recognize O 0 4.446532784641022e-06
both O 0 2.6854831958189607e-07
nuclear O 0 9.049939762917347e-06
membrane O 0 2.2709502900397638e-06
and O 0 1.4844388829260424e-07
intercalated O 0 1.4130740055406932e-05
discs O 0 3.0494258680846542e-05
but O 0 2.6876611514126125e-07
, O 0 6.601760560442926e-08
after O 0 1.1986962533683254e-07
affinity O 0 6.691923317703186e-07
purification O 0 3.0528046863764757e-06
against O 0 1.6495361876422976e-07
a O 0 9.47671736639677e-08
pure O 0 1.0297682138116215e-06
- O 0 9.390058403369039e-05
emerin O 0 0.00011718041059793904
band O 0 4.357621889994334e-07
on O 0 6.702193644514409e-08
a O 0 6.164806620745367e-08
western O 0 1.8709523885718227e-07
blot O 0 2.9076785722281784e-05
, O 0 1.376431555399904e-07
it O 0 7.462561768534215e-08
stained O 0 6.087251676945016e-05
only O 0 6.809283803477229e-08
the O 0 2.4397283482358034e-07
nuclear O 0 6.612859579036012e-05
membrane O 0 5.2180261263856664e-05
. O 0 1.321987383562373e-05

These O 0 1.734771649353206e-05
results O 0 7.982805982464924e-06
would O 0 5.613158009509789e-07
not O 0 7.318348593798873e-08
be O 0 3.9722142020082174e-08
expected O 0 3.4687138850131305e-07
if O 0 2.0161063218893105e-07
immunostaining O 0 0.00012287875870242715
at O 0 4.660413424062426e-07
intercalated O 0 5.769592007709434e-06
discs O 0 7.540650130977156e-06
were O 0 6.668021512723499e-08
due O 0 1.6046051598550548e-07
to O 0 2.1971530372866255e-08
a O 0 4.330135183749917e-08
product O 0 9.036504877713014e-08
of O 0 1.1510848274554064e-08
the O 0 3.061402864545926e-08
emerin O 0 3.006777842529118e-05
gene O 0 1.930678052985968e-07
and O 0 8.360032666132611e-08
, O 0 6.736836866139129e-08
therefore O 0 7.011096414544227e-08
, O 0 6.045222278316942e-08
cast O 0 1.86599166340784e-07
some O 0 3.139057369594411e-08
doubt O 0 2.8702154963866633e-07
upon O 0 4.3907562030653935e-08
the O 0 6.499396931758383e-08
hypothesis O 0 3.573761659936281e-06
that O 0 2.4709299850655952e-06
cardiac B-Disease 1 0.9902682900428772
defects I-Disease 1 0.8138909339904785
in O 0 6.744795427948702e-06
EDMD B-Disease 1 0.9998705387115479
are O 0 7.469353704436799e-07
caused O 0 2.7321445941197453e-06
by O 0 2.1221302404228481e-07
absence O 0 1.603165742380952e-06
of O 0 6.878400995447009e-07
emerin O 0 0.0020636694971472025
from O 0 2.456894890201511e-06
intercalated O 0 0.00027565701748244464
discs O 0 0.0003578302566893399
. O 0 2.4590897737652995e-05

Although O 0 5.992202568450011e-05
emerin O 0 0.002430480206385255
was O 0 4.191785592411179e-06
abundant O 0 2.153910145352711e-06
in O 0 1.7063446478005062e-07
the O 0 7.33634948346662e-08
membranes O 0 1.4254665074986406e-06
of O 0 9.273271217580259e-08
cardiomyocyte O 0 0.0005279346369206905
nuclei O 0 7.673340405744966e-06
, O 0 1.0999119837151738e-07
it O 0 3.5166571876743546e-08
was O 0 1.6144102232829027e-07
absent O 0 5.560173121921252e-07
from O 0 4.6608221282440354e-08
many O 0 5.519693146993632e-08
non O 0 1.3604117157228757e-06
- O 0 0.004966245032846928
myocyte O 0 0.1763932704925537
cells O 0 9.600028533895966e-06
in O 0 2.6107875328307273e-07
the O 0 8.765548500377918e-07
heart O 0 0.0004329192452132702
. O 0 1.6039874026319012e-05

This O 0 3.500533921396709e-06
distribution O 0 2.9502214147214545e-06
of O 0 6.209829166436975e-07
emerin O 0 0.0018386214505881071
was O 0 7.942966817608976e-07
similar O 0 2.3579775643156609e-07
to O 0 4.9041599226029575e-08
that O 0 2.122963671524758e-08
of O 0 6.335641700161432e-08
lamin O 0 0.06927350908517838
A O 0 1.971979145309888e-06
, O 0 3.3093266438299906e-07
a O 0 2.939084993158758e-07
candidate O 0 3.1726015095046023e-06
gene O 0 1.0803379382195999e-06
for O 0 3.057315893784107e-07
an O 0 5.018567890147096e-07
autosomal O 0 9.459854481974617e-05
form O 0 1.1279317959633772e-06
of O 0 7.255128821270773e-06
EDMD B-Disease 1 0.9991230368614197
. O 0 7.716685649938881e-05

In O 0 3.1513478461420164e-05
contrast O 0 8.537547546438873e-05
, O 0 1.2400658306432888e-05
lamin O 1 0.9403953552246094
B1 O 1 0.8916986584663391
was O 0 4.867359621130163e-06
absent O 0 7.556941454822663e-06
from O 0 4.666582071877201e-07
cardiomyocyte O 0 9.907305502565578e-05
nuclei O 0 4.134613845963031e-06
, O 0 2.346547915976771e-07
showing O 0 8.781991027717595e-07
that O 0 2.783073114187573e-07
lamin O 1 0.9389175772666931
B1 O 1 0.7617760300636292
is O 0 1.6921843837280903e-07
not O 0 3.059698627794205e-08
essential O 0 8.0805968138975e-08
for O 0 3.539199155966344e-08
localization O 0 8.15939529275056e-07
of O 0 1.3751326832789346e-07
emerin O 0 8.435114432359114e-05
to O 0 2.1157404717087047e-07
the O 0 7.25501422493835e-07
nuclear O 0 0.0006807047757320106
lamina O 0 0.32814541459083557
. O 0 1.728160168568138e-05

Lamin O 1 0.99457848072052
B1 O 1 0.9930058717727661
is O 0 2.373912684561219e-05
also O 0 2.4240350740001304e-06
almost O 0 1.6364963357773377e-06
completely O 0 7.157234904298093e-06
absent O 0 2.244457573397085e-05
from O 0 3.5502680475474335e-06
skeletal O 0 0.003940442111343145
muscle O 0 0.0005988781922496855
nuclei O 0 0.00027795095229521394
. O 0 2.5222436306648888e-05

In O 0 7.202347478596494e-05
EDMD B-Disease 1 0.9873168468475342
, O 0 4.444566002348438e-06
the O 0 2.9088994324411033e-07
additional O 0 4.3752822875831043e-07
absence O 0 1.2583070656546624e-06
of O 0 1.2508783129305812e-06
lamin O 1 0.9980668425559998
B1 O 1 0.9924847483634949
from O 0 8.29331656859722e-06
heart O 0 0.002172387670725584
and O 0 4.4273729145061225e-06
skeletal O 0 0.0016166853019967675
muscle O 0 6.03130720264744e-05
nuclei O 0 4.981986876373412e-06
which O 0 1.1329432680895479e-07
already O 0 5.112394774187123e-07
lack O 0 1.3996990446685231e-06
emerin O 0 0.02453567273914814
may O 0 1.2520621339717763e-06
offer O 0 2.2239267138957075e-07
an O 0 2.294166634442263e-08
alternative O 0 1.920900132290626e-07
explanation O 0 1.937633840043418e-07
of O 0 4.852574519986774e-08
why O 0 4.319436754940398e-07
these O 0 6.668428653711089e-08
tissues O 0 4.705547780758934e-06
are O 0 1.24952464375383e-07
particularly O 0 2.8870847472717287e-06
affected O 0 2.6512034310144372e-06
. O 0 1.0407170520920772e-06
. O 0 7.037717296043411e-06

Genetic O 0 0.0003991727717220783
mapping O 0 5.488650276674889e-05
of O 0 1.5344737676059594e-06
the O 0 1.956193045771215e-06
copper B-Disease 0 0.00045860218233428895
toxicosis I-Disease 0 0.025103550404310226
locus O 0 1.9978968339273706e-05
in O 0 7.883567718636186e-07
Bedlington O 0 5.597110794042237e-05
terriers O 0 2.1315921912901103e-05
to O 0 9.653723509472911e-07
dog O 0 5.104181036585942e-05
chromosome O 0 1.643691211938858e-05
10 O 0 5.723949811908824e-07
, O 0 1.242996034989119e-07
in O 0 3.900135325807241e-08
a O 0 1.5584657830913784e-07
region O 0 1.1314862149447436e-06
syntenic O 0 0.0001610640756553039
to O 0 1.4576166051938344e-07
human O 0 8.095003067865036e-07
chromosome O 0 3.137694875476882e-05
region O 0 1.2152301678725053e-05
2p13 O 0 0.0021998253650963306
- O 0 0.001915138796903193
p16 O 0 0.0006579743348993361
. O 0 2.1921565348748118e-05

Abnormal O 1 0.9933475852012634
hepatic B-Disease 1 0.9997133612632751
copper I-Disease 0 0.12327607721090317
accumulation I-Disease 0 0.0009732776670716703
is O 0 3.1802655939827673e-06
recognized O 0 2.408430191280786e-06
as O 0 8.94737127055123e-07
an O 0 2.108222179231234e-05
inherited B-Disease 1 0.999993085861206
disorder I-Disease 1 0.9999381303787231
in O 0 3.48644766745565e-06
man O 0 3.760480467462912e-05
, O 0 1.7174410231746151e-06
mouse O 0 4.776278365170583e-05
, O 0 2.783885065582581e-06
rat O 0 0.0002614456752780825
and O 0 3.092766746704001e-06
dog O 0 0.0003223528910893947
. O 0 1.771386814652942e-05

The O 0 1.8255777831654996e-05
major O 0 3.495148484944366e-05
cause O 0 2.9579310648841783e-05
of O 0 5.474505542224506e-06
hepatic B-Disease 1 0.998849630355835
copper I-Disease 0 0.032113008201122284
accumulation I-Disease 0 0.00030264543602243066
in O 0 1.06110474007437e-06
man O 0 3.2877017019927735e-06
is O 0 8.81023751730936e-08
a O 0 3.3105894203799835e-07
dysfunctional O 0 0.0003620664356276393
ATP7B O 0 0.09770127385854721
gene O 0 2.1917927369941026e-05
, O 0 5.6514140851504635e-06
causing O 0 0.0024700770154595375
Wilson B-Disease 1 0.5841207504272461
disease I-Disease 0 0.1264607459306717
( O 0 1.1366621038177982e-05
WD B-Disease 1 0.9412286281585693
) O 0 8.513758075423539e-06
. O 0 1.3700861018151045e-05

Mutations O 0 0.000719600822776556
in O 0 3.9254382500075735e-06
the O 0 1.0006751836044714e-06
ATP7B O 0 0.011055453680455685
genes O 0 2.47783464146778e-06
have O 0 1.5596627633840399e-07
also O 0 7.053105122167835e-08
been O 0 1.0622919432989875e-07
demonstrated O 0 1.0019452929554973e-06
in O 0 2.2762878870707937e-07
mouse O 0 4.5596319978358224e-05
and O 0 3.932853815058479e-06
rat O 0 0.0010056932223960757
. O 0 1.4230529814085457e-05

The O 0 3.057620779145509e-05
ATP7B O 0 0.004986266605556011
gene O 0 2.5214836568920873e-05
has O 0 5.624834784612176e-07
been O 0 1.4649775437192147e-07
excluded O 0 1.0506905709917191e-06
in O 0 6.254546747186396e-08
the O 0 6.460933121843482e-08
much O 0 9.76337446445541e-07
rarer O 0 0.00039009610190987587
human O 0 2.3845563191571273e-05
copper B-Disease 1 0.6188249588012695
overload I-Disease 1 0.9660703539848328
disease O 0 0.0012198948534205556
non B-Disease 0 1.1943550816795323e-05
- I-Disease 0 0.010973676107823849
Indian I-Disease 0 6.391106580849737e-05
childhood I-Disease 0 0.22401303052902222
cirrhosis I-Disease 1 0.9996293783187866
, O 0 1.3645145372720435e-05
indicating O 0 0.0002730108972173184
genetic O 0 0.0003676342312246561
heterogeneity O 0 0.0023490118328481913
. O 0 7.588050357298926e-05

By O 0 5.2065934141865e-05
investigating O 0 0.00018196033488493413
the O 0 9.343733836431056e-06
common O 0 0.00020036047499161214
autosomal O 1 0.5692789554595947
recessive O 1 0.7389153838157654
copper B-Disease 1 0.8275188207626343
toxicosis I-Disease 1 0.9978436231613159
( O 0 3.886771537509048e-06
CT B-Disease 0 0.07078251242637634
) O 0 2.171295108155391e-07
in O 0 1.5528208052728587e-07
Bedlington O 0 2.5817671485128812e-05
terriers O 0 2.5066336093004793e-05
, O 0 4.083422879830323e-07
we O 0 9.985706128645688e-08
have O 0 6.558961018754417e-08
identified O 0 1.9388741634429607e-07
a O 0 9.236465814410622e-08
new O 0 3.189941537584673e-07
locus O 0 6.845152256573783e-06
involved O 0 5.434529157355428e-06
in O 0 4.416472074808553e-05
progressive O 1 0.9993226528167725
liver B-Disease 1 0.9999982118606567
disease I-Disease 1 0.9989058971405029
. O 0 0.00011179509601788595

We O 0 2.6982705094269477e-05
examined O 0 9.137584856944159e-05
whether O 0 5.460478860186413e-06
the O 0 1.1151546459586825e-06
WD B-Disease 0 0.18313369154930115
gene O 0 1.3508276424545329e-05
ATP7B O 0 0.0008570713107474148
was O 0 1.1454886816864018e-06
also O 0 1.6949881853633997e-07
causative O 0 2.119910277542658e-06
for O 0 1.8812367841292144e-07
CT B-Disease 0 0.047245316207408905
by O 0 4.024929864954174e-07
investigating O 0 4.629543582268525e-06
the O 0 3.3908179375430336e-07
chromosomal O 0 0.047816239297389984
co O 0 0.00010395854042144492
- O 0 4.0577702748123556e-05
localization O 0 1.461776378164359e-06
of O 0 1.2412392891292257e-07
ATP7B O 0 0.0018157665617763996
and O 0 5.069640565125155e-07
C04107 O 0 2.2544476451002993e-05
, O 0 6.575032074351839e-08
using O 0 7.328419826535537e-08
fluorescence O 0 1.7615371916690492e-06
in O 0 1.3474642912569834e-07
situ O 0 2.513611070753541e-05
hybridization O 0 7.606563485751394e-06
( O 0 1.0896339972532587e-06
FISH O 0 3.8620382838416845e-06
) O 0 1.3979074537928682e-06
. O 0 5.237753612163942e-06

C04107 O 0 0.007045567035675049
is O 0 1.5435178283951245e-05
an O 0 1.6366711861337535e-06
anonymous O 0 5.817205874336651e-06
microsatellite O 0 0.0006985718500800431
marker O 0 7.648624887224287e-05
closely O 0 6.001834208291257e-06
linked O 0 2.0935323846060783e-05
to O 0 4.843313945457339e-06
CT B-Disease 0 0.4545135498046875
. O 0 3.547668893588707e-05

However O 0 3.6758254282176495e-05
, O 0 9.057546776602976e-06
BAC O 0 9.772295015864074e-05
clones O 0 7.240464037749916e-05
containing O 0 5.294614311424084e-06
ATP7B O 0 0.0010982718085870147
and O 0 8.466452641187061e-07
C04107 O 0 6.812701758462936e-05
mapped O 0 7.612376521137776e-06
to O 0 1.8074121044264757e-07
the O 0 2.4412202037638053e-07
canine O 0 4.972624810761772e-05
chromosome O 0 1.3972975466458593e-05
regions O 0 1.5806546116436948e-06
CFA22q11 O 0 0.00013750928337685764
and O 0 6.754244168405421e-07
CFA10q26 O 0 0.0004205417353659868
, O 0 3.4175428709204425e-07
respectively O 0 5.935414151281293e-07
, O 0 2.601179573957779e-07
demonstrating O 0 2.241904439870268e-06
that O 0 5.685610062755586e-07
WD B-Disease 0 0.4156535565853119
cannot O 0 9.259429134544916e-07
be O 0 8.23538499616916e-08
homologous O 0 5.419169156084536e-06
to O 0 2.446879761919263e-06
CT B-Disease 0 0.44070640206336975
. O 0 2.74340964097064e-05

The O 0 1.6586584024480544e-05
copper O 0 7.56465015001595e-05
transport O 0 1.1757274478441104e-05
genes O 0 3.760623485504766e-06
CTR1 O 0 0.0004628088790923357
and O 0 6.17357954979525e-07
CTR2 O 0 0.0007427296950481832
were O 0 1.5484080506666942e-07
also O 0 4.3169325891767585e-08
excluded O 0 5.373492513172096e-07
as O 0 2.8942796603814713e-08
candidate O 0 5.446844966172648e-07
genes O 0 1.6341259367891325e-07
for O 0 1.6561612881105248e-07
CT B-Disease 0 0.07309965789318085
since O 0 3.5548345067581977e-07
they O 0 5.2812222151032984e-08
both O 0 7.184386419112343e-08
mapped O 0 4.041012743982719e-06
to O 0 7.764112979202764e-07
canine O 0 0.00037708538002334535
chromosome O 0 0.00011936524242628366
region O 0 3.14194658130873e-05
CFA11q22 O 0 0.002695264760404825
. O 0 3.087483855779283e-05

2 O 0 0.0002510560443624854
- O 0 0.0008127839537337422
22 O 0 6.610432319575921e-05
. O 0 2.9399216145975515e-05

5 O 0 0.0012829797342419624
. O 0 0.0005756250466220081

A O 0 3.9577171264681965e-05
transcribed O 0 3.710792225319892e-05
sequence O 0 6.809829301346326e-06
identified O 0 3.391152176845935e-06
from O 0 1.1251090370478778e-07
the O 0 1.0133405936585405e-07
C04107 O 0 7.730105426162481e-05
- O 0 6.198165647219867e-05
containing O 0 6.749916678927548e-07
BAC O 0 6.367712558130734e-06
was O 0 1.3816976718317164e-07
found O 0 5.657026491689976e-08
to O 0 2.2651693853958932e-08
be O 0 1.768704471771798e-08
homologous O 0 4.080223163782648e-07
to O 0 5.3544024325447026e-08
a O 0 2.320192180604863e-07
gene O 0 7.221782425403944e-07
expressed O 0 2.3121386050206638e-07
from O 0 1.1503598784656788e-07
human O 0 3.549340021891112e-07
chromosome O 0 1.9255974621046335e-05
2p13 O 0 0.00031432375544682145
- O 0 0.00039800588274374604
p16 O 0 3.0063964004511945e-05
, O 0 1.722527827041631e-07
a O 0 1.0426974483834783e-07
region O 0 4.6349450144589355e-07
devoid O 0 9.163545087176317e-07
of O 0 9.417453838977963e-08
any O 0 2.4115919927680807e-07
positional O 0 6.117046723375097e-06
candidate O 0 1.7758929971023463e-05
genes O 0 1.0995006050507072e-05
. O 0 1.2803679055650719e-05

Molecular O 0 0.00022004357015248388
analysis O 0 1.0060548447654583e-05
of O 0 6.300579116214067e-07
the O 0 2.827930245530297e-07
APC B-Disease 0 1.268412779609207e-05
gene O 0 7.397901526928763e-07
in O 0 1.2234265511779086e-07
205 O 0 2.557625748522696e-06
families O 0 7.345464041463856e-07
: O 0 2.4201995074690785e-07
extended O 0 1.0275138038196019e-06
genotype O 0 0.00016391453391406685
- O 0 0.004842132329940796
phenotype O 0 5.531062197405845e-05
correlations O 0 2.7298388886265457e-05
in O 0 4.721275104202505e-07
FAP B-Disease 0 0.00030510799842886627
and O 0 2.400836649485427e-07
evidence O 0 2.1750236101070186e-07
for O 0 6.194946422510839e-08
the O 0 2.997784420699645e-08
role O 0 1.0762745006331897e-07
of O 0 1.288800461907158e-07
APC B-Disease 0 3.571383058442734e-05
amino O 0 1.0639276979418355e-06
acid O 0 3.1990828119887738e-06
changes O 0 3.1387037324748235e-06
in O 0 0.0007383381016552448
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999967813491821
predisposition O 1 0.9882650375366211
. O 0 0.0001786066422937438

BACKGROUND O 0 0.00028962441137991846
/ O 0 0.0002393707982264459
AIMS O 0 2.0163181034149602e-05
The O 0 8.347300308741978e-07
development O 0 5.147323463461362e-06
of O 0 0.0013584534171968699
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999990463256836
and O 0 4.434823040355695e-06
a O 0 8.970063163360464e-07
variable O 0 3.3183287087013014e-06
range O 0 1.2696258409050643e-06
of O 0 4.236262896029075e-07
extracolonic O 0 0.005687718745321035
manifestations O 0 0.0001736863487167284
in O 0 5.454019992612302e-05
familial B-Disease 1 0.999975323677063
adenomatous I-Disease 1 0.9999966621398926
polyposis I-Disease 1 0.9999986886978149
( O 0 3.5236418625572696e-05
FAP B-Disease 0 0.023783713579177856
) O 0 5.163972787158855e-07
is O 0 9.009709600604765e-08
the O 0 4.9932609158531704e-08
result O 0 9.543322931904186e-08
of O 0 3.909996593165488e-08
the O 0 3.7997961044311523e-07
dominant O 0 1.713466008368414e-05
inheritance O 0 0.00030113468528725207
of O 0 0.0006023983005434275
adenomatous B-Disease 1 0.9999985694885254
polyposis I-Disease 1 0.9999979734420776
coli I-Disease 1 0.9997894167900085
( O 0 2.343973028473556e-05
APC B-Disease 0 0.000714823545422405
) O 0 3.3724527384038083e-06
gene O 0 2.2724238078808412e-05
mutations O 0 4.002240893896669e-05
. O 0 1.8111553799826652e-05

In O 0 6.553299044753658e-06
this O 0 6.63866842387506e-07
study O 0 1.032491127261892e-06
, O 0 1.1131619004345339e-07
direct O 0 1.6366712429771724e-07
mutation O 0 6.511917831630853e-07
analysis O 0 1.1563004420622747e-07
of O 0 4.118994212376492e-08
the O 0 8.837350407020494e-08
APC B-Disease 0 1.4763797480554786e-05
gene O 0 6.697771937069774e-07
was O 0 9.455718696926851e-08
performed O 0 1.5552514298633469e-07
to O 0 7.497701659531231e-08
determine O 0 1.907797013700474e-06
genotype O 0 0.00015350559260696173
- O 0 0.0009335721260868013
phenotype O 0 3.4673015761654824e-05
correlations O 0 4.640364295482868e-06
for O 0 2.1546999562360725e-07
nine O 0 1.3074419484837563e-06
extracolonic O 0 0.0021885940805077553
manifestations O 0 7.55859173295903e-06
and O 0 1.6134805491674342e-07
to O 0 1.0158311170016532e-07
investigate O 0 3.855043360090349e-06
the O 0 3.2076687261906045e-07
incidence O 0 8.408844587393105e-05
of O 0 4.776172204401519e-07
APC B-Disease 0 0.0008088867762126029
mutations O 0 4.829435511055635e-06
in O 0 5.170497274775698e-07
non O 0 0.00018649850971996784
- O 1 0.9998500347137451
FAP O 1 0.9999805688858032
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999935626983643
. O 0 0.0003284417325630784

METHODS O 0 0.0001415558363078162
The O 0 7.1720892265147995e-06
APC B-Disease 0 0.00011364348756615072
gene O 0 9.515234523860272e-06
was O 0 6.017951932335563e-07
analysed O 0 2.327586116734892e-06
in O 0 1.7217904257904593e-07
190 O 0 2.475760766174062e-06
unrelated O 0 1.0631341865519062e-05
FAP B-Disease 0 0.00015365028230007738
and O 0 4.65761445411772e-07
15 O 0 2.1061428014945704e-06
non O 0 0.000125673454022035
- O 1 0.9997872710227966
FAP O 1 0.9999948740005493
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999994039535522
patients O 0 0.010002879425883293
using O 0 3.49528659171483e-06
denaturing O 0 0.145883709192276
gradient O 0 0.007962043397128582
gel O 0 0.008378352969884872
electrophoresis O 0 0.00030502944719046354
, O 0 2.69885191528374e-07
the O 0 4.89509481838013e-08
protein O 0 2.493165709438472e-07
truncation O 0 3.1498555017606122e-06
test O 0 1.1179199645994231e-06
, O 0 1.4063996900404163e-07
and O 0 2.2605000538078457e-07
direct O 0 1.1952207614740473e-06
sequencing O 0 2.1709774955525063e-05
. O 0 8.913092642615084e-06

RESULTS O 0 0.0005429708398878574
Chain O 0 0.000183632510015741
terminating O 0 4.039769555674866e-05
signals O 0 6.166721959743882e-06
were O 0 2.9186364258748654e-07
only O 0 1.5006341413936752e-07
identified O 0 1.730541157485277e-06
in O 0 7.758133051538607e-07
patients O 0 3.650199141702615e-05
belonging O 0 1.2454646594051155e-06
to O 0 6.804479824040754e-08
the O 0 1.571553553958438e-07
FAP B-Disease 0 0.00045615065027959645
group O 0 2.4028208827076014e-06
( O 0 5.481043103827687e-07
105 O 0 2.494704858690966e-05
patients O 0 0.00018506014021113515
) O 0 1.7357576780341333e-06
. O 0 6.455836228269618e-06

Amino O 0 7.778419239912182e-05
acid O 0 2.06479035114171e-05
changes O 0 1.1349216038070153e-06
were O 0 2.4646996621413564e-07
identified O 0 8.331377898684877e-07
in O 0 9.073274753745864e-08
four O 0 8.117173706523317e-07
patients O 0 0.00017570334603078663
, O 0 1.3915439467382384e-07
three O 0 5.584778861589257e-08
of O 0 1.6556637660869455e-07
whom O 0 2.5727708816702943e-06
belonged O 0 1.2532018445199355e-06
to O 0 6.216239967216097e-08
the O 0 6.80553142728968e-08
non O 0 5.464943569677416e-06
- O 0 0.06891360133886337
FAP O 0 0.0892363041639328
group O 0 0.0001059336427715607
of O 0 0.009446394629776478
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999996423721313
patients O 1 0.9635913372039795
. O 0 0.00011530539632076398

Genotype O 0 0.1267102211713791
- O 0 0.12674479186534882
phenotype O 0 0.004690946079790592
correlations O 0 0.004387170076370239
identified O 0 4.2174229747615755e-05
significant O 0 6.188892712089e-06
differences O 0 1.2064380825904664e-05
in O 0 3.2080359346764453e-07
the O 0 2.3412771099629026e-07
nature O 0 4.5335133336266153e-07
of O 0 1.0183957499521057e-07
certain O 0 9.341828786091355e-07
extracolonic O 0 0.022312019020318985
manifestations O 0 6.413335358956829e-05
in O 0 9.449313438381068e-06
FAP B-Disease 1 0.9599898457527161
patients O 0 0.002703464590013027
belonging O 0 3.636751671365346e-06
to O 0 3.2002256489249703e-07
three O 0 1.831712324928958e-06
mutation O 0 3.8322192267514765e-05
subgroups O 0 0.00013020441110711545
. O 0 2.0269138985895552e-05

CONCLUSIONS O 0 0.0002599028230179101
Extended O 0 8.001364767551422e-05
genotype O 0 0.0020417773630470037
- O 0 0.006292256992310286
phenotype O 0 0.00010023456707131118
correlations O 0 3.122117050224915e-05
made O 0 1.933534008458082e-07
in O 0 6.384308903761848e-08
this O 0 3.872235154744885e-08
study O 0 8.271795195469167e-07
may O 0 4.914863325211627e-07
have O 0 3.262571723894325e-08
the O 0 2.631654894003077e-08
potential O 0 3.0497358238790184e-07
to O 0 3.28184484033045e-08
determine O 0 2.5881590204335225e-07
the O 0 3.983435448162709e-08
most O 0 3.779304691420293e-08
appropriate O 0 1.7297281829087297e-07
surveillance O 0 4.612580596585758e-06
and O 0 6.875160920571943e-07
prophylactic O 0 0.02961757965385914
treatment O 0 0.0007968646823428571
regimens O 0 0.0007197802187874913
for O 0 1.0452736205479596e-06
those O 0 1.2293342479097191e-05
patients O 0 0.00124364101793617
with O 0 2.502935785742011e-06
mutations O 0 8.277430606540293e-05
associated O 0 5.1124707169947214e-06
with O 0 1.485805910306226e-06
life O 0 4.901963620795868e-05
threatening O 0 0.0172862708568573
conditions O 0 0.0008514893124811351
. O 0 3.47032182617113e-05

This O 0 6.788082373532234e-06
study O 0 9.597401003702544e-06
also O 0 8.121231189761602e-07
provided O 0 5.536035132536199e-07
evidence O 0 1.030928615364246e-06
for O 0 2.425534830763354e-07
the O 0 4.207531105748785e-07
pathological O 0 0.0001289851061301306
nature O 0 6.916295660630567e-07
of O 0 1.3411887778147502e-07
amino O 0 7.715265724073106e-07
acid O 0 1.3289179605635582e-06
changes O 0 1.3070999216324708e-07
in O 0 1.4645040380401042e-07
APC O 0 2.9800214178976603e-05
associated O 0 6.25582345037401e-07
with O 0 1.3794225139918126e-07
both O 0 2.5216618837475835e-07
FAP B-Disease 0 8.547543257009238e-05
and O 0 1.8521287756811944e-06
non O 0 0.0004073173622600734
- O 1 0.9999195337295532
FAP O 1 0.9999957084655762
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999996423721313
patients O 1 0.8615804314613342
. O 0 1.500389953434933e-05
. O 0 4.572049874695949e-05

Inherited B-Disease 1 0.9998960494995117
colorectal I-Disease 1 0.9999994039535522
polyposis I-Disease 1 0.9999914169311523
and O 1 0.5659916996955872
cancer B-Disease 1 0.9999231100082397
risk O 0 0.0004287647607270628
of O 0 1.4968750292609911e-06
the O 0 4.780314611707581e-06
APC O 0 0.008273487910628319
I1307K O 0 0.00599122466519475
polymorphism O 0 0.0009766502771526575
. O 0 4.1110062738880515e-05

Germ O 0 0.039488352835178375
- O 0 0.000843015790451318
line O 0 2.4699927962501533e-05
and O 0 1.139933033300622e-06
somatic O 0 4.186923251836561e-05
truncating O 0 0.0003810273774433881
mutations O 0 8.0855970736593e-06
of O 0 2.594671286715311e-07
the O 0 3.729401498731022e-07
APC B-Disease 0 3.215214383089915e-05
gene O 0 1.3389003470365424e-06
are O 0 5.992083629280387e-08
thought O 0 3.0014606977601943e-07
to O 0 7.290622647815326e-07
initiate O 0 0.04525529220700264
colorectal B-Disease 1 0.9999996423721313
tumor I-Disease 1 0.9995794892311096
formation O 0 0.010122553445398808
in O 0 0.0007518220809288323
familial B-Disease 1 0.9999935626983643
adenomatous I-Disease 1 0.9999991655349731
polyposis I-Disease 1 0.9999998807907104
syndrome I-Disease 1 0.9999946355819702
and O 0 0.0005629687802866101
sporadic O 1 0.9415112137794495
colorectal O 1 0.9999995231628418
carcinogenesis O 1 0.9997754693031311
, O 0 8.584693568991497e-05
respectively O 0 6.278954970184714e-05
. O 0 2.5298368200310506e-05

Recently O 0 0.0002020517858909443
, O 0 5.141229848959483e-06
an O 0 7.368842034338741e-07
isoleucine O 0 0.00040614837780594826
- O 0 0.001939794048666954
- O 0 0.0014948713360354304
> O 0 5.576216062763706e-05
lysine O 0 4.766702659253497e-06
polymorphism O 0 3.7910942864982644e-06
at O 0 3.5449289725875133e-07
codon O 0 1.255000597666367e-06
1307 O 0 2.7278741981717758e-05
( O 0 2.2318474179883196e-07
I1307K O 0 2.7582066195463995e-06
) O 0 2.2588487524899392e-08
of O 0 1.265534166350335e-08
the O 0 3.5272101683858637e-08
APC B-Disease 0 6.950156148377573e-06
gene O 0 5.038099857301859e-07
has O 0 5.1170768955444146e-08
been O 0 3.525333980292089e-08
identified O 0 1.3908726259614923e-07
in O 0 2.463127124485709e-08
6 O 0 4.0027165937317477e-07
% O 0 1.9769811387959635e-07
- O 0 5.5077085562516004e-05
7 O 0 1.1412470257710083e-06
% O 0 9.214892315867473e-08
of O 0 3.201146725473336e-08
the O 0 2.596884201011562e-07
Ashkenazi O 0 7.210586772998795e-05
Jewish O 0 3.6422773064259673e-06
population O 0 1.8143751958632492e-06
. O 0 6.71292218612507e-06

To O 0 2.822505666699726e-05
assess O 0 0.00016733602387830615
the O 0 3.419581389607629e-06
risk O 0 1.1255935532972217e-05
of O 0 2.7270164082437987e-07
this O 0 3.701727564475732e-07
common O 0 3.326576461404329e-06
APC B-Disease 0 0.00019867156515829265
allelic O 0 0.0003904160694219172
variant O 0 7.624491991009563e-05
in O 0 2.2428999727708288e-05
colorectal O 1 0.9999980926513672
carcinogenesis O 1 0.9954826831817627
, O 0 7.835537871869747e-06
we O 0 3.9300428511523933e-07
have O 0 1.1711964731375701e-07
analyzed O 0 8.830103297441383e-07
a O 0 1.7791941786526877e-07
large O 0 8.229046670749085e-07
cohort O 0 1.0666785783541854e-05
of O 0 3.647651283245068e-07
unselected O 0 0.000814113300293684
Ashkenazi O 0 0.00011817055201390758
Jewish O 0 4.3960953917121515e-06
subjects O 0 5.530148428078974e-06
with O 0 1.3101494005240966e-05
adenomatous B-Disease 1 0.9997988343238831
polyps I-Disease 1 0.9935857653617859
and O 0 1.6868052625795826e-05
. O 0 3.435035250731744e-05
or O 1 0.8730430603027344
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999984502792358
, I-Disease 0 3.872446086461423e-06
for O 0 8.035071346057521e-07
the O 0 2.4327518985955976e-06
APC O 0 0.0017961421981453896
I1307K O 0 0.0021797483786940575
polymorphism O 0 0.00042641101754270494
. O 0 4.7755496780155227e-05

The O 0 3.152168574160896e-05
APC O 0 0.00020986946765333414
I1307K O 0 0.000215223990380764
allele O 0 2.1647359972121194e-05
was O 0 1.5498204675168381e-06
identified O 0 1.2541487421913189e-06
in O 0 9.385033195030701e-08
48 O 0 7.456009143425035e-07
( O 0 5.321649254597105e-08
10 O 0 4.9165318927180124e-08
. O 0 1.8217054531532995e-08
1 O 0 1.3002669163597602e-07
% O 0 6.573201005721785e-08
) O 0 3.7701607169537965e-08
of O 0 1.909890983142759e-07
476 O 0 0.0010118396021425724
patients O 0 0.0004476223257370293
. O 0 1.1981733223365154e-05

Compared O 0 0.0001290773943765089
with O 0 2.091154101435677e-06
the O 0 3.2522402193535527e-07
frequency O 0 7.201603580142546e-07
in O 0 8.230720283108894e-08
two O 0 4.926322816345419e-08
separate O 0 1.9592198441387154e-07
population O 0 8.638711079811401e-08
control O 0 2.6424822863191366e-07
groups O 0 9.296222458488046e-08
, O 0 6.929652585085933e-08
the O 0 6.307499234026182e-08
APC O 0 1.24495009004022e-05
I1307K O 0 3.785883745877072e-05
allele O 0 2.169592789869057e-06
is O 0 1.1682715239658137e-07
associated O 0 2.3838487095417804e-07
with O 0 6.339509184272174e-08
an O 0 6.8941368169817e-08
estimated O 0 1.9216711280023446e-06
relative O 0 3.299786840216257e-05
risk O 0 8.19221168057993e-06
of O 0 3.411421118926228e-07
1 O 0 5.07255435877596e-06
. O 0 9.518056685919873e-06

5 O 0 0.000365033105481416
- O 0 0.0012946712085977197
1 O 0 5.8729263400891796e-05
. O 0 3.8636117096757516e-05

7 O 0 0.0004241747665219009
for O 0 0.00030453840736299753
colorectal B-Disease 1 0.9999973773956299
neoplasia I-Disease 1 0.9996626377105713
( O 0 8.610763870819937e-06
both O 0 2.6723998871602817e-06
P O 0 0.09088609367609024
= O 0 1.8735658159130253e-05
. O 0 6.415510256374546e-07
01 O 0 3.115707659162581e-05
) O 0 1.2789504353349912e-06
. O 0 4.693151367973769e-06

Furthermore O 0 0.0001273489324375987
, O 0 9.281529855797999e-06
compared O 0 7.774303412588779e-06
with O 0 1.4121926596999401e-06
noncarriers O 0 0.004757678601890802
, O 0 1.80896222445881e-06
APC O 0 6.627891707466915e-05
I1307K O 0 8.207961218431592e-05
carriers O 0 3.412798150748131e-06
had O 0 1.2335240739957953e-07
increased O 0 1.0759173107999231e-07
numbers O 0 1.0068536937524186e-07
of O 0 2.4032627266024065e-07
adenomas B-Disease 1 0.926476776599884
and O 0 0.0006351993652060628
colorectal B-Disease 1 0.9999998807907104
cancers I-Disease 1 0.9907710552215576
per O 0 1.5828021787456237e-05
patient O 0 0.0026864390820264816
( O 0 1.7318158143098117e-06
P O 0 0.12243309617042542
= O 0 7.014158654783387e-06
. O 0 6.978023492365537e-08
03 O 0 1.6458982372569153e-06
) O 0 2.4747116356138577e-08
, O 0 2.451045411078212e-08
as O 0 1.0663190330717498e-08
well O 0 2.2734280236136328e-08
as O 0 3.002499227022781e-08
a O 0 1.8853424421649834e-07
younger O 0 1.230406360264169e-05
age O 0 9.179365406453144e-06
at O 0 2.131405199179426e-05
diagnosis O 0 0.034367360174655914
. O 0 2.3492118998547085e-05

We O 0 2.2104410163592547e-05
conclude O 0 3.3049582270905375e-05
that O 0 9.061079708772013e-07
the O 0 6.719812972733052e-07
APC O 0 9.073998808162287e-05
I1307K O 0 0.00031090647098608315
variant O 0 9.303854312747717e-06
leads O 0 2.7230739760852885e-06
to O 0 3.565097870250611e-07
increased O 0 2.519964618841186e-05
adenoma B-Disease 1 0.9998764991760254
formation O 0 1.610719846212305e-05
and O 0 2.1974261699142517e-07
directly O 0 7.208227970068037e-08
contributes O 0 1.250595147439526e-07
to O 0 2.935565746042812e-08
3 O 0 1.970511789295415e-07
% O 0 1.1804408472926298e-07
- O 0 1.1399198228900786e-05
4 O 0 2.622708734634216e-07
% O 0 4.3242422975708905e-08
of O 0 2.374085639189616e-08
all O 0 5.701328973373165e-07
Ashkenazi O 0 0.22718338668346405
Jewish O 1 0.5500811338424683
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.999987006187439
. O 0 0.00020723376655951142

The O 0 1.7041738828993402e-05
estimated O 0 3.1831168598728254e-05
relative O 0 0.00020295774447731674
risk O 0 9.143372881226242e-05
for O 0 1.204831733048195e-06
carriers O 0 4.630209514289163e-05
may O 0 1.2022927649013582e-06
justify O 0 7.76824072090676e-06
specific O 0 1.0934303418252966e-06
clinical O 0 3.250737427151762e-05
screening O 0 1.1066960723837838e-05
for O 0 1.2608725796781073e-07
the O 0 9.805592071643332e-08
360 O 0 8.839945166982943e-07
, O 0 1.804112486070153e-07
000 O 0 5.114150098961545e-07
Americans O 0 1.5991940927051473e-07
expected O 0 2.0400661071562354e-07
to O 0 1.3561442813170288e-07
harbor O 0 1.865243939391803e-05
this O 0 4.8806818142566044e-08
allele O 0 7.993249937499058e-07
, O 0 1.4595973141240393e-07
and O 0 1.7302494370596833e-07
genetic O 0 2.3865379716880852e-06
testing O 0 1.1771439858421218e-06
in O 0 3.237991563764808e-08
the O 0 2.1567943875311357e-08
setting O 0 8.828977371422297e-08
of O 0 6.197522850470705e-08
long O 0 4.443252237251727e-06
- O 0 0.0002451127511449158
term O 0 5.668638095812639e-06
- O 0 6.109297828515992e-05
outcome O 0 4.504484877543291e-06
studies O 0 7.218160362754134e-07
may O 0 5.807095817544905e-07
impact O 0 1.8495940139473532e-06
significantly O 0 6.723924161633477e-05
on O 0 0.08082816749811172
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999995231628418
prevention O 0 0.05005420371890068
in O 0 1.187762222798483e-06
this O 0 9.96207631942525e-07
population O 0 2.9490006454579998e-06
. O 0 1.1475704013719223e-05

Localization O 0 0.00016565971600357443
of O 0 5.038305516791297e-06
human O 0 9.159314686257858e-06
BRCA1 O 0 0.0005516780074685812
and O 0 9.199769692713744e-07
its O 0 4.414899876792333e-07
loss O 0 1.4231778550310992e-05
in O 0 2.1515440096209204e-07
high O 0 5.719306955143111e-06
- O 0 0.0014364428352564573
grade O 0 7.759239088045433e-05
, O 0 8.712178214409505e-07
non B-Disease 0 4.01386059820652e-05
- I-Disease 1 0.9948728680610657
inherited I-Disease 1 0.9992268085479736
breast I-Disease 1 0.9999557733535767
carcinomas I-Disease 1 0.9999834299087524
. O 0 0.00021823978750035167

Although O 0 2.6782736313180067e-05
the O 0 1.8557178691480658e-06
link O 0 7.131119673431385e-06
between O 0 9.109288612307864e-07
the O 0 1.0821032674357411e-06
BRCA1 O 0 0.11592181771993637
tumour B-Disease 1 0.9995179176330566
- O 0 0.0007349537336267531
suppressor O 0 0.00022988513228483498
gene O 0 1.1397720300010405e-05
and O 0 1.1115956112917047e-05
hereditary B-Disease 1 0.9873365759849548
breast I-Disease 1 0.999988317489624
and I-Disease 1 0.997063934803009
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999982118606567
is O 0 3.4950699046021327e-06
established O 0 1.0958826806017896e-06
, O 0 2.637278555539524e-07
the O 0 7.128232226705222e-08
role O 0 4.79587185964192e-07
, O 0 2.2278750577697792e-07
if O 0 7.818371017265235e-08
any O 0 2.3046442976237813e-08
, O 0 3.527970804384495e-08
of O 0 4.240991913206926e-08
BRCA1 O 0 4.893052755505778e-05
in O 0 3.4262887993463664e-07
non B-Disease 0 7.494020974263549e-05
- I-Disease 1 0.9950331449508667
familial I-Disease 1 0.9996625185012817
cancers I-Disease 1 0.9964403510093689
is O 0 5.9155445342184976e-06
unclear O 0 2.252296508231666e-05
. O 0 1.5092529793037102e-05

BRCA1 O 1 0.6851006746292114
mutations O 0 0.0022171144373714924
are O 0 4.412906037032371e-06
rare O 0 1.4120112609816715e-05
in O 0 1.8111838926415658e-06
sporadic B-Disease 0 0.011279051192104816
cancers I-Disease 1 0.9922742247581482
, O 0 3.1730160117149353e-06
but O 0 1.0268212236042018e-06
loss O 0 1.3009174836042803e-05
of O 0 5.384634960137191e-07
BRCA1 O 0 0.0015624149236828089
resulting O 0 4.059217189933406e-06
from O 0 2.690505027658219e-07
reduced O 0 1.5016763654784882e-06
expression O 0 2.797159766032564e-07
or O 0 9.387916577452415e-08
incorrect O 0 3.633849701145664e-07
subcellular O 0 4.339761744631687e-06
localization O 0 1.0952138609354733e-06
is O 0 6.594763135581161e-08
postulated O 0 3.228482512440678e-07
to O 0 2.548149247161291e-08
be O 0 2.1343156575426292e-08
important O 0 6.728284063228784e-08
in O 0 1.305321148947769e-07
non B-Disease 0 1.5630277630407363e-05
- I-Disease 1 0.9313350915908813
familial I-Disease 1 0.9995741248130798
breast I-Disease 1 0.9999822378158569
and I-Disease 1 0.990970253944397
ovarian I-Disease 1 0.9999998807907104
cancers I-Disease 1 0.9999865293502808
. O 0 0.0002884389541577548

Epigenetic O 0 0.0544147714972496
loss O 0 0.015208981931209564
, O 0 1.0612853657221422e-05
however O 0 1.4074989849177655e-06
, O 0 2.88241920998189e-07
has O 0 1.3016787647757155e-07
not O 0 3.710081841745705e-08
received O 0 1.194585621533406e-07
general O 0 3.4098403034477087e-07
acceptance O 0 1.3428538295556791e-05
due O 0 8.023784516808519e-07
to O 0 1.7297644205882534e-07
controversy O 0 9.674663488112856e-07
regarding O 0 1.9388704686207348e-07
the O 0 6.839808008862747e-08
subcellular O 0 5.49751530343201e-06
localization O 0 1.3585693068307592e-06
of O 0 1.209898528031772e-07
BRCA1 O 0 5.809952926938422e-05
proteins O 0 2.319413283657923e-07
, O 0 9.458406680096232e-08
reports O 0 1.0483670109806553e-07
of O 0 2.5643608125847095e-08
which O 0 7.72039001617486e-08
have O 0 6.391534412841793e-08
ranged O 0 2.412377170912805e-06
from O 0 3.499020451158685e-08
exclusively O 0 1.0255162408157048e-07
nuclear O 0 7.718717824900523e-06
, O 0 4.4965347001379996e-08
to O 0 2.725008840798182e-08
conditionally O 0 1.0703632142394781e-05
nuclear O 0 1.5204316696326714e-05
, O 0 4.325396929516501e-08
to O 0 2.0548819534838003e-08
the O 0 4.993413327269991e-08
ER O 0 0.00016729549679439515
/ O 0 1.2002662515442353e-05
golgi O 0 9.889814828056842e-05
, O 0 1.1368059915639606e-07
to O 0 9.079629137431766e-08
cytoplasmic O 0 3.0479841370834038e-06
invaginations O 0 3.743855995708145e-05
into O 0 3.5306032941662124e-07
the O 0 5.419042281573638e-07
nucleus O 0 1.599571442056913e-05
. O 0 6.356888206937583e-06

In O 0 1.1976891983067617e-05
an O 0 7.422041221616382e-07
attempt O 0 4.022645043733064e-06
to O 0 6.518410486933135e-07
resolve O 0 1.2023582712572534e-05
this O 0 1.6208741726586595e-07
issue O 0 1.6785174921096768e-06
, O 0 2.6357599836046575e-07
we O 0 1.283198116652784e-07
have O 0 2.2035330005110154e-07
comprehensively O 0 9.502892498858273e-05
characterized O 0 2.7028569093090482e-05
19 O 0 5.5739515119057614e-06
anti O 0 0.00015910595539025962
- O 0 0.06016318127512932
BRCA1 O 0 0.010376271791756153
antibodies O 0 7.623896090080962e-05
. O 0 1.3108255188853946e-05

These O 0 2.3754142603138462e-05
reagents O 0 0.00016931755817495286
detect O 0 6.660528015345335e-05
a O 0 1.1993564612566843e-06
220 O 0 3.399256229386083e-06
- O 0 3.6704939702758566e-05
kD O 0 0.00014659389853477478
protein O 0 1.3301491890160833e-06
localized O 0 1.5117792599994573e-06
in O 0 7.719933137195767e-08
discrete O 0 1.2326556770858588e-06
nuclear O 0 1.2565428733068984e-05
foci O 0 7.442281003022799e-06
in O 0 9.093389508052496e-08
all O 0 8.725068312287476e-08
epithelial O 0 0.0035033170133829117
cell O 0 8.928809256758541e-05
lines O 0 2.8100735107727814e-06
, O 0 1.9233233672366623e-07
including O 0 2.2295924395621114e-07
those O 0 2.355287307409526e-07
derived O 0 1.127794234889734e-06
from O 0 3.0652911391371163e-06
breast B-Disease 1 0.9851033091545105
malignancies I-Disease 1 0.696654200553894
. O 0 4.263477603672072e-05

Immunohistochemical O 0 0.01441762875765562
staining O 0 0.0016404781490564346
of O 0 1.0873733117477968e-05
human O 0 0.00012157329911133274
breast O 1 0.9893035888671875
specimens O 0 0.00032164991716854274
also O 0 2.8591857699211687e-06
revealed O 0 7.105008990038186e-05
BRCA1 O 0 0.002714845584705472
nuclear O 0 0.0004469654813874513
foci O 0 0.0007111849263310432
in O 0 1.3730737009609584e-05
benign O 1 0.9924739003181458
breast O 1 0.9990957975387573
, O 0 0.00020549596229102463
invasive B-Disease 1 0.9912359714508057
lobular I-Disease 1 0.9999947547912598
cancers I-Disease 1 0.997170627117157
and O 0 2.0110523109906353e-05
low B-Disease 0 0.010186346247792244
- I-Disease 1 0.9469637274742126
grade I-Disease 1 0.8615689873695374
ductal I-Disease 1 0.9999417066574097
carcinomas I-Disease 1 0.9999600648880005
. O 0 0.00012332681217230856

Conversely O 0 0.003004348836839199
, O 0 3.265944906161167e-05
BRCA1 O 0 0.0006768550956621766
expression O 0 9.817380487220362e-06
was O 0 1.456261998100672e-06
reduced O 0 4.7067237574083265e-06
or O 0 1.3400449461187236e-06
undetectable O 0 2.3873461032053456e-05
in O 0 3.889749322638636e-08
the O 0 2.8061311496685448e-08
majority O 0 1.81051404979371e-07
of O 0 6.14622095440609e-08
high O 0 1.5873916709097102e-05
- O 0 0.0088922418653965
grade O 0 0.0012540484312921762
, O 0 2.3111289920052513e-05
ductal B-Disease 1 0.9998928308486938
carcinomas I-Disease 1 0.9999910593032837
, O 0 5.000164492230397e-06
suggesting O 0 2.3241127564688213e-06
that O 0 7.243897215403194e-08
absence O 0 4.3788637071884295e-07
of O 0 2.321088459211751e-07
BRCA1 O 0 0.0013168775476515293
may O 0 6.141839321571751e-07
contribute O 0 1.2438415808446734e-07
to O 0 4.019750576844672e-08
the O 0 8.538523843526491e-08
pathogenesis O 0 2.636236786202062e-05
of O 0 5.2060034505529984e-08
a O 0 2.0550784540773748e-07
significant O 0 6.36698075595632e-07
percentage O 0 3.2957696021185257e-06
of O 0 6.202501481311629e-07
sporadic B-Disease 0 0.02498929761350155
breast I-Disease 1 0.9999619722366333
cancers I-Disease 1 0.9965176582336426
. O 0 1.1776913197536487e-05
. O 0 2.4364726414205506e-05

